#CLS_PREDICTION_ENTITY|MASK_PREDICTION_ENTITY|ACTUAL_ENTITY|CLS_PREDICTIONS|MASKED_PREDICTIONS|MASKED_WORD|SENTENCE
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium carbamazepine lamotrigine phenobarbital valproate|lithium|is being evaluated as a monotherapy and in the iti-007-402 trial , lumateperone is being evaluated as an adjunctive therapy with entity or valproate .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 3)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium antidepressants antipsychotics neuroleptics stimulants|lithium|current drug therapy for bipolar disorder includes the use of entity and anti-depressants .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium antidepressants antipsychotics benzodiazepines valproate|lithium|mood-stabilizing drugs can treat bipolar symptoms when they are present , including entity and anticonvulsants , such as valproic acid and lamotrigine .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|generic sold purchased tablets pharmaceuticals|lithium|retail sales of energizers entity and rechargeable products increased 22% in the quarter while our price-oriented product sales declined 12% .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|linezolid clozapine doxycycline carbamazepine minocycline|lithium|to date , the only drug that interacted with zs-9 is entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|medicinal patent biomedical healthcare pharmaceutical|lithium|mr . friess and mr . schwartz sold most of their shares of pisv for $275 , 000 and pisv became china entity technologies inc . listed on the otcbb symbol ( cltt ) .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|electrically battery internally externally mechanically|lithium|chairman of cardiac pacemakers , inc . , a company founded by mr . villafana to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium battery electrochemical ceramic semiconductor|lithium|the e-go is an all-electric vehicle powered by advanced entity batteries .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium potassium monovalent titanium battery|lithium|inc . , a company that is engaged in the manufacture , commercialization and distribution of a wide variety of standard and customized entity ion rechargeable batteries .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|bupropion risperidone olanzapine clozapine topiramate|lithium|these adjunctive agents may include atypical antipsychotics , like aripiprazole and quetiapine , or other agents such as buproprion and entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|bupropion donepezil nicotine memantine levodopa|lithium|in the last few years several academic research initiatives were conducted to explore the efficacy of approved drugs such as entity , varenicline ( chantix ® ) , riluzol and dalfampridine .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium carbamazepine lamotrigine quetiapine risperidone|lithium|for the treatment of patients with depressive episodes associated with bipolar i disorder as monotherapy and as adjunctive therapy with entity or valproate , which expires in june 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|electrically internally externally battery implantable|lithium|( now a division of guidant corporation ) , a company founded by mr . villafaña to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium carbamazepine lamotrigine quetiapine aripiprazole|lithium|in the iti-007-402 trial , patients receive lumateperone or placebo adjunctive to their existing mood stabilizer entity or valproate .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium battery potassium cobalt fluoride|lithium|and as director to aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state entity ion battery for electric vehicles and smart grid applications .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium potassium ceramic battery titanium|lithium|the car is all-electric and powered by advanced entity ion batteries .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|bilirubin electrolytes creatinine vitamins lipids|lithium|· with further investment , other patches can be developed which are able to measure alternative analytes , including lactates , uric acid , entity and drugs .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|batteries battery disposable lithium portable|lithium|recently , higher power , higher priced entity and rechargeable batteries have grown in response to more demanding power needs of more advanced devices .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium carbamazepine lamotrigine quetiapine phenobarbital|lithium|abilify®  in february , the fda approved abilify as an adjunct to mood stabilizers entity or valproate for the maintenance treatment of bipolar i disorder .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|drug|lithium lamotrigine antidepressant carbamazepine antidepressants|lithium ceramic battery plastic biodegradable|lithium|the u . s . retail battery category is defined as alkaline , carbon zinc , entity , rechargeable and specialty batteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|vec atropine succinyl scopolamine nicotine|vecuronium|( sugammadex ) injection 100 mg / ml was approved by the fda for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|intubation infusion titrated sedation reversal|vec succinyl atropine isoflurane scopolamine|vecuronium|is specifically designed to reverse the effects of certain muscle relaxants , marketed in the united states as zemuron ( r ) ( rocuronium bromide ) and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|potassium bromide ethidium lithium atropine|vecuronium|we initiated a recall of a batch of entity bromide , a product we 43 market on behalf of a third party , in february 2001 due to concerns with filtration-testing
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|intubation infusion titrated sedation reversal|vincristine bupivacaine dexamethasone doxorubicin amiodarone|vecuronium|the first u . s . regulatory approvals on products that are difficult to produce , such as etoposide ( with gll ) , bleomycin , pancuronium and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|dextro bromide potassium ethidium dimethyl|vecuronium|the company is manufacturing and marketing entity bromide prior to expiration of the patent covering this product pursuant to a licensing arrangement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|alendronate doxycycline dexamethasone minocycline calcitonin|vecuronium|nevzat ilac sanayii a . s . , a subsidiary of amgen , inc . , ( mn ) to acquire the rights to three products : methylprednsilone sodium succinate , entity and pamidronate disodium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|vec fentanyl magnesium isoflurane metoclopramide|vecuronium|in december 2015 , the fda approved bridion for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|vec propofol sevoflurane lidocaine caffeine|vecuronium|of a clinical trial site for sugammadex , mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|vec atropine scopolamine succinyl nicotine|vecuronium|demand of bridion ( sugammadex ) injection 100 mg / ml , a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|intubation infusion titrated sedation reversal|docetaxel gemcitabine bevacizumab trastuzumab carboplatin|vecuronium|in addition , we have been able to help alleviate market shortages through the launches of entity and paclitaxel .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|potassium bromide benzyl ethidium lithium|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity bromide under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|potassium atropine ethidium quinidine lithium|vecuronium|for purposes of this paragraph , the term " krypton products " refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|propofol sevoflurane lidocaine vec caffeine|vecuronium|sugammadex sodium injection is mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|potassium quinidine ethidium atropine bromide|vecuronium|dosage product portfolio are 45 products for which the company is currently the sole generic source , one of which is entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intubation infusion titrated sedation reversal|bromide lithium potassium aluminum thallium|vecuronium|due to deviations from the fda  s manufacturing regulations , we are conducting voluntary product recalls of entity bromide and pte-4 products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|intubation infusion titrated sedation reversal|vaccines cigarettes tablets pharmaceuticals biologics|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|potassium bromide ethidium lithium benzyl|vecuronium|we initiated a recall of a batch of entity bromide , a product we market on behalf of a third party , in february 2001 due to concerns with filtration- testing
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|intubation infusion titrated sedation reversal|atropine ethidium potassium chlorpromazine lithium|vecuronium|for purposes of this paragraph , the term krypton products refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|intubation infusion titrated sedation reversal|propofol fentanyl sevoflurane caffeine clonidine|vecuronium|for odanacatib for osteoporosis , suvorexant for insomnia and sugammadex sodium injection for reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|intubation infusion titrated sedation reversal|vaccines cigarettes pharmaceuticals tablets condoms|vecuronium|in march 2000 , schein resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|tobramycin gentamicin piperacillin amikacin vancomycin|avibactam|the ceftazidime / entity combination product forest expects will receive three years of hatch-waxman exclusivity upon approval .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|amikacin cefotaxime tobramycin imipenem piperacillin|avibactam|for cre infections , physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime / entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|meropenem linezolid ceftazidime daptomycin piperacillin|avibactam|entity is a novel , non beta-lactam , beta lactamase inhibitor , quite a mouthful , itself as a molecule does not possess intrinsic antibacterial
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|daptomycin moxifloxacin linezolid meropenem ciprofloxacin|avibactam|entity is currently being developed in combination with ceftazidime , a cephalosporin antibiotic .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|edta zinc rifampin ciprofloxacin rifampicin|avibactam|the addition of entity to ceftazidime protects ceftazidime from breakdown by β-lactamases .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|ceftriaxone amikacin piperacillin cefotaxime ciprofloxacin|avibactam|it consists of a combination of entity and ceftazidime - a third generation antipseudomonal cephalosporin with a well-established efficacy and safety profile .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|edta rifampin imipenem ciprofloxacin ampicillin|avibactam|the addition of entity protects ceftazidime from being broken down by beta-lactamases that are produced by resistant bacteria .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|daptomycin imipenem colistin linezolid moxifloxacin|avibactam|it has structural similarities to entity , a bli recently approved in combination with ceftazidime ( avycaz ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|ceftazidime ceftriaxone amikacin gentamicin imipenem|avibactam|almirall for las100977   0 . 25 licensing payment to astrazeneca for entity and ceftazidime / entity   0 . 75 rounding  
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|gentamicin tobramycin ceftriaxone piperacillin amikacin|avibactam|actavis and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|linezolid fda china india penicillin|avibactam|entity is also protected by an issued united states patent directed to combinations with an antibiotic that expires in 2026 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|ceftazidime meropenem piperacillin daptomycin ipm|avibactam|entity is a first-in-class broad-spectrum β-lactamase inhibitor , which protects ceftazidime against degradation by class a , c and some d , β-lactamases .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|marijuana fda cannabis canada china|avibactam|in addition , entity is protected by a united states composition-of-matter patent that expires in 2022 , without pte .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|amikacin piperacillin imipenem tobramycin meropenem|avibactam|based on the results of these studies , we and astrazeneca initiated phase iii studies for ceftazidime / entity in patients with ciai in december 2011 and in patients with cuti in july 2012 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|amikacin tobramycin piperacillin cefotaxime imipenem|avibactam|in fiscal 2013 , these costs were largely related to clinical trials for nebivolol / valsartan , aclidinium / formoterol , vilazodone , memantine , and ceftazidime / entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|gentamicin ceftriaxone amikacin tobramycin piperacillin|avibactam|actavis plc and astrazeneca plc are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|too correctly again themselves soon|avibactam|so we are very excited to introduce to you entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin daptomycin imipenem ceftazidime colistin|gentamicin tobramycin ceftriaxone piperacillin amikacin|avibactam|forest laboratories and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|capecitabine irinotecan gemcitabine docetaxel bevacizumab|irinotecan|erbitux product labeling to include overall survival data as a single agent in egfr-expressing mcrc patients after failure of both entity- and oxaliplatin-based regimens .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan oxaliplatin cpt sorafenib temozolomide|irinotecan|sn38 is the active metabolite of cpt-11 ( entity ) , which is approved for the treatment of colorectal cancer .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan etoposide paclitaxel cpt oxaliplatin|irinotecan|the fda approved entity as camptosar in 1994 for use in colorectal cancer .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|docetaxel paclitaxel capecitabine gemcitabine bevacizumab|irinotecan|erbitux ( r ) is approved in united states , austria , canada , germany and switzerland for metastatic colorectal in combination with entity in entity-refractory patients .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan cetuximab cpt oxaliplatin tmz|irinotecan|we did observe statistically significant improvements in progression free survival , or pfs , and other efficacy endpoints for ha-entity compared with irinotecan alone .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|etoposide gemcitabine docetaxel paclitaxel irinotecan|irinotecan|entity and cisplatin are two established anticancer drugs which together constitute an active combination for treating sclc .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|bevacizumab vincristine temozolomide capecitabine dexamethasone|irinotecan|note : chemotherapy regimens included temozolomide and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan erlotinib bevacizumab capecitabine docetaxel|irinotecan|is to assess the safety and pharmacokinetics of mm-121 in combination with cetuximab and mm-121 in combination with cetuximab and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|paclitaxel bevacizumab sunitinib temozolomide mmf|irinotecan|one of our clinical development strategies is to replace the use of entity with mm-398 by demonstrating that mm-398 has favorable efficacy and safety characteristics compared to entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|itself today markets europe themselves|irinotecan|that are currently conducted by aventis , together with certain patents and other assets relating to territories where pfizer currently markets entity , including the united states .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|paclitaxel docetaxel gemcitabine oxaliplatin doxorubicin|irinotecan|” the study was initiated following the demonstration of synergy between nimotuzumab and entity in the laboratories of daiichi sankyo in gastric cancer cell lines .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan capecitabine fluorouracil bevacizumab mitomycin|irinotecan|advanced colorectal cancer in which nuc-3373 will be combined with many of the agents typically combined with 5-fu , including leucovorin , entity , oxaliplatin and monoclonal antibodies .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|immunotherapy immunosuppression regimens therapeutics translation|irinotecan|clinical development of mm-398 we are pursuing two approaches in the ongoing clinical development of mm-398 : replace entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan etoposide gemcitabine oxaliplatin paclitaxel|irinotecan|two camptothecin derivatives , topotecan and entity , have been approved by the fda for the treatment of small-cell lung , ovarian , and colorectal cancers .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan capecitabine fluorouracil oxaliplatin mitomycin|irinotecan|most systemic therapies for colorectal cancer include 5-fu , either as monotherapy or in combination with another chemotherapeutic , typically oxaliplatin or entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan fluorouracil capecitabine gemcitabine bevacizumab|irinotecan|this study enrolled 463 patients with metastatic colorectal cancer who had failed standard entity- and oxaliplatin-containing chemotherapy .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|irinotecan temozolomide paclitaxel gemcitabine oxaliplatin|irinotecan|these two adcs facilitate targeted delivery of sn-38 , the active metabolite of entity , an effective , yet toxic chemotherapeutic , directly to tumor cells .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|gemcitabine paclitaxel docetaxel doxorubicin irinotecan|irinotecan|entity and cisplatin combinations were evaluated systematically for drug ratio-dependent synergy in vitro using a panel of 20 tumor cell lines .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|methotrexate bortezomib thalidomide dexamethasone mitoxantrone|irinotecan|our clinical strategy is to administer birinapant with therapies ( for example , azacitidine or entity ) that induce the production of tnf or related molecules .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|irinotecan paclitaxel tolerated capecitabine pharmacokinetics|lmwh enoxaparin dabigatran rivaroxaban thrombin|irinotecan|since that time he has had increasing responsibility for overseeing the global research plans and teams for entity and dalteparin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|minocycline mic intravitreal rifampin vancomycin|name ingredient counterpart constituent word|minocycline|“its quite unique in that its a entity topical ; i dont like a lot of the entity oral [ products ] , but entity topical – i can certainly get excited about .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|doxycycline retinoids tetracycline ciprofloxacin steroids|minocycline|reported novel imaging techniques , suggesting that bpx-01 effectively targets p . acnes in the skin without the systemic side effects of oral entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|retinoid tetracycline metronidazole cosmetic acne|minocycline|in october , they received approval for their first product , amzeeq , a topical entity formulation for the treatment of acne .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|minocycline mic intravitreal rifampin vancomycin|cream formaldehyde sls lidocaine chlorhexidine|minocycline|in this study , no serious adverse events were observed and the treatment-related adverse events were related to dermal irritation in the 2% entity treatment arm .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|clindamycin minocycline metronidazole moxifloxacin azithromycin|minocycline|our lead product candidate , fmx101 for moderate-to-severe acne , is a novel topical foam formulation of the antibiotic entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|vec prostaglandin potassium polyvinyl liposomal|minocycline|in september 1999 we recognized a gain of $2 . 7 million on the sale of our vectrin ( r ) entity hcl product line .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|retinoid contraceptive tetracycline corticosteroid cream|minocycline|solodyn , a branded oral entity , the current standard of care for moderate-to-severe acne , accounted for nearly one half of the total branded oral market for
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|lactate prostacyclin epinephrine fluorescein creatinine|minocycline|thus , it has been demonstrated that the amount of either entity or edetate that leaks into the serum is very low or none at all .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|vancomycin azithromycin ciprofloxacin gentamicin linezolid|minocycline|limitations of use : this formulation of entity has not been evaluated in the treatment of infections .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|misoprostol azithromycin valsartan enoxaparin rosiglitazone|minocycline|are marketed outside the u . s . during 1998 , the company filed anda  s for two products previously selected , from which one product , entity , received approval in march 1999 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|erythema epidermis dermis burns dermatitis|minocycline|dose a resulted in 5 mg / cm2 of entity , which translates to approximately about 1 mg / g of skin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|retinoids retinoid metronidazole pharmacotherapy tetracycline|minocycline|limitations of current standard of care for acne : oral entity , such as solodyn , is the current standard of care for moderate-to-severe acne .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|multidrug rifampicin clarithromycin antibacterial metronidazole|minocycline|mpts in blood serum and saliva in order to observe the drug release profile , and to assess the development of entity resistance .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|minocycline mic intravitreal rifampin vancomycin|ketoprofen paclitaxel bleomycin diclofenac ibuprofen|minocycline|bpx-04 is designed to deliver the active , entity , into the skin without further irritating the skin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|minocycline mic intravitreal rifampin vancomycin|annual entire monthly sales projected|minocycline|the prior year sales included $6 , 373 of entity sales which the company stopped selling in late 1999 because of deteriorating market conditions .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|metronidazole doxycycline tetracycline retinoids retinoid|minocycline|oral entity has been a commonly used treatment for acne for years .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|paclitaxel curcumin egcg resveratrol flavonoids|minocycline|this approach was via structure-activity relationship chemistry-based modifications of the seven and nine positions of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|minocycline mic intravitreal rifampin vancomycin|artemisinin steroidal tubulin taxol aptamer|minocycline|used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the entity core structure .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|vaginal foam ophthalmic topical impregnated|minocycline|success in iga @ week 12 difference from vehicle fmx103 entity foam , 1 . 5% 10-week study epsolay® ( † ) sol-gel did not conduct a head-to-head comparison trial or study .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|minocycline mic intravitreal rifampin vancomycin|crude pure raw pharmaceutical approved|minocycline|or the cipan agreement , which provides the terms and conditions under which cipan will manufacture and supply to the company entity starting material and crude omadacycline .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|reduces antidepressant sine improves approved|gdnf thalidomide rapamycin others bevacizumab|rasagiline|that are intended to alter the course of the disease , including the investigational drugs known as cep-1347 , gdnf , tch-346 and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|drug|reduces antidepressant sine improves approved|rot bot tal sine pallid|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|reduces antidepressant sine improves approved|abt az donepezil amt abbott|rasagiline|a number of mao inhibitors are approved for pd therapy , including zelapar ( selegiline / valeant ) and azilect ( entity ; teva / lundbeck ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces antidepressant sine improves approved|draft latest entire interim biologics|rasagiline|teva and its strategic partner h . lundbeck a / s recently submitted the entity regulatory file to the european agency for evaluation of medicinal products .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|reduces antidepressant sine improves approved|levodopa chewing apomorphine pallid pant|rasagiline|about azilect® ( united states ) indication azilect® ( entity tablets ) is indicated for the treatment of the signs and symptoms of parkinsons disease ( pd ) both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|reduces antidepressant sine improves approved|egcg ketamine honey catechin melatonin|rasagiline|youdim has published numerous articles describing entity  s neuroprotective and neurorescue activities in various laboratory models .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|levodopa chewing apomorphine sine once|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|levodopa approval neuroprotection sildenafil apomorphine|rasagiline|completion of the two phase iii clinical trials in march , teva submitted to the fda a new drug application for entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|reduces antidepressant sine improves approved|levodopa apomorphine dopamine bromocriptine methylphenidate|rasagiline|developed by teva , entity tablets are approved in over 40 countries for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|levodopa apomorphine chewing smart dopamine|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|reduces antidepressant sine improves approved|propranolol dopamine clonidine metoprolol quinidine|rasagiline|selectivity was tested by evaluating the interaction between tyramine and entity in healthy subjects .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|levodopa apomorphine chewing smart rotating|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|rot bot bos tal reb|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease and its second innovative drug , is now available in 29 countries .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|pacs pharmaceuticals tablets statins linezolid|rasagiline| teva pharmaceutical industries ltd . ( israel ) : we are in collaboration with teva pharmaceutical industries ltd . to develop and commercialize entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|reduces antidepressant sine improves approved|sc otc od levodopa tablets|rasagiline|about azilect&reg azilect&reg tablets ( entity ) 1 mg / day are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces antidepressant sine improves approved|soon itself again freely globally|rasagiline|teva expects to market entity in europe with h . lundbeck a / s , and in the united states with its new strategic partner eisai inc . teva
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant sine improves approved|levodopa slow anticholinergic smart floating|rasagiline|about azilect &reg azilect&reg 1 mg tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|reduces antidepressant sine improves approved|chewing sublingual once levodopa lyophilized|rasagiline|azilect® ( entity tablets ) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|reduces antidepressant sine improves approved|levodopa smart apomorphine dopamine parkinson|rasagiline|about azilect® azilect® tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinsons disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|reduces antidepressant sine improves approved|chewing sublingual once levodopa 3m|rasagiline|azilect® ( entity tablets ) is indicated as an initial monotherapy and as an adjunct to levodopa for the treatment of the signs and
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|nicotine sulfated morphine scopolamine inhaled|quinidine potassium magnesium lithium ferrous|bethanechol|according to wolters kluwer , total sales of generic entity chloride 5mg , 10mg and 25mg tablets at awp were $56 million in 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antidepressant reduces tricyclic improves amitriptyline|dexamethasone cyclophosphamide prednisolone theophylline tacrolimus|nortriptyline|crx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|antidepressant reduces tricyclic improves amitriptyline|desipramine fluoxetine venlafaxine imipramine bupropion|nortriptyline|clinical trials of the antiepileptic agents gabapentin and lamotrigine and the antidepressants entity and amitriptyline have all been negative .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|antidepressant reduces tricyclic improves amitriptyline|betamethasone methotrexate vehicle prednisolone corticosteroids|nortriptyline|on multiple measures such as psoriatic infiltrate thickness , erythema and clinical skin condition and produced greater improvements than mometasone and entity alone .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|antidepressant reduces tricyclic improves amitriptyline|nsaids opioids ssris antidepressants benzodiazepines|nortriptyline|the 2 most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|antidepressant reduces tricyclic improves amitriptyline|melatonin benzodiazepines diazepam paroxetine pregabalin|nortriptyline|procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|antidepressant reduces tricyclic improves amitriptyline|melatonin benzodiazepines pregabalin midazolam paroxetine|nortriptyline|license from procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5mg to 10mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antidepressant reduces tricyclic improves amitriptyline|tacrolimus prednisolone dexamethasone curcumin nac|nortriptyline|crx-170 did not show a modulation of the inflammatory marker cd163 from the treatment baseline , although entity clearly did decrease cd163 on its own .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant reduces tricyclic improves amitriptyline|imipramine desipramine amitriptyline venlafaxine fluoxetine|nortriptyline|crx-191 contains a mid- potency glucocorticosteroid , mometasone , and a low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant reduces tricyclic improves amitriptyline|imipramine desipramine amitriptyline venlafaxine fluoxetine|nortriptyline|crx-191 contains a mid-potency glucocorticosteroid , mometasone , and a very low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antidepressant reduces tricyclic improves amitriptyline|nsaids opioids ssris corticosteroids benzodiazepines|nortriptyline|the most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|antidepressant reduces tricyclic improves amitriptyline|melatonin benzodiazepines diazepam paroxetine pregabalin|nortriptyline|license from procom one , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant reduces tricyclic improves amitriptyline|imipramine desipramine amitriptyline fluoxetine clonidine|nortriptyline|about crx-170 crx-170 is an oral synergistic combination drug candidate containing low doses of the steroid prednisolone and the anti-depressant entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|itraconazole voriconazole mic amphotericin metabolite|statins antipsychotics aeds nsaids fluoroquinolones|terbinafine|we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|itraconazole voriconazole mic amphotericin metabolite|voriconazole itraconazole ivermectin acyclovir ketoconazole|terbinafine|mycova™ combines an existing , approved drug for nail fungus , entity , with the nexact® technology that enhances the absorption of the drug through the skin .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|itraconazole voriconazole mic amphotericin metabolite|antipsychotics medicines risperidone opioids statins|terbinafine|consistent with this strategy , during fiscal 2006 we commenced sales of generic entity in certain european markets through an out-licensing arrangement .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|itraconazole voriconazole mic amphotericin metabolite|corticosteroids pharmaceuticals tacrolimus hydrocortisone cyclosporine|terbinafine|“novartis formulation”means any topical formulation of entity ( other than the nexmed formulation ) developed by or on behalf of novartis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|fluconazole itraconazole voriconazole ketoconazole amphotericin|terbinafine|nm100060 is topically applied , and incorporates entity , a currently marketed oral anti-fungal drug , with the nexact® technology , which facilitates the permeation of the drug through the nail
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|itraconazole voriconazole mic amphotericin metabolite|hydrochloride hydrate bromide chloride aerosol|terbinafine|aerosol no protection lamisil entity ( entity hydrochloride ) fungal infection of the skin and nails caused by dermatophyte fungi tinea capitis fungal infections of the skin
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|topical antifungal cosmetic medicinal nail|terbinafine|worldwide sales of the branded entity product lamisil , the most prescribed systemic drug for onychomycosis , were $1 . 2 billion in 2004 and $978 million in 2006 , when
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|itraconazole voriconazole mic amphotericin metabolite|ongoing pivotal randomised aforementioned pilot|terbinafine|umang vohra though the entity trials are ongoing , we have not got an early read kind of a methodology for that trial and we hope
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|itraconazole voriconazole mic amphotericin metabolite|glibenclamide metformin pioglitazone rosiglitazone olanzapine|terbinafine|significant product launches in fiscal 2006 included glimepiride tablets and zonisamide tablets in the united states and entity tablets in the united kingdom .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|itraconazole voriconazole mic amphotericin metabolite|corticosteroids fluconazole itraconazole retinoids metronidazole|terbinafine|treatments are segmented into two approaches , either oral therapies , such as entity , or topical products , such as jublia , an azole , and kerydin , an oxaborole .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|itraconazole voriconazole mic amphotericin metabolite|pharmaceutical medicinal investigational generic finished|terbinafine|evolved for promius pharma as a whole and how do you see that going forward and some update on your entity product for which you had phase three already enrolled?
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|venlafaxine paroxetine fluoxetine citalopram risperidone|terbinafine|new product launches in fiscal 2006 included the generic versions of glimepiride , lansoprazole , lisinopril , sertraline and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|levofloxacin azithromycin amoxicillin omeprazole erythromycin|terbinafine|during fiscal 2008 , we launched carvedilol tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , entity and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|statins etanercept adalimumab voriconazole cyclosporine|terbinafine|despite its high labeled efficacy ( 38% ) , we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|itraconazole voriconazole mic amphotericin metabolite|lam lev roche mf slit|terbinafine|lamisil ( entity ) , a systemic drug approved for onychomycosis , had worldwide peak sales of $1 . 2 billion in 2004 , before generic entry .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|fluconazole voriconazole ketoconazole itraconazole amphotericin|terbinafine|preclinical studies have shown that itraconazole , the antifungal agent in hyphanox , has a broader spectrum of activity than entity , the antifungal agent in lamisil .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|itraconazole voriconazole mic amphotericin metabolite|paroxetine fluoxetine venlafaxine bupropion citalopram|terbinafine|however , this was offset to some extent by a decrease in sales of entity and sertraline .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|itraconazole voriconazole mic amphotericin metabolite|pregabalin risperidone dabigatran statins celecoxib|terbinafine|period ending june 30 , 2010 , 1 . 4 million new prescriptions were filled in the united states for both branded and generic versions of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|lam lev lm lms mf|terbinafine|lamisil ( entity ) is a treatment for fungal nail infection ( onychomycosis ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|itraconazole voriconazole mic amphotericin metabolite|etanercept rituximab hence adalimumab budesonide|terbinafine|a generic version of lamisil , entity , recently became available .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|replicon approved integrase tenofovir investigational|ribavirin ritonavir rifampicin tenofovir lamivudine|ledipasvir|harvoni combines the ns5a inhibitor entity with sofosbuvir and is indicated for an eight , 12 or 24 week treatment duration depending on prior treatment history , cirrhosis
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|replicon approved integrase tenofovir investigational|lamivudine ribavirin tenofovir ritonavir sof|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni , a entity / sofosbuvir combination for patients with genotype 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|replicon approved integrase tenofovir investigational|ribavirin tenofovir lamivudine rbv sof|ledipasvir|pending patent applications directed to the use of combinations for the treatment of hcv , and , specifically , to the combination of entity and sofosbuvir .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|replicon approved integrase tenofovir investigational|ribavirin lamivudine tenofovir rifampicin ritonavir|ledipasvir|gilead sciences markets harvoni as a  cure  for hepatitis c . it combines two drugs : sovaldi ( sofosbuvir ) and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|replicon approved integrase tenofovir investigational|mercury metals fluorine copper iodine|ledipasvir|additionally , abbvie has obtained canadian patent no . 2 , 857 , 339 ( the 339 patent ) which purports to cover a solid composition that contains entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|replicon approved integrase tenofovir investigational|ribavirin lamivudine ritonavir tenofovir efavirenz|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|replicon approved integrase tenofovir investigational|ritonavir lamivudine tenofovir ribavirin efavirenz|ledipasvir|in october 2014 , we also received approval of the fixed-dose combination of entity and sofosbuvir , now known commercially as harvoni .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|replicon approved integrase tenofovir investigational|ribavirin lamivudine rbv ritonavir rifampicin|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni® , a fixed-dose combination of sofosbuvir and entity ( a ns5a inhibitor ) for patients with genotype 1 hcv .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|replicon approved integrase tenofovir investigational|ribavirin pis interferons daa tenofovir|ledipasvir|the hcv ns5a drug resistance assay assesses resistance to entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|replicon approved integrase tenofovir investigational|ribavirin rbv ritonavir tenofovir rifampicin|ledipasvir|resistance to sofosbuvir , which was approved as a single daa in 2013 and as a co-formulation with the ns5a inhibitor , entity , in 2014 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|replicon approved integrase tenofovir investigational|ritonavir sof lamivudine tenofovir tdf|ledipasvir|separately , results from a phase 2 study demonstrated the safety and efficacy of entity / sofosbuvir in patients with genotypes 4 or 5 infection .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|replicon approved integrase tenofovir investigational|lamivudine ribavirin ritonavir tenofovir efavirenz|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi® ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|replicon approved integrase tenofovir investigational|ribavirin ritonavir rifampicin tenofovir lamivudine|ledipasvir|entity inhibits the ns5a hcv viral protein .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|responders nonresponders clozapine ssris sertraline|fluoxetine|as cured ( with a ham-d score lower than 8 ) , we had between 37% and 39% , of a similar order to entity .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|sertraline desipramine paroxetine fluoxetine citalopram|fluoxetine|vilazodone has greater in vitro potency and selectivity for serotonin reuptake than compounds such as entity .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|fluoxetine sertraline citalopram amitriptyline venlafaxine|fluoxetine|compete with newer generation anti-depressants used to treat hot 17 table of contents flash frequency , such as venlafaxine by wyeth , entity by eli lilly and paroxetine by glaxo smith kline .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|fluoxetine citalopram venlafaxine sertraline paroxetine|fluoxetine|entity is the generic equivalent of eli lilly  s prozac antidepressant , which is patent protected and had annual sales of $1 . 7 billion for the twelve months ended september 30 , 1997 .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|paroxetine sertraline fluoxetine citalopram venlafaxine|fluoxetine|in the same preclinical studies , the ssri entity did not induce rapid onset antidepressant-like responses .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 4)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|pharmacotherapy antidepressants clozapine antidepressant risperidone|fluoxetine|entity capsules central nervous system anti-psychotic rs .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|raloxifene aspirin celecoxib progesterone prednisone|fluoxetine|product sales , excluding entity and tamoxifen , were approximately $122 million during the third quarter .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|fluoxetine paroxetine venlafaxine bupropion citalopram|fluoxetine|commonly prescribed drugs for other symptoms include ditropan or detrol for bladder dysfunction , provigil for fatigue , entity for depression , and amitriptyline for pain .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|you anesthesiologists doctors dentistry dentists|fluoxetine|you can see that the adverse effects are relatively traditional for entity : essentially digestive , gastrointestinal orders and nausea and disappear in function of time .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|fluoxetine amitriptyline venlafaxine sertraline citalopram|fluoxetine|major marketed brands include tofranil ( imipramine ) , prozac ( entity ) , paxil ( paroxetine ) , luvox ( fluoxamine ) and zoloft ( sertaline ) .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|api glibenclamide omeprazole metformin thereof|fluoxetine|the api entity has been the subject of multiple studies in humans and has been approved for use in humans for decades .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|marketing approval patents patent registration|fluoxetine|the company filed its application for entity in january 1996 , and has been sued for patent infringement by eli lilly , initiating the patent challenge process .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antidepressant fluoxetine sertraline bupropion citalopram|cannabis pharmaceuticals methamphetamine pubmed cigarettes|fluoxetine|based on a recent federal court of appeals ruling , lilly  s composition of matter patent on entity will expire in the summer of 2001 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bupropion antidepressant approved discontinuation prescribed|ketamine codeine caffeine levodopa nicotine|bupropion|/ mecamylamine tablets formulation and method of making tablets containing entity and mecamylamine issued march 9 , 2010 expires july 25 , 2027 us appl .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion nicotine sertraline fluoxetine caffeine|bupropion|neuropsychiatric reactions in patients taking entity for smoking cessation serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|bupropion antidepressant approved discontinuation prescribed|topiramate lamotrigine metformin pregabalin pilocarpine|bupropion|adverse events and laboratory findings appeared to be consistent with the individual components of empatic , entity and zonisamide .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|naltrexone oxycodone buprenorphine bupropion methadone|bupropion|however , we could be exposed to potential patent infringement liability from other third parties who hold patents on various formulations of entity and naltrexone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bupropion antidepressant approved discontinuation prescribed|vehicle bupropion pla gum sal|bupropion|approximately 60 smokers interested in quitting will be randomized in a 1 : 1 ratio to receive either axs-05 or entity for 4 weeks .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|metformin valsartan ketoconazole rifampicin ritonavir|bupropion|for all doses tested , administration of dm in combination with entity resulted in substantial increases in auc0‑12 and cmax values of dm on day 8 as compared to day 1 of dosing .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bupropion antidepressant approved discontinuation prescribed|genistein quercetin kaempferol rutin resveratrol|bupropion|in addition , empatic contains entity , the same active ingredient that gave rise to the fdas concerns regarding the cardiovascular safety profile of nb32 , which depending
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|bupropion antidepressant approved discontinuation prescribed|scopolamine atropine metoclopramide quinidine chlorpromazine|bupropion|aplenzin is a once-daily formulation of entity hydrobromide and has been approved in 174mg , 348mg , and 522mg extended-release tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|bupropion antidepressant approved discontinuation prescribed|nonresponders others responders nonusers another|bupropion|we are very encouraged by the magnitude of superiority in responders over entity , the active control .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion pilocarpine quetiapine omeprazole metformin|bupropion|in 2001 , we licensed our once-daily formulation of entity hcl to gsk and have been collaborating with them to seek regulatory approval of wellbutrin xl .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|raloxifene ee venlafaxine bupropion omeprazole|bupropion|for this period also includes a $3 . 0 million bond received from glaxo to settle all patent infringement litigation relating to entity hcl , er 100 mg and 150 mg tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|bupropion antidepressant approved discontinuation prescribed|za dexamethasone alendronate ptx zol|bupropion|that we are pursuing ; however , generic forms of the active ingredients of our product candidates , including zoledronic acid , dm , and entity , are available and could be used off‑label .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|bupropion antidepressant approved discontinuation prescribed|naltrexone hydroc dextro reb mao|bupropion|we have entered into long-term supply agreements for the supply of naltrexone and entity api .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|omeprazole bupropion ranitidine tramadol dabigatran|bupropion|biovail also acquired the right to market its once-daily formulation of entity hcl in canada under the trade name wellbutrin® xl if regulatory approval is received .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('DIS', 3), ('OTHER', 3)])|drug|bupropion antidepressant approved discontinuation prescribed|immunogenicity paclitaxel allergy risperidone rituximab|bupropion|for example , we have in-licensed from glaxosmithkline certain formulation patents related to entity that expand our formulation options as we develop our commercial formulation of contrave .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion naltrexone quetiapine venlafaxine paroxetine|bupropion|the basis of the pet results , we added a second set of patients randomized either to 32mg naltrexone plus 400mg entity sr or a double placebo .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion transdermal nicotine risperidone venlafaxine|bupropion|forfivo xl® ( entity extended-release ) is the first 450 mg bupropion hcl tablet indicated for major depressive disorder , approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion imipramine fluoxetine amitriptyline venlafaxine|bupropion|cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bupropion antidepressant approved discontinuation prescribed|bupropion imipramine fluoxetine amitriptyline venlafaxine|bupropion|: cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|ipv vaccines others ribavirin adenovirus|albuterol|for which we provide sterile manufacturing services include several influenza 2 table of contents vaccines , xopenex® , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|inhaled aerosol inhalation reduces nebul|smokers cigarettes nonsmokers others pathogens|albuterol|in the respiratory market , we compete primarily against entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|inhaled aerosol inhalation reduces nebul|salbutamol atropine theophylline dexamethasone prednisolone|albuterol|we also evaluated rpl554 administered as an add-on therapy to either entity or ipratropium , in each case as compared to entity or ipratropium alone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|inhaled aerosol inhalation reduces nebul|budesonide slit ics vehicle tacrolimus|albuterol|symbicort demonstrated a 51% reduction in the rate of annual asthma exacerbations , compared to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|inhaled aerosol inhalation reduces nebul|salbutamol cfc metoprolol epinephrine theophylline|albuterol|xopenex inhalation solution and generic entity inhalation solution currently account for the majority of beta-agonist inhalation solution prescriptions in the market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|hcl lidocaine omeprazole ranitidine epinephrine|albuterol|the second quarter 2007 to institute a new , bundled payment amount for xopenexò brand leventity hcl inhalation solution and generic entity inhalation solution products .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhaled aerosol inhalation reduces nebul|salbutamol epinephrine theophylline opioids fentanyl|albuterol|effective january 1 , 2007 , cms established new billing codes and payment methodologies for other compounded inhalation drugs , including entity and ipratropium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|inhaled aerosol inhalation reduces nebul|salbutamol morphine magnesium atropine nicotine|albuterol| proair digihaler ( entity sulfate 117 mcg ) inhalation powder is the first and only digital inhaler with built-in sensors which connects to a companion
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|drug|inhaled aerosol inhalation reduces nebul|injectable approved inhaled investigational entirely|albuterol|in 1998 , ivax also applied for approval to market an entity non-cfc formulation in various european countries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|inhaled aerosol inhalation reduces nebul|budesonide salbutamol mdi theophylline cfc|albuterol|entity is the most widely used mdi product approved for the treatment of asthma , accounting for nearly $680 million in sales
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|inhaled aerosol inhalation reduces nebul|prf plc clopidogrel prp pregabalin|albuterol|entity is marketed by glaxowellcome plc ( " glaxowellcome " ) , schering-plough and others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|inhaled aerosol inhalation reduces nebul|powder meter press budesonide jet|albuterol|with xopenex hfa , we compete with generic chlorofluorocarbon-based entity metered-dose inhalers and brand-name hfa entity metered-dose inhalers .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|cfc spacer mdi powder biphasic|albuterol|cfc-containing entity mdis are required to be phased-out before the end of 2008 , with patients increasingly transitioning to hfa 2 mdis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhaled aerosol inhalation reduces nebul|dexamethasone cyclophosphamide prednisone prednisolone tobramycin|albuterol|there was no difference in the exacerbation rate between symbicort and twice-daily maintenance budesonide plus entity , despite a 52% reduction in the mean steroid dose with symbicort .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhaled aerosol inhalation reduces nebul|salbutamol epinephrine bronchodilator theophylline adrenaline|albuterol|upon commercialization , zambon will be entitled to certain royalties on payments received by us for entity , ipratropium and cromolyn sales for specified periods .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhaled aerosol inhalation reduces nebul|buprenorphine dexmedetomidine propofol remifentanil tramadol|albuterol|entity has been marketed for many years , is well established and sells at prices substantially lower than xopenex inhalation solution .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|copolymer cfc mdi powder coated|albuterol|this increase was principally due to the continued transition of patients previously using chlorofluorocarbon ( cfc ) entity mdis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|cfc mdi powder dpi coated|albuterol|almost one-half of the market is still comprised of cfc entity mdis , representing a sizeable remaining market opportunity for the xopenex hfa product .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhaled aerosol inhalation reduces nebul|nhs federal scottish government fair|albuterol|non-refundable $65 million cash deposit and issuance of letters of credit for the remaining balance , to be held by the entity settlement trust fund as security for potential future payments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|drug|inhaled aerosol inhalation reduces nebul|allergen allergy generic allergenic pharmaceutical|albuterol|this reflected the impact of generic entity substitutes on ventolin in the us , the impact of covid-19 pandemic related destocking in europe and allergy market contraction in
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|abstract law rule example fda|tromethamine|pursuant to the sprix purchase agreement , the company acquired specified assets and liabilities associated with sprix ( ketorolac entity )
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|hydrochloride acetate chloride ophthalmic ketorolac|tromethamine|entities acting in concert with them , are enjoined from making any preparations to make , sell , or offer for sale ketorolac entity ophthalmic solution 0 . 5% in the united states .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|ophthalmic hydrochloride ketorolac cream topical|tromethamine|district court for the eastern district of texas alleging patent infringement claims against the company relating to the 0 . 4% ketorolac entity formulation .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|acetate ketorolac hydrochloride hcl aspart|tromethamine|egalet has two approved products : oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|hydrochloride mesylate hcl acetate palmitate|tromethamine|the company has two vda drug candidates currently being tested in clinical trials , fosbretabulin entity , or fosbretabulin , and oxi4503 .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|bevacizumab monotherapy infusion approval mesylate|tromethamine|the fosbretabulin entity is being provided to ctep under a cooperative research and development agreement ( crada ) with oxigene and the bevacizumab is being
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|hydrochloride acetate ketorolac chloride hcl|tromethamine|for example , ketorolac entity is an injectable nsaid that had significant sales prior to the fdas imposing a black box warning limiting the combined
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|ketorolac acetate hydrochloride hcl aspart|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|ketorolac acetate hydrochloride hcl aspart|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|acetate hydrochloride succinate ketorolac carbonate|tromethamine|drug substances the api used in sprix nasal spray is ketorolac entity , in oxaydo is oxycodone hydrochloride , in arymo er is morphine sulfate , and in egalet‑002 is oxycodone hydrochloride .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|example glycol pharmaceuticals eu abstract|tromethamine|pursuant to which the company engaged jhs to provide certain services related to the manufacture and supply of sprix® ( ketorolac entity )
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|ketorolac acetate hydrochloride hcl aspart|tromethamine|use only cii , developed using egalets proprietary guardian technology , oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|acetate ketorolac hydrochloride hcl aspart|tromethamine|we are marketing two innovative pain products , sprix® ( ketorolac entity ) nasal spray and oxaydotm ( oxycodone hci , usp ) tablets for oral use onlycii .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|monophosphate diphosphate acetate mesylate hydrochloride|tromethamine|our lead compound is ca4p , which is also known as combretastatin a4-phosphate , fosbretabulin entity , fosbretabulin and zybrestat® .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|law example code approved abstract|tromethamine|pursuant to the purchase agreement , the company acquired specified assets and liabilities associated with sprix® ( ketorolac entity )
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride scopolamine chloride ketorolac metabolite|ketorolac hydrochloride acetate hcl aspart|tromethamine|the company is currently marketing sprix® ( ketorolac entity ) nasal spray ( “sprix nasal spray” ) and oxaydo® ( oxycodone hci , usp ) tablets for oral use only—cii ( “oxaydo” ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 3)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|erythropoietin hydroxyurea thalidomide epo hepcidin|ceftriaxone|the increase in other u . s . sales was primarily due to increased sales of new products ( entity and deferoxamine ) to alternate site healthcare customers .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ceftriaxone penicillin azithromycin gentamicin tetracycline|ceftriaxone|the current standard of treatment for bacterial urethritis / gonorrhea requires combination therapy including both an intramuscular injection of entity and oral azithromycin ( 1000 mg ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|vancomycin antimicrobials colistin ciprofloxacin linezolid|ceftriaxone|cdi , c . difficile associated diarrhea ( cdad ) and aad in patients hospitalized for a lower respiratory tract infection and receiving iv entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|medicines pharmaceuticals therapeutics biologics pharmacotherapy|ceftriaxone|to utilize ihma  s expertise and experience in " bridge " oral drug delivery techniques to research , develop and commercialize oral forms of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|gross purchased raw approved processed|ceftriaxone|included in the amount pending approval at june 30 , 2005 was $7 . 4 million of entity raw material and finished product .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|pregabalin bevacizumab linezolid clopidogrel risperidone|ceftriaxone|included in the amount pending approval at december 31 , 2005 was $7 . 4 million of entity , which was approved by the fda in february 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|azithromycin doxycycline amoxicillin ceftriaxone erythromycin|ceftriaxone|study with a single oral dose of 1000 mg of solithromycin compared with the standard of care , 500 mg of entity administered intramuscularly and 1000 mg of oral azithromycin .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ceftriaxone penicillin tetracycline ciprofloxacin amoxicillin|ceftriaxone|current treatment of bacterial urethritis includes two drugs : entity administered intramuscularly and oral azithromycin , which is added to treat co-infections with chlamydia .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|monotherapy etanercept moxifloxacin adalimumab simvastatin|ceftriaxone|there was one treatment-related serious adverse event in the entity group .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ciprofloxacin cefotaxime ceftazidime ceftriaxone imipenem|ceftriaxone|in a recent survey , 95% and 76% of the esbl isolates of escherichia coli found in utis were resistant to entity and levofloxacin , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ceftriaxone penicillin azithromycin metronidazole tetracycline|ceftriaxone|intramuscular entity now represents the last-resort treatment option for gonorrhea , although resistant strains are beginning to emerge .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|linezolid levofloxacin imipenem minocycline oseltamivir|ceftriaxone|of the most common treatments for serious bacterial infections , vancomycin , daptomycin , entity and tigecycline are only available as injectable or iv formulations .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|sc orally ti qd intramuscular|ceftriaxone|treatment related diarrhea was reported by one subject following sulopenem single dose iv , and by a further two subjects following entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|sc qd bid orally ti|ceftriaxone|itt patients were similar on each regimen ( 9 / 10 , 9 / 11 and 7 / 12 , on sulopenem single iv dose , sulopenem multidose iv and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ceftriaxone penicillin azithromycin metronidazole tetracycline|ceftriaxone|of a single 1000 mg dose of oral solithromycin in patients with uncomplicated gonorrhea and chlamydia infections compared with intramuscular entity plus oral azithromycin .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|levofloxacin amoxicillin ciprofloxacin azithromycin comparator|ceftriaxone|treatment-emergent adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the entity group .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|daptomycin linezolid bevacizumab vancomycin trastuzumab|ceftriaxone|entity is currently only marketed in an intravenous formulation .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|ceftriaxone penicillin azithromycin amoxicillin metronidazole|ceftriaxone|the current standard of treatment for gonorrhea is a single intramuscular injection of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|sildenafil metformin gabapentin pregabalin celecoxib|ceftriaxone|there is no oral formulation of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ceftriaxone mic ciprofloxacin pharmacokinetics ceftazidime|cab erlotinib cas risperidone paclitaxel|ceftriaxone|develop existing pre-clinical and clinical candidates , including cab-175 and an oral version of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|acetate quercetin phenolic ether del|vi vii ic ti iva|vilanterol|for the treatment of copd , the collaboration is developing combination products , relovair and the lama / laba ( gsk573719 / entity or 719 / vi ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|acetate quercetin phenolic ether del|iodide vi iodine fumarate potassium|vilanterol|anoro™ ellipta® ( umeclidinium bromide / entity , umec / vi ) on april 28 , 2014 , gsk and theravance announced that anoro™ ellipta® , the first once-daily product approved in the u . s .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|acetate quercetin phenolic ether del|budesonide salbutamol erythromycin hydrocortisone betamethasone|vilanterol|are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|acetate quercetin phenolic ether del|lithium vanadium ammonium arsenic chromium|vilanterol|the lead laba candidate , entity trifenatate ( or vi ) , is a gsk-discovered laba and gsk and we have jointly determined to focus the collaborations laba development
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|acetate quercetin phenolic ether del|budesonide salbutamol ics propionate ribavirin|vilanterol|therefore fluticasone furoate / entity should be used with caution in patients with severe cardiovascular disease .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|acetate quercetin phenolic ether del|azithromycin adalimumab statin rituximab aripiprazole|vilanterol|our economic interest will not include any payments associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|acetate quercetin phenolic ether del|potassium betamethasone vi chromium triamcinolone|vilanterol|· fluticasone furoate ( ff ) and entity trifenatate ( vi ) are promising agents for a combined , long-acting , once-daily treatment of asthma .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|acetate quercetin phenolic ether del|aripiprazole statin pioglitazone adalimumab olanzapine|vilanterol|our economic interest does not include any payments by gsk associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|acetate quercetin phenolic ether del|salbutamol germany sildenafil roche sweden|vilanterol|anoro® ellipta® ( umeclidinium / entity ) to be reimbursed in australia for chronic obstructive pulmonary disease - administered using a new dry powder inhaler called
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|acetate quercetin phenolic ether del|budesonide ribavirin propionate salbutamol prednisolone|vilanterol|donohue october 26 , 2014 , 1 : 30 pm - 3 : 00 pm cdt efficacy and safety of once-daily umeclidinium added to fluticasone furoate / entity in chronic obstructive pulmonary disease :
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|acetate quercetin phenolic ether del|vi ti tdf iiib qd|vilanterol|lama / laba combination ( gsk573719 / entity or 719 / vi ) the phase 3a program for the once-daily lama / laba dual bronchodilator 719 / vi is progressing well .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|acetate quercetin phenolic ether del|ranibizumab propranolol timolol lamotrigine metformin|vilanterol|our economic interest will not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|acetate quercetin phenolic ether del|ranibizumab propranolol timolol lamotrigine tacrolimus|vilanterol|our economic interest does not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|acetate quercetin phenolic ether del|iodide vi potassium iodine fumarate|vilanterol|closed triple or ff / umec / vi ( fluticasone furoate / umeclidinium bromide / entity )
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|drug|acetate quercetin phenolic ether del|potassium vi inhaled chromium fumarate|vilanterol|at 24h being developed for use as a monotherapy for asthma and in combination with a once-daily long-acting beta2 agonist ( laba ) , entity trifenatate ( vi , gw642444m ) , for asthma and copd .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|acetate quercetin phenolic ether del|budesonide vehicle ribavirin salbutamol prednisolone|vilanterol|had , or were at high-risk for , cardiovascular disease ; the primary objective was to evaluate the impact of fluticasone furoate ( ff ) / entity ( vi ) on all-cause mortality .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|acetate quercetin phenolic ether del|salbutamol budesonide valsartan isoproterenol furosemide|vilanterol|breo is a fixed-dose combination of the inhaled corticosteroid ( ics ) fluticasone furoate ( ff ) and the long-acting beta2-agonist ( laba ) entity ( vi ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|acetate quercetin phenolic ether del|budesonide salbutamol hydrocortisone betamethasone erythromycin|vilanterol|ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|rituximab cetuximab paclitaxel docetaxel bevacizumab|roche europe france abbott germany|arcitumomab|we continue to strengthen our u . s . and european sales and marketing effort for cea-scan ( r ) ( entity ) as well as our european effort for leukoscan ( r ) ( sulesomab ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|prophylaxis ganciclovir universal cmv acyclovir|ganciclovir|cell / bone marrow and solid organ transplant patients at risk for cmv infection or with active cmv disease receive entity or valentity ( both marketed by f . hoffmann-la roche ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|roche cmv ganciclovir vc val|ganciclovir|valcyte , the oral pro-drug of cytovene ( entity ) , is the most widely prescribed anti-cmv medication in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ribavirin acyclovir oseltamivir interferons haart|ganciclovir|demonstrated activity in cell culture against both clinical isolates and viruses which have become resistant to current therapies , such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir pis tenofovir cmv acyclovir|ganciclovir|in 2008 , the market for cmv drugs was $600 million with entity controlling over 90% of the market .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|acyclovir ivermectin chlorhexidine azithromycin doxycycline|ganciclovir|development of products that have achieved cumulative sales of close to $2 , 000 , 000 , 000 , including monistat ; delfen cream , for herpes virus infection ; entity ; solaraze ; and maci .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir zidovudine corticosteroids ribavirin|ganciclovir|currently approved drugs for cmv retinitis are entity , foscarnet , cidofovir and fomivirsen , or vitravene .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir zidovudine cmv ribavirin|ganciclovir|the company is aware that a number of physicians have prescribed cytogam in combination with entity for the prevention of cmv disease in certain patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|acyclovir ivermectin chlorhexidine ganciclovir vaccinia|ganciclovir|products that have achieved cumulative sales of close to two billion dollars including , monistat , delfen cream for herpes virus infectons , entity , solaraze , and maci .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir bleomycin radioiodine doxorubicin hydroxyurea|ganciclovir|the hytk gene was used to mark the cells and allow for ablation of the cells by administration of entity if undesirable side effects resulted from the therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|suspension facs detail hybridomas duplicate|ganciclovir|cells will be stimulated with anti-ig antibodies , and selected in entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir ribavirin zidovudine tenofovir|ganciclovir|drug therapies approved or commonly used for cmv infection include antiviral compounds such as entity , valentity , cidofovir and foscarnet .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|toxin prodrug phage ribozyme nuclease|ganciclovir|cells containing the tk reporter will be killed by the entity unless a peptide inhibitor is present which inhibits the gene  s expression ( appendix h ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|bevacizumab ranibizumab dexamethasone voriconazole vancomycin|ganciclovir|entity is available in intravenous and oral doses , as well as in an intraocular implant form .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|thymidine ganciclovir acyclovir azt zidovudine|ganciclovir|in vivo activity for a bacterial strain which expresses the herpes simplex virus thymidine kinase gene for the conversion of entity to its toxic phosphorylated forms .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir ivig cmv rituximab|ganciclovir|in spite of trials conducted with entity for cmv prevention , entity is approved for use only as a preemptive therapy or treatment for cmv in hct .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|methotrexate thalidomide bortezomib rituximab acyclovir|ganciclovir|entity was limited in its ability to be used as a preventive therapy by the risk of significant neutropenia , which has
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir ribavirin tenofovir zidovudine|ganciclovir|dr . martin is the co-inventor of entity , a pharmaceutical now used for treatment of cytomegalovirus infection .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir zidovudine corticosteroids ribavirin|ganciclovir|the company believes that , with the exception of oral entity , none of the drugs described above are currently administered prophylactically prior to manifestation of cmv retinitis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|bevacizumab gonadotropins corticosteroids fsh hormones|ganciclovir|our one commercial product , vitrasert , primarily competes with treatments involving the systemic delivery of entity , a roche holdings ag product , and other drugs .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir pharmacokinetics cytomegalovirus suspension acyclovir|ganciclovir acyclovir ribavirin gemcitabine vsv|ganciclovir|such as tumor cells , the tk gene renders these cells sensitive to the toxic effect of the fda-approved antiviral drug , entity ( " gcv " ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|vehicle taxol equivalent imatinib others|talazoparib|bmn-673 means sellers proprietary compound known as bmn-673 or entity , having the chemical structure set forth in schedule 1 ( d ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|elsewhere industry others profit today|talazoparib|good presentation , and i agree that the offer from sanofi really substantially undervalued the business and the pipeline and especially entity .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|infliximab rituximab adalimumab etanercept methotrexate|talazoparib|we are excited about entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|temozolomide capecitabine everolimus sorafenib gemcitabine|talazoparib|for a select group of patients with hr-d breast cancer , entity , an oral parp inhibitor , was approved by the fda in 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|pay return consent submit disclose|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc . ### 11
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|lessons contributions approval funding itself|talazoparib|through acquisition of medivation in aug , 2016 , medivation acquired entity from biomarin in 2015 .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|rituximab infliximab adalimumab etanercept bortezomib|talazoparib|trials , and our future drug development activities , including those with respect to pidilizumab ( which is referred to as mdv9300 ) and entity ( which is referred to as mdv3800 ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|tal abbott roche mta ta|talazoparib|business development at medivation , identified and led the acquisition of a compound that was subsequently developed and approved as talzenna ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|approval chemoprevention nsclc oncology monotherapy|talazoparib|to start potential registrational trials  many of which will be the first initiated for a parp inhibitor  for entity in multiple other tumor types by the end of 2016 .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|move profit trade grow choose|talazoparib|similarly , the company acquired the worldwide rights to entity just seven months ago from biomarin , again demonstrating an ability to move quickly and boldly by 9 table of
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|trastuzumab rnai nanotechnology ngs proteomics|talazoparib|entity would complement our solid tumor pipeline with potential in a variety of cancers , both in our current pipeline such as
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|capecitabine sorafenib docetaxel bevacizumab everolimus|talazoparib|based on these data , we initiated a phase 1 / 2 clinical trial of the combination of telaglenastat plus entity in patients with rcc and tnbc in march 2019 .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|pay consent return submit disclose|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|rituximab infliximab etanercept adalimumab bortezomib|talazoparib|xtandi , we are well positioned for long-term sustainable growth with a promising pipeline that includes two late-stage wholly owned assets : entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|meaning insight insights ideas english|talazoparib|bofa merrill lynch - analyst can you talk a little bit about the process that you went through to acquire entity from biomarin?
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|dabigatran rivaroxaban clopidogrel enoxaparin sorafenib|temozolomide celecoxib everolimus oxaliplatin sorafenib|talazoparib|approved parp inhibitors include olaparib , entity and niraparib .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|topical herbal proprietary latest pharmaceutical|ropinirole|partner for jzp-4 , its potential treatment for epilepsy and bipolar , disorder and will no longer pursue development of jzp-7 , its entity gel product candidate for restless legs syndrome .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|investigational medicinal pharmaceutical generic proprietary|ropinirole|we were previously targeting an nda submission for our entity product candidate in calendar 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|platform abstract consortium initiative pharmaceuticals|ropinirole|staccato entity we have identified two new preclinical product candidates for development based on the single-dose staccato platform currently being manufactured in
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|capsaicin scopolamine botulinum pilocarpine atropine|ropinirole|entity oral spray is ideal for the geriatric population who may be suffering from dysphagia ( difficulty swallowing ) ; 85% of sufferers of
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|levodopa apomorphine pregabalin btx baclofen|ropinirole|our formulation of entity oral spray may represent a more convenient way for the patient or healthcare provider to deliver entity to patients suffering stiffness and / or tremors .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|levodopa apomorphine bromocriptine dopamine baclofen|ropinirole|entity is indicated for the treatment of the signs and symptoms of idiopathic parkinson  s disease .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|dopamine apomorphine levodopa pharmacotherapy bromocriptine|ropinirole|we completed a non-clinical study with long-term delivery of dopamine agonists which supports the potential to develop an implant delivering entity for treating parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 3)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|bromocriptine levodopa risperidone metoclopramide apomorphine|ropinirole|commonly prescribed dopamine agonists that directly activate dopamine receptors include agents such as mirapex ( pramipexole / bi ) and requip ( entity / glaxosmithkline ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|levodopa apomorphine bromocriptine chlorpromazine methylphenidate|ropinirole|japan , and in 2006 in the u . s . the competition for parkinson  s disease drugs includes l-dopa , cabergoline , bromocriptine , pergolide , lisuride and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|levodopa apomorphine bromocriptine melatonin methylphenidate|ropinirole|the new prolonged release tablet of entity is taken once daily , and is indicated for the treatment of parkinson  s disease ( pd ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|apomorphine bromocriptine levodopa methylphenidate dopamine|ropinirole|we have performed the preclinical development work on a transdermal formulation of entity , a proven and fda-approved dopamine agonist for treating parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|approved therapeutics pharmaceuticals tablets capsules|ropinirole|our proprietary pipeline also includes corplex entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|antipsychotic levodopa dopaminergic bupropion dopamine|apomorphine bromocriptine levodopa methylphenidate aripiprazole|ropinirole|entity is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of parkinson  s disease
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|drug|carvedilol metoprolol atenolol reduces valsartan|osteoporosis acupuncture sepsis epilepsy autism|nebivolol|the decrease in research and development expenses is the result of the completion of clinical studies related to entity , for which a nda was filed on april 30 , 2004 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|bupropion ketamine sertraline fluoxetine venlafaxine|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan inc . ( mylan ) and expires in 2020 and we submitted a patent term extension application to
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|managing treating worsening your decompensated|nebivolol|could you give us a little bit more color on the timing of the nda filing for entity congestive heart failure?
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|carvedilol metoprolol atenolol reduces valsartan|carvedilol metoprolol atenolol 1c valsartan|nebivolol|bystolic® ( entity ) , a beta-blocker for the treatment of hypertension , recorded sales of $142 . 9 millionin in the fourth quarter 2014 , an increase of
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|bupropion ketamine sertraline fluoxetine venlafaxine|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan laboratories inc . and expires in 2020 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|amlodipine valsartan carvedilol losartan pioglitazone|nebivolol|* trial 305 ( general population ) trial 202 ( african-american patients ) add-on therapy vs . placebo trial 321 ( entity added to current antihypertensive treatment )
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|carvedilol metoprolol atenolol reduces valsartan|melanoma paclitaxel docetaxel bevacizumab trastuzumab|nebivolol|brand segment r&d is primarily the result of the completion , during fiscal 2004 , of the phase iii clinical studies for entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|itself him marketing otc fda|nebivolol|today , we are announcing that the best available option is to out license entity to a major brand pharmaceutical company , which will co develop and commercialize this product .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|recurring rising financial sales excessive|nebivolol|eps to gaap diluted eps : adjusted diluted eps $ 0 . 26 mylan bertek and entity expenses ( $0 . 05 ) restructuring charges and other non-recurring expenses ( $0 . 02 ) contingent legal liability
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|ongoing entire approved nih innovative|nebivolol|we expect to experience increased research and development expenses in support of the entity clinical program , as well as milestone payments under our license agreement .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|carvedilol metoprolol atenolol reduces valsartan|vaccines carcinogenicity carcinogenesis epidemiology pharmacokinetics|nebivolol|the restructuring , while r&d expense increased as a result of an increase in ongoing studies , including those with respect to entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|admissions medicaid hospitalizations mammography prescriptions|nebivolol|the overall decrease is primarily the result of the outlicensing of entity , which occurred late in fiscal 2006 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|japan germany sweden brazil spain|nebivolol|the irs regarding whether the proceeds received by the company in connection with the 2008 sale of its rights in entity constituted a capital gain or ordinary income .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|drug|carvedilol metoprolol atenolol reduces valsartan|osteoporosis statins bevacizumab biologics aki|nebivolol|the increase was primarily attributable to research and development expense due to ongoing clinical studies related to entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|medicare bill gross medicaid price|nebivolol|number one , ed , can you walk me through the five-cent charge in entity and bertek expenses and point me to where i can find it on the p&l?
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|carvedilol metoprolol atenolol reduces valsartan|statins cardiology cardiologists stents telemedicine|nebivolol|the opportunity to launch entity will significantly expand our existing cardiovascular franchise .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol atenolol reduces valsartan|teaching residents instruction trainees graduates|nebivolol|changes of the king business and the lack of appropriate other acquisition alternatives we have chosen a different course for entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol atenolol reduces valsartan|losartan valsartan amlodipine sildenafil captopril|nebivolol|our flagship product , altaceò . this is a perfect fit with mylan because of its growing pipeline of proprietary products , including entity , a hypertension product .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|carvedilol metoprolol atenolol reduces valsartan|az bb carvedilol roche mb|nebivolol|bystolic ( entity ) , our beta-blocker indicated for the treatment of hypertension launched in january 2008 , achieved sales of $59 , 522 , an increase of $21 , 857
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol atenolol reduces valsartan|carvedilol salbutamol metoprolol atenolol amlodipine|nebivolol|for the same period last year , third party development costs were largely related to clinical trials for entity , aclidinium / formoterol , vilazodone and roflumilast .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|metronidazole clarithromycin ciprofloxacin mic pylori|metronidazole levamisole albendazole ganciclovir itraconazole|tinidazole|nitroimidazoles for use in the invention include metronidizole , ornidazole , secnidazole , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|metronidazole clarithromycin ciprofloxacin mic pylori|besides named beside defining termed|tinidazole|entity vaginal effervescent tablet the key component of entity vaginal effervescent tablet is entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metronidazole clarithromycin ciprofloxacin mic pylori|infliximab metronidazole methotrexate prednisone adalimumab|tinidazole|six ulcerative colits patients with ipaa ( 3 refractory pouchitis , 2 crohns disease , 1 irritable pouch syndrome ) received entity plus xifaxan or ciprofloxacin for 2-4 weeks .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|lif beads microparticles coated polyethylene|others artemisinin ipm ivermectin celecoxib|lifitegrast|( “r&d” ) was up 6% particularly due to investment in new uses for ldx ( the active ingredient in vyvanse ) , shp602 and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|drug|lif beads microparticles coated polyethylene|psoriasis osteoporosis osteoarthritis oab nsclc|lifitegrast|the new drug application for entity included data from four randomized , controlled clinical trials with more than 1 , 800 patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lif beads microparticles coated polyethylene|dexamethasone diclofenac dextrose moxifloxacin timolol|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lif beads microparticles coated polyethylene|bevacizumab cetuximab sorafenib rgd sunitinib|lifitegrast| shire plc has a small molecule integrin antagonist , entity , which is formulated for topical , ophthalmic delivery and is currently in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|lif beads microparticles coated polyethylene|pharmacotherapy ranibizumab acupuncture immunotherapy medicines|lifitegrast| if approved , shire would benefit from the launch of entity for dry eye disease in 2016 , and hopes to increase awareness , diagnosis and treatment of this condition .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lif beads microparticles coated polyethylene|curcumin thalidomide contains carboplatin paclitaxel|lifitegrast|leukocytes [ ] selected based on its properties for further development as a candidate to treat dry eye disease [ graphic omitted ] entity ( formerly sar 1118 ) mw 610 g / mol 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lif beads microparticles coated polyethylene|diclofenac fluorouracil moxifloxacin dexamethasone tobramycin|lifitegrast|these relate to the xiidra ( entity ophthalmic solution ) product which takeda had subsequently announced a sale agreement for .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|lif beads microparticles coated polyethylene|forward science therapeutics ahead oncology|lifitegrast|“our commitment to moving entity forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lif beads microparticles coated polyethylene|pharmaceuticals itself ranibizumab approved azithromycin|lifitegrast|shire plc recently received fda approval to market entity for the treatment of dry eye and will be launching the product in the u . s . restasis , and other products , have
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lif beads microparticles coated polyethylene|bevacizumab rosiglitazone everolimus sorafenib etanercept|lifitegrast|shire plc is developing its product candidate , entity , and is in pivotal phase 3 clinical trials in the u . s . shire has said it plans to resubmit an nda for entity in 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|lif beads microparticles coated polyethylene|approval example licensing indications consideration|lifitegrast|press release www . shire . com shire plans to submit a new drug application to fda for entity for dry eye disease in adults · fda submission planned for 1st quarter 2015 · shire forms business
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lif beads microparticles coated polyethylene|diclofenac pilocarpine moxifloxacin epinephrine dexamethasone|lifitegrast|these relate to the xiidra® ( entity ophthalmic solution ) product which takeda has subsequently announced a sale agreement for , as included in note 33 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|lif beads microparticles coated polyethylene|approval marketing licensing example registration|lifitegrast|of any of our product candidates , such as our planned submission of a new drug application to the fda for entity , may be delayed for any number of reasons and , once submitted ,
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lif beads microparticles coated polyethylene|sustainability others workshops fortification vaccines|lifitegrast|on shp602 ( formerly known as spd602 ) for iron overload and on development programs acquired through business development in 2013 , including entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lif beads microparticles coated polyethylene|diclofenac dexamethasone moxifloxacin timolol epinephrine|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra&#xae ; ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|lif beads microparticles coated polyethylene|occasion page board going request|lifitegrast|maybe to refresh the topic , on entity , obviously the other key near-term event with the october 25 pdufa date .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|lif beads microparticles coated polyethylene|adalimumab everolimus aripiprazole pioglitazone rituximab|lifitegrast|opus-3 , a randomized , double-masked , 12-week phase 3 study enrolled 711 patients to evaluate the efficacy and safety of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lif beads microparticles coated polyethylene|bevacizumab azithromycin moxifloxacin tacrolimus pregabalin|lifitegrast|in addition , patients treated with entity showed a statistically significant improvement in ocular discomfort and eye dryness , symptoms of dry eye disease , as reported by patients
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|lif beads microparticles coated polyethylene|desensitization washout tears trabeculectomy slit|lifitegrast|when i look at restasis relative to entity , in terms of efficacy measures , sustaining tear production and goblet cell density , i think restasis is a great option .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lif beads microparticles coated polyethylene|tacrolimus cyclosporine dexamethasone triamcinolone diclofenac|lifitegrast|in the united states , yet only two drugs are approved for dry eye disease treatment , restasis® ( cyclosporine 0 . 05% ) and xiidra® ( entity 5% ) .
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|thymidine lamivudine ganciclovir fluorouracil capecitabine|paclitaxel carboplatin doxorubicin oxaliplatin gemcitabine|floxuridine|the 1 : 1 molar ratio of irinotecan : entity was frequently synergistic and avoided antagonism whereas other ratios exhibited a loss of synergy and in some cases the appearance
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|thymidine lamivudine ganciclovir fluorouracil capecitabine|carboplatin gemcitabine doxorubicin paclitaxel dox|floxuridine|range of preclinical solid tumor models , cpx-1 consistently provided dramatic improvements in therapeutic efficacy over the unencapsulated free-drug cocktail of irinotecan : entity .
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|thymidine lamivudine ganciclovir fluorouracil capecitabine|doxorubicin docetaxel paclitaxel carboplatin liposome|floxuridine| cpx-1 is a liposomal formulation of irinotecan : entity , which is a clinical stage product candidate ;  cpx-8 is a hydrophobic docetaxel prodrug nanoparticle which is a preclinical stage
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|thymidine lamivudine ganciclovir fluorouracil capecitabine|paclitaxel gemcitabine oxaliplatin carboplatin capecitabine|floxuridine|scientific rationale of cpx-1 the combination of irinotecan and entity was screened for drug ratio dependent synergy in vitro in a panel of tumor cell lines .
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|thymidine lamivudine ganciclovir fluorouracil capecitabine|fluorouracil capecitabine oxaliplatin irinotecan gemcitabine|floxuridine|from 7 . 8 months to 12 . 0 months ( p = 0 . 05 ) for patients with advanced , unresectable colorectal liver metastases receiving sir-spheres and entity ( fudr ) vs fudr alone .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces qt potentiated metoprolol antidepressant|spain italy france az iran|eszopiclone|additionally , in early 2003 , sepracor filed an nda for estorra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|reduces qt potentiated metoprolol antidepressant|pharmaceuticals antimicrobials artemisinin medicines vaccines|eszopiclone|in exchange , sepracor permitted aventis to assign sepracors obligation to pay a royalty on sales of entity in the u . s . to a third party .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|reduces qt potentiated metoprolol antidepressant|baclofen theophylline cpap melatonin methylphenidate|eszopiclone|in addition , patients on entity reported improved daytime alertness ( p less than 0 . 005 ) and improved daytime ability to function ( p less than 0 . 001 ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|reduces qt potentiated metoprolol antidepressant|melatonin pregabalin aripiprazole gabapentin sertraline|eszopiclone|furthermore , patients treated with entity 2 mg reported significant improvements in daytime alertness ( p<0 . 03 ) and sense of physical well-being ( p<0 . 05 ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|reduces qt potentiated metoprolol antidepressant|cannabinoids pharmaceuticals cannabis benzodiazepines pesticides|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity outside of the united states , canada and mexico and with respect to several other compounds .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|reduces qt potentiated metoprolol antidepressant|investigational generic herbal proprietary pharmaceutical|eszopiclone|our entity product will be marketed by gsk in its territory primarily as lunivia® brand entity for the treatment of insomnia .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|reduces qt potentiated metoprolol antidepressant|pregabalin lamotrigine risperidone etanercept adalimumab|eszopiclone|no decline in therapeutic effect was observed on any outcome parameter over the course of the trial , and entity was well tolerated .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|reduces qt potentiated metoprolol antidepressant|curcumin artemisinin taxol resveratrol ivermectin|eszopiclone|upon approval of estorra , during which the fda would not approve an abbreviated new drug application for any product containing entity , the active ingredient of estorra .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|reduces qt potentiated metoprolol antidepressant|oxycodone sildenafil amlodipine pregabalin ibuprofen|eszopiclone|has filed an abbreviated new drug application ( anda ) with the u . s . food and drug administration ( fda ) for generic versions of entity tablets ( 1 mg , 2 mg and 3 mg ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces qt potentiated metoprolol antidepressant|capsules generic brands manufacturers brand|eszopiclone|products that we launched in the united states during the year ended march 31 , 2015 : product innovatorsbrand innovator entity lunesta® seprocor fenofibrate capsules
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|reduces qt potentiated metoprolol antidepressant|melatonin bupropion topiramate sertraline fluoxetine|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , which was approved in december 2004 by the fda and launched in the first quarter of 2005 , and rozerem® ( ramelteon ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|reduces qt potentiated metoprolol antidepressant|citalopram sertraline olanzapine quetiapine linezolid|eszopiclone|in clinical trials with entity , one case of overdose with up to 36 mg of entity was reported in which the subject fully recovered .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces qt potentiated metoprolol antidepressant|tablets name names inserts cigarettes|eszopiclone|the fda is currently reviewing our nda for estorra brand entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|reduces qt potentiated metoprolol antidepressant|cigarette name pharmaceutical allergen brand|eszopiclone|as a result of this policy , we capitalized $1 , 735 , 000 of lunesta brand entity inventory during the first quarter of 2005 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|reduces qt potentiated metoprolol antidepressant|cannabinoids benzodiazepines cannabis celecoxib aspirin|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity in japan and with respect to several other compounds .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces qt potentiated metoprolol antidepressant|next entire approved intended newer|eszopiclone|we cannot assure you that we adequately responded to the fdas concerns or that the entity nda will be approved .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|reduces qt potentiated metoprolol antidepressant|q10 3m topiramate xl cpap|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , marketed by sepracor , inc . , which was approved in december 2004 by the fda and launched in the first quarter of
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|reduces qt potentiated metoprolol antidepressant|youth psoriasis marketing approval japan|eszopiclone|assuming favorable results from the ongoing studies , we anticipate submitting an nda for entity to the fda , in 2002 , which , if approved , we would market under the name estorra .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces qt potentiated metoprolol antidepressant|contains approved offers marketed name|eszopiclone|other events on april 4 , 2005 , sepracor commercially launched lunesta brand entity 1 mg , 2 mg and 3 mg tablets for the treatment of insomnia .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|reduces qt potentiated metoprolol antidepressant|diazepam benzodiazepines midazolam levodopa propofol|eszopiclone|individuals have fully recovered from racemic zopiclone overdoses up to 340 mg ( 56 times the maximum recommended dose of entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|atropine antagonized scopolamine antagonize antagonists|oxycodone fentanyl epinephrine vancomycin lidocaine|atropine|between august and october , 2010 , we reintroduced entity , morphine , dextrose , and epinephrine prefilled syringes .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|magnesium ferrous copper codeine zinc|atropine|in november 2000 , we received our first fda approval to manufacture and sell diphenoxylate with entity sulfate tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|quinidine atropine magnesium propranolol metoprolol|atropine|for propranolol er driven by price , tempered by the impact of the second quarter 2017 launch of diphenoxylate hydrochloride and entity sulfate .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|hydrochloride timolol pilocarpine atropine phenylephrine|atropine|while macrodose entity 1% is currently fda-approved for pupil dilation in the united states , its significant side effect profile has impeded clinical utility
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|atropine antagonized scopolamine antagonize antagonists|atropine gentamicin colistin morphine cefotaxime|atropine|trobigard is designed for intramuscular self- or buddy-administration of entity sulfate and obidoxime chloride for pre-hospital intervention .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atropine antagonized scopolamine antagonize antagonists|pilocarpine timolol balanced lutein dexamethasone|atropine|anticipated milestone : initiate and complete phase iii vision trials in 2020 about micropine for progressive myopia micropine ( entity ophthalmic solution )
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|salbutamol copper magnesium atropine ferrous|atropine|“micropine product” means entity sulfate , as the sole active pharmaceutical ingredient , formulated and loaded into a cartridge for delivery using , and delivered by means
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atropine antagonized scopolamine antagonize antagonists|optics myopia glasses lenses topography|atropine|for example , our micropine program which is a micro-formulation of entity , is intended to slow myopia progression in the pediatric population .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|lidocaine ketamine methylprednisolone atropine amitriptyline|atropine|exposed to approximately 75% less nerve agent and then treated immediately with the current standard therapy , a three-drug cocktail of entity , 2-pam and diazepam .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|atropine antagonized scopolamine antagonize antagonists|atropine lidocaine amitriptyline morphine suramin|atropine|contract by dod valued at up to approximately $23 million to develop a multi-drug auto-injector for nerve agent antidote delivery ( entity and pralidoxime chloride ) , which we refer to as d4 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|atropine antagonized scopolamine antagonize antagonists|timolol epinephrine drops atropine lidocaine|atropine|despite activity , safety concerns such as pupil dilation , photosensitivity and accommodation difficulties associated with standard entity , 1% have tempered initial clinical adoption .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine antagonized scopolamine antagonize antagonists|melatonin pharmaceuticals retinoids ranibizumab acetazolamide|atropine|the first pipeline opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|atropine antagonized scopolamine antagonize antagonists|pharmaceuticals melatonin acetazolamide atropine pilocarpine|atropine|the first pipeline 4 table of contents opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|atropine antagonized scopolamine antagonize antagonists|benzodiazepines corticosteroids steroids oxime atropine|atropine|the standard of care for post-exposure treatment involves repeated doses of a cocktail of drugs including entity , oxime reactivators ( " 2-pam " ) and anti-convulsants .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atropine antagonized scopolamine antagonize antagonists|experts agencies standards committee nurse|atropine|the director ( nih od ) , and the ninds competition the current standard of care for nerve agent exposure is entity® and benzodiazepines .
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|midazolam hydrochloride naltrexone naloxone morphine|mtx racemic gsk inh thf|naldemedine| acquired rights to commercialize symproic® ( entity ) tablets 0 . 2 mg in the u . s . on april 4 , with bdsis sales force fully trained and actively promoting symproic as of may
OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|midazolam hydrochloride naltrexone naloxone morphine|pregabalin buprenorphine naltrexone naloxone oxycodone|naldemedine|shionogi & co . is developing entity , another mu-opioid receptor antagonist , for patients with oic .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methacholine asthmatics fev1 inhaled inhalation|roche 3m fx acetaminophen a1c|methacholine|the only fda-approved direct test is provocholine® ( entity ) , marketed by methapharm inc .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methacholine asthmatics fev1 inhaled inhalation|formaldehyde ozone toluene sevoflurane xylene|methacholine|entity is inhaled as a vapour and causes bronchial constriction in asthmatic patients .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine acetylcholine carbachol bradykinin adenosine|methacholine|the first category , known as direct challenge tests , use either histamine or entity to directly cause airway narrowing .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine acetylcholine tryptase bradykinin serotonin|methacholine|the response from the direct tests ( entity and histamine ) are not dependent on the presence of inflammatory cells and their mediators and have a poor sensitivity for
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine bronchodilator salbutamol histamine isoproterenol|methacholine|volume in 1 second ( fev1 ) > 65% ;  increase in fev1 of at least 12% with bronchodilator use over baseline fev1 ;  entity challenge test with a pc20 £ 8mg / ml .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 2)])|drug|methacholine asthmatics fev1 inhaled inhalation|allergen methacholine histamine allergic immediate|methacholine|entity challenge treatment differences ( pc20 ) performed 25h post-dose and 24h following an inhaled allergen challenge table 1 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine allergen histamine inhalation aspirin|methacholine|the primary phenotypes for analysis include lifetime history of asthma , age of asthma onset , entity challenge response , smoking history , and skin prick tests for twelve common allergens .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine salbutamol histamine mch feno|methacholine|aridol also had similar specificity to entity , ( 66% versus 70% respectively ) in subjects without exercise induced bronchoconstriction .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine histamine mch acetylcholine mannitol|methacholine|efficacy will be evaluated using standard measures of respiratory function , e . g . , fev1 , entity challenge , serial spirometry .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine mannitol acetylcholine bradykinin histamine|methacholine|s . spector et al . , mannitol inhalational challenge : will it replace entity or histamine?
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methacholine asthmatics fev1 inhaled inhalation|acetylcholine carbachol methacholine phenylephrine serotonin|methacholine|moreover , ck-2018571 relaxed entity pre-constricted tracheal rings in a concentration-dependent manner , suggesting its potential utility as a bronchodilator .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine histamine bronchodilator salbutamol mannitol|methacholine|the 500 mg tid treatment group , including serial spirometry , morning and evening peak flow rates and pc20 values in a entity challenge test ( common measures of respiratory function ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|methacholine asthmatics fev1 inhaled inhalation|methacholine mch histamine airways co2|methacholine|· adding vi to ff also provided further reduction of ahr as measured by entity responsiveness 24h after the allergen provocation .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|methacholine asthmatics fev1 inhaled inhalation|involves follows recommends necessitates utilizing|methacholine|provocholine diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma entity chloride immunoglobulins ivig 5% treatment
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|methacholine asthmatics fev1 inhaled inhalation|spirometry fev1 radiography scintigraphy lavage|methacholine|in comparison entity , an approved lung function test in the u . s . , identified 54% of cases .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methacholine asthmatics fev1 inhaled inhalation|serotonin acetylcholine histamine bradykinin dopamine|methacholine|examples include entity and histamine .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|methacholine asthmatics fev1 inhaled inhalation|evaluating assessing describing comparing examining|methacholine|to an individual or company to sell a product meta-analysis pooling and examining data from a number of studies entity inhalation test a test used in the diagnosis of asthma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|methacholine asthmatics fev1 inhaled inhalation|hba1c spirometry echocardiography colonoscopy crp|methacholine|of 501 patients , and the study showed that aridol performed as well or better than the only currently approved test , entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|morphine opioids baclofen ropivacaine bupivacaine|cytarabine|for safety reasons , continuous intrathecal infusion of entity is not a viable option .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cytarabine paclitaxel mic liposomal carboplatin|platinum bevacizumab docetaxel carboplatin paclitaxel|cytarabine|these patients typically receive frontline therapy , usually chemotherapy , including entity and an anthracycline , a therapy that has not changed in over 40 years .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|pegylated cationic injectable lyophilized encapsulated|cytarabine|products the products prepared for enzon by skyepharma are defined in the supply agreement including depocyt® , ( entity liposome injection , sky0101 ) formulation 1 . 5 ( us ) iii .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|methotrexate cytarabine cyclophosphamide corticosteroids dexamethasone|cytarabine|% can be achieved , and patients with good-risk or standard-risk chromosomal changes will typically receive post-remission therapy with high dose entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|cytarabine paclitaxel mic liposomal carboplatin|amiodarone propofol metformin methotrexate melatonin|cytarabine|entity is one of several drugs most commonly used for this therapy .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine daunorubicin dexamethasone atra mitoxantrone|cytarabine|in may 2007 , our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda after accrual of 268 patients .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine cyclophosphamide cytosine methotrexate cytidine|cytarabine|from the trial showed positive safety and response rate data for subjects treated with a combination of motixafortide and high-dose entity ( ara-c ) , or hidac .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine mitoxantrone atra bortezomib tmz|cytarabine|an investigator-sponsored phase i / ii trial in combination with entity for elderly patients with previously untreated aml was initiated in may 2008 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine fludarabine gemcitabine ribavirin capecitabine|cytarabine|a number of nucleoside drugs , such as gemcitabine and entity , also known as ara-c , both generic drugs , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine dexamethasone atra daunorubicin methotrexate|cytarabine|is in the efficacy portion of a phase 2 clinical trial for acute myeloid leukemia ( “aml” ) in combination with low-dose entity ( “ldac” ) and in combination with decitabine .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cytarabine paclitaxel mic liposomal carboplatin|methotrexate ceftriaxone mtx dexamethasone vancomycin|cytarabine|because the therapeutic half-life of entity in the csf is relatively short , frequent and repeated injections are necessary for effective treatment .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|amiodarone omeprazole theophylline erythromycin aspirin|cytarabine|certain compositions containing vosaroxin , with expiry in 2030 ; and · u . s . patent no . 7 , 968 , 565 claims a combination of vosaroxin and entity , with expiry in 2026 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cytarabine paclitaxel mic liposomal carboplatin|fluconazole digoxin omeprazole doxycycline levofloxacin|cytarabine|the rate of serious adverse events was 55 . 5% in the vosaroxin combination arm compared to 35 . 7% in the placebo and entity arm .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|cytarabine paclitaxel mic liposomal carboplatin|antidepressants buprenorphine opioids tablets antipsychotics|cytarabine|clinical trials have demonstrated , however , that depocyt provides certain clinical advantages versus generic entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine cyclophosphamide methotrexate epirubicin etoposide|cytarabine|patients who achieve a cr after induction will go on to receive consolidation therapy with high dose entity ( hidac ) with ento or placebo as per their randomization assignment .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|fludarabine cytarabine capecitabine etoposide hydroxyurea|cytarabine|a number of nucleoside drugs , such as gemcitabine , or gemzar® , from eli lilly , and entity , also known as ara-c , a generic drug , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|cytarabine paclitaxel mic liposomal carboplatin|doxorubicin cytarabine carboplatin paclitaxel liposomal|cytarabine|our lead product is vyxeostm , a nano-scale liposomal formulation of entity : daunorubicin , completed a phase 3 clinical trial for the treatment of acute myeloid leukemia ( aml ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cyclophosphamide delivered carboplatin ifosfamide doxorubicin|cytarabine|high-intensity induction chemotherapy is typically entity plus an anthracycline ( so called 7+3 ) administered over a 28-day cycle .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine paclitaxel mic liposomal carboplatin|cytarabine daunorubicin dexamethasone atra mitoxantrone|cytarabine|our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda in may 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|cytarabine paclitaxel mic liposomal carboplatin|etoposide hydroxyurea doxorubicin adriamycin methotrexate|cytarabine|entity acts by inhibiting a vital enzyme in dna synthesis , resulting in death of a dividing cell .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|inhaled topical parenteral intranasal subcutaneous|mometasone|three of the patients who responded received entity steroids tapered to zero by day 21 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide betamethasone hydrocortisone tacrolimus dexamethasone|mometasone|we are also developing a topical water-based hydrogel formulation of entity , a medium-potency steroid , primarily for the treatment of atopic dermatitis .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide betamethasone salbutamol amlodipine fentanyl|mometasone|to $160 million in the first six months of 2013 compared with the same periods of 2012 . global sales of dulera ( entity furoate / formoterol fumarate dihydrate )
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide triamcinolone dexamethasone prednisolone betamethasone|mometasone|^ nasonex and entity are currently the only other intranasal steroids approved for the treatment of nasal polyps .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|chitosan alginate plga pva biodegradable|mometasone|we are currently in formulation development with entity hydrogel and expect to file an investigational new drug application , or ind , in 2006 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide salbutamol spacer mas sal|mometasone|indacaterol as a single agent and in combination with an ics ( entity ) , is being developed by novartis and schering-plough .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide betamethasone ketorolac triamcinolone prednisolone|mometasone|respiratory global sales of nasonex ( entity furoate monohydrate ) , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , increased 3% in the first quarter of
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|betamethasone timolol testosterone naf budesonide|mometasone|sc loading dose followed by q8w 150mg sc and ( iii ) placebo , in each case concomitant with 400 micrograms daily of entity furoate nasal spray .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|betamethasone mom methotrexate tacrolimus budesonide|dexamethasone hydrocortisone prednisolone betamethasone cortisone|mometasone|crx-191 contains a mid-potency glucocorticoid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|betamethasone potassium timolol testosterone atropine|mometasone|a decision issued in june 2013 held that the merck patent covering entity furoate monohydrate was valid , but that it was not infringed by apotex corp . s proposed product .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|betamethasone mom methotrexate tacrolimus budesonide|dexamethasone budesonide hydrocortisone prednisolone triamcinolone|mometasone|crx-191 contains a mid-potency glucocorticosteroid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|betamethasone mom methotrexate tacrolimus budesonide|betamethasone budesonide testosterone timolol erythromycin|mometasone|patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo , each in combination with entity furoate nasal spray as background therapy .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide salbutamol theophylline prednisolone prednisone|mometasone|sch 418131 , mff , is a combination of two previously approved drugs for the treatment of asthma : entity ( asmanex ) and formoterol ( foradil ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|corticosteroid topical vehicle dermatological cosmetic|mometasone|ovixan® is an improved prescription entity cream for the treatment of psoriasis and eczema , and oviderm® is a moisturizer for the treatment of dry skin .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|betamethasone mom methotrexate tacrolimus budesonide|betamethasone budesonide salbutamol timolol flu|mometasone| qmf149 ( indacaterol acetate / entity furoate ) is a once daily fixed-dose combination being investigated in asthmatic patients who are uncontrolled on an inhaled corticosteroid .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|theophylline salbutamol atropine anticholinergic budesonide|mometasone|novartiss qvm-149 ( entity / glycopyrronium / indacaterol ) is under review by the ema for asthma .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide salbutamol triamcinolone hydrocortisone betamethasone|mometasone|during the first quarter of 2004 is primarily due to the purchase of raw materials related to the eligard , atrisone , entity and fluticasone products .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|betamethasone mom methotrexate tacrolimus budesonide|css corticosteroids scl cls tcs|mometasone|prior to treatment with nomacopan ( coversin ) , two out of the three patients were already on topical corticosteroids ( entity ) while a third was naïve to steroid treatment .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide salbutamol dexamethasone theophylline prednisolone|mometasone|new combinations of formoterol with ciclesonide , fluticasone or entity are being developed by sanofi-aventis , abbott ( with skyepharma ) , and novartis ( with schering-plough ) respectively .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|betamethasone mom methotrexate tacrolimus budesonide|budesonide betamethasone octreotide flu erythromycin|mometasone|nasonex , or entity furoate nasal spray , is currently the only other branded ins approved by the fda for the treatment of nasal polyps .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|bupivacaine epinephrine lidocaine sevoflurane betamethasone|prilocaine|phn to receive the qutenza patch application after a 60-minute pretreatment with an fda-approved topical anesthetic ( 2 . 5% lidocaine / 2 . 5% entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|bupivacaine ropivacaine epinephrine fentanyl lidocaine|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two , well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine adrenaline bupivacaine dexamethasone chlorpromazine|prilocaine|emla ( lidocaine + entity ) is a local anaesthetic for topical application .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|bupivacaine ropivacaine epinephrine fentanyl dexmedetomidine|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine bupivacaine adrenaline dexamethasone chlorpromazine|prilocaine|> emla ( lidocaine and entity ) is used as a local anaesthetic for topical application to prevent pain associated with injections and superficial surgical procedures .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine dexamethasone bupivacaine betamethasone lidocaine|prilocaine|the skin permeation data compares a 2 . 5% lidocaine gel and the emla cream , which contains 2 . 5% lidocaine and 2 . 5% entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine lidocaine bupivacaine betamethasone dexamethasone|prilocaine|this product in the third quarter of 2018 . on july 2 , 2018 , we announced approval of an anda for lidocaine and entity cream usp , 2 . 5% / 2 . 5% .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|lidocaine max usa bupivacaine lma|prilocaine|local intracervical anesthetic block is achieved using 8 . 8 ml citanest ( entity ) with octapressin .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine dexamethasone betamethasone ciprofloxacin adrenaline|prilocaine|in particular , the dojs subpoena to impax focused on four generic medications : digoxin tablets , terbutaline sulfate tablets , entity / lidocaine cream , and calcipotriene topical solution .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|hydrochloride name cover alfa acetate|prilocaine|number of products marketed under lidocaine entity topical cream 1 number of product
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|epinephrine adrenaline bupivacaine dexamethasone chlorpromazine|prilocaine|> emla ( lidocaine + entity ) is used as a local anaesthetic for topical application .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lidocaine hydrochloride bupivacaine cocaine chlorhexidine|xyl mep artic lignoc proc|prilocaine|for example , one non-injectable , subsurface local anesthetic commercially available today is oraqix® ( lidocaine and entity periodontal gel ) .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|tot tn dox aq ta|dexrazoxane|totect&#xa0 ; &#xae ; &#xa0 ; ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|tacrolimus fk506 methylprednisolone prednisolone rapamycin|dexrazoxane|bulk drug substances the muscle relaxants atracurium besylate , pancuronium bromide and vecuronium bromide , the immunosuppressant drug cyclosporine and the prodrug entity .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|doxorubicin dox anthracycline trastuzumab epirubicin|dexrazoxane|totect® ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|anthracycline doxorubicin adriamycin daunorubicin quinone|dexrazoxane|entity metabolites trap the iron ions involved in the process which leads to myocardial damage caused by anthracycline oncolytic agents such as doxorubicin .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|artemisinin ivermectin vancomycin ffp aat|dexrazoxane|we launched totect during a national shortage of entity in late 2017 , resulting in strong initial demand for the product .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|misoprostol mesh curcumin rituximab crt|dexrazoxane|entity is manufactured using a proprietary process covered by patents filed in several countries .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|pharmaceuticals atropine quinine digoxin cocaine|dexrazoxane|( f ) " cardioxane-trademark- " means the substance known by the chemical name of entity , and any analogues or derivatives thereof .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|pharmaceuticals medicines vaccines tablets cigarettes|dexrazoxane|sicor s . p . a . manufactures entity according to a proprietary process covered by process patents filed in many countries .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|doxorubicin ketamine lidocaine trastuzumab vincristine|dexrazoxane|the companys entry into the oncology specialty includes two initial supportive care medications : ethyol® ( amifostine ) injection and totect® ( entity hydrochloride ) injection .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|powder ready capsules trastuzumab tablets|dexrazoxane|zinecard ( r ) ( entity for injection ) sold in the u . s . and canada , is a preparation for reducing cardiac side effects in women with metastatic
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|equipment cigarettes brands supplies chemicals|dexrazoxane|he oversaw the distribution of our new totect brand during a national shortage of entity resulting in many new customer relationships for the company .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|dox adm anthracycline doxorubicin aq|dexrazoxane|apricus bio currently markets totect® ( entity hcl ) , the only drug approved in the us for the treatment of anthracycline extravasation .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|partnerships cooperation collaboration expertise projects|dexrazoxane|sicor s . p . a . developed entity with chiron bv , including performing clinical trials , developing dosage form manufacturing , marketing and sales .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|pharmaceutical pharmacological pharmacology medicinal patent|dexrazoxane|totect was acquired by clinigen in march 2016 to expand its entity portfolio and enter the u . s . market .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|doxorubicin adriamycin taxol aq dox|dexrazoxane|” about totect® ( entity ) totect is an anthracycline extravasation agent approved by the united states food and drug administration .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|dox doxorubicin liposomal paclitaxel anthracycline|dexrazoxane|totect® ( entity hcl ) was approved by the fda in 2007 for the treatment of anthracycline extravasation , which is the leaking of chemotherapy
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|adenovirus adenoviruses vaccines doxorubicin ganciclovir|dexrazoxane|administration of entity with such oncolytic agents protects tissues of the heart and allows for higher dosages of the oncolytic agent .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|doxorubicin adriamycin trastuzumab epi dox|dexrazoxane|about totect® ( entity ) injectiontotect is an anthracycline extravasation agent approved by the fda .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|pharmaceutical proprietary patent marketing pharmacology|dexrazoxane|totect was acquired by clinigens specialty pharmaceuticals ( sp ) division in march 2016 to expand its entity portfolio for the u . s . market .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|reduces antidepressant clozapine haloperidol anxiolytic|oseltamivir diltiazem bupropion donepezil oxycodone|dexrazoxane|totect® cumberland announced fda approval of new labeling of totect® ( entity hydrochloride ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|ingredients api ingredient tablets glibenclamide|phenylephrine|each 5ml dose contains the api entity hci , pyrilamine maleate and dextromethorphan hbr .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|diclofenac acetaminophen ibuprofen dexamethasone tramadol|phenylephrine|european medicines agencys committee for medicinal products for human use had adopted a positive opinion for omeros drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|phenylephrine capsaicin neomycin lidocaine pilocarpine|phenylephrine|pse also competes against entity , an alternate nasal decongestant available in non-prescription products .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|phenylephrine ketamine clonidine hydrochloride yohimbine|phenylephrine|biorphen ( entity hcl injection ) is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|diclofenac dexamethasone ketorolac bevacizumab epinephrine|phenylephrine|the companys drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% is marketed for use during cataract surgery or intraocular lens ( iol ) replacement to maintain
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|pharmaceutical generic annual pesticide manufacturing|phenylephrine|ongoing entity supply disruptions from 503b compounding facilities , including the announced shutdown of compounding industry leader pharmedium in january , have highlighted the
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|caffeine neomycin lecithin lactose mannitol|phenylephrine|otc products contain any one of several active ingredients including glycerin , entity , pramoxine , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|diclofenac dexamethasone bevacizumab acetaminophen ketorolac|phenylephrine|our marketed drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% was broadly launched in the u . s . in april 2015 for use during cataract surgery or intraocular
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|nifedipine verapamil diltiazem propranolol propofol|phenylephrine|ventrus is also required to reimburse s . l . a . for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|verapamil nifedipine propranolol metoprolol atenolol|phenylephrine|is also required to reimburse s . l . a . pharma for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|scopolamine caffeine ibuprofen atropine codeine|phenylephrine|these products generally contain active ingredients such as acetaminophen , dextromethorphan , diphenhydramine , guaifenesin , loratadine , entity , and pseudoephedrine .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|lidocaine gtn nitroglycerin capsaicin pilocarpine|phenylephrine|: 267  270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|metoclopramide cimetidine codeine ranitidine propranolol|phenylephrine|aldex ct is an antihistamine / decongestant combination administered orally in a chewable tablet form containing the api diphenhydramine hcl and entity hcl .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|diclofenac dexamethasone ketorolac acetaminophen bevacizumab|phenylephrine|our marketed drug product omidria™ ( entity and ketorolac injection ) 1% / 0 . 3% is approved in the u . s . for use during cataract surgery or intraocular lens , or iol , replacement
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|pe ranibizumab phenylephrine paclitaxel ppe|phenylephrine|microdose delivery of entity 10% ( pe - µd ) was associated with significantly less systemic exposure than traditional eye drops ( pe 10% ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|diclofenac acetaminophen fentanyl dexamethasone oxycodone|phenylephrine|application seeking approval from the u . s . food and drug administration to market a generic version of the companys drug omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|propofol lidocaine verapamil ondansetron midazolam|phenylephrine|on june 28 , 2013 , the group filed an nda for vazculep ( entity hydrochloride injection ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|metronidazole lidocaine capsaicin silicone nitroglycerin|phenylephrine|entity gel ( ven 308 ) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis , an fda orphan indication .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|paclitaxel docetaxel tams oxaliplatin chemicals|phenylephrine|because of the extensive patient exposure to entity , we intend to develop ven 308 as a topical formulation through a section 505 ( b ) nda .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|phenylephrine phentolamine antagonized hydrochloride evoked|lidocaine gtn nitroglycerin capsaicin pilocarpine|phenylephrine|: 267 - 270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel carboplatin capecitabine docetaxel gemcitabine|pemetrexed|in the th-302 plus entity arm , th-302 is administered intravenously on days 1 and 8 of a 21 day cycle .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|methotrexate hydroxyurea pemetrexed tenofovir mitoxantrone|pemetrexed|obtain approval for talotrexin , we will compete with existing antifolate therapies currently being sold by pfizer ( trimetrexate ) , eli lilly & co . ( entity ) and novartis ( edatrexate ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|ow tw dw yr ww|pemetrexed|pth-305 : nsclc ( w / entity ) 2 / 2006 to 6 / 2007 400 , 600 136 138 os was lower in talabostat vs placebo .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|propofol omeprazole lidocaine rosiglitazone epinephrine|pemetrexed|eagle  s solution : ep-5101 ( pemfexy™ ) ep-5101 is an rtd liquid formulation of entity .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel etoposide ifosfamide gemcitabine rituximab|pemetrexed|interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , entity and bavituximab .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|gemcitabine paclitaxel doxorubicin pemetrexed cetuximab|pemetrexed|administered as monotherapies , these include entity ( alimta® ) , docetaxel ( taxotere® ) , or erlotinib ( tarceva® ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel gemcitabine etoposide pemetrexed docetaxel|pemetrexed|the addition of apatorsen to carboplatin and entity therapy did not demonstrate an overall survival benefit in the study ( hr= 1 . 067 ; 80% ci : 0 . 838-1 . 359 ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|hence thereafter meanwhile next accordingly|pemetrexed|entity , supply agreement term sheet in december 2016 , we entered into a binding term sheet with nang-kuang pharmaceutical co . , ltd and
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|gemcitabine carboplatin paclitaxel doxorubicin pemetrexed|pemetrexed|of the thirty-two patients with relapsed or refractory nsclc treated with th-302 in combination with either docetaxel or entity , eight patients achieved prs and fourteen patients achieved sd .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel etoposide gemcitabine pemetrexed docetaxel|pemetrexed|·a phase ib ist evaluating bavituximab in combination with carboplatin and entity in up to 25 patients with previously untreated stage iv nsclc .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|docetaxel gemcitabine paclitaxel doxorubicin etoposide|pemetrexed|with docetaxel in metastatic squamous nsclc that has progressed after previous therapy ( arm b ) ; or · in combination with entity and cisplatin in mesothelioma ( arm c ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|pregabalin bevacizumab capecitabine topiramate etanercept|pemetrexed|entity is dosed according to its package insert .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|packaging contraception manufacturing sterilization manufacture|pemetrexed|which we allege infringement against apotex inc . ( apotex ) in response to its application to market products using alternative forms of entity .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel gemcitabine etoposide capecitabine pemetrexed|pemetrexed|the aim of the trial is to determine if adding apatorsen to carboplatin and entity therapy could extend pfs outcome .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|aspirin clopidogrel statins methotrexate metformin|pemetrexed|the second 400-patient trial , evaluating the combination of talabostat with entity versus placebo and entity opened to enrollment in february 2006 .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|capecitabine sorafenib gefitinib gemcitabine cetuximab|pemetrexed|each study will combine pf-3512676 with either avastin® ( bevacizumab ) , erbitux® ( erlotinib ) or alimta® ( entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|immunotherapy chemoradiotherapy sunitinib bevacizumab sequentially|pemetrexed|patients continued entity with weekly apatorsen or placebo infusions as maintenance treatment until disease progression if they completed a minimum of 3 cycles of chemotherapy treatment .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|roche tacrolimus mitoxantrone everolimus enoxaparin|pemetrexed|some of our competitors include pfizer ( trimetrexate ) , eli lilly & co . ( entity ) , novartis ( edatrexate ) , and allos ( pdx ) , respectively .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|gefitinib erlotinib sunitinib bevacizumab tki|pemetrexed|strata 1 and 3 also had maintenance entity or continued egfr-tki therapy , respectively .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pemetrexed erlotinib paclitaxel docetaxel bortezomib|paclitaxel gemcitabine pemetrexed docetaxel etoposide|pemetrexed|the denali trial is testing demcizumab with entity and carboplatin versus entity and carboplatin alone in first-line advanced non-small cell lung cancer patients .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|quercetin genistein inhibits radix inhibit|formulated whose topical promising ingredient|moxidectin|both products  entity formulations offer numerous advantages over traditional deworming agents .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|quercetin genistein inhibits radix inhibit|licensed veterinary topical medicinal patent|moxidectin|cydectin , a entity product to control parasites in animals , will have patent protection until at least 2011 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|drug|quercetin genistein inhibits radix inhibit|injectable pharmaceutical otc equine transdermal|moxidectin|the first entity formulation for horses , equest gel , was launched in new zealand .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|historical comparator historic comparative adjuvant|oxaliplatin|this data represents a five-fold improvement to results seen from the entity arm of the study .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|trastuzumab bevacizumab pfs chemotherapeutic tamoxifen|oxaliplatin|also performed a gene identification study which analyzed over 700 new genes , and identified 16 genes as being predictive of entity benefit for use in patients with stage iii disease .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|statins medicines biologics pharmaceuticals pregabalin|oxaliplatin|in 2010 ) , following a court ruling barring manufacturers of generics in the u . s . from selling their unapproved generic versions of entity from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|oxaliplatin irinotecan capecitabine gemcitabine sorafenib|oxaliplatin|currently in clinical trials , including trials for hormone refractory prostate cancer , inoperable liver cancer , and in combination with capecitabine or entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|fluorouracil anthracycline capecitabine irinotecan platinum|oxaliplatin|the company began offering the oncotype dx colon cancer test for use in patients with stage iii disease treated with entity containing adjuvant therapy .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|oxaliplatin irinotecan gemcitabine paclitaxel bevacizumab|oxaliplatin|other chemotherapies include capecitabine ( xeloda® ) , entity ( eloxatin® ) , fluorouracil or leucovorin .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|biologics statins pharmaceuticals medicines risperidone|oxaliplatin|in the first half of 2010 ) after a court ruling barred generics manufacturers from selling their unauthorized generic versions of entity in the united states from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|chemotherapeutic irinotecan capecitabine oxaliplatin adjuvant|oxaliplatin|two weeks in patients with advanced non-small cell lung cancer ; and ø a u . s . phase iii trial in patients undergoing treatment with entity regimens for advanced colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|epirubicin doxorubicin etoposide carboplatin paclitaxel|oxaliplatin|marketed products in oncology include padexol injection ( paclitaxel ) , didox capsule ( doxifluridine ) , oxp injection ( entity ) and crabcan injection ( irrinotecan ) .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|gemcitabine carboplatin capecitabine oxaliplatin paclitaxel|oxaliplatin|entity , a formulation of dach platinum , is a chemotherapeutic which was initially approved in france and in europe in 1999 for
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|generic cosmetic proprietary medicinal prototype|oxaliplatin|on june 30 , 2010 , the company ceased selling sun pharmas entity product in the united states market , pending the appeal .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|paclitaxel etoposide docetaxel gemcitabine carboplatin|oxaliplatin|the originator of the drug , and several generic manufacturers ; ▪ carboplatin , marketed by bristol-myers squibb in the us ; and ▪ entity , marketed exclusively by sanofi-aventis .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|subcutaneous intravitreal once botulinum intramuscular|oxaliplatin|entity injection 50mg / 10ml and 100mg / 20ml are the ab-rated generic versions of eloxatin® , which had annual sales of approximately $1 . 4 billion for
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|carboplatin doxorubicin oxaliplatin gemcitabine cyclophosphamide|oxaliplatin|other combinations of gemcitabine with cisplatin , entity , irinotecan or docetaxel tested in phase 3 trials have not been of superior benefit to gemcitabine alone .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|oxaliplatin irinotecan uracil bevacizumab cyclophosphamide|oxaliplatin|for most patients , initial chemotherapy is based on folfox ( 5-fu , leucovorin and entity ) , or similar agents .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|pharmaceuticals biologics medicines therapeutics opioids|oxaliplatin|the growth was driven by an increase in specialty injectable pharmaceuticals , primarily a result of the third-quarter launch of entity in solution form in the united states .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|gemcitabine doxorubicin carboplatin paclitaxel docetaxel|oxaliplatin|demonstrated preliminary evidence of efficacy but grade 2 innate immune adverse effects were seen with standard doses of gemcitabine and entity and 10 µg / kg doses of mt-3724 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|oxaliplatin irinotecan capecitabine cetuximab gemcitabine|oxaliplatin|aroplatin aroplatin is a novel liposomal formulation of a third-generation platinum chemotherapeutic structurally similar to entity , a recently approved treatment for colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|intravitreal subcutaneous silicone disposable intramuscular|oxaliplatin|on august 11 , 2009 , teva commenced sales of its 50mg / 10ml and 100mg / 20ml entity injection products .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|capecitabine oxaliplatin paclitaxel docetaxel irinotecan|gemcitabine oxaliplatin carboplatin capecitabine pemetrexed|oxaliplatin|entity , a compound of dach platinum , is a chemotherapeutic which was initially approved in europe in 1999 for the treatment of
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|thyroxine gh thyrotropin oestrogen testosterone|levothyroxine|skin reactions , hypothyroidism in patients taking entity replacement , gi perforation , in some cases fatal and tumor lysis syndrome , which can be life threatening , have also been reported
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|alendronate omeprazole diclofenac usp acetaminophen|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales decreased to $26 million during the second quarter ended june 30 , 2007 from $29 million during the second
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac losartan mycophenolate generic alendronate|levothyroxine|if the fda were to determine that another entity sodium product is bioequivalent to levoxyl® , generic substitution for levoxyl® may become possible which could result in a decrease in
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|mycophenolate losartan lithium elemental generic|levothyroxine|could be affected by future actions of the fda and by uncertainty in the entity sodium product market .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|medicare medicaid cms congress industry|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement with entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|alendronate usp omeprazole diclofenac acetaminophen|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales totaled $32 million during the fourth quarter and $100 million for the year ended december 31 , 2007 , compared
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac alendronate losartan enoxaparin mycophenolate|levothyroxine|in december 2004 , the entity sodium tablet product received the ab rating to synthroid® .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac mycophenolate enoxaparin diltiazem phenytoin|levothyroxine|on august 14 , 1997 , the fda announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 1)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diltiazem omeprazole alendronate diclofenac injectable|levothyroxine|net sales of levoxyl ( r ) ( entity sodium tablets , usp ) equaled $28 . 7 million during the first quarter ended march 31 , 2004 , a decrease of 14% from $33 . 2
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|medicines tablets pharmaceuticals antimicrobials biologics|levothyroxine|volumes were favorably impacted due to increased sales of entity as customer demand increased in anticipation of the transition of the product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|labor healthcare readiness residents leadership|levothyroxine|complementing our second quarter performance was a well-executed plan associated with the transition of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac mycophenolate fentanyl penicillin ciprofloxacin|levothyroxine|nitrofurantoin during our 180-day exclusivity period ; the delay in the launch of our fentanyl product and the regulatory actions surrounding entity sodium .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac alendronate phenytoin losartan enoxaparin|levothyroxine|worldwide agreement with jerome stevens pharmaceuticals , inc . to market and distribute jerome stevens  nda ( new drug application ) approved form of entity sodium , usp tablets .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac losartan alendronate mycophenolate enoxaparin|levothyroxine|of $2 , 220 , 931 due to an improvement in timely collections , and the launch of the company  s new product sales campaign for entity sodium tablets in april 2003 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac mycophenolate quaternary hypertonic enoxaparin|levothyroxine|drug administration , which we refer to as the fda ,  announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|diclofenac generic losartan naproxen lithium|levothyroxine|this dual approval will now allow pharmacists to substitute entity sodium tablets for both dominant brands .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|thyroxine alendronate triiodothyronine amiodarone pilocarpine|levothyroxine|thyromed chewable tablets contain the active ingredient entity sodium , which is a clinically proven replacement for the naturally occurring hormone secreted by the thyroid gland .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|alendronate hydrocortisone spironolactone equine phenytoin|levothyroxine|these chewable tablets , which are administered daily for the life of the dog , provide entity sodium , a replacement therapy for the hormone normally produced by the dog .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|medicare healthcare medicaid canada reimbursement|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement for entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|levo amiodarone pharmacokinetics thyroxine trastuzumab|generic mycophenolate diclofenac losartan potassium|levothyroxine|application for an equivalent product after august 14 , 2001 must submit an anda seeking approval of a generic substitute for a entity sodium product with an approved nda .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|sulphate hydrochloride chloride mic dissolved|betamethasone triamcinolone bleomycin hydrocortisone corticosteroids|neomycin|triamcinolone acetonide and entity paste used for neurodermatitis circumscripta and chronic eczema .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|sulphate hydrochloride chloride mic dissolved|rifampicin gentamicin doxycycline ribavirin minocycline|neomycin|existing drugs , such as tobramycin , entity , zithromax® and zyvox® , demonstrate that successful medicines can modulate rna function .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|sulphate hydrochloride chloride mic dissolved|tetracycline doxycycline erythromycin chloramphenicol minocycline|neomycin|our products that contain virginiamycin , oxytetracycline or entity are classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|sulphate hydrochloride chloride mic dissolved|tetracycline erythromycin doxycycline chloramphenicol minocycline|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antibacterials .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sulphate hydrochloride chloride mic dissolved|gentamicin zinc clindamycin chlorhexidine neomycin|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sulphate hydrochloride chloride mic dissolved|clindamycin vancomycin ciprofloxacin penicillin gentamicin|neomycin|the company believes that current antibiotic therapies , including entity and metronidazole , are inadequate treatments , however , due to their limited antibacterial spectrum and side effects .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulphate hydrochloride chloride mic dissolved|casein hc cg methionine arginine|neomycin|the abnormal plasma amino acid pattern characterized by decreased levels of bcaas and elevated levels of aaas , as compared to entity , which was used as an active control .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|sulphate hydrochloride chloride mic dissolved|midazolam citalopram phenytoin diazepam etoposide|neomycin|nexavar exposure decreases when coadministered with oral entity .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|sulphate hydrochloride chloride mic dissolved|tetracycline erythromycin doxycycline chloramphenicol minocycline|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|sulphate hydrochloride chloride mic dissolved|gentamicin neomycin zinc clindamycin copper|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate ( neosporin-registered trademark- ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir lamivudine adv hepatitis ade|tenofovir|the later stages of the phase iii clinical trials for adefovir dipivoxil will not arise in the clinical trials for entity df or that we will achieve adequate treatment benefits .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tenofovir lamivudine acetate ftc discontinuation|lamivudine adv tenofovir rbv lam|tenofovir|initiate in 2017 the phase 2b clinical trial to evaluate sb 9200 as a monotherapy and in combination with viread ( entity ) targeting approximately 200 patients with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|lamivudine tenofovir ribavirin etv tdf|tenofovir|entity has potent activity against chronic hepatitis b . it is particularly useful in patients who have developed drug resistance to other
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir erythromycin lamivudine morphine testosterone|tenofovir|unenforceable and / or will not be infringed by teva  s manufacture , use or sale of a generic fixed-dose combination of emtricitabine and entity disoproxil fumarate .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir lamivudine etv tdf zidovudine|tenofovir|the most commonly used therapy for chronic hbv is life-long suppressive therapy with nrtis , like entity or entecavir .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir erythromycin budesonide inhaled doxycycline|tenofovir| viread sales of viread® ( entity disoproxil fumarate ) were $189 . 4 million in the third quarter of 2005 , a two percent decrease from $193 . 9 million in the
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|pis lamivudine zidovudine tenofovir mvc|tenofovir|use of viread should be considered for treating adult patients with hiv-1 strains that are expected to be susceptible to entity as assessed by laboratory testing or treatment history .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir lamivudine acetate ftc discontinuation|ftc tdf nvp ddi azt|tenofovir|nrtis , such as epivir ( 3tc ) , emtriva ( ftc ) , viread ( entity ) , retrovir ( azt ) and zerit ( d4t ) , have become the predominant class of drugs in hiv therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir penc cid ribavirin bn|tenofovir|txl is a highly potent analog of the antiviral drug entity df ( viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|formerly pegylated termed named liposomal|tenofovir|which gilead is funding and conducting a phase 2 clinical trial examining the co-administration of inarigivir and vemlidy® 25 mg ( entity alafenamide ) in patients infected with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir minnesota roche fumarate ciprofloxacin|tenofovir|addendum to entity disoproxil fumarate manufacturing supply agreement the parties hereby acknowledge and agree to the following :
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|ribavirin acyclovir ganciclovir ritonavir efavirenz|tenofovir|nucleotide compound , uses the same proprietary lipid technology as cmx001 to deliver high intracellular concentrations of another potent antiviral drug , entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir ferric fumarate potassium depot|tenofovir|and in april 2013 , gilead and teva reached an agreement in principle to settle the lawsuit on the patents covering entity disoproxil fumarate contained in the atripla*
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|tenofovir lamivudine acetate ftc discontinuation|grounds ground prem premise assumption|tenofovir|we cannot predict the outcome of these proceedings on our entity df patent application .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir lamivudine acetate ftc discontinuation|vaccines medicines kits insecticides ads|tenofovir|in addition , in late 2011 , generic entity also became available in turkey , which resulted in an increase in the rebate for viread in turkey .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir lamivudine adv tdf ade|tenofovir|entity df is in the same class of drugs as adefovir dipivoxil .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir tdf lamivudine ftc 3t|tenofovir|of cmx157 in healthy volunteers and are on track to complete the ongoing phase 2a head-to-head study of cmx157 vs . entity df ( tdf , gileads viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir lamivudine etv zidovudine clarithromycin|tenofovir|entity and entecavir have emerged as the standard of care in this disease with very low rates of resistance over five
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|ribavirin methotrexate dexamethasone isoniazid prednisolone|tenofovir|the replicor 401 study , a study of naps in combination with entity and pegylated interferon , reported a 39% functional cure rate .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|tenofovir lamivudine acetate ftc discontinuation|tenofovir irinotecan cytosine fumarate pegylated|tenofovir|in the notice related to teva  s anda for a generic version of truvada , teva challenged four patents related to entity disoproxil fumarate and two additional patents related to emtricitabine .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|amiodarone melatonin dexamethasone lithium caffeine|amifostine|we are also aware of research relating to the use of high doses of entity ( a drug used to control some of the side effects of chemotherapy and radiation therapy ) for the protection of hearing
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|gemcitabine paclitaxel doxorubicin capecitabine oxaliplatin|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 and irofulven .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|ebp ow ils ebs org|amifostine|we anticipate that ethyolregistered trademark ( entity ) will be a meaningful product for medimmune following our merger .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|dtc ds wp sg dw|amifostine|sales of ethyol-registered trademark- ( entity ) increased 48% and 23% for the quarter and six months ended june 30 , 1999 , respectively , compared to the same periods
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|uva 3m usa germany tps|amifostine|medical applications the arsenal of medical radiation-protectors is limited to ethyol™ ( entity ) , sold by medimmune , and acquired by astrazeneca international .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|itraconazole ketoconazole voriconazole fluconazole albendazole|amifostine|mycelex-registered trademark- ( clotrimazole ) troche , which alza began marketing in the second half of 1997 , and increased sales of ethyol-registered trademark- ( entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|everolimus sorafenib metformin spironolactone sirolimus|amifostine|entity ( ethyolâ ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1), ('BIO', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|steroids corticosteroids dexamethasone aminoglycosides glucocorticoids|amifostine|we are also aware of research relating to the use of high dose entity for the protection of hearing in connection with platinum-based chemotherapy .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|inhaled intranasal lidocaine aerosol inhalation|amifostine|we market synagis ( palivizumab ) , flumist ( influenza virus vaccine live , intranasal ) , ethyol ( entity ) and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|aq e1 eo eth otc|amifostine|sun pharmaceutical industries limited has submitted an abbreviated new drug application to the fda for a generic version of ethyol ( entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|everolimus sorafenib metformin spironolactone sirolimus|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|etoposide acyclovir ribavirin oseltamivir cytarabine|amifostine|the company markets synagis ( palivizumab ) , ethyol ( entity ) , and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|carboplatin methotrexate cyclophosphamide hydroxyurea temozolomide|amifostine|neupogen ( r ) currently faces market competition from a competing csf product , granulocyte macrophage colony stimulating factor ( " gm-csf " ) and from the chemoprotectant , entity .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|curcumin lycopene melatonin resveratrol capecitabine|amifostine|entity ( ethyol® ) is approved by the fda as a radioprotector .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|dtc ds lsd pdf dbs|amifostine|in december 1995 , alza entered into a marketing and distribution agreement with u . s . bioscience , inc . ( " u . s . bioscience " ) for ethyol-registered trademark- ( entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|erlotinib bevacizumab capecitabine metformin gemcitabine|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity and radiation-induced xerostomia ( damage to the
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|pentoxifylline allopurinol spironolactone metformin acetylcysteine|amifostine|entity ( ethyol ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|capecitabine metformin bevacizumab hydroxyurea gabapentin|amifostine|there is one drug , entity , approved for use in reducing side effects from radiation therapy .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|gemcitabine paclitaxel doxorubicin oxaliplatin capecitabine|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 , and irofulven .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel capecitabine gemcitabine anthracycline everolimus|h1n1 sc gras max 1a|amifostine|product sales of $66 million , including $33 million in worldwide sales of synagis and $25 million in sales of ethyol® ( entity ) .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|neither hydrocortisone acetate cortisone dexamethasone|bupivacaine epinephrine tramadol ropivacaine dexmedetomidine|hydrocortisone|· igi will formulate four combination products of entity and lidocaine at different strengths : 1 .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|curcumin dexamethasone resveratrol berberine doxycycline|hydrocortisone|at 4 µm , 42% at 8 µm and 52% at 16 µm . therefore , the ic50 was 16 µm . by comparison , entity at 10 µm caused a 54% reduction in il-8 expression .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|hydrocortisone diclofenac dexamethasone triamcinolone ointment|hydrocortisone|in canada , 0 . 5% entity , a common anti-inflammatory product , described in the monograph , hydrocortisone topical published by health canada on january 22 , 2007 , can be
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|drug|neither hydrocortisone acetate cortisone dexamethasone|abbreviated injectable generic otc progesterone|hydrocortisone|on november 15 , 2011 , we acquired rights to plenadren® ( entity , modified release tablet ) for treatment of ai .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|dox hydro tacrolimus topical menth|hydrocortisone|entity rectal cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|neither hydrocortisone acetate cortisone dexamethasone|ketoconazole itraconazole fluconazole metronidazole rifampin|hydrocortisone|discuss how fda views our package of the us experience with ketoconazole and entity combination and discuss how much value in the historical experience will be accepted .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|neither hydrocortisone acetate cortisone dexamethasone|another potassium butyrate topical adding|hydrocortisone|this was partially offset by the product launch of entity butyrate lotion .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|amoxicillin trimethoprim sulfamethoxazole penicillin chlorhexidine|hydrocortisone|the launch of entity with acetic acid along with strong sales of sulfamethoxazole with trimethoprim and fluticasone propionate nasal spray also contributed to the
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|neither hydrocortisone acetate cortisone dexamethasone|ophthalmic topical occlusive tacrolimus ointment|hydrocortisone|-jun-11 t36® 0 . 5% entity ointment 80026139 30-jun-11 pedia-safe polyvitamin drops1 80001571 05-apr-06 ferroheme2 1 licensed to the company by canagen in an agreement dated
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|neither hydrocortisone acetate cortisone dexamethasone|celecoxib csa nac curcumin indomethacin|hydrocortisone|cbn was similar to entity with respect to anti-inflammatory activity in this model .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|corticosteroid prostaglandin vasoconstrictor analgesic glucocorticoid|hydrocortisone|anamantlehc , launched in january 2003 , is a prescription cream containing a topical anesthetic and entity , which treats hemorrhoids and anal fissures .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|capsaicin propolis honey zinc corticosteroids|hydrocortisone|the combination of aloe vera and entity offers therapeutic benefits for skin irritations such as minor burns , allergic itch , insect bite itch , sun burn itch , eczema in
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|neither hydrocortisone acetate cortisone dexamethasone|intravascular subcutaneous heroin accidental intramuscular|hydrocortisone|entity injection toxic symptom caused by various infections , hypocorticoidism caused by various infections , anaphylactic shock .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neither hydrocortisone acetate cortisone dexamethasone|aspirin ibuprofen nifedipine alendronate omeprazole|hydrocortisone|cma issued a statement of objections to a third party and the company in relation to the supply of 10mg entity tablets in the u . k . between 2013 and 2016 .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|neither hydrocortisone acetate cortisone dexamethasone|lutein sucrose resveratrol curcumin chlorhexidine|hydrocortisone|both products are formulated with aloe vera and cortiveraä contains 0 . 5% entity and cortivera plusä contains 1% entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|neither hydrocortisone acetate cortisone dexamethasone|comfortable cream topical safer viable|hydrocortisone|formulation design up to 8 78 , 600 · igi will formulate a entity cream product .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|neither hydrocortisone acetate cortisone dexamethasone|zinc antioxidants adiponectin selenium glutamine|hydrocortisone|lidamantle®hc also contains entity , which helps to reduce inflammation .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|glibenclamide metformin pioglitazone rosiglitazone statin|rosiglitazone|commonly prescribed drugs include diabetic medicines such as metformin , entity and sulfonylurea .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|france canada usa spain va|rosiglitazone|for the district of colorado into the group  s us sales and promotional practices and for product liability cases regarding avandia ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|metformin valsartan amlodipine tacrolimus rosiglitazone|rosiglitazone|a fixed combination product of starlix and entity was approved by fda in 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone metformin glibenclamide pioglitazone niacin|rosiglitazone|will compete with cs-917 include the insulin sensitizers actos , or pioglitazone , co-marketed by takeda and eli lilly , and avandia , or entity , marketed by glaxosmithkline .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone pioglitazone glibenclamide metformin ribavirin|rosiglitazone|cvr number : 24256790 the three lead® studies showed that liraglutide in combination with either glimepiride or metformin or metformin and entity is well tolerated .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|pioglitazone rosiglitazone glibenclamide simvastatin atorvastatin|rosiglitazone|the study investigated the effect of different doses of liraglutide in combination with metformin and entity , and included 533 patients with type 2 diabetes .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|artemisinin sildenafil ivermectin cocaine amiodarone|rosiglitazone|june 2007 the group voluntarily dismissed its infringement claims in respect of the patent covering the maleate salt form of entity ( the active ingredient in avandia ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|metformin glibenclamide pioglitazone rosiglitazone gabapentin|rosiglitazone|starlix ( diabetes ) was also filed in the us in december for use in combination with entity , a commonly used oral antidiabetic .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|arginine rosiglitazone enalapril metformin timolol|rosiglitazone|with respect to avandamet ( entity maleate / metformin hydrochloride ) tablets , the company anticipates resupplying the distribution channels within two weeks .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|metformin glibenclamide pioglitazone atenolol rosiglitazone|rosiglitazone|this weight loss was achieved with blood sugar-lowering efficacy comparable to entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|sertraline paroxetine imipramine fluoxetine citalopram|rosiglitazone|site at cidra , puerto rico ; product liability and anti-trust litigation relating to paxil ( paroxetine ) , and product liability cases regarding avandia ( entity ) and other products .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|testosterone timolol estrone rosiglitazone simvastatin|rosiglitazone|for example , recent studies have suggested an increased cardiovascular risk in patients using avandia® ( entity maleate ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|pioglitazone rosiglitazone metformin statins clozapine|rosiglitazone|there also have been concerns of other cardiovascular issues with entity and also concerns raised regarding bladder cancer associated with treatment with tzds .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone fenofibrate metformin pioglitazone trogl|rosiglitazone|insulin sensitizing agents approved to treat t2d are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|metformin glibenclamide pioglitazone rosiglitazone aspirin|rosiglitazone|of starlix® ( nateglinide ) improves glycemic control and is well-tolerated in patients whose type 2 diabetes is inadequately controlled by taking entity alone .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone metformin pioglitazone glibenclamide simvastatin|rosiglitazone|after a run-in period of metformin and entity , patients in the study were randomised to add-on treatment with either liraglutide or placebo .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone metformin quercetin curcumin berberine|rosiglitazone|entity ( avandia® ) and pioglitazone ( actos® ) fall into this category of anti-diabetic agent .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone metformin pioglitazone quetiapine fenofibrate|rosiglitazone|tzds include pioglitazone , marketed by eli lilly & company and takeda pharmaceutical company limited as actos , and entity , marketed by glaxosmithkline plc as avandia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|risperidone fluoxetine donepezil dexamethasone rosiglitazone|rosiglitazone|a comparator with entity , which has been shown to have some efficacy in humans , indicates the mgl-3196 performs better than entity in this study .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone metformin fenofibrate metabolite|rosiglitazone fenofibrate pioglitazone metformin trogl|rosiglitazone|insulin sensitizing agents approved to treat type 2 diabetes are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine bupivacaine dexamethasone betamethasone methylprednisolone|tetracaine|we entered into a license agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch ( zars agreement ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine bupivacaine dexamethasone adrenaline methylprednisolone|tetracaine|license agreement with zars pharma that will give it the exclusive north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|bupivacaine epinephrine adrenaline fentanyl tramadol|tetracaine|the drug formulation is a eutectic mixture of lidocaine 70 mg and entity 70 mg .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine fentanyl bupivacaine adrenaline ketamine|tetracaine|this product combines our peel technology with a proprietary formulation of lidocaine and entity to safely and efficiently anesthetize contoured areas of the body .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine bupivacaine dexamethasone adrenaline methylprednisolone|tetracaine|we entered into a license agreement with zars pharma for the north american rights to synera® ( lidocaine 70 mg and entity 70 mg ) topical patch , referred to as the zars agreement .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine lidocaine dexamethasone hydrocortisone betamethasone|tetracaine|allergy u . s . rx lidocaine ointment xylocaine™ dermatologics and topicals u . s . rx lidocaine / entity gel pliaglis® dermatologics and topicals u . s . rx loratadine solution claritin® allergy
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine bupivacaine fentanyl ropivacaine adrenaline|tetracaine|it uses our chadd technology and a proprietary formulation of lidocaine and entity to provide more convenient and faster anesthetic effect compared to the most commonly used product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride dissolved chloride contains cocaine|colorimetric microbiological manual spectrophotometric enzymatic|tetracaine|the fda has specified a limit of 1 . 5% tetra acid relative to entity assay .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride dissolved chloride contains cocaine|requiring unlike besides hence whose|tetracaine|must demonstrate an acceptable level of tetra acid , which is a compound that is formed as the active product ingredients , entity assay , degrade over time .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride dissolved chloride contains cocaine|epinephrine bupivacaine dexamethasone adrenaline methylprednisolone|tetracaine|we entered into an agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|quinine phen meth iodine folate|morphine gabapentin pregabalin lidocaine ketamine|pramoxine|current phn treatments are symptomatic , affecting the pain signaling circuit ( such as novocaine , entity , capsaicin , etc . ) , and do not produce lasting control .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|quinine phen meth iodine folate|acetate sulphate hydrochloride benzoate chloride|pramoxine|manufacture had to be obtained by copley before it shipped in interstate commerce and distributed for human use , brompheril , hydrocortisone entity , potassium chloride or procainamide .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|quinine phen meth iodine folate|lidocaine capsaicin histamine propranolol phenylephrine|pramoxine|preparation h® or similar products for symptomatic relief ( active ingredients can vary by country but generally include glycerin , phenylephrine hcl , entity hcl , and white petrolatum ) .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|quinine phen meth iodine folate|phenylephrine propranolol caffeine capsaicin lidocaine|pramoxine|otc products contain any one of several active ingredients including glycerin , phenylephrine , entity , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lu wu han hb del|curcumin resveratrol berberine artemisinin capsaicin|liothyronine|entity , a concordia product , was included in the initial draft .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|lu wu han hb del|linezolid risperidone sildenafil artemisinin citalopram|liothyronine|we believe that due to the fact that the market for entity is small , the manufacture and sale of generic forms of this compound are not economically attractive to potential competitors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lu wu han hb del|diclofenac alendronate losartan naproxen mycophenolate|liothyronine|entity sodium , one of the company  s products , was included in the initial draft .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lu wu han hb del|diclofenac penicillin clindamycin ceftriaxone vancomycin|liothyronine|the company recorded a total impairment charge of $301 , 538 , primarily related to entity sodium - $128 , 191 , fusidic acid -
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lu wu han hb del|replace contain eliminate remove raise|liothyronine|during the second quarter of 2017 , the company also became aware of the anticipated launch of a competitive product to entity sodium .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lu wu han hb del|omeprazole amiodarone theophylline hydroxyurea tenofovir|liothyronine|amcos product portfolio in the united kingdom is its largest and is predominantly comprised of products such as levothyroxine , entity and nitrofurantoin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lu wu han hb del|diclofenac losartan alendronate naproxen mycophenolate|liothyronine|generic entity sodium tablets are also available from coastal pharmaceuticals , mylan , and sigma pharmaceuticals .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|lu wu han hb del|diclofenac mycophenolate enoxaparin prednisolone alendronate|liothyronine|the remaining decrease of 13% is due to volume declines on key products including entity sodium , prednisolone and nefopam .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|lu wu han hb del|generic ibuprofen diltiazem oxycodone sildenafil|liothyronine|the cma pricing investigation , which commenced in october 2016 , relates to three products , including entity tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|lu wu han hb del|trimethoprim omeprazole chloramphenicol theophylline ampicillin|liothyronine|concordia international sells products such as entity , nitrofurantoin and levothyroxine within this category of the pharmaceutical market .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2)])|drug|crystall pharmacokinetics uro haem rituximab|fsh abstract inhibin gnrh semen|urofollitropin|entity - this is fsh derived from the urine of postmenopausal women .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|crystall pharmacokinetics uro haem rituximab|progesterone melatonin amh testosterone metabolomics|urofollitropin|entity is used in research to develop fertility drugs and in basic endocrinology research .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|crystall pharmacokinetics uro haem rituximab|pharmaceuticals chemicals pesticides biomolecules pcbs|urofollitropin|sicor currently expects to file a process patent covering purification of entity in early 1997 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|crystall pharmacokinetics uro haem rituximab|pharmaceuticals biologics fibrinogen artemisinin endotoxin|urofollitropin|sicor currently expects to file a process patent covering purification of entity in 1997 and is in discussions with potential partners about marketing the product in the u . s . and europe .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|crystall pharmacokinetics uro haem rituximab|approved biologics marketed pharmaceuticals investigational|urofollitropin|in order to commercialize therapeutics , initially entity , the company must outsource the manufacturing to a fda-regulated facility .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|crystall pharmacokinetics uro haem rituximab|hyaluronidase fsh oxytocin progesterone thrombin|urofollitropin|the company  s present product candidates targeted to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|crystall pharmacokinetics uro haem rituximab|lactoferrin ovalbumin lysozyme fibronectin chitosan|urofollitropin|in addition , at its facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2)])|drug|crystall pharmacokinetics uro haem rituximab|microorganisms estrogens exosomes mscs isoflavones|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post- menopausal women .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|drug|crystall pharmacokinetics uro haem rituximab|progesterone fsh gnrh melatonin oxytocin|urofollitropin|entity is involved in the stimulation of ovulation and is used in the treatment of certain types of infertility .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2)])|drug|crystall pharmacokinetics uro haem rituximab|microorganisms estrogens exosomes mscs isoflavones|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post-menopausal women .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|crystall pharmacokinetics uro haem rituximab|lactoferrin fibronectin transferrin laminin ovalbumin|urofollitropin|in addition , at its santhia facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('BIO', 1), ('DIS', 1)])|drug|crystall pharmacokinetics uro haem rituximab|fsh spermatozoa progesterone hyaluronidase thrombin|urofollitropin|the company  s present products envisioned to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|metformin garlic trastuzumab aspirin ginseng|eravacycline|we may be unable to develop and commercialize entity or any other product candidate and , even if we do , may never achieve profitability .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|pharmaceutical vaccines biologics pharmaceuticals biotechnology|eravacycline|our operations to date have been limited to financing and staffing our company , developing our technology and developing entity and other product candidates .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|xl xp glu gla lam|eravacycline|the companys commercial product , xerava ( entity ) , a fully synthetic fluorocycline , is an intravenous ( iv ) antibiotic that is approved for use as a first-line empiric monotherapy for
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|vaccines trastuzumab pacs dbs apps|eravacycline|our current plan is to commercialize entity outside the united states with collaborators .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|linezolid vancomycin daptomycin aminoglycosides ceftazidime|eravacycline|xerava was investigated for the treatment of ciai as part of the companys ignite ( investigating gram-negative infections treated with entity )
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|doxycycline moxifloxacin minocycline azithromycin tetracycline|eravacycline|the companys lead product candidate , entity , is a fully synthetic tetracycline derivative that the company is developing as a broad-spectrum intravenous and oral antibiotic for use
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|quickly options globally indications extensively|eravacycline|tetraphase pharmaceuticals is developing entity for complicated urinary and intra-abdominal infections , as well as pneumonia .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|sorafenib sunitinib bevacizumab everolimus rituximab|eravacycline|for example , although entity achieved favorable results in the lead-in part of our phase 3 clinical trial in cuti , the pivotal portion of the
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|consumers pharmacists athletes veterinarians producers|eravacycline|this may make it difficult for entity to compete with these products .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|approval infliximab japan fda consideration|eravacycline|its phase 3 clinical trials ( ignite1 and ignite4 ) would be sufficient to support submission of a new drug application for entity for the treatment of ciai .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|linezolid daptomycin vancomycin glycopeptides aminoglycosides|eravacycline|approval of xerava was based on our ignite ( investigating gram-negative infections treated with entity ) phase 3 program .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|daptomycin linezolid penicillin vancomycin metronidazole|eravacycline|moreover , the company does not believe that the statement indicates in any respect that entity covers any or all of these infections .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|metformin bevacizumab trastuzumab statins aspirin|eravacycline|if clinical trials of entity or of any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|metformin sildenafil aspirin bevacizumab marijuana|eravacycline|if entity is approved , it may be priced at a significant premium over other competitive products .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|medicines cigarettes pharmaceuticals chemicals foods|eravacycline|prior written notice if any governmental agency takes any action that prevents the company from importing , exporting , purchasing or selling entity .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|otc xl amd ald xp|eravacycline|tetraphase is currently selling xeravatm ( entity ) in the united states .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|linezolid vancomycin daptomycin ceftriaxone azithromycin|eravacycline|however , we do not believe these limitations would apply to entity or any of our other investigational antibiotics .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|manufacturers biotechnology nanotechnology companies automation|eravacycline|entity , along with the companys proprietary drug discovery platform technology , make tetraphase an exceptional opportunity that i look forward to being
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|daptomycin moxifloxacin colistin pharmacokinetics noninferior|vancomycin propofol methadone antipsychotics buprenorphine|eravacycline|case based on our achievement of company goals with respect to the development of the intravenous and oral formulations of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|chloride gave acetate yielded bromide|lidocaine bupivacaine ropivacaine ketamine epinephrine|dyclonine|a bema ( tm ) product containing entity as a local anesthetic prior to dental procedures and for the treatment of canker sores has been consumer tested .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|chloride gave acetate yielded bromide|vehicle hydrophilic ibuprofen progesterone carrier|dyclonine|mucosal surfaces single claim  layered bioerodable pharmaceutical ( entity only ) carrier device .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|warrant require merit warrants deserve|atosiban|the safety and pharmacokinetics of obe022 administered to pregnant women , who are receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|yohimbine naloxone oxytocin ondansetron prazosin|atosiban|these effects were blocked by the oxytocin receptor antagonist , entity , indicating the effects of intranasal oxytocin were mediated by oxytocin receptors .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|misoprostol aspirin omeprazole ppis salbutamol|atosiban|in singleton pregnancies , 12 . 5% of women receiving ebopiprant plus entity delivered within 48 hours compared to 26 . 8% receiving entity only ( or 90% ci : 0 . 39 ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|alfa org mesylate oxytocin hydrochloride|atosiban|ferring pharmaceuticals entity , an oxytocin receptor antagonist , has been used in investigator initiated trials in connection with ivf outside the united states .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|roche tenofovir l1 azithromycin nvp|atosiban|with respect to obe022 , tractocile ( entity ) is approved to delay preterm birth outside of the united states , and we anticipate potential competition as a single agent ,
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|mifepristone misoprostol oxytocin yohimbine ondansetron|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the united states .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|yohimbine oxytocin naloxone ondansetron phentolamine|atosiban|to exacerbate behavioral changes , entity , an oxytocin antagonist , was administered to the pups by slow intravenous push .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|morphine naloxone aspirin dexamethasone propranolol|atosiban|two groups were given placebo in place of entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|warrant require merit warrants deserve|atosiban|the safety and pharmacokinetics of obe022 in pregnant women , who were already receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|dabigatran rivaroxaban metabolized paclitaxel capecitabine|yohimbine mifepristone misoprostol oxytocin dexmedetomidine|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the u . s . the usefulness of these ß2-adrenergic
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|allergen der fc inn crm|suvorexant|franchises grew · fda approved grastek and ragwitek sublingual allergen extract immunotherapy tablets and accepted filings for v503 and entity
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|metabolite suv corrected biomarker outperformed|topiramate melatonin ondansetron naltrexone orexin|suvorexant|these may include the following :  entity , an orexin receptor antagonist , is being developed by merck & co . , inc . for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|gabapentin donepezil pregabalin propofol midazolam|suvorexant|three of these medicines were filed in the u . s . ( entity for insomnia ; sugammadex for neuromuscular blockade and a combination of ezetimibe and atorvastatin for atherosclerosis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|metabolite suv corrected biomarker outperformed|marketing licensing registration deployment approval|suvorexant|the company is continuing with plans to seek approval for entity in other countries around the world .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|drug|metabolite suv corrected biomarker outperformed|insomnia narcolepsy japan melatonin antidepressants|suvorexant|· received a complete response letter from the fda regarding the new drug application for entity , mercks investigational medicine for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|topiramate melatonin orexin pregabalin gabapentin|suvorexant|if approved , entity would be the first in a new class of medicines , called orexin receptor antagonists , for use in patients with insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|metabolite suv corrected biomarker outperformed|orexin topiramate ondansetron melatonin intranasal|suvorexant|in august 2014 , merck & co . s dual orexin receptor antagonist , entity , was approved by the fda and is currently marketed under the name belsomra® .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|metabolite suv corrected biomarker outperformed|opioids baclofen benzodiazepines morphine levodopa|suvorexant|the effects produced by doras on rem sleep explain the motor effects and other side effects seen with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|metabolite suv corrected biomarker outperformed|proposals plans articles claims approval|suvorexant|entity will be evaluated by the controlled substance staff of the fda during nda review .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|metabolite suv corrected biomarker outperformed|roche melatonin canada italy fluoxetine|suvorexant|for the treatment of advanced melanoma and metastatic nsclc in patients whose disease has progressed after other therapies , and belsomra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|biologics pbdes pharmaceuticals pesticides chemicals|suvorexant|merck has announced that it plans to file regulatory applications for entity in 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|orexin dor 3m ox sal|suvorexant|merck is marketing belsomra® ( entity ) , which is a dual orexin receptor anatomist indicated for insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|metabolite suv corrected biomarker outperformed|roche canada quetiapine bz topiramate|suvorexant|in august 2014 , merck announced that the fda approved belsomra ( entity ) for the treatment of adults with insomnia who have difficulty falling asleep and / or staying asleep .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|pregabalin topiramate gabapentin melatonin venlafaxine|suvorexant|seeing significant progress in the pipeline this year , and we expect six major filings over the next 18 months , including entity for insomnia and odanacatib for osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|metabolite suv corrected biomarker outperformed|az mb cbd bv vb|suvorexant|neurosciencebelsomra ( entity ) , an orexin receptor antagonist indicated for the treatment of insomnia , characterized by difficulties with sleep onset and / or sleep maintenance .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|metabolite suv corrected biomarker outperformed|clozapine buprenorphine trastuzumab infliximab methamphetamine|suvorexant|both fda approval and a separate scheduling determination by the u . s . drug enforcement administration are required before merck can introduce entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|metabolite suv corrected biomarker outperformed|pregabalin gabapentin memantine amitriptyline donepezil|suvorexant|on may 22 , 2013 , the fdas peripheral and central nervous system drugs advisory committee will meet to discuss the nda for entity ( mk-4305 ) tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|metabolite suv corrected biomarker outperformed|memantine lamotrigine pregabalin orally fda|suvorexant|mk-4305 , entity , is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|rituximab infliximab humanized cetuximab monoclonal|etanercept adalimumab infliximab methotrexate thalidomide|guselkumab|entity is currently being investigated in clinical studies in several indications , including plaque psoriasis , pediatric psoriasis , psoriatic arthritis , crohns disease , hidradenitis
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|rituximab infliximab humanized cetuximab monoclonal|p19 infliximab p13 trastuzumab etanercept|guselkumab|entity ( tremfya® ) is the first approved antibody binding the p19 subunit of il-23 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|rituximab infliximab humanized cetuximab monoclonal|etanercept uva adalimumab fc phototherapy|guselkumab|in july , subsequent to the quarter , the fda approved tremfya™ ( entity ) for the treatment of adults living with moderate to severe plaque psoriasis .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|infliximab rituximab adalimumab etanercept bortezomib|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand and are specific to the il-23 pathway , which is believed to be
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|rituximab infliximab humanized cetuximab monoclonal|infliximab adalimumab thalidomide biologics etanercept|guselkumab|of morphosys ag , said : we are very pleased that our licensee janssen has further expanded the clinical development program of entity by initiating a clinical study in ulcerative colitis .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|trastuzumab rituximab bevacizumab infliximab adalimumab|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosyss proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|adalimumab etanercept infliximab rituximab everolimus|guselkumab|to the same period a year ago driven by strong uptake of stelara® ( ustekinumab ) and the u . s . launch of tremfya® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|rituximab infliximab humanized cetuximab monoclonal|ongoing comparative unpublished pivotal multicenter|guselkumab|more information about entity clinical studies is available on clinicaltrials . gov .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|rituximab infliximab humanized cetuximab monoclonal|etanercept adalimumab infliximab thalidomide methotrexate|guselkumab|moreover , entity is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2 / 3 clinical study program in crohns disease .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|rituximab infliximab adalimumab cetuximab trastuzumab|guselkumab|entity ( tremfya ® ) overview guselkumab ( tremfya ® ) is a human hucal antibody targeting the p 19 subunit of il - 23 that is being
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|rituximab infliximab humanized cetuximab monoclonal|infliximab adalimumab sc fc etanercept|guselkumab|in july 2018 , morphosys announced that its licensee , janssen , initiated a clinical development program with tremfya® ( entity ) in crohns disease .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|infliximab rituximab adalimumab etanercept cetuximab|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il‑23 ligand and are specific to the il‑23 pathway , which is believed to be
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|rituximab infliximab humanized cetuximab monoclonal|uva adalimumab etanercept fc phototherapy|guselkumab|the european commission approved tremfya® ( entity ) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|rituximab infliximab humanized cetuximab monoclonal|etanercept adalimumab methotrexate infliximab cyclosporine|guselkumab|entity is currently approved in the eu for the treatment of moderate to severe plaque psoriasis in adults who are candidates
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|rituximab infliximab humanized cetuximab monoclonal|adalimumab etanercept infliximab methotrexate rosiglitazone|guselkumab|in november 2017 , the eu commission granted european approval of entity ( tremfya® ) for the treatment of patients with moderate-to-severe plaque psoriasis .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|trastuzumab bevacizumab rituximab infliximab adalimumab|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosys  s proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|rituximab infliximab humanized cetuximab monoclonal|etanercept adalimumab infliximab methotrexate thalidomide|guselkumab|entity is currently being investigated in clinical studies in several indications , including additional studies in plaque psoriasis , pediatric psoriasis , psoriatic arthritis ,
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|rituximab infliximab humanized cetuximab monoclonal|rituximab infliximab adalimumab bortezomib etanercept|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand to confer specificity for the il-23 pathway that is believed to be
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|depot testosterone reduces contains cannot|clozapine buprenorphine medicare bevacizumab trastuzumab|triptorelin|entity is in pre-registration in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|depot testosterone reduces contains cannot|usa york netherlands kingdom company|triptorelin|two additional agents are also currently marketed , trelstar by watson , delivers entity , and zoladex marketed by astrazeneca , a biodegradable rod , that contains goserelin .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|depot testosterone reduces contains cannot|bromocriptine thalidomide octreotide tamoxifen mifepristone|triptorelin|in addition , in europe or certain other parts of the world , entity ( debiopharm s . a . ) and buserelin ( hoechst marion roussel , inc . ) are also approved and being marketed .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|depot testosterone reduces contains cannot|raloxifene mifepristone progesterone tamoxifen misoprostol|triptorelin|women were randomized to one of four mvt-602 dose groups ( 0 . 1 µg , 0 . 3 µg , 1 µg or 3 µg ) , to entity , 0 . 2 mg , or to placebo .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|depot testosterone reduces contains cannot|testosterone bromocriptine progesterone lhrh mifepristone|triptorelin|entity marketed as trelstar® ( watson pharmaceuticals ) and marketed as decapeptyl® ( ipsen ) is also a lhrh agonist .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine trastuzumab irinotecan dexamethasone erlotinib|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine irinotecan gemcitabine trastuzumab bevacizumab|rasburicase|dr . bizzari was the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of oxaliplatin , docetaxel and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1), ('BIO', 1)])|drug|metformin glibenclamide add dabigatran potassium|allopurinol epo roche calcitriol nac|rasburicase|a specific r&d effort has already culminated in the launch of fasturtec® ( entity ) in 2001 , for prevention of the increase in blood uric acid levels during chemotherapy of acute leukemia .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine trastuzumab gemcitabine sorafenib paclitaxel|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine irinotecan fluorouracil doxorubicin trastuzumab|rasburicase|for sanofi-aventis ( formerly rhône-poulenc , rhône-poulenc rorer and aventis ) where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine trastuzumab doxorubicin irinotecan gemcitabine|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metformin glibenclamide add dabigatran potassium|capecitabine trastuzumab irinotecan dexamethasone erlotinib|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|clopidogrel antiplatelet aspirin reduces concerns|potassium codeine bismuth aluminium aluminum|clopidogrel|to $5 . 3 billion in 2007 compared to 2006 due to loss of exclusivity of pravachol and the impact of generic entity bisulfate , partially offset by growth in other key products .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|potassium magnesium bismuth ferric clopidogrel|clopidogrel|filed a revocation action before the scottish court of session seeking to invalidate the sanofi-aventis patent in the uk claiming entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|barium potassium bismuth generic acetaminophen|clopidogrel|apotex filed a notice of appeal appealing the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clopidogrel antiplatelet aspirin reduces concerns|usp drg beer srm section|clopidogrel|growth in total prescriptions ( trx ) of entity 82 table of contents bisulfate remained strong , at 11 . 8% ( ims npa 3 channels  q4 2006 ) in the fourth
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel statin aspirin capecitabine omeprazole|clopidogrel|however , the presence of less common cyp2c10 non-functional alleles or variation in other genes may negatively impact the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel antiplatelet aspirin reduces concerns|entitled law publication enac statement|clopidogrel|drug interactions medco health solutions inc . robert epstein , said it is an example of the " law of unintended consequences " entity ( plavix ( r ) )
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|clopidogrel antiplatelet aspirin reduces concerns|statin clopidogrel aspirin omeprazole metformin|clopidogrel|medco outcomes study entity alone 0 . 18 entity+ppi 0 . 25 relative risk 1 . 50 ( 1 . 39-1 . 62 ) podium-presented at american heart association 11 / 11 / 08 *
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel aspirin celecoxib misoprostol tamoxifen|clopidogrel|however , this is confounded by the fda warning against the use of certain ppis , such as omeprazole , with entity ( plavix ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|clopidogrel antiplatelet aspirin reduces concerns|egcg glucuronide ddd clopidogrel omeprazole|clopidogrel|o comment : entity is expected to be converted efficiently to its active metabolite in patients with this genotype .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|clopidogrel antiplatelet aspirin reduces concerns|barium bismuth potassium magnesium strontium|clopidogrel|on august 12 , 2008 , the federal court of australia held that claims of patent no . 597784 covering entity bisulfate , hydrochloride , hydrobromide , and taurocholate salts were valid .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clopidogrel antiplatelet aspirin reduces concerns|infusion emulsion suspension prostacyclin dipyridamole|clopidogrel|captisol-enabled intravenous entity is an intravenous formulation of the anti-platelet medication designed for situations where the administration of oral platelet inhibitors is not
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel asa dapt aspirin ibu|clopidogrel|plavix® / iscover® plavix® ( entity ) , a platelet adenosine diphosphate ( adp ) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|bismuth barium potassium acetaminophen generic|clopidogrel|genrx-apotex appealed the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel ppi aspirin statin antiplatelet|clopidogrel|the presence of less common cyp2c19 alleles or variations in other genes may additionally enhance or reduce the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel bms enoxaparin everolimus pes|clopidogrel|stent thrombosis at 48 hours had been met , as cangrelor demonstrated statistically significant improvement for this endpoint as compared to entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|clopidogrel antiplatelet aspirin reduces concerns|acetaminophen codeine carbamazepine theophylline caffeine|clopidogrel|the federal court also held that the process claims , pharmaceutical composition claims , and claim directed to entity and its pharmaceutically acceptable salts were invalid .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel moxifloxacin ibuprofen omeprazole celecoxib|clopidogrel|when pa32540 and entity were dosed 10 hours apart , data from the study indicate no ex-vivo drug-drug interaction based on the study  s pre-specified primary analysis .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|clopidogrel antiplatelet aspirin reduces concerns|potassium bismuth magnesium codeine doxycycline|clopidogrel|and the minister of health in response to a notice of allegation from apotex directed against canadian patent 1 , 336 , 777 covering entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|clopidogrel antiplatelet aspirin reduces concerns|omeprazole ranitidine clarithromycin amoxicillin misoprostol|clopidogrel|us launch of tacrolimus ( prograf® ) ; and the launches in various european countries of pantoprazole ( marketed in the us as protonix® ) , entity ( plavix® ) , and esomeprazole ( nexium® ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|clopidogrel antiplatelet aspirin reduces concerns|clopidogrel dipyridamole statins statin aspirin|clopidogrel|according to present plans , all patients will receive background treatment including heparin , aspirin and entity ( plavix® ) , if not contraindicated .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('BIO', 1)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone cefotaxime vancomycin amoxicillin cephalosporins|cefadroxil|crude bulk drugs of the cephalosporin division and cefalexin and entity of the penicillin division were new products the company introduced during the six-month period of 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone cefotaxime ceftazidime vancomycin clindamycin|cefadroxil|cefalexin and entity are penicillin g downstream products that are widely used to treat urinary tract infections , respiratory tract , skin and soft tissue
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|bupropion bromocriptine misoprostol progesterone venlafaxine|cefadroxil|the increase was lead by increases in market share for medroxyprogesterone , naltrexone , danazol and sales of entity , which the company launched in june 1999 .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|aspirin misoprostol hydroxyurea metformin raloxifene|cefadroxil|the increase was led by higher sales of warfarin sodium , naltrexone , medroxyprogesterone , danazol , entity and hydroxyurea .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|omeprazole theophylline doxycycline ciprofloxacin tetracycline|cefadroxil|for sake of clarity and avoidance of doubt , " product " does not include any non-oral suspension forms or formulations of duricef ( r ) ( entity monohydrate ) .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone amoxicillin cefotaxime ceftazidime levofloxacin|cefadroxil|cefzil* cefprozil , an oral cephalosporin used in the treatment of respiratory infections and sinusitis duricef* entity , an oral cephalosporin .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|cephalosporin decreases cephalosporins comparing reduces|cefadroxil|offset by the decrease in gross margins in cephalosporin crude bulk drugs , cephalosporin formulation drugs as well as cefalexin and entity divisional revenues and gross margin analysis
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|linezolid azithromycin daptomycin ciprofloxacin ceftriaxone|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|taz cephal clindamycin gentamicin cef|cefadroxil|% 9 . 94 % cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|linezolid azithromycin daptomycin ciprofloxacin ceftriaxone|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|iva va ivig oseltamivir lidocaine|cefadroxil|although ivax remains the only fda approved generic manufacturer of entity , the company marketing the brand name version of this drug is marketing its own generic form of this product .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|statins ivermectin bupropion misoprostol azithromycin|cefadroxil|net revenues attributable to sales of entity , approved in march 1996 , were $17 . 1 million in the 1996 second quarter .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|taz cephal clindamycin gentamicin cef|cefadroxil|% 9 . 94% cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone cefotaxime amoxicillin vancomycin gentamicin|cefadroxil|sales for the cefalexin and entity for the first quarter of 2010 were approximately 3% lower than the same period in 2009 , because of a 4%
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone cefotaxime amoxicillin ceftazidime ampicillin|cefadroxil|the penicillin division currently operates the production and sales of clavulanic acid , cefalexin and entity .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin ceftriaxone ceftazidime vancomycin piperacillin|ceftriaxone cefotaxime vancomycin ceftazidime linezolid|cefadroxil|cefalexin and entity were launched and included in the companys product portfolio only at the beginning of 2008 .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|docetaxel tamoxifen paclitaxel capecitabine erlotinib|alpelisib|qd : once daily 111 table of contents we also assessed the anti-tumor activity of zn-c5 , alongside fulvestrant and entity , in each case as monotherapy , in preclinical models .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|everolimus imatinib ly294002 sorafenib trastuzumab|alpelisib|• byl719 ( entity , approved in the us as piqray ) is an orally bioavailable , alpha-specific pi3k inhibitor approved in combination with fulvestrant for the
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|trastuzumab bevacizumab sorafenib sunitinib everolimus|alpelisib|· byl719 ( entity ) phase iii solar-1 trial data presented at esmo showed byl719 plus fulvestrant nearly doubles median progression free survival in patients with
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|vor tamoxifen org sorafenib pivotal|alpelisib|· byl719 ( entity ) solar-1 trial of the investigational alpha-specific inhibitor byl719 in combination with fulvestrant met its primary endpoint showing an improvement in
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|imatinib gsk sorafenib nvp gefitinib|alpelisib| byl719 ( entity ) is an orally bioavailable , alpha isoform-specific pi3k inhibitor .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|manuscript patent abstract candidate tracer|alpelisib|·entity ( byl719 ) is on track for a us submission in pik3ca-related overgrowth spectrum ( pros ) in 2021 .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|ly294002 sorafenib everolimus gefitinib rapamycin|alpelisib|% of pi3k mutated late stage breast cancer patients achieved an objective response in a phase iii clinical trial with entity , a recently approved pi3k inhibitor .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|bevacizumab rituximab everolimus donepezil trastuzumab|alpelisib|therapy in this population , including ibrance , kisqali , afinitor , verzenio , and other therapies currently in phase 3 clinical development such as entity .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|tamoxifen raloxifene celecoxib curcumin bortezomib|alpelisib|biomedical research , inc . , or novartis , to evaluate the combination of op-1250 and novartis ribociclib , a cdk4 / 6 inhibitor , as well as entity , their pi3kα inhibitor .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|curcumin tam tamoxifen paclitaxel dox|alpelisib|we also observed that the combination of zn-c5 and entity had more potent anti-tumor activity than the combination therapy using 3 mg / dose of fulvestrant and 50 mg / kg of entity .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|tamoxifen docetaxel tam paclitaxel doxorubicin|alpelisib|zn-c5 and fulvestrant were also assessed in combination with entity .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|ly294002 imatinib wortmannin tamoxifen sunitinib|alpelisib|more recently piqray® ( entity ) , an inhibitor of the alpha isoform phosphatidylinositol-3-kinase , became the first agent approved for use in a specific subpopulation of hr+
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|v600e her2 gsk pi3k az|alpelisib|about piqray® ( entity ) piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women , and men , with hr+ / her2- ,
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|ptx cddp dox paclitaxel doxorubicin|alpelisib|even greater anti-tumor activity was observed with the combination of 1 mg / kg of zn-c5 and 50 mg / kg of entity .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|capecitabine everolimus sorafenib erlotinib trastuzumab|alpelisib|fulvestrant used in combination with entity , an oral pi3k inhibitor marketed as piqray® by novartis approved by the fda in may 2019 , has demonstrated improved clinical
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|trastuzumab approved europe her2 nvp|alpelisib|approved may 2019 ( breast cancer ) [ accelerated approval ] limited toxicities to date does not cross blood-brain barrier ü û ü piqray ( entity )
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|sorafenib everolimus imatinib sunitinib erlotinib|alpelisib|entity , marketed as piqray® by novartis , is the only fda-approved inhibitor for cancers with mutated pi3kα .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|bevacizumab capecitabine erlotinib sunitinib sorafenib|alpelisib|the study showed that entity added toxicity with only marginal additional activity , therefore the beacon crc trial will replace it with binimetinib in the triplet
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|curcumin lovastatin tamoxifen fenofibrate rosiglitazone|alpelisib|in contrast , entity and gdc-0077 ( an orthosteric pi3kα inhibitor currently in development ) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency .
OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|bortezomib everolimus rivaroxaban rituximab dabigatran|trastuzumab imatinib sorafenib cetuximab sunitinib|alpelisib|while these factors limit the clinical utility of entity , these data nonetheless establish mutant pi3kα as a clinically validated target in breast cancer .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|rituximab etanercept thalidomide infliximab sorafenib|omadacycline|to depend on independent clinical investigators and cros to conduct our clinical trials , including our planned phase 3 trials of entity in absssi .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|everolimus bevacizumab sorafenib bortezomib paclitaxel|omadacycline|entity is ready to advance into phase 3 , the final stage of clinical development .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|daptomycin vancomycin tacrolimus thalidomide infliximab|omadacycline|entity ( paratek pharmaceuticals ) and lefamulin ( nabriva therapeutics ) , and dalafloxcacin ( melinta ) all are expected to be pursued as a possible treatment for
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|osteoporosis endometriosis epilepsy psoriasis acupuncture|omadacycline|in hong kong and three pending patent applications in taiwan , respectively that relate to different methods of treatment related to entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|companies industry pharmaceuticals pharmacists others|omadacycline|under the novartis agreement , novartis was to have led development activities for entity , and the company was to have co-developed and contributed a share of the development expense .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|levofloxacin linezolid azithromycin colistin moxifloxacin|omadacycline|if approved by the fda , entity will also compete with other antibiotics in the community-acquired pneumonia market .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|melanoma nsclc aml osteoporosis oncology|omadacycline|payment of $50 , 000 to tufts for achieving the first milestone following commencement of the phase 3 non-registration clinical trial for entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|linezolid sildenafil dabigatran bevacizumab trastuzumab|omadacycline|this prsu was awarded under the 2015 plan and vests upon fda approval of entity , and shall , upon achievement of the milestone , be eligible to vest as to 100% of the prsus subject to the
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|linezolid paclitaxel risperidone oseltamivir daptomycin|omadacycline|our success is currently dependent on the successful development and commercialization of our most advanced product candidates , entity and sarecycline .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|approved latest principal intended investigational|omadacycline|to working with the fda as it considers the comments from the committee members and completes its review of the entity new drug applications .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|pregabalin aripiprazole metformin adalimumab everolimus|omadacycline|in all three studies , entity met all primary and secondary efficacy outcomes designated by the fda and was generally safe and well-tolerated .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|linezolid daptomycin vancomycin moxifloxacin imipenem|omadacycline|in addition , achaogen , inc . developed and gained approval for plazomicin and paratek pharmaceuticals , inc . developed and gained approval for entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|biologics vaccines pharmaceuticals patents trastuzumab|omadacycline|to obtain a return on the investments we have made in our or any of our partners product candidates , including entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|precipitation abortion ginseng beef petroleum|omadacycline|“crude entity” has the meaning set forth in the recitals hereto .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|mars telemedicine ketamine cpr tips|omadacycline|we believe entity , if approved , will be used in the emergency room , hospital and community care settings .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|linezolid daptomycin paclitaxel risperidone oseltamivir|omadacycline|if entity and sarecycline are not successfully developed and commercialized , we will not have any product candidates under development from which we
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|rituximab infliximab ivig linezolid etanercept|omadacycline|under our spa agreement , we plan to commence a pivotal registration program including two phase 3 registration trials of entity for the treatment of absssi in the second half of 2012 .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|paclitaxel trastuzumab artemisinin erlotinib bevacizumab|omadacycline|substantial additional funding in connection with the companys continuing operations to support commercial activities associated with its lead product candidate , entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|linezolid daptomycin minocycline moxifloxacin doxycycline|omadacycline|our two lead antibacterial product candidates are entity and sarecycline .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antidepressant hydrochloride pharmacokinetics ondansetron capecitabine|omeprazole ranitidine clopidogrel naproxen fluconazole|omadacycline|for oral therapy , patients randomized to entity received 200 mg of entity ( dosed as two 100 mg capsules ) every 24 hours .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|venlafaxine sertraline paroxetine antidepressants bupropion|tamoxifen|increased product sales were due mainly to the introduction of fluoxetine in august 2001 , as well as , increased sales of entity and other products .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|tamoxifen magnesium potassium ferric gallium|tamoxifen|soltamox ( entity citrate ) oral solution , our first proprietary , fda approved product , is a drug primarily used to treat breast cancer .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|brachytherapy tamoxifen cryotherapy bromocriptine propranolol|tamoxifen|external beam radiation and entity are both used to treat gynecomastia .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|ferric potassium magnesium sildenafil lithium|tamoxifen|the company acquired exclusive u . s . marketing rights to its &#160 ; first commercial , fda-approved proprietary product license &#160 ; soltamox&#174 ; ( entity citrate ) oral solution .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|mpa paclitaxel tamoxifen nvp efavirenz|tamoxifen|femara is generally well tolerated and adverse reactions rates in the first-line study in which femara was compared to entity were similar with those seen in second-line studies .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|ferric potassium magnesium zinc ferrous|tamoxifen|the alamo sales team , in addition to promoting our products soltamox ( entity citrate ) and gelclair , also promotes two mission products : ferralet® 90 , and aquoral® .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|trastuzumab tamoxifen capecitabine adjuvant paclitaxel|tamoxifen|entity therapy is currently indicated by the fda for breast cancer patients for five years .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|honey tea caffeine melatonin propofol|tamoxifen|nevertheless , we believe that soltamox being the first and only liquid form of entity to successfully make some in roads in to that market .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|tamoxifen metformin raloxifene progesterone statins|tamoxifen|during 2001 , we announced the issuance of an u . s . patent on the use of our anti-estrogen compound in combination with entity .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|brachytherapy bcs ibr dcis mastectomy|tamoxifen|a dcis score result , to help guide treatment decision-making in women with dcis treated by local excision , with or without entity .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|federal insurance private trade business|tamoxifen|we maintain $20 million of product liability insurance and have an indemnification provision in our entity agreement .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|investigational proprietary approved companion generic|tamoxifen|us revenues for nolvadex fell 27% to $337 million , as sales of our entity products fell as a result of the expiry of our distribution agreement with barr laboratories .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|methotrexate sildenafil thalidomide azathioprine retinoids|tamoxifen|however , a number of medical therapies have been used to treat peyronies including vitamin e , colchicine , potassium aminobenzoate ( potaba ) , entity , interferon a2a and corticosteroids .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|tamoxifen adjuvant oestrogen replacement progesterone|tamoxifen|women were assessed for risk of developing breast cancer using the brevagen test to determine eligibility for five years of entity therapy .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|monthly annual pharmaceutical cigarette aspirin|tamoxifen|entity sales increased 56% from $145 , 161 to $226 , 749 .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|laparoscopy endoscopy colonoscopy fluoroscopy echocardiography|tamoxifen|due to its proven superiority over entity , it has won category leadership in france , spain , belgium , mexico , switzerland and australia .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|bevacizumab erlotinib docetaxel dexamethasone carboplatin|tamoxifen|treatment was stopped due to toxicities in three patients in the everolimus plus entity arm and in four patients in the entity-only arm .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|chemotherapeutic trastuzumab tamoxifen biologic projected|tamoxifen|oncotype dx predicts likelihood of recurrence because it predicts both prognosis and entity benefit .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|plans plan insurance beneficiaries income|tamoxifen|the plaintiff in this action , however , asserts that the companys alleged misclassification of entity improperly denied plan benefits and breached an alleged fiduciary duty under erisa .
OrderedDict([('OTHER', 4), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|tamoxifen trastuzumab her2 aromatase paclitaxel|tamoxifen raloxifene genistein tam progesterone|tamoxifen|entity , the most commonly used serm treatment for breast cancer , also inhibits this action by estradiol , but with less affinity for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|van der du que als|allopurinol metformin losartan linezolid atorvastatin|lesinurad|entity is a selective inhibitor of urat1 , a transporter in the proximal tubule cells of the kidney that regulates uric acid
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|germany usp tablets otc switzerland|lesinurad|about zurampic ( entity ) 200mg tablets zurampic ( entity ) works in combination with xanthine oxidase inhibitors ( xois ) to treat hyperuricemia associated with uncontrolled gout .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|malpractice entire prison pharmacy temporary|lesinurad|closing of the entity transaction is subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|gross annual entire monthly planned|lesinurad|the write-down was recorded as write-down of entity commercial supply to net realizable value in the companys condensed consolidated statement of operations .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|federal tax military insurance government|lesinurad|to $140 million ) , and · amortization of intangible assets to be $8 million ( not applicable prior to the u . s . entity license ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|van der du que als|allopurinol metformin methotrexate clopidogrel aspirin|lesinurad|astrazeneca entered into a licensing agreement with ironwood pharmaceuticals for the exclusive us rights to zurampic and the fixed-dose combination of entity and allopurinol .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|van der du que als|infliximab etanercept adalimumab rituximab lamotrigine|lesinurad|however , entity , like all other ults , has been shown to increase flares upon initiation of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 3)])|drug|van der du que als|allopurinol urate metformin hyperuricemia dabigatran|lesinurad|entity is an oral inhibitor of urat1 , which is the transporter that mediates reuptake of uric acid from the proximal tubules of the kidney and drives renal elimination of uric acid .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|van der du que als|sorafenib clopidogrel capecitabine everolimus sunitinib|lesinurad|entity is a drug in phase 3 development by astrazeneca plc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|van der du que als|allopurinol statins ppis sildenafil thalidomide|lesinurad|we are developing entity to be used as both monotherapy and in combination with drugs like allopurinol and febuxostat to treat the large number
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|van der du que als|allopurinol acetylcysteine urate pentoxifylline dipyridamole|lesinurad|for patients who require more control or who are contraindicated , the uricosuric agent , entity , may be prescribed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|cur fort amongst preclinical notice|lesinurad|entity entity , our most advanced product candidate , previously called rdea594 , is an inhibitor of urat1 , a transporter in the kidney that regulates uric acid excretion from the body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|van der du que als|pharmaceutical purchased medicinal herbal imported|lesinurad|we calculated gross product revenue based on the wholesale acquisition cost that we charged our distributors for the entity products .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 2)])|drug|van der du que als|allopurinol colchicine spironolactone atorvastatin simvastatin|lesinurad|entity has been shown to normalize the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|van der du que als|infliximab adalimumab rituximab etanercept bevacizumab|lesinurad|these drugs are entity , sifalimumab , anifrolumab , mavrilimumab and brodalumab .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|van der du que als|dabigatran carboplatin cyclosporine sorafenib metformin|lesinurad|entity carries a black box warning associated with renal toxicity and is contraindicated in patients with renal impairment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|van der du que als|massachusetts medicare cms federal pharmacy|lesinurad|january 2007 , as amended , for our cambridge , massachusetts corporate headquarters and a reduction in reimbursement obligations to astrazeneca under the entity license .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 2)])|drug|van der du que als|allopurinol colchicine atorvastatin simvastatin spironolactone|lesinurad|entity normalizes the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|van der du que als|allopurinol metformin rosuvastatin atorvastatin pioglitazone|lesinurad|entity is being studied as an add-on treatment to allopurinol patients not reaching target sua levels , as an add-on to febuxostat
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|van der du que als|metformin methotrexate pravastatin pioglitazone atorvastatin|lesinurad|the combination of entity and allopurinol has been generally well tolerated in the ongoing extension portion of study 203 .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|clozapine reduces mesylate haloperidol ver|metronidazole erythromycin baclofen paracetamol amitriptyline|prucalopride|compared to the group receiving entity ( an fda approved drug for the treatment of chronic idiopathic constipation ) , the pcs12852 dose groups showed higher stool frequency for
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|clozapine reduces mesylate haloperidol ver|biofeedback pregabalin misoprostol topiramate paroxetine|prucalopride|entity has been approved for commercialization in certain european countries for the treatment of chronic constipation in women but has not yet been launched .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clozapine reduces mesylate haloperidol ver|approval biologics pharmaceuticals canada consumers|prucalopride|shire has discussed with the fda the requirements for filing an nda for entity and is currently working towards fulfilling those requirements in anticipation of an nda submission .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|clozapine reduces mesylate haloperidol ver|metformin misoprostol clozapine linezolid telemedicine|prucalopride|entity was launched in several european markets .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|italy spain europe france germany|prucalopride|phase 3 globally global ( excluding italy and latin america ) resolor ( entity ) chronic constipation ( males ) phase 3 in eu europe spd 556 ( m0002 )
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|standards legislation cpg algorithms telemedicine|prucalopride|shire intends to develop entity in the united states for cc .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clozapine reduces mesylate haloperidol ver|omeprazole probiotics tablets capsules budesonide|prucalopride|alan has played a major role in development of gastroenterology products such as motilium® and entity and has considerable experience and knowledge of the gastrointestinal ( gi ) space .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|trade operate compete grow thrive|prucalopride|johnson & johnson has rights to entity in north american and certain european countries and we expect entity to provide competition in markets around the world .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clozapine reduces mesylate haloperidol ver|roche sc etanercept rsv budesonide|prucalopride|shire plc obtained approval of motegrity™ ( entity ) in the u . s . for the treatment of cic in adults in december 2018 .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|clozapine reduces mesylate haloperidol ver|pregabalin gabapentin tramadol celecoxib opioids|prucalopride|sloots ej , et al . efficacy and safety of entity in patients with chronic non-cancer pain suffering from oic .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|vaccines standards funding legislation diagnostics|prucalopride|movetis was acquired by shire in september 2010 , which intends to develop entity in the u . s . for cc .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|withdrawn released marketed approved converted|prucalopride|another prokinetic compound in development in europe , with the potential for commercialization in the united states and asia , is entity from movetis .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|clozapine reduces mesylate haloperidol ver|pharmaceuticals ocs trastuzumab ssris fda|prucalopride|shire has recently announced it acquired rights to develop and commercialize entity in the u . s . for the cc indication .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|clozapine reduces mesylate haloperidol ver|telemedicine nice ict prep pep|prucalopride|entity was launched in germany in january 2010 , in the u . k . in march 2010 and in belgium in september 2010 .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|clozapine reduces mesylate haloperidol ver|metronidazole erythromycin metoclopramide baclofen paracetamol|prucalopride|pcs12852 increased stool frequency with faster onset when compared to entity , an fda approved drug for the treatment of chronic idiopathic constipation .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|others etc resveratrol gsk graphene|prucalopride|a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|others resveratrol etc gsk graphene|prucalopride|held a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|clozapine reduces mesylate haloperidol ver|pregabalin biofeedback gabapentin probiotics topiramate|prucalopride|janssen belgium exclusive license agreement to develop and market entity as a treatment for chronic constipation in the u . s . motegrity , approved in december 2018 .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|clozapine reduces mesylate haloperidol ver|biofeedback pregabalin probiotics gabapentin baclofen|prucalopride|trials are on-going in europe testing entity in the treatment of chronic constipation in men .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|clozapine reduces mesylate haloperidol ver|france canada italy germany switzerland|prucalopride|the most recent entrant to the cc marketplace , solely in europe , is resolor ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|foam dissolved acetate paclitaxel coated|next fda entire ongoing eu|polidocanol|additional manufacturing information and documentation is also being prepared by kreussler for submission to the fda to support the entity nda .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|foam dissolved acetate paclitaxel coated|caffeine isoflurane lidocaine propofol formaldehyde|polidocanol|in contrast , aethoxysklerol contains entity , a chemical with anesthetic properties , which we believe may be one of the key advantages of aethoxysklerol .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|foam dissolved acetate paclitaxel coated|see abstract preparing accepting awaiting|polidocanol|entity nda submission and review  in july 2009 , bioform medicals partner , chemische fabrik kreussler & co . gmbh ( kreussler ) , submitted
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|foam dissolved acetate paclitaxel coated|pharmaceuticals medicines cigarettes biologics vaccines|polidocanol|the $0 . 7 million milestone payment pursuant to our agreement with kreussler for exclusive united states licensing and distribution rights of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|foam dissolved acetate paclitaxel coated|approved marketed generic investigational licensed|polidocanol|the definition of product ( s ) may be amended from time to time to include additional entity product ( s ) in accordance with article ii ( b ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|foam dissolved acetate paclitaxel coated|proteomics biotechnology science pharmaceuticals photosynthesis|polidocanol|our partner , kreussler , is also making good progress in the nda review of entity , our future sclerotherapy product .  31 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|docetaxel trastuzumab capecitabine ned rituximab|diclofenac valproate naproxen pentobarbital mycophenolate|nedocromil|brannan jd , anderson sd , freed r , leuppi jd , koskela h , chan h-k . entity sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|docetaxel trastuzumab capecitabine ned rituximab|diclofenac prednisolone theophylline mycophenolate naproxen|nedocromil|the basic chemical patents for sodium cromoglycate have already expired , and such patents for entity sodium expire principally between 1998 and 2006 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|docetaxel trastuzumab capecitabine ned rituximab|salbutamol theophylline diclofenac hydrocortisone ranitidine|nedocromil|“bulk form” means cromolyn sodium micronized stage 9 ( the “intal bulk form” ) and entity sodium dried stage 11 ( the “tilade bulk form” ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|etv epo adv abbott opt|etravirine|during 2008 , the company received regulatory approval in the u . s . , canada and european union for intelencetm ( entity ) for hiv combination therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|tenofovir ritonavir efavirenz lamivudine ribavirin|etravirine|while at johnson & johnson , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|raloxifene tib tcm china mifepristone|etravirine|tibotecs drug , entity , received fda marketing approval in early 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|eu ic od otc api|etravirine|in january 2008 , the company received accelerated approval from the u . s . food and drug administration ( fda ) for intelence ( entity ) tablets , an anti-hiv medication .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|tenofovir efavirenz ritonavir lamivudine ribavirin|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|tenofovir ritonavir efavirenz lamivudine ribavirin|etravirine|while at j&j , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|efavirenz tenofovir lamivudine ritonavir zidovudine|etravirine|two new drugs , intelence ( entity ) and prezista ( darunavir ) from tibotec therapeutics , a division of ortho biotech products , l . p . , are included in the revised drug resistance
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|tenofovir efavirenz ritonavir lamivudine ribavirin|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|tenofovir efavirenz ritonavir lamivudine ribavirin|etravirine|the development and launches of several products , including page 1 of 3 remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|tenofovir hydrochloride lamivudine ribavirin pharmacokinetics|lamivudine ritonavir efavirenz tenofovir zidovudine|etravirine|company group chairman for johnson & johnsons worldwide virology business unit , where she oversaw the launches of prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dimer crosslinked labelled haem biotin|arsenic herbal topical cosmetic intramuscular|dimercaprol|bal in oil is a therapeutic entity injection used to treat arsenic , gold and mercury poisoning .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|boron cation protonated amine hydrochloride|alkaloids volatiles pigments flavonoids ingredients|galantamine|reminyl was launched using natural entity extracted from daffodil bulbs .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|boron cation protonated amine hydrochloride|donepezil sertraline topiramate methylphenidate metoprolol|galantamine|related to ad , patients with ad are prescribed drugs for enhancing their cognition , and include acetylcholinesterase inhibitors such as , donepezil , entity , rivastigmine and memantine .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|boron cation protonated amine hydrochloride|ortho rx quick xl ultra|galantamine|entity ir tablets are the ab-rated generic versions of ortho-mcneil and janssen&#8217 ; s razadyne &#174 ; , which had annual sales of approximately
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|boron cation protonated amine hydrochloride|generic proprietary patent marketed approved|galantamine|successful in their allegations of patent infringement , barr could be required to pay damages relating to the sale of its entity ir tablets .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|boron cation protonated amine hydrochloride|donepezil memantine others therapeutics statins|galantamine|he contributed to the clinical development of currently marketed drugs in epilepsy ( topiramate and levetiracetam ) and entity in alzheimers .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 3)])|drug|boron cation protonated amine hydrochloride|memantine donepezil statins curcumin risperidone|galantamine|seeking a declaration to nullify the supplementary protection certificate ( " spc " ) for ep 236684 ( the patent that claims the use of entity for the treatment of alzheimer  s disease ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|boron cation protonated amine hydrochloride|donepezil memantine simvastatin atorvastatin statins|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimers drug entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|drug|boron cation protonated amine hydrochloride|medicines stimulants acupuncture antidepressants cbt|galantamine|deemed to include all parents licensed to shire or its affiliates in the territory in respect of the use of entity for cfs ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|boron cation protonated amine hydrochloride|generic risperidone valsartan nifedipine progesterone|galantamine|in october 2008 , barr commenced sales of its 8 mg , 16 mg and 24 mg entity extended release ( er ) capsules .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|boron cation protonated amine hydrochloride|memantine donepezil simvastatin propranolol pregabalin|galantamine|other drugs commonly used to treat ad , such as donepezil and entity , inhibit acetylcholinesterase but not butyrylcholinesterase .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|boron cation protonated amine hydrochloride|donepezil sertraline methylphenidate topiramate citalopram|galantamine|treatments for ad patients are only indicated for enhancing cognition in ad patients , and include acetylcholinesterase inhibitors such as donepezil , entity , rivastigmine and memantine .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|boron cation protonated amine hydrochloride|pharmaceuticals cannabis medicines vaccines probiotics|galantamine|the first european application for marketing of entity was submitted in march 1999 ; subsequently , various other applications have been made .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|boron cation protonated amine hydrochloride|donepezil memantine minocycline simvastatin statins|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimer  s drug entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|boron cation protonated amine hydrochloride|scopolamine atropine codeine naloxone metoclopramide|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|boron cation protonated amine hydrochloride|venlafaxine oxycodone ortho quetiapine olanzapine|galantamine|entity er capsules are the ab-rated generic versions of ortho-mcneil and janssens razadyne er® , which had annual sales of approximately $110
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|boron cation protonated amine hydrochloride|donepezil memantine methylphenidate acetylcholinesterase levodopa|galantamine|in a pre-clinical animal model of cognition , prx-03140 demonstrated synergistic activity when combined with the acetylcholinesterase inhibitor entity ( razadyne ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|boron cation protonated amine hydrochloride|donepezil memantine sertraline methylphenidate bromocriptine|galantamine|namzaricin the market for alzheimers disease treatments , namzaric competes or will compete with branded and generic products such as entity , rivastigmine , memantine , and donepezil .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|boron cation protonated amine hydrochloride|scopolamine atropine codeine naloxone metoclopramide|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|boron cation protonated amine hydrochloride|generic valsartan risperidone marketed omeprazole|galantamine|in august 2008 , barr commenced sales of its 4 mg , 8 mg and 12 mg entity immediate release ( ir ) tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|enoxaparin clopidogrel dabigatran rivaroxaban aspirin|protamine|entity , a drug that reverses the anticoagulant effect of heparin , is rarely used in pci due to its unpredictable effect and
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|protamine quaternary cationic abstract chloride|ketamine cocaine metformin lithium acupuncture|protamine|in medical studies , entity has been associated with adverse side effects , such as abnormal changes in blood pressure , depression of heart function and acute
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|protamine aspirin anticoagulant enoxaparin lmwh|protamine|phase ii clinical trials indicate that neutralase can reverse heparin anticoagulation without the adverse changes in blood pressure associated with entity usage .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|protamine quaternary cationic abstract chloride|chemically newly molecularly genetically locally|protamine|our preclinical data demonstrated improved antigen expression at the site of injection if the entity formulated vaccine was injected via a needle free jet device .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|protamine quaternary cationic abstract chloride|penicillin vancomycin chloramphenicol streptomycin neomycin|protamine|one patient that died was found to have used entity and not neutralase .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|enoxaparin aspirin dabigatran protamine edta|protamine|although entity is available as an antidote for heparin , it does not work with lmwh and there currently are no antidotes for
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|enoxaparin lmwh aspirin clopidogrel tpa|protamine|arc183 has shown potential in preclinical studies to be equally effective , with fewer side effects than heparin and entity in combination .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|protamine quaternary cationic abstract chloride|newly chemically molecularly conventionally adjuvant|protamine|bi1361849 was administered via conventional needle based intradermal injection , later shown to be a suboptimal mode of injection for the entity formulated rabies vaccine .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|rivaroxaban dabigatran enoxaparin lmwh aspirin|protamine|in the ufh antagonist market , entity is the only available antidote for and antagonist to ufh and , as such , entity currently dominates this market .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|protamine quaternary cationic abstract chloride|warning hope doubt ruling financial|protamine|because of entitys virtual monopoly of the ufh antidote / antagonist market , we believe that it may be
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|protamine quaternary cationic abstract chloride|protamine aspirin clopidogrel asa antiplatelet|protamine|be safely used in the general cardiac surgery patient population by demonstrating similar results to a regimen of heparin plus entity reversal .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|protamine quaternary cationic abstract chloride|hope alarming suspect concern immunosuppressant|protamine|because of entitys potentially problematic side effect profile , we believe that our heptagonist products may penetrate into
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|aspirin protamine corticosteroids epinephrine enoxaparin|protamine|in addition , the effects of heparin are routinely reversed with entity , the use of which has been associated with an allergic reaction and a subsequent increase in the risk of death
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|aspirin protamine enoxaparin lmwh aprotinin|protamine|reversed at the end of the procedure and which does not have the significant side effects associated with heparin and entity would result in improved outcomes for patients undergoing ohs .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 1)])|drug|protamine quaternary cationic abstract chloride|aprotinin fibrinogen platelets antithrombin urokinase|protamine|that directly or indirectly support clotting , such as vitamin k ; fresh frozen plasma , or ffp ; prothrombin complex concentrates , or pccs ; entity ; and recombinant factor viia , or rfviia .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|dabigatran enoxaparin lmwh protamine rivaroxaban|protamine|currently , entity is the only product commercially available for the reversal of heparin anticoagulation .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|protamine quaternary cationic abstract chloride|protamine enoxaparin lmwh aspirin clopidogrel|protamine|the efficacy of rpf4 for the reversal of the anticoagulant effects of heparin in cardiac catheterization patients in comparison to entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|protamine quaternary cationic abstract chloride|reversal potassium itself infusion today|protamine|market opportunity unfractionated heparin ( ufh ) entity is the only available reversing agent for ufh .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|protamine quaternary cationic abstract chloride|ribosomes trna dsrna ribosome hsp70|protamine|an antigenic protein that is expressible in human cells as well as the same mrna formed as a complex with entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|drug|protamine quaternary cationic abstract chloride|pcc lmwh platelets ffp cpd|protamine|k , ffp and , more recently , pccs , while low molecular weight heparin patients needing reversal are often managed with ffp or entity .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|citalopram antidepressant ssri initiated venlafaxine|prednisone aspirin metformin allopurinol digoxin|escitalopram|( n=301 ) for the first eight weeks , followed by a two-week period in which patients discontinued study drug but continued receiving entity and placebo .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|citalopram antidepressant ssri initiated venlafaxine|fluoxetine citalopram misoprostol sertraline ondansetron|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) , effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|fluoxetine imipramine desipramine venlafaxine paroxetine|escitalopram|these results showed an increase of serotonin and dopamine after a single dose of min-117 , unlike the reference antidepressant entity which only induced a modest and transient increase .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|citalopram antidepressant ssri initiated venlafaxine|hb bupropion sertraline bz citalopram|escitalopram|to approximately 195 legal actions asserting product liability claims relating to the use of celexa® ( citalopram hbr ) ( celexa ) or lexapro® ( entity oxalate ) ( lexapro ) .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|citalopram antidepressant ssri initiated venlafaxine|reb esc dul snr sert|escitalopram|sales of lexapro® ( entity oxalate ) , an ssri indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults ,
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|citalopram antidepressant ssri initiated venlafaxine|fluoxetine sertraline venlafaxine citalopram desipramine|escitalopram|is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with entity , an anti-depressant drug .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|prototype nanocomposite fabricated polymeric promising|escitalopram|our entity thin film is currently in pre-clinical development .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|citalopram antidepressant ssri initiated venlafaxine|neuroimaging therapeutics standards informatics clozapine|escitalopram|cns clinical research division ; and forest laboratories , as director , cns clinical development , where he was involved in the development of entity ( lexapro ) .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|ind h1 2c lan pant|escitalopram|ranitidine 170 152 gemcitabine 153 143 entity oxalate 128 227 others 2 , 246 3 , 105
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|prototype polymeric vaginal nanostructured buccal|escitalopram|our entity thin film is currently in pre-clinical development and we expect to conduct pilot bioavailability / bioequivalence clinical trials during the first half
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|citalopram antidepressant ssri initiated venlafaxine|sertraline fluoxetine citalopram imipramine venlafaxine|escitalopram|that affect the serotonin system , as 176 table of contents shown recently in generalized anxiety disorder trials with the ssris entity and paroxetine .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|citalopram antidepressant ssri initiated venlafaxine|fluoxetine citalopram sertraline amitriptyline paroxetine|escitalopram|major brands include prozac ( fluoxetine ) , lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) and effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|author pri generic medic exem|escitalopram|patent infringement based on tevas filing of an abbreviated new drug application for a generic equivalent to our lexapro brand entity oxalate .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|citalopram antidepressant ssri initiated venlafaxine|statins biologics linezolid misoprostol infliximab|escitalopram|this reduction was principally due to the launch of entity in the first quarter of 2012 , our most significant product launch with shared exclusivity in the prior year .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|immigration inflation urbanization competition unemployment|escitalopram|excluding the impact of entity in both periods , third party net revenues in north america were essentially flat on a year-over-year basis .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|citalopram antidepressant ssri initiated venlafaxine|esc reb snr sert bz|escitalopram|· lexapro® ( entity oxalate ) , an ssri for the initial and maintenance treatment of mdd in adults and adolescents and generalized anxiety disorder in
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|citalopram antidepressant ssri initiated venlafaxine|curcumin donepezil bevacizumab resveratrol azithromycin|escitalopram|entity is marketed by forest laboratories , inc . under the brand name lexapro® and generated sales of $2 . 0 billion in 2006 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|another defining today what once|escitalopram|entity oxalate entity is in a class of drugs called selective serotonin reuptake inhibitors .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|citalopram antidepressant ssri initiated venlafaxine|hb bb bs bg fb|escitalopram|lexapro® : lexapro ( entity oxalate ) , our single isomer version of citalopram hbr , for the treatment of mdd in adults and adolescents and generalized anxiety
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|citalopram antidepressant ssri initiated venlafaxine|fluoxetine sertraline citalopram misoprostol ondansetron|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertaline ) and effexor xr ( venlafaxine ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|tio inhaled anticholinergic inhaler receive|theophylline budesonide corticosteroids ics ribavirin|tiotropium|boehringer-ingelheim is developing a combination product with entity and the long-acting beta agonist bi-1744 for the treatment of copd .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tio inhaled anticholinergic inhaler receive|budesonide salbutamol prednisone omeprazole vehicle|tiotropium|explore efficacy and safety at doses of 15 . 6 to 125mcg od and 15 . 6mcg and 31 . 25mcg twice daily ( bid ) compared with entity od or placebo in subjects with copd .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol budesonide theophylline prednisone ics|tiotropium|significantly greater than placebo and similar in magnitude to a combination therapy active control of salmeterol dosed twice daily plus entity dosed once daily .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tio inhaled anticholinergic inhaler receive|budesonide prednisone theophylline ics prednisolone|tiotropium|separately , a phase iii study showed that once-daily nva237 is superior to placebo and similar to entity in improving lung function in patients with moderate-to-severe copd .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tio inhaled anticholinergic inhaler receive|budesonide salbutamol vehicle ics theophylline|tiotropium|% of the patients in the study , yupelri demonstrated nominally statistically significant and clinically relevant improvements in trough fev1 versus entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol corticosteroids ics theophylline steroids|tiotropium|the studies showed that when used in conjunction with entity , indacaterol produces a significantly greater improvement in lung function than entity alone .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol theophylline budesonide mch mdi|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity , a commonly used long-acting bronchodilator , in approximately 30 patients .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|tio inhaled anticholinergic inhaler receive|clopidogrel sunitinib imatinib mtx methotrexate|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity in approximately 30 patients .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol theophylline budesonide isoproterenol erythromycin|tiotropium|phase 2a clinical trial in the united kingdom evaluating rpl554 in approximately 30 patients with copd as an add-on therapy to entity , a commonly used bronchodilator .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|tio inhaled anticholinergic inhaler receive|ics corticosteroids spirometry tio ribavirin|tiotropium|no : p27 ( a6797 ) umec / vi as step-up therapy from entity in moderate symptomatic copd : a randomized , 12-week study exhibit 99 . 4 press release issued : wednesday 18th may 2016
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tio inhaled anticholinergic inhaler receive|inhalation pharmacodynamics bronchodilator bioavailability hypothesized|tiotropium|early post-dose spirometry data suggested a more rapid onset of action than entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol budesonide theophylline atenolol atropine|tiotropium|mg and 6 mg , or placebo , dosed twice-daily for three days , in addition to a dual bronchodilator therapy comprising entity and olodaterol , a commonly used lama / laba , dosed once daily .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tio inhaled anticholinergic inhaler receive|bupivacaine ropivacaine morphine tramadol diclofenac|tiotropium|the primary analysis was to determine non-inferiority ( based on a margin of -50ml ) or superiority of umeclidinium to entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tio inhaled anticholinergic inhaler receive|oseltamivir rosiglitazone risperidone haloperidol aripiprazole|tiotropium|showed that nva237 was well-tolerated with a similar incidence of adverse events for patients treated with nva237 , placebo and open-label entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tio inhaled anticholinergic inhaler receive|od capsule tablet racemic oxycodone|tiotropium|· in both studies , placebo and open-label od entity 18mcg were comparators .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|tio inhaled anticholinergic inhaler receive|anticholinergic bronchodilator inhaled inhalation supportive|tiotropium|•verona pharma announced positive data in a 4-week phase 2b copd trial with nebulized ensifentrine on top of entity therapy .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tio inhaled anticholinergic inhaler receive|bromide atropine scopolamine anticholinergic tio|tiotropium|table of contents  braltus® ( entity bromide ) , a long-acting muscarinic antagonist , indicated for adult patients with copd , delivered via the zonda® inhaler , was launched in europe
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tio inhaled anticholinergic inhaler receive|salbutamol theophylline budesonide prednisolone bromide|tiotropium|when compared to placebo , glycopyrronium 50 mcg was also numerically higher than ol entity 18 mcg versus placebo at all-time points for trough fev1 ( day 1 and weeks 12 , 26 and 52 ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|tio inhaled anticholinergic inhaler receive|anticholinergic potassium bromide atropine tio|tiotropium|been playing a central role in the management of copd , and are currently the most common therapy in copd ( e . g . , entity bromide ; a long-acting bronchodilator ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|tio inhaled anticholinergic inhaler receive|budesonide salbutamol morphine mannitol paracetamol|tiotropium|patients were randomised 1 : 1 to umeclidinium 62 . 5mcg inhalation powder or entity 18mcg .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|reduces metabolite antidepressant clozapine improves|donepezil memantine citalopram quetiapine pregabalin|flutemetamol|in october 2013 , the fda approved entity , under the name vizamyltm , for adults being evaluated for ad and dementia with pet brain imaging .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|reduces metabolite antidepressant clozapine improves|gadolinium 123i trastuzumab 18f 99mtc|flutemetamol|in addition to fluorbetapir , there are two other beta-amyloid imaging agents available : florbetaben from piramal enterprises , imaging division , and entity from ge healthcare .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|reduces metabolite antidepressant clozapine improves|fluorodeoxyglucose flt dopa fluoride choline|flutemetamol|the filing also includes data from a recently completed [ 18f ] entity pet image reader training validation study , results of which will be presented at a scientific forum in coming months .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|reduces metabolite antidepressant clozapine improves|donepezil pittsburgh memantine sertraline risperidone|flutemetamol|as an aid to the evaluation of patients with signs of alzheimers disease : amyvid® ( florbetapir ) , marketed by lilly , and vizamyl® ( entity ) , marketed by ge healthcare .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|reduces metabolite antidepressant clozapine improves|fluorescein gadolinium egfp 123i 99mtc|flutemetamol|in addition to fluorbetipir , there are two other beta-amyloid imaging agents in late stage development : florbetaben from bayer schering and entity from general electric .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|depot acetate bromocriptine octreotide gonadotrophin|lhrh leu octreotide hmg nph|goserelin|among the different classes of peptides , gnrh / lhrh agonists ( leuprorelin , entity ) account for almost 50 percent of the market .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|depot acetate bromocriptine octreotide gonadotrophin|testosterone octreotide bromocriptine tamoxifen melatonin|goserelin|formulations such as lupron and eligard , which deliver leuprolide , trelstar , which delivers triptorelin , and zoladex , a biodegradable rod , which delivers entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|hydrocortisone docetaxel methylprednisolone fludarabine prednisolone|goserelin|patients in the second arm will receive bnt112 combined with entity acetate and cemiplimab , and patients in the third arm will receive bnt112 combined with entity acetate alone .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|depot acetate bromocriptine octreotide gonadotrophin|octreotide hydrocortisone tenofovir prednisolone mycophenolate|goserelin|primary objective of this study will be to establish the safety and tolerability of bnt112 alone , or in combination with entity acetate with or without cemiplimab .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|testosterone tamoxifen hydrocortisone octreotide estrone|goserelin|zoladex ( entity acetate implant ) is a lhrh agonist for treating prostate and breast cancer .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|depot acetate bromocriptine octreotide gonadotrophin|methylprednisolone hydrocortisone nicotine dexamethasone testosterone|goserelin|for all classes , the only astrazeneca drug at issue is zoladex™ ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|lithium strontium octreotide dexamethasone testosterone|goserelin|astrazeneca announced that it had entered into an agreement with tersera therapeutics llc ( tersera ) for the commercial rights to zoladex ( entity acetate implant ) in the u . s . and canada .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|depot acetate bromocriptine octreotide gonadotrophin|amlodipine zol dabigatran metoprolol omeprazole|goserelin|launches of generic entity ( the active ingredient in zoladex ) are expected in europe during 2012 .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|testosterone depot octreotide lhrh estrone|goserelin|zoladex ( entity acetate implant ) , available in one month and three month depots , is the worlds second largest lhrh agonist by value .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|lithium quetiapine octreotide dopamine testosterone|goserelin|in the us , the us department of justice has been conducting an investigation into the sales and marketing of zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|zol testosterone aripiprazole risperidone melatonin|goserelin|competition in the lhrh agonist market is expected to increase in europe during 2011 , with further launches of generic entity ( the active ingredient in zoladex ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|depot acetate bromocriptine octreotide gonadotrophin|testosterone hydrocortisone lhrh octreotide oestradiol|goserelin|examples of commercially marketed lhrh agonists are lupron® ( leuprolide acetate ) , zoladex® ( entity acetate ) , viadur® ( leuprolide acetate ) and eligard® ( leuprolide acetate ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|depot acetate bromocriptine octreotide gonadotrophin|ai tamoxifen ais tam ful|goserelin|lee011 + tamoxifen + entity or nsai + entity hr+ / her2- premenopausal abc 1st line 2018 iii - fully enrolled lee011 + fulvestrant hr+ / her2- postmenopausal abc 1st / 2nd line 2018 iii
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|depot acetate bromocriptine octreotide gonadotrophin|lithium metoprolol strontium cortisone hydrocortisone|goserelin|for all classes , the only astrazeneca drug at issue is zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|van bip triangle der fur|ketamine morphine oxycodone tramadol buprenorphine|biperiden|increases over the same quarter in the prior year in certain molecules including cyclizine hydrochloride , codeine phosphate + paracetomol and entity hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|octreotide depot lan somatostatin monotherapy|progesterone bioactive testosterone pegylated encapsulated|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|octreotide depot lan somatostatin monotherapy|acetate mesylate lar palmitate alfa|lanreotide|somatuline entity ( " somatuline " ) is another long- acting somatostatin analog .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|drug|octreotide depot lan somatostatin monotherapy|somatostatin octreotide bromocriptine gh testosterone|lanreotide|we look forward to advancing mycapssa as a preferred treatment option for patients with acromegaly treated with octreotide and entity injectables ,  mr . kannan concluded .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide bromocriptine somatostatin gh dexamethasone|lanreotide|on june 26 , 2020 , chiasma received fda approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|octreotide depot lan somatostatin monotherapy|progesterone bioactive nicotine testosterone pegylated|lanreotide|we do not have composition of matter patent coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide somatostatin subcutaneous depot bromocriptine|lanreotide|receptor type 2 ( sst2 ) biased agonist , in patients with acromegaly whose disease is not biochemically controlled by octreotide lar or entity depot alone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|octreotide depot lan somatostatin monotherapy|artemisinin pure bioactive inactive folate|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® autogel® ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|octreotide depot lan somatostatin monotherapy|octreotide lan somatostatin subcutaneous depot|lanreotide|hormone levels used to measure disease at 24 weeks versus continued treatment with the long acting release form of octreotide , or entity autogel , meeting the primary endpoint .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide bromocriptine gh somatostatin dexamethasone|lanreotide|week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand ( srl ) depot of either octreotide or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|octreotide depot lan somatostatin monotherapy|paclitaxel acyclovir budesonide curcumin slowly|lanreotide|the somatuline® autogel® formulation requires no excipient other than water and releases entity over a period of at least 28 days and up to 56 days .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|drug|octreotide depot lan somatostatin monotherapy|bromocriptine octreotide somatostatin gh levodopa|lanreotide|approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|octreotide depot lan somatostatin monotherapy|octreotide cetuximab trastuzumab doxorubicin mibg|lanreotide|a pilot trial involving six children with neuroblastoma cancer and seven adults with neuroendocrine cancer has been completed using entity as the targeting agent .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|octreotide depot lan somatostatin monotherapy|sc octreotide depot subcutaneous zinc|lanreotide|these products include sandostatin lar depot ( octreotide / im injection ) by novartis a . g . , and somatuline depot ( entity acetate ) by tercica inc .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|somatostatin ghrelin testosterone melatonin octreotide|lanreotide|active substance the active substance in somatuline® depot is entity , which inhibits the growth and secretion of several endocrine , exocrine and paracrine functions .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide somatostatin lan bromocriptine ghrelin|lanreotide|somatuline® depot is an injectable sustained-release formulation containing entity , a somatostatin analogue .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide somatostatin bromocriptine lan clonidine|lanreotide|surgical removal of the pituitary tumor consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide bromocriptine somatostatin clonidine lan|lanreotide|care for patients diagnosed with acromegaly consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide somatostatin lan bromocriptine analogues|lanreotide|long-acting analogues of the hormone somatostatin , such as octreotide and entity have established themselves as a primary treatment of neuroendocrine tumors , although with limited efficacy .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|somatostatin octreotide bromocriptine ghrelin lan|lanreotide|somatostatin analogs octreotide ( marketed as sandostatin ) and entity ( marketed as somatuline ) are selective for sst2 receptors and are the preferred first-line pharmacologic treatments .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|octreotide depot lan somatostatin monotherapy|octreotide bromocriptine somatostatin lar depot|lanreotide|acromegaly in the united states : sandostatin lar ( octreotide ) marketed by novartis ; signifor lar ( pasireotide ) marketed by novartis ; and somatuline depot ( entity ) marketed by ipsen .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|ceftriaxone ceftazidime colistin cefotaxime daptomycin|cefotetan|entity disodium injectable ( vial ) 1gr , 2gr , 10gr vials entity ® nda / anda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|ceftriaxone ceftazidime linezolid cefotaxime daptomycin|cefotetan|entity is a second-generation cephalosporin with a broad range of anti-microbial activity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|ceftriaxone ceftazidime cefotaxime imipenem colistin|cefotetan|entity disodium 20mg / ml injectable ( bag ) 50ml bags entity ® nda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|powder ready injectable approved propofol|cefotetan|we received fda approval for and launched our first injectable product , cefotan® ( entity for injection ) , in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|pregabalin entities itself mpa champ|cefotetan|we launched entity in september 2007 and are currently the only company to market entity in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|taxol celecoxib paclitaxel docetaxel trastuzumab|cefotetan|march 31 , 2007 were $23 . 6 million of paclitaxel ( whole plant ) , $3 . 9 million in other abraxane® related materials and $3 . 0 million of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|approved ready propofol epinephrine powder|cefotetan|and ·in december 2015 , the company received approval of its supplemental new drug application from the fda for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|propofol intended approved ready powder|cefotetan|received approval of the company  s supplemental new drug application ( snda ) from the u . s . food and drug administration ( fda ) for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|pacs projects cards prep cba|cefotetan|we launched entity in september 2007 and are currently the only company to market entity vials in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|propofol ready epinephrine powder approved|cefotetan|we have received fda approval for our first product in this portfolio , cefotan® ( entity for injection ) , which we launched in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|lidocaine betamethasone methylprednisolone diclofenac bupivacaine|cefotetan|·the company launched cefotan® ( entity disodium for injection ) and lidocaine 5% ointment in march of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|gentamicin ceftriaxone phenytoin ciprofloxacin paracetamol|cefotetan|entity is often used for surgical prophylaxis and offers the longest half-life of any cephalopsorin .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|cef ceftriaxone ciprofloxacin cephalosporin ceftazidime|alendronate betamethasone oseltamivir methylprednisolone fentanyl|cefotetan|in the third quarter , app launched entity disodium for injection .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|bupropion caffeine amphetamine topiramate clonidine|topiramate|an overactive thyroid ; by patients taking a type of anti-depressant called maoi ; or by patients who are allergic to phentermine , entity , or any of the ingredients in qsymia .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate metformin naltrexone bupropion naloxone|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus :
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|amphetamine citalopram fda ssri approved|topiramate|we anticipate that the label for qnexa , if approved , will contain the similar suicidality warnings to those contained in the entity label .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|cocaine methadone methamphetamine ssris acetaminophen|topiramate|the exercise primarily includes identifying these mother-infant pairs exposed to entity at the doses that the fda has recommended .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate bupropion naltrexone caffeine metformin|topiramate|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , phentermine / entity , under the trade name qsymia .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|carbamazepine lamotrigine topiramate valproate phenobarbital|topiramate|immediate release formulations of entity and oxcarbazepine are available in generic form and are marketed under the brand names of topamax and trileptal , respectively .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|lamotrigine carbamazepine valproate phenytoin gabapentin|topiramate|et-104 is one of etons three neurology-focused liquid product candidates , along with et-105 ( lamotrigine oral suspension ) and et-101 ( entity oral solution ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|lamotrigine topiramate carbamazepine pregabalin gabapentin|topiramate|the company has two marketed products for epilepsy , oxtellar xr ( extended-release oxcarbazepine ) and trokendi xr ( extended-release entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|raloxifene sertraline fluoxetine paroxetine tamoxifen|topiramate|in the qnexa studies , which included 15 offspring from women exposed to qnexa or entity , there were no reports of congenital malformations .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate naltrexone naloxone bupropion amphetamine|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus : authors : w . timothy garvey , md ( a ) ; craig a .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|melatonin magnesium adenosine acupuncture bdnf|topiramate|entity is believed to work in epilepsy through various mechanisms .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|naltrexone bupropion clonidine phent amphetamine|topiramate|in addition , we currently do not have manufacturing agreements in place for entity or phentermine .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate bupropion naltrexone caffeine metformin|topiramate|in july 2012 , vivus , inc . obtained fda approval for its combination product , phentermine / entity .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|lamotrigine topiramate carbamazepine pregabalin gabapentin|topiramate|the company has two marketed products for epilepsy , oxtellar xr® ( extended-release oxcarbazepine ) and trokendi xr® ( extended-release entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate bupropion naloxone naltrexone amphetamine|topiramate|and patient market research to assess potential growth of the obesity therapeutics market as well as preference shares between nb32 , phentermine / entity and lorcaserin .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|paclitaxel cyclosporine artemisinin fluoxetine carbamazepine|topiramate|the pharmaceutical company performing research of entity alone announced they had discontinued development of a time-release formulation due to side effects at high doses .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|naltrexone caffeine amphetamine topiramate bupropion|topiramate|<a  leland wilson> : we typically characterize our product as the low-dose combination of phentermine and entity , so thats what thats referring to , yes .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|taxol imatinib acetaminophen rosiglitazone roche|topiramate|u . s . attorneys office in boston , massachusetts seeking documents relating to the marketing , including alleged off-label marketing , of the drug topamax® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate bupropion quetiapine amphetamine risperidone|topiramate|qsymia® ( phentermine and entity extended release ) is approved by fda for chronic weight management .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|topiramate lamotrigine carbamazepine metabolite antiepileptic|topiramate gabapentin phenytoin phenobarbital valproate|topiramate|or aeds , available in the united states and worldwide , including the generic products levetiracetam , lamotrigine , carbamazepine , oxcarbazepine , valproic acid and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|gemcitabine carboplatin propofol ribavirin metformin|theophylline|fully funds a 36 patient phase 1 / 2 investigator-sponsored phase 1 / 2 study for use of hs-110 as a combination therapy with entity and oxygen .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|paroxetine fluoxetine midazolam sertraline citalopram|theophylline|therapeutic monitoring of cyp1a2 substrates with a narrow therapeutic index ( e . g . entity and tizanidine ) is recommended when coadministered with ocaliva .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|trough tacrolimus theophylline vancomycin cyclosporine|theophylline|monitor entity levels if concurrent administration cannot be avoided .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|salbutamol sildenafil theophylline histamine adenosine|theophylline|entity relaxes the smooth muscle of the bronchial airways and thus acts mainly as a bronchodilator .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|aspirin levodopa prednisone corticosteroid amiodarone|theophylline|when taking zyflo , entity dose should be reduced by 50% and appropriately monitored ; patients taking propranolol or warfarin should be monitored and doses adjusted
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|inhaler brand bronchodilator innovation controller|theophylline|respiratory sales growth was moderated in 1995 by lower sales of theo-dur , a sustained-action entity , due to increased generic competition .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|cosmetic contraceptive medicinal consumer herbal|theophylline|the company noted that it discontinued marketing its u . s . entity products in june 2001 and that proventil repetabs have not been available since july 2001 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|salbutamol theophylline budesonide caffeine isoproterenol|theophylline|the most commonly used oral bronchodilator is entity , a drug with good efficacy but which is capable of producing certain undesirable side effects such as disturbances in heart
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|corticosteroids theophylline steroids opioids salbutamol|theophylline|the bronchodilator agents most often used are ß2 agonists , anticholinergics , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|caffeine berberine nicotine theophylline capsaicin|theophylline|euphyllin , a drug based on a substance called entity , is used for the treatment of asthma and copd .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|standards wine cheese tablets cigarettes|theophylline|[ * * * ] entity ( including product sold under the theochron ( r ) trademark )
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|salbutamol theophylline budesonide isoproterenol methacholine|theophylline|entity and albuterol are frequently prescribed to produce dilation of bronchioles for both emphysema and chronic bronchitis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|mmf ics asa aspirin qd|theophylline|patients taking zyflo cr and entity should reduce the entity dose by 50% .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|usp tablets salbutamol otc ics|theophylline|decree also includes a recall , initiated in early may 2002 and directed to u . s . trade accounts , of all lots of entity , usp tablets and proventil ( albuterol sulfate , usp ) repetabs .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|salbutamol theophylline atropine caffeine indomethacin|theophylline|antihistamines , antiemetics , histamine h-2 receptor antagonists , barbiturates , prostoglandins , and bronchial dilators selected from the group consisting of terbutaline , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|theophylline caffeine choline adenosine atropine|theophylline|other products choledyl ( r ) choledyl ( r ) ( oxtriphylline ) is the choline salt of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|lutein sold pigments rbcs qds|theophylline|[ * * * ] entity in elixir form sold under the elixophyllin ( r ) trademark [
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|theophylline salbutamol corticosteroids prednisone aspirin|theophylline|offices and central labs to measure patient blood drug levels for the most commonly prescribed therapeutic drugs to control asthma ( entity ) and epilepsy ( carbamazepine , and phenytoin ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 1)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|allopurinol caffeine theophylline xanthine pentoxifylline|theophylline|bronchodilators dilate the airways and include beta agonists ( such as albuterol and bitolterol ) , xanthines ( such as entity ) and anticholinergics ( such as ipratropium ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|theophylline pharmacokinetics inhibits corrected pharmacokinetic|gentamicin levofloxacin ofloxacin metronidazole amikacin|theophylline|serious and fatal reactions have been reported in patients receiving concur-rent administration of ciprofloxacin and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|fur der die eine von|roche imatinib paris berlin sunitinib|inotersen|the company holds the rights for the commercialization of tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) for the treatment of rare diseases in countries in latin america and the caribbean .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|fur der die eine von|isoflurane sevoflurane ether halothane formaldehyde|inotersen|slower rate than revenue with the increase primarily due to higher sg&a expenses as ionis prepares to commercialize volanesorsen and entity this year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|fur der die eine von|pharmaceutical inventory proprietary market pharmacy|inotersen|commercial entity inventory acquired from ionis commercial inventory acquired clinical material acquired from ionis clinical material acquired liability for costs incurred and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|fur der die eine von|ada medicare fda law euthanasia|inotersen|that the defendants breached their fiduciary duties in connection with the licensing transaction that we and ionis entered into regarding entity and akcea-ttr-lrx .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|fur der die eine von|antisense imatinib oligonucleotide tacrolimus sirolimus|inotersen|akcea has received marketing approval for an antisense drug , entity that was developed by ionis , in the u . s . , the eu and canada , for the treatment of hattr amyloidosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|fur der die eine von|medicare trastuzumab dabigatran inr ngs|inotersen|the parties agree to maintain books and records for entity and ionis-ttr-lrx that will allow each party to provide the other party with net revenues , expenses ( including each cost category
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|fur der die eine von|ttr rituximab fenofibrate imatinib thalidomide|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  potentially best-in-class oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|fur der die eine von|roche ebola abbott paris france|inotersen|today announced a collaboration under which ptc will commercialize two of akceas rare disease drugs in latin america ( latam ) : tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|fur der die eine von|hamilton berlin google fda edwards|inotersen|both entity and volanesorsen are progressing toward regulatory filings for marketing authorization .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|fur der die eine von|propofol ketamine sevoflurane isoflurane dexmedetomidine|inotersen|icon clinical research limited , inc research toronto , inc . and medpace for the clinical studies for our drugs , including volanesorsen and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|fur der die eine von|thalidomide imatinib simvastatin fenofibrate others|inotersen|ag10 also will not be the first treatment on the market for attr-pn as tafamidis , patisiran , and entity are approved for the treatment of attr-pn in a variety of countries globally .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|fur der die eine von|rnai ttr imatinib ngs roche|inotersen|we created tegsedi™ ( entity ) the worlds first rna-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin ( ttr ) amyloidosis ( attr ) in adult patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2)])|drug|fur der die eine von|ttr rituximab imatinib attr fenofibrate|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|fur der die eine von|discovery integration entire construction communications|inotersen|for ionis , this transaction achieves all the goals we laid out at the outset of our entity process .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|amiodarone antiarrhythmic moxifloxacin quinidine verapamil|diclofenac ketoprofen celecoxib lidocaine pregabalin|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%fda approval received for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|amiodarone antiarrhythmic moxifloxacin quinidine verapamil|diclofenac tacrolimus budesonide azithromycin ketoprofen|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%launched in the us , received ema approval and launched in europe , and received health canada approval for the
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|amiodarone antiarrhythmic moxifloxacin quinidine verapamil|meanwhile adalimumab hence generic alternatively|nepafenac|entity , new formulation anti-inflammatory us 2011 eu 2012 approved approved - ilevro approved in q4 2012 - ilevro approved q2 2013
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|amiodarone antiarrhythmic moxifloxacin quinidine verapamil|moxifloxacin azithromycin voriconazole bevacizumab ofloxacin|nepafenac|· alcon received approval to market ilevro , a new formulation of entity ophthalmic suspension ( 0 . 3% ) , in the us .
OrderedDict([('DRUG', 5), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|amiodarone antiarrhythmic moxifloxacin quinidine verapamil|lidocaine diclofenac capsaicin celecoxib hydrocortisone|nepafenac|in august 2005 , the fda approved nevanac ( entity ophthalmic suspension ) 0 . 1% for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|malpractice civil tort criminal court|phentermine|sus has been named as a defendant in a total of 4 , 196 such entity lawsuits , in respect of which sus has been dismissed as a defendant in 3 , 936 cases .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine pregabalin gabapentin aripiprazole carbamazepine|phentermine|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , entity / topiramate , under the trade name qsymia .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine gabapentin pregabalin valproate sertraline|phentermine|qnexa is our investigational drug candidate involving low doses of entity and topiramate .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|bupropion fluoxetine metformin naltrexone topiramate|phentermine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including entity , phendimetrazine , mazindol , benzphetamine and diethylpropion .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|unlike notice fort cur meant|phentermine|entity hcl , usp sales in the year ended december 31 , 2001 reflected an increase in unit volume from the refilling of distribution
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine valproate carbamazepine gabapentin topiramate|phentermine|in particular , it is possible that patients will seek to acquire entity and topiramate , the generic components of qsymia .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|fluoxetine amphetamine bromocriptine methamphetamine bupropion|phentermine|a defendant in more than two thousand five hundred multi-defendant lawsuits involving the manufacture and sale of dexfenfluramine , fenfluramine , and entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|cannabis aspirin amiodarone methadone propofol|phentermine|the lawsuits allege that the manufacturers of entity knew that its use could cause serious side effects , but failed to warn against those dangers .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|topiramate metformin olanzapine lithium bupropion|phentermine|to fisons ) and 585 ( as to rugby ) personal injury lawsuits in the u . s . ( including class actions ) concerning the weight-loss drug entity ( fisons brand name ionamin ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|pregabalin lamotrigine topiramate gabapentin quetiapine|phentermine|the equate study also contained a mid-dose of qnexa containing 46 mg of topiramate cr and 7 . 5 mg of entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|topiramate gabapentin pregabalin bupropion lamotrigine|phentermine|drug candidate for the treatment of obesity , incorporating low doses of active ingredients from two previously approved products , topiramate and entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|topiramate metformin fluoxetine olanzapine quetiapine|phentermine|contrary to the approved labelling of these products , physicians in the us co-prescribed entity with fenfluramine or dexfenfluramine for management of obesity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine aripiprazole gabapentin topiramate risperidone|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( &#x201c ; fda&#x201d ; ) for chronic weight management .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|bupropion fluoxetine metformin topiramate naltrexone|phentermine|entity is the largest selling antiobesity therapeutic and is available in several generic forms .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|nicotine bupropion fluoxetine papaverine sertraline|phentermine|&#160 ; the company had one approved and marketed product , suprenza ( entity hydrochloride ) , which it had out licensed for promotion in the united states , canada and mexico .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|fluoxetine bupropion venlafaxine sertraline paroxetine|phentermine|to a decline in both unit volume and selling prices of fluvoxamine maleate and a decline in unit volume of entity hcl , usp .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|gabapentin topiramate lamotrigine diazepam metformin|phentermine|as expected , the chmp recommended against approval of the marketing authorization application ( maa ) for qsiva ( entity / topiramate er ) for the treatment of obesity in the european union .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine pregabalin gabapentin cbt ketamine|phentermine|entity is sold at much lower prices than we charge for qsymia .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|metformin olanzapine statins topiramate bupropion|phentermine|there are a number of generic pharmaceutical drugs that are prescribed for obesity , predominantly entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|methamphetamine hydrochloride cocaine ingested amphetamine|lamotrigine gabapentin aripiprazole topiramate risperidone|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( “fda” ) for chronic weight management .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|erythropoietin melatonin oxytocin curcumin testosterone|carvedilol|which is available as both an oral and an iv formulation , and querto® , a therapeutic based on a substance called entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|metoprolol succinate carvedilol propranolol atenolol|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|carvedilol metoprolol atenolol propranolol sildenafil|carvedilol|coreg ( entity ) is a beta-blocker indicated for the treatment of congestive heart failure and flomax ( tamsulosin ) is indicated for the treatment of
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|dexamethasone mycophenolate dextran pyridoxal oseltamivir|carvedilol|flamel technologies has collaborations with a number of leading pharmaceutical and biotechnology companies , including glaxosmithkline ( coreg cr® , entity phosphate ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|potassium creatine pyridoxal sildenafil atorvastatin|carvedilol|entity phosphate is indicated for the treatment of hypertension and heart failure .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|proprietary investigational pharmaceutical approved generic|carvedilol|teva and numerous other generic producers began selling their entity tablets ( the generic version of coreg® ) in september of 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|rapamycin carvedilol cyclosporine sildenafil dabigatran|carvedilol|european marketing application submitted in october 2014 ; and ( ix ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|gsk investigational approved proprietary generic|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|clindamycin dexamethasone oseltamivir codeine sildenafil|carvedilol|this technology has successfully transitioned to commercial stage with coreg cr® , a micropump-based controlled-release formulation of entity phosphate , sold in the us since 2007 by gsk .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|budesonide ibuprofen paracetamol misoprostol aspirin|carvedilol|first part of the market includes generic drugs based on the immediate release of the generic active ingredient known as entity ( such as coreg® produced by glaxosmithkline ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|dexamethasone clindamycin codeine oseltamivir betamethasone|carvedilol|when we entered into a license agreement for use of our micropump platform for an extended release formulation of entity phosphate .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|rapamycin donepezil artemisinin dabigatran rosiglitazone|carvedilol|planned for the third quarter of 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|rapamycin carvedilol dabigatran enoxaparin cyclosporine|carvedilol|european marketing application submitted in october 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|omeprazole levofloxacin ciprofloxacin amoxicillin metronidazole|carvedilol|during fiscal 2008 , we launched entity tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , terbinafine and ciprofloxacin er tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|proprietary pharmaceutical approved medicinal investigational|carvedilol|teva would be permitted to continue selling its entity products , given that gsk  s patent has expired .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|valsartan amlodipine carvedilol losartan spironolactone|carvedilol|since 1991 , entity has been approved as a treatment for hypertension in several european countries , and in september 1995 , it was approved by
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|comparator diuretic dihydropyridine bronchodilator statin|carvedilol|bucindolol in sort of all comers , what you see is a data set that compares favorably to metoprolol or a entity , at least on the data that are available .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|medicinal pharmaceutical proprietary herbal patent|carvedilol|successful in its allegations of patent infringement , teva could be required to pay damages relating to past sales of its entity products .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|gsk investigational approved proprietary generic|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol pharmacokinetics metabolite tolerated|metoprolol succinate carvedilol propranolol atenolol|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|yellow agar gave blue saccharomyces|melatonin topiramate ondansetron bupropion orexin|lemborexant|merck is marketing belsomra® ( suvorexant ) and eisai is marketing dayvigo® ( entity ) which are dual orexin receptor antagonists indicated for insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|yellow agar gave blue saccharomyces|ox dor intranasal max sal|lemborexant|in december 2019 , eisai announced u . s . fda approval of dayvigo™ ( entity ) , a dual orexin receptor antagonist for the treatment of insomnia in adult patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|yellow agar gave blue saccharomyces|ssris topiramate memantine ondansetron cannabinoids|lemborexant|purdue and eisai are developing entity and glaxosmithkline is developing sb-649868 which are also dual orexin receptor antagonists .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|omeprazole ppis bismuth reduces pylori|enoxaparin rivaroxaban lmwh dabigatran clopidogrel|lansoprazole|volume was flat as a result of competition on us sales of enoxaparin , lost us authorized generics of gemcitabine and entity in the prior year , and lower sales in germany .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|omeprazole ppis bismuth reduces pylori|ppi omeprazole hcl sc ta|lansoprazole|the principal indications for prevacid ( entity ) , a proton pump inhibitor , are for short-term treatment of duodenal ulcers , gastric ulcers and erosive esophagitis .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|omeprazole ppis bismuth reduces pylori|olanzapine methylphenidate azithromycin oxycodone cyclosporine|lansoprazole|in september 2008 , abbott and takeda settled that patent infringement lawsuit against apotex and apotex was allowed to begin selling generic entity capsules in canada on may 1 , 2009 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|omeprazole ppis bismuth reduces pylori|celecoxib pregabalin clopidogrel metformin donepezil|lansoprazole|the original united states compound patent covering entity is licensed by tap from takeda and will expire in 2009 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|omeprazole ppis bismuth reduces pylori|name proprietary intended generic approved|lansoprazole|with tap pharmaceutical products inc . , or tap , granting tap the right to develop one or more products based on its entity ppi product and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole ranitidine cimetidine misoprostol amoxicillin|lansoprazole|in the treatment of reflux oesophagitis , it provides healing and symptom relief in more patients than losec / prilosec , entity or pantoprazole .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|omeprazole ppis bismuth reduces pylori|chemicals pharmaceuticals nucleotides pesticides dyes|lansoprazole|to tap the north american rights to develop , manufacture and sell products resulting from the use of our technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|omeprazole ppis bismuth reduces pylori|liposomes vaccines paclitaxel sirna pharmaceuticals|lansoprazole|our ongoing work with tap pharmaceuticals on an improved formulation of entity continues to progress smoothly .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|omeprazole ppis bismuth reduces pylori|newly brand marketing generic simultaneously|lansoprazole|million ) , which caused pricing to decline , as well as nearly usd 100 million of prior-year sales of sandozs gemcitabine and entity authorized generics .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|omeprazole ppis bismuth reduces pylori|ranitidine cimetidine omeprazole naproxen erythromycin|lansoprazole|dosage forms of acetaminophen , and an improved method of manufacturing for drugs requiring protection from stomach acid , such omeprazole and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|omeprazole ppis bismuth reduces pylori|purity purification potency impurities reproducibility|lansoprazole|with respect to omeprazole and entity , we believe that we have created an improved method of manufacture , requiring less time and producing higher purity amid better
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole ppis ppi prodrugs analogs|lansoprazole|the north american rights to develop , manufacture and sell products resulting from the use of our immediate-release ppi technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole ranitidine clarithromycin cimetidine amoxicillin|lansoprazole|nexium ( esomeprazole ) is the first proton pump inhibitor ( ppi ) to offer significant clinical improvements over losec / prilosec and its main competitors , entity and pantoprazole .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|omeprazole ppis bismuth reduces pylori|prep ppt pit tps ppm|lansoprazole|tap also markets prevacid-registered trademark- ( entity ) , a proton pump inhibitor , and has a co-promotion arrangement with the company for prevacid-registered trademark- .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|omeprazole ppis bismuth reduces pylori|celecoxib misoprostol diclofenac omeprazole cimetidine|lansoprazole|prevonco™ for the treatment of solid tumors , contains a currently third-party marketed anti-ulcer compound , entity , for the treatment of solid tumors .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|omeprazole ppis bismuth reduces pylori|risperidone donepezil celecoxib sildenafil metformin|lansoprazole|sales of entity , which was launched in december 2004 , accounted for 8% of our branded pharmaceutical revenues during the six months ended june 30 , 2005
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole tablets ppis xl retard|lansoprazole|pantoprazole faces competition from various other branded ppis , including takedas entity and astrazenecas esomeprazole .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|omeprazole ppis bismuth reduces pylori|celecoxib curcumin berberine misoprostol diclofenac|lansoprazole|prevonco™ for the treatment of solid tumors , contains a marketed anti-ulcer compound , entity , that could be used alone or in combination with other chemotherapeutic agents .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole max ppi csa inh|lansoprazole|tap also markets prevacid® ( entity ) , a proton pump inhibitor .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|omeprazole ppis bismuth reduces pylori|omeprazole ppis ranitidine misoprostol cimetidine|lansoprazole|preceding these notable launches , takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990s with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|topical itraconazole cream reduces ketoconazole|fluconazole voriconazole itraconazole ketoconazole metronidazole|terconazole|prescription drugs in the antifungal field include nizoral ( ketoconazole ) , sporanox ( itraconazole ) , terazol ( entity ) and daktarin ( miconazole nitrate ) antifungal products .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|topical itraconazole cream reduces ketoconazole|ketoconazole itraconazole fluconazole voriconazole metronidazole|terconazole|product in this category which does not contain a fungicide such as 95 table of contents clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|topical itraconazole cream reduces ketoconazole|itraconazole voriconazole ketoconazole metronidazole fluconazole|terconazole|the approved prescription therapies for vvc are diflucan ( fluconazole ) and terazol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|topical itraconazole cream reduces ketoconazole|itraconazole ketoconazole fluconazole voriconazole neomycin|terconazole|a probiotic , purfem is the only product in this category which does not contain a fungicide such as clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|ast otc acetaminophen xl inh|azelastine|the astelin ( entity ) tablet nda for asthma will be withdrawn as soon as it is no longer needed to support the other two
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|ast otc intranasal ai alt|azelastine|the astelin ( entity ) tablet nda for rhinitis is pending at the fda .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|3m mel tma 1a grass|azelastine|division the division had a successful year highlighted by the first full year of marketing a new antihistamine , 2 astelin ( entity ) nasal spray .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|histamine scopolamine hydrocortisone omeprazole oseltamivir|azelastine|in august 2002 , we entered into an agreement with medpointe inc . to co-promote medpointe  s nasal-spray antihistamine , astelin® ( entity hcl ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|histamine 3m hcl intranasal h2|azelastine|in august 2002 , we signed an agreement with medpointe , inc . for the co-promotion of astelin® ( entity hcl ) , a nasal-spray antihistamine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antihistamines dabigatran topical pharmacokinetics antihist|intranasal budesonide generic lot spray|azelastine|on october 1 , 2004 , we terminated our co-promotion agreement with medpointe , inc . , or medpointe , for the co-promotion of astelin brand entity hcl for the treatment of allergic rhinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|von van ku za your|roche omeprazole budesonide nov sc|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of april 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|von van ku za your|roche xl valsartan everolimus q10|patiromer|on october 21 , 2015 , the u . s . food and drug administration , or fda , approved our first drug , veltassa® ( entity ) for oral suspension , or veltassa , for the treatment of hyperkalemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|von van ku za your|potassium binder spironolactone losartan everolimus|patiromer|relypsas lead product candidate is entity , which is also known as rly5016 , is a non-absorbed potassium binder that is currently being evaluated for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|von van ku za your|spironolactone losartan valsartan amlodipine amiloride|patiromer|also aware of two products for which regulatory approval in the united states has been sought for treatment of hyperkalemia , entity from relypsa and zs-9 from zs pharma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1), ('BIO', 1)])|drug|von van ku za your|psychiatry infertility epilepsy telemedicine abortion|patiromer|veitinger , a member of our board of directors , under which dr . veitinger provides certain consulting services to us in connection with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|von van ku za your|roche cfc xl 3m gras|patiromer|to hospitals / other institutions for the full month of march and the three month period ended march 31 , 2016 for veltassa ® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|von van ku za your|pharmaceuticals medicines japan taiwan india|patiromer|the agreement , dsm fine chemicals has agreed to manufacture and supply for commercial sale the active pharmaceutical ingredient ( api ) for entity , the companys lead product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|von van ku za your|another marketed artemisinin antimalarial antiretroviral|patiromer|drug discovery technology or by selectively pursuing the in-licensing or acquisition of additional compounds that would be commercially synergistic with entity fos .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|drug|von van ku za your|osteoporosis psoriasis osteoarthritis epilepsy oncology|patiromer|if the companys new drug application for entity is not accepted by the fda on or before december 31 , 2013 , 25% of the shares subject to the option shall
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|von van ku za your|roche q10 h1n1 inh rsv|patiromer|we are substantially dependent on the success of our first and only drug , veltassa® ( entity ) for oral suspension , or veltassa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|von van ku za your|pharmaceuticals pay substitute market medicines|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the u . s . until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|drug|von van ku za your|nd nip injectable intranasal inhaled|patiromer|we are not permitted to market entity fos in the u . s . until we receive approval of our nda from the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|drug|von van ku za your|rhu vi cand rfvi injectable|patiromer|in this offer to purchase ) with vifor fresenius medical care renal pharma ltd . ( vfmcrp ) , an affiliate of galenica , to commercialize entity fos outside of the united states and japan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|von van ku za your|roche omeprazole budesonide sc nov|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of february 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|von van ku za your|pay pharmaceuticals substitute prescribe market|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the united states until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|drug|von van ku za your|topical inhaled intranasal injectable subcutaneous|patiromer|relypsa intends to commercialize entity fos , if approved , with its own dedicated u . s . -based commercial team and specialty sales force of approximately 120 sales representatives .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|von van ku za your|potassium spironolactone kcl bicarbonate acetate|patiromer|the challenge all potassium binders ( e . g . entity ) have limited efficacy on per gram basis therapeutic dose for kayexelate , entity or zs-9 substantially the same ( 15-30 g / day )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|von van ku za your|your partnership innovative accelerated oncology|patiromer|business entity clinical development program—pivotal phase 3 trial , page 101 please expand your discussion of your results to identify the serious adverse
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|von van ku za your|chitosan inulin cellulose mannitol metformin|patiromer|entity is a non-absorbed , potassium binding polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|von van ku za your|vel nov vb vic bay|patiromer|veltassa ( entity fos ) , an oral , polymer-based potassium binder , was approved for marketing by the fda in october 2015 and was commercially launched
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion methylphenidate amphetamine chlorpromazine methamphetamine|benzphetamine|several older agents , indicated for short-term administration , are amphetamine-like compounds including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion topiramate naltrexone quetiapine clozapine|benzphetamine|in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion topiramate naltrexone quetiapine metformin|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion naltrexone topiramate chlorpromazine methylphenidate|benzphetamine|several older drugs , indicated for short-term administration , include phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|metabolite metabolized benzodiazepine cocaine racemic|hydrochloride benzoate agonists esters palmitate|benzphetamine|the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , 33 table of contents entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion naltrexone topiramate quetiapine bromocriptine|benzphetamine|products in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion methylphenidate chlorpromazine amphetamine risperidone|benzphetamine|several older drugs , indicated for short-term administration , have an amphetamine-like profile , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|metabolite metabolized benzodiazepine cocaine racemic|fenofibrate atorvastatin bel 5mg tablets|benzphetamine|mg tab mysoline® promethazine 12 . 5 , 25 , 50mg tab ( 2 separate andas ) phenergan® fenofibrate 54 , 160mg tab lofibra® entity 50mg tab didrex® not currently marketed .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|metabolite metabolized benzodiazepine cocaine racemic|bupropion topiramate naltrexone quetiapine metformin|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , mazindol , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|ceftriaxone ciprofloxacin vancomycin rifampicin minocycline|ciprofloxacin|infecton® is the proprietary combination of the widely used antibiotic , entity , with technetium ( 99mtc ) , the most commonly used radioisotope in nuclear medical imaging .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('DIS', 2), ('OTHER', 2)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|antipsychotics benzodiazepines neuroleptics cannabis opioids|ciprofloxacin|should inform their physician if they are taking , or planning to take , any prescription or over-the-counter drugs , especially antidepressants and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|moxifloxacin ciprofloxacin levofloxacin fluoroquinolone topical|ciprofloxacin|about otiprio® otiprio ( entity otic suspension ) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|ciprofloxacin antibacterial azithromycin topical injectable|ciprofloxacin|bayer corporation has developed a once-daily entity product for the treatment of urinary tract infections , which is currently marketed by schering-plough corporation .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|bupropion donepezil fluoxetine ketamine sertraline|ciprofloxacin|and we agreed to settle the then pending litigation regarding bayer  s patent protecting entity hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|patent proprietary landmark federal unpublished|ciprofloxacin|carlsbad has withdrawn all other defenses it had originally raised challenging the validity and enforceability of bayer ag  s entity patent .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|metformin dabigatran donepezil ibuprofen enoxaparin|ciprofloxacin|we intend to begin marketing and selling the tablet dosage form of entity through our alliance with lannett if and when anda approval is given by the fda and following the expiration of
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|topical lidocaine pilocarpine budesonide prostaglandin|ciprofloxacin|otiprio ( entity otic suspension ) is the first drug approved in the united states for use during tympanostomy tube placement ( ttp ) surgery and
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|metronidazole azithromycin ceftriaxone ciprofloxacin amoxicillin|ciprofloxacin|entity is approved as therapy for infectious diarrhea with a dosing regimen of twice daily administrations for five to seven days .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|expiration money employers medicare pay|ciprofloxacin|if we lost our patent protection for entity , or if the expiration of the patent were accelerated to october 2002 , we believe that we would forego significant revenue .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|another your what my whatever|ciprofloxacin|if we are not already distributing the product , we , along with our partner , will have the right to begin distributing entity product manufactured by bayer .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|proprietary pharmaceutical finished entire generic|ciprofloxacin|the decrease in the quarter reflects the launch of the company  s entity product on june 9 , 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|ciprofloxacin metronidazole ceftriaxone ampicillin azithromycin|ciprofloxacin|limitations of entity , rifaximin and tmp / smx , three of the most commonly prescribed treatments for infectious diarrhea , include one or more of the following :
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|benzodiazepines acetaminophen marijuana cocaine aspirin|ciprofloxacin|based on the plaintiffs expert testimony in the california case , estimated sales of entity in california were approximately $500 million during the alleged damages period .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|surveys condoms news vaccines reminders|ciprofloxacin|pursuant to the terms of the agreement , we began distributing entity on june 9 , 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|meeting scot annual grant spring|ciprofloxacin|year ended march 31 , 2002 2003 entity hcl rs .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|ciprofloxacin levofloxacin quinolones moxifloxacin fluoroquinolones|ciprofloxacin|gyra and parc are the targets of the fluoroquinolone class of antibacterial agents , such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|gsk qt valsartan rosiglitazone org|ciprofloxacin|the fda placed the valortim® / entity study on partial clinical hold pending the outcome of the investigation .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|ciprofloxacin moxifloxacin levofloxacin doxycycline ofloxacin|ciprofloxacin|proquin® xr ( entity hydrochloride ) is a once-daily treatment for uncomplicated urinary tract infections that the company no longer manufactures or markets .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ciprofloxacin mic vancomycin ofloxacin fluoroquinolone|private patent civil pharmaceutical federal|ciprofloxacin|we intend to continue taking vigorous action to maintain our entity patent rights in the united states through their normal expiry in december 2003 .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|chloride sulphate hydroxide sulfide gluconate|sulfadiazine|the most common topical antimicrobial agent used is silver entity cream .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|chloride sulphate acetate hydroxide sulfide|sulfadiazine|wound epithelialization was 11 days for patients treated with transcyte as compared to 18 days for patients treated with silver entity cream .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|dressings dressing chloride patches tape|sulfadiazine|as compared to silver entity , dermagraft-tc may reduce the pain , time and cost associated with once or twice daily dressing changes and excision .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|chloride sulphate hydroxide dressings ointment|sulfadiazine|a number of studies have been conducted which compared the efficacy of collagenase santyl ( r ) to standard treatment ( silver entity ) for deep second degree burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|dressing dressings allergy hydroxide coating|sulfadiazine|intended for delivery through the skin ) for the treatment of burns that is expected to not only reduce infection ( silver entity ) , but also enhance tissue growth .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|aeruginosa glycoprotein carinii glutathione selectin|sulfadiazine|in this same model , d2a21 demonstrated significant improvement in percent survival ( 85% versus 0% in the control group , p entity ( ssd ) and sulfamylon .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|sulphate dressings chloride dressing powder|sulfadiazine|in a clinical trial under a physician  s ide , transcyte was evaluated as an alternative to silver entity in the treatment of patients with limited to moderate partial-thickness burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|dressings dressing ointment sulphate patches|sulfadiazine|transcyte was compared to silver entity which had twice daily dressing changes and wound debridement as per the burn center  s standard practice .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|chloride sulphate sulfide citrate granules|sulfadiazine|sildaflo is a dressing that incorporates silver 6 entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|dressings chloride sulphate dressing patches|sulfadiazine|in partial-thickness burns , dermagraft-tc , as compared to silver entity , has been shown to significantly reduce pain and to heal burns faster and with less scarring .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|topical formulated injectable proprietary investigational|sulfadiazine|entity silver ointment health product designed to assist in the prevention of infections related to burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|sulphate chloride dressings hydroxide powder|sulfadiazine|transcyte , as compared to silver entity in treating second degree burns , has been shown to heal burns faster .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|chloride sulphate sulfide acetate hydroxide|sulfadiazine|sildaflo is a dressing that incorporates silver entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|topical injectable prophylactic formulated liposomal|sulfadiazine|entity silver ointment designed to the treatment or the prevention of infections related to burns .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|topical transdermal patent injectable fine|sulfadiazine|banlangen tablets , dansheng tablets and entity silver ointment remain listed in the updated state insurance catalogue .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|drug|sulph sulf trimethoprim sulfamethoxazole sulfon|topical fine injectable sublingual transdermal|sulfadiazine|at present , xuesaitong soft capsules and entity silver ointment have already been listed in the insurance catalogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ser fue ile del que|aripiprazole quetiapine spironolactone olanzapine topiramate|conivaptan|the study evaluated both 20 and 40 mg / day doses of entity in hyponatremic patients and was conducted at 26 u . s . and 2 international centers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ser fue ile del que|vap roche rsv psi h1n1|conivaptan|of an open label multicenter study adding to the growing body of literature supporting the efficacy and use of vaprisol ( entity ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ser fue ile del que|metoclopramide lidocaine ondansetron olanzapine phenylephrine|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ser fue ile del que|glycine metoclopramide lidocaine phenylephrine dopamine|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol is an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|linezolid enoxaparin haloperidol risperidone doxycycline|roflumilast|two of our newest products , daliresp ( entity ) and viibryd ( vilazodone hcl ) became available to patients during the june 2011 quarter and were formally launched in late august
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|atenolol metoprolol carvedilol timolol atropine|roflumilast|and these products were nebivolol , milnacipran , ceftaroline , entity , aclidinium , linaclotide , levomilnacipran and cariprazine .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|ice metronidazole capsaicin progesterone nicotine|roflumilast|pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing entity cream , entity foam , arq-252 or arq-255 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|sildenafil ppi mdi tad pde|roflumilast|one such treatment is an oral formulation of a pde4 inhibitor ( entity ) with anti-inflammatory properties , although frequency of adverse events has limited its use in copd patients .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|sildenafil roche canada rsv xl|roflumilast|this year in addition to teflaro . in addition , we are hopeful to obtain fda approval later this quarter for daxas ( entity ) , for the treatment of copd .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|ds ads q10 dds das|roflumilast|q31 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|dpi budesonide salbutamol theophylline azithromycin|roflumilast|* forced expiratory volume in 1 second , primary endpoint of the ratio trial table of contents pharmaceuticals 9 entity , administered at a daily dose of 500 µg , is an effective product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|ld dex lev xl lt|roflumilast|daliresp ( entity ) , our selective phosphodiesterase 4 ( pde4 ) enzyme inhibitor indicated for the treatment to reduce risk of exacerbations in patients with severe
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|others contraindications beyond tolerability smokers|roflumilast|as oral administration ariflo® ( cilomilast ) of glaxosmithkline pharmaceuticals , recently found approvable for maintenance of lung function in certain patients , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|unpublished usp fda phd canada|roflumilast|daliresp ( entity ) us patent proceedings in 2015 and subsequently , in response to paragraph iv notices from multiple anda filers , astrazeneca filed patent
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|corticosteroids steroids retinoids anesthetics pharmacotherapy|roflumilast|each of these areas present a variety of treatment challenges which may be well suited to treatment with topical entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|sildenafil theophylline misoprostol tad bupropion|roflumilast|in addition , we did not observe the gastrointestinal or other side effects associated with entity , the only pde4 inhibitor currently on the market approved for the treatment of copd .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|sildenafil azithromycin tio moxifloxacin carvedilol|roflumilast|entity was generally well tolerated in the treatment of patients with copd .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|unpublished eu usp fda phd|roflumilast|daliresp ( entity ) patent proceedings in the us in april 2015 , astrazeneca received several paragraph iv notices challenging certain patents listed in the
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|ds ads q10 d3 qt|roflumilast|q34 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|sildenafil theophylline tad papaverine venlafaxine|roflumilast|our clinical trials , and has not been observed to result in the gastrointestinal or other side effects commonly associated with entity , the only pde4 inhibitor currently on the market .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|ds ads q10 d2 d3|roflumilast|q33 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|cer aver ce savings gdp|roflumilast|daliresp / daxas ( entity ) copd $215m , up 14% ( 15% at cer ) growth driven by favourable affordability-programme changes and inventory movements in the us .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|dmso nacl ipm naoh naocl|roflumilast|we therefore elected to reduce the maximum concentration from 0 . 5% entity to 0 . 3% entity for subsequent development .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|noninferior rosiglitazone dexamethasone erlotinib xr|pharmaceutical generic tablet nicotine compact|roflumilast|page 4 investment projects 2003 altana pharma will establish an ultra-modern entity tablet-producing factory in cork , ireland .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|reduces corrected chloroquine hydrochloride prevents|valsartan losartan enalapril atenolol atorvastatin|levamlodipine|simceres strategic cardiovascular portfolio also continues to grow with our recently launched cholesterol lowering drug rosuvastatin and hypertension drug entity both performing well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|what another why your neither|potassium zinc copper nitrite ferrous|butoconazole|the caption immediately below the picture of gynazole-1 ( r ) reads : " gynazole-1 ( r ) ( entity nitrate ) vaginal cream 2% only one dose .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|what another why your neither|potassium sildenafil magnesium nitroglycerin gallium|butoconazole|the product combines roche  s proprietary entity nitrate with kv  s proprietary site release ( r ) drug delivery technology .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|what another why your neither|tamoxifen topical econ octyl vaginal|butoconazole|its licensing partner , ferring , inc . of canada has received approval from the canadian regulatory agency , hpb to market kv  s gynazole-1 ( r ) ( entity nitrate 2% vaginal cream ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|what another why your neither|cellulose chlorhexidine ferric topical metronidazole|butoconazole|important safety information for gynazole-1 ( entity nitrate vaginal cream usp , 2% ) 5 . 7% of patients enrolled in the gynazole●1 clinical trials reported complaints such as vulvar / vaginal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|what another why your neither|ferric potassium ethanolic topical chlorhexidine|butoconazole|gynazole-1 ( r ) ( entity nitrate 2% ) is a rapidly growing branded prescription vaginal antifungal product indicated for the local treatment of vulvovaginal candidiasis in butoconazole 
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 3)])|disease|dysplasia mimic chondro mimics resembles|t1dm t1d ibd jia t2dm|achondroplasia|january 2014 , we announced the initiation of a phase 2 clinical trial for vosoritide for the treatment of children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 3)])|disease|dysplasia mimic chondro mimics resembles|t1dm t1d ibd jia iddm|achondroplasia|the phase 3 study is a randomized , placebo-controlled study of vosoritide in approximately 110 children with entity ages 5-14 for 52 weeks .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|dysplasia mimic chondro mimics resembles|fibromyalgia rls psoriasis oab osteoporosis|achondroplasia|currently , there are no medical therapies for entity approved by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dysplasia mimic chondro mimics resembles|osteoporosis oi pah ckd osteopenia|achondroplasia|in animal models of entity , administration of synthetic cnp and cnp analogues rescued the impaired bone growth phenotype without significant adverse effects .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|dysplasia mimic chondro mimics resembles|neuroblastoma leukemia aml medulloblastoma autism|achondroplasia|we announced the initiation of a phase 2 clinical trial for bmn 111 for the treatment of children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|dysplasia mimic chondro mimics resembles|epilepsy disabilities autism psychosis aphasia|achondroplasia|this is approximately 25 percent of people with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|dysplasia mimic chondro mimics resembles|epilepsy disabilities autism psychosis ckd|achondroplasia|this is approximately 25% of people with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|dysplasia mimic chondro mimics resembles|melanoma oncology registration approval biologics|achondroplasia| bmn-111 for entity : the company expects to initiate a phase 2 trial in patients in mid 2013 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 2)])|disease|dysplasia mimic chondro mimics resembles|t1d jia t1dm ibd psoriasis|achondroplasia|on july 23 , 2020 , the company announced that it had submitted the maa for vosoritide for the treatment of children with entity to the ema .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|dysplasia mimic chondro mimics resembles|cnp osteoporosis glaucoma acromegaly osteoarthritis|achondroplasia|the goal is to provide a safer and more efficacious therapy for entity , than daily administration of short-acting cnp analogues .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|dysplasia mimic chondro mimics resembles|adv aml rhabdomyosarcoma t1d ae|achondroplasia|global phase 2 multiple dose , randomized study to assess the safety , tolerability , pharmacokinetics and efficacy of recifercept in children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 4)])|disease|dysplasia mimic chondro mimics resembles|t1d t1dm t2dm jia iddm|achondroplasia|continuing studies include our phase 3 study of vosoritide in approximately 110 children with entity for 52 weeks and a long-term open-label phase 2 study of approximately 23 children .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dysplasia mimic chondro mimics resembles|acromegaly scoliosis thalassaemia autism pws|achondroplasia|transcon cnp is being developed for the treatment of entity , the most common form of dwarfism .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|dysplasia mimic chondro mimics resembles|chf cancers malignancies cachexia sepsis|achondroplasia|genetically-defined cancers , and bmn-111 , a modified c-natriuretic peptide , which is currently in phase i clinical development for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|dysplasia mimic chondro mimics resembles|syndromes osteoporosis immunodeficiency cancers deletions|achondroplasia|natriuretic peptide , or cnp , is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause entity resulting in dwarfism .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|dysplasia mimic chondro mimics resembles|psoriasis osteoarthritis t2dm sepsis osteoporosis|achondroplasia|rapid clinical development and ( iv ) the possible approval and commercialization of biomarins product candidates , including vosoritide for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|dysplasia mimic chondro mimics resembles|gestational chronological corrected documented menstrual|achondroplasia|the phase 2 study is a randomized , placebo-controlled study of vosoritide in approximately 70 infants and young children with entity ages zero to less than 60 months for 52 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial hereditary infantile autosomal inherited|ald hemodialysis neuroblastoma retinoblastoma europe|adrenoleukodystrophy|we will also regain control of the preclinical programs in entity ( ald ) and two ophthalmic programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|familial hereditary infantile autosomal inherited|aneurysms infarction ischaemia vasospasm palsy|adrenoleukodystrophy|european medicines agency ( ema ) granted an accelerated assessment to elivaldogene autotemcel ( eli-cel , lenti-d gene therapy ) for the treatment of cerebral entity ( cald ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial hereditary infantile autosomal inherited|crystallography immunodeficiency thrombocytopenia immunoassay inheritance|adrenoleukodystrophy|trb : x-linked entity , plans current status evaluation of vk0214 ongoing , encouraging in vitro results in vivo model in progress poc results expected 2016
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial hereditary infantile autosomal inherited|palsy microdialysis dystrophy hypoperfusion revascularization|adrenoleukodystrophy|cerebral entity ( cald ) the cald platform includes three patent portfolios , described below .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|familial hereditary infantile autosomal inherited|osteoporosis psoriasis osteoarthritis epilepsy autism|adrenoleukodystrophy|our lenti-d product candidate has been granted orphan drug status by the fda and the ema for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|familial hereditary infantile autosomal inherited|ald thrombocytopenia amyloidosis recessive hypercholesterolemia|adrenoleukodystrophy|our second trß agonist is vk0214 , which we are evaluating in the orphan disease known as x-linked entity , or x-ald .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|familial hereditary infantile autosomal inherited|palsy vasospasm ischaemia aneurysms toxoplasmosis|adrenoleukodystrophy|our lenti-d product candidate to treat cerebral entity ( cald ) •
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial hereditary infantile autosomal inherited|genetics palsy sequencing tdt tomography|adrenoleukodystrophy|on our two most advanced programs in tdt and cerebral entity , these data will dictate the timing and path for future regulatory submissions in the us and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|familial hereditary infantile autosomal inherited|ald amyloidosis steatohepatitis hypercholesterolemia thrombocytopenia|adrenoleukodystrophy|vk0214 is being evaluated as a potential treatment for x-linked entity ( x-ald ) , a devastating disease caused by a defect in a peroxisomal transporter called abcd1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|disease|familial hereditary infantile autosomal inherited|acetazolamide glaucoma ranibizumab bevacizumab memantine|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|familial hereditary infantile autosomal inherited|myeloma oncology leukemia sarcoma melanoma|adrenoleukodystrophy|clinical study of our bb2121 product candidate in relapsed / refractory multiple myeloma and updates on our lenti-d program in cerebral entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|familial hereditary infantile autosomal inherited|others thalassemia autism thalassaemia gout|adrenoleukodystrophy|diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases , such as krabbe syndrome , metachromatic leukodystrophy , hurler syndrome and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|disease|familial hereditary infantile autosomal inherited|acetazolamide glaucoma ranibizumab bevacizumab memantine|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|familial hereditary infantile autosomal inherited|palsy hemorrhage atrophy haemorrhage lobar|adrenoleukodystrophy|bio intends to use the net proceeds of this offering primarily to advance its clinical studies in ccald ( childhood cerebral entity ) , beta-thalassemia major and sickle cell disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|familial hereditary infantile autosomal inherited|ald nafld als cca cah|adrenoleukodystrophy|the worldwide incidence rate for entity , or ald , the superset of ccald , is approximately one in 20 , 000 newborn males .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|familial hereditary infantile autosomal inherited|ataxia autism als ald adren|adrenoleukodystrophy|entity , or ald , is a genetically determined neurological disorder that affects 1 in every 17 , 900 boys worldwide or 1 in 50 , 000
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|familial hereditary infantile autosomal inherited|glaucoma uveitis blindness acetazolamide cataract|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial hereditary infantile autosomal inherited|eclampsia cdh asphyxia neuroblastoma preeclampsia|adrenoleukodystrophy|entity is a rare , often fatal condition believed to occur with an incidence of approximately one in 17 , 000 births .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial hereditary infantile autosomal inherited|ald amyloidosis thrombocytopenia nephropathy neutropenia|adrenoleukodystrophy|▪ evaluation of vk0214 in an in vivo model of x-linked entity ( x-ald ) recently completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial hereditary infantile autosomal inherited|ald amyloidosis thrombocytopenia hl angioedema|adrenoleukodystrophy|▪ advancing ind-enabling work for vk0214 in x-linked entity ( x-ald ) ; ind filing planned in 2h19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|gestation antenatal karyotype gestational cystic|hydrocephalus microcephaly hypospadias others hydronephrosis|anencephaly|ntds include often devastating abnormalities such as spina bifida and entity .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|disease|arginine corrected homocysteine normalized citrulline|spasticity sma dystonia dmd psp|argininemia|own decreased spasticity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|arginine corrected homocysteine normalized citrulline|rhabdomyolysis als dmd gout myopathy|argininemia|enzyme activity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('DRUG', 1), ('OTHER', 1)])|disease|allergy exacerbations improves triggers atopic|psoriasis osteoarthritis sarcoidosis gout pemphigus|asthma|acute inflammatory disease , as well as an oral anti-cytokine therapy that could be directed at chronic inflammatory diseases such as entity , rheumatoid arthritis and crohns disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|allergy exacerbations improves triggers atopic|allergy immunology dermatitis genetics fever|asthma|we currently have programs in entity / allergy , autoimmunity , transplant rejection , rheumatoid arthritis / inflammatory bowel disease , and tumor growth .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2)])|disease|allergy exacerbations improves triggers atopic|nsclc sorafenib paclitaxel aml enrollment|asthma|we remain on track to initiate a phase 1a single ascending dose clinical trial for entity in the second quarter with preliminary data anticipated by the end of 2014 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|allergy exacerbations improves triggers atopic|ige psoriasis allergic aforementioned approved|asthma|•we reported positive , pivotal , phase 2b data for dupilumab in the entity indication and completed enrollment of three phase 3 studies of dupilumab in atopic dermatitis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|allergy exacerbations improves triggers atopic|neurology nephrology gastroenterology neuroscience ophthalmology|asthma|acuspheres three initial product candidates are designed to address large unmet clinical needs within cardiology , oncology and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|allergy exacerbations improves triggers atopic|sepsis ibd sle psoriasis thrombosis|asthma|vla-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|allergy exacerbations improves triggers atopic|psoriasis sepsis ibd osteomyelitis sle|asthma|the primary focus of the collaboration will be to discover orally available vla-4 antagonists as treatments for entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|allergy exacerbations improves triggers atopic|cough urticaria rhinitis headaches asthmatics|asthma|cromolyn is considered first line therapy in mild persistent entity and is frequently prescribed for children .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|allergy exacerbations improves triggers atopic|rhinitis dermatitis conjunctivitis eczema aspergillosis|asthma|is designed to mediate the suppression of ige and ige-producing cells and originally was developed for the treatment of allergic entity and other ige-mediated diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|allergy exacerbations improves triggers atopic|chf ckd chd angina sepsis|asthma|development program to date for prv-300 included studies in healthy adult volunteers and adult patients with stable ( mild to moderate ) entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|allergy exacerbations improves triggers atopic|allergy allergies dermatitis allergic hypersensitivity|asthma|are engaged in the discovery , development and commercialization of novel therapeutics based on synthetic dna for the treatment of cancer , entity / allergies and infectious diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|allergy exacerbations improves triggers atopic|pneumonia gastroenteritis esophagitis fasciitis bronchitis|asthma|glaxosmithklines , or gsk  s , mepolizumab ( nucala ) which targets il-5 was approved for severe eosinophilic entity in adults and children older than 12 in 2015 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|allergy exacerbations improves triggers atopic|bronchiectasis bronchiolitis bronchitis cough wheezing|asthma|beclomethasone is a steroid used to treat the inflammatory component of entity and certain symptoms of copd .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|allergy exacerbations improves triggers atopic|asthmatic pregnant allergic asian cirrhotic|asthma|receptor subtypes , it can cause unwanted side effects including flushing , dyspnea and headache , and it should not be used in entity patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|allergy exacerbations improves triggers atopic|psoriasis sle ibd ipf uc|asthma|the first human proof-of-concept data being obtained in a phase 2 study of genentechs anti-il-13 antibody lebrikizumab for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|allergy exacerbations improves triggers atopic|asthmatic allergic gout ischaemic panic|asthma|however , in certain instances , the process may be overly active , such as during an acute entity attack where an immediate inflammatory reaction occurs .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|allergy exacerbations improves triggers atopic|allergy allergic psoriasis atopic musculoskeletal|asthma|xmab7195 were developing for entity and allergic disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|allergy exacerbations improves triggers atopic|hyperresponsiveness obstruction spasm hypersensitivity constriction|asthma|it is a prophylactic agent indicated for the management of bronchial entity and exercise-induced bronchospasm .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|allergy exacerbations improves triggers atopic|psoriasis osteoarthritis ipf ibd sle|asthma|clinical development program for zyflo consisted of 21 safety and efficacy trials in an aggregate of approximately 3 , 000 patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|allergy exacerbations improves triggers atopic|leprosy vl leishmaniasis ptb ebola|asthma|and sales infrastructure to promote zyflo and the controlled-release formulation of zileuton that we are developing for the treatment of entity upon regulatory approval from the fda .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|chord chondrosarcoma schwannoma glomus meningioma|leiomyosarcoma mesothelioma chondrosarcoma osteosarcoma melanoma|chordoma|we are conducting a multi-cohort , global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|chord chondrosarcoma schwannoma glomus meningioma|surviving seropositive deceased seronegative als|chordoma|the other three entity subjects in the study have been diagnosed with progressive disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|chord chondrosarcoma schwannoma glomus meningioma|sarcoma melanoma osteosarcoma mesothelioma leukemia|chordoma|the trial was an open-label , phase 1 trial and enrolled 38 patients with metastatic cancer or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|chord chondrosarcoma schwannoma glomus meningioma|japan melanoma nsclc europe oncology|chordoma| a phase 2 study in entity is being prepared for initiation at the nci .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|hnscc nsclc npc glioblastoma osteosarcoma|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma schwannoma glomus meningioma|eligible evaluable hundred enrolled surviving|chordoma|the company believes that the summary results from the 11 entity patients enrolled in this trial compare favorably with historically published data .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|melanoma sarcomas lymphomas mesothelioma myeloma|chordoma|additional phase ib / ii clinical trials in various indications are newly opened , including for colorectal and hepatocellular cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|chord chondrosarcoma schwannoma glomus meningioma|neuroblastoma rhabdomyosarcoma melanoma others medulloblastoma|chordoma|trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|chord chondrosarcoma schwannoma glomus meningioma|nsclc melanoma sclc glioblastoma aml|chordoma|we are excited about the recent initiation of the phase 2 trial of gi-6301 at the nci for patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chord chondrosarcoma schwannoma glomus meningioma|adjuvant melanoma hence immunotherapy named|chordoma|mva-bn brachyury for the treatment of metastatic cancer and entity mva-bn brachyury is a cancer immunotherapy developed using our proprietary validated mva-bn platform .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|chord chondrosarcoma schwannoma glomus meningioma|rms sts hl mrt rhabdomyosarcoma|chordoma|we have obtained orphan drug designations for tazemetostat for the treatment of patients with fl , entity , malignant rhabdoid tumors , or mrt , soft tissue sarcoma , or sts , and mesothelioma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|hnscc nsclc npc glioblastoma osteosarcoma|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity is still enrolling patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|chord chondrosarcoma schwannoma glomus meningioma|aml gbm tnbc discovery entire|chordoma|we added the entity cohort due to the high rate of enrollment of these patients in the other ini1-negative cohort and the observed clinical
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|melanoma cirrhosis mesothelioma cholangiocarcinoma myeloma|chordoma|the clinical and commercial landscape for pancreas cancer , non-small cell lung cancer , colorectal cancer , mtc , entity and chronic hepatitis b infection is rapidly changing .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|others neuroblastoma rhabdomyosarcoma schwannomas melanoma|chordoma|which we collectively refer to as ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma schwannoma glomus meningioma|columbia canada california science hope|chordoma|dr . mahony also serves on the board of entity foundation , a nonprofit organization dedicated to improving the lives of those affected by chordoma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|melanoma osteosarcoma sarcoma gist mesothelioma|chordoma|are conducting a multi-cohort global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma schwannoma glomus meningioma|melanoma nsclc gist glioblastoma osteosarcoma|chordoma|it is believed that radiation therapy can reduce the risk of recurrence after surgery and prolong survival for entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|chord chondrosarcoma schwannoma glomus meningioma|melanoma nsclc glioblastoma sarcoma osteosarcoma|chordoma|the company believes that the gi-6301 tarmogen® , exclusively licensed to celgene corporation , has demonstrated promising initial results in entity patients evaluated in a recent phase 1 study .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|chord chondrosarcoma schwannoma glomus meningioma|paediatric hospitalized geriatric juvenile oncology|chordoma|the cohort of patients in the phase 2 study of entity patients is ongoing , and we are evaluating tazemetostat in the dose-expansion portion of a phase 1 study in pediatric patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|choroidal hereditary inherited choroid familial|psoriasis melanoma glioblastoma pah aml|choroideremia|the company&#8217 ; s lead product candidate , nsr-rep1 , for the treatment of entity is in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|others hemophilia osteoporosis haemophilia gout|choroideremia|products for the treatment of the indications for which we have product candidates , including fabry disease , cystic fibrosis , xlrp and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|als glaucoma melanoma gliomas dmd|choroideremia|we are aware that biogen inc . , or biogen , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|others generic manufacturers potency vancomycin|choroideremia|the designation of the first [ *** ] such roche product classes under section 2 . 2 ( including entity ) is included in the initiation payment set forth in section 12 . 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|choroidal hereditary inherited choroid familial|nsclc melanoma glioblastoma aml crpc|choroideremia|the pipeline also includes spk-7001 in an ongoing phase 1 / 2 clinical trial for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|choroidal hereditary inherited choroid familial|glaucoma amd dme uveitis retinoblastoma|choroideremia|spk-rpe65 to address a broad spectrum of blinding conditions , starting with the development of spk-chm for the potential treatment of entity , currently in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|choroidal hereditary inherited choroid familial|cataract cataracts retinitis retinopathy uveitis|choroideremia|these diseases include entity , diabetic retinopathy , glaucoma , lebers congenital amaurosis ( lca ) , macular telangiectasia , retinitis pigmentosa , wet amd and xlrs , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|osteoporosis epilepsy cancers leukemia rabies|choroideremia|spk-7001 has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|choroidal hereditary inherited choroid familial|melanoma nsclc aml cancers leukemia|choroideremia|has been granted orphan product designation by the european commission and fda for its product candidate for the treatment of entity that is in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|disease|choroidal hereditary inherited choroid familial|ebv pcsk9 hgf cll cml|choroideremia|our pipeline includes : a product candidate targeting entity , or chm , currently in a phase 1 / 2 clinical trial ; a product candidate for hemophilia a , currently in a phase 1 / 2
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|choroidal hereditary inherited choroid familial|keratoconus glaucoma myopia nystagmus microcephaly|choroideremia|some irds , such as retinitis pigmentosa ( rp ) , usher syndrome , or entity ( chm ) are associated with a gradual loss of vision , eventually leading to complete blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|choroidal hereditary inherited choroid familial|roche japan germany china europe|choroideremia|in addition , roche currently holds a license to 4d-110 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|choroidal hereditary inherited choroid familial|als glaucoma dmd epilepsy autism|choroideremia|we are aware that nightstarx is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|cancers epilepsy malignancies leukemia leprosy|choroideremia|spk-chm has also been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|choroidal hereditary inherited choroid familial|http gov registration abstract https|choroideremia|entity : spark therapeutics is enrolling patients in its first phase 1 / 2 clinical trial of spk-chm , an aav-based gene therapy for the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|epilepsy psoriasis leprosy sle vitiligo|choroideremia|our first such follow-on product candidate is spk-chm for the treatment of entity , or chm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|epilepsy sle cfs pah glioma|choroideremia|our lead product candidate , nsr-rep1 , for the treatment of entity , or chm , is entering phase 3 clinical development in the first half of 2018 and represents the most clinically advanced
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|cancers leukemia epilepsy malignancies leprosy|choroideremia|spk-chm has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|rabies leishmaniasis cancers anthrax epilepsy|choroideremia|as a result , we have not sought , and may be unable to seek , patent protection for spk-chm to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|choroidal hereditary inherited choroid familial|als glaucoma epilepsy narcolepsy psoriasis|choroideremia|we are aware that nightstar therapeutics plc , or nightstar , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|citrulline hereditary undiagnosed familial inherited|neurofibromatosis ckd nash eds aih|citrullinemia|current therapy for entity type 1 is considered difficult for patients and generally ineffective , including diet restriction and nitrogen scavengers , and the only curative
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|citrulline hereditary undiagnosed familial inherited|eds mps arginase gaucher citrulline|citrullinemia|individuals with entity type i can build-up excessive levels of ammonia and citrulline in their blood , potentially resulting in neurological deficits and other toxicities .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|citrulline hereditary undiagnosed familial inherited|pku phe nbs hba hb|citrullinemia|*** revision to work plans for pku and entity
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|citrulline hereditary undiagnosed familial inherited|gaucher alcoholic wilson hepatitis cirrhotic|citrullinemia|to evaluate the therapeutic response to dtx601 , we plan to measure ammonia levels , which is a well-established measure of entity type i disease status .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|citrulline hereditary undiagnosed familial inherited|pku what wilson you know|citrullinemia|you know , wilson , or pku or entity?
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|citrulline hereditary undiagnosed familial inherited|neurofibromatosis gaucher sma oi aih|citrullinemia|the incidence of entity type 1 is estimated at approximately 1 per 250 , 000 live births , affecting more than 2 , 000 individuals worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|coagulation hereditary inherited fibrinogen coagul|hemophilia haemophilia hae angioedema ttp|afibrinogenemia|entity , the condition where the factor i is completely absent , is estimated to afflict one in one million , or 300 patients
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|epilepsy ckd ibd oab adpkd|homocystinuria|the company is orphan medical  s exclusive direct-to-patient distributor for cystadane ( tm ) , indicated for patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial inherited carriers homocysteine|japan europe germany canada france|homocystinuria|acn00177 in entity in the second quarter of 2020 , we announced the approval of our clinical trial application , or cta , by the united
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|hereditary familial inherited carriers homocysteine|ibd psoriasis epilepsy sle melanoma|homocystinuria|there are approximately 1 , 000 patients with entity in the united states .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('DIS', 2), ('OTHER', 2)])|disease|hereditary familial inherited carriers homocysteine|autism alcoholism dm1 hyperhomocysteinemia gout|homocystinuria|humans and an antidote for methanol or suspected methanol ingestion in humans ; and cystadane® ( betaine anhydrous for oral solution ) , for entity , a genetic disease .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|epilepsy gout endometriosis osteoarthritis cystitis|homocystinuria|cystadane is a known compound which has already been used to treat entity and is , therefore , not patentable for this indication .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|adpkd epilepsy leishmaniasis schistosomiasis toxoplasmosis|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|hereditary familial inherited carriers homocysteine|pku amyloidosis lca hus ks|homocystinuria|elevated blood levels of this amino acid arise in the rare genetic disease of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hereditary familial inherited carriers homocysteine|sle pah als lupus hh|homocystinuria|for aeb4104 demonstrating decreases in plasma homocysteine levels that improved important disease-related abnormalities and survival in a preclinical model of entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|hereditary familial inherited carriers homocysteine|psoriasis scleroderma gout sle vitiligo|homocystinuria|( “orphan” ) , a privately held , clinical-stage biopharmaceutical company focused on the development of product candidate ot-58 for the treatment of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hereditary familial inherited carriers homocysteine|stillbirth rop ntd sga cdh|homocystinuria|it has been estimated that entity occurs about once in every 200 , 000 live births worldwide .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|disease|hereditary familial inherited carriers homocysteine|homocysteine methionine mma hyperhomocystein cobalamin|homocystinuria|understanding entity entity is an inherited disorder of methionine metabolism that results in elevated homocysteine and homocystine , or thcy , in plasma and urine .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|adpkd epilepsy leishmaniasis schistosomiasis toxoplasmosis|homocystinuria|the company obtained orphan drug status for cystadane for the treatment of entity , which provided marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|therapeutics pharmaceutical bio print silico|homocystinuria|acn00177 in entity overview : our product candidate , acn00177 , is a novel pegylated , or polyethylene glycol modified , human enzyme engineered to degrade free homocysteine and
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|hereditary familial inherited carriers homocysteine|biotechnology immunotherapy oncology ced radiosurgery|homocystinuria|we believe classical entity represents a viable market opportunity with significant unmet medical need , which we plan to address by continuing our preclinical development
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('DRUG', 4), ('OTHER', 2)])|disease|hereditary familial inherited carriers homocysteine|dyslipidemia gout hyperuricemia dm1 hypertriglyceridemia|homocystinuria|it is the first agent approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hereditary familial inherited carriers homocysteine|thalassemia haemophilia vhl neurofibromatosis hemophilia|homocystinuria|the board of hcu network america , a non-profit which provides advocacy and support for patients affected by the rare disease entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hereditary familial inherited carriers homocysteine|adpkd epilepsy leishmaniasis schistosomiasis toxoplasmosis|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 24 , 2003 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 3)])|disease|hereditary familial inherited carriers homocysteine|gout hyperuricemia adpkd hyperhomocysteinemia autism|homocystinuria|cystadane is approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|hereditary familial inherited carriers homocysteine|cbs als pku ws asd|homocystinuria|the majority of entity patients suffer mutations of a gene that regulates the production of the enzyme known as cystathionine beta-synthase , or cbs , which
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial inherited carriers homocysteine|japan europe australia germany france|homocystinuria|trial in patients with arginase 1 deficiency and closing cancer trials ; offset by a ramp-up in manufacturing for acn00177 in entity and higher personnel-related expenses .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|disease|hereditary familial carriers inherited adpkd|nephropathy hypercholesterolemia hyperhomocysteinemia hyperuricemia insufficiency|cystinuria|tablets ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial carriers inherited adpkd|discovery researchers hts proteomics automation|cystinuria|aeglea has an active discovery platform , with the most advanced program for entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|disease|hereditary familial carriers inherited adpkd|urolithiasis gout adpkd cystine hyperuricemia|cystinuria|entity is an inherited disease that causes stones made of the amino acid cystine to form in the kidneys , bladder and / or
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hereditary familial carriers inherited adpkd|asthmatic ipf hospitalized asian treating|cystinuria|our patent-pending customizable delayed-release tiopronin medications that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial carriers inherited adpkd|consortium projects dedicated genetics platform|cystinuria|aeglea has two programs in ind-enabling studies for homoentity and cystinuria and an active discovery pipeline .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hereditary familial carriers inherited adpkd|leukemia aml melanoma epilepsy psoriasis|cystinuria|additionally , we have commenced ind-enabling studies for our aeb5100 program for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|disease|hereditary familial carriers inherited adpkd|nephropathy hyperuricemia gout hypercholesterolemia hyperparathyroidism|cystinuria|( tiopronin ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hereditary familial carriers inherited adpkd|fsgs igan proteinuria pemphigus psoriasis|cystinuria|evaluating sparsentan for fsgs and iga nephropathy , and the recent approval and launch of thiola ec for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary familial carriers inherited adpkd|nephropathy chf pah angioedema proteinuria|cystinuria|captopril is not fda approved for the treatment of entity but has been prescribed for patients with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|hereditary familial carriers inherited adpkd|adpkd preeclampsia glomerulonephritis fsgs others|cystinuria|evaluating the suitability of our ersg library for development in additional renal disorders , including autosomal dominant polycystic kidney disease , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|disease|hereditary familial carriers inherited adpkd|urolithiasis uc ckd adpkd hyperuricemia|cystinuria|and cysteine , decreased the amount of cystine in the urine and reduced kidney stone formation in a preclinical model of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial carriers inherited adpkd|hereditary suspected inherited hemophilia homozygous|cystinuria|aeb5100 in patients with entity aeb5100 is a novel recombinant human enzyme that degrades plasma cystine and cysteine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hereditary familial carriers inherited adpkd|asthmatic hospitalized ipf asian chf|cystinuria|our patent-pending tiopronin delayed-release compounded formulations that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|disease|hereditary familial carriers inherited adpkd|mma hyperhomocysteinemia hyperuricemia adpkd cystine|cystinuria|entity occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hereditary familial carriers inherited adpkd|osteoarthritis psoriasis glaucoma osteoporosis insomnia|cystinuria|thiola•in 2018 , the company expects an nda to be filed for its new formulation of thiola for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|disease|hereditary familial carriers inherited adpkd|gout urolithiasis adpkd hyperuricemia cystine|cystinuria|entity is a chronic genetic disease that causes stones made of the amino acid cystine to form in the kidneys , bladder
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|hereditary familial carriers inherited adpkd|emphysema hyperparathyroidism hypercholesterolemia nephropathy fh|cystinuria|( tiopronin ) is approved in the united states for the prevention of cysteine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary familial carriers inherited adpkd|fsgs ckd proteinuria amyloidosis mcd|cystinuria|clinical development programs and evaluating the suitability of our ersg library for development in additional renal disorders , including adpkd and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hereditary familial carriers inherited adpkd|ckd hemodialysis hospitalized pregnant ibd|cystinuria|citrate delayed release compounded formulations that may be prescribed by physicians as a lower-cost therapeutic alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|hereditary familial carriers inherited adpkd|psoriasis melanoma epilepsy pah ibd|cystinuria|the company believes there are 10 , 000-12 , 000 patients with entity in the united states , of which 4 , 000-5 , 000 patients may be appropriate candidates for treatment .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|galactose undiagnosed diagnose hereditary prevents|eligible enrolled fifty forty eighteen|galactosemia|entity patients will be eligible for treatment up to 28 days total ( single dose followed by 27 consecutive days of dosing ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 4)])|disease|galactose undiagnosed diagnose hereditary prevents|t2dm t2d nafld t1d dm1|galactosemia|therapeutics plans to leverage recent fda guidance permitting biomarker-based development in low prevalence , slowly progressing rare metabolic diseases , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|galactose undiagnosed diagnose hereditary prevents|cancers osteoporosis neuropathy nephropathy malignancies|galactosemia|in particular , the company is currently targeting treatments for cardiovascular disease , entity and diabetic complications .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|galactose undiagnosed diagnose hereditary prevents|multidisciplinary invited expert canadian technical|galactosemia|we also hosted an educational symposium featuring a panel of entity experts .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|ibd oncology sle aml pah|galactosemia|we will continue to characterize at-007 long-term safety in adult entity patients and intend to initiate a pediatric study .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|galactose undiagnosed diagnose hereditary prevents|t2dm t1d igan ckd nafld|galactosemia|the key biomarker outcome of the study was reduction in galactitol , an aberrant toxic metabolite of galactose , formed by ar in entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|disease|galactose undiagnosed diagnose hereditary prevents|t1d ibd t1dm fabry coeliac|galactosemia|at-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in adult entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|galactose undiagnosed diagnose hereditary prevents|melanoma psoriasis aml nsclc glioblastoma|galactosemia|” recent highlights ·presented data on at-007 for treatment of entity at the entity foundation 2020 virtual conference .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|enrolled responding hospitalized eligible evaluable|galactosemia|at-007 was well tolerated , with no drug-related adverse events noted to date in entity patients or in the 72 healthy volunteers treated in part 1 of the trial .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|galactose undiagnosed diagnose hereditary prevents|japan china europe korea canada|galactosemia|· received fda orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|galactose undiagnosed diagnose hereditary prevents|osteoporosis rabies leishmaniasis melanoma psoriasis|galactosemia|· presented data highlighting at-007 for the treatment of entity at the ashg annual meeting .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|pilot pharmacokinetic investigational pharmacokinetics pharmacology|galactosemia|·announced start of at-007 pediatric entity study ; released additional 40mg / kg data from adult entity study .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|rodents cats monkeys pigs rabbits|galactosemia|june 2020 , we announced additional supportive biomarker efficacy and safety data for at-007 in entity at 40 mg / kg .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|galactose undiagnosed diagnose hereditary prevents|japan china korea taiwan india|galactosemia|in may 2019 , we received orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|ibd ckd psoriasis sle t1d|galactosemia|in june 2019 we initiated a pivotal phase 1 / 2 study in healthy volunteers and adults with entity to evaluate safety , pharmacokinetics , and biomarker endpoints in adults with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|galactose undiagnosed diagnose hereditary prevents|japan nsclc china europe korea|galactosemia|we initiated a phase 1 / 2 study of at-007 in entity in june 2019 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|galactose gal galact hereditary streptococcus|mammals drosophila dictyostelium vertebrates sum|galactosialidosis|in entity , the missing protease , cathepsin a , is a lysosomal stabilizing agent for the two other enzymes : sialidase and beta-galactosidase .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|galactose gal galact hereditary streptococcus|mps gaucher incl scd fabry|galactosialidosis|rhppca is in preclinical development as an enzyme replacement therapy for entity , a rare lysosomal storage disease for which there are no currently approved drug therapies .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|galactose gal galact hereditary streptococcus|run healthcare dots clinics hope|galactosialidosis|emil : well entity is another small enzyme therapy program like our mps7 program .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|galactose gal galact hereditary streptococcus|google kegg pubmed comet others|galactosialidosis|how the opportunities at dimension compared to those in your own pipeline at a similar stage such as arcturus and entity?
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|galactose gal galact hereditary streptococcus|osteoporosis osteoarthritis epilepsy psoriasis wounds|galactosialidosis|currently no issued patents that cover the rhppca composition of matter or the use of rhppca for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|glioblastoma glioma gliomas hallmarks multiforme|rabies autism epilepsy osteoporosis psoriasis|glioma|in january 2013 , the ema also granted orphan drug protection to val-083 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioblastoma glioma gliomas hallmarks multiforme|glioma gliomas nhl lymphomas astrocytomas|glioma|in february 2018 , an investigator-sponsored trial was initiated evaluating day101 in pediatric low-grade entity ( plgg ) , for which sunesis believes the scientific rationale is compelling .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma acne psoriasis leukemia endometriosis|glioma|california , san francisco , which is conducting phase 2 clinical trials of prophage series g-100 and g-200 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma cholangiocarcinoma sarcoma neuroblastoma mesothelioma|glioma|research our primary business focus is the clinical development of litx for the treatment of hepatoma , metastatic colorectal cancer , entity and one or more possible follow-on indications .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|japan europe germany canada china|glioma|rcc tumors received and approximately 85% of the tumors received from patients in our ongoing phase 2 clinical trials in entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma glioma mesothelioma gliomas ascites|glioma|by nih , a third party might be able to develop a cintredekin besudotox based drug for the treatment of malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma glioma gliomas mesothelioma lymphomas|glioma|the company has completed a phase ii clinical trial for use of su101 as a treatment for refractory malignant entity and has recently initiated a phase iii clinical trial in first relapse entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma mesothelioma leukemia nsclc glioblastoma|glioma|investigator sponsored trials include a phase 2 clinical trial in colorectal cancer and a phase 1 clinical trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|glioblastoma glioma gliomas hallmarks multiforme|glioma melanoma mesothelioma hyperthermia astrocytoma|glioma|the median survival time was over 609 days ( approximately 21 months ) , which compares favorably to the survival historically recorded for malignant entity patients ( approximately 12 months ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioblastoma glioma gliomas hallmarks multiforme|glioblastoma glioma gliomas gbm astrocytomas|glioma|in vivo studies that cannabinoids have a synergistic effect with temozolomide , the standard chemotherapeutic agent used in the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|glioblastoma glioma gliomas hallmarks multiforme|leukemia psoriasis rabies epilepsy osteoporosis|glioma|sl-701 was awarded orphan drug designation from the fda for the treatment of entity in january 2015 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glioblastoma glioma gliomas hallmarks multiforme|neoplastic glioma cns neural tumoral|glioma|hypericin compounds to inactivate viruses and retroviruses , as a therapeutic or preventative for viral or retroviral diseases , and for anti- entity ( brain tumor ) indications .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioblastoma glioma gliomas hallmarks multiforme|osteoporosis rabies leukemia autism leishmaniasis|glioma|ca4p has been granted orphan drug designation for the treatment of entity in the united states .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma glioma mesothelioma gliomas tumours|glioma|orphan drug act , gliadel® wafer became entitled to seven years of market exclusivity for the treatment of patients with malignant entity undergoing primary surgical resection .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|glioblastoma glioma gliomas hallmarks multiforme|glioblastoma glioma medulloblastoma astrocytoma gbm|glioma|phase 2 clinical trials in a range of indications and is currently in a phase 2 clinical trial in recurrent entity , a type of brain cancer .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma glioma mesothelioma gliomas effusion|glioma|the first of these trials was a phase i / ii recurrent malignant entity clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioblastoma glioma gliomas hallmarks multiforme|glioma glioblastoma sarcoma melanoma hepatocellular|glioma|is overexpressed in numerous difficult to treat tumors including lung , breast , bladder , gastric , ovarian , endometrial , cervical , melanoma , esophageal , pancreatic , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|glioblastoma glioma gliomas hallmarks multiforme|psoriasis melanoma osteoarthritis osteoporosis epilepsy|glioma|our product pipeline also includes compounds in phase 1 and 2 clinical development for entity , ulcerative colitis type 2 diabetes and schizophrenia .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|melanoma nsclc crc glioblastoma osteosarcoma|glioma|the crada also covers research to determine whether expression of a component of this pathway correlates with prognosis in entity patients .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioblastoma glioma gliomas hallmarks multiforme|cancers malignancies gliomas gbm neoplasms|glioma|granted protection under the orphan drug act by the united states food and drug administration ( “fda” ) for the treatment of entity , including gbm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|prog hereditary let familial frontotemporal|duchenne lethal mosaic syndromic bullous|progeria|we are also developing lonafarnib monotherapy for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prog hereditary let familial frontotemporal|next entire funded eu nih|progeria|( a ) the parties acknowledge that a priority review voucher may be available and awarded to eiger as the sponsor of the entity nda ( “entity prv” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|prog hereditary let familial frontotemporal|prog encephalopathy retraction ascites cough|progeria|eiger has initiated a rolling new drug application ( nda ) submission process for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|prog hereditary let familial frontotemporal|hepatitis encephalopathy hemorrhagic uremic ascites|progeria|licensed field of use under the merck agreement to include all uses of lonafarnib related to the treatment of hutchinson-gilford entity syndrome ( entity ) in humans .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prog hereditary let familial frontotemporal|ei wi metaph gi ic|progeria|eiger agrees not to retain the entity prv for itself or any of its affiliates .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|prog hereditary let familial frontotemporal|hereditary duchenne degenerative lamin dystrophic|progeria|with prf any proceeds from the monetization of any prv that we may receive for lonafarnib for the treatment of entity and progeroid laminopathies to support future entity research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|prog hereditary let familial frontotemporal|prog encephalopathy retraction cough ascites|progeria|eiger is preparing an nda and maa for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies with plans to file in q4 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|prog hereditary let familial frontotemporal|lamin duchenne degenerative lamellar dystrophic|progeria|the u . s . food and drug administration ( fda ) accepted the new drug application ( nda ) for accelerated review of zokinvytm ( lonafarnib ) for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|prog hereditary let familial frontotemporal|duchenne hereditary dmd dystrophic lamin|progeria|and data controlled by prf to prepare and file any new drug application ( “nda” ) for a product containing lonafarnib for entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|prog hereditary let familial frontotemporal|ds drosophila mammals msa als|progeria|that progerin may make the nucleus unstable , and that cellular instability may lead to the process of premature aging in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|prog hereditary let familial frontotemporal|prog encephalopathy retraction ascites ovary|progeria|hutchinson-gilford entity syndrome ( entity ) overview ultra-rare , fatal , premature aging pediatric disease point mutation in the lamin a gene results in a farnesylated aberrant protein ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prog hereditary let familial frontotemporal|chd ds scd sca fh|progeria|children with entity die of the same heart disease that affects millions of normally aging adults ( arteriosclerosis ) , but at an average age of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prog hereditary let familial frontotemporal|indications neuroprotection dabigatran indication ich|progeria|as a result we may not successfully obtain approval by the fda of an nda for lonafarnib for entity in the near term , or at all .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|nausea dizziness vomiting fever flushing|hydrocephalus|two events occurred in one patient , these were headache and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hydrocephalus intracranial shunt diagnose personality|obstructive hydrocephalus atypical aneurysmal communicating|hydrocephalus|prevents obstruction in the cerebrospinal fluid ( csf ) catheters implanted in the ventricle of the brain of patients who suffer from entity or normal pressure hydrocephalus ( nph ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|lumbar vp programmable subarachnoid cerebrospinal|hydrocephalus|we believe that our cerebral spinal fluid ( csf ) pressure management product line , including the advanced orbis sigma ii entity shunt , is unsurpassed in the industry .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hydrocephalus intracranial shunt diagnose personality|shunt intracranial intrahepatic vp intrathecal|hydrocephalus|entity shunt designs have changed little since their introduction in the 1950s .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hydrocephalus intracranial shunt diagnose personality|myelopathy headache headaches ataxia vertigo|hydrocephalus|bone sclerosis impinges cranial nerve and spinal foramina with resulting neurologic abnormalities , including entity , progressive blindness and auditory impairment .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hydrocephalus intracranial shunt diagnose personality|thrombosis hydrocephalus encephalopathy hemorrhage ich|hydrocephalus|entity has also been reported in children with severe hypoplasminogenemia , apparently related to the deposition of fibrin in the cerebral ventricular
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus glaucoma palsy deficit zone|hydrocephalus|the same condition , known as normal pressure entity ( nph ) , presented mostly in the elderly population , causing thinking and reasoning problems , difficulty walking , etc .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|ascites hydrocephalus empyema sepsis lymphedema|hydrocephalus|implantable drainage valve for treatment of entity - french patent application no . 9306356 filed june 27 , 1993 ( docket 91087 ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus intracranial shunt diagnose personality|cysts hydrocephalus ascites tumours aneurysms|hydrocephalus|this slow accumulation means that the fluid pressure may not be as high as in other types of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus epilepsy icp bcs tbi|hydrocephalus|wayne state university , which supports the scstms potential as a viable technology for preventing occlusion in shunts used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus icp headaches hyponatremia vasospasm|hydrocephalus|shunts in the brain to help drain excess csf either externally or into the body for reabsorption to help treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|autism stillbirth preeclampsia epilepsy microcephaly|hydrocephalus|entity occurs in about 1 in every 500 births in the u . s . alone1 , 2 over 1 , 000 , 000 people in the united states currently
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hydrocephalus intracranial shunt diagnose personality|rls als nph cpp icp|hydrocephalus|microbot is developing scs as a device for the treatment of entity and nph and is developing tipcat as an endoscopic tool , with colonoscopy as the most immediate application of the tipcat
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus intracranial shunt diagnose personality|shunt communicating obstructive atypical subacute|hydrocephalus|virob platform , microbot is currently developing its first product candidate : the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus epilepsy microcephaly seizures encephalitis|hydrocephalus|tuberous sclerosis complex is also associated with a variety of resulting disorders including seizures , swelling in the brain ( entity ) , developmental delays and skin lesions , , .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus nph icp epilepsy vps|hydrocephalus|entity is most often treated by the surgical insertion of a shunt system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hydrocephalus intracranial shunt diagnose personality|glaucoma allergy headache nephropathy retinopathy|hydrocephalus|mannitol injection entity , glaucoma , edema caused by deep burning or scald , acute renal failure and ascites .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus glaucoma endocarditis regurgitation scoliosis|hydrocephalus|silicone products , state of the art implanted application systems for spinal opiates and market leading valve systems for treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|shunt communicating obstructive atypical hydrocephalus|hydrocephalus|using the virob platform , microbot is currently developing the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|hydrocephalus intracranial shunt diagnose personality|hydrocephalus spasticity icp seizures scs|hydrocephalus|the proposed indication for use of the scs device would be for the treatment of entity as a component of a shunt system when draining or shunting of csf is indicated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|hyperprolactin accompanies improves accompany reduces|hyperprolactin hypothyroidism amenorrhea hypogonadism hypokalemia|hyperprolactinemia|both sgas and fgas can cause entity , a hormonal imbalance resulting from d2 receptor blockade , which can lead to enlargement of breast tissue in males and infertility .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hyperprolactin accompanies improves accompany reduces|hypogonadism hypercalcemia osteoporosis prolactin prl|hyperprolactinemia|x213 could be developed to treat entity in prolactinomas , a condition of benign tumors on the pituitary gland that leads to sexual dysfunction , infertility , and osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hyperprolactin accompanies improves accompany reduces|stratum scenario indication table visit|hyperprolactinemia|treated for potential oncology indications for up to 48 weeks ; doses up to 20x higher than expected clinical dose for entity 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hyperprolactin accompanies improves accompany reduces|osteoporosis epilepsy glaucoma psoriasis osteoarthritis|hyperprolactinemia|by fda for use in humans for more than 15 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hyperprolactin accompanies improves accompany reduces|concern livestock youth poverty mind|hyperprolactinemia|corporation ) , and we exercised our right to bring the product back into our portfolio to develop it for diseases of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|hyperprolactin accompanies improves accompany reduces|acromegaly hypothyroidism epilepsy osteoporosis dystonia|hyperprolactinemia|respect to the other approved indications , and bromocriptine remains on the market for the treatment of parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hyperprolactin accompanies improves accompany reduces|pah osteoporosis als ipf chf|hyperprolactinemia|finalized the design of a proof-of-concept study for xoma 213 , which may offer a new therapeutic option for patients with entity , and anticipate initiating the study midyear .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|hyperprolactin accompanies improves accompany reduces|acromegaly osteoporosis epilepsy headache melanoma|hyperprolactinemia|upjohn announced nda submissions to the fda for pramipexole for parkinson  s disease , remisar ( r ) for bladder cancer and dostinex ( r ) ( cabergoline ) for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hyperprolactin accompanies improves accompany reduces|seizures tremor parkinsonism sedation falls|hyperprolactinemia|this mechanism likely contributes to the favorable safety profile of iti-007 , with reduced risk for entity , akathisia , extrapyramidal symptoms , and other motoric side effects .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|hyperprolactin accompanies improves accompany reduces|tolerability seizures tremor nausea parkinsonism|hyperprolactinemia|the favorable safety profile of iti-007 with reduced risk for akathisia , extrapyramidal side effects and other motoric side effects , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('DRUG', 2), ('OTHER', 2)])|disease|hyperprolactin accompanies improves accompany reduces|acromegaly prolactin prl hyperthyroidism rls|hyperprolactinemia|cabergoline was recently launched in certain european countries for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|disease|hyperprolactin accompanies improves accompany reduces|dyskinesia sedation aes ataxia hypoglycemia|hyperprolactinemia|iti- 2 007 likely contributes to its favorable clinical profile with motoric tolerability similar to placebo and without entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hyperprolactin accompanies improves accompany reduces|osteoporosis epilepsy glaucoma osteoarthritis psoriasis|hyperprolactinemia|approved by fda for use in humans for approximately 20 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|hyperprolactin accompanies improves accompany reduces|others aromatase prolactin her2 lactation|hyperprolactinemia|our endocrine portfolio also includes a phase 2-ready product candidate , xoma 213 , targeting the prolactin receptor , and entity , and multiple research-stage programs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hyperprolactin accompanies improves accompany reduces|acromegaly prolactin hyperthyroidism headache hypothyroidism|hyperprolactinemia|inhibit prolactin secretion with no reported effect on other pituitary hormones and are therefore generally the drugs of choice for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hyperprolactin accompanies improves accompany reduces|conclusions abstract pharmacodynamics relevance tolerability|hyperprolactinemia|entity : as with other drugs that antagonize dopamine d2 receptors , fanapttm elevates prolactin levels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|hypophosph hereditary corrected rick inherited|melanoma aml medulloblastoma glioblastoma neuroblastoma|hypophosphatasia|asfotase alfa has shown very compelling phase ii clinical data in infants and juveniles with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hypophosph hereditary corrected rick inherited|osteoarthritis osteopenia osteoporosis osteonecrosis sarcopenia|hypophosphatasia|we note that other examples of animal models of bone disease such as osteoporosis and entity have previously translated in vivo findings into the clinic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|hypophosph hereditary corrected rick inherited|haemophilia hypertriglyceridemia hemophilia psoriasis pph|hypophosphatasia|time investing in preparations for the anticipated 2015 launch of our second commercial product , asfotase alfa for the treatment of entity ( hpp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kur ji kar shan nin|stock bu pri trade bad|kuru|and related stockholder matters market information our common stock is traded on the nasd  s over-the-counter bulletin board under the symbol " entity ob " since november 6 , 2008 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|mycobacterium lepr abscess brasiliensis diagnose|makes unlike characterizes characterize resembles|leprechaunism| type a and type b syndrome  rabson-mendenhall syndrome  entity type a syndrome patients have high circulating concentrations of insulin with impaired glucose tolerance or diabetes .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|mycobacterium lepr abscess brasiliensis diagnose|others acromegaly hypoglycemia immunodeficiency cardiomyopathy|leprechaunism|defects in the insulin receptor or insulin signaling pathways and include type a and type b syndromes , rabson-mendenhall syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mycobacterium lepr abscess brasiliensis diagnose|others fibromyalgia sarcoidosis autism scleroderma|leprechaunism|these conditions include :  type a and type b syndrome ,  rabson-mendenhall syndrome , and  entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cystic lymphangi muscular familial interstitial|lam fibrosarcoma leiomyoma lipoma hemangioma|lymphangioleiomyomatosis|the exist-2 study will evaluate everolimus in patients with angiomyolipoma associated with either ts or sporadic entity ( lam ) 9 .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|medulloblastoma astrocytoma meningioma glioblastoma glioma|medulloblastoma|the following tumor types were treated thus far : high-grade glioma , entity , neuroblastoma , and ependymoma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|rhabdomyosarcoma neuroblastoma glioma leukemia medulloblastoma|medulloblastoma|of five childhood cancers typically treated with intensive cisplatin therapy , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|glioma astrocytoma medulloblastoma glioblastoma gliomas|medulloblastoma|the work at nih has now extended to the most common brain tumor of children , entity , and to the most common cancer of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|glioma medulloblastoma astrocytoma glioblastoma gliomas|medulloblastoma|the work at nih was then extended to the most common brain tumor of children , entity , and to the most common extracranial solid tumor of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|melanoma medulloblastoma glioma osteosarcoma neuroblastoma|medulloblastoma|in addition , compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme , neuroblastoma , and entity , all cancers of neural tissue .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|meningioma medulloblastoma schwannoma neuroblastoma osteosarcoma|medulloblastoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , entity , and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|osteosarcoma melanoma rhabdomyosarcoma medulloblastoma retinoblastoma|medulloblastoma|joint patent applications with nih have been filed for the treatment of glioblastoma multiforme , entity , and neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|rhabdomyosarcoma neuroblastoma melanoma glioma medulloblastoma|medulloblastoma|of one of five childhood cancers typically treated with intensive cisplatin therapy , including hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|melanoma endometrial neuroblastoma uterine glioblastoma|medulloblastoma|in 2016 , the fda also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|nsclc cancers nci melanoma leukemia|medulloblastoma|ii - paragon-hf to start aug . 2014 29 lde225 solid tumors ≥ 2018 i entity ≥ 2018 iii lee011 breast cancer 2016 iii - phase iii registration study enrolling solid tumors ≥
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|melanoma neuroblastoma leukemia medulloblastoma hematopoietic|medulloblastoma|sl-301 has demonstrated activity against brain and pancreatic cscs and tumor bulk in vitro , and against glioblastoma and entity cscs in in vivo animal models .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|medulloblastoma gliomas neuroblastoma glioblastoma glioma|medulloblastoma|have presented data indicating that val-083 offers potential therapeutic alternatives for the treatment of pediatric brain tumors including shh-p53 mutated entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|aml ibd neuroblastoma leukemia epilepsy|medulloblastoma|phase i clinical trials that are designed to evaluate dose and safety of gdc-0449 in pediatric and adult patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|lymphocytes cancers nsclc keratinocytes neutrophils|medulloblastoma|emory studies so far have indicated that entity may be particularly vulnerable to the ability of wp1066 to block the activated form of stat3 , a key signaling protein
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|rhabdomyosarcoma melanoma myeloma leukemia retinoblastoma|medulloblastoma|treated with intensive cisplatin therapy for localized and disseminated disease , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|medulloblastoma rhabdomyosarcoma neuroblastoma etc teratoma|medulloblastoma|no conventional therapy exists , or a relapsed brain tumor with a predilection for lm dissemination ( primitive neuroectodermal tumor , rhabdoid tumor , entity ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|melanoma endometrial neuroblastoma uterine glioblastoma|medulloblastoma|the fda has also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|medulloblastoma glioblastoma astrocytoma glioma melanoma|medulloblastoma|pre-clinical studies of lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , entity and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|medulloblastoma anaplastic neuroblastoma glioblastoma malignancy|melanoma neuroblastoma leukemia mesothelioma sarcoma|medulloblastoma|we have been granted orphan drug designation in the united states for gbm , ovarian cancer , and entity , and in europe for gbm .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|melanoma glioma schwannoma meningioma mesothelioma|meningioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , medulloblastoma , and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|melanoma glioblastoma neuroblastoma glioma leukemia|meningioma|in february 2012 , the fda granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|melanoma glioblastoma neuroblastoma leukemia glioma|meningioma|the fda has granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|glioblastoma melanoma meningioma glioma neuroblastoma|meningioma|in addition , preclinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness , neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|glioblastoma melanoma glioma meningioma neuroblastoma|meningioma|in addition , pre-clinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma meningiomas schwannoma intracranial mimic|meningioma hemangioma meningiomas schwannoma neuroblastoma|meningioma|entity and schwannoma are rare , benign tumors that can present in different locations within the brain and the spinal cord and
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|meningioma meningiomas schwannoma intracranial mimic|glioma melanoma sarcoma glioblastoma medulloblastoma|meningioma|intend to collaborate with ohio state to conduct a phase 0 investigator-initiated study of ar-42 in patients with schwannoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|osteosarcoma sarcoma malignancy nhl glioblastoma|meningioma|this patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma meningiomas schwannoma intracranial mimic|glioma melanoma schwannoma astrocytoma gliomas|meningioma|lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , medulloblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|meningioma meningiomas schwannoma intracranial mimic|melanoma glioma glioblastoma neuroblastoma osteosarcoma|meningioma|in preclinical studies , ar-42 has demonstrated anti-tumor activity in both entity and schwannoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|reduces personality trajectory predicts comorbidities|hypogonadism osteoporosis cvd htn comorbidities|obesity|in the majority of these men , often with co-morbid entity , t replacement is not optimal and indeed may be counterproductive .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|reduces personality trajectory predicts comorbidities|tax inflation financial price recession|obesity|eps growth  restating 2012 to exclude the 2012 entity impact of $0 . 10 and including the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|reduces personality trajectory predicts comorbidities|approved investigational orphan fda oncology|obesity|development of the pyy compound and has recently announced that it expects to file an ind on pyy for an entity indication in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|reduces personality trajectory predicts comorbidities|melanoma pivotal oncology multicenter randomised|obesity|exhibit 99 . 01 regeneron initiate phase ii entity clinical trial tarrytown , new york ( march 28 , 2000 ) - regeneron pharmaceuticals , inc . ( nasdaq : regn ) announced that it has initiated a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|reduces personality trajectory predicts comorbidities|syndromes narcolepsy phenotypes cah nos|obesity|with open-label one year extensions , and was planned to include approximately four to six patients with genetically confirmed pomc deficiency entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|disease|reduces personality trajectory predicts comorbidities|reproductive fertility contraception reproduction genitourinary|obesity|-k . about vivus vivus , inc . is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing entity and sexual health .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|reduces personality trajectory predicts comorbidities|osteoporosis epilepsy glaucoma prostatitis osteoarthritis|obesity|the company also has drug candidates or development programs for entity , erectile dysfunction , cardiovascular diseases , pulmonary diseases , inflammatory diseases and dermatologic diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|reduces personality trajectory predicts comorbidities|another competitive immediate private foreign|obesity|strong business momentum continues to accelerate sales & eps growth * sales growth in local currency retrospectively adjusted to exclude entity intervention business .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|reduces personality trajectory predicts comorbidities|grant pharmaceutical pharmacology demonstration medicaid|obesity|in addition , outsourced clinical expenses in the companys entity program increased by $0 . 3 million in 2007 for phase 1 clinical trials on the companys lead compound , ngd-4715 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|reduces personality trajectory predicts comorbidities|epilepsy insomnia autism ocd rls|obesity|tolerability of topiramate , which was the scientific rationale for combining these two agents at low doses for the treatment of entity and related co-morbidities .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|reduces personality trajectory predicts comorbidities|nephropathy genetics glaucoma retinopathy neurology|obesity|dr . amatruda was the senior vice president and franchise head , diabetes and entity at merck research laboratories .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|reduces personality trajectory predicts comorbidities|unemployment financial tax budget inflation|obesity|* 2012 eps growth includes the 2012 entity impact of $0 . 10 and the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|disease|reduces personality trajectory predicts comorbidities|cachexia dyslipidemia hyperglycemia hypercholesterolemia osteoporosis|obesity|axokine is being developed for the treatment of entity and complications of entity such as type ii diabetes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|reduces personality trajectory predicts comorbidities|ageing incontinence immobilization immobility malnutrition|obesity|incontinence may be caused by a wide range of factors , including childbirth , menopause , surgery , entity , drugs and neurological damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|reduces personality trajectory predicts comorbidities|environmentally experimentally meal lifestyle adiposity|obesity|academic researchers have increasingly linked chronic entity induced inflammation with type 2 diabetes and the potential role of inflammation in promoting insulin resistance in type 2 diabetes
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|reduces personality trajectory predicts comorbidities|waist distributions tendency circumference clustering|obesity|● increased waist circumference ( central or apple-shaped entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|reduces personality trajectory predicts comorbidities|narcolepsy acromegaly osteoporosis t2dm dyslipidemia|obesity|about orexigen therapeutics orexigen therapeutics , inc . is a biopharmaceutical company focused on the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|reduces personality trajectory predicts comorbidities|epilepsy preeclampsia autism tumorigenesis neurodegeneration|obesity|we believe that this discovery indicates that overactivity of this gpcr may be associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|reduces personality trajectory predicts comorbidities|melanoma nsclc psoriasis tnbc osteoporosis|obesity|the companys lead combination product candidates targeted for entity are contrave , which is in phase 3 clinical trials , and empatic , which is in the later stages of phase 2
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|reduces personality trajectory predicts comorbidities|dyslipidemia adiposity steatohepatitis hypertriglyceridemia nash|obesity|conversely , transgenic mice that overexpress dgat-1 in adipose tissue are predisposed to entity when fed a high-fat diet and have elevated levels of circulating free fatty acids .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|acne eczema mastitis varicella rabies|osteoporosis|the revenue decline in the second quarter largely reflects lower sales of fosamax for the treatment and prevention of entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis falls involves osteopenia predicts|hospitalized insured geriatric hospice uninsured|osteoporosis|ystps trademarks xiangbala jidan and zangyu in particular are well recognized in china among physicians and hospital administrators , pharmacists and entity patients .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|adjuvant pharmacologic approved newer promising|osteoporosis|other entity therapies include estrogen replacement therapy , selective estrogen receptor modulators , bisphosphonates and several new biologics that are under development .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|angina pneumonia hypercholesterolemia osteoporosis arrhythmias|osteoporosis|and outcomes management programs targeted at major categories of disease commonly found in the elderly , such as congestive heart failure , entity and atrial fibrillation .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|osteoporosis falls involves osteopenia predicts|osteoporosis acromegaly psoriasis bisphosphonates ibd|osteoporosis|a key set of parameters in the monitoring of entity , both before and after therapy , are biochemical markers of bone metabolism .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis falls involves osteopenia predicts|money marketing prophylaxis purchase substitution|osteoporosis|under the asset purchase agreement , par acquired certain assets pertaining to calcitonin nasal spray for entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteoporosis falls involves osteopenia predicts|osteoporosis syndromes amenorrhea atrophy acne|osteoporosis|and estraderm mx ( estradiol ) transdermal patches are treatments for symptoms of estrogen deficiency in post-menopausal women , and prevention of post-menopausal entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|osteoporosis periodontitis gout haemophilia osteomyelitis|osteoporosis|▪ approved for treatment of adult entity ▪ synthetic analogues of pyrophosphate ▪ inhibit bone resorption ▪ can be given orally or intravenously , depending on compound ▪
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|acne dyslipidemia hypertriglyceridemia preeclampsia periodontitis|osteoporosis|portfolio will include two drug candidates in advanced clinical trials for the treatment of types 1 and 2 diabetes , severe entity and polycystic ovary syndrome .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteoporosis falls involves osteopenia predicts|sarcopenia osteoporosis anorexia cachexia others|osteoporosis|currently in preclinical development as a potential treatment for age-related muscle loss , frailty , weight loss associated with cancer cachexia and entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|osteoporosis falls involves osteopenia predicts|lifestyle genomics gastroenterology reproduction genetics|osteoporosis|since 1990 , he has been the organizer and chairman of the international symposia on nutrition and entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteoporosis falls involves osteopenia predicts|psychiatry neurology neuroscience gastroenterology dermatology|osteoporosis|he is treasurer of the international foundation of entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis falls involves osteopenia predicts|technologies equipment healthcare lifestyles supplies|osteoporosis|also organize free community healthcare activities , such as arranging for bone density tests and organizing seminars on our products and entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|osa tbi sepsis asthmatic burn|osteoporosis|we believe this study population contains a patient population reflective of the type of severe entity patients that specialists will treat in their practices .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 2)])|disease|osteoporosis falls involves osteopenia predicts|hypercholesterolemia osteoarthritis hyperlipidemia osteoporosis dyslipidemia|osteoporosis|we also anticipate using our sales force to promote pharmaceutical products that address other midlife conditions such as hypertension , entity , depression and incontinence .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|malignancies falls cancers seizures suicide|osteoporosis|is also associated with a wide range of adverse events , including high blood pressure , weight gain , diabetes , serious infections and entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|osteoporosis falls involves osteopenia predicts|osteoporosis glaucoma sepsis osteoarthritis epilepsy|osteoporosis|company and sb will continue to work together to develop one or more novel therapeutic approaches to the treatment of entity utilizing the company  s calcium receptor technology .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|osteoporosis falls involves osteopenia predicts|osteoporosis osteopenia hpt hyperparathyroidism pth|osteoporosis|we have licensed worldwide rights to our manufacturing and delivery technologies for pth for the treatment of entity to gsk .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|osteoporosis falls involves osteopenia predicts|addiction psychosis osteoporosis alcoholism infertility|osteoporosis|pursuant to a tenth amendment , we have been granted the exclusive right to negotiate an expansion of the field of use to include treatment of entity ( the &#8220 ; option&#8221 ; ) .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|disease|osteoporosis falls involves osteopenia predicts|syphilis hepatitis cocaine methamphetamine marijuana|osteoporosis|hepatitis c , and multiple sclerosis business categories , as well as other lower margin business categories , including human immunodeficiency virus and entity , versus the prior year .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma hyperparathyroidism neuroblastoma acromegaly neurofibromatosis|paraganglioma|we will make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma neuroblastoma melanoma cholangiocarcinoma hyperparathyroidism|paraganglioma|administration ( fda ) has designated azedra as a breakthrough therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma neuroblastoma melanoma another neuroendocrine|paraganglioma|agent for prostate cancer phase 2 testing completed azedra™ treatment of pheochromocytoma and entity phase 2b registrational trial under special protocol assessment ( spa ) relistor®
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|carcinoid neuroblastoma pheochromocytoma sclc acromegaly|paraganglioma|study of azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers , pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma hypercalcemia acromegaly crpc pah|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma neuroblastoma hyperparathyroidism neurofibromatosis melanoma|paraganglioma|a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma pgl adenoma hyperparathyroidism acromegaly|paraganglioma|to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with pheochromocytoma / entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|endometrial cervix stomach ovary uterine|paraganglioma|twenty-four subjects were enrolled ( 11 female , 13 male ) , and seven subjects experienced stable disease in breast , neuroendocrine , entity , head / neck or colorectal cancer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|sporadic rarely familial retroperitoneal ectopic|paraganglioma|about pheochromocytoma and entity pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma acromegaly neuroblastoma hypercalcemia hyperparathyroidism|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity , an ultra-orphan indication .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma hyperparathyroidism neuroblastoma acromegaly mtc|paraganglioma|under compassionate use and named patient programs in 10 european countries in almost 1 , 300 patients , including those with pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|stomach endometrial neuroblastoma esophageal cervix|paraganglioma|or disease stabilization was observed in several cancer types , including parotid gland adenocarcinoma , colon , kaposi  s sarcoma , melanoma , ovarian , pancreatic and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|carcinoid pheochromocytoma neuroblastoma nets sclc|paraganglioma|dysregulation of hif-2α under pseudohypoxia is thought to contribute to pah and entity , a neuroendocrine tumor .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma neuroblastoma acromegaly melanoma carcinoid|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine tumors .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|pheochromocytoma neuroblastoma acromegaly carcinoid melanoma|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|neuroblastoma pheochromocytoma melanoma glioblastoma glioma|paraganglioma|candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|carcinoid neuroblastoma pheochromocytoma sclc melanoma|paraganglioma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable pheochromocytoma and entity , which are rare neuroendocrine tumors .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|neuroblastoma pheochromocytoma melanoma sarcoma carcinoid|paraganglioma|other than azedra , there are currently no approved anticancer treatments in the u . s . for malignant , recurrent , and / or unresectable pheochromocytoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|paragangli schwannoma glomus pheochromocytoma schwannomas|stomach endometrial uterine esophageal neuroblastoma|paraganglioma|stable disease was observed in several cancer types , including melanoma , ovarian , kaposi  s sarcoma , angiosarcoma , parotid gland adenocarcinoma , colorectal , pancreatic and entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial inherited phenylalanine pku|annual american summer philadelphia 2nd|phenylketonuria|camp km , et al . entity scientific review conference : state of the science and future research needs .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|hereditary familial inherited phenylalanine pku|pku epilepsy mma md hh|phenylketonuria|table of contents until march 2020 , we had been developing rtx-134 for the treatment of entity , or pku .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hereditary familial inherited phenylalanine pku|hereditary familial atypical juvenile uncomplicated|phenylketonuria|page 2 of 3 about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 2)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine pku pheochromocytoma hydroxylase hyperhomocysteinemia|phenylketonuria|kuvan is a commercialized product for the treatment of patients with entity ( pku ) and / or for primary bh4 deficiency in certain countries .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 2), ('DIS', 2)])|disease|hereditary familial inherited phenylalanine pku|pku phenylalanine pheochromocytoma hyperhomocysteinemia newborns|phenylketonuria|privately held biotechnology company focused on developing therapies for orphan metabolic diseases , to evaluate sepiapterin ( " cnsa-001 " ) for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 2)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine pku pheochromocytoma homocysteine hypothyroidism|phenylketonuria|company will use intrexons technology relating to the development and commercialization of novel biotherapeutics for the treatment of patients with entity ( pku ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hereditary familial inherited phenylalanine pku|cancers tumours psoriasis anthrax wounds|phenylketonuria|or in-license are currently pending patent applications except that we own one issued u . s . patent directed to methods of treating entity with rtx-134 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 2), ('DIS', 2)])|disease|hereditary familial inherited phenylalanine pku|pku phenylalanine hyperhomocysteinemia pheochromocytoma newborns|phenylketonuria|privately held biotechnology company focused on developing therapies for the orphan metabolic diseases , is developing cnsa-001 for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|disease|hereditary familial inherited phenylalanine pku|pku phenylalanine medicines agriculture pharmaceuticals|phenylketonuria|· october 1 , 2015 , biomarin to acquire rights to entity ( pku ) franchise from merck serono : the company announced that it has entered into a definitive agreement to acquire all
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine pku hyperuricemia hyperhomocysteinemia hyperglycemia|phenylketonuria|• pegvaliase for entity ( pku ) : pivotal results for the phase 3 prism-2 study ( formerly referred to as 165-302 ) that pegvaliase met the primary endpoint
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 2)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine pku microcephaly hyperhomocysteinemia homocysteine|phenylketonuria|investigational product candidates include phenoptin ( sapropterin hydrochloride ) , a phase 3 product candidate for the treatment of entity ( pku ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|hereditary familial inherited phenylalanine pku|example medicines publication registration france|phenylketonuria|and in the third quarter of 2017 , both france and germany had their first commercial sales . • kuvan® for entity :
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine hereditary recessive causing africa|phenylketonuria|about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|hereditary familial inherited phenylalanine pku|iiib iva vi ia vii|phenylketonuria|mucopolysaccharidosis iv type a , or mps iva mucopolysaccharidosis vi , or mps vi entity , or pku 6 kuvan has been granted orphan drug status in the eu , which together with pediatric
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|hereditary familial inherited phenylalanine pku|niddm dyslipidemia hypercholesterolemia osteoporosis t2d|phenylketonuria|substantial progress has been made over the past six decades , beginning with the first report of dietary control of entity in the early 1950s .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hereditary familial inherited phenylalanine pku|pku autism amyloidosis microcephaly gout|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad ) and entity ( mead johnson phenyl-free ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 2)])|disease|hereditary familial inherited phenylalanine pku|pku phenylalanine autism microcephaly gout|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad® ) and entity ( mead johnson phenyl-free® ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|hereditary familial inherited phenylalanine pku|phenylalanine recessive hydroxylase hereditary inherited|phenylketonuria|about entity ( pku ) pku is caused by a defect in the gene encoding phenylalanine hydroxylase ( pah ) , a liver enzyme that metabolizes phe .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma neuroblastoma neurofibromatosis mtc melanoma|pheochromocytoma|we will make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|glioma melanoma gliomas lymphomas melanomas|pheochromocytoma|azedra program " means the company  s therapeutic program for the treatment of malignant entity , pediatric neuroblastoma and carcinoid cancers with ultratrace iobenguane i 131 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma pgl mtc pcc acromegaly|pheochromocytoma|trial to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with entity / paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma schwannomas meningiomas mtc pgl|pheochromocytoma|although the majority of entity and paragangliomas are benign , approximately 10-25% of these tumors present with metastasis , and up to 35% of these cases are
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|pheochromocytoma familial hereditary develops sporadic|leukemia rhabdomyosarcoma osteosarcoma melanoma nhl|pheochromocytoma|we are currently pursuing adult clinical trials for entity and pediatric clinical trials for neuroblastoma , which are detailed below .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 2)])|disease|pheochromocytoma familial hereditary develops sporadic|neuroblastoma sclc melanoma carcinoid medulloblastoma|pheochromocytoma|the company is conducting azedra pivotal trials for both adult entity and pediatric neuroblastoma neuroendocrine tumor indications .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|melanoma neuroblastoma carcinoid pheochromocytoma glioblastoma|pheochromocytoma|azedra clinical development plan azedra is under development for the systemic treatment of the metastatic neuroendocrine cancers entity and neuroblastoma .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma neuroblastoma melanoma neurofibromatosis mtc|pheochromocytoma|to become a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma melanoma mtc glioma schwannoma|pheochromocytoma|that the first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant entity and paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma schwannoma melanoma schwannomas meningioma|pheochromocytoma|two product candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant entity and paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|pheochromocytoma familial hereditary develops sporadic|carcinoid melanoma neuroendocrine sclc pheochromocytoma|pheochromocytoma|azedra is currently in a phase 1 trial for entity or carcinoid tumors , and has received orphan drug status and a fast track designation by the united states food and
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma mtc neuroblastoma pgl carcinoid|pheochromocytoma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable entity and paraganglioma , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma schwannomas ganglia syndromes tumours|pheochromocytoma|about entity and paragangliomas entitys and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma mtc pgl neuroblastoma pcc|pheochromocytoma|perelman school of medicine presented preliminary dosimetry data from the phase 2 study in patients with iobenguane-avid metastatic and / or recurrent entity / paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma neuroblastoma dopaminergic mesencephalic pc12|pheochromocytoma|pharmacology 2005 ; 74 : 65-78 . " local anesthetic procaine protects rat entity pc12 cells against beta-amyloid-induced neurotoxicity " .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma mtc carcinoid neuroblastoma acromegaly|pheochromocytoma|in addition to potentially treating entity and paraganglioma , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma familial hereditary develops sporadic|pheochromocytoma neuroblastoma ccrcc carcinoid adrenocortical|pheochromocytoma|patients harboring a rare head and neck cancer , known as paraganglioma , and a rare adrenal or extra-adrenal cancer , known as entity , and rare subset clear cell rcc .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|mimicking mimic pituitary prolactin meningioma|acromegaly prolactin hyperprolactin pheochromocytoma hyperthyroidism|prolactinoma|entity is a condition in which a non-cancerous tumor of the pituitary gland overproduces prolactin .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|mimicking mimic pituitary prolactin meningioma|psychosis mania ocd prolactin parkinsonism|prolactinoma|study for xoma 213 , which , if successful , will allow us to advance the compound into a phase 2 study for entity and potentially into anti-psychotic medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|mimicking mimic pituitary prolactin meningioma|asthmatic ibd hospitalized psoriasis melanoma|prolactinoma|for ten percent of the 140 , 000 entity patients in the united states , existing therapies are poorly tolerated or not effective .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mimicking mimic pituitary prolactin meningioma|acromegaly adenoma meningioma pheochromocytoma neurofibromatosis|prolactinoma|entity is a condition of benign tumors on the pituitary gland .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mimicking mimic pituitary prolactin meningioma|purposes hyperthyroidism amenorrhea indications augmentation|prolactinoma|we intend to move xoma 213 into clinical development , initially for symptomatic entity potentially followed by medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|familial ldl sit improves causing|framingham gerd ash bav aha|sitosterolemia|treatment experience with zetia in the pediatric population is limited to 4 patients ( 9 to 17 years ) in the entity study and 5 patients ( 11 to 17 years ) in the hofh study .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|familial ldl sit improves causing|dengue syphilis brucellosis haemophilia hemophilia|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain blood test results .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|familial ldl sit improves causing|hypothyroidism autism hypoglycemia thrombocytopenia epilepsy|sitosterolemia|this finding indicated that the infant definitely has entity , despite the prior contradictory test results .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|familial ldl sit improves causing|allergic leprosy allergy brucellosis hypersensitivity|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain test results .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|disease|familial ldl sit improves causing|fh hypercholesterolemia bav nafld ldl|sitosterolemia|treatment experience with ezetimibe in the pediatric population is limited to 4 patients ( 9 to 17 years ) with homozygous entity and 5 patients ( 11 to 17 years ) with hofh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|resembles diagnose complicates improves familial|ocd gambling alcoholism bulimia mania|trichotillomania|patent claims the use of opioid antagonists , including nalmefene , for the treatment of impulse control disorders with the exception of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|resembles diagnose complicates improves familial|tics autism ocd psychosis asd|trichotillomania|dr . blochs research interests focus on studying tourette syndrome , ocd , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|resembles diagnose complicates improves familial|epilepsy tics ocd autism narcolepsy|trichotillomania|yale school of medicine - n oted researcher on the study of tourette syndrome , obsessive - compulsive disorder and entity prof . daniele piomelli
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|resembles diagnose complicates improves familial|ocd autism tics bpd asd|trichotillomania|dr . blochs research interests focus on studying ts , ocd , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|phototherapy psoriasis vitiligo urticaria acne|vitiligo|has registered a variety of domain names and established an initial website to include in depth information regarding psoriasis , eczema , entity , and the psoria-light device .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|autoimmunity autoantibodies tregs proteinuria tams|vitiligo|two prior clinical trials of immunotherapies conducted by others suggest that the development of entity was correlated with a favorable response to therapy in melanoma patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis ak uc vitiligo ce|vitiligo|the enrollment and / or results for a number of phase 2 studies with ati-502 for the topical treatment of aa and entity , including results from its auatb-201 study .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis acne vitiligo candidiasis alopecia|vitiligo|specified dermatological conditions , including alopecia areata , or aa , androgenetic alopecia , or aga , also known as male or female pattern baldness , entity and atopic dermatitis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis vitiligo acne pemphigus melanoma|vitiligo|raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts , alopecia areata , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|acne dermatitis vitiligo eczema psoriasis|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the patient significant psychosocial stress .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|acne dermatitis vitiligo eczema psoriasis|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the client significant psychosocial stress .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|pneumonitis keratitis rash neutropenia uveitis|vitiligo|to date , some patients have experienced entity and uveitis , but there has been no other evidence of off-target effects associated with til therapy .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo acne eczema urticaria telangiectasia|vitiligo|pharos 2 excimer laser system is fda-cleared and is used as a tool in the treatment of psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|melanoma melanomas psoriasis vitiligo malignancies|vitiligo|we have demonstrated that plasma from individuals with entity contains anti-melanoma activities , and we are attempting to develop vitigam for the treatment of stage iii and stage iv melanoma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo eczema urticaria acne psoriasis|vitiligo|pharos was granted ce mark clearance in september of 2016 for use in the treatment of psoriasis , entity , atopic dermatitis and leukoderma by the application of uvb ultraviolet light .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis vitiligo pemphigus melanoma scleroderma|vitiligo|vitigam is an igg-based product manufactured from the plasma of donors with entity , a benign skin condition affecting up to 2% of the general population .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis urticaria dermatitis eczema vitiligo|vitiligo|the continued development of arq-151 for atopic dermatitis , arq-154 for seborrheic dermatitis and scalp psoriasis , arq-252 for hand eczema and entity , and arq-255 for alopecia areata .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|vitiligo vulgaris psoriasis refers pigment|psoriasis pah melanoma nsclc t2dm|vitiligo|we plan to commence a phase 2 clinical trial for ati-50002 , for the treatment of entity , in the second half of 2017 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo eczema urticaria acne psoriasis|vitiligo|the fda has granted 510 ( k ) clearance to market pharos in the u . s . for psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vitiligo vulgaris psoriasis refers pigment|rebleeding fever restenosis pneumonia dvt|vitiligo|as of september 8 , 2011 , entity was observed in four out of 25 ( 16% ) patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo psoriasis scleroderma acne ssc|vitiligo|we also plan to develop ati-50001 and ati-50002 as potential treatments for entity , a disorder in which white patches of skin appear on different parts of the body .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|eczema acne urticaria psoriasis vitiligo|vitiligo|otc aoxing ointment walnut meat and camphor used to treat psoriasis , entity and various dermatitis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo melanoma psoriasis sarcoidosis pigmentation|vitiligo|entity is an autoimmune condition in which the patient  s immune system attacks melanoctyes , the cells responsible for skin pigmentation and potential melanoma cancer cells .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vitiligo vulgaris psoriasis refers pigment|vitiligo acne psoriasis urticaria eczema|vitiligo|developing the xtrac laser system to be the standard of care for psoriasis , and expanded its utilization to include dermatitis , entity and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|sarcoma mimic mimics mimicking resembles|glioblastoma melanoma gist neuroblastoma pheochromocytoma|angiosarcoma|first quarter highlights , we recently announced the fda has granted us orphan drug designation for oraxol for the treatment of entity , a rare form of malignant blood vessel cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|sts osteosarcoma sarcoma rhabdomyosarcoma leiomyosarcoma|angiosarcoma|a phase 3 study in entity is planned , and stratification of pfs in the phase 2 trial by tumor endoglin expression may identify other sarcoma histologies
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|sarcoma mimic mimics mimicking resembles|psoriasis mf melanoma sle wg|angiosarcoma|¡ in addition , one patient with entity who had a dramatic initial response on skin lesions was not evaluable for response due to death from sepsis ( not
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|glioblastoma melanoma nsclc gbm hnscc|angiosarcoma|we are also evaluating oral paclitaxel in the treatment of entity and in combination with other therapies , including anti-vegf and anti-pd-1 therapies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|sarcoma mimic mimics mimicking resembles|prolonging achieving extending producing predicting|angiosarcoma|cr cr trc105 + votrient is active in entity pfs in 13 vegf inhibitor-naïve patients of 7 . 8 months vs . 3 month pfs expected with votrient most vegf inhibitor patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|melanoma scc malignancies melanomas leishmaniasis|angiosarcoma|in may 2019 , we announced early and complete response data from a clinical study of oral paclitaxel in cutaneous entity , and the study is continuing to enroll .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|sarcoma mimic mimics mimicking resembles|nsclc melanoma aml myeloma psoriasis|angiosarcoma|• announcement of the results of the interim analysis from the phase 3 pivotal tappas trial of trc105 in entity is expected in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|sarcoma mimic mimics mimicking resembles|glioblastoma glioma gbm neuroblastoma medulloblastoma|angiosarcoma|we are initially focused on entity which is a tumor that highly expresses endoglin , the target of trc105 , and therefore may be more responsive to treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|sarcoma mimic mimics mimicking resembles|melanoma nsclc glioblastoma oncology psoriasis|angiosarcoma|trc105 is currently being studied in a pivotal phase 3 trial in entity and multiple phase 2 clinical trials , in combination with vegf inhibitors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|melanoma nsclc crc crpc osteosarcoma|angiosarcoma|efficacy in the phase 3 tappas trial evaluating trc105 in combination with votrient® ( pazopanib ) in patients with advanced or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|sarcoma mimic mimics mimicking resembles|leishmaniasis melanoma psoriasis malignancies sarcoidosis|angiosarcoma|xiangxue life sciences ( xlifesc )  reported promising clinical results from a clinical study of oraxol in cutaneous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|sarcoma mimic mimics mimicking resembles|leiomyosarcoma rhabdomyosarcoma osteosarcoma sts rms|angiosarcoma|a total of five patients with entity , a sarcoma subtype known to express high levels of endoglin , have been evaluated for response in the phase 1b / 2 study .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|sarcoma mimic mimics mimicking resembles|rituximab aml thymoma thrombocytopenia eosinophilia|angiosarcoma|one of these patients , with entity , has an ongoing complete response at month 4 of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sarcoma mimic mimics mimicking resembles|leiomyosarcoma osteosarcoma rhabdomyosarcoma sts liposarcoma|angiosarcoma|received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue sarcoma , including entity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoma mimic mimics mimicking resembles|melanoma europe japan oncology nsclc|angiosarcoma|we have leveraged this platform in all of our ongoing clinical trials including our international phase 3 tappas trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|glioblastoma melanoma neuroblastoma gbm mesothelioma|angiosarcoma|we are particularly excited by the ongoing complete responses seen in entity , a tumor type known to express high levels of endoglin , and expect to initiate a phase 3 trial in this
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoma mimic mimics mimicking resembles|glioblastoma glioma nsclc mesothelioma melanoma|angiosarcoma| presented preclinical data on oraxol in the treatment of entity at the american association for cancer research ( aacr ) annual meeting on april 3 , 2019  announced acceptance of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|sarcoma mimic mimics mimicking resembles|japan china india europe germany|angiosarcoma|we plan to initiate a phase 3 study in entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|sarcoma mimic mimics mimicking resembles|gtn mcc gbm choriocarcinoma eoc|angiosarcoma|we have seen complete ongoing responses in these tumor types and plan to initiate initial phase 3 development in entity and an international multicenter phase 2 trial in gtn in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoma mimic mimics mimicking resembles|nsclc melanoma crc gist mpm|angiosarcoma|phase 3 tappas trial ( a randomized phase 3 trial of trc105 and pazopanib versus pazopanib alone in patients with advanced entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|viruses chik fever serotype flavivirus|dengue homologous pandemic h5n1 h3n2|chikungunya|the interim analysis has shown that with a single dose administered , up to 98% of study participants produced a neutralizing antibody response against the entity virus by day 7 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|viruses chik fever serotype flavivirus|dengue wnv vzv hev rabies|chikungunya|is vector test systems , inc . , vector test systems , inc . markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|viruses chik fever serotype flavivirus|tetanus others hepatitis rabies leprosy|chikungunya|to manufacture virus-like particle based vaccines for third parties for indications other than respiratory viruses , certain allergies , hiv , malaria and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|viruses chik fever serotype flavivirus|dengue measles mumps ebola rabies|chikungunya|hds is also in the process of developing the platform for the qualitative testing for other infectious diseases including typhoid , entity , zika and other diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|viruses chik fever serotype flavivirus|dengue ebola borrelia chlamydia toxoplasma|chikungunya|there are also a number of emerging markets for lateral flow tests for infectious diseases such as burkholderia , entity , lassa , leptospirosis , marburg , rickettsia and zika .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|viruses chik fever serotype flavivirus|ebola rabies vaccinia measles dengue|chikungunya|•antibody against entity virus ( mrna-1944 ) : we announced positive interim data in the first analysis of safety and activity in a phase 1 clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|viruses chik fever serotype flavivirus|rabies dengue measles sars anthrax|chikungunya|vaxart may consider developing vaccines targeting other infectious diseases including entity , ebola , hepatitis b , herpes simplex virus 2 , or hsv-2 , and venezuelan equine encephalitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|ebola zika dengue others sars|chikungunya|chembio to fund the 12-month development of a dpp® fever panel assay to simultaneously detect malaria , dengue , ebola , lassa , marburg , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|rotavirus pneumococcal h1n1 rabies pertussis|chikungunya|solicited aes after each study vaccination for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo % ( no . with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|viruses chik fever serotype flavivirus|dengue wnv vzv rabies hev|chikungunya|is vector test systems inc . vector test systems inc markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests . .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|cmv monoclonal polyclonal neutralizing rubella|chikungunya|specifically , the positive phase 1 results from our cmv vaccine and entity antibody programs provide important validation for our approach as we move ahead .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|dengue schistosomiasis toxoplasmosis syphilis rabies|chikungunya|today announced the signing of a long-term agreement with bio-manguinhos to commercialize chembios poc diagnostic tests for dengue , zika and entity in brazil .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|zika dengue ebola schistosomiasis mumps|chikungunya|expanding beyond sexually transmitted disease , to include future poc tests for fever and tropical diseases such as malaria , dengue , zika , entity , ebola , lassa and marburg .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|viruses chik fever serotype flavivirus|vaccinia measles dengue polio mumps|chikungunya|all subjects reported full resolution by day 4 post vaccination , and thereby distinct from the persistent type observed in post entity virus infection arthralgias .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|rotavirus pneumococcal rabies pertussis h1n1|chikungunya|unsolicited aes reported for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo no . , % of
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|viruses chik fever serotype flavivirus|ebola dengue plague rabies leishmaniasis|chikungunya|zydus cadilaindiapartnership agreement to address the global threat of entity and develop a entity vaccine an emerging infectious disease in africa , asia and the indian subcontinent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|viruses chik fever serotype flavivirus|vaccinia ebola rabies dengue measles|chikungunya|the antibody against entity virus is our first systemic secreted therapeutic for which we have filed an ind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|viruses chik fever serotype flavivirus|zika dengue ebola rabies sars|chikungunya|cepis priority diseases include ebola virus , lassa virus , middle east respiratory syndrome coronavirus , nipah virus , rift valley fever and entity virus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|viruses chik fever serotype flavivirus|rsv hsv measles cytomegalovirus poliovirus|chikungunya|vaccine pre-clinical phase i hiv-1 x rsv on hold hsv on hold malaria x influenza x entity x 5 hiv-1 and aids hiv-1 ( human immunodeficiency virus type 1 ) is a retrovirus
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|viruses chik fever serotype flavivirus|serological neutralization stat hbsag genotyping|chikungunya|of vaccines , diagnostics and biopharmaceuticals , primarily to meet the demands of brazil  s national public health system , related to the dpp® entity assay .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|causing botulinum foodborne clostridium produces|hepatitis streptococcus streptococci encephalitis prrsv|botulism|in addition , our botvax® b vaccine has successfully protected hundreds of thousands of horses and foals against type b entity ( commonly known as shaker foal syndrome ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|disease|causing botulinum foodborne clostridium produces|organophosphate paraquat pesticide cyanide pq|botulism|of the national institutes of health ( contract no . hhsn272200800028c ) , to support ongoing development of drug candidates for the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|causing botulinum foodborne clostridium produces|dengue ebola rabies plague measles|botulism|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , tularemia , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|causing botulinum foodborne clostridium produces|tetanus poisoning anthrax rabies diphtheria|botulism|entity is a frequently fatal disease caused by botulinum toxins produced by the bacterium clostridium botulinum .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|causing botulinum foodborne clostridium produces|shellfish mercury copper cadmium mushroom|botulism|zebra mussels are also believed to be the source of deadly avian entity poisoning that has killed tens of thousands of birds in the great lakes since the late 1990s .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|disease|causing botulinum foodborne clostridium produces|organophosphate paraquat pesticide cyanide op|botulism|an additional contract with niaid to support our on-going development of drug candidates toward clinical trials in the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|causing botulinum foodborne clostridium produces|anthrax tetanus rabies typhoid plague|botulism|we evaluated the use of mrna for passive immunization in two indications , rabies and entity , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|causing botulinum foodborne clostridium produces|cholera rabies encephalitis brucellosis leishmaniasis|botulism|sales of neogens vaccine for equine entity and amvet veterinary pharmaceuticals experienced strong increases as they continued to gain market acceptance .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|causing botulinum foodborne clostridium produces|hepatitis toxin botulinum rabies encephalitis|botulism|in addition , the companys botvax b vaccine has successfully protected thousands of high-value horses and foals against type b entity , commonly known as shaker foal syndrome .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|causing botulinum foodborne clostridium produces|streptococcus seed bacillus botulinum streptococcal|botulism|the companys boxvax b vaccine is also produced in the tampa , facility , utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|causing botulinum foodborne clostridium produces|anthrax anaphylaxis poisoning sar rabies|botulism|supply of 200 , 000 doses of bat that are intended for treating individuals who have been exposed to the toxins that cause entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|causing botulinum foodborne clostridium produces|hepatitis streptococci prrsv hev streptococcus|botulism|our botvax® b product is the only usda-approved vaccine for the prevention of type b entity in horses .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|causing botulinum foodborne clostridium produces|anthrax rabies tetanus measles cholera|botulism|david scarlett a complaint was filed on july 16 , 2008 by counsel representing mr . scarlett in ohio who alleges to have contracted entity from a castleberrys product .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|causing botulinum foodborne clostridium produces|outbreaks tetanus pertussis sequelae disabilities|botulism|entity can also be contracted if botulinum bacteria contaminate wounds or colonize in the intestine of infants , which is referred to as infant botulism .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|causing botulinum foodborne clostridium produces|rabies viruses mycobacteria parasites nematodes|botulism|expands our capabilities in biological warfare defense research and allows for the development of vaccines for smallpox , anthrax and plague , entity and other biological pathogens .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|disease|causing botulinum foodborne clostridium produces|xo acetaminophen organophosphate cyanide op|botulism|other companies are developing other products targeting entity poisoning , and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|causing botulinum foodborne clostridium produces|botulinum streptococcus streptococcal bacillus seed|botulism|the companys botvax ®b vaccine is also produced in the lansing facility utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|disease|causing botulinum foodborne clostridium produces|cyanide acetaminophen organophosphate copper mercury|botulism|other companies are developing other products targeting entity poisoning and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|causing botulinum foodborne clostridium produces|anaphylaxis spasticity seizures attacks spasms|botulism|bat is indicated for the treatment of symptomatic entity following documented or suspected exposure to botulinum neurotoxin serotypes a , b , c , d , e , f , or g in adults and
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|causing botulinum foodborne clostridium produces|botulinum bont hepatitis toxin bot|botulism|in the veterinary market , neogen markets botvax b , the only usda approved vaccine for the prevention of entity type b in horses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|atypical diagnose sporadic familial causing|csd bart tick scratch cmt|bartonellosis|entity ( cat scratch fever ) vaccine bartonella henselae is the causative agent of cat scratch fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|cystic segmental familial plantar multiplex|oblique vertical midline anteroposterior hanging|torticollis|the patient  s head may turn to the right or left ( entity ) , may tilt to one side ( laterocollis ) , or may tilt upwards ( retrocollis ) or downwards ( anterocollis ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|cystic segmental familial plantar multiplex|dyskinesia dystonia spasm tort ataxia|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( “twstrs” ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|cystic segmental familial plantar multiplex|spasm dyskinesia headache vertigo tremor|torticollis|also known as spasmodic entity , cervical dystonia is a painful and debilitating neurological movement disorder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2)])|disease|cystic segmental familial plantar multiplex|dystonia dyskinesia spasm tremor aura|torticollis|cervical dystonia ( also referred to as spasmodic entity ) may be primary ( meaning that it is the only apparent neurological disorder , with or without a family history ) or may
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|cystic segmental familial plantar multiplex|spasm dyskinesia legs headache headaches|torticollis|units or 250 units showed a statistically significant greater change from baseline as measured on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2)])|disease|cystic segmental familial plantar multiplex|dyskinesia dystonia dysph tort spasm|torticollis|cervical dystonia affects approximately three in every 10 , 000 people , or about 90 , 000 people in the united states , according to the national spasmodic entity association .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|cystic segmental familial plantar multiplex|dyskinesia dystonia spasm ataxia tort|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) -total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|cystic segmental familial plantar multiplex|dyskinesia dystonia spasm ataxia tort|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|cystic segmental familial plantar multiplex|spasm dyskinesia headaches headache legs|torticollis|treatment until the return of signs and symptoms that warrant retreatment , based on subjects reaching their target toronto western spasmodic entity rating scale ( twstrs ) score .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|hodgkin follicular indolent lymphoproliferative cd30|malignancies lymphomas blasts lymphocytes autoantibodies|lymphoma|first , the cd19 antigen is used in the clinic to distinguish entity derived from b cells from those derived from t cells .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl leukemia hodgkin malignancies|lymphoma|plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin entity and chronic lymphocytic leukemia .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl sarcoma cancers tumours|lymphoma|for which a u . s . marketing application is currently being reviewed by the fda for the treatment of relapsed aggressive non-hodgkin  s entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl cll leukemia neoplasms|lymphoma|inc . yeah , so invariably we want to look for drugs which are active in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|rabies brucellosis leishmaniasis osteoarthritis diarrhea|lymphoma|we currently have two products ( at-004 and at-005 ) for treatment of entity in dogs which have received a conditional license from the u . s . department of agriculture , or the usda .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hodgkin follicular indolent lymphoproliferative cd30|autoantibodies cytotoxicity immunogenicity autoimmunity bioactivity|lymphoma|the treatment of generalized lipodystrophy , and carries a boxed warning for the risks of anti-metreleptin antibodies with neutralizing activities and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas leukemia sarcoma lymphoid leukaemia|lymphoma|type : debit period type : duration x - definitionrepresents the maximum amount of grants to be received from the leukemia and entity society ( lls ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas dlbcl nhl malignancy tumours|lymphoma|approximately 50% to 60% of dlbcl patients are cured with first-line therapy and do not have recurrence of their entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl leukaemia malignancies leukemia|lymphoma|to finance the analysis of unblinded data on biovaxidtm , an active immunotherapeutic in a pivotal phase 3 study of non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas leukemia carcinomas neoplasms malignancies|lymphoma|phase ii clinical trials to assess the oms electroimmunotherapy technology in patients with melanoma , merkel cell carcinoma and cutaneous t-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl cancers sarcoma tumours|lymphoma|we are also aware of other potentially competitive biologic therapies for non-hodgkin  s entity in development .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl leukemia lymphoproliferative leukaemia|lymphoma|this trial will seek to treat both non-hodgkins entity and chronic lymphocytic leukemia patients that have failed venetoclax .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl leukemia leukaemia sarcoma|lymphoma|morphosys will continue to be responsible for its ongoing clinical studies with tafasitamab in non-hodgkins entity ( nhl ) , cll , r / r dlbcl and first-line dlbcl .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|leukemia leukemias myeloma lymphomas malignancies|lymphoma|an open-labeled , uncontrolled , dose-escalation , phase i clinical trial of cudc-427 ( nct01226277 ; iam4914g ) began in patients with refractory solid tumors or entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl cll leukemia malignancies|lymphoma|one of the issues is even in the novel space there are a limited number of agents which have significant activity in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas myeloma nhl melanoma autoimmunity|lymphoma|cancers because the therapy can deplete all b cells or t cells including normal and cancer cells in leukemia and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl malignancies leukemia leukaemia|lymphoma|designed to assess the safety and tolerability of vegf trap in patients with solid tumor malignancies and subjects with non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|leukemia cll leukaemia nhl lymphomas|lymphoma|a large proportion of t-cell entity patients are refractory to or relapse following treatment with standard therapies and there remains a need to develop an effective
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas leukemia dlbcl nhl leukaemia|lymphoma|in february 2013 , we received clia approval for matba®-dlbcl , our proprietary microarray for diagnosis , prognosis and patient monitoring in diffuse large b cell entity ( dlbcl ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hodgkin follicular indolent lymphoproliferative cd30|lymphomas nhl leukaemia leukemia malignancies|lymphoma|process for review of inds , initiate a clinical trial of adi-001 targeting cd20 for the treatment of patients with non-hodgkins entity and treat the first patient in the first half of 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cystic lumbosacral refers involves caudal|ntd asd hydrocephalus cdh bifida|myelomeningocele|dr . moise is also actively involved in the open fetal surgical repair program for entity ( spina bifida ) at the fetal center .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis myelopathy neuropathy|leukoencephalopathy|this decision was based on reports of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalopathy encephalomyelitis myelopathy sclerosis encephalitis|leukoencephalopathy|these include : fatal infusion reactions , tumor lysis syndrome ( tls ) with associated acute renal failure , severe mucocutaneous reactions and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis myelopathy encephalitis|leukoencephalopathy|in immunosuppressed individuals , jc virus is responsible for a life-threatening infection of the brain and spinal cord called progressive multifocal entity , or pml .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis encephalitis myelopathy|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain which usually leads to death or severe disability .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|sclerosis atrophy glomerulonephritis glomerulosclerosis neuropathy|leukoencephalopathy|dyspnea and bronchospasm have been reported , and due to the mechanism of action , increased risk for infections and progressive multifocal entity must be advised and monitored .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis encephalitis myelopathy|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalopathy sclerosis encephalomyelitis atrophy encephalitis|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis myelopathy encephalitis|leukoencephalopathy| progressive multifocal entity ( pml ) : jc virus infection resulting in pml and death has been reported in adcetris-treated patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis myelopathy encephalitis|leukoencephalopathy|these events involved two cases of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis encephalitis pneumonia|leukoencephalopathy|shown a reduction in arr of 67% , but it may cause serious side effects including increased risk of progressive multifocal entity ( pml ) , a rare and potentially fatal viral disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis encephalitis myelopathy|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain that usually leads to death or severe disability .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis sclerosis encephalopathy myelopathy encephalitis|leukoencephalopathy|the new label identifies anti-jc virus ( jcv ) antibody status as a risk factor for progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|subcortical hereditary familial multifocal periventricular|sclerosis lymphocytes pml palsy cns|leukoencephalopathy|however , tysabri  s association with progressive multifocal 69 table of contents entity , " pml , " has limited its usage to patients for whom other treatment has failed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy sclerosis myelopathy encephalitis|leukoencephalopathy|several initiatives under way that may lead to defi ning patients who are at greater risk of developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis sclerosis encephalopathy myelopathy encephalitis|leukoencephalopathy|inclusion of anti-jcv antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalopathy encephalomyelitis sclerosis myelopathy encephalitis|leukoencephalopathy|we have also begun animal studies related to two orphan diseases , multiple system atrophy ( msa ) and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalopathy encephalomyelitis myelopathy sclerosis encephalitis|leukoencephalopathy|collaboration will focus on the discovery and development of therapeutics based on rnai for the potential treatment of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|subcortical hereditary familial multifocal periventricular|sclerosis encephalomyelitis encephalopathy myelopathy neuropathy|leukoencephalopathy|progressive multifocal entity ( pml )  a rare and potentially fatal demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|sclerosis atrophy encephalomyelitis neuropathy glomerulonephritis|leukoencephalopathy|biologics used for multiple sclerosis increased the risk of infections and progressive multifocal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subcortical hereditary familial multifocal periventricular|encephalomyelitis encephalopathy myelopathy sclerosis encephalitis|leukoencephalopathy|to inform physicians and patients of the benefits and risks of tysabri treatment and minimize potential risk of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|keratoconus acanthamoeba keratitis fusarium endophthalmitis|keratoconus|in 2000 , this patient underwent corneal transplantation caused by entity , simultaneously with extraction of a cataract and implantation of an artificial lens .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|corneal keratoconus cornea undergoes develops|myopia opacity keratitis astigmatism opacities|keratoconus|are the only fda-approved riboflavin ophthalmic formulations used with our kxl system to treat progressive 122 table of contents entity and corneal ectasia following refractive surgery .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|glaucoma keratoconus cataract immunocompromised amd|keratoconus|literature estimates that as many as 20% of entity patients ultimately require a corneal transplant , a costly and invasive procedure with high failure rates .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|corneal keratoconus cornea undergoes develops|myopia retinopathy blindness cataract rop|keratoconus|trial underway ; us clinical trial planned • 38 globally issued patents with 59 pending patent applications vision correction pipeline $3b entity $15b presbyopia $8b low myopia
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|corneal keratoconus cornea undergoes develops|keratoconus kc myopia cle lca|keratoconus|typically diagnosed in a patients teenage years , entity is characterized by progressive thinning and weakening of the cornea , resulting in vision loss .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|glaucoma cataract uveitis endophthalmitis cataracts|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|keratoconus glaucoma cataracts cataract keratitis|keratoconus|ten patients with advanced entity , or severe corneal scarring , were implanted with the recombinant collagen implants and have been followed for more than five years .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal keratoconus cornea undergoes develops|keratoconus kc glaucoma cle keratitis|keratoconus|entity is a degenerative corneal disease that impairs vision and is characterized by progressive thinning of the cornea and the development
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|corneal keratoconus cornea undergoes develops|keratoconus myopia glaucoma lasik cataract|keratoconus|one significant cause of night myopia is entity , an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|corneal keratoconus cornea undergoes develops|glaucoma cataract cataracts amd rop|keratoconus|i  d say there  s  if you look at the prevalence now , there  s 1 . 1 million eyes that are available that have entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|corneal keratoconus cornea undergoes develops|pharmacological psoriasis periodontal immunomodulatory glaucoma|keratoconus|unlike conventional entity treatments , studies have found that avedros photrexa® actually slows or halts disease progression .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|glaucoma cataract uveitis cataracts conjunctivitis|keratoconus|of the enzyme hyaluronidase 7 8 to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|corneal keratoconus cornea undergoes develops|epilepsy als sle psoriasis ibd|keratoconus|we believe that there are approximately 400 , 000 people in the united states , western europe and japan who currently have entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|corneal keratoconus cornea undergoes develops|antiretroviral orphan eradication antihypertensive antidiabetic|keratoconus|avedro estimates the total u . s . opportunity for its entity therapy to be approximately $3 billion .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|glaucoma cataract uveitis endophthalmitis cataracts|keratoconus|to digest proteoglycans to treat a variety of eye diseases and conditions , including vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|corneal keratoconus cornea undergoes develops|what something your another you|keratoconus|know were going to probably get bogged down in migs shortly but just when you think a little bit about entity , arguably an undiagnosed or under diagnosed , i should say , disease state .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal keratoconus cornea undergoes develops|glaucoma cataract uveitis cataracts endophthalmitis|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|corneal keratoconus cornea undergoes develops|keratoconus vitiligo psoriasis rop periodontitis|keratoconus|for our latest-generation kxl system , its associated investigational drug formulations and our investigational boost goggles for the treatment of progressive entity in an epi-on procedure .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|corneal keratoconus cornea undergoes develops|psoriasis scoliosis epistaxis emphysema glaucoma|keratoconus|keraform we are developing keraform , our proprietary system for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteoporosis osteoarthritis fibromyalgia psoriasis glaucoma|osteonecrosis|thus , we expect that new clinical indications may include orthopedics , secondary osteoporosis ( including glucocorticoid induced osteoporosis ) , entity , and osteoarthritis .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis avn osteoarthritis osteoporosis osteosarcoma|osteonecrosis|in march 2006 , our proprietary trcs received an orphan drug designation from the fda for use in the treatment of entity of the femoral head .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|harm damages discomfort damaging insult|osteonecrosis|plaintiffs allege aredia causes entity to the jaw .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteoporosis osteolysis frailty infarction|osteonecrosis|“entity” means the death of bone cells due to decreased blood flow .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteolysis avn osteoarthritis osteoporosis|osteonecrosis|entity of the femoral head involves the death of cells in the bone and marrow within the femur head and in
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis genotoxicity thrombocytopenia cardiotoxicity neurotoxicity|osteonecrosis|in our original ind submission , we described a finding of entity ( microscopic evidence of bone and bone marrow death ) in a toxicity study of gen-003 conducted in mice .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteosarcoma osteomyelitis dislocation osteoporosis|osteonecrosis|there have been no cases of entity of the jaw or atypical femoral fracture in the entire tymlos development program .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteomyelitis osteosarcoma osteoporosis cancers|osteonecrosis|describing changes to the label for zometa and aredia , another intravenous bisphosphonate used to treat metastatic bone disease , relating to entity of the jaw .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteoporosis osteoarthritis hyperparathyroidism hypercalcemia osteomyelitis|osteonecrosis|additional patent applications are for specific methods of manufacturing strontium salts and for other clinical indications , such as treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|hypoglycaemia hepatotoxicity cardiotoxicity hypoglycemia intolerance|osteonecrosis|there were no events of entity observed in the trial .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|amputation amputations wounds ulcers gangrene|osteonecrosis|more severe complications can occur , such as deep tissue infections and entity threatening life of the limb .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis swelling osteomyelitis cellulitis ulceration|osteonecrosis|plaintiffs claim to have experienced entity of the jaw after having been treated with zometa or aredia , which are used to treat patients whose cancer has
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteoarthritis avn osteolysis osteosarcoma|osteonecrosis|the orthopaedic institute , könig-ludwig-haus , university of würzburg , germany , involving the first use of our brcs to treat patients suffering from entity of the femoral head .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteomyelitis osteosarcoma osteoporosis arthropathy|osteonecrosis|entity of the jaw ( onj ) : onj has been reported in patients with cancer receiving treatment including bisphosphonates , chemotherapy and / or corticosteroids .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis osteoarthritis osteoporosis osteolysis avn|osteonecrosis|aastrom product candidates to treat entity of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis swelling osteomyelitis osteosarcoma osteoporosis|osteonecrosis|the most frequent serious adverse reactions were entity of the jaw , bone giant cell tumor , anemia , pneumonia , and back pain .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteoarthritis osteoporosis osteonecrosis dislocations deformities|osteonecrosis|other potential orthopedic applications include wrist fractures , poor-healing fractures , and entity , or conditions of bone degeneration .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteonecrosis avascular involves osteoarthritis sclerosis|osteonecrosis swelling numbness dryness cellulitis|osteonecrosis|the most frequent adverse reaction resulting in discontinuation of xgeva® was entity of the jaw .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteomyelitis abscess septic aureus fungal|endocarditis osteomyelitis pneumonia vap peritonitis|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing , such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|osteomyelitis abscess septic aureus fungal|hospitalized ibd asthmatic immunocompromised burn|osteomyelitis|most entity patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|osteomyelitis abscess septic aureus fungal|pharmaceutical cigarette chiropractic cannabis methamphetamine|osteomyelitis|increase in marketing expenses , which increased from $43 , 000 to $95 , 000 as a result of a commissioned research study on the entity market .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteomyelitis abscess septic aureus fungal|cellulitis osteomyelitis keratitis endophthalmitis acne|osteomyelitis|lefamulin has shown substantial tissue penetration and activity against the most common causative organism in all forms of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis abscess septic aureus fungal|encephalitis endocarditis osteomyelitis pneumonia bacteremia|osteomyelitis|invasive pneumococcal disease includes bacteremic pneumonia , bacteremia , sepsis , meningitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteomyelitis abscess septic aureus fungal|osteomyelitis endophthalmitis abscesses endocarditis cellulitis|osteomyelitis|up to 90% of cases of hematogenous entity , most frequently in children , are caused by s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|bacteremia sepsis osteomyelitis pneumonia bacteraemia|osteomyelitis|these data indicate that s . aureus bloodstream infections including infective endocarditis and entity may be a potentially promising area of clinical development with ceftobiprole .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|osteomyelitis endocarditis sepsis septicemia encephalitis|osteomyelitis|is exebacase , a lysin which targets staph aureus , including methicillin-resistant strains , which causes serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|sepsis osteomyelitis endocarditis pneumonia septicemia|osteomyelitis|organisms , such as methicillin-resistant staph aureus ( mrsa ) and p . aeruginosa , which can cause serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis abscess septic aureus fungal|osteomyelitis osteonecrosis osteoporosis nonunion loosening|osteomyelitis|are currently one of the few resorbable bone void fillers available in international markets for the prevention and treatment of entity , an acute or chronic infection of the bone .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteomyelitis abscess septic aureus fungal|osteomyelitis periodontitis endocarditis ulcers pneumonia|osteomyelitis|could fulfill the need for a safe , long-term oral therapy to treat chronic infections such as prosthetic joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|osteomyelitis abscess septic aureus fungal|qi tcm osteoporosis sui herbal|osteomyelitis|sui yan pian kang gu sui yan pian ( entity treatment tablets ) is used to treat bone and bone marrow inflammations .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|pneumonia sepsis osteomyelitis septicemia bacteremia|osteomyelitis|gram-positive bacteria can also cause other serious illnesses , including pediatric and adult entity , community- and habp , including vabp , bacteremia and diabetic foot infection .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|osteomyelitis abscess septic aureus fungal|osteoporosis osteomyelitis osteonecrosis osteoarthritis periodontitis|osteomyelitis|medicated pellets are currently the only synthetic resorbable bone void filler available on the international market for the treatment of entity , an acute or chronic inflammation of bone .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteomyelitis abscess septic aureus fungal|osteoporosis osteoarthritis osteomyelitis others myositis|osteomyelitis|for example , applications of mdp-25 include metastatic bone disease , pagets disease , arthritic disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|malignancies hemophilia sepsis osteomyelitis osteoarthritis|osteomyelitis|mtf-101 , a diaminopyrimidine that may be suitable for testing in clinical trials to demonstrate safety and efficacy in patients with entity and patients with prosthetic joint infections .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteomyelitis abscess septic aureus fungal|endocarditis osteomyelitis pneumonia peritonitis vap|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|osteomyelitis osteoporosis osteoarthritis osteonecrosis sepsis|osteomyelitis|the need for a safe , long-term oral therapy to treat chronic infections such as refractory bone and joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|osteomyelitis abscess septic aureus fungal|psoriasis osteoporosis oab sepsis rls|osteomyelitis|our goal is to develop an effective therapy for entity that permits infrequent dosing .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|osteomyelitis abscess septic aureus fungal|psoriasis vitiligo sle pemphigus nash|osteomyelitis|we believe that lefamulin has the potential to be an effective treatment option for entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|dermatomyositis lupus myositis polymy vulgaris|another japan american canadian sponsored|dermatomyositis|entity clinical program update corbus is currently evaluating anabasum in an on-going phase 2 study for the treatment of skin-predominant dermatomyositis .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis dermatitis colitis amyloidosis lupus|dermatomyositis|change in the cutaneous entity activity and severity index ( “cdasi” ) activity score is a secondary efficacy outcome .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis lupus myositis polymy vulgaris|sle lupus vitiligo pemphigus urticaria|dermatomyositis|above disease programs , we performed phase i pilot clinical trials with eculizumab in patients afflicted with the chronic autoimmune disorders entity , psoriasis , and bullous pemphigoid .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis myositis scleroderma gca fibromyalgia|dermatomyositis|servier also began testing gevokizumab in a variety of small clinical studies , including polymyositis / entity and schnitzler syndrome .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis scleroderma pemphigus vitiligo vasculitis|dermatomyositis|in patients with any one of the following six different autoimmune diseases : cle , sle , sjögrens syndrome , systemic sclerosis , polymyositis and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|scleroderma vitiligo vasculitis psoriasis dermatomyositis|dermatomyositis|resunab is currently in phase 2 studies for the treatment of diffuse cutaneous systemic sclerosis and skin-predominant entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis scleroderma pemphigus lupus vitiligo|dermatomyositis|two rare autoimmune connective tissue conditions , polymyositis and entity , have been alleged to occur with increased frequency in patients who have received cosmetic collagen treatments .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|dermatomyositis lupus myositis polymy vulgaris|myositis dermatomyositis ibm fibromyalgia dmd|dermatomyositis|new drug application with the fda to commence a phase ib pilot clinical study trial with 5g1 . 1 in patients with entity , a severe inflammatory muscle disorder .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|dermatomyositis lupus myositis polymy vulgaris|ibm dermatomyositis dm1 myositis scleroderma|dermatomyositis|based on these ongoing efforts , we have focused our development strategy on entity , a form of the disease in which there is muscle and skin involvement .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis pemphigus scleroderma vitiligo dermatomyositis|dermatomyositis|lenabasum is currently being evaluated in entity and systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis myasthenia myositis dm1 myopathy|dermatomyositis|age , and the treatment of certain rheumatology related conditions , including the treatment of the rare and closely related neuromuscular disorders entity and polymyositis .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis osteoporosis bronchiectasis osteoarthritis others|dermatomyositis|continue to increase as we advance to clinical trials for indications for the treatment of cystic fibrosis , systemic sclerosis and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis scleroderma sle vitiligo lupus|dermatomyositis|forms of b-cell lymphoma , including waldenströms macroglobulinemia and diffuse large b-cell lymphoma , and in orphan autoimmune diseases , including polymyositis and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis pemphigus neuroblastoma melanoma sarcoidosis|dermatomyositis|we are developing imo-8400 for the treatment of a rare disease called entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis pemphigus bronchiectasis dermatomyositis scleroderma|dermatomyositis|lenabasum is currently being evaluated in systemic sclerosis , cystic fibrosis , entity , and systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis pemphigus epilepsy bronchiectasis uveitis|dermatomyositis|lenabasum is not approved for the treatment of systemic sclerosis , entity , cystic fibrosis or systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis myositis scleroderma gca fibromyalgia|dermatomyositis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / entity , schnitzler syndrome , and giant cell arteritis .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis lupus myositis polymy vulgaris|psoriasis bronchiectasis osteoarthritis melanoma scleroderma|dermatomyositis|dose in the phase 2 clinical trials currently underway and recently completed with jbt-101 in cystic fibrosis , systemic sclerosis and entity , respectively .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|dermatomyositis lupus myositis polymy vulgaris|myositis dermatomyositis scleroderma myasthenia fibromyalgia|dermatomyositis|entity is an autoimmune disorder in which the immune system attacks the patients muscles and skin , which may cause extensive rash
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|dermatomyositis lupus myositis polymy vulgaris|dermatomyositis epilepsy myositis myopathy infantile|dermatomyositis|by therapeutic area paid prescriptions multiple sclerosis ( ms ) nephrotic syndrome ( ns ) infantile spasms ( is ) entity / polymyositis ( dm / pm ) ** jan-10 67 6 26 feb-10 72
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|leprosy lepr leprae suspect vulgaris|leprosy brucellosis enl sle immunosuppression|leprosy|enl , a complication of entity , is a chronic bacterial disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('DRUG', 2), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|leprosy enl sepsis psoriasis gout|leprosy|enl , an inflammatory complication of entity , is a chronic bacterial disease associated with excess tumor necrosis factor alpha , or tnf ( alpha ) production .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|leprosy lepr leprae suspect vulgaris|ebola leprosy schistosomiasis brucellosis dengue|leprosy|novartis as the pharmaceutical partner in the global alliance set up by the who for the elimination of entity takes great pride in having been able to contribute to this achievement .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|leprosy lepr leprae suspect vulgaris|hepatitis leprosy cholera epilepsy tetanus|leprosy|we expanded our programs designed to facilitate the supply of drugs to indigent patients suffering from entity , malaria , tuberculosis and chronic myeloid leukemia ( cml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|leprosy enl psoriasis sle autoimmunity|leprosy|from the fda which allowed us to market thalomid® for the treatment and suppression of enl , an inflammatory complication of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|sle leprosy immunocompromised ibd hospitalized|leprosy|enl occurs in about 30% of entity patients , and is characterized by cutaneous lesions , acute inflammation , fever , and anorexia .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|leprosy lepr leprae suspect vulgaris|leprosy sle endometriosis psoriasis lupus|leprosy|enl is an inflammatory complication of entity associated with excess tnf ( alpha ) production .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|leprosy lepr leprae suspect vulgaris|leprosy immunocompromised melanoma immunosuppressed lupus|leprosy|approval from the fda to market thalidomide for the treatment of erythema nodosum leprosum , an inflammatory skin condition of some entity patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|leprosy lepr leprae suspect vulgaris|antimalarial imported artemisinin expensive malarial|leprosy|the group provided further support for patients in developing countries by supplying entity drugs free of charge and by selling coartem , our new antimalarial treatment , to the who at cost .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|leprosy lepr leprae suspect vulgaris|leprosy immunosuppression immunodeficiency psoriasis malignancy|leprosy|market and sell thalomid ( thalidomide ) for the treatment of erythema nodosum leprosum ( enl ) , a severe and debilitating condition associated with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 4)])|disease|leprosy lepr leprae suspect vulgaris|antipsychotic psychotropic antidepressant antihypertensive prophylactic|leprosy|we have given entity medication free of charge since the year 2000  again to 3 million patients and on an ongoing basis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|leprosy lepr leprae suspect vulgaris|leishmaniasis schistosomiasis leptospirosis dengue brucellosis|leprosy|this approval reinforces the company  s commitment to reduce the burden of neglected tropical diseases including fascioliasis , entity and malaria .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|leprosy lepr leprae suspect vulgaris|leprosy brucellosis acne psoriasis sarcoidosis|leprosy|when given orally , dapsone is used for the treatment of such diseases as entity , malaria and dermatitis herpetiformis , an autoimmune skin disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|leprosy lepr leprae suspect vulgaris|brucellosis psoriasis sarcoidosis leptospirosis rabies|leprosy|entity afflicts millions worldwide , although the disease is relatively rare in the united states .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|sle leprosy ibd immunocompromised hospitalized|leprosy|enl occurs in about 30% of entity patients and is characterized by skin lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|leprosy lepr leprae suspect vulgaris|leishmaniasis cellulitis psoriasis dermatitis pemphigus|leprosy|infection caused by a protozoal parasite that affects the skin and abdominal organs , causing ulcers or skin disorders that resemble entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|sle leprosy ibd immunocompromised lupus|leprosy|enl occurs in about 30% of entity patients and is characterized by cutaneous lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|leprosy lepr leprae suspect vulgaris|psoriasis melanoma rheumatic cancers leukemia|leprosy|approved for sale in the u . s . , thalidomide has been used as an investigational agent to treat thousands of patients for entity and other diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|leprosy lepr leprae suspect vulgaris|sarcoidosis brucellosis psoriasis ibd leprosy|leprosy|although entity is relatively rare in the united states , the disease afflicts millions worldwide .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|leprosy lepr leprae suspect vulgaris|autoimmunity hyperhomocysteinemia ageing immunodeficiency hyperuricemia|leprosy|the fda an approvable letter for its nda for thalomid for the treatment of enl , a disease state associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|zoonotic ehrlich granulocytic avian named|rabies canine abstract veterinary dog|ehrlichiosis|entity diseases quilvax-l ( tm ) 10 million licensing schering- product to prevent dogs at risk efficacy and plough .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|zoonotic ehrlich granulocytic avian named|toxoplasmosis leptospirosis dengue leishmaniasis schistosomiasis|ehrlichiosis|the most prevalent and well known tick-borne disease is lyme disease , but there are others such as anaplasmosis , entity , and babesiosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|zoonotic ehrlich granulocytic avian named|pneumonia sarcoma encephalomyelitis leishmaniasis encephalitis|ehrlichiosis|aquila also has several issued and pending patents in the field of lyme disease and human granulocytic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|zoonotic ehrlich granulocytic avian named|igm ige ix igg1 igg4|ehrlichiosis|x2 ehrlichia equi igg & igm ( hge ) abs each [ *** ] * 7846 86609x2 ; 86618x2 entity ( granulocytic ) & lyme disease evaluation each
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|epidemic measles know mumps varicella|mumps varicella cholera anthrax dengue|mumps|other diseases such as rubella , polio , measles , entity , chickenpox , and typhoid are nowhere near as common as they were a hundred years ago .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|epidemic measles know mumps varicella|rubella mumps ebola varicella zika|mumps|polio , measles , entity and many other viral illnesses are now controllable and smallpox has been eradicated from nature .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|epidemic measles know mumps varicella|mumps varicella polio rubella hepatitis|mumps|the company recently applied for regulatory clearance in canada to market episcreen for the detection of measles , entity and rubella .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|epidemic measles know mumps varicella|measles feline rabies tetanus simian|mumps|product portfolio includes vaccines against hepatitis a and b , seasonal influenza , h5n1 pandemic influenza ( avian flu ) , h1n1 influenza ( swine flu ) , entity and canine rabies .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|epidemic measles know mumps varicella|candidate pertussis rabies anthrax typhoid|mumps|in december 2011 , sinovac dalian , an operating subsidiary of the company obtained the production license from the sfda for its entity vaccine .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|epidemic measles know mumps varicella|mumps cytomegalovirus measles dengue cmv|mumps|legionella and influenza ,  epstein barr virus , and  other viral pathogens , including measles , entity , rubella and varicella .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|epidemic measles know mumps varicella|mumps polio varicella tetanus pneumonia|mumps|mercks sales of m‑m‑r ii , a vaccine to help protect against measles , entity and rubella , were $103 million for the third quarter of 2015 compared with $86 million for the third quarter of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|epidemic measles know mumps varicella|mumps cytomegalovirus cmv adenovirus sv40|mumps|these viruses include measles , entity , rubella , varicella , and epstein-barr and may be involved in the pathogenesis of ms in several ways : transient or persistent
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|epidemic measles know mumps varicella|polio cholera rubella tetanus pertussis|mumps|( e ) annual medical report indicating satisfactory health status , including immunization for communicable disease such as hepatitis b , entity , measles , rubeola and tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|epidemic measles know mumps varicella|mumps measles varicella polio hepatitis|mumps|conjugate , enterovirus 71 ( ev71 ) ( against hand , foot & mouth disease ) , japanese encephalitis , animal and human rabies , hib and epidemic meningitis , chickenpox , entity and rubella .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|epidemic measles know mumps varicella|pneumonia anaphylaxis sepsis measles suicide|mumps|while death from entity is rare , it can be associated with a number of serious complications , such as meningitis and encephalitis , especially in older
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|epidemic measles know mumps varicella|mumps varicella tetanus measles dengue|mumps|live virus vaccines , including those for smallpox , polio , measles , entity , rubella and chicken pox , have had a long record of preventing disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|epidemic measles know mumps varicella|mumps measles tetanus polio pneumonia|mumps|examples include the measles , entity , rubella ( mmr ) , yellow fever ( a flavivirus ) , varicella , influenza , smallpox and the oral vaccine against polio , which has been widely deployed
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|epidemic measles know mumps varicella|measles polio tetanus rabies pertussis|mumps|company overview china bio-immunity corporation ( the “company” or “we” ) , a nevada corporation , is a leading provider of rabies and entity vaccines in the peoples republic of china ( “prc” ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|epidemic measles know mumps varicella|pertussis polysaccharide investigational adjuvant principal|mumps|things , that the company defrauded the u . s . government by falsifying data in connection with a clinical study conducted on the entity component of the companys m-m-r ii vaccine .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|epidemic measles know mumps varicella|herpes measles vaccinia mumps dengue|mumps|dth skin tests have been commonly used to detect t cell responses to tuberculosis , fungal pathogens , and entity virus .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|epidemic measles know mumps varicella|mumps tetanus streptomycin pneumonia pertussis|mumps|claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and / or the measles , entity and rubella ( mmr ) vaccine .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|epidemic measles know mumps varicella|mucosal fungal wildlife veterinary avian|mumps|&nbsp ; revenue for animal and entity vaccines without a right of return provided to customers is recognized when delivery has occurred .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|epidemic measles know mumps varicella|mumps varicella polio pertussis cholera|mumps|priorix tetra , which builds on gsks existing entity , measles and rubella vaccine with the addition of varicella protection , will be filed in european and international markets .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|epidemic measles know mumps varicella|mumps tetanus varicella polio typhoid|mumps|these cell lines have been successfully used to produce a number of human vaccines ( rubella , entity , measles , rabies and hepatitis a ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|asbestos precedes pleural pneumonia predicts|follows example instance note regard|asbestosis|that entity , lung cancer , and other rare types of cancer have been associated with exposure primarily in asbestos-related industries where
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|asbestos precedes pleural pneumonia predicts|mesothelioma bronchitis pneumonia leukemia asbestos|asbestosis|when inhaled , asbestos fibers can cause certain diseases , including entity , mesothelioma and lung cancer ( and risks for smokers are dramatically compounded ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|asbestos precedes pleural pneumonia predicts|pneumonia exacerbations exacerbation mesothelioma emphysema|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity and cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|asbestos precedes pleural pneumonia predicts|pneumonia exacerbation mesothelioma exacerbations emphysema|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity or cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|legionella pneumonia complicates nosocomial diagnose|pneumonia cough ari aom bronchitis|legionellosis|of contents serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|legionella pneumonia complicates nosocomial diagnose|aom ari pneumonia conjunctivitis cough|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 73 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|legionella pneumonia complicates nosocomial diagnose|pneumonia cough ari aom legionella|legionellosis|against several serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|legionella pneumonia complicates nosocomial diagnose|aom ari pneumonia conjunctivitis cough|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 75 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|calcification osteoporosis oste refers calcifications|histology histopathology remission ipf worsening|osteomalacia|entity was characterized by the pathologist as improving from severe to mild disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|calcification osteoporosis oste refers calcifications|neurotoxicity hypercalcemia myopathy weakness nephropathy|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dementia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|calcification osteoporosis oste refers calcifications|neurotoxicity hypercalcemia nephropathy encephalopathy weakness|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dialysis dementia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|calcification osteoporosis oste refers calcifications|adverse immunosuppression immunomod deaths neurotoxicity|osteomalacia|with respect to the tumor-induced entity indication , this goal measured completion of enrollment for our phase 2 study , generation of data to support proof of concept
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|calcification osteoporosis oste refers calcifications|hypercalcemia osteoporosis hyperparathyroidism hypocalcemia osteopenia|osteomalacia|tio results from typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , bone fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|calcification osteoporosis oste refers calcifications|cachexia osteolysis anorexia pneumonitis immunosuppression|osteomalacia| krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|calcification osteoporosis oste refers calcifications|osteoporosis osteolysis osteonecrosis osteosarcoma osteogenesis|osteomalacia|crysvita is being studied for the treatment of tumor induced entity ( tio ) , a rare disease that impairs bone mineralization .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|disease|calcification osteoporosis oste refers calcifications|histology indices osteoclasts histopathology bm|osteomalacia|the bone biopsy data demonstrated substantial improvement in entity from severe to mild disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|calcification osteoporosis oste refers calcifications|osteoporosis osteoarthritis fibromyalgia menopause immobilization|osteomalacia|entity leads to severe bone pain , fatigue , muscle weakness and risk of recurring bone fractures .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|calcification osteoporosis oste refers calcifications|osteoporosis osteopenia osteonecrosis calcification hypercalcemia|osteomalacia|bone growth plates at the end of adolescence , in addition to continuing vascular and organ calcification , enpp1 deficiency manifests as entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|calcification osteoporosis oste refers calcifications|cognition hrqol iq neurodevelopment intelligence|osteomalacia|in our past discussions with fda , they emphasized that improvement in entity could also be considered an important outcome for adults with xlh .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|calcification osteoporosis oste refers calcifications|osteopenia hyperparathyroidism hypercalcemia osteoarthritis gout|osteomalacia|of pth lead to excessive release of calcium and phosphorus from bones , causing debilitating metabolic bone diseases , such as osteoporosis , entity , rickets and renal osteodystrophy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|calcification osteoporosis oste refers calcifications|tio pneumonitis pneumonia osteolysis cachexia|osteomalacia|krn23 ( ux023 ) for the treatment of tio krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|calcification osteoporosis oste refers calcifications|hypercalcemia osteoporosis hyperparathyroidism osteopenia hypocalcemia|osteomalacia|for tio , a disease characterized by typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|calcification osteoporosis oste refers calcifications|hypercalcemia osteoporosis osteolysis hyperparathyroidism osteosarcoma|osteomalacia|crysvita is being developed to treat xlh and tumor-induced entity ( tio ) , diseases characterized by excess levels of fgf23 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|calcification osteoporosis oste refers calcifications|tio pneumonitis pneumonia osteolysis cachexia|osteomalacia|krn23 ( ux023 ) for the treatment of tio we are also developing krn23 for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|familial hereditary cerebellar frontotemporal cystic|encephalopathy dysplasia neuropathy dystrophy astrocytoma|leukodystrophy|trauma has a neurosteroid compound intended to treat rare brain disorders , such as als , niemann picks disease , krabbes disease , metachromatic entity and other leukodystrophies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|familial hereditary cerebellar frontotemporal cystic|neurodegeneration neuropathy degenerative polyneuropathy neurodegenerative|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain , which prevents proper synaptic communication of neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|familial hereditary cerebellar frontotemporal cystic|neurodegenerative neurodegeneration degenerative polyneuropathy neuropathy|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|familial hereditary cerebellar frontotemporal cystic|dysplasia neurodegeneration retinopathy granules neuropathy|leukodystrophy|with regard to our biomarker for metachromatic entity , we own two separate patent families .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|pertussis serotype bacillus toxin streptococcus|measles rubella pertussis pathogens cmv|pertussis|and one of the ways of blocking the transmission of entity to newborns is to create an immunized cocoon around them so that all of the adults that are in contact
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pertussis serotype bacillus toxin streptococcus|pertussis tetanus diphtheria polio cholera|pertussis|accordingly , the company has been selling its acellular entity toxoid to ssi for formulation into dtap and dtap-ipv for sale in sweden and 12 denmark , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|disease|pertussis serotype bacillus toxin streptococcus|pseudomonas mrsa acinetobacter staphylococcal legionella|pertussis|to date , we have initiated development of a mab therapy for the treatment of entity and acinetobacter infections .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pertussis serotype bacillus toxin streptococcus|measles pertussis varicella intussusception mumps|pertussis|the incidence of entity is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated , exposure
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|pertussis serotype bacillus toxin streptococcus|meningococcal pertussis lyme pneumococcal chagas|pertussis|certiva [ trademark ] is the company  s investigational vaccine against diphtheria , tetanus and entity disease .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|pertussis serotype bacillus toxin streptococcus|dengue rabies brucellosis measles leptospirosis|pertussis|entity is an endemic disease , but epidemics occur every 3 - 5 years .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|pertussis serotype bacillus toxin streptococcus|pertussis polio toxoid poliovirus rubella|pertussis|quadracel® , a quadrivalent booster vaccine ( fifth dose ) including diphtheria , tetanus , accelular entity and ipv is being developed for the u . s . market .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|pertussis serotype bacillus toxin streptococcus|botulinum diphtheria cholera anthrax cry|pertussis|the validity of the italian counterpart of connaught  s european patent 0 322 115 ( the "  115 patent " ) which allegedly relates to entity toxin mutants .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|pertussis serotype bacillus toxin streptococcus|tetanus pertussis ipv mumps mmr|pertussis|full-year polio / entity / hib vaccines sales were down 0 . 7% to 1 , 749 million .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|pertussis serotype bacillus toxin streptococcus|bronchiolitis cdh pneumonia rds chd|pertussis|infants with entity often require hospitalization in pediatric intensive care units , frequently requiring mechanical ventilation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pertussis serotype bacillus toxin streptococcus|tetanus pertussis ipv diphtheria piv|pertussis|reported 2013 reported change on a reported basis change at constantexchange rates polio / entity / hib vaccines ( including pentacel® and pentaxim® ) 1 , 154 1 , 148 +0 . 5% +1 . 9%
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|pertussis serotype bacillus toxin streptococcus|pertussis polio cholera conjugate varicella|pertussis|the company  s manufacturing operations for neisvac-c ( tm ) , certiva ( r ) and its acellular entity vaccine are located principally in one facility .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|pertussis serotype bacillus toxin streptococcus|leprosy sarcoidosis melanoma psoriasis brucellosis|pertussis|worldwide , nearly 50 million cases of entity are diagnosed annually and about 350 , 000 people die of the disease .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pertussis serotype bacillus toxin streptococcus|pertussis vaccines cough gg canis|pertussis|illumigene® bordetella entity ( whooping cough )  commercialized in march 2014 6 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pertussis serotype bacillus toxin streptococcus|tetanus pertussis ipv diphtheria piv|pertussis|+33 . 3 % total vaccines 1 , 800 1 , 422 +26 . 6 % +24 . 5 % polio / entity / hib vaccines posted 2017 first-half net sales of 901 million , up 41 . 3% cer .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|involves familial segmental thumb symmetrical|scarring atrophy alopecia ulceration pruritus|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin atrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|involves familial segmental thumb symmetrical|atrophy alopecia scarring atrophic hypertrophic|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin 82 table of contents atrophy .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hyperparathyroidism osteoporosis hypercalcemia ckd php|hypoparathyroidism|we believe transcon pth may provide patients suffering from entity with a pth replacement therapy that is designed to fully address all aspects of the disease more than standard of
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|osteoarthritis psoriasis epilepsy glaucoma osteoporosis|hypoparathyroidism|we now have the financial resources to fund the continued u . s . development of preos in a variety of indications , including entity and osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|psoriasis acne attacks ocd exacerbations|hypoparathyroidism|treatment , even with the less frequent regimens , may be an effective treatment option for those patients suffering from less severe entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|vte hit pe dvt acs|hypoparathyroidism|eb612 for the treatment of entity we believe eb612 may offer several advantages over natpara for the following reasons : • eb612 is designed to be dosed
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|psoriasis pah osteoarthritis oab osteoporosis|hypoparathyroidism|would enable us to seek u . s . marketing approval of npsp558 as a new standard of care for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hypercalcemia hyperparathyroidism osteoporosis ckd shp|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|sbs bms srs crs ns|hypoparathyroidism|we believe positive results from steps and replace will enable us to seek u . s . marketing approval of gattex for sbs and npsp558 for entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|osteoporosis menopause hypogonadism bph acromegaly|hypoparathyroidism|origin ] injection ) is being evaluated in a phase 3 registration study known as replace as a hormone replacement therapy for entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hypercalcemia hyperparathyroidism osteoporosis ckd shp|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|ckd osteoporosis crf urolithiasis hyperparathyroidism|hypoparathyroidism|showed the predicted pharmacokinetic and pharmacodynamic response , suggesting the ability to normalize serum and urinary calcium levels in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hyperparathyroidism hypercalcemia osteoporosis osteoarthritis osteopenia|hypoparathyroidism|candidate we chose to pursue was pth , which has the potential for therapeutic use in a number of indications including entity , osteoporosis and non-union fractures .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|volunteers recipients outpatients ckd cats|hypoparathyroidism|( sbs ) and a phase 3 registration study has been completed for natpara ( recombinant human parathyroid hormone ( rhpth [ 1-84 ] ) in adult entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|sbs ds eds hsp fd|hypoparathyroidism|while sbs and entity are relatively rare disorders , we believe they represent a substantial commercial opportunity to us due to the significant unmet need
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hemodialysis ckd oncology osteosarcoma oncologic|hypoparathyroidism|replace , a phase 3 registration study of npsp558 , the companys bioengineered replica of human parathyroid hormone ( rhpth 1-84 ) , in adult entity patients .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hypercalcemia osteoporosis hyperparathyroidism hypocalcemia ckd|hypoparathyroidism|the symptoms of entity are typically managed with large doses of oral calcium supplementation and active vitamin d therapy to reduce the severity of
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|hyperparathyroidism hypercalcemia osteoporosis hypocalcemia pth|hypoparathyroidism|short bowel syndrome ) and our study of npsp558 is known as replace ( recombinant parathyroid hormone to normalize calcium and treat entity ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|vte thrombosis hit dvt thromboembolism|hypoparathyroidism|criteria for 20 , 250 of these options was satisfied when the fda accepted the bla for natpara for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|china japan europe india healthcare|hypoparathyroidism|we are committed to advancing the development of preos in entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|pah osteoporosis ich pheochromocytoma itp|hypoparathyroidism|we are also developing natpara® ( rhpth [ 1-84 ] ) for the treatment of adult entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism develops hyperparathyroidism thyroiditis parathyroid|ckd malignancy ibd esrd osteoporosis|hypoparathyroidism|reported the fdas approval of natpara as an adjunct to calcium and vitamin d to control hypocalcemia in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever season typh scrub rickettsia|chlamydia mycoplasma leptospirosis brucellosis measles|typhus|doxycycline is an antibiotic used to treat anthrax , rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|fever season typh scrub rickettsia|chlamydia campylobacter cytomegalovirus tetanus cryptosporidium|typhus|diseases that can be acquired from such accidents include hiv / aids , hbv , hcv , diphtheria , gonorrhea , entity , herpes simplex virus , malaria , syphilis and tuberculosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever season typh scrub rickettsia|brucellosis leptospirosis chlamydia mycoplasma campylobacter|typhus|doxycycline is an antibiotic used to treat rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies vaccines dog diagnose centre|rotavirus adenoviruses viruses rsv poliovirus|rabies|these efforts , we will continue the development of these drugs , as well as our other drug development endeavors that include entity , dengue viruses , and ebola / marburg viruses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|rabies vaccines dog diagnose centre|rubella pertussis diphtheria syphilis measles|rabies|talecris also has a line of hyperimmune therapies that provide treatment for tetanus , entity , hepatitis b , hepatitis a and rh factor control during pregnancy and at birth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|rabies vaccines dog diagnose centre|ebola candidate engineered dengue rabies|rabies|the candidate ligands for this nanoviricide were designed by the company using publicly available information regarding the interaction of the entity virus with cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|rabies vaccines dog diagnose centre|pertussis pneumococcal rotavirus dengue candidate|rabies| an additional phase ii study in healthy adults evaluating crucells monoclonal antibody in combination with a entity vaccine is scheduled to start in india in the second quarter of 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|rabies vaccines dog diagnose centre|cytomegalovirus syphilis dengue rubella adenovirus|rabies|seasonal influenza , hiv , oral and genital herpes ( hsv ) , viral diseases of the eye including ekc and herpes keratitis , hepatitis c , entity , dengue fever , and ebola virus , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies vaccines dog diagnose centre|rabies measles street vaccinia rab|rabies|cv7202 is an mrna that encodes the entity virus glycoprotein , rabv-g , formulated with lnps .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|rabies vaccines dog diagnose centre|polyclonal monoclonal lymphoblastoid tetanus pooled|rabies|sales volume for human albumin and human immunoglobulin for intravenous decreased by 19 . 4% and 24 . 3% , respectively , while human entity immunoglobulin recorded an increase of 94 . 9% .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|rabies vaccines dog diagnose centre|immunization oncology approval ebola licensing|rabies|nihe thereafter requested that we develop a drug for entity , a request to which we agreed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies vaccines dog diagnose centre|dengue cytomegalovirus measles rabies poliovirus|rabies|types i , ii , iii , & iv ; · hepatitis b virus ( hbv ) ; · hepatitis c virus ( hcv ) ; · entity ; · ebola and marburg viruses ; · japanese encephalitis ; and · west nile virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies vaccines dog diagnose centre|rabies dengue leptospirosis fmd brucellosis|rabies|our lead vaccine program , cv7202 , is being developed for prophylactic vaccination against entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies vaccines dog diagnose centre|rabies mosquitoes anthrax ebola leishmaniasis|rabies|rabicide , a nanoviricide against entity finished its first set of animal studies in the first quarter of 2007 in vietnam .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies vaccines dog diagnose centre|measles rsv pneumonia ppv viruses|rabies|[ **** ] against rsv , para influenza , cmv pneumo ( including s . pneumoniae , branhamalla , non-typable haemophilus influenza and otitis media ) and entity in the field in the territory .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|rabies vaccines dog diagnose centre|rabies tetanus anthrax measles narcolepsy|rabies|we evaluated the use of mrna for passive immunization in two indications , entity and botulism , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|rabies vaccines dog diagnose centre|rabies dengue varicella measles rubella|rabies|anti-entity immune globulin therapy is prescribed for individuals suspected of recent exposure to the entity virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|rabies vaccines dog diagnose centre|rabies leishmaniasis brucellosis leptospirosis measles|rabies|entity is commonly transmitted by infectious saliva from the bite of a rabid animal .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|rabies vaccines dog diagnose centre|rabies veterinary inactivated rotavirus mucosal|rabies|since 2010 , isconova and vetbiochem have collaborated on the development of entity vaccines for dogs and cats .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|rabies vaccines dog diagnose centre|nsclc aml melanoma ipf sclc|rabies|in january 2020 , we reported preliminary data from our phase 1 trial of cv7202 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|rabies vaccines dog diagnose centre|ebola dengue zika vaccinia h5n1|rabies|have entered into work orders for the preclinical development of a lassa virus vaccine , a yellow fever vaccine and our entity virus vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies vaccines dog diagnose centre|rabies dengue ebola sars polio|rabies|licenses in perpetuity for technologies developed by theracour for the virus types : hiv , hcv , herpes , asian ( bird ) flu , influenza and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|rabies vaccines dog diagnose centre|dengue rabies sars schistosomiasis h5n1|rabies|further , the company has identified highly active nanoviricide drug candidates against ebola / marburg , and against entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|mycobacterium genus mimic psi resembles|rabies brucellosis toxoplasmosis anthrax measles|psittacosis|dr . moore has conducted clinical research on infectious diseases such as venezuelan equine encephalitis , tuberculosis , listeriosis , entity , human orf , malaria , and hiv / aids .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|trach conjunctivitis chlamydia trachomatis corneal|trach trachomatis ocular sic fel|trachoma|chlamydia entitytis also causes the ocular disease entity , which is a form of vesicular conjunctivitis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|trach conjunctivitis chlamydia trachomatis corneal|plague endophthalmitis toxoplasmosis blindness leprosy|trachoma|through the iti , we donate the antibiotic zithromax to combat blinding entity in developing countries .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|trach conjunctivitis chlamydia trachomatis corneal|blindness endophthalmitis cataract glaucoma leprosy|trachoma|we intend to help the world health organization achieve its goal of eliminating blinding entity by the year 2020 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|trach conjunctivitis chlamydia trachomatis corneal|toxoplasmosis trach keratitis conjunctivitis syphilis|trachoma|increase in annual dividends to $1 . 36 from $0 . 80•since 2010 , donated more than 580 million doses of zithromax ( azithromycin ) to treat entity , the leading cause of infectious blindness .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|trach conjunctivitis chlamydia trachomatis corneal|translation bridge trade telemedicine rural|trachoma|internationally , we have two innovative access programs : the international entity initiative ( iti ) and the diflucan partnership program ( dpp ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|trach conjunctivitis chlamydia trachomatis corneal|cooperation collaboration standardization consultation collaborative|trachoma|dr . feczko is a member of the technical expert committee for the international entity initiative of the task force for global health .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|trach conjunctivitis chlamydia trachomatis corneal|trachomatis trach fel psi mur|trachoma|because c . entitytis also causes entity , the world  s most common form of preventable blindness , the who estimates chlamydia is responsible for at least 15 percent of
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|trach conjunctivitis chlamydia trachomatis corneal|legal preventable avoidable night cataract|trachoma|in response , the number of people at risk of entity blindness worldwide has been reduced to 158 million from more than 300 million in 2010 . shantanu narayen , lead independent director of
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|trach conjunctivitis chlamydia trachomatis corneal|ophthalmic trachomatis cornea corneal rodent|trachoma|because c . entitytis also causes entity , the worlds most common form of preventable blindness , the who estimates c . entitytis is responsible for at least 15 percent of the
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|trach conjunctivitis chlamydia trachomatis corneal|cataract glaucoma blindness retinoblastoma rop|trachoma|entity is the leading cause of preventable blindness worldwide .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|trach conjunctivitis chlamydia trachomatis corneal|bacteremia osteomyelitis sepsis sinusitis gastroenteritis|trachoma|medicine for human diseases to treat a host of bacterial infections , including acute otitis media infection , pharyngitis , pneumonia , skin infection , entity , and etc .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|trach conjunctivitis chlamydia trachomatis corneal|demonstration pilot immunization outreach marketing|trachoma|the iti , in which pfizer is a partner , has initiated entity programs in nine developing countries to date and plans to launch programs in an additional 10 countries .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|trach conjunctivitis chlamydia trachomatis corneal|trachomatis trach fel psi mur|trachoma|because c . entitytis also causes entity , the worlds most common form of 4 preventable blindness , the who estimates chlamydia is responsible for at least 15 percent
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|cellulitis osteomyelitis sepsis abscess otitis|erysipelas|in this trial , patients with wound infections , major abscesses , and entity / cellulitis were enrolled in equal numbers .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|cellulitis acne osteomyelitis abscess mastitis|erysipelas|a lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|cellulitis osteomyelitis acne abscess sepsis|erysipelas|is defined as a bacterial infection of the skin with a lesion size area of at least 75 cm and includes cellulitis / entity , wound infections , and major cutanenous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|osteomyelitis pneumonia sepsis cellulitis peritonitis|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection and major cutaneous abscess .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|cellulitis acne osteomyelitis abscess mastitis|erysipelas|lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|concussion falls headache dizziness seizure|erysipelas|reported for at least 0 . 1% of subjects and for which p<0 . 01 included concussion ( denosumab <0 . 1% , n=1 ; placebo 0 . 3% , n=11 ) and entity ( denosumab 0 . 2% , n=7 ; placebo 0% , n=0 ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|cellulitis osteomyelitis sepsis abscess otitis|erysipelas|examples of absssi are cellulitis / entity , wound infection , major cutaneous abscess and burn infections .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vulgaris cellulitis ery abscess aureus|leptospirosis anthrax septicemia dengue cholera|erysipelas|in pairs or chains , many species of which destroy red blood cells and cause various diseases in human beings , including entity , scarlet fever , and septic sore throat .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|vulgaris cellulitis ery abscess aureus|osteomyelitis pneumonia cellulitis bacteremia sepsis|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection , and major cutaneous abscess .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|pah pmr aip ipf ssc|sarcoidosis|the primary treatment for entity is corticosteroids ; however , the outcome of this treatment on the ph is unclear .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|thrombosis carcinogenesis neurodegeneration cvd periodontitis|sarcoidosis|there are a number of different mechanisms linking ph with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis embolism ild ipf amyloidosis|sarcoidosis|we selected pulmonary entity as our first ild indication and we are currently enrolling a proof-of-concept phase 1b / 2a clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis scleroderma myocarditis myopathy cardiomyopathy|sarcoidosis|in 2018 , we also initiated development of inopulse for the treatment of ph associated with entity ( ph-sarc ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|another neither planned my ongoing|sarcoidosis|entity initial phase ii trial completed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|ntm aspergillosis others pneumonia pcp|sarcoidosis|that we are exploring in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|embolism sarcoidosis aspergillosis emphysema pah|sarcoidosis|phase 1b / 2a clinical trial and , if that trial is successful , we believe we can expedite development of atyr1923 for pulmonary entity towards regulatory approval .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis embolism ild amyloidosis ipf|sarcoidosis|we selected pulmonary entity as our first ild indication and initiated a phase 1b / 2a proof-of-concept clinical trial in december 2018 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis brucellosis leprosy schistosomiasis psoriasis|sarcoidosis|entity is a multi-system disease which is characterized by the growth of granulomas ( inflammatory cells ) in one or more organs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sepsis ards pneumonia emphysema hemorrhage|sarcoidosis|by mondobiotech and the ema has designated aviptadil an orphan medicinal product for the treatment of acute lung injury and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|asthmatics pah bronchiectasis airways smokers|sarcoidosis|for example , we are just now beginning to explore the potential for acthar in symptomatic entity with a small pilot selling effort to pulmonologists .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|ntm sarcoidosis ards pcp aspergillosis|sarcoidosis|that we are evaluating in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|nsclc sclc dlbcl aml bm|sarcoidosis|the presence of ph in entity is associated with a poor prognosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis scleroderma cardiomyopathy myocarditis ssc|sarcoidosis|inopulse for ph-sarc we are also developing inopulse for the treatment of ph associated with entity , or ph-sarc .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|cirrhosis ssc malignancy gerd ibd|sarcoidosis|there is no approved therapy for ph associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|pah ssc ild chd hh|sarcoidosis|who group v consists of ph with multifactorial mechanisms , of which we are focusing on a subset of patients with entity that has caused ild .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis granulomatous sarc diagnose granuloma|sarcoidosis scleroderma myocarditis cardiomyopathy sarc|sarcoidosis|in 2018 , we initiated development of inopulse for the treatment of ph associated with entity ( “ph-sarc” ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus diphtheria pertussis bacillus cholera|tetanus|the same participants when stimulated with 85 table of contents cytomegalovirus ( cmv ) , epstein barr virus ( ebv ) , influenza virus and entity toxoid-derived immuno- dominant peptide panels .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|tetanus fear toxin toxoid clostridium|toxoid pertussis booster conjugate tetanus|tetanus|and is manufacturing and marketing , a line of vaccines including whole virus and split virus influenza vaccines , a combined diphtheria entity vaccine and a vaccine to prevent tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus diphtheria botulinum rabies pertussis|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|tetanus fear toxin toxoid clostridium|tetanus pertussis rubella shigella typhoid|tetanus|response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , diphtheria and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|tetanus fear toxin toxoid clostridium|measles tetanus rubella cytomegalovirus rabies|tetanus|hyperimmune products currently available include hepatitis b , entity , rabies cytomegalovirus and rhod immune globulins .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|tetanus fear toxin toxoid clostridium|rotavirus cholera pertussis polio rabies|tetanus|during 2000 , we anticipate that innovaccines will begin to scale up an oral entity vaccine to take into human clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|tetanus fear toxin toxoid clostridium|polyclonal monoclonal lymphoblastoid tetanus tear|tetanus|human entity immunoglobulin – 250iu mainly used for the prevention and therapy of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|tetanus fear toxin toxoid clostridium|tetanus pertussis polio mumps meningococcal|tetanus|if ssi fails to continue to supply the company with these components , the company has a royalty-bearing license to produce diphtheria and entity toxoids for this purpose .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus diphtheria cholera pertussis staphylococcal|tetanus|then the antigenic proteins , entity toxoid and candida albicans were applied topically to the treated skin sites .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus diphtheria botulinum rabies pertussis|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tetanus fear toxin toxoid clostridium|polymeric monoclonal polyclonal proper pooled|tetanus|for our plasma products , entity immunoglobulin , factor viii and pcc are included on the life-saving essential drug list in most chinese provinces , for which drug
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus rabies cholera lymphoblastoid monoclonal|tetanus|three of our approved products , human albumin , human rabies immunoglobulin and human entity immunoglobulin are affected by the 2013 adjustments .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|pertussis tetanus typhoid anthrax shigella|tetanus|vaccines against two life-threatening bacterial diseases , diphtheria and entity , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|tetanus fear toxin toxoid clostridium|ova dsdna gal ovalbumin cd20|tetanus|xmab5871 inhibited anti-entity antibody responses in mice engrafted with human b cells and immunized with entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus polyclonal diphtheria cholera rabies|tetanus|human entity immunoglobulin  250iu mainly used for the prevention and therapy of tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus fear toxin toxoid clostridium|rubella mumps tetanus cytomegalovirus varicella|tetanus|ivig product enriched with naturally occurring polyclonal anti-pathogen antibodies , such as streptococcus pneumonia , h . influenza type b , cytomegalovirus , measles and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tetanus fear toxin toxoid clostridium|tetanus pertussis polio diphtheria flu|tetanus|sales of adacel ( adult entity / diphtheria / whooping cough booster ) , launched in the united states in july 2005 , reached 154 million in 2006 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|disease|tetanus fear toxin toxoid clostridium|tetanus pertussis diphtheria acellular cholera|tetanus|sp0173 : the current adacel® ( tdap booster vaccine containing entity toxoid , diphtheria toxoid , and 5-component acellular pertussis ) is not indicated in the us for persons aged over 64 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|tetanus fear toxin toxoid clostridium|rubella cytomegalovirus mumps varicella adenovirus|tetanus|streptococcus pneumoniae , h . influenza type b , cmv , measles , entity etc . ) as well as high levels of antibodies targeted to respiratory syncytial virus , or rsv .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|tetanus fear toxin toxoid clostridium|tetanus mumps pertussis hepatitis pneumonia|tetanus|food and drug administration ( " fda " ) to market its dtap vaccine ( certiva ( registered ) ) in the united states for the prevention of diphtheria , entity , and pertussis ( whooping cough ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|toxoid conjugate booster polysaccharide acellular|diphtheria|vaccines business segment :  march 27 , 2007 : akorn announced the signing of a three-year exclusive distribution agreement for tetanus entity vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|rubella brucellosis pertussis hepatitis typhoid|diphtheria|they have eradicated smallpox and dramatically reduced the mortality and morbidity associated with many other infectious diseases , such as entity , measles , polio and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|pertussis diphtheria rubella mumps typhoid|diphtheria|adaptive immune response is the basis for preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|pertussis diphtheria rubella mumps shigella|diphtheria|adaptive immune response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity , and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis typhoid measles anthrax|diphtheria|vaccines against two life-threatening bacterial diseases , entity and tetanus , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis measles polio penicillin|diphtheria|under supply agreements , the company manufactures the acellular pertussis component , and ssi manufactures the entity , tetanus and ipv components for the dtap and dtap-ipv vaccines .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis measles polio varicella|diphtheria|total sales of rotarix , for rotavirus , boostrix , for prevention of entity , tetanus and whooping cough , and influenza vaccines , fluarix / flulaval , reached £274 million , up 91% .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria tetanus cholera botulinum pertussis|diphtheria|according to the world health organization , the majority of the western world  s population is immunized to entity toxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis polio measles tetanus|diphtheria|the company produces the monocomponent acellular pertussis toxoid and formulates the final product with entity and tetanus toxoids manufactured and supplied by ssi .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|tetanus diphtheria cholera pertussis toxoid|diphtheria|the peptide is joined to a carrier , entity toxoid , to enhance the immune response .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria measles hepatitis polio varicella|diphtheria|vaccination against entity , tetanus and pertussis is mandated by most states for all children with a total of five doses administered at two ,
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|anthrax diphtheria tetanus cholera botulinum|diphtheria|using a plasmid with an expression cassette of the entity toxin , no immune response will be encountered as happens when using a virus ; moreover , people born in western countries are routinely
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria cholera tetanus pertussis anthrax|diphtheria| crm197  we have several development and commercial partnerships in place for crm197 , which is a non-toxic mutant of entity toxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis tetanus polio typhoid|diphtheria|we obtain some of the key components , including entity toxoid ( dt ) and tetanus toxoid ( tt ) , through a supply contract with aventis pasteur , one of our strategic collaborators .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|diphtheria tox tetanus toxin corynebacterium|toxin anticancer cytotox pay killer|diphtheria|gtb-1550 binds to cancer cells , the cancer cells internalize gtb-1550 , and are killed due to the action of drugs cytotoxic entity toxin payload .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|diphtheria tox tetanus toxin corynebacterium|rotavirus pertussis cytomegalovirus cmv rubella|diphtheria|expanded its internal research and development efforts with emphasis on a mucosal vaccine against chlamydia and a mucosal vaccine against entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria tetanus cholera pertussis dt|diphtheria|biocancell  s leading drug , bc-819 , is a double stranded dna plasmid construct that incorporates the gene for entity toxin ( dta ) under the regulation of the promoter sequence for h19 gene .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria measles hepatitis mumps polio|diphtheria|daptacel® , a trivalent vaccine against pertussis , entity and tetanus , was launched in the united states in 2002 and has become a strong sales contributor due to its
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria pertussis polio tetanus typhoid|diphtheria|the supply commitment of materials suitable for human use consists of entity toxoid and / or tetanus toxoid .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|diphtheria tox tetanus toxin corynebacterium|diphtheria measles pertussis polio example|diphtheria|also launched in 1995 was infanrix , the combined acellular vaccine for entity , tetanus and pertussis ( whooping cough ) in switzerland .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|choroid choroidal lupus multifocal uveitis|him see read blindness learn|choroiditis|as a student during the 1950s he had lost much of the sight in his right eye to entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|choroid choroidal lupus multifocal uveitis|endophthalmitis cataract endocarditis glaucoma neuropathy|choroiditis|no vasculitis , retinitis , or entity were observed .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|choroid choroidal lupus multifocal uveitis|uveitis sarcoidosis paraneoplastic vasculitis granulomatous|choroiditis|this type of uveitis is called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|segmental dorsal polyd thumb familial|cataracts deafness scoliosis cardiomyopathy myopathy|polydactyly|early onset obesity and hyperphagia often associated with bbs , a rare genetic disorder that is also characterized by vision loss , entity , kidney abnormalities , and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|segmental dorsal polyd thumb familial|deafness cataracts neuropathy cardiomyopathy myopathy|polydactyly|it is a rare monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|segmental dorsal polyd thumb familial|deafness cataracts cardiomyopathy seizures myopathy|polydactyly|bardet-biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|segmental dorsal polyd thumb familial|enrolled represented contributed yielded comprises|polydactyly|acrania / turner syndrome / prader willi syndrom / left ventricular hypoplasia entity 112 table of contents in the trial , ongoing pregnancies were followed up to 28 days post-delivery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|segmental dorsal polyd thumb familial|deafness cataracts cardiomyopathy myopathy seizures|polydactyly|bardet‑biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|foodborne listeria nosocomial diagnose disseminated|neutropenia thrombocytopenia pneumonitis rash myelosuppression|listeriosis|entity has also been reported as a grade 3 ae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|foodborne listeria nosocomial diagnose disseminated|dyspnea tachycardia hyperglycemia seizures hypoglycemia|listeriosis|examples of the aes experienced include , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity among others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|foodborne listeria nosocomial diagnose disseminated|dyspnea tachycardia hyperglycemia hypoglycemia anaphylaxis|listeriosis|examples of the aes experienced include among others , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|foodborne listeria nosocomial diagnose disseminated|anaphylaxis suicide intussusception overdose hypoglycemia|listeriosis|the event was diagnosed by the treating investigator as being a case of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|foodborne listeria nosocomial diagnose disseminated|gastroenteritis sepsis enteritis diarrhea septicemia|listeriosis|when ingested , some strains of listeria can cause entity , which affects primarily the elderly , pregnant women , newborns and adults with weakened immune systems .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|disease|foodborne listeria nosocomial diagnose disseminated|sunitinib gefitinib bevacizumab sorafenib erlotinib|listeriosis|one grade 3 serious ae of entity was reported .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|foodborne listeria nosocomial diagnose disseminated|tetanus rabies cholera polio fmd|listeriosis|the overhalla facility was purchased by the aahd in november 1994 and presently manufactures ringworm vaccines for cattle and entity vaccines for sheep and goats .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|foodborne listeria nosocomial diagnose disseminated|reproduction genetics abortion vaccines oncology|listeriosis|dr . lorbers major interest in infectious diseases is in human entity , an area in which he is regarded as an international authority .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|foodborne listeria nosocomial diagnose disseminated|eradication profit gains gain pathogens|listeriosis|the attenuation of the listeria strains used in advaxis immunotherapies , these listeria are nonpathogenic and therefore limit the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|foodborne listeria nosocomial diagnose disseminated|eradication gains cure gain profit|listeriosis|advaxis immunotherapies , the listeria do not replicate and spread from cell to cell at this point , limiting the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|onchocerc parasitic parasites africa plasmodium|schistosomiasis mosquito leishmaniasis leprosy worm|onchocerciasis|apply outside the disease endemic countries , or in relation to sales of the product for purposes other than filariasis or entity control .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|deformity club osteoarthritis tendon deformities|ribs pelvis hips scoliosis femur|clubfoot|hips at birth , prominent chin and forehead , flat feet , soft skin , floppy heart valve ( mitral valve prolapse ) , curved spine and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|improves develops gastro dyspepsia complicates|maneuver phenomenon toxin abnormality alteration|gastroparesis|dr . aurora reported that this entity can result in up to an 80% slower rate of digestion , or gastric motility , in migraineurs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|improves develops gastro dyspepsia complicates|neuropathy ileus polyneuropathy ulcers diarrhea|gastroparesis|this protein may have utility in the treatment of post-operative ileus and gastrointestinal motility disorders , such as diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|neuropathy mellitus ketoacidosis polyneuropathy ulcers|gastroparesis|agonist of the motilin receptor that enhances esophageal motility in gerd patients and accelerates gastric emptying in patients with diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|psoriasis fibromyalgia vibration allergy anaphylaxis|gastroparesis| the results of the recent atopic dermatitis ( epione ) , entity ( vly686-2301 ) and motion sickness ( motion sifnos ) studies have all been submitted to peer-review publications .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|improves develops gastro dyspepsia complicates|dysphagia dyspepsia ileus diarrhoea nausea|gastroparesis|post-surgical entity is often associated with peptic ulcer surgery , bariatric procedures or esophageal procedures and is thought to result from damage / desensitization of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|neuropathy ketoacidosis cystitis ulcers polyneuropathy|gastroparesis|results from a phase 3 clinical trial of gimoti in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|improves develops gastro dyspepsia complicates|oab autism rhinosinusitis ptsd crs|gastroparesis|we believe our novel intranasal delivery formulation will address a significant unmet market need for patients with the symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|improves develops gastro dyspepsia complicates|achalasia constipation fd fap mmc|gastroparesis|in march 2015 , we initiated a phase 2b study of velusetrag for the treatment of patients with entity and other gastrointestinal motility disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|improves develops gastro dyspepsia complicates|neuropathy ulcers ketoacidosis retinopathy wounds|gastroparesis|are the only products currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|improves develops gastro dyspepsia complicates|constipation dyspepsia oab ibd uc|gastroparesis|ati-7505 has potential use in five indications : chronic constipation , functional dyspepsia , gerd , entity and ibs with constipation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|rhinitis ulcers neuropathy rhinosinusitis conjunctivitis|gastroparesis|spray , the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|improves develops gastro dyspepsia complicates|psoriasis pruritus urticaria eczema vitiligo|gastroparesis|neurokinin-1 receptor ( nk-1r ) antagonist , which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|neuropathy nephropathy retinopathy polyneuropathy ketoacidosis|gastroparesis|the results of these clinical trials support our belief that relamorelin has the potential to be a safe and effective treatment for diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|improves develops gastro dyspepsia complicates|neuropathy ulcers cystitis ketoacidosis retinopathy|gastroparesis|in april 2014 , we commenced a phase 3 clinical trial of evk-001 in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|improves develops gastro dyspepsia complicates|neither esophagus others dysphagia swallowing|gastroparesis|subjects with no history of migraine , migraineurs experienced , to varying degrees , paralysis of the muscles of the stomach , or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|neuropathy cachexia ketoacidosis anorexia ulcers|gastroparesis|motus has the worldwide rights to rm-131 ( relamorelin ) , a peptide ghrelin agonist being developed for the treatment of diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|improves develops gastro dyspepsia complicates|ketoacidosis neuropathy polyneuropathy ulcers diarrhoea|gastroparesis|the company believes that emitasol ( r ) , when given intranasally , may be effective in treating diabetic entity and in preventing delayed onset emesis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|improves develops gastro dyspepsia complicates|nausea vomiting emesis agitation constipation|gastroparesis|metoclopramide is the only product currently approved in the united states to treat entity , and is currently available only in oral and intravenous forms .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|improves develops gastro dyspepsia complicates|osa crs asd osas autism|gastroparesis|the primary endpoint will be the effect of velusetrag on symptoms in subjects with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|improves develops gastro dyspepsia complicates|hyperglycemia neuropathy ketoacidosis mellitus hypoglycemia|gastroparesis|emitasol ( r ) is proposed as a method to control diabetic entity and to prevent delayed emesis associated with cancer chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|develops aspergillosis diagnose disseminated cystic|psoriasis osteoporosis osteoarthritis epilepsy autism|cryptococcosis|in addition , the fda has granted orphan drug designation to mat2203 for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|develops aspergillosis diagnose disseminated cystic|official updated vital annual epidemiological|cryptococcosis|according to entity statistics maintained on the centers for disease control and preventions website from february 2014 , the greatest burden of this disease
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|develops aspergillosis diagnose disseminated cystic|cryptococcus toxoplasmosis pneumonia syphilis aspergillosis|cryptococcosis|cryptococcal meningitis has become the most common cause of adult meningitis in many parts of africa , where entity now rivals tuberculosis in all-case mortality .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|develops aspergillosis diagnose disseminated cystic|psoriasis melanoma autism epilepsy mdd|cryptococcosis|●as previously reported , during the fourth quarter of 2019 , fda granted mat2203 orphan drug designation for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|develops aspergillosis diagnose disseminated cystic|aspergillosis candidiasis cryptococcus fusarium aspergillus|cryptococcosis|the three major types of these infections are candidiasis , aspergillosis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|develops aspergillosis diagnose disseminated cystic|aspergillosis pneumonia cryptococcus candidiasis mycosis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|develops aspergillosis diagnose disseminated cystic|toxoplasmosis aspergillosis cryptococcus candidiasis leprosy|cryptococcosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , coccidioidomycosis , entity and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|develops aspergillosis diagnose disseminated cystic|aspergillosis pneumonia cryptococcus candidiasis mycosis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common life-threatening fungal
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|develops aspergillosis diagnose disseminated cystic|brucellosis leptospirosis plague ebola anthrax|cryptococcosis|in april 2015 , the ema granted two orphan drug designations for ar-12 for the treatment of entity and tularaemia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|arachnoid cystic causing intracranial degenerative|burns poisoning hepatitis burn intoxication|arachnoiditis|if left untreated , chemical entity may be fatal .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|arachnoid cystic causing intracranial degenerative|burns hepatitis cystitis burn pneumonitis|arachnoiditis|the incidence and severity of chemical entity can be reduced by coadministration of dexamethasone .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|arachnoid cystic causing intracranial degenerative|pneumonitis encephalopathy cystitis hepatitis hypersensitivity|arachnoiditis|patients receiving depocyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|arachnoid cystic causing intracranial degenerative|cystitis intolerance hypersensitivity hepatitis encephalopathy|arachnoiditis|in all clinical studies , chemical entity , a syndrome manifested primarily by nausea , vomiting , headache and fever , was a common adverse event .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|microspor zo genus spor alga|innovative newer ophthalmic ocular promising|aniridia|entity therapeutic interventions , such as artificial iris implantation , are being developed by humanoptics ag . •emflaza for dmd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|microspor zo genus spor alga|fals als cmt poag sma|aniridia|we estimate that approximately one-third of all entity cases are due to a nonsense mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|microspor zo genus spor alga|lca ebs ws retinoblastoma nystagmus|aniridia|entity is a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|microspor zo genus spor alga|europe pigs rodents china silico|aniridia|· translarna pipeline will expand with a proof of concept study in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|microspor zo genus spor alga|retinoblastoma lca microcephaly ds glaucoma|aniridia|entity is a rare genetic disorder that results in disruption in the development of the eye .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|microspor zo genus spor alga|retinoblastoma ws pax strabismus nystagmus|aniridia|for example , investigators studying entity , a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms in which
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|microspor zo genus spor alga|carriers diagnostics therapeutics oncology hcm|aniridia|ptc plans to initiate a phase 2 proof of concept study in nonsense mutation entity by year end 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|microspor zo genus spor alga|iva iia vi iib iiia|aniridia|in addition to its advanced dmd and cf programs , ptc is now pursuing two additional indications , mps i and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|falciparum plasmodium vivax know malarial|leishmaniasis immunodeficiency cancers pox rabies|malaria|other pox virus vectors are being evaluated in experimental models of human entity and , in a hybrid regimen combining doses of a modified live virus , with a subunit hiv vaccine to protect high
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|disease|falciparum plasmodium vivax know malarial|rabies candidate inactivated approved h1n1|malaria|ema regulatory decision on glaxosmithklines entity vaccine candidate rts , s , which contains agenuss qs-21 stimulon® adjuvant .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1), ('BIO', 1)])|disease|falciparum plasmodium vivax know malarial|pertussis pneumococcal allergy rotavirus inactivated|malaria| entity vaccine based on advac® / per . c6® technologies : crucell and its collaborator , the us national institute of allergy and infectious diseases ( niaid ) , part
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum plasmodium vivax know malarial|mosquito insect dengue arthropod anopheles|malaria|the global plan for insecticide resistance management in entity vectors , released in 2012 , contains a five-pillar strategy on managing the threat of insecticide resistance .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|plasmodium antimalarial malarial chloroquine french|malaria|as per the entity foundation international , malaria now kills more people than it did 3 decades ago .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|falciparum plasmodium vivax know malarial|insomnia headache epilepsy psychosis constipation|malaria|quinine , a natural product from the bark of the cinchona tree , was one of the first treatments for entity and appeared in the 17 ( th ) century .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|falciparum plasmodium vivax know malarial|breeding annual expanded entire return|malaria|in 2004 , the entity program revenue was limited to breeding activities to create a new founder line .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|falciparum plasmodium vivax know malarial|dengue mosquitoes mosquito wnv leishmaniasis|malaria|currently pursuing our negotiation with several countries in africa to introduce our larvicide product , greenex™ as a prevention agent for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|medicines sick profit healthcare another|malaria|dr . rosenberg also serves on the boards of directors of lovelace respiratory research institute , karo bio ab , and medicines for entity venture .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|rubella cmv rabies vzv ebv|malaria|we expect similarly to advance our novel non-clinical prophylactic vaccine and immunotherapy programs against chlamydia , hsv-2 and entity through human 3 table of contents proof of concept .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum plasmodium vivax know malarial|mosquito fly dengue insect rodent|malaria|mosquito resistance to at least one insecticide used for entity control has been identified in 64 countries around the world .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|falciparum plasmodium vivax know malarial|approved procurement candidate named category|malaria|currently , both our cassette entity pf and entity pf / pv have been listed under the who procurement process .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|dengue rotavirus ebola pneumococcal rabies|malaria|we are collaborating with the bill & melinda gates foundation on entity vaccine research .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|vaccines breastfeeding haart immunization polio|malaria|the who has made the roll back of entity , by 50% during the decade ending 2011 , one of its 4 major objectives of the current decade .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|falciparum plasmodium vivax know malarial|investigational newer ultimate hypothetical next|malaria|in the case of our entity product candidate , we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|sepsis osteomyelitis pneumonia endocarditis uti|malaria|as well as an extended spectrum of activity against ca-mrsa , streptococci , haemophilus , enterococci , mycobacterium avium and in animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|falciparum plasmodium vivax know malarial|fever vivax parasitemia carriers sepsis|malaria|who currently recommends chloroquine for the treatment of p . vivax entity where the drug remains effective .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|disease|falciparum plasmodium vivax know malarial|cytology hematology microbiology histopathology immunology|malaria|the kemri / cdc research and public health collaboration has well-developed entity , hiv , microbiology , and tuberculosis laboratories that perform a range of standard diagnostic procedures .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|disease|falciparum plasmodium vivax know malarial|parasites parasitemia fever carriers anaemia|malaria|who recommends acts for the treatment of chloroquine-resistant p . vivax entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|falciparum plasmodium vivax know malarial|rabies anthrax rubella poliovirus measles|malaria|u . s . naval medical research center ( nmrc ) allowing them to use our proprietary adenovector technology for the development of vaccines against entity and dengue virus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|disease|fungal blast aspergillus candida fungus|fungi others yeasts mycobacteria aspergillus|blastomycosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fungal blast aspergillus candida fungus|blast aspergillosis leukemia others mycosis|blastomycosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fungal blast aspergillus candida fungus|toxoplasmosis aspergillosis candidiasis leprosy brucellosis|blastomycosis|examples of such infections include aspergillosis , entity , candidiasis , coccidioidomycosis , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fungal blast aspergillus candida fungus|blast aspergillosis leukemia leishmaniasis sarcoidosis|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fungal blast aspergillus candida fungus|blast aspergillosis others leukemia leishmaniasis|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|inherited hereditary cystic muco causing|mps phosphodiesterase gaucher glycoprotein peptidase|mucopolysaccharidosis|if approved , this would be the first human enzyme replacement therapy for the treatment of hunter syndrome , also known as entity ii ( mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|inherited hereditary cystic muco causing|mps cmt aps scid sma|mucopolysaccharidosis|entity i , or mps i lambert eaton myasthenic syndrome , or lems firdapse has not received
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|inherited hereditary cystic muco causing|mps gaucher dnase transglutaminase hemophilia|mucopolysaccharidosis|the u . s . patent and trademark office issued to us the u . s . patent no . 6 , 426 , 208 covering aldurazyme for the treatment of entity i ( or mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|disease|inherited hereditary cystic muco causing|mps peptidase glycogen trisomy phosphodiesterase|mucopolysaccharidosis|alpha-n-acetylglucosaminidase ( naglu ) with a peptide derived from insulin-like growth factor 2 ( igf2 ) for the treatment of sanfilippo b syndrome or entity iiib ( mps iiib ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|inherited hereditary cystic muco causing|mps sca sg san msa|mucopolysaccharidosis|hgt- 1410 for sanfilippo a syndrome ( entity iiia ) hgt- 1410 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|inherited hereditary cystic muco causing|mps san sca spa sma|mucopolysaccharidosis|shp610 for sanfilippo a syndrome ( entity iiia ) shp610 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome , a lysosomal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|inherited hereditary cystic muco causing|mps gaucher thrombospondin neurofibromatosis thrombocytopenia|mucopolysaccharidosis|our most advanced programs are for the treatment of two severe genetic diseases , homozygous familial hypercholesterolemia ( hofh ) and entity type i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|inherited hereditary cystic muco causing|mps hemophilia gaucher histiocytosis cmt|mucopolysaccharidosis|entity i , or mps i , is a rare genetic disorder that affects many body systems and that leads to organ damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|inherited hereditary cystic muco causing|mps gaucher eds neurofibromatosis sma|mucopolysaccharidosis|elaprase elaprase is a treatment for hunter syndrome ( also known as entity type ii or mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|inherited hereditary cystic muco causing|mps eds cmt gd hae|mucopolysaccharidosis|alexion decided to reduce its investment in sbc-103 , a recombinant form of the naglu enzyme being evaluated in patients with entity iiib , or mps iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|inherited hereditary cystic muco causing|mps phosphodiesterase glycosaminoglycans gaucher neurofibromatosis|mucopolysaccharidosis|naglazyme is a recombinant form of n-acetylgalactosamine 4-sulfatase ( arylsulfatase b ) indicated for patients with entity vi ( mps vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|inherited hereditary cystic muco causing|mps gaucher phosphodiesterase carboxypeptidase peptidase|mucopolysaccharidosis|agreement with genzyme to establish a joint venture ( biomarin / genzyme llc ) for the worldwide development and commercialization of aldurazyme to treat entity i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|inherited hereditary cystic muco causing|mps subtypes gaucher pms collagens|mucopolysaccharidosis|our initial programs are focused on lsds such as entity ( mps ) iiia and iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|inherited hereditary cystic muco causing|gaucher mps neurofibromatosis sma fap|mucopolysaccharidosis|this model , initially focused on gaucher disease , has extended to fabry disease , entity type i , and pompe disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|inherited hereditary cystic muco causing|mps gaucher trisomy chiari neurofibromatosis|mucopolysaccharidosis|decreased levels of the alpha-l-iduronidase enzyme result in -------------- individuals having entity i ( " mps i " ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis segment endophthalmitis spondylitis pituitary|uveitis|we believe that reproxalap and certain of our other product candidates may qualify as an orphan drug for noninfectious anterior entity , and possibly other diseases that we may test .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis keratitis endophthalmitis cataract cataracts|uveitis|patients with noninfectious anterior entity generally experience severe pain , sensitivity to light , and vision loss .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis vasculitis ocular lupus nod|uveitis segment endophthalmitis shoulder vitrectomy|uveitis| clinical trials in 2015 , pending successful ind submissions , we intend to initiate clinical trials in sls and noninfectious anterior entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis vasculitis ocular lupus nod|dme amd glaucoma pcv uveitis|uveitis|in december 2018 for xipere , and , if approved , xipere will be the first therapy indicated for macular edema associated with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|uveitis vasculitis ocular lupus nod|psoriasis colitis sepsis anaphylaxis hepatitis|uveitis|we have conducted with our mc1r peptide drug candidates have shown positive results in experimental models of inflammatory bowel disease , entity and nephritis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis vasculitis ocular lupus nod|glaucoma cataract cataracts amd others|uveitis|the company is planning phase ii studies for age-related macular degeneration ( later diabetic macular edema , proliferative vitreoretinopathy and entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|uveitis vasculitis ocular lupus nod|glaucoma dme uveitis ranibizumab neuroprotection|uveitis|value . ”about ebi-031 eleven biotherapeutics  most advanced preclinical product candidate is ebi-031 for treatment of diabetic macular edema , or dme , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|uveitis vasculitis ocular lupus nod|modifying flare biomarker initiative oriented|uveitis|and drug administration ( fda ) to review the phase 3 eyeguard-b data together with the data from the two behçets disease entity phase 2 studies conducted independently by xoma and servier .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis vasculitis ocular lupus nod|amd dme glaucoma pdr uveitis|uveitis|also demonstrate comparability of the proposed drug , which we believe may require a clinical trial in macular edema associated with entity , against our product , unless a biowaiver is obtained .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uveitis vasculitis ocular lupus nod|uveitis vitrectomy segment pituitary circulation|uveitis|both the sjögren-larsson syndrome ( sls ) trial and noninfectious anterior entity trial have begun enrollment and we expect to begin to provide preliminary data for these indications by the end of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis endophthalmitis cnv retinopathy vitreous|uveitis|lombs ) product retisert ( a surgically implanted intravitreal drug delivery device containing fa approved for the treatment of chronic non-infectious posterior entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|uveitis vasculitis ocular lupus nod|hepatitis thyroiditis encephalomyelitis encephalitis uveitis|uveitis|due to its th17 activity , we believe vtp-43742 will be most effective in psoriasis , ms , behcet  s disease and autoimmune entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|glaucoma uveitis endophthalmitis cataract cataracts|uveitis|develop and sell psividas proprietary delivery device for indications for diseases outside of the eye or for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|uveitis vasculitis ocular lupus nod|melanoma nsclc aml sclc cml|uveitis|the second quarter of 2016 ; and ( ii ) planning on initiating a phase ii study of cf101 for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis vasculitis ocular lupus nod|uveitis endophthalmitis amd glaucoma cme|uveitis|bausch + lomb markets retisert , an intravitreal implant of the corticosteroid fluocinolone acetonide , for the treatment of non-infectious entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|cataract uveitis glaucoma cataracts conjunctivitis|uveitis|diseases , including inflammatory bowel disease , nephritis , which is inflammation of the kidneys , and rheumatoid arthritis , and ocular indications such as entity and dry eye .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis segment keratitis endophthalmitis cataract|uveitis|trial of the ns2 eye drop formulation in a serious and , we believe , poorly treated ocular disease called noninfectious anterior entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis segment conjunctivitis keratitis chambers|uveitis|in noninfectious anterior entity , aldehydes may mediate , at least in part , inflammation , pain , fibrotic changes , and lipid destruction leading to dryness and surface irritation .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|uveitis vitrectomy retinoblastoma endophthalmitis cataracts|uveitis|novartis ( esba105 ) and eyegate pharmaceuticals , inc . ( egp-437 ) have conducted or are conducting clinical trials in anterior entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis vasculitis ocular lupus nod|pcv amd dme cnv glaucoma|uveitis|in addition to entity , rvo and wet amd , there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|typhoid typhi enteritidis enterica typhimurium|rheumatic typhoid yellow enteric hay|typhoid|these vaccines , which currently include vaccines to prevent urinary tract infections and entity fever , are all in basic research or preclinical stage of development .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|typhoid typhi enteritidis enterica typhimurium|pneumococcal dengue rotavirus polio typhoid|typhoid|company also anticipates continued investment in its advanced product development pipeline , including an anthrax ig therapeutic , hepatitis b therapeutic and entity vaccine , among others .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow typhoid enteric hemorrhagic haemorrhagic|typhoid|innovative vector vaccine delivery , manufacturing and preservation technologiesthe technology behind our single dose , oral , rapidly protecting vaccines for cholera and entity fever .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|typhoid typhi enteritidis enterica typhimurium|rabies polio cholera hepatitis typhoid|typhoid|establishing a travel vaccines franchise through its us-based subsidiary berna products corporation , which markets vivotif® , the worlds only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|typhoid typhi enteritidis enterica typhimurium|candidate dengue prototype pneumococcal meningococcal|typhoid|a two-year extension of the development program with brookwood pharmaceuticals and a commercial evaluation license with nih for developing a entity vaccine with gelsiteò polymer .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow typhoid hemorrhagic dengue ebola|typhoid|avant is also developing an oral entity fever vaccine , ty800 , for global health needs .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|typhoid typhi enteritidis enterica typhimurium|rotavirus cholera pertussis polio varicella|typhoid|one oral entity vaccine and one injectable entity vaccine are currently approved and administered in the united states and europe .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow hemorrhagic typhoid dengue haemorrhagic|typhoid|of health ( nih ) initiated a phase 1 / 2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|typhoid typhi enteritidis enterica typhimurium|polio cholera pertussis poliovirus rabies|typhoid|acambis  us-based subsidiary berna products corporation markets vivotif ( r ) , the world  s only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|typhoid typhi enteritidis enterica typhimurium|haemorrhagic hemorrhagic enteric epidemic vibrio|typhoid|status bacterial vaccines global health choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 travelers  etec enterotoxigenic e coli infection  pre-clinical
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|typhoid typhi enteritidis enterica typhimurium|pertussis dengue rotavirus polio measles|typhoid|patents for the technology used in the cholera and entity vaccines expire between 2013 and 2016 .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5)])|disease|typhoid typhi enteritidis enterica typhimurium|abstract randomised another adjuvant ongoing|typhoid|entity phase 2 medeva tolerising peptide ( rye grass ) . . . . .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|dengue ebola polio rabies leprosy|typhoid|emergent biosolutions program pipeline currently includes programs focused on anthrax , tuberculosis , entity , influenza and chlamydia .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow enteric typhoid haemorrhagic hemorrhagic|typhoid|a broad portfolio of vaccines against viral and bacterial diseases , including single-dose oral vaccines aimed at protecting travelers from cholera , entity fever and other illnesses .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|typhoid typhi enteritidis enterica typhimurium|haemorrhagic hemorrhagic epidemic vibrio enteric|typhoid|pre-clinical infectious disease choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 etec enterotoxigenic e coli infection nih pre-clinical
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|dengue ebola rabies measles cryptosporidium|typhoid|emergents clinical pipeline includes programs focused on anthrax , botulism , entity , tuberculosis , hepatitis b and chlamydia .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow typhoid hemorrhagic dengue haemorrhagic|typhoid|to conduct a phase i in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|typhoid typhi enteritidis enterica typhimurium|yellow typhoid hemorrhagic dengue haemorrhagic|typhoid|niaid to conduct a phase i in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|typhoid typhi enteritidis enterica typhimurium|typhoid enteric hay yellow rheumatic|typhoid|thus immunity to an intestinal disease such as entity fever , is best induced by giving the vaccine orally , so that the antigens are presented directly to the lining of
OrderedDict([('OTHER', 5), ('DIS', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|typhoid typhi enteritidis enterica typhimurium|dengue toxoplasmosis cryptosporidium brucellosis cytomegalovirus|typhoid|including rheumatoid arthritis , or ra , and systemic lupus erythematosus , or sle ; and other infectious diseases such as tuberculosis , influenza and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|porphyr hereditary familial sporadic attacks|glaucoma amd mci aphasia epilepsy|porphyria|people with entity should not be treated with visudyne .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|porphyr hereditary familial sporadic attacks|claudication paralysis paraplegia ischaemia hypoxemia|porphyria|the most advanced of these programs are the following : amt-021 for acute intermittent entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|porphyr hereditary familial sporadic attacks|epilepsy smi insomnia disabilities psychosis|porphyria|people with entity should not be treated .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|porphyr hereditary familial sporadic attacks|porphyrin allergic bilirubin electrophilic p450|porphyria|doses of aln-as1 resulted in lowering of aminolevulinic acid ( ala ) and porphobilinogen ( pbg ) , the toxic heme synthesis intermediates that mediate entity attacks .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|porphyr hereditary familial sporadic attacks|hepatitis porphyr attacks aip leukemia|porphyria|or pnh ;  filed a cta to initiate a phase 1 trial with aln-as1 in acute intermittent entity , or aip patients ;  initiated a phase 1 trial with aln-pcssc in normal human volunteers with elevated
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|porphyr hereditary familial sporadic attacks|hepatitis porphyr cholestasis uveitis claudication|porphyria|this trial are encouraging , the data are preliminary in nature , based on a limited number of patients with acute intermittent entity , or aip .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|porphyr hereditary familial sporadic attacks|hepatitis porphyr cholestasis cholangitis encephalopathy|porphyria|we and our collaborator digna biotech are developing amt-021 as a gene therapy for acute intermittent entity , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|porphyr hereditary familial sporadic attacks|panic hemorrhagic fatal hypoglycemic febrile|porphyria|excluding entity attacks , three patients had four saes , including one previously reported fatal episode of hemorrhagic pancreatitis ; none of these saes were
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|porphyr hereditary familial sporadic attacks|angioedema panic gout hae angina|porphyria| present data from the ongoing phase 1 study  including initial data in patients that experience recurring entity attacks  in late 2016 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porphyr hereditary familial sporadic attacks|familial infantile cholestatic intermittent sporadic|porphyria|acute intermittent entity aip disease and market background aip is a rare metabolic liver disorder resulting from mutations in the pbgd gene .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|porphyr hereditary familial sporadic attacks|encephalopathy decompensation porphyr exacerbation coma|porphyria|advanced investigational rnai therapeutic , givosiran , targets aminolevulinic acid synthase 1 , or alas1 , for the treatment of patients with acute hepatic entity , or ahp .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|porphyr hereditary familial sporadic attacks|encephalopathy decompensation coma exacerbation paralysis|porphyria|food and drug administration ( fda ) approved givlaari ( givosiran ) injection for subcutaneous use for the treatment of adults with acute hepatic entity ( ahp ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|disease|porphyr hereditary familial sporadic attacks|gout panic asthmatic headache hypoglycemic|porphyria|defined mutation in the pbgd gene and elevated urinary levels of ala and pbg , but no current entity attacks .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|porphyr hereditary familial sporadic attacks|porphyr hepatitis intermittent hyperbilirubin hemat|porphyria|amt-021 for acute intermittent entity we are developing amt-021 as a gene therapy for acute intermittent porphyria , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|disseminated necrotizing granulomatous develops aspergillus|dengue encephalitis rabies leptospirosis ebola|coccidioidomycosis|status in the united states for vt-1129 for the treatment of cryptococcal meningitis and for vt-1598 for the treatment of entity , also known as valley fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated necrotizing granulomatous develops aspergillus|aspergillosis candidiasis dengue leishmaniasis vl|coccidioidomycosis|our third program , vt-1598 for the treatment of entity , a fungal infection in the southwestern united states also known as valley fever , is in ind-enabling studies targeting an ind
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|disseminated necrotizing granulomatous develops aspergillus|dengue fever leptospirosis encephalitis measles|coccidioidomycosis|these diseases include entity , commonly known as valley fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|disseminated necrotizing granulomatous develops aspergillus|toxoplasmosis leprosy candidiasis aspergillosis cryptococcus|coccidioidomycosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , entity , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated necrotizing granulomatous develops aspergillus|ebola fever dengue wnv vl|coccidioidomycosis|vt-1598 for entity ( valley fever ) vt-1598 is an orally available inhibitor of fungal cyp51 that has shown high potency and selectivity in in vitro studies .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|osteoporosis osteosarcoma histiocytosis osteomyelitis hypercalcemia|osteopetrosis|infantile malignant entity ( imo ) : imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|immunodeficiency epilepsy neutropenia pneumonia alf|osteopetrosis|imo is a severe form of entity that typically presents in the first year of life and is associated with severe manifestations leading to death within the
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis mesothelioma melanoma neutropenia hyperthermia|osteopetrosis|hcv collaboration with roche and sales of actimmune® , which is approved for two indications , chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis lymphomas sarcoidosis mesothelioma nhl|osteopetrosis|actimmune is currently approved in the united states for the treatment of chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis osteosarcoma osteoporosis osteomyelitis hypercalcemia|osteopetrosis|infantile malignant entity ( “imo” ) imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis lymphomas sarcoidosis lymphadenopathy neutropenia|osteopetrosis|is approved in the united states and numerous other countries for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis lymphomas sarcoidosis neutropenia lymphadenopathy|osteopetrosis|actimmune has been approved by the fda f16 for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis hyperthermia lymphomas melanoma ascites|osteopetrosis|frequency and severity of serious infections associated with chronic granulomatous disease ( cgd ) and to slow the worsening of severe malignant entity ( smo ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|melanoma gliomas glioma mesothelioma ascites|osteopetrosis|the fda approved actimmune as a treatment to delay the time to disease progression in patients with severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|melanoma mesothelioma gliomas histiocytosis hyperthermia|osteopetrosis|in the united states , the company estimates that there are approximately 1 , 200 patients with cgd and less than 500 patients with severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|melanoma histiocytosis hemangioma mesothelioma hyperthermia|osteopetrosis|is also targeting research in other diseases such as pyruvate kinase deficiency ( pkd ) , leukocyte adhesion deficiency-i ( lad-i ) , and infantile malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis melanoma mesothelioma lymphomas neutropenia|osteopetrosis|actimmune we currently market our lead product , actimmune , for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis eosinophilia sarcoidosis thrombocytopenia anaphylaxis|osteopetrosis|actimmune is approved by the fda for use in children and adults with chronic granulomatous disease ( cgd ) and severe , malignant entity ( smo ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|osteoarthritis mammals reality bones osteoporosis|osteopetrosis|in entity , the cells that break down bone ( osteoclasts ) do not work properly , which leads to the bones becoming thicker and not as healthy .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|psoriasis epilepsy osteoporosis osteoarthritis t2dm|osteopetrosis|for example , we have ongoing phase 4 post-marketing commitments to the fda relating to actimmune for the treatment of entity , including a registry and drug interaction study .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis lymphomas lymphadenopathy sarcoidosis melanoma|osteopetrosis|we currently market actimmune in the united states for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|osteoporosis osteoarthritis scoliosis osteopenia dysplasia|osteopetrosis|entity is a disorder of bone development in which the bones become thickened .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|osteoporosis osteoarthritis ckd haemophilia ds|osteopetrosis|in people with entity , this balance is not maintained and the resorption of old bone material decreases while the formation of new bone continues .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|hyperthermia histiocytosis neutropenia hypercalcemia thrombocytopenia|osteopetrosis|severe , malignant entity is a life-threatening , congenital disorder that primarily affects children .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vertebral osteoporosis osteopenia osteoporotic postmenopausal|histiocytosis lymphomas lymphadenopathy sarcoidosis neutropenia|osteopetrosis|actimmune has been approved by the fda for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis pneumonia aspergillus sinusitis rhinosinusitis|aspergillosis|entity , a fungal infection caused by aspergillus , begins as an upper airway infection and can become a systemic fungal infection in
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis aspergillus mycosis rhinosinusitis|aspergillosis|astellas commercially launched isavuconazole in the united states in april 2015 for the treatment of invasive entity and invasive mucormycosis in adults .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis candida fungi|aspergillosis|overview until recently , we were focused on developing our novel antifungal vl-2397 , for the treatment of patients with invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis cancers pathogens leishmaniasis|aspergillosis|the fda has also granted vical qualified infectious disease product ( qidp ) , orphan drug and fast track designations for vl‑2397 for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|nsclc leukemia cml sclc mcl|aspergillosis|compound , cancidastm ( caspofungintm ) or mk-0991 , in the same class as our v-echinocandin , recently received fda approval for salvage therapy in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|toxoplasmosis aspergillosis leprosy anthrax rabies|aspergillosis|indications currently being explored for mat2203 include resistant candidiasis , cryptococcal meningoencephalitis , entity and leishmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis rhinosinusitis sinusitis|aspergillosis|it is indicated for primary treatment of acute invasive entity and salvage therapy for rare but serious fungal infections caused by the pathogens scedosporium apiospermum and fusarium spp .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis cancers melanoma nsclc|aspergillosis|fda has advised that vl‑2397 would be eligible for a limited use indication ( lui ) approval for the treatment of invasive entity for patients with limited treatment options .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis aspergillus nsclc|aspergillosis|with soc vs . aspergillus spp . , we plan to initiate a phase 2 study of oral scy-078 in patients with invasive entity in the third quarter of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis candida aspergillus|aspergillosis|we market amphotec® worldwide for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis uses melanoma neurosurgery cancers|aspergillosis|although we market amphotec for invasive entity , we do not believe that it will provide sufficient revenue to us in the near future , if ever , and , consequently ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis disseminated candidiasis pneumonia endocarditis|aspergillosis|development history of mat2203 mat2203 was extensively studied in animal model studies of various fungal infections including invasive candidiasis , entity , and visceral leichmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis candida rhinosinusitis|aspergillosis|amphotec is an fda-approved lipid-complexed form of amphotericin b indicated for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis melanoma candidiasis neuroblastoma mole|aspergillosis|an estimated 200 , 000 cases of invasive entity are diagnosed annually worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|fungal candida cns cryptococcus aspergillus|aspergillosis|sequus is conducting a phase iii double-blind , randomized study comparing amphotec with amphotericin b in treating patients with first-line entity infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillus staphylococcus candida cryptococcus bacillus|aspergillosis|the amphotericin b cochleate demonstrated reasonable activity against at least one strain of entity fumigatus and one strain of candida albicans in vitro .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis mycosis candidiasis dysplasia fungal|aspergillosis| received a second qidp status for pulmazole to treat fungal infections in the airways of allergic bronchopulmonary entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis cdi candida pneumonia|aspergillosis|cancidas  has not been studied as an initial therapy for invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis mycosis fungal leishmaniasis|aspergillosis|hepatitis c virus ( hcv ) , infections , and amphotec® ( amphotericin b cholesteryl sulfate complex for injection ) , approved for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillus aspergillosis fumigatus fungal necrotizing|aspergillosis candidiasis cancers melanoma neuroblastoma|aspergillosis|we have world-wide marketing rights to amphotec for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails leishmaniasis vl worms|schistosomiasis|three months ended march 31 , 2012 , approximately 60% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis helminth schistosoma hydatid|schistosomiasis|deuterated praziquantel in collaboration with the therapeutics for rare and neglected diseases division of the nih for the treatment of entity and other parasitic diseases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis snails vl worms|schistosomiasis|three months ended june 30 , 2009 , approximately $943 , 137 or 15 . 52% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|mansoni japonica schistosomiasis eggs japonicum|leishmaniasis schistosomiasis toxoplasmosis epilepsy rabies|schistosomiasis|lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails leishmaniasis vl worms|schistosomiasis|three months ended june 30 , 2011 , approximately 22% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis snails worms vl|schistosomiasis|the three months march 31 , 2010 , approximately $830 , 600 , or 17% of total revenues , resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis snails vl worms|schistosomiasis|ended december 31 , 2010 , approximately $12 , 198 , 522 or 25 . 7% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis snails worms vl|schistosomiasis|three months ended september 30 , 2009 , approximately $3 , 330 , 000 or 26% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|mansoni japonica schistosomiasis eggs japonicum|nematodes cattle sheep ticks insects|schistosomiasis|it is an anthelmintic effective against entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|mansoni japonica schistosomiasis eggs japonicum|leishmaniasis schistosomiasis toxoplasmosis brucellosis leptospirosis|schistosomiasis|entity is a parasitic disease that affects both animals and humans .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis vl snails worms|schistosomiasis|during the three months ended june 30 , 2010 , approximately $1 , 864 , 203 or 33 . 7% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis cholera dengue cryptosporidium leptospirosis|schistosomiasis|entity is prevalent in southern china where there are a lot of fresh water lakes and rivers .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails worms leishmaniasis vl|schistosomiasis|nine months ended september 30 , 2012 , approximately 44% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis leishmaniasis vl snails worms|schistosomiasis|during the three months ended september 30 , 2010 , approximately $5 , 104 , 961 or 41% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|mansoni japonica schistosomiasis eggs japonicum|leishmaniasis schistosomiasis toxoplasmosis rabies epilepsy|schistosomiasis|table of contents lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails leishmaniasis worms vl|schistosomiasis|during year ended december 31 , 2011 , approximately 36% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails leishmaniasis vl parasites|schistosomiasis|during the three months ended march 31 , 2011 , approximately 1 , 058 , 132 or 15% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis nematodes leishmaniasis parasites rabies|schistosomiasis|praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent entity in livestock .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mansoni japonica schistosomiasis eggs japonicum|schistosomiasis snails leishmaniasis worms vl|schistosomiasis|three months ended september 30 , 2011 , approximately 26% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|mansoni japonica schistosomiasis eggs japonicum|toxoplasmosis cryptosporidium schistosomiasis candidiasis syphilis|schistosomiasis|examples of analytes in this field are : aspergillus , candida , markers or antibodies associated with entity , giardia lamblia , leishmaniasis , lyme disease , chagas , toxoplasmosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|lymphangi cystic cysts hemangioma lymphatic|schwannoma leiomyosarcoma others hemangioma glomus|lymphangioma|aortic body and other paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|lymphangi cystic cysts hemangioma lymphatic|schwannoma leiomyosarcoma others hemangioma sarcoma|lymphangioma|paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|cholera foodborne vibrio epidemic o1|next sars 2nd fifth pandemic|cholera|during the entity outbreak we responded to a further specific request for antibiotics and donated £250 , 000 to the british red cross to support
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|cholera foodborne vibrio epidemic o1|parasites vaccines viruses bcg wnv|cholera|quarter of 2000 , will test the safety , immunogenecity and protective capacity of the vaccine against a challenge with live virulent entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cholera foodborne vibrio epidemic o1|fever brucellosis enteritis pneumonia epidemic|cholera|qilian shan® oxytetracycline api used for treating following diseases : rickettsia , mycoplasma infection , chlamydia infection , regression fever , brucellosis entity , rabbit fever and plague .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|cholera foodborne vibrio epidemic o1|cholera gastroenteritis diarrhea leptospirosis diarrhoea|cholera|( the causative agent of entity ) are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cholera foodborne vibrio epidemic o1|rotavirus cryptosporidium cholera norovirus gastroenteritis|cholera|in human patients with various types of watery diarrhea , including traveler  s diarrhea , hiv-related diarrhea and other acute infectious diarrheas , including entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|cholera foodborne vibrio epidemic o1|constipation fd cma cdi psc|cholera|in addition , an early stage cftr inhibitor program is planned for the treatment of secretory diarrhea disorders , including entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cholera foodborne vibrio epidemic o1|cholera rotavirus norovirus dehydration diarrhea|cholera|entity is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|cholera foodborne vibrio epidemic o1|dengue schistosomiasis measles polio brucellosis|cholera|and supported the start of phase ii trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cholera foodborne vibrio epidemic o1|dengue leptospirosis rabies je hev|cholera|investigation , peru-15 may be an excellent candidate as a potential single dose , oral vaccine for travelers going to areas where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|cholera foodborne vibrio epidemic o1|cholera diarrhea gastroenteritis rotavirus diarrhoea|cholera|entity / general watery diarrhea we are investigating lechlemer for the indication of cholera / general watery diarrhea in adults and children .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|cholera foodborne vibrio epidemic o1|mucosal prophylactic pneumococcal candidate cholera|cholera|development of a safe , effective entity vaccine is the first step in establishing avants single-dose , oral bacterial vaccine franchise .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|cholera foodborne vibrio epidemic o1|cholera pertussis typhoid polio pneumococcal|cholera|ctb has already been administered to hundreds of thousands of patients worldwide and is a major component of an existing oral entity vaccine and traveler  s diarrhea vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|cholera foodborne vibrio epidemic o1|causative infecting pertussis pneumococcal homologous|cholera|published results have shown the vaccine to be well tolerated and immunogenic against the entity organism in the adult portion of this trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholera foodborne vibrio epidemic o1|cholera tetanus anthrax diphtheria botulinum|cholera|maxvax mucosal vaccine carrier / adjuvant platform maxvax is a mucosal vaccine carrier / adjuvant platform based on the entity toxin b subunit ( ctb ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholera foodborne vibrio epidemic o1|cholera tetanus polio pertussis rabies|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminium-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholera foodborne vibrio epidemic o1|cholera polio tetanus pertussis rabies|cholera|crucell also markets travel vaccines , such as an oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|cholera foodborne vibrio epidemic o1|dengue measles schistosomiasis polio brucellosis|cholera|this vaccine and supported the start of phase 2 trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|disease|cholera foodborne vibrio epidemic o1|candidate investigational inactivated rsv pneumococcal|cholera|we will then determine our commercialization strategy with respect to the entity vaccine based on clinical data from the trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholera foodborne vibrio epidemic o1|cholera polio tetanus pertussis rabies|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|cholera foodborne vibrio epidemic o1|oab convenience chemoprevention dyspepsia omeprazole|cholera|in addition , a second-generation proprietary anti-secretory agent is in development for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|ichthy hereditary involves dermatitis inherited|immunodeficiency alopecia ichthy erythema insensitivity|ichthyosis|the loss of tgm-1-activity results in the severe genetic skin disease autosomal recessive congenital entity ( arci ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|ichthy hereditary involves dermatitis inherited|hypothyroidism toxoplasmosis glaucoma hydrocephalus nystagmus|ichthyosis|there is no prescription drug currently approved in the united states that is indicated for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|ichthy hereditary involves dermatitis inherited|hypothyroidism toxoplasmosis syphilis malformations glaucoma|ichthyosis|announced that the united states food and drug administration ( fda ) granted adx-102 orphan drug designation for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy hereditary involves dermatitis inherited|pemphigus psoriasis acne eczema urticaria|ichthyosis|entity vulgaris is the most common form of ichthyosis affecting around one in 250 people worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|ichthy hereditary involves dermatitis inherited|acne dermatitis psoriasis eczema urticaria|ichthyosis|moisturizers that are used for the treatment of dry skin or certain inflammatory skin conditions , such as psoriasis , eczema or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|ichthy hereditary involves dermatitis inherited|hypothyroidism lymphedema angioedema vitiligo nystagmus|ichthyosis| liarozolean oral therapeutic for the treatment of congenital entity , a rare genetic disease characterized by dryness and scaling of the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|ichthy hereditary involves dermatitis inherited|neuropathy neutropenia cataract nystagmus deafness|ichthyosis|kb105 , delivers functional human transglutaminase-1 , or tgm1 genes using our gene therapy platform to patients with tgm1-deficient autosomal recessive congenital entity , or arci .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|ichthy hereditary involves dermatitis inherited|hyperbilirubinemia neurodegeneration seizures encephalopathy ataxia|ichthyosis|a dermatologic form of adx-102 is in late-stage clinical development for the treatment of entity due to sjögren-larsson syndrome , an inborn error of aldehyde metabolism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|ichthy hereditary involves dermatitis inherited|pruritus itching dermatitis sls itch|ichthyosis|thus , ns2 may be partially or wholly effective in preventing and treating entity or other dermal symptoms , signs , or pathologies in sls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ichthy hereditary involves dermatitis inherited|deformity immunodeficiency weakness rash scoliosis|ichthyosis|sls patients are generally diagnosed as neonates given the severe entity that presents at birth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ichthy hereditary involves dermatitis inherited|nystagmus immunodeficiency neutropenia deafness cataracts|ichthyosis|- dosing of the 4th patient in the phase 1 / 2 study of kb105 in patients with tgm1 deficient autosomal recessive congenital entity ( arci ) has completed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|ichthy hereditary involves dermatitis inherited|keratitis keratoconus keratoplasty leishmaniasis hemangioma|ichthyosis|compared to the same periods 2006 due to the completion of our phase 2 / 3 trial for the treatment of lamellar entity in april 2007 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|ichthy hereditary involves dermatitis inherited|hypothyroidism malformations hypercholesterolemia microcephaly osteoporosis|ichthyosis|in june , barrier therapeutics announced that liarozole was granted orphan drug status from the fda for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy hereditary involves dermatitis inherited|acne psoriasis pemphigus vitiligo scleroderma|ichthyosis|frequently results in lethargy and reduced libido in men above the age of 40 , and glylorin ( tm ) , a novel treatment for entity vulgaris , a debilitating skin disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|ichthy hereditary involves dermatitis inherited|aplasia nevus dystrophy dermatitis alopecia|ichthyosis|“primary indication” means the netherton syndrome , also known as comel-netherton syndrome , ns , bamboo hair syndrome , and entity linearis cirumflexa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|ichthy hereditary involves dermatitis inherited|keratitis dermatitis planus leishmaniasis warts|ichthyosis|barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis , lamellar entity , acne , psoriasis and fungal infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|ichthy hereditary involves dermatitis inherited|cardiomyopathy myopathy cataract cataracts immunodeficiency|ichthyosis|of fatty aldehydes in sjögren-larsson syndrome , an orphan disease caused by mutations in fatty acid aldehyde dehydrogenase , lead to severe entity , retinal disease and neurological disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy hereditary involves dermatitis inherited|acne psoriasis pemphigus vitiligo urticaria|ichthyosis|table of contents was licensed to ohr cosmetics for dermatological uses was evaluated in a moisturizer formulation in subjects with entity vulgaris at a non-us testing site .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|ichthy hereditary involves dermatitis inherited|sls lymphedema vitiligo ichthy keratitis|ichthyosis|in april 2017 , we announced that the fda granted reproxalap orphan drug designation for the treatment of congenital entity , a severe skin disease characteristic of sls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|ichthy hereditary involves dermatitis inherited|toxoplasmosis syphilis malformations anomalies rubella|ichthyosis|in or entering phase 3 clinical trials for the treatment of seborrheic dermatitis , fungal infections , including vaginal candidiasis , and congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis aspergillosis candidiasis cryptococcus cytomegalovirus|histoplasmosis|among the most common systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis allergy melanoma sarcoidosis malignancy|histoplasmosis|visudyne is also used for the treatment of subfoveal cnv due to pathologic myopia , or severe near-sightedness , and presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|aspergillosis aspergillus candidiasis mycosis toxoplasmosis|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|aspergillosis candidiasis aspergillus candida cryptococcus|histoplasmosis|in conjunction with fujisawa , is conducting two phase iii clinical trials of ambisome in the u . s . for the treatment of entity and for the treatment of cryptococcus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis melanoma sarcoidosis malignancy syphilis|histoplasmosis|other macular neovascular conditions such as minimally classic and occult with no classic amd lesions , pathologic myopia and presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis sarcoidosis neovascular neovascularization melanoma|histoplasmosis|in some countries , including the u . s . and canada , visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis aspergillosis cryptococcus candidiasis cytomegalovirus|histoplasmosis|among the most common 5 8 systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|aspergillus fusarium aspergillosis penicillium candida|histoplasmosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|disease|disseminated mycosis candida histoplasm develops|fungi india aspergillus fluconazole mycobacteria|histoplasmosis|the trial for entity is being monitored and analyzed by the mycology study group of the national institutes of health .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated mycosis candida histoplasm develops|cytomegalovirus cmv candida hepatitis herpes|histoplasmosis|many antibody drugs are immunosuppressive , which may lead to increased risk of serious or opportunistic infection , such as tuberculosis , entity and hepatitis b , or malignancy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|aspergillosis aspergillus mycosis candidiasis toxoplasmosis|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|nystagmus myopia dryness ice sympathetic|histoplasmosis|visudyne has recently been launched for two new indications , pathologic myopia ( in the united states and europe ) and ocular entity syndrome ( in the united states ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis sarcoidosis neovascular melanoma neovascularization|histoplasmosis|in some countries ( including the u . s . and canada ) visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|aspergillosis aspergillus mycosis candidiasis toxoplasmosis|histoplasmosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|disseminated mycosis candida histoplasm develops|histoplasm hypersensitivity herpes tick allergy|histoplasmosis|presumed ocular entity syndrome ( ohs ) is a condition caused by a fungal infection endemic to certain areas in the central and eastern u . s .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|disseminated mycosis candida histoplasm develops|toxoplasmosis sarcoidosis neovascular melanoma allergy|histoplasmosis|in some countries visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|disseminated mycosis candida histoplasm develops|another investigational pivotal abstract adjuvant|histoplasmosis|entity phase iii cryptococcal meningitis phase iii daunoxome advanced kaposi  s sarcoma approved for marketing in the u . s . , canada and 12 western
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated mycosis candida histoplasm develops|intolerance toxicities neurotoxicity tolerability irritation|histoplasmosis|in the us , visudyne has received an additional approval for cnv due to presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|disseminated mycosis candida histoplasm develops|hypoxic hyperventilation hypotensive dryness myopia|histoplasmosis|due to pathologic myopia in the united states , canada and the european union and for cnv due to presumed ocular entity syndrome ( " ohs " ) in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy aeds seizures prophylaxis pregnancies|epilepsy|mothers exposed to other antiepileptic drugs , or aeds , and a purported prevalence of 0 . 07% in infants born to mothers without entity or treatment with other aeds .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|epilepsy seizures seizure epileptic antiepileptic|allergy immunology rhinitis allergies cardiology|epilepsy|the company has clinical stage programs in entity and asthma .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|epilepsy seizures seizure epileptic antiepileptic|allergy osteoporosis osteoarthritis neurodegeneration allergies|epilepsy|the company is conducting research and development activities in a number of disease areas , including entity , pain and inflammation .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy autism ocd ds gad|epilepsy|we are also preparing for the potential commercial launch of diazepam nasal spray , a treatment for people with entity who experience cluster seizures .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|osteoporosis epilepsy dyslipidemia osteoarthritis hyperlipidemia|epilepsy|the products are intended to treat a variety of disorders including the following : hypertension , arthritis , seizures , entity , diabetes and pain management .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|epilepsy seizures seizure epileptic antiepileptic|continued continuing ongoing maintaining renewed|epilepsy|continue making payments to parteq of c$108 , 000 each quarter as a result of the renewal of the alzheimers agreement and entity agreement with parteq .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|antidepressant psychotropic psychoactive antipsychotic suicide|epilepsy|in 2005 , the fda requested that all makers of entity drugs analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|seizures jer movements attacks seizure|epilepsy|myoclonic entity 0 1 ( 3 . 4% ) 2 ( 6 . 9% ) serious aes , or saes , of seizure were reported
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|neuroprotection neurotoxicity epilepsy neurodegeneration cognition|epilepsy|to evaluate cbd and cbdvhs ( and possibly additional cbd-derivatives ) in a human in vitro neural model with an application to entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|childbirth epilepsy fertility maternity miscarriage|epilepsy|the uk entity and pregnancy register reported a similarly increased prevalence of oral clefts ( 3 . 2% ) among infants born to mothers exposed to topiramate
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy neuroprotection neurodegeneration neuroscience neurogenesis|epilepsy|amarins cns development pipeline includes two programs in parkinsons disease , one in entity and one in memory and cognition .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|epilepsy seizures seizure epileptic antiepileptic|candidate reporter mucin precursor homeobox|epilepsy|a patent application relating to the epm1 entity gene is pending in the uspto .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy seizures insomnia headache addiction|epilepsy|patients with refractory focal seizures , which we refer to as the star 1 ( synthetic transdermal cannabidiol for the treatment of entity ) trial .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy seizures spasms ige tsc|epilepsy|in chronic use for the treatment of entity , vigabatrin has been generally well tolerated with lower than average neurological side effects compared to other approved entity therapies .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy insomnia osteoporosis gout psoriasis|epilepsy|sales of drugs for the treatment of entity decreased by approximately $967 , 000 in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 because
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy dystonia fibromyalgia tinnitus seizures|epilepsy|electrical neurostimulation technology has seen growing use in recent years for numerous applications– such as chronic pain , parkinsons , essential tremor , entity , and others .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|science iranian pharmaceutical alzheimer nih|epilepsy|this study was sponsored by the entity foundation , and conducted in 2013 in the laboratory of dr . annamaria vezzani at the mario negri institute for pharmacological research
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|epilepsy seizures seizure epileptic antiepileptic|epilepsy psoriasis seizures pah acromegaly|epilepsy|we are developing sage-217 so that it will have what we believe is an optimal profile as a monotherapy for entity in many forms .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|epilepsy seizures seizure epileptic antiepileptic|melanoma nsclc glioblastoma aml psoriasis|epilepsy|with janssen pharmaceuticals , inc . , is scheduled to enter a phase 2a proof of concept clinical study for the treatment of entity in h1 2021 .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|epilepsy seizures seizure epileptic antiepileptic|pharmaceutical approved promising principal generic|epilepsy|our two entity product candidates are spn-538 ( extended release topiramate ) , for which we submitted a new drug application , or nda , that was accepted
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis nausea fever jaundice cholelithiasis|cholecystitis|these include entity ( gallbladder inflammation ) , seizure , palpitations , paresthesia and vertigo .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cystic perforation abscess gallbladder gallstone|hepatotoxicity neutropenia cardiotoxicity diarrhea myelosuppression|cholecystitis|there was one report of entity in a phase 1 clinical trial of lum001 and one report of elevated levels of alanine aminotransferase and aspartate aminotransferase ,
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis peritonitis diverticulitis appendicitis hemorrhage|cholecystitis|ciai diagnoses include intra-abdominal abscess , stomach or intestinal perforation , peritonitis , appendicitis , entity , or diverticulitis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis cholangitis appendicitis hepatitis abdomen|cholecystitis|a single patient during the extension study developed acute entity and cholelithiasis later treated with cholecystectomy .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|cystic perforation abscess gallbladder gallstone|hepatitis bronchitis urticaria sinusitis gastroenteritis|cholecystitis|one subject had a baseline pro-c3 of 9 . 9 ng / ml , experienced a serious ae of acute entity , stopped taking axa1125 at the end of week 1 and then discontinued from the study on week 5 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cystic perforation abscess gallbladder gallstone|vomiting diarrhea diarrhoea anorexia headache|cholecystitis|serious adverse events reported in the trial included disease progression , pyrexia , mastitis , pneumonia , nausea , entity and pain in extremity , each of which was reported only once .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|cystic perforation abscess gallbladder gallstone|hepatitis diarrhea hepatotoxicity urticaria cough|cholecystitis|a single patient during the extension study experienced acute entity classified as a serious adverse event but deemed unlikely related to sbc-102 by the investigator .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cystic perforation abscess gallbladder gallstone|vomiting nausea diarrhea constipation dyspepsia|cholecystitis|the one subject who received akr-001 70mg iv had a serious adverse event of entity initially reported as abdominal pain beginning on day 11 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|cystic perforation abscess gallbladder gallstone|cellulitis sinusitis gastroenteritis conjunctivitis bronchitis|cholecystitis|two study group subjects experienced saes , severe acute entity and moderate cellulitis , with the latter subject discontinuing treatment prior to end of treatment .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis gallbladder cholecystectomy ascites cholangitis|cholecystitis|serious adverse events included skin infection ( cellulitis , two cases ) , abdominal pain and inflammation of the gall bladder ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis appendicitis gastritis cholelithiasis diverticulitis|cholecystitis|findings from a subsequent cholecystectomy were consistent with chronic entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|cystic perforation abscess gallbladder gallstone|cholangitis sludge jaundice strictures adenomas|cholecystitis|with respect to hepatobiliary events , more patients ( 3% ) on oca 25 mg experienced gallstones or entity compared to <1% on placebo and 1% on oca 10 mg .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cystic perforation abscess gallbladder gallstone|cholestasis gallstones cirrhosis cholelithiasis cholangitis|cholecystitis|the biliary system is a significant target for many conditions , including drug toxicities , entity , and liver-related abnormal function associated with the cystic fibrosis mutation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|cystic perforation abscess gallbladder gallstone|gallstones gallstone cholelithiasis cholecystitis gallbladder|cholecystitis|this potentially represents a previously unrecognized factor in the development of entity and cholelithiasis disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cystic perforation abscess gallbladder gallstone|cholecystitis hepatitis gallstones colitis gastritis|cholecystitis|the project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory ( entity ) and calcific pathologic ( cholelithiasis ) disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cystic perforation abscess gallbladder gallstone|urticaria gastroenteritis cellulitis headache cough|cholecystitis|there were two serious aes reported , acute entity and right toe infection , which were deemed not reasonably associated with the study product , and more likely due to subject  s
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|cystic perforation abscess gallbladder gallstone|exacerbation hemolysis sepsis flare attack|cholecystitis|the subject  s end-of-study pro-c3 level was 31 . 9 ng / ml , reflecting both the acute inflammatory state ( i . e . , acute entity ) and also likely a washout effect of axa1125 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|cystic perforation abscess gallbladder gallstone|pneumonia diarrhea cellulitis gastroenteritis anaphylaxis|cholecystitis|one patient was hospitalized for entity , a serious ae , two days after receiving seven days of treatment with torezolid phosphate , which the clinical investigator determined to
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|cystic perforation abscess gallbladder gallstone|gallstones cholelithiasis cholecystitis cholecystectomy gastritis|cholecystitis|both consisted of entity , or gall bladder inflammation , which is common in people who experience rapid or significant weight loss .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|cystic perforation abscess gallbladder gallstone|etc jaundice cholelithiasis stone hyperlipidemia|cholecystitis|lidan paishi pian clear heat and promote diuresis , cholagogue and remove calculi , biliary tract infection , entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|subspecies diagnose causing zoonotic produces|dengue ebola measles rabies rubella|tularemia|category is category a . the six agents that the cdc has classified as category a are anthrax , botulism , plague , smallpox , entity and viral hemorrhagic fevers .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|plague ebola rabies dengue sars|tularemia|barda is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|ebola dengue rabies listeria plague|tularemia|equally compelling , restanza has shown effectiveness against several lethal pathogens , including anthrax , plague , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|leishmaniasis rabies ebola candidiasis dengue|tularemia|cethromycin is also being developed as a biodefense agent for use in the treatment of anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|subspecies diagnose causing zoonotic produces|anthrax encephalitis cholera plague diarrhea|tularemia|these two bacteria species are considered potential bioweapons and are the causative agents for plague and entity , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|subspecies diagnose causing zoonotic produces|vaccinia adenovirus bcg poliovirus tuberculin|tularemia|the company has been in contractual negotiations for the first two products , entity and vaccinia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|subspecies diagnose causing zoonotic produces|ebola dengue rabies encephalitis leishmaniasis|tularemia|preliminary data from our preclinical experiments indicates that our product candidates have potent activity against biowarfare agents that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|subspecies diagnose causing zoonotic produces|pneumonia plague endocarditis anthrax lethal|tularemia|these tests have been completed in non-human primates and have shown that solithromycin is effective in treating anthrax and entity when the infection was initiated by the pulmonary route .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|dengue rabies measles ebola sars|tularemia|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , entity , and botulism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|others leishmaniasis dengue leprosy encephalitis|tularemia|the bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|subspecies diagnose causing zoonotic produces|rabies ebola leishmaniasis anthrax encephalitis|tularemia|the fda has granted cethromycin an orphan drug designation for the prophylactic treatment of inhalation anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|leptospirosis toxoplasmosis leishmaniasis dengue encephalitis|tularemia|other tick-borne diseases include rocky mountain spotted fever , babesiosis , erlichiosis , anaplasmosis , powassan disease , tick-borne relapsing fever and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|subspecies diagnose causing zoonotic produces|india canada australia uganda china|tularemia|· received fda orphan drug designation for restanza in plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|subspecies diagnose causing zoonotic produces|dengue leptospirosis typhoid streptococcal malarial|tularemia|a non-exclusive , royalty-bearing license to use certain of our patents and related know how for the prevention or treatment of entity and viral hemorrhagic fever indications .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|subspecies diagnose causing zoonotic produces|plague ebola rabies dengue measles|tularemia|barda funded studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|subspecies diagnose causing zoonotic produces|ebola rabies plague dengue encephalitis|tularemia|for the treatment of serious hospital infections as well as the treatment of bioterror pathogens , such as anthrax , plague and entity after signs and symptoms are present .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|subspecies diagnose causing zoonotic produces|ebola rabies cholera dengue pneumonia|tularemia|is focused on the development of antibiotic compounds to treat biowarfare agents , including the highly infectious bacteria that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|listeria plague ebola dengue yersinia|tularemia|solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens , specifically anthrax and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|subspecies diagnose causing zoonotic produces|plague ebola rabies dengue sars|tularemia|barda also is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|subspecies diagnose causing zoonotic produces|plague rodents mammals sepsis rabbits|tularemia|after symptoms developed ; · pivotal primate study showing protective efficacy in plague ; · pivotal animal study showing 100% survival in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia hepatitis thalassemia amphotericin|hemophilia|used in the trial consistently led to long-term expression of the hfix transgene at therapeutic levels in patients with severe entity b , without acute or long-lasting toxicity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|hepatitis hemophilia haemophilia amphotericin category|hemophilia|we further note that you cite uniqure and spark therapeutics as competitors with treatments for entity b in phase 3 clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia hepatitis thrombocytopenia coagulopathy|hemophilia|human coagulation factor ix prevention and control of bleeding in patients who suffer from entity b . completed the clinical trial and preparing documentation for the registration purpose .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|concentrates hemophilia fviii ix coagulation|sepsis cancers epilepsy hepatitis oncology|hemophilia|kedrion markets therapies globally for entity , hemolytic disease of the newborn , immune and neurological disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|concentrates hemophilia fviii ix coagulation|him psychiatry england dermatology london|hemophilia|he has served as baxters global franchise head for entity since june 2012 and is expected to continue in that role until the separation is completed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|concentrates hemophilia fviii ix coagulation|him centuries assistance psychiatry contributions|hemophilia|he served as baxters global franchise head for entity from 2012 until the separation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|sepsis osteomyelitis scid hemophilia leukemia|hemophilia|for example : · porcine spleen tissue was successfully implanted into a mouse , effectively treating entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|concentrates hemophilia fviii ix coagulation|nash cirrhosis nafld hepatitis hepatoma|hemophilia| continue to build a liver-directed gene therapy platform , with an initial focus on the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|concentrates hemophilia fviii ix coagulation|choosing implementing funding designing defining|hemophilia|spark hereby grants pfizer the exclusive right to negotiate an agreement with spark with respect to the entity a program subject to the terms of this section 2 . 9 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|prophylaxis substitution anticoagulation hemophilia replacement|hemophilia|the treatment concept is similar to entity , in which a patient is treated regularly with the particular clotting factor in which he is deficient .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|concentrates hemophilia fviii ix coagulation|haemophilia hemophilia sle ibd itp|hemophilia|vwd may experience mild symptoms , but some patients can experience severe bleeding events similar to bleeding experienced by patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia hepatitis hit genotypes|hemophilia|an improved next-generation coagulation factor viia variant , cb 813d , that has successfully completed a phase 1 clinical trial in severe entity a and b patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia hepatitis amyloid cyclosporin|hemophilia|therapeutic proteins are increasingly used to treat diseases , including interferon beta for multiple sclerosis , factor viii for entity a , and monoclonal antibodies for various disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia hepatitis haemophilia coagulopathy thrombocytopenia|hemophilia|of our collaboration agreement for the development of coagulin-b , our product candidate that we were developing for the treatment of entity b , involving administration to the liver .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia hepatitis haemophilia abstract streptococcus|hemophilia| entity b . entity b patients typically are treated by a variety of plasma-derived , recombinant or long-acting products that are produced by a number of companies , including pfizer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2), ('BIO', 1)])|disease|concentrates hemophilia fviii ix coagulation|rituximab immunoglobulins platelets corticosteroids plasmapheresis|hemophilia|in june 2014 , we acquired medpro , a specialty pharmacy focused on specialty infusion including entity and immune globulin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|hepatitis hemophilia haemophilia amphotericin thalassemia|hemophilia|many other companies are developing gene therapies to treat entity b , including baxter , uniqure and dimension .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia apolipoprotein mps hit|hemophilia|preliminary data in entity b mice indicate that treatment with amt-060 induces normalization of fix levels as well as clotting time .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|concentrates hemophilia fviii ix coagulation|hemophilia haemophilia thrombocytopenia itp epistaxis|hemophilia|in december 2013 , we acquired ahf , which provides specialty drugs and infusion services for bleeding disorders , principally entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|concentrates hemophilia fviii ix coagulation|amphotericin hepatitis candidate hit aurora|hemophilia|outlook 2017 in 2017 we plan to : · drive our entity b program towards late stage clinical development ; · continue non-clinical and preclinical studies that are expected to support an ind
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|prototype entire investigational finished draft|leptospirosis|we are completing the manufacture of the entity product so that we can provide evaluation lots and documentation to fiocruz for their regulatory approval submission of this product
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|ntm mtb mdr cmv vl|leptospirosis|similar increases in both clinical and analytical sensitivity were observed for our human tb and entity assays .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|leishmaniasis leishmania indeterminate leishman syphilis|leptospirosis|agreements are for the following rapid test products : i ) dpp® hiv 1 / 2 screen , ii ) dpp® hiv 1 / 2 confirmatory , iii ) dpp® entity and iv ) dpp® leishmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|toxoplasmosis dengue leprosy mumps rabies|leptospirosis|we also have licensed the antigens used in other tests including our syphilis , tuberculosis , entity , leishmaniasis and chagas tests , and we may enter other license agreements .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|objectives conclusions abstract business note|leptospirosis|dpp® entity – in june 2009 , as we previously reported , we were awarded a three-year $3 million small business innovative research ( sbir )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|agreement agreements transparency collaboration cooperation|leptospirosis|entity [ member ] refers to agreements relates to research and development arrangements .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|pneumonia typhoid cholera shigella plague|leptospirosis|in addition to viral vaccines , diamond also manufactures vaccines against bacterial infections , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|leprosy toxoplasmosis dengue schistosomiasis chlamydia|leptospirosis|the five products under agreement with fiocruz are for dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|chlamydia syphilis igm dengue ana|leptospirosis|believe fiocruz will receive during 2011 the required approvals from anvisa for the second dpp® syphilis test and the dpp® entity test , although there can be no assurance of this .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|proficiency usability chemistry compatibility certification|leptospirosis|with respect to chembio  s dpp® entity test , bio-manguinhos had not qualified to request the technology transfer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|what conclusions objectives yes online|leptospirosis|dpp® entity – we have approximately nine months left of the three-year $3 million small business innovative research ( sbir ) phase ii grant
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|chlamydia leprosy dengue hepatitis schistosomiasis|leptospirosis|separate right to request a technology transfer for that product only are : dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|cholera typhoid diarrhoea anthrax tetanus|leptospirosis|bacterial vaccines are bacterial products that are used on a routine basis to prevent diseases such as black leg , entity , red water and shipping fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|leptospirosis dengue syphilis chlamydia gbs|leptospirosis|from the united states national institutes of health ( nih ) to fully develop , validate , and commercialize a rapid diagnostic test for entity for general use worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|funded government industry nhs grant|leptospirosis|· dpp® entity phase ii grant – in 2009 we were awarded a three year , $1 . 9 million small business innovative research ( sbir ) phase
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|leishmaniasis leishmania syphilis toxoplasmosis leishman|leptospirosis|three of these products ( leishmaniasis and the hiv screening and confirmation tests ) , and we have substantially completed development of the entity test .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|syphilis cmv chlamydia cryptosporidium leprosy|leptospirosis|this new patent-pending platform , including the testing of our current hiv test strip ( as well as our human tb and entity assays ) that was recently approved in this new platform .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|syphilis autism osteoporosis chlamydia ptsd|leptospirosis|to be completed three-year grant from the united states national institutes of health to complete development of a test for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|papillomavirus cancers saliva melanoma autoantibodies|leptospirosis|a press release entitled “chembio awarded three year $3mm nih sbir phase ii grant to complete dpp® test for human entity ” .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|leptospirosis epidemic epidemiology outbreaks diagnose|paclitaxel oncology melanoma nsclc sorafenib|leptospirosis|three year , $3mm phase ii nih grant for entity awarded june 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|autism involves familial prenatal malformations|marfan overgrowth turner lymphedema craniofacial|craniosynostosis|of limb and lungs and unregulated fgf signaling leads to a variety of human bone morphogenic disorders , including dwarfism and entity syndromes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autism involves familial prenatal malformations|scoliosis osteogenesis cdh asd ossification|craniosynostosis|his research interests include the molecular mechanism of entity , which is the premature fusion of calvarial suture line in infants and tissue engineering of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hereditary develops hfe prevents familial|thalassemia thalassaemia ida cirrhosis rls|hemochromatosis|u . s . safety information for auryxia® ( ferric citrate ) contraindication auryxia® ( ferric citrate ) is contraindicated in patients with iron overload syndromes , e . g . , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|disease|hereditary develops hfe prevents familial|enoxaparin urokinase fibrinogen fx prothrombin|hemochromatosis|prontotm prothrombin ( factor ii ) approved f9923 prontotm thromborisktm approved f9949 prontotm entity approved f9904 prontotm fmf basic approved f9946 prontotm cf euro i
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hereditary develops hfe prevents familial|hh angioedema hb ataxia pah|hemochromatosis|beta thalassemia patients suffering from iron overload and the initiation of a phase 2 study for ljpc-401in patients with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary develops hfe prevents familial|melanoma cancers angioedema lymphedema syndromes|hemochromatosis|it is also estimated that one million americans are afflicted with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary develops hfe prevents familial|thalassemia thalassaemia ckd cirrhosis schistosomiasis|hemochromatosis|we are developing ljpc-401 for the treatment of conditions characterized by iron overload , such as entity and beta thalassemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|hereditary develops hfe prevents familial|recessive mediterranean named heterogeneous termed|hemochromatosis|hereditary entity hereditary hemochromatosis is an iron overload disease that can lead to life-threatening conditions such as cirrhosis , liver cancer , diabetes , heart failure and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary develops hfe prevents familial|syndromes telangiectasia malignancies cancers thrombocytopenia|hemochromatosis|treatment of patients with polycythemia vera , myelodysplastic syndromes and hereditary entity may represent additional opportunities for future development of ptg-300 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hereditary develops hfe prevents familial|embolism hepatitis osteoporosis hemorrhage thrombocytopenia|hemochromatosis|in addition , savyon  s products are used in clinical laboratories performing pre-disposition testing ( thrombosis , entity , certain cancers and several other diseases and conditions ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hereditary develops hfe prevents familial|ckd thalassemia india esrd china|hemochromatosis|and chief executive officer of bond biosciences , inc . , a private start-up biotechnology company focused on addressing the iron overload in entity , from july 2016 to may 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|hereditary develops hfe prevents familial|hh haem anaemia ataxia hem|hemochromatosis|ferisk ( tm ) is intended to become a standard in the screening , diagnosis and follow-up of hereditary entity patients , as well as others who suffer from iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hereditary develops hfe prevents familial|thalassemia ida cirrhosis thalassaemia rls|hemochromatosis|important safety information contraindication : patients with iron overload syndrome , e . g . entity , should not take auryxia ( ferric citrate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hereditary develops hfe prevents familial|hh hypothyroidism cirrhosis angioedema hypercholesterolemia|hemochromatosis|in addition , hereditary entity and the more severe form , juvenile hemochromatosis , are both inherited disorders of reduced hepcidin production and consequently iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|hereditary develops hfe prevents familial|thalassemia thalassaemia myeloma hyperthyroidism sarcoidosis|hemochromatosis|iron levels can be found in disorders such as cooley  s anemia , sickle cell anemia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|hereditary develops hfe prevents familial|syndromes angioedema anaemia ataxia hemolysis|hemochromatosis|iron overload is also associated with hereditary entity where a genetic defect in a protein involved in iron absorption leads to excess absorption of iron and iron overload
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('DIS', 3), ('OTHER', 3)])|disease|hereditary develops hfe prevents familial|hemophilia hh hypercholesterolemia hypothyroidism hyperhomocysteinemia|hemochromatosis|evaluate the safety and efficacy of ljpc-401 , la jollas proprietary formulation of synthetic human hepcidin , as a treatment for hereditary entity ( hh ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|hereditary ker fatal simplex resembles|hyperbilirubinemia jaundice encephalopathy phototherapy prematurity|kernicterus|in june 2001 , the center for disease control  s morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary ker fatal simplex resembles|rarely you sometimes ever what|kernicterus|the national quality forum has in the past described entity as a “never event , ” one which physicians should ensure never occurs in their practice .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hereditary ker fatal simplex resembles|cirrhosis malignancy hepatotoxicity cholestasis hepatitis|kernicterus|however , phototherapy rapidly becomes less effective following puberty , increasing the risk for entity , resulting in the need for liver transplantation to control the disease .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|hereditary ker fatal simplex resembles|hepatotoxicity rash hypoglycemia hypoglycaemia nephrotoxicity|kernicterus|use : atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary ker fatal simplex resembles|articles journals annually tables thereof|kernicterus|the center for disease controls morbidity and mortality weekly report published four case studies of 7 table of contents entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|hereditary ker fatal simplex resembles|eclampsia epilepsy concussion delirium narcolepsy|kernicterus|entity is a completely preventable condition that often results in permanent neurological damage brought on by the known toxic effects of
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|hereditary ker fatal simplex resembles|hyperbilirubinemia jaundice bilirubin phototherapy prematurity|kernicterus|the center for disease controls report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|hereditary ker fatal simplex resembles|hyperbilirubinemia jaundice encephalopathy phototherapy tetanus|kernicterus|in june 2001 , the center for disease controls morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|hereditary ker fatal simplex resembles|jaundice encephalopathy cirrhosis neuropathy polyneuropathy|kernicterus|bilirubin toxicity can ultimately result in a chronic , severe , and disabling condition called entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hereditary ker fatal simplex resembles|pnd nd nss ns nbd|kernicterus|the total loss of ugt1a1 activity and the resulting severe jaundice and risk of neurological sequelae ( entity ) are associated with cn type 1 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hereditary ker fatal simplex resembles|thrombocytopenia abortion stillbirth prematurity convulsions|kernicterus|its effects on the fetus or newborn include hemolytic anemia , hyperbilrubinemia , entity , or intrauterine deaths due to hydrous fetalis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|hereditary ker fatal simplex resembles|hyperbilirubinemia jaundice bilirubin phototherapy prematurity|kernicterus|the center for disease control  s report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|hereditary ker fatal simplex resembles|spasticity dystonia hemiparesis autism sma|kernicterus|entity is a cerebral palsy-like condition in which the patient lacks muscle tone and motor control , cannot operate self-sufficiently , and typically requires long-term care .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|trophoblast villous scattered undifferentiated nucleated|platelets erythrocytes fibroblasts lymphocytes monocytes|cytotrophoblasts|high complexity probes according to claim 28 wherein said fetal cells are leukocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|axons astrocytes oligodendrocytes demyelination proteases|oligodendrocytes|the pathology of spinal cord injury involves extensive loss of the myelin sheath produced by entity at the site of injury .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes microglia fibroblasts lymphocytes pericytes|oligodendrocytes|was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , astrocytes , microglial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|astrocytes glia oligodendrocytes axons collaterals|oligodendrocytes|occurs in a diffuse fashion throughout the adult brain and appears to reflect a loss of axonal support by local entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes astrocytes microglia oligodendrocyte ols|oligodendrocytes|in our preclinical research , we have shown that hucns-sc cells differentiate into entity , the myelin producing cells , and produce myelin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes opc astrocytes mscs hmscs|oligodendrocytes|mechanism of action underlying the enhanced remyelination in vivo and shown that multistem cells and secreted factors increase differentiation of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|myelin oligodendrocytes axons astrocytes synapses|oligodendrocytes|remyelination remyelination is the process propagating oligodendrocyte precursor cells to form entity to create new myelin sheaths on demyelinated axons in the cns .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|astrocytes interneurons synapses microglia glia|oligodendrocytes|entity are natures neuronal insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes astrocytes dcs myelin microglia|oligodendrocytes|deficient in myelin production , transplantation of hcns-sc into the brain resulted in widespread engraftment of human cells that matured into entity , the myelin producing cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|microglia oligodendrocytes pericytes fibroblasts motoneurons|oligodendrocytes|q-cells produce astrocytes and entity , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|astrocytes interneurons what synapses mscs|oligodendrocytes|entity are natures neural insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|mscs nscs constructs therapeutics scaffolds|oligodendrocytes|japan patent 2011-047716 – entity derived from human embryonic stem cells for remyelination and treatment of spinal cord injury are described .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|axon oligodendrocyte oligodendrocytes myelin sheath|oligodendrocytes|myelin sheath that insulates nerve fibres , or axons , in the central nervous system and the cells that make myelin , the entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|nerves microelectrodes mns pins dbs|oligodendrocytes|like the insulation covering an electrical wire , entity enable the conduction of electrical impulses along nerve fibers throughout the central and peripheral nervous system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|astrocytes oligodendrocytes nscs fibroblasts neurones|oligodendrocytes|$ 4 , 000 tissue culture - culture of primary entity derived from mixed glial cultures .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes progenitors astrocytes glia precursors|oligodendrocytes|financial statements gpc program our gpc program aims to deliver healthy allogeneic gpcs , the precursors to both astroglia and myelin-producing entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|ipscs cardiomyocytes blastocysts embryos colonies|oligodendrocytes|the patent relates to methods of making entity from human embryonic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes astrocytes myelin oligodendrocyte survived|oligodendrocytes microglia neurones fibroblasts pericytes|oligodendrocytes|the resulting differentiated cells ( astrocytes and entity , shown in figure 2 ) then can perform the support functions of these glial cells in vivo as described above .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|surrounded resembled osteoblasts resemble adhered|osteoblasts osteoclasts chondrocytes fibroblasts adipocytes|osteocytes|sclerostin is produced in entity , which are mature bone cells that are thought to be the mechanoreceptor cells that regulate the activity of bone-building osteoblasts
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|surrounded resembled osteoblasts resemble adhered|chondrocytes osteoblasts hepatocytes cardiomyocytes keratinocytes|osteocytes|the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least adipocytes , entity , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|surrounded resembled osteoblasts resemble adhered|osteoclasts chondrocytes fibroblasts adipocytes osteoblasts|osteocytes|merits bone formation involves the migration of undifferentiated mesenchymal cells , differentiation into cartilage , and subsequent bone replacement by osteoblasts and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts osteoclast osteoblast osteoclastogenesis|osteoclasts|in addition , unlike currently marketed ra 1 table of contents drugs , fpa008 directly inhibits bone-destroying cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoclastogenesis resorption osteoclast osteogenesis|osteoclasts|gallium acts upon bone by enhancing the formation of osteoblasts and inhibiting entity , thereby increasing bone deposition and reducing bone turnover .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts osteoclast bisphosphonates osteoclastogenesis|osteoclasts|up to now , bisphosphonates have been most effective in tumors where bone destruction is caused primarily by overstimulation of entity , which abnormally accelerate the breakdown of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts chondrocytes fibroblasts osteoblasts adipocytes|osteoclasts|two main types of cells are responsible for this process : entity , which break down bone tissue , and osteoblasts , which secrete new bone tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts osteoclast osteoblast osteoblastic|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone‑resorbing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts chondrocytes neutrophils bisphosphonates|osteoclasts|entity resorb bone by secreting protons and generating an acidic extracellular microenvironment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts osteoclast osteoblast ocs|osteoclasts|sct is a hormone that inhibits the bone-tissue resorbing activity of specialized bone cells called entity , enabling the bone to retain more of its mass and functionality .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoclast chondrocytes osteoblasts fibroblasts|osteoclasts|bone health is maintained through regulation of the competing activities of bone forming cells ( osteoblasts ) and bone resorbing cells ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|osteoclast secrete activate multinucleated kill|neutrophils monocytes fibroblasts lymphocytes eosinophils|osteoclasts|treatment of ra in which it reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation ( e . g . macrophages , entity , mast cells and b cells ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|osteoclast secrete activate multinucleated kill|truncated fragment secreted murine immature|osteoclasts|( osteopenia ) • ( a ) when bone marrow derived macrophages ( bmdm ) from nomid mice are stimulated with rankl ( rank ligand ) , they differentiate into entity • : 1315-1325 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|osteoclast secrete activate multinucleated kill|elicited recovered incubated yielded harvested|osteoclasts|rankl stimulation macrophages entity nomid bmdm nomid bmdm plus ati-450 ( a ) ( b ) bone marrow derived macrophages ( bmdm ) from nomid mice 19© copyright 2020 aclaris
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts fibroblasts osteoclast osteoclastogenesis|osteoclasts|zoledronic acid is the most potent bisphosphonate , a class of drugs known to inhibit entity , which are key cells involved in the maintenance , repair and remodeling of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts chondrocytes osteoclast osteoblasts fibroblasts|osteoclasts|cells called osteoblasts cause new bone formation while other cells called entity remove old bone through a process called resorption .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts fibroblasts mscs chondrocytes|osteoclasts|axs‑02 is a potent inhibitor of entity , which are bone remodeling cells that break down bone tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts fibroblasts osteoclast osteoblast|osteoclasts|bisphosphonate drugs slow down the rate at which entity , which are cells which resorb or take away bone , reduce the bones mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoclast secrete activate multinucleated kill|bones joints vertebrae lungs osteoblasts|osteoclasts|in people with osteopetrosis , this balance is not maintained because their entity do not function properly .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|osteoclast secrete activate multinucleated kill|osteoclasts osteoblasts osteoclast osteoblast osteoblastic|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone-resorbing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|osteoclast secrete activate multinucleated kill|osteoblasts osteoclasts bones osteoblast osteoclast|osteoclasts|calcitonin , a peptide , inhibits bone resorption by acting on specific receptors on entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|osteoclast secrete activate multinucleated kill|immunoassay indirectly itself simply radioimmunoassay|osteoclasts|ntx serum became the first and only commercially available test in the united states that measures specific bone breakdown by entity using a blood sample .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|osteoclast secrete activate multinucleated kill|neutrophils lymphocytes monocytes granulocytes platelets|osteoclasts|the drug appears to be selectively toxic for activated entity , displaying a negligible effect on bone marrow stromal cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|dcs neutrophils osteoclasts microglia granulocytes|monocytes|csf-1r is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|leukocytes progenitors lymphocytes monocytes fibroblasts|monocytes|this is an exclusive license to a stem cell technology in which adult pluripotent stem cells are derived from entity obtained from the patient  s own blood .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|volunteer leukemia person recipient pbmc|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|neutrophils granulocytes monocytes lymphocytes microglia|monocytes|targets the colony stimulating factor-1 receptor , or csf-1r , a cell surface protein thought to control the survival and function of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|hepatocytes adipocytes fibroblasts precursors islets|monocytes|researchers have been able to turn these dedifferentiated entity into several different types of cells including islet cells , nerve cells , liver cells , blood vessel cells and skin cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|microglia axons astrocytes leukocytes oligodendrocytes|monocytes|in january 2017 , we reported that targeting of mospd2 inhibits chemotaxis of entity and neuropils , and that unpublished vbl data also show mospd2 expression on certain tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|neutrophils monocytes lymphocytes granulocytes dcs|monocytes|fpa008 ( cabiralizumab ) : an investigational antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|neutrophils lymphocytes monocytes dcs phagocytes|monocytes|cells ; and  these proteins secondarily activate other innate immune cells such as natural killer cells and entity , which become able to recognize and kill some tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes microglia monocyte neutrophils eosinophils|monocytes|eascs exhibit broad immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , entity or macrophages and neutrophils .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes pbmcs lymphocytes pbmc neutrophils|monocytes|when applied to human immune cells such as entity , selective immunoproteasome inhibitors , like kzr-616 and onx 0914 , blocked the release of inflammatory cytokines following cell stimulation .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes leukocytes lymphocytes leucocytes mononuclear|monocytes|the companys stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes neutrophils granulocytes basophils fibroblasts|monocytes|patients with various diseases , as well as established cell lines from immune and non-immune cell lineages , including t cell subsets , entity , macrophage subpopulations and cancer cell lines .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|lymphocytes neutrophils monocytes eosinophils granulocytes|monocytes|fcgri is expressed in certain human immune cells including entity , macrophages and dendritic cells and may function to activate these immune cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes leukocytes lymphocytes mononuclear leucocytes|monocytes|our stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes monocyte microglia lymphocytes m1|monocytes|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and entity / macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|volunteer leukemia person recipient pbmc|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes neutrophils granulocytes eosinophils basophils|monocytes|cells with the cd4 receptor are critical components of the immune system and include t lymphocytes , entity , macrophages and dendritic cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|neutrophils monocytes lymphocytes granulocytes dcs|monocytes|developments clinical pipeline : cabiralizumab ( fpa008 ) : an antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes lymphocytes leukocytes mononuclear leucocytes|monocytes|our novel multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|monocytes activate proinflammatory polymorphonuclear neutrophils|monocytes lymphocytes leukocytes mononuclear leucocytes|monocytes|our multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts contain fibroblast besides adhered|eggs carcasses filters foods spores|fibroblasts|the entity are then harvested , tested by quality control and released by quality assurance prior to shipment .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts embryos homogenates heads caps|fibroblasts|of disease causing ability , was accomplished by making over 500 passages of the virus in chicken embryos or chick embryo entity which resulted in large genomic deletions .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts fibroblast homogenates nuclei embryos|fibroblasts|products and reagents like avian cell substrates have rt activity that does not represent adventitious infectious retroviruses ( e . g . chicken embryo entity , dermal cells and eggs ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblast fibroblasts macrophage neovascularization melanocyte|fibroblasts|method of enhancing wound healing by stimulating entity and keratinocyte growth in vivo , utilizing amphipathic peptides .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts lymphocytes keratinocytes megakaryocytes platelets|fibroblasts|the company has produced clonal populations of human entity which have been transfected to express factor viii in vitro , demonstrated that the protein is properly processed and achieved protein
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts melanocytes elastin adipocytes myofibroblasts|fibroblasts|hses are composed of both a dermal layer containing entity and an epidermal layer containing keratinocytes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts keratinocytes lymphocytes hepatocytes melanocytes|fibroblasts|cold selectively inhibits akt activation in human cancer cells compared to normal proliferating cells ( e . g . , human entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts contain fibroblast besides adhered|autologous transplanted exogenous viable multipotent|fibroblasts|used are fat injections and cell injections , which are mainly based on enriching the damaged tissue with external source of entity cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts papillae keratinocytes papilla epithelium|fibroblasts|furthermore , ccl24 is constitutively expressed by skin and dermal entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts chondrocytes lymphocytes leukocytes monocytes|fibroblasts|pierer m , brentano f , rethage j , et al . the tnf superfamily member light contributes to survival and activation of synovial entity in rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts fibroblast myofibroblasts myofibroblast macrophage|fibroblasts|● increase in apoptosis of inflammatory cells , including neutrophil and pro-fibrotic cells , including entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblast melanoma keratinocyte keratinocytes epidermis|fibroblasts|product consisting of a cream vehicle blended with the conditioned media extract from the cell culture of a customers own entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts mscs lymphocytes pbmcs astrocytes|fibroblasts|we isolated and cultured entity from lhon-nd4 patients .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts fibroblast equivalents myofibroblasts keratinocytes|fibroblasts|the rheumatic diseases 72 adenosine a2a receptor activation stimulates collagen production in sclerodermic dermal entity either directly and through a cross-talk with the cannabinoid system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts contain fibroblast besides adhered|respects works laboratories circumstances fibroblasts|fibroblasts|in these entity , we demonstrated that gs010 restores mitochondrial function , including complex i activity and atp production , to the level of normal entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts monocytes neutrophils pericytes lymphocytes|fibroblasts|in ssc patients , increased production of no is suggested by increased expression of inos in endothelial cells , entity , mononuclear cells infiltrating ssc skin and alveolar macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts contain fibroblast besides adhered|keratinocytes fibroblasts melanocytes fibroblast keratinocyte|fibroblasts|much of tkt  s work has focused on gene therapy using entity , a cell type present in the skin ( and throughout the body ) that is readily obtained from patients and propagated in
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts proteoglycans mmps integrins myofibroblasts|fibroblasts|entity are also found in the dermis and are responsible for creating collagen and elastin that provide strength and flexibility to
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts equivalents papilla precursors dermis|fibroblasts|dermagraft dermagraft is a dermal substitute grown from human dermal entity and has received pma approval for the treatment of dfus .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts contain fibroblast besides adhered|fibroblasts lymphocytes cardiomyocytes keratinocytes hepatocytes|fibroblasts|von zglinicki t , saretzki g , docke w , lotze c . mild hyperoxia shortens telomeres and inhibits proliferation of entity : a model for senescence? .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|thymus globulin lymphocytes thymocytes immunoglobulins|thymocytes|description thymoglobulin* [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|thymocytes dcs monocytes lymphocytes apcs|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells , known as t cells , created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|thymocytes dcs lymphocytes monocytes apcs|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|lymphocytes dps pbl ctl thymocytes|thymocytes|implants in the haart and nanoviricide treatment groups exhibited 80-85% cd4+ , cd8+ dp cells while the vehicle control groups had only approximately 30% cd4+cd8+ entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|globulin lymphocytes erythrocytes thymocytes cytomegalovirus|thymocytes|description thymoglobulin® [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|monocytes neutrophils osteoclasts fibroblasts eosinophils|thymocytes|its cognate receptor , pd-1 , is a co-inhibitory transmembrane protein expressed on t cells , b cells , natural killer cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|thymocytes lymphocytes thymus thymocyte hybridomas|parasites microorganisms pathogens viruses microbes|thymocytes|senescos technology allowed for approximately 90% greater survival of these entity in the presence of lps .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|consciousness excitability contractility spermatogenesis respiration|neutrophils|the effect of the drug on the recovery of entity is slow .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils granulocytes platelets erythrocytes monocytes|neutrophils|in preclinical studies , plinabulin increased the survival of entity , a type of white blood cell important in the prevention of bacterial infections .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|lysozyme antimicrobials proteases hypochlorite pathogens|neutrophils|factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species ( ros ) and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils granulocytes leukocytes lymphocytes platelets|neutrophils|neulasta selectively stimulates the production of entity that are depleted by cytotoxic chemotherapy , a condition called neutropenia that makes it more difficult for the body to fight
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|pathophysiology nephritis sera colitis synovium|neutrophils|role of c5a and c5ar in hs entity are believed to play an important disease-promoting role , as well as certain cytokines and mediators commonly found in autoimmune diseases ,
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|anc neutrophils counts lymphocytes platelets|neutrophils|patients treated with omidubicel recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|eosinophils neutrophils lymphocytes leukocytes pmns|neutrophils|in addition , 10150 decreased sm-induced increase in the numbers of bal entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils granulocytes others platelets lymphocytes|neutrophils|immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , monocytes or macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|eosinophils lymphocytes neutrophils basophils monocytes|neutrophils|addition to its expression on b cells , cd32b is also expressed on other immune cells such as dendritic cells , macrophages , entity , and mast cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils kill neutrophil activate|leukocytes granulocytes leucocytes erythrocytes lymphocytes|neutrophils|these cells are programmed to end up as blood cells of a specific type , such as entity , red blood cells and platelets .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|polymorphonuclear neutrophils kill neutrophil activate|nkt nk lak monocytes dendritic|neutrophils|blood versus the lymphoid tissues , you have a preferential depletion of cd4 , cd8 and b cells , much greater than nk , entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|fever platelets neutropenia neutrophils dosage|neutrophils|in addition , the treatment is associated with considerable adverse events like neutropenia ( low entity ) and neuropathy ( damage to the peripheral nervous system ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils leukocytes monocytes eosinophils leucocytes|neutrophils|although these conditions have multiple causes , each involves neutrophil adhesion to the blood vessel wall and the subsequent migration of entity into the tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils kill neutrophil activate|lymphocytes neutrophils leukocytes eosinophils granulocytes|neutrophils|also treated with viprovex , did not develop the clinical symptoms of viral infection , which included increases in alveolar macrophages and entity in broncho-alveolar lavage fluid .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils platelets neutropenia neutrophil granulocytes|neutrophils|the studys primary endpoint was time to neutrophil engraftment , and was met based on recovery of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|anc neutrophils counts lymphocytes platelets|neutrophils|patients treated with nicord recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|mediators hormones mediator adipokines reactants|neutrophils|animal studies to allow manipulation and control of oxidative biomarkers of protein and dna , nitric oxide , antioxidant enzymes and inflammatory entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils eosinophils neutrophil granulocytes lymphocytes|neutrophils|second , pep005 activates the bodys immune system , causing entity , a type of white blood cell , to infiltrate the treated site .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|polymorphonuclear neutrophils kill neutrophil activate|qol mucositis remission hrqol engraftment|neutrophils|companies such as amgen inc . have developed or are developing products to boost entity after chemotherapy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|polymorphonuclear neutrophils kill neutrophil activate|neutrophils leukocytes leucocytes lymphocytes keratinocytes|neutrophils|once in the tissue , entity release toxins which attack normal cells as well as the antigen .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|commitment decisions specification precursors switches|lymphocytes|approximately 80% of all all cases involve lineage entity in the bone marrow .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte subpopulations suppressors lineages|lymphocytes|were generated in the t cell transfer model which utilizes immunodeficient mice which are deficient in functional b and t entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphomas nhl neoplasms immunophenotype|lymphocytes|there are two main categories of entity : b-entity , or b-cells , and t-entity , or t-cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes helper lymphocyte subset itself|lymphocytes|the immune system is composed of a network of immune cells that include t entity ( t cells ) and b entity ( b cells ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes monocytes eosinophils autoantibodies microglia|lymphocytes|the most crucial types of cells are antigen-presenting cells , or apcs , and entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes immunoglobulins neutrophils tregs lymphocyte|lymphocytes|to the occurrence and severity of these adverse events due to its role in inducing lymphopenia , or low levels of entity in the blood , and enhanced car t cell activity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes pbmc monocytes splenocytes pbmcs|lymphocytes|or more diagnostic antigens for detection of tuberculosis infection by measuring g-ifn ( gamma-interferon ) ( or , in field b , other cytokine- ) secreting entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes leukocytes pathogens gvhd neutrophils|lymphocytes|allogeneic bone marrow transplant in which tissues of the host , most frequently the gut , liver , and skin , are attacked by entity in the donor ( graft ) marrow .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes erythrocytes leukocytes granulocytes neutrophils|lymphocytes|abnormally large numbers of immature , abnormal entity called lymphoblasts are produced and released into the bloodstream .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte effectors leukocytes blasts|lymphocytes|as shown below , following gp2 immunotherapy , cd8+ cytotoxic t entity recognize and destroy her2 / neu-expressing cancer cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte leukocytes helper leucocytes|lymphocytes|lymphokine any of a number of soluble physiologically active factors produced by t entity in response to specific antigens .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes neutrophils phagocytes leukocytes pathogens|lymphocytes|ceplene is designed to protect entity responsible for immune-mediated destruction of residual leukemic cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphomas lymphocyte blasts progenitors|lymphocytes|white blood cells that have differentiated to produce a specific antibody are called b entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|dcs apcs lymphocytes monocytes phagocytes|lymphocytes|the type of immune response is characterized by the way the response was initiated through specialized cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte leukocytes leukocyte leucocytes|lymphocytes|as predefined in the clinical protocol , patient subgroups were evaluated for levels of tumor infiltrating entity ( til ) and for pd-l1 checkpoint protein expression on tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|clones lymphocytes ctl sera mabs|lymphocytes|consequently , in each persons bloodstream , only a relatively few entity will recognize the same antigen .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes leukocytes leucocytes monocytes lymphocyte|lymphocytes|til means tumor infiltrating entity that are collected from a tumor cell , including naturally-occurring t cells with specificity against such tumor .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes apcs leukocytes effectors phagocytes|lymphocytes|itk , an enzyme that functions in t‑cell signaling and differentiation , is expressed predominantly in t‑cells , which are entity that play a vital role in immune responses .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte leukocytes leukocyte leucocytes|lymphocytes|) – lion biotechnologies , inc . ( otcqb : lbio ) , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating entity ( til )
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|lymphocytes lymphocyte polymorphonuclear circulating cd8|lymphocytes lymphocyte precursors blasts subpopulations|lymphocytes|although the exact mechanism of action for alemtuzumab is unknown , it is presumed to deplete circulating t and b entity after each treatment course .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1), ('BIO', 1)])|cell|platelets kill aggregate concentrates aggregates|vwf fviii thrombin fibrinogen platelets|platelets|genetically linked by an amino acid linker , targeting the a1 domain of vwf and inhibiting the interaction between ulvwf and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|cell|platelets kill aggregate concentrates aggregates|platelets leukocytes viruses autoantibodies fibrin|platelets|the ellipse in the upper left- hand corner contains the phrase " virally inactivated red blood cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|cell|platelets kill aggregate concentrates aggregates|fibrinogen platelets erythrocytes fibronectin rbcs|platelets|against acutect® because fibrimage® binds to fibrin , which comprises 75-80% of an actively forming blood clot , whereas acutect® binds to entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|cell|platelets kill aggregate concentrates aggregates|platelets fibrinogen immunoglobulins erythrocytes prostaglandins|platelets|blood and immune systems , including : t cells and b cells to fight infections ; red blood cells to carry oxygen and entity to control bleeding .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|platelets kill aggregate concentrates aggregates|platelets immunoglobulins eosinophils lymphocytes ige|platelets|immune thrombocytopenia ( itp ) - itp is an uncommon autoimmune bleeding disorder characterized by insufficient entity in the blood .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|platelets kill aggregate concentrates aggregates|platelets macromolecules erythrocytes leukocytes neutrophils|platelets|these agents work by preventing the ability of entity to aggregate together .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1), ('BIO', 1)])|cell|platelets kill aggregate concentrates aggregates|sugar sugars counts lipids platelets|platelets|we have contributed novel research and technologies for approved medicines that treat cancer , osteoporosis , fungal infections and low blood entity , among others .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|platelets kill aggregate concentrates aggregates|platelets reticulocyte megakaryocytes granulocytes neutrophils|platelets|are overproduced in the bone marrow affecting the synthesis of normal blood cells , causing a decrease in red blood cells , entity and normal white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|platelets kill aggregate concentrates aggregates|platelets leukocytes organelles agonists substrates|platelets|glutamate release by a platelet acts to stimulate release of glutamate from other entity , potentially leading to aggregation and the formation of the thrombus .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|platelets kill aggregate concentrates aggregates|platelets concentrates erythrocytes immunoglobulins minerals|platelets|banks or transfusion centers because the main objective of these banks and centers is to obtain the blood cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|platelets kill aggregate concentrates aggregates|astrocytes microglia neurones glia oligodendrocytes|platelets|released glutamate acts by binding cell surface glutamate receptors expressed on entity themselves .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|platelets kill aggregate concentrates aggregates|platelets fviii fibrinogen vwf proteases|platelets|the affected individuals make antibodies against their own entity leading to the entity  destruction , which in turn leads to the abnormal bleeding .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|platelets kill aggregate concentrates aggregates|cardiomyocytes pah endothelium vasodilation atherogenesis|platelets|the effects of integrilin are specific to entity , avoiding interference with other normal cardiovascular processes .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|platelets kill aggregate concentrates aggregates|platelets megakaryocytes monocytes lymphocytes eosinophils|platelets|in many hematological disorders , there is abnormal proliferation and differentiation of the progenitor cells for red blood cells , entity and neutrophils .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|platelets kill aggregate concentrates aggregates|sugar counts platelets viscosity volumes|platelets|in addition to anemia , fatigue , hair-loss , reduction in blood entity and white and red blood cells , and bone pain , one of the most common side effects of chemotherapy is nausea
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|platelets kill aggregate concentrates aggregates|platelets neutrophils erythrocytes rbcs monocytes|platelets|our laboratory personnel had previously developed a pre-clinical itp model with data showing that prtx-100 inhibits the phagocytosis ( ingestion ) of entity in vitro .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|platelets kill aggregate concentrates aggregates|platelets erythrocytes neutrophils leukocytes megakaryocytes|platelets|integrilin is a small synthetic peptide administered by injection that prevents the aggregation of entity by blocking the platelet receptor glycoprotein , or gp , iib-iiia .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|platelets kill aggregate concentrates aggregates|platelets astrocytes neutrophils microglia megakaryocytes|platelets|a2 ( blocked by aspirin ) and adenosine diphosphate ( blocked by plavix® ) , researchers have recently demonstrated the release of glutamate by entity during platelet activation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|platelets kill aggregate concentrates aggregates|platelets leukocytes erythrocytes leucocytes granulocytes|platelets|plasma donation means that donors give only plasma but not the other blood components such as entity , red cells and infection-fighting white cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cell|platelets kill aggregate concentrates aggregates|coagulation thrombin osteoclastogenesis mmps telomerase|platelets|training he performed basic research at the royal prince of wales hospital to develop a new monoclonal antibody to inhibit entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2), ('DIS', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|fibronectin integrins leukocytes platelets laminin|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd‑peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|healthcare medicines pharmaceuticals biologics antimicrobials|leukocytes|the costs and availability of entity are subject to fluctuation depending on a variety of factors beyond our control , including competitive factors , changes in technology , and
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|beings hybridomas lymphocytes hosts sera|leukocytes|human entity produce millions of different types of antibodies , all with varying shapes that allow them to attach to and , as a
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2), ('DIS', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|fibronectin integrins leukocytes platelets laminin|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd-peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|leukocytes lymphocytes leucocytes granulocytes monocytes|leukocytes|manufacture of interferon human white blood cells , also known as entity , and a stimulating agent are needed to produce human leukocyte derived interferon .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|precision equipment instruments quantities functionality|leukocytes|if we are unable to obtain the necessary entity , we may be required to scale back our operations or stop manufacturing multiferon® .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|wbc rbcs hscs pbmcs pmns|leukocytes|in inflammation , white blood cells ( entity ) move out of the bloodstream into the inflamed tissue , for example , the cns in ms , and the lung airways in
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|substituent phosphoryl sugar substitution hydroxyl|leukocytes|comprising phosphosugar residues , that play a central role in the entry of is , sugar residues bearing at least one entity into inflammatory sites .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|platelets leukocytes neutrophils integrins fibroblasts|leukocytes|the next stage of development of integrins as drug targets has focused on integrin receptors on entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|saliva faeces seeds sweat foods|leukocytes|edinburgh , scotland , and has the physical and , with the company  s proprietary technology , the technical capacity to manufacture omniferon ( tm ) from human entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|neutrophils leukocytes lymphocytes eosinophils leucocytes|leukocytes|in addition , the bronchoalveolar lavage of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|leukocytes microorganisms leucocytes platelets pathogens|leukocytes|revenue was derived from the commercial sales of its leukonet system , a medical device designed for the removal of contaminating entity from donated blood .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|neutrophils leukocytes lymphocytes eosinophils leucocytes|leukocytes|in addition , the bronchoalveolar lavage ( bal ) of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|lymphocytes leukocytes leucocytes neutrophils eosinophils|leukocytes|chemokines are cytokines which regulate the trafficking patterns of entity , the effector cells of the human immune system .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|granulocytes monocytes leukocytes lymphocytes neutrophils|leukocytes|antibodies are made in the immune system by human white blood cells , called entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|donations donated drawn banks pools|leukocytes|by the first quarter 2007 , we anticipate preparing new alferon n injection ( r ) lots from blood entity at our new jersey facility .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|constituents contaminants stains pigments parasites|leukocytes|typically by extraction with vegetable oil and hydrophobic chromatography , and sterile filtering to remove bacteria , parasites and all undesirable blood entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|monocytes platelets lymphocytes erythrocytes neutrophils|leukocytes|monocytes phagocytic blood entity , originating from the bone marrow .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|leukocytes leucocytes neutrophils phagocytes granulocytes|leukocytes|addition of sialyl lewis x ( " slex " ) carbohydrate side chains yielding scr1sle x . slex is a carbohydrate which mediates binding of entity including neutrophils to selectin proteins .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2), ('BIO', 1)])|cell|polymorphonuclear neutrophils leukocytes circulating lymphocytes|bilirubin crp wbc creatinine leukocyte|leukocytes|risk of poorer clinical outcomes as measured by atlas score , a tool for evaluating cdi in patients by age , temperature , entity and albumin levels , and use of systemic antibiotics .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|monocytes malignancies cancers neoplasms carcinomas|macrophages|abx-cbl the cbl antigen is selectively over-expressed on activated immune cells including t-cells , b-cells and certain entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|platelets monocytes microglia neutrophils leukocytes|macrophages|activated entity release a variety of mediators of inflammation that contribute to a broad range of diseases , such as rheumatoid arthritis , osteoarthritis ,
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|hmgb1 autophagy perforin phagocytosis survivin|macrophages|the targeting of cd47 to make cancer cells susceptible to entity , a component of the innate immune system , is analogous to the approach that has been applied with checkpoint inhibitors and
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|neutrophils monocytes platelets leukocytes lymphocytes|macrophages|beyond cancer , we have discovered that activated entity , a type of white blood cell found at sites of acute and chronic inflammation , also over-express the folate receptor .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|phagocytic activate macrophage monocytes phagocytosis|granulocytes lymphocytes neutrophils platelets eosinophils|macrophages|this is carried out primarily by some specialized cells in the blood ( e . g . , monocytes and entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|lymphocytes phagocytes neutrophils monocytes platelets|macrophages|these compounds , intended for use as immuno- pharmaceutical agents , activate entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 3)])|cell|phagocytic activate macrophage monocytes phagocytosis|macrophage basophils dcs lymphocytes eosinophils|macrophages|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and monocytes / entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|myeloid m1 dendritic macrophage monocytes|macrophages|in patients with cancer , immuno-evasion occurs as a result of suppressor entity ( m2 ) and inhibitory myeloid suppressive cells and treg cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|phagocytic activate macrophage monocytes phagocytosis|lymphocytes neutrophils monocytes leukocytes leucocytes|macrophages|entity are cells found in the blood which recognize and destroy malignant cells and invading microbes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|platelets lymphocytes microglia monocytes neutrophils|macrophages|the mt-2000 series is designed to modulate activated entity from a classically activated phenotype to the alternatively activated phenotype .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|phagocytic activate macrophage monocytes phagocytosis|fibroblasts melanocytes lymphocytes keratinocytes adipocytes|macrophages|recent experiments have shown that complex polynucleotides administered topically are absorbed by cells such as keratinocytes and entity within the superficial skin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|lymphocytes hscs leukocytes neutrophils monocytes|macrophages|the mt-1000 series is designed to deplete activated entity via apoptosis and / or alter the phenotype of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|dcs ctls monocytes neutrophils lymphocytes|macrophages|expressed by tumor cells and have been modified to more efficiently attract immune effector cells , such as nk cells and entity , to effectively kill tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|phagocytic activate macrophage monocytes phagocytosis|lymphocytes eosinophils basophils platelets granulocytes|macrophages|phagocytes are a class of white blood cells , which include monocytes , entity and neutrophils , found in abundant quantities in and around tumors and areas of infection .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|phagocytic activate macrophage monocytes phagocytosis|neutrophils lymphocytes granulocytes dcs platelets|macrophages|we believe that by inhibiting csf-1r activation on monocytes and entity , that axatilimab has the potential to be used to treat cgvhd .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|fibroblasts hepatocytes erythrocytes islets adipocytes|macrophages|entity affected by the disease become highly enlarged due to the accumulation of glccer and are referred to as “gaucher cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|accumulate fibroblasts resident apcs monocytes|macrophages|our anti-mirs promotes reverse cholesterol transport , or rct , which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells called entity in atherosclerotic plaques .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|phagocytic activate macrophage monocytes phagocytosis|granulocytes neutrophils monocytes lymphocytes basophils|macrophages|absence of an active gcd enzyme leads to the accumulation of glccer in lysosomes of certain white blood cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|lymphocytes monocytes fibroblasts macrophage thymocytes|macrophages|the surface of almost all nucleated cells , and mhc class ii , expressed constitutively on professional antigen presenting cells ( apc ) , including entity and dendritic cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|phagocytic activate macrophage monocytes phagocytosis|dcs monocytes ctls lymphocytes ctl|macrophages|growth factor receptors known as her2 and her3 , as well as recruit immune killer cells , such as nk cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|proliferating immature neoplastic circulating resting|plasmablasts|promising approach for the treatment of rrmm patients due to the restriction of bcmas expression solely on the surface of entity and differentiated plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|pbmcs ascs tonsils meps ctcs|plasmablasts|entity are highly enriched for vaccine-specific b cells and , therefore , negligible in pre-vaccination , day 0 samples .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|dendritic b1 lymphocytes follicular follicles|plasmablasts|disease , and other conditions such as kidney transplant , are associated with autoantibodies secreted by a subset of b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|lymphocytes lymphomas clones follicles hybridomas|plasmablasts|cd19 is a cell surface molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|repertoire transcripts homing subset subtypes|plasmablasts|we presented data from the study demonstrating that our vaccine elicited a significant expansion of mucosal homing receptor entity to approximately 60% of all activated b cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|transcripts contaminants analytes impurities mrnas|plasmablasts|if entity are elevated in a particular sample , we then employ a multi-step process to generate a potential product candidate .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|dendritic lymphocytes b1 follicular follicles|plasmablasts|other conditions such as kidney transplant desensitization , are associated with autoantibodies secreted by a subset of immune b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|dendritic lymphocytes b1 follicles follicular|plasmablasts|in the autoantibody pathway , autoantibodies are secreted by a subset of immune system b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|epitopes titers autoantibodies lymphocytes signatures|plasmablasts|we believe these mucosal entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|lymphocytes hybridomas monocytes precursors progenitors|plasmablasts|in in vitro studies using human immune cells , cpi-006 led to activation of b cells and differentiation into antibody producing entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|lymphocytes lymphomas clones hybridomas follicles|plasmablasts|cd19 is a molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|neutrophils lymphocytes oligodendrocytes astrocytes granulocytes|plasmablasts|mechanism of action a number of autoimmune diseases , including nmosd , are associated with autoantibodies secreted by entity and some plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|neutrophils ascs dcs eosinophils chemokines|plasmablasts|we believe entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|monocytes lymphocytes pbmc pbmcs dcs|plasmablasts|pbmcs were collected at day 0 and day 7 , enriched for entity and analyzed in elisas against either the prefusion or the postfusion version of the f protein antigen .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|ascs abs nab autoantibodies baff|plasmablasts|for those patients , we then examine their samples for rare antibody-producing b cells called entity that are elevated during an active immune response .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|erythroid monocytes hematopoietic lymphocytes precursors|clones hybridomas lymphocytes colonies transcripts|plasmablasts|we start by isolating single entity and determining the sequences of the co-expressed antibody genes using our proprietary immune repertoire capture® technology .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cell|pericytes endothelium capillaries circulating besides|monocytes pericytes lymphocytes adipocytes chondrocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|pericytes fibroblasts astrocytes leukocytes myofibroblasts|pericytes|in wet amd abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|pericytes endothelium capillaries circulating besides|platelets pericytes astrocytes fibroblasts capillaries|pericytes|entity then intimately cover the outside of these blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|pericytes fibroblasts endothelium myofibroblasts elastin|pericytes|these normal , blood vessel endothelial cells have matured , and have much greater supporting structures such as entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|pericytes endothelium capillaries circulating besides|pericytes astrocytes epcs platelets fibroblasts|pericytes|entity locally supply the endothelial cells with growth and survival factors , including vegf , and play a major role in endothelial cell survival .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|ecs pericytes epcs avms ctcs|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for anti-endoglin antibodies
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|pericytes endothelium capillaries circulating besides|capillaries fibroblasts vessels filters platelets|pericytes|after the entity are stripped from the new blood vessels , endothelial cells located inside the newly formed blood vessels are left unprotected and
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|pericytes endothelium capillaries circulating besides|fibroblasts vsmcs myocytes keratinocytes myoblasts|pericytes|the binding of pdgf provides an important cell survival signal to entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes endothelium capillaries circulating besides|photoreceptors rgcs rpe rgc pericytes|pericytes|function of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|pericytes endothelium capillaries circulating besides|pericytes platelets mscs astrocytes epcs|pericytes|entity also physically support and stabilize the abnormal new blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes endothelium capillaries circulating besides|rgcs epcs pericytes nscs rgc|pericytes|of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal -21- cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes endothelium capillaries circulating besides|vegfr2 ctcs her2 pericytes hif|pericytes|this increased resistance to vegf inhibitors is thought to be related to the presence of entity as a result of cancers up-regulating other angiogenesis pathways including those involving pdgfrβ .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|pericytes fibroblasts leukocytes monocytes myofibroblasts|pericytes|( va ) from baseline over time abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|pericytes epcs monocytes ecs leukocytes|pericytes|pdgfrβ signaling is responsible for recruiting cells called entity which play a key role in the development and stabilization of blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|pericytes monocytes platelets leukocytes smcs|pericytes|pdgf also recruits entity to the abnormal new blood vessel , where they mature and cover the endothelial cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|pericytes endothelium capillaries circulating besides|ecs avms epcs pericytes meningiomas|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for endoglin 13
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes endothelium capillaries circulating besides|capillaries vessels fibroblasts sutures filters|pericytes|after the entity are stripped from the new blood vessels , endothelial cells lining the inside of the newly formed blood vessels are left
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|pericytes endothelium capillaries circulating besides|monocytes pericytes lymphocytes adipocytes cardiomyocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|pericytes endothelium capillaries circulating besides|pericytes fibroblasts ecs astrocytes epcs|pericytes|in addition , the impact of vegf inhibitors may be limited by the activity of entity , which are the cells that cover the outside of blood vessels and support and stabilize newly formed vessels .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|colonies monocytes lymphocytes platelets progenitors|granulocytes|the enzyme tyrosine kinase in the bone marrow , which causes too many stem cells to develop into white blood cells ( entity or blasts ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|cardiomyocytes granulocytes monocytes hscs platelets|granulocytes| enables aml blast cells to differentiate into entity and may be applicable in a broad range of aml patients .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|neutrophils granulocytes lymphocytes leukocytes platelets|granulocytes|oncology biosimilar udenyca™ stimulates production of entity ( a type of white blood cell ) in order to promote the bodys ability to fight infections .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|erythrocytes sweat saliva platelets sera|granulocytes|for up to two years after treatment , as well as preliminary efficacy as measured by changes in cystine levels in entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|basophils neutrophils eosinophils lymphocytes granulocytes|granulocytes|of naive and activated immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , entity , mast cells and monocytes / macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|granulocytes neutrophils monocytes granulocyte lymphocytes|granulocytes|responses detected in treated pts  klh carrier as immune stimulant  gm-csf stimulates entity and macrophages antigen binding site = idiotype ( id ) biovaxld : id-klh + gm-csf  first in a
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|granulocytes neutrophils monocytes progenitors leukocytes|granulocytes|in apl , there is an abnormal accumulation of immature entity called promyelocytes .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|leukocytes leucocytes fibrin monocytes erythrocytes|granulocytes|soluble fibrin and formed elements in the blood , maintains the deformability of red blood cells , non-adhesiveness of unactiviated platelets and entity and the normal viscosity of blood .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|neutrophils lymphocytes dcs monocytes granulocytes|granulocytes|immune cells recruited by the antibody to kill the cancer include entity , macrophages and nk cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|leukocytes granulocytes leucocytes lymphocytes neutrophils|granulocytes|cml is a clonal bone marrow stem cell disorder in which proliferation of mature entity ( neutrophils , eosinophils , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 2), ('DIS', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|zinc neutrophils endotoxin clarithromycin leukocytes|granulocytes|in an animal model of infection , the antibacterial activity of sivextro was reduced in the absence of entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|neutrophils granulocytes eosinophils platelets basophil|granulocytes|mg / kg alx377 in mouse models and measured red blood cell , or rbc , platelet and white blood cell ( lymphocyte , monocytes and entity ) counts .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|granulocytes neutrophils monocytes lymphocytes fibroblasts|granulocytes|gm-csf stimulates the growth and differentiation of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|neutrophils lymphocytes granulocytes eosinophils basophils|granulocytes|however , cll-1 is also expressed on normal hematopoietic cells such as entity and monocytes .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|apl cardiomyocytes cscs granulocytes colonies|granulocytes|aslan003 has demonstrated the ability to differentiate aml blast cells into entity in a variety of aml cell lines that do not respond to atra .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|granulocytes neutrophils lymphocytes eosinophils monocytes|granulocytes|evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , metamyelocytes and entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|leukocytes granulocytes aggregates colonies phagocytes|granulocytes|in aml , blast cells are unable to differentiate and form entity , such as neutrophils and eosinophils , causing depletion of white blood cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|neutrophils monocytes basophils granulocytes lymphocytes|granulocytes|lymphocytes : the white blood cells ( leukocytes ) that include the b cells and t cells , but not the others ( such as entity and eosinophils ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|osteoclasts granulocytes basophils neutrophils osteoblasts|granulocytes|the lead compound , lg7455 , activates the gcsf-gcsfr signaling pathway and induces the differentiation of human bone marrow cells into entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|polymorphonuclear granulocytes granulocyte neutrophils neutrophil|erythroid lymphoid monocytic myeloid lymphocytes|granulocytes|clone 818-18 produces a murine igg1 monoclonal antibody which recognizes a nuclear antigen expressed in human entity and myeloid precursors and acute and chronic myeloid leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils neutrophils basophils lymphocytes th17|eosinophils|it has also been shown to impact some diseases , such as asthma , that are driven by entity , another important class of immune cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|basophils eosinophils neutrophils mcs lymphocytes|eosinophils|despite the knowledge that entity and mast cells drive many pathological conditions , there are no approved therapies that selectively target both entity and mast cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3), ('DRUG', 1)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|basophils eosinophils neutrophils lymphocytes histamine|eosinophils|believes that it is helpful to provide investors with an overview of the types of diseases that are affected by entity and / or mast cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|basophils neutrophils eosinophils lymphocytes monocytes|eosinophils|ak002 binds to siglec-8 , an inhibitory receptor found on entity and mast cells , which represents a novel way to selectively deplete or inhibit these important immune cells and thereby resolve
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils lymphocytes neutrophils leukocytes leucocytes|eosinophils|eg is a rare disease that is characterized by chronic inflammation due to patchy or diffuse infiltration of entity into layers of the stomach .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils monocytes lymphocytes platelets megakaryocytes|eosinophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , entity , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|neutrophils microglia astrocytes eosinophils monocytes|eosinophils|in ad , entity are important effector cells that promote inflammation and tissue damage .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils neutrophils keratinocytes fibroblasts monocytes|eosinophils|eotaxin-1 is expressed on type 2 t helper ( “th2” ) cells and entity in bp lesions and an increasing body of data documents the role of these cells in both the innate and
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|stained counted phagocyt infiltrating infiltrated|eosinophils|** ** prs-060 48-hr 1 1006 ** * 0 total macrophages entity lymphocytes 48hr timepoint anticaln control *p 34 . 5 µm 60?
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|platelets neutrophils erythrocytes lymphocytes eosinophils|eosinophils|entity are a type of white blood cell .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils neutrophils monocytes lymphocytes leukocytes|eosinophils|bertilimumab may prevent eotaxin-1-induced chemotaxis of entity and neutralize eotaxin-1 in the circulation , preventing eosinophil migration .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|suspicion cardiotoxicity comorbidity ctd troponin|eosinophils|cardiac screening should be considered in patients with hes / cel , and patients with mds / mpd with high level of entity ( echocardiogram , serum troponin level ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils neutrophils leukocytes lymphocytes eosinophil|eosinophils|background on eoe and current treatments eoe results from a dysregulation of th2-mediated immunity that drives recruitment of entity to the esophagus .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|nk monocytes neutrophils lymphocytes myeloid|eosinophils|provided data on the mechanism of anticancer activity for il-17e , showing that il-17e activated the immune system , specifically acting on entity and b cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|monocytes eosinophils lymphocytes platelets basophils|eosinophils|in aml , blast cells are unable to differentiate and form granulocytes , such as neutrophils and entity , causing depletion of white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|basophils eosinophils neutrophils monocytes keratinocytes|eosinophils|importantly , and in contrast to other agents , hgen005 appears to have an effect solely on entity , without impacting other populations , such as mast cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|chemistry analytes collection biochemistry cotinine|eosinophils|outcomes associated with asthma symptoms , as measured using the asthma control questionnaire 5 and biomarker levels as measured using blood entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils leukocytes lymphocytes neutrophils basophils|eosinophils|eotaxin  a protein that attracts entity into tissues , where they degranulate and cause tissue damage .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|lymphocytes eosinophils monocytes neutrophils dcs|eosinophils|in addition to the effects on neutrophils and cytokines , a trend towards reduction in other immune cells in sputum , namely entity and macrophages , was also observed .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|eosinophils eosinophil eosinophilic degranulation neutrophils|eosinophils leukocytes lymphocytes neutrophils basophils|eosinophils|wo 97 / 00960 also discloses methods of use of the eotaxin proteins in the recruitment of entity to a particular site or in the treatment of allergic conditions .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|toxins vaccines viruses plasmids pathogens|erythrocytes|we are aware of an issued patent outside the united states that is directed to entity that comprise exogeneous polypeptides .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes granulocytes platelets megakaryocytes osteoblasts|erythrocytes|shown that our imids ( r ) can interact with stem cells and modulate them in such a way that they differentiate into entity , or red blood cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|oocytes erythrocytes spermatozoa lymphocytes hepatocytes|erythrocytes|dna , genes , and transcription factors dna is present in all cells , except mature entity , and encodes the inherited characteristics of all living organisms .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|beyond lethal whose regardless requiring|erythrocytes|ra101495 protects against complement-mediated hemolysis of type dose response iii pnh entity drug concentration no drug ra101495
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes precursors crystals pigments granules|erythrocytes|bilirubin entity ( red blood cells ) circulating in the blood stream have a life expectancy of 120 days .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|platelets monocytes erythrocytes lymphocytes granulocytes|erythrocytes|these cells have a limited life span ; neutrophils live a few hours and entity or red blood cells survive for a few weeks .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes monocytes granulocytes neutrophils eosinophils|erythrocytes|with an increased likelihood of sle . test method description results were obtained using flow cytometry for complement c4d fragment bound to entity ( ec4d ) and b-lymphocytes ( bc4d ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes platelets rbcs granulocytes neutrophils|erythrocytes|and inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ; red cells that carry oxygen through our bodies ( entity ) ; and platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|capillaries pores erythrocytes vessels filters|erythrocytes|the entity are then separated from the other blood compounds and opened by osmotic hemolysis , thus releasing the hemoglobin molecules .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|hepatocytes kidneys lungs intestine cardiomyocytes|erythrocytes|drugs like ribavirin to infected liver cells while reducing the amount of drug going to other cells and tissues , including entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|rbcs neutrophils endothelium erythrocytes capillaries|erythrocytes|up to 20 percent of the eculizumab-treated population , is most commonly attributable to extravascular hemolysis driven by intense c3 deposition on entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes platelets rbcs granulocytes neutrophils|erythrocytes|inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes rbcs predominantly nuclei lymphocytes|erythrocytes|the nine month post-infusion data point , with total hemoglobin levels of 11 . 9 g / dl , 10 . 1 g / dl fetal hemoglobin and 99 . 8 percent f-cells ( entity expressing fetal hemoglobin ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|monocytes fibroblasts platelets neutrophils hepatocytes|erythrocytes|( hsa ) , a glycoprotein expressed on the surface of many human cell types , including immature human hematopoietic cells , peripheral blood lymphocytes , entity , and many human carcinomas .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes hepatocytes parasites lymphocytes monocytes|erythrocytes|strong cell mediated immunity ( e . g . th1 biased cd4+ ad cd8+ ) to reduce parasitemia by clearing infected cells ( liver cells or entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|peroxidase ceruloplasmin catalase bilirubin h2o2|erythrocytes|blood : this test is based on the pseudo peroxidase action of hemoglobin and entity which catalyzes the reaction of 3 , 3 , 5 , 5-tetramethyl-benzidine and buffered organic peroxide .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|you she vessels others lungs|erythrocytes|it provides vital oxygen supplies to places in the human body entity cannot reach for instance due to arterial sclerosis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes platelets rbcs granulocytes megakaryocytes|erythrocytes|( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes erythrocyte bloodstream platelets alternate|erythrocytes|for example , the deposition of the c4d fragment to entity forms erythrocyte c4d , or ec4d .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|erythrocytes erythrocyte pigment platelets glycosylated|erythrocytes rbcs transferrin neutrophils platelets|erythrocytes|unlike cd47-blocking antibodies , tti-622 bound minimally to human entity and did not induce hemagglutination in vitro .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes zone hepatocyte parenchyma zones|hepatocytes|target of 10% enzyme replacement at all doses in otc-deficient mouse model lunar-otc treatment increases otc expression in mouse periportal entity ( main site of ureagenesis )
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes fibroblasts keratinocytes chondrocytes osteoblasts|hepatocytes|in the companys preclinical studies , transduction of primary human entity with aavs3 pseudotyped vectors was significantly higher as compared with the other vectors listed above .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepg2 contain hepatocyte transfected|utero mammals tandem itself silico|hepatocytes|our initial focus is on monogenic diseases with clear biology linking the missing activity of a gene in entity to a disease outcome .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes microsomes fibroblasts lysosomes lymphocytes|hepatocytes|the polymer is targeted to the asialoglycoprotein receptor on liver entity by the inclusion of a galnac moiety to one end of the polymer .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes hepg2 contain hepatocyte transfected|mscs hepatocytes fibroblasts keratinocytes hscs|hepatocytes|improvements in the function of our immortalized entity will open more markets and expand the usage in the current markets for our cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|neonates hepatocytes mammals livestock rabbits|hepatocytes|mrt5201 , is designed to address the underlying cause of otc deficiency by delivering mrna encoding fully functional otc enzyme to entity through intravenous administration .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|livers hepatocytes parenchyma epithelia endothelium|hepatocytes|have shown that the rap receptor , lrp1 , is well expressed on human hcc and under-expressed on non-cancerous , but otherwise diseased , entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocytes hepg2 contain hepatocyte transfected|fibroblasts explants microsomes slices hepatocytes|hepatocytes|we recently demonstrated that liver entity show a rapid , primary nf-kb activation response following in vivo administration of cblb502 in mice and nhps .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes transporters livers substrates mitochondria|hepatocytes|however , combining multiple interventions , particularly multiple small molecules , places an additional burden of drug metabolism and clearance upon already stressed entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes hepatocyte fibroblasts hsc fibroblast|hepatocytes|these cells have been shown to retain many key synthetic and metabolic processes of normal human entity , the primary functional cell of the liver .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepg2 contain hepatocyte transfected|microsomes homogenates cytosol homogenate slices|hepatocytes|pmx-30063 has been tested for stability in the presence of mouse and human liver entity to investigate the extent to which liver metabolism could be a factor upon compound administration .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|microsomes homogenate homogenates cytosol esterase|hepatocytes|pmx-30063 demonstrated high stability in the presence of liver entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes livers pixels voxels nuclei|hepatocytes|percentage of entity showing steatosis , or fatty change , mean ± sd ( n ) 54 . 8 ± 21 . 2 49 . 9 ± 24 . 3
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|spermatogenesis reproduction respiration steroidogenesis cognition|hepatocytes|it has been previously demonstrated that impairment of entity by ethanol is associated with the production of free radical and oxidative stress .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes hepg2 contain hepatocyte transfected|keratinocytes mscs ipscs hepatocytes fibroblasts|hepatocytes|these efforts have been towards improving the functionality of our immortalized entity , introducing products utilizing these cells and expanding our intellectual property base .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes fibroblasts mscs microenvironment hscs|hepatocytes|our liversafe 3d™bioassay system uses our stem cell-derived entity , or liver cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 2)])|cell|hepatocytes hepg2 contain hepatocyte transfected|oocytes testis mitochondria intestine astrocytes|hepatocytes|for example , the asg receptor exists primarily in entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes peroxisomes aggregates intracellularly lysosomes|hepatocytes|patient has a mutation in both copies of the serpina1 gene , which causes aat to aggregate inside liver cells , or entity , rather than being secreted from the liver .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes adipocytes erythrocytes lymphocytes platelets|hepatocytes|entity are the most biochemically complex cells in the human body and play an important role in the synthesis and metabolism
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|hepatocytes hepg2 contain hepatocyte transfected|hepatocytes fibroblasts hsc hepatocyte peroxisomes|hepatocytes|apoptosis of entity manifests as ballooning of the cells , a characteristic microscopic feature of nash liver tissue .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|platelets megakaryocytes microparticles progenitors mcs|megakaryocytes|lx-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|platelets megakaryocytes cardiomyocytes hscs hepatocytes|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hescs or ipscs as the starting materials .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|hscs granulocytes progeny eosinophils progenitors|megakaryocytes|in addition , bet proteins promote the generation of entity from hematopoietic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|platelets megakaryocytes cardiomyocytes hscs hescs|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hes or ips cells as the starting materials .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes platelets hscs eosinophils monocytes|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelet counts .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|megakaryocytes platelets megakary erythroid circulating|neutrophils monocytes eosinophils lymphocytes granulocytes|megakaryocytes|we believe that the blood cells most responsible for bone marrow scarring in mf are dysfunctional entity , which produce inflammatory molecules in part through elevated nf-kb signaling .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|progenitors platelets megakaryocytes granulocytes hscs|megakaryocytes|the angiopoietins are in preclinical studies for their abilities to promote growth and mobilization of hemopoietic stem cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|leukemia hypermethylation carcinogenesis demethylation cytogenetics|megakaryocytes|an editorial entitled , myelodysplasia , entity , and methylation was also published in the same issue of leukemia research ( steensma , leuk .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes platelets monocytes endothelium fibroblasts|megakaryocytes|precursors of the red blood cells or of the granulocytes and macrophages , which are also of the immune system , and entity , which produces platelets .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes platelets hscs monocytes hsc|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelets .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes monocytes platelets neutrophils leukocytes|megakaryocytes|entity normally function to produce platelets , which are small blood cells involved in blood clotting .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes monocytes platelets granulocytes neutrophils|megakaryocytes|entity , which are large cells found in the bone marrow , are the source of platelets that are released into the bloodstream .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes platelets monocytes hscs basophils|megakaryocytes|these cells , known as entity , are found in the bone marrow and are the precursor cells to platelets .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes precursors platelets progenitors hscs|megakaryocytes|specifically , jak2 activation leads to proliferation of red blood cell progenitors and platelet progenitors , or entity , that fail to mature to platelets .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|mscs hscs msc hsc osteoblasts|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow ,
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|megakaryocytes platelets granulocytes monocytes neutrophils|megakaryocytes|entity are the bone marrow cells that give rise to blood platelets . 13 about eltrombopag eltrombopag was given accelerated approval by the
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|megakaryocytes platelets megakary erythroid circulating|platelets megakaryocytes hepatocytes endothelium mitochondria|megakaryocytes|itp can also result in damage to entity , leading to impaired platelet production .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|worms embryos mosquitoes parasites oocytes|megakaryocytes|we could not readily identify entity in our conditions on morphological grounds despite some effort with mgdf and therefore do not know which of our sampled
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|megakaryocytes platelets megakary erythroid circulating|mscs hscs osteoblasts msc hmscs|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow , which further exacerbates the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|podocyte podocytes gbm glomeruli cytoskeleton|podocytes|inhibition of calcineurin within the entity can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin cytoskeletion within the podocyte .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|podocytes podocyte mesangial involve lose|mtdna chr icd retina microrna|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity : 931-8 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|cytoskeleton microvasculature vasculature microcirculation ecm|podocytes|additionally , recent evidence suggests that inhibition of calcineurin has direct physical impacts on the entity within the kidney .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cell|podocytes podocyte mesangial involve lose|autoantibodies autoantibody gfr igm immunoglobulins|podocytes|voclosporin also potentially stabilizes disease modifying entity , which protects against proteinuria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|podocytes podocyte mesangial involve lose|proteinuria glomeruli podocytes albuminuria glomerulosclerosis|podocytes|( a and b ) gl-3 reduction in entity was closely paralleled by a reduction in podocyte volume .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|podocytes podocyte mesangial involve lose|icd chromosomes proteome cas nt|podocytes|immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity 8 of the entity : 931-8 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|podocytes podocyte mesangial involve lose|podocytes microtubules fibronectin glomeruli ecm|podocytes|voclosporin also potentially stabilizes entity , which can protect against proteinuria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|cell|podocytes podocyte mesangial involve lose|glutathione gsh cysteine cys thiols|podocytes|voclosporin also potentially stabilizes entity , s-12 table of contents which can protect against proteinuria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|podocytes podocyte mesangial involve lose|cns producing gn sc pacap|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 29 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|podocytes podocyte mesangial involve lose|cns producing sc gn pacap|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 30 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|lenses gbm erythrocytes neutrophils pbmcs|podocytes|there were statistical trends towards associations between 24-hr urine protein and % change in gl-3 inclusion content of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|podocytes erythrocytes platelets proteoglycans leukocytes|podocytes|entity form part of the barrier that enable the glomerulus to filter the blood in a manner that retains large molecules
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|podocytes kidneys rodents fibroblasts cardiomyocytes|podocytes|curr pharm des 21 overactive cannabinoid 1 receptor in entity drives type 2 diabetic nephropathy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|podocytes podocyte mesangial involve lose|podocytes fibroblasts glomeruli monocytes vsmcs|podocytes|gas6 is upregulated in either endothelial / mesangial cells or entity in igan dual involvement of growth arrest-specific
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|podocytes podocyte mesangial involve lose|podocytes tubules glomeruli fibroblasts pericytes|podocytes|combined with reduction of local hypoxia , plxdc2 can improve the health and homeostasis of renal epithelial cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|podocytes podocyte mesangial involve lose|cns producing gn predominate pag|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 32 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|podocytes podocyte mesangial involve lose|putamen als striatum hippocampus gbm|podocytes|( c ) volume fraction of gl-3 inclusions in entity did not change during the 6 months migalastat treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|fibroblasts etc lymphocytes hepatocytes astrocytes|podocytes|endothelial cells , tubular epithelial cells , cns mc5r cns , exocrine glands , lymphocytes , entity adapted from gong 2011 , catania 2004 , schioth 1997
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|podocytes podocyte mesangial involve lose|cochlea bbb retina cns cornea|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|podocytes podocyte mesangial involve lose|podocytes podocyte pericytes fibroblasts myofibroblasts|podocytes|fsgs is understood to start with damage to entity , cells that wrap around capillaries of the glomerulus .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|basophils basophil degranulation eosinophils granules|basophils lymphocytes monocytes fibroblasts platelets|basophils|neutrophils , eosinophils and entity , which are types of mature leukocytes , are normally formed only in the bone marrow and are stored there until they
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|basophils basophil degranulation eosinophils granules|ige mab fc recognize igg1|basophils|high affinity anti-human ige- 12 / 31 / 87 s / n 140 , 036 u . s . monoclonal antibody which bind to igge-bearing b cells and not entity tnx87-12a change et al .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils monocytes lymphocytes megakaryocytes fibroblasts|basophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , eosinophils , and entity ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|basophils basophil degranulation eosinophils granules|eosinophils lymphocytes dcs microglia basophils|basophils|vista is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils , monocytes , macrophages , entity and dcs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|monocytes lymphocytes eosinophils basophils neutrophils|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic 50 of approximately 1 . 5 nm , which is approximately 15-fold greater
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|basophils basophil degranulation eosinophils granules|ige binds mab recognizes igg1|basophils|high affinity anti-human ige- 7 / 29 / 88 s / n 226 , 421 u . s . monoclonal antibody which binds to ige-bearing b cells and not entity tnx87-12aa chang et al .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils lymphocytes neutrophils keratinocytes|basophils|e25 blocks ige from binding to mast cells and entity , thereby inhibiting the allergic response .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|monocytes lymphocytes eosinophils basophils neutrophils|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic50 of approximately 1 . 5 nm , which is approximately 15-fold greater than
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|lymphocytes eosinophils basophils fibroblasts neutrophils|basophils|mast cells , entity , goblet cells and other cells also play a role .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils lymphocytes neutrophils platelets|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity through specific ige receptors on the cell surface .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils neutrophils lymphocytes keratinocytes|basophils|pci-32765 is a potent inhibitor of histamine release ( also known as degranulation ) from mast cells and entity , which are specific immune cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils lymphocytes keratinocytes neutrophils|basophils|to the antigen , or allergen in this case , by producing ige . ige binds to the surface of mast cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils keratinocytes neutrophils lymphocytes|basophils|these ige molecules attach to the surfaces of mast cells or entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils lymphocytes keratinocytes neutrophils|basophils|and masking the binding site for the ige receptor which prevents ige from binding to and arming mast cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|basophils basophil degranulation eosinophils granules|mediators lymphocytes leukocytes granules basophils|basophils|similarly , calcium ions also play a central role in the activation and degranulation of tissue mast cells and circulating counterpart entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils keratinocytes lymphocytes neutrophils|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity , thereby arming these cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 3)])|cell|basophils basophil degranulation eosinophils granules|neutrophils granulocytes lymphocytes dcs basophils|basophils|in animal models that ccr2 is important for host defense , inflammation and immunity mediated through hematopoietic cells including monocytes and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|basophils basophil degranulation eosinophils granules|neutrophils basophils monocytes lymphocytes keratinocytes|basophils|siglec-8 is an inhibitory receptor located selectively on eosinophils , mast cells and , to a lesser extent , on entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|basophils basophil degranulation eosinophils granules|basophils eosinophils neutrophils lymphocytes monocytes|basophils|omalizumab works by binding to the immune mediator immunoglobulin e , or ige , and inhibiting ige-mediated activation of mast cells and entity , types of white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|basophils basophil degranulation eosinophils granules|fibroblasts lymphocytes monocytes neutrophils keratinocytes|basophils|cd123 is also expressed by plasmacytoid dendritic cells , or pdcs , entity , endothelial cells and , to a lesser extent , monocytes and eosinophils .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|ganglion dendritic glial neuron sensory|neurones axons afferents fibres somata|neurons|in parallel , electrophysiology recordings of single ganglion entity that innervate the craniofacial muscles were performed ( 33 masticatory muscle mechanoreceptors ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|ganglion dendritic glial neuron sensory|astrocytes neurones synapses leukocytes ganglia|neurons|amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|ganglion dendritic glial neuron sensory|interneurons circuits neurones ganglia nuclei|neurons|these entity are responsible for producing dopamine , an essential brain signaling chemical , or neurotransmitter , that enables smooth , coordinated movements of both voluntary
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|photoreceptors photoreceptor outer nuclei neuron|neurons|these results suggest that the photoreceptor entity and pigmented retinal epithelial cells  cell types that are both lost in ga  are sandwiched between deposits of
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|ganglion dendritic glial neuron sensory|astrocytes neurones microglia platelets lymphocytes|neurons|as a result , entity are unable to respond to normal stimuli and can become over-stimulated by a neurotransmitter or be unable to respond to
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|ganglion dendritic glial neuron sensory|plaques neurites neuropil axons neurones|neurons|in ad , tau protein is misfolded , becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary tangles within entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|neurones axons terminals fibres interneurons|neurons|these symptoms are caused by the degeneration of dopaminergic entity in the substantia nigra and depletion of dopamine in the striatum .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|ganglion dendritic glial neuron sensory|axons synapses neurotransmitters oligodendrocytes neurones|neurons|can transition into mild , moderate and , finally , severe stages of alzheimers disease that are characterized by greater systemic loss of entity and synapses in the brain tissue .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|ganglion dendritic glial neuron sensory|neurotoxicity neurones neuron terminals neurotransmission|neurons|parkinsons disease ( the “mptp model” ) showed that when administered orally , aeol 11207 crosses the blood brain barrier and protected dopamine entity in a dose-dependent manner .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|cns retina neuron cerebellum photoreceptors|neurons|the dendrites and axons , or nerve endings , of the entity contain an elaborate series of thin tubes , or microtubules , which serve to support them and transport nutrients down to the
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|ganglion dendritic glial neuron sensory|axons neuron neurones nerves motoneurons|neurons|sma is caused by a genetic defect in the smn1 gene that codes smn , a protein necessary for survival of motor entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|ganglion dendritic glial neuron sensory|oligodendrocytes myelin axons synapses mitochondria|neurons|accumulation of mhtt protein causes progressive loss of entity in the brain .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|ganglion dendritic glial neuron sensory|neurones neuron oligodendrocytes astrocytes axons|neurons|cord in commercial quantities , and the ability to control the differentiation of these cells constitutively into mature , physiologically relevant human entity and glia .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|neurones mammals astrocytes vertebrates others|neurons|neurotoxic peptiderefers to a small protein ( called a peptide ) that can be toxic to entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|cochlea ears listeners compensate thresholds|neurons|· ep1937352 sub-threshold stimulation to precondition entity for supra-threshold stimulation – opposition hearing is scheduled for january 21 , 2015 in munich , germany .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|ganglion dendritic glial neuron sensory|axons circuits synapses innervation circuitry|neurons|limitations of current therapies als is a neurodegenerative disorder that involves gradual breakdown of motor entity leading to muscle weakness , disability , and ultimately death .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|ganglion dendritic glial neuron sensory|axons neurones oligodendrocytes neurites motoneurons|neurons|which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|ganglion dendritic glial neuron sensory|pag thalamus amygdala drg vta|neurons|to further demonstrate this , we utilized in vivo electrophysiology where cbn blocked the pain signals in the entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ganglion dendritic glial neuron sensory|interneurons axons motoneurons neurones glia|neurons|loss of dopamine causes critical nerve cells , or entity , in the brain , to fire out of control , leaving patients unable to direct or control their movement in a normal
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|ganglion dendritic glial neuron sensory|axons neurones neuron innervation fibres|neurons|about sma sma is a severe neuromuscular disease characterized by the loss of motor entity leading to progressive muscle weakness and paralysis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|resemble aggregate involve activate kill|cardiomyocytes cd133 bdnf nep mscs|cardiomyocytes|we have derived human entity ( grncm1 ) from hescs for the potential treatment of heart disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|resemble aggregate involve activate kill|predicts causing hereditary systolic produces|cardiomyocytes|cm1 – entity heart failure 6 million total patients in u . s . cells derived and characterization studies performed ( parameters analyzed showed normal cell functions
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|resemble aggregate involve activate kill|brands producers brand manufacturers manufacturer|cardiomyocytes|product sales for both 2012 and 2013 is primarily attributable to an increase in unit volume sales of our icell entity and , in 2012 , to our icell neurons .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|resemble aggregate involve activate kill|causing corrected familial heritable attributable|cardiomyocytes|cm1 - entity heart failure 6 million total patients in u . s . cells derived and fully characterized ( all normal cell functions verified in vitro ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|resemble aggregate involve activate kill|cardiomyocytes hearts therapeutics myocytes myocardium|cardiomyocytes|gerons grncm1 program is developing hesc-derived entity for the treatment of heart failure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|resemble aggregate involve activate kill|myocytes cardiomyocytes fibroblasts trabeculae myocardium|cardiomyocytes|in human entity isolated from the left ventricle of patients with end-stage heart failure , serca2a levels were correlated with improved diastolic function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|resemble aggregate involve activate kill|myocytes cardiomyocytes mitochondria trabeculae hearts|cardiomyocytes|isolated entity from aav-s100a1 treated pig heart showed superior systolic and diastolic performance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|resemble aggregate involve activate kill|cardiomyocytes leukocytes myocytes myocardium lymphocytes|cardiomyocytes|moreover , old g5terc-null mice exhibited shorter telomeres in entity than did younger counterparts , and this led to ventricular dilation , page .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|resemble aggregate involve activate kill|constructs therapeutics adenoviruses technologies carriers|cardiomyocytes|the targeted entity are expected to produce sustained therapeutic protein levels in the myocardium where it is needed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|resemble aggregate involve activate kill|striated diaphragm somatic myocardium muscular|cardiomyocytes|such cells include entity or heart muscle cells , neural cells , hepatic cells and pancreatic ( logo ) islet cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|resemble aggregate involve activate kill|islets hepatocytes cardiomyocytes ipscs fibroblasts|cardiomyocytes|the first product developed under the alliance , human entity derived from hescs , was launched in october 2010 by gehc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|resemble aggregate involve activate kill|cardiomyocytes myocardium hearts myocytes atria|cardiomyocytes|specific precursor cells which , together with a specific combination of growth factors , develop full culture wells of functional , beating human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|resemble aggregate involve activate kill|myocytes cardiomyocytes strips trabeculae microspheres|cardiomyocytes|the product is predominantly composed of ventricular entity which have been shown to electrically and mechanically couple to the animal myocardium in which they are injected and contract
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|resemble aggregate involve activate kill|hescs pharmaceuticals chemicals medicines pluripotency|cardiomyocytes|u . s . patent no . 7 , 425 , 448 was issued to geron with broad claims to entity derived from hescs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|cell|resemble aggregate involve activate kill|vaccines therapeutics medicines cardiomyocytes pharmaceuticals|cardiomyocytes|that asterias will reach an agreement for support in the manufacture of vac2 or the development of hes cell derived entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|resemble aggregate involve activate kill|cardiomyocytes cms mscs cscs myocytes|cardiomyocytes|heart muscle cells ( entity ) do not regenerate during adult life .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|resemble aggregate involve activate kill|hepatocytes fibroblasts cardiomyocytes chondrocytes keratinocytes|cardiomyocytes|dbcm is caused by metabolic derangements in entity that result in cell death and fibrosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|resemble aggregate involve activate kill|fibroblasts exosomes progenitors colonies micrornas|cardiomyocytes|cm1 , hes cell-derived entity , have been extensively characterized in vitro and in vivo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|resemble aggregate involve activate kill|cardiomyocytes mscs fibroblasts hepatocytes msc|cardiomyocytes|we used our hpsc-derived entity ( human heart cells ) in cardiosafe 3d™ , our novel , customized in vitro bioassay system for predicting potential cardiotoxicity of drug rescue
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|resemble aggregate involve activate kill|transplanted cloned tried transplants explored|cardiomyocytes|today we have entity , two types of neural cells -- dopaminergic neurons and oligodendrocytes -- and hematopoietic cells in animal models , and we hope
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|chondrocytes cardiomyocytes adipocytes osteoblasts monocytes|keratinocytes|these supported isolation , expansion and long-term culture of entity , fibroblasts , smooth muscle cells and mesenchymal stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes neutrophils monocytes eosinophils leukocytes|keratinocytes|il-17 binding to il-17ra on entity stimulates and perpetuates the inflammation cascade of psoriasis .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes fibroblasts epidermis melanocytes leukocytes|keratinocytes|believes that the therapeutic utility of 2-cdap in psoriasis would result from its ability to gain direct access to hyperproliferating entity in a form that would be rapidly effective .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes epidermis epithelia langerhans|keratinocytes|apligraf contains living human skin cells , entity and fibroblasts , organized in an epidermal and dermal layer .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes epidermis fibroblasts melanocytes keratinocyte|keratinocytes|hyperproliferation of entity contributes to psoriasis , and work by sugen and others has demonstrated that egf tk signalling is required for the growth of entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes epithelia melanocytes fibroblasts epidermis|keratinocytes|hemidesmosome formation also occurs during normal differentiation of entity as they mature from the basal layer , not only in a wound-healing situation .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|person warts chronically tumours vertically|keratinocytes|etiology – entity infected by human papillomavirus ( hpv ) ; manifests as common warts , plantar warts or genital warts virus spreads via direct contact or
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes fibroblasts sheets melanocytes progenitors|keratinocytes|revitix provides a more complete array of growth factors than those produced by dermal fibroblasts or epidermal entity alone , which helps to speed the healing process of skin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|epidermis dermis circulation cornea periphery|keratinocytes|tanning is mediated by melanocytes producing melanin , which is subsequently transferred to the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes papillomas epidermis colonies fibroblasts|keratinocytes|in in vitro skin models , p529 was shown to inhibit keratinocyte proliferation ( growth of entity ) and induce apoptosis ( cause death of hyperproliferating entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|epidermis vasculature keratinocytes microenvironment dermis|keratinocytes|in preclinical studies , xcur17 inhibited il-17ra in the entity of the skin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes lcs fibroblasts eosinophils|keratinocytes|entity are the most abundant cells in the epidermis and account for 80 to 90% of the total epidermal cellular population .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|ak keratinocytes kc hacat fibroblasts|keratinocytes|kx-01 inhibits the proliferation of entity and up-regulates p53 so its utility in clinically treating ak was of interest .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes fibroblasts myofibroblasts lcs|keratinocytes|the epidermis is comprised mainly of cells known as entity that are continually regenerated and move toward the skin surface where they flatten , lose their nucleus , and become the outermost
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|clones oncogenes lymphocytes fibroblasts keratinocytes|keratinocytes|this exposure can lead to oncogenic changes , such as inactivation of p53 , and consequential hyper-proliferation of mutated entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes lcs fibroblasts langerhans|keratinocytes|entity are the predominant cell type in the epidermis , the outermost layer of the skin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes fibroblasts keratinocyte melanocytes fibroblast|keratinocytes|first , il-8 is produced by a type of skin cell called entity , and is a potent growth factor for these skin cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes chemotaxis permeability neutrophils|keratinocytes|as p529 has been shown to inhibit neovascularization , together with its effect on entity , p529 is expected to show activity in psoriasis and atopic dermatitis .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes eosinophils neutrophils lymphocytes fibroblasts|keratinocytes|barrier function and inflammation in atopic dermatitis the most abundant cells in the epidermis are entity , shown in figure 16 below .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|keratinocytes epidermal hacat keratinocyte epidermis|keratinocytes melanocytes fibroblasts myofibroblasts langerhans|keratinocytes|the epidermis is comprised mainly of cells known as entity which are continually regenerated and move toward the skin surface where they flatten , loose their nucleus and become the outermost
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|astrocytes astrocyte glial microglia involve|astrocytes oligodendrocytes lymphocytes monocytes dcs|astrocytes|the chronic activation of microglia and entity has been implicated as an important disease mechanism in huntingtons disease , progressive ms , and other neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|astrocytes astrocyte glial microglia involve|microglia astrocytes neutrophils monocytes leukocytes|astrocytes|when innate immune dysfunction causes chronic inflammation , activated microglial cells produce soluble tnf that activates entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|astrocytes astrocyte glial microglia involve|glia astrocytes interneurons oligodendrocytes microglia|astrocytes|in addition , the target cells , motor neurons and entity , or cells supporting the neurons , reside within and surrounding the spinal cord and brain stem , which we believe can be
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|astrocytes astrocyte glial microglia involve|astrocytes microglia vessels osteoblasts fibroblasts|astrocytes|when ipsc-derived hgpcs were transplanted into these mice , the cells spread widely throughout the brain , developing as entity and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|astrocytes astrocyte glial microglia involve|astrocytes oligodendrocytes lymphocytes astrocyte macrophage|astrocytes|cells that repair damage to myelin and neurons and prevent chronic activation of inflammatory cells of the brain , microglia and entity , which is implicated in neurodegenerative diseases .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|astrocytes astrocyte glial microglia involve|astrocytes microglia monocytes leukocytes cns|astrocytes|jun ; 71 : 1500-4 ; modulation of interleukin-1beta mediated inflammatory response in human entity by flavonoids : implications in neuroprotection . brain res bull .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|astrocytes astrocyte glial microglia involve|astrocytes microglia fibroblasts neurones interneurons|astrocytes|entity and oligodendrocytes , the other two principle types of central nervous system cells , are also generated from the human neural stem
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|astrocytes astrocyte glial microglia involve|nmdar astrocytes erk microglia ecs|astrocytes|av-101s ability to activate entity for focal delivery of an anti-epileptic principle , and its dual action as a nmdar glyb antagonist and quinolinic acid synthesis
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|astrocytes astrocyte glial microglia involve|astrocytes microglia glia fibroblasts oligodendrocytes|astrocytes|together , these activities lead to a cascade of enhanced disease responses in neurons , oligodendrocytes , and entity , cell types that are most vulnerable to energetic deficiencies .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|astrocytes astrocyte glial microglia involve|astrocytes microglia glia oligodendrocytes neurones|astrocytes|spinal cord are damaged , guanosine , which is present normally in every cell , can be released in high concentrations to stimulate entity to produce these protective factors .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|astrocytes astrocyte glial microglia involve|synapses spines dendrites astrocytes mitochondria|astrocytes|conditions anavex®3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|astrocytes astrocyte glial microglia involve|astrocytes fibroblasts lymphocytes neurones neutrophils|astrocytes|pre-clinical data suggest that ccr2 , and mcp-1 , are upregulated in cells , such as macrophages , microglial cells and entity which play a central role in the origination of pain signals .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|astrocytes astrocyte glial microglia involve|scientists researchers attempts others investigators|astrocytes|customers frequently request entity to build a more complete human neurological model .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|astrocytes astrocyte glial microglia involve|synapses spines dendrites mitochondria neurites|astrocytes|anavex 3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|astrocytes astrocyte glial microglia involve|astrocytes fibroblasts glia microglia interneurons|astrocytes|the effect of iw-6463 was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , entity , microglial cells and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|astrocytes astrocyte glial microglia involve|astrocytes retina retinas brains nscs|astrocytes|clr1501 uptake was visualized with confocal microscopy and compared to matched sergbm , normal human entity , and human nscs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|astrocytes astrocyte glial microglia involve|astrocytes pericytes fibroblasts glia oligodendrocytes|astrocytes|glioblastoma are tumors that arise from entity , which are star-shaped cells making up the supportive tissue of the brain .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|astrocytes astrocyte glial microglia involve|astrocytes myelin microglia fibroblasts osteoblasts|astrocytes|q-cells produce entity and oligodendrocytes , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|astrocytes astrocyte glial microglia involve|unlike amongst besides neural glial|astrocytes|entity cells found in the brain that support neuronal function these cells are synergistic with icell neurons .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|astrocytes astrocyte glial microglia involve|glia astrocytes oligodendrocytes synapses elsewhere|astrocytes|aß peptides are derived from the amyloid precursor protein , or app , an integral membrane protein , in neurons and entity in the brain .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1), ('DIS', 1)])|cell|adipocytes resemble adipocyte adipose contain|adipocytes lymphocytes cardiomyocytes monocytes myocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1), ('DIS', 1)])|cell|adipocytes resemble adipocyte adipose contain|adipocytes lymphocytes cardiomyocytes monocytes myocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|adipocytes resemble adipocyte adipose contain|adipocytes fibroblasts adipocyte preadip adipogenesis|preadipocytes|a paper entitled “chromium picolinate depressed proliferation and differentiation of 3t3-l1 entity” was published in nutrition research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast fibroblasts chondrocytes osteoclasts|osteoblasts|only a portion of the bone remodeling process : they either block bone breakdown by osteoclasts or stimulate bone formation by entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts chondrocytes fibroblasts myofibroblasts osteoblast|osteoblasts|small areas of bone are constantly being broken down by special cells called osteoclasts , then made again by cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|inhibit resemble activate involve kill|therapeutics aiming therapeutically treating notably|osteoblasts|entity for osteoporosis and non-union bone fractures we have made osteoblasts from hescs and are now conducting preclinical tests in animals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast neutrophils osteoclasts monocytes|osteoblasts|n / a ( generic ) ​ in osteoporosis patients , who have normal basal levels of pth , therapeutic administration of pth activates osteoclasts and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoclasts chondrocytes osteoblast precursors|osteoblasts|it has a potent anabolic effect on bone tissues , stimulating the formation and maturation of bone-forming entity which in turn causes significant increases in new bone formation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast osteoclasts fibroblasts chondrocytes|osteoblasts|k , arris and its partner believe that a new drug may be able to re-balance the activity of osteoclasts and entity and arrest the bone-destroying effects of osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|inhibit resemble activate involve kill|rankl osteoclasts trap osteocalcin bisphosphonates|osteoblasts|intravenously administered antibody that is designed to inhibit sclerostin , a protein that inhibits the activity of bone-forming cells , known as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoclasts chondrocytes fibroblasts monocytes|osteoblasts|while both types of cells are activated when pth is administered , entity are activated to a greater extent , increasing net bone formation and bone mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|inhibit resemble activate involve kill|nscs mscs hescs hmscs cardiomyocytes|osteoblasts|current work focuses on confirming their characteristics as entity , improving cell yields , testing function in vitro and then testing the cells in animals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|inhibit resemble activate involve kill|mscs osteoblasts chondrocytes bmscs bmc|osteoblasts|we intend to infuse entity derived from hescs to treat osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast osteoblastic periosteal lining|osteoblasts|bone loss ( mediated by osteoclasts  cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity  cells which form new bone ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteosarcoma osteoblasts osteogenesis infancy adolescence|osteoblasts|because osteosarcoma usually develops from entity , it most commonly affects children and young adults experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|inhibit resemble activate involve kill|another roughly maximally merely altogether|osteoblasts|while both types of cells are activated when pth is administered , entity 92 table of contents are activated for a longer period , increasing bone formation and bone mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast osteoblastic fibroblasts osteoclasts|osteoblasts|cells called entity cause new bone formation while other cells called osteoclasts remove old bone through a process called resorption .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast fibroblasts monocytes precursors|osteoblasts|the condition is the stimulation of a population of normal bone cells ( osteoclasts ) relative to another population of bone cells ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|inhibit resemble activate involve kill|infancy osteosarcoma osteoblasts adolescence osteogenesis|osteoblasts|because osteosarcoma usually develops from entity , it most commonly develops in teenagers who are experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|inhibit resemble activate involve kill|osteoblasts osteoclasts osteoblast fibroblasts osteoclast|osteoblasts|forteo ( marketed as forsteo in europe ) builds bone primarily by increasing the activity of entity ( cells that deposit bone ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|inhibit resemble activate involve kill|osteoblasts consequently hence fibroblasts osteoclasts|osteoblasts|osteoclasts mediate destruction of bone and entity are responsible for bone growth and mineral production .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast fibroblasts chondrocytes adipocytes|osteoblasts|bone loss ( mediated by osteoclasts -- cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity -- cells which form new bone ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|inhibit resemble activate involve kill|osteoblasts osteoblast fibroblasts chondrocytes osteoclasts|osteoblasts|normal functioning of bone depends on osteoclasts and entity acting in concert .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|erythroid erythro erythrocytes nucleated megakaryocytes|oocytes embryos lymphocytes ones phenotypes|erythroblasts|b , which are more immature entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|erythroid erythro erythrocytes nucleated megakaryocytes|monocytes granulocytes fibroblasts platelets neutrophils|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|erythroid erythro erythrocytes nucleated megakaryocytes|spores oocytes erythrocytes ery conidia|erythroblasts|c , which is the population of mature entity , in comparison to ery .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythroid erythro erythrocytes nucleated megakaryocytes|platelets rbcs erythrocytes granulocytes monocytes|erythroblasts|reactivation of hbf occurs in immature rbcs , known as entity and reticulocytes .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|erythroid erythro erythrocytes nucleated megakaryocytes|monocytes granulocytes fibroblasts platelets neutrophils|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes , and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|epithelium luminal tubular colonic mucin|adverse detrimental herd harmful deleterious|transitional|the initial application of ifrs 9 at january 1 , 2018 has resulted in no significant entity effects for immunic .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|patent expiration approval registration comment|transitional|after the expiry of any applicable entity period , only ivds that have been ce marked under the ivd regulation may be placed on the market in the
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|expanded stock transfusion pharmacy healthcare|transitional|as per the benefit arrangement contemplated by the entity services agreement , the existing stock shall be delivered to purchaser exw - incoterms 2010 , delivery in monheim or other sellers
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|neuropsychological vestibular formal neurocognitive sensory|transitional|the provisions of sfas 142 require that a entity impairment test be performed as of the beginning of the year the statement is adopted .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|epithelium luminal tubular colonic mucin|transitional squamous urothelial giant spindle|transitional|entity cell carcinoma of the bladder frequently occurs in adolescents with costello syndrome , a presentation that is rare in the general
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|indirect financial monetary zero productivity|transitional|“entity costs” shall mean all costs incurred by seller that are identified in exhibit “j” .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|innovative interactive online abstract english|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|consumer user client private sales|transitional|will also pay bms for any required product supply at a price approximating the product cost as well as negotiated entity service fees .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|wrong proper name entire designated|transitional|( ii ) and section 2 . 2 , in no event shall aetna use or permit any affiliate to use any mark or the entity mark
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|strict guideline revised standards next|transitional|we elected to use the entity practical expedient allowing the standard to be applied only to contracts that were previously identified as leases under ias 17
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|legal technical administrative legislative privacy|transitional|retrospectively from january 1 , 2019 , but has not restated comparatives for the 2018 reporting period , as permitted under the specific entity provisions in the standard .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|epithelium luminal tubular colonic mucin|healthcare client pharmacy pharmaceutical consumer|transitional|and the buyer are expected to enter into related transaction agreements at the closing of the proposed transaction , including a entity services agreement .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|interim disclosure penal funding retraction|transitional|respect to any grant ( including the grant made on the effective date ) a-3 to secure the benefit of any applicable entity rule promulgated under section 409a of the code .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|medicare nhs healthcare insurance universal|transitional|internal costs and out-of-pocket expenses shall not exceed the corresponding agreed to budget for such services set forth in the entity service plan .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|financial eligibility funding revised payment|transitional|the entity requirements of sfas 148 are effective for all financial statements for fiscal years ending after december 15 , 2002 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|security legal draft decision technical|transitional|we elected the optional entity guidance under asc 842 that allowed the initial recognition of the operating right-of-use assets and the corresponding lease liabilities as
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|financial tax largest price budget|transitional|the entity impact was finalized during the fiscal year ended june 30 , 2019 , with no significant impact on income tax expense .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|ethical healthcare legal biomedical technical|transitional|acquisition by cytyc corporation , a diagnostic and medical device company , he served as a consultant to cytyc to assist with entity matters from 2001 to 2002 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|innovative interactive online abstract english|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium luminal tubular colonic mucin|code guideline checklist guidance format|transitional|we adopted these changes using the prospective application entity alternative in accordance with the entity provisions of cica handbook section 3870 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|embryos oocytes semen ucb platelets|oocytes|we anticipate that in the unites states cryopreservation of entity will be regulated similarly to viacords family umbilical cord blood cryopreservation product .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2)])|cell|fertilized retrieved recovered matured immature|oocytes follicles embryos spermatozoa oocyte|oocytes|if successful , the ovature treatment could reduce , or possibly eliminate , the need for hormonal hyperstimulation for the maturation of multiple entity prior to egg retrieval in the ivf process .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|embryos oocytes gametes semen eggs|oocytes|with a number of in vitro fertility clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|embryos oocytes hescs blastocysts semen|oocytes|media supplier will be required to obtain 510 ( k ) clearance for the technology we have licensed for use in the cryopreservation of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|eggs oocytes embryos erythrocytes frogs|oocytes|“raw material” means conforming rana pipiens entity to be supplied to spl by alfacell .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|cell|fertilized retrieved recovered matured immature|oocytes embryos eggs ovaries gametes|oocytes|cancer research technology limited rnai uses in mammalian entity , preimplantation embryos and somatic cells ( ep only : wherein the rnai compound is at least 25 base pairs ) 11 / 19 / 1999
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|fertilized retrieved recovered matured immature|embryos gametes spermatozoa oocytes eggs|oocytes|which includes the production of human differentiated cells from stem cells and involves the use of nuclear transfer technology , human entity , and embryonic material .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|embryos oocytes gametes eggs semen|oocytes|a number of in vitro fertility ( “ivf” ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|fertilized retrieved recovered matured immature|eggs oocytes ova embryos spermatozoa|oocytes|the first patent covers the use of fertilized human entity for the creation of human embryonic stem cell lines , and was issued in great britain .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|fertilized retrieved recovered matured immature|oocytes spermatozoa eggs gametes embryos|oocytes|another opportunity in the use of cells for therapy relates to entity , which are female egg cells essential to reproduction .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|cell|fertilized retrieved recovered matured immature|embryos oocytes platelets leukocytes saliva|oocytes|of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|fertilized retrieved recovered matured immature|embryos oocytes gametes eggs rbcs|oocytes|a number of in vitro fertility ( ivf ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|fertilized retrieved recovered matured immature|eggs oocytes ova embryos gametes|oocytes|iscos core technology , parthenogenesis , results in the creation of pluripotent human stem cells from unfertilized entity ( eggs ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fertilized retrieved recovered matured immature|embryos genetics hepatocytes volunteers leukocytes|oocytes|is focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|fertilized retrieved recovered matured immature|eggs gametes oocytes embryos spermatozoa|oocytes|viacyte , a product expected to offer women the ability to preserve or extend their fertility through the cryopreservation of their entity ( eggs ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fertilized retrieved recovered matured immature|embryos genetics hepatocytes volunteers leukocytes|oocytes|are focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|fertilized retrieved recovered matured immature|oocytes embryos spermatozoa eggs oocyte|oocytes|the second and third patents , both covering parthenogenetic activation of human entity , were 47 table of contents issued in japan and korea .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|fertilized retrieved recovered matured immature|oocytes mscs hmscs embryos ascs|oocytes|for ovature , ovascience was exploring different subculture systems that allow for even further maturation of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|fertilized retrieved recovered matured immature|eggs oocytes embryos ova gametes|oocytes|although our focus is on stem cells derived from unfertilized entity , certain aspects of that work may involve the use of nuclear transfer technology or material deemed to be embryonic material .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|fertilized retrieved recovered matured immature|eggs oocytes ova embryos oocyte|oocytes|although our focus is on parthenogenetic stem cells derived from unfertilized entity , certain aspects of that work may involve the use of embryonic stem cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes rpe chondrocyte platelets mscs|chondrocytes|autologous cultured entity ( " carticel ( tm ) aucc " ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|mutated biomarker candidate causative relevance|chondrocytes|chnd1 : entity for cartilage disorders and degenerative disc disease articular cartilage is the shock absorber for joints .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|keratinocytes chondrocytes fibroblasts chondrocyte fibroblast|chondrocytes|maci® ( autologous cultured entity on porcine collagen membrane ) is an autologous cellularized scaffold product indicated for the repair of symptomatic , single or multiple full-thickness
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|mscs ascs ipscs chondrocytes pellets|chondrocytes|use of hystem® hydrogels with purestem™ progenitors resulting in a combined product that produces cartilage- producing cell masses known as entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|prescriptions visits payments reimbursement claims|chondrocytes|some third party payers , however , do not cover carticel entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|companies makers ups kits outs|chondrocytes|the commercial success of carticel-registered trademark- entity will depend on many factors , including the following : - positive results from post-marketing studies .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|flaps dressings transplants sutures prostheses|chondrocytes|compared to the same period a year ago due primarily to decreased shipments of both epicel skin grafts and carticel entity during the three months ended march 31 , 2002 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|companies outs makers owners offs|chondrocytes|some third-party payers , however , do not cover carticel-registered trademark- entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes mscs scaffolds bmscs ascs|chondrocytes|preclinical studies have shown that entity embedded in bst-gel ( tm ) produce a matrix having the characteristics of normal cartilage tissue .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|inserts pins approved guides kits|chondrocytes|genzyme biosurgery has developed a device to improve the procedure for implanting carticel-registered trademark- entity and has filed for marketing approval with the fda .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes bmscs chondrocyte fibroblasts mscs|chondrocytes|as reported in this article , 19 of 23 patients had restored or improved joint function after treatment with cultured autologous entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|alfa tablets capsule tablet depot|chondrocytes|since the fda approved carticel entity , genzyme has seen a substantial increase in the number of third party payers who cover it .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes mscs bmscs ascs prp|chondrocytes|gtr is aware of at least one other company that is culturing autologous entity for cartilage repair in europe .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|plate ossification joints articulation osteonecrosis|chondrocytes|there are two type of entity , “articular” and “growth plate” .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes osteoblasts surfaces proteoglycans fibroblasts|chondrocytes|articular entity are responsible for cartilage that lines our joints , whereas growth plate entity are involved with new bone formation .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|makers outs owned companies representatives|chondrocytes|the increase in sales of carticel-registered trademark- entity was a result of continued increases in the numbers of patients treated and surgeons trained as well as an increase
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|embryos chondrocytes mscs fibroblasts keratinocytes|chondrocytes|the process used by gtr to grow autologous entity is not patentable , and gtr does not yet have significant patent protection covering the other methodologies used in providing carticel ( tm )
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|approved rx app tag mark|chondrocytes|since the fda approved carticel-registered trademark- entity , genzyme has seen a substantial increase in the number of third-party payers who cover it .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes biomaterials scaffolds matrices fibroblasts|chondrocytes|solid tissue cell therapies one of the newest areas of cell therapy involves the production of entity for the restoration of cartilage .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|chondrocytes proliferated articular osteoarthritis proliferating|chondrocytes chondrocyte proteoglycan pellet proteoglycans|chondrocytes|chondrocyte therapy involves the surgical removal of a small amount of tissue from the patient  s knee and a therapeutic quantity of entity is produced from this surgical biopsy .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|myofibroblasts fibroblasts myofibroblast hypertrophy scars|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic tissues .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|stroma fibroblasts pericytes microvessels nerves|myofibroblasts|in a sampling of approximately 200 tumors , epha2 was found to be expressed in tumor cells , entity and / or tumor-associated blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|myofibroblasts contain surrounded fibroblasts scar|myofibroblasts pericytes fibroblasts monocytes keratinocytes|myofibroblasts|fezagepras has been observed to regulate several cell types involved in the fibrotic pathway : macrophages , fibroblasts / entity and epithelial cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|myofibroblasts contain surrounded fibroblasts scar|osteoclasts fibroblasts osteoblasts myofibroblasts capillaries|myofibroblasts|the number of entity and hydroxyproline ( i . e . , collagen ) content was also significantly reduced in both organs .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myofibroblasts contain surrounded fibroblasts scar|myofibroblasts fibroblasts emt hscs myofibroblast|myofibroblasts|moreover , ehp-101 has been shown to inhibit the tgfβ-associated differentiation of cells ( called entity ) that are responsible for fibrosis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts neutrophils monocytes pericytes myofibroblasts|myofibroblasts|vla-1 is found on a variety of cells associated with tissue inflammation and fibrosis , including activated t-cells , macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts myofibroblasts keratinocytes chondrocytes pericytes|myofibroblasts|ctgf increases the abundance of entity , a cell type that drives wound healing , and stimulates them to deposit ecm proteins such as collagen at the site of tissue injury .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts leukocytes neutrophils lymphocytes leucocytes|myofibroblasts|in the skin , it has been shown to reduce scar formation by reduction of infiltration of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts myofibroblasts collagens myofibroblast ecm|myofibroblasts| anti-fibrosiscysteamine blocks tgf-ß signaling and thereby inhibits the production and proliferation of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts hscs mmps hsc mapks|myofibroblasts|constant myofiber breakdown results in persistent activation of entity and altered production of ecm resulting in extensive fibrosis in skeletal muscles of dmd patients .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|hscs fibroblasts stat3 hsc emt|myofibroblasts|in fibrotic conditions , excess ctgf results in chronic activation of entity , which leads to chronic ecm deposition and fibrosis ( see figure above ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|proliferating perivascular fibroblastic contractile proliferative|myofibroblasts|anti-tshr antibodies also increase the proliferation of adipose or fat cells as well as entity , smooth muscle-like cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|myofibroblasts fibroblasts myofibroblast hypertrophy scars|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic connecting tissues .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|myofibroblasts contain surrounded fibroblasts scar|cardiomyocytes myocytes myoblasts fibroblasts myocardium|myofibroblasts|research programs involving cell-based approaches to restoring cardiac function and a research program involving a gene therapy approach to converting entity into cardiac muscle .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|myofibroblasts contain surrounded fibroblasts scar|fibroblasts myofibroblasts chondrocytes keratinocytes myocytes|myofibroblasts|in the case of normal healing of a limited tissue injury , entity eventually die by programmed cell death , or apoptosis , and the fibrous scarring process recedes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 2)])|cell|myofibroblasts contain surrounded fibroblasts scar|myofibroblasts fibroblasts leukocytes lipids glycosaminoglycans|myofibroblasts|fibrosis is the formation of excess connective tissue ( collagen and other proteins plus cellular elements such as entity ) in response to damage , inflammation or repair .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|myofibroblasts contain surrounded fibroblasts scar|hscs hepatocytes hsc lymphocytes leukocytes|myofibroblasts|additionally supported by the anti-inflammatory effects , including downregulation of tnf and il-6 , that can reduce the proliferation and activation of entity in the liver .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes lds lcs sc scs|adipocytes|the ultrashape system targets and selectively destroys fat cells ( entity ) , leaving critical surrounding structures such as blood vessels , nerves and connective tissue unharmed .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|stroma parenchyma epithelium dermis medulla|adipocytes|in addition , the fraction also contains blood cells from the capillaries supplying the entity and the extracellular matrix .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|lymphocytes hepatocytes fibroblasts adipocytes keratinocytes|adipocytes|in non-cancerous tissues , it is predominantly found at low levels on entity , or fat cells , and briefly on precursors to b-cells , or pre-b-cells , during normal b-cell maturation .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes enterocytes nerves neurones fibroblasts|adipocytes|vitro studies have shown that activation of the beta-3 adrenergic receptor in the colon causes the release of somatostatin from entity , or fat cells , which causes pain relief .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|adipocytes adipocyte adipose adiponectin characterize|lymphocytes keratinocytes thymocytes hepatocytes cardiomyocytes|adipocytes|antibodies form against the thyroid-stimulating hormone receptor , or tshr , which is present in the thyroid and other cells such as entity and fibroblasts .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|neutrophils mitochondria hepatocytes elastin platelets|adipocytes|this attenuation by protein-rich tissue results in the preferential destruction of entity by atx-101 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes hepatocytes fibroblasts chondrocytes osteoblasts|adipocytes|mechanism of action atx-101 is designed to be a locally-injected drug that causes proximal , preferential destruction of entity , or fat cells , with minimal effect on surrounding tissue .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|ecs mammals oocytes rice insects|adipocytes|believe that rnai could potentially be a reliable method to selectively inhibit certain genes and their corresponding protein expression in entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes fibroblasts adipocyte preadip hepatocytes|adipocytes|the research is focused on using cultured entity ( fat cells ) as a model system for studying the regulation of gene expression involved in adipocyte differentiation and function .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|mammals drosophila embryos flies rodents|adipocytes|rnai delivery for therapeutic gene silencing in cells and animals ; and  inhibition of gene expression in entity using rnai .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes progenitors adipocyte precursors adipose|adipocytes|initial product development plans include : pluripotent stem cell-derived brown entity ( agex-bat1 ) ; vascular progenitors ( agex-vasc1 ) ; and induced tissue regeneration ( itr ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes lipids adipokines triglycerides adipocyte|adipocytes|the destruction of entity , or adipocytolysis , elicits a natural response in which macrophages are attracted to remove cellular debris and fat particles through the
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes plaques islets adipocyte tumours|adipocytes|in addition , msi-1436 was shown to reduce the size of entity , reduce body fat with no reduction of lean mass , and improve glucose tolerance via inhibition of a unique combination of
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|fibroblasts adipocytes sc fibroblast fbs|adipocytes|cells obtained from the blood vessels in the lipoaspirate from the small volume of fat harvested , minus the fat cells ( entity ) and non-cellular material .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|osteoblasts chondrocytes adipocytes fibroblasts cardiomyocytes|adipocytes|by the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least entity , osteocytes , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|adipocytes adipocyte adipose adiponectin characterize|myofibroblasts lymphocytes astrocytes chondrocytes keratinocytes|adipocytes|these antibodies activate certain cell types , such as fibroblasts and entity , present in the extraocular space , which are known to highly express tshr .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes fibroblasts ascs osteoblasts hepatocytes|adipocytes|namodenoson was also shown to inhibit the proliferation of entity , further hampering the expansion of fat producing cells .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 2)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes islets monocytes osteoblasts cardiomyocytes|adipocytes|metabolic benefits of the lancl2 signaling axis are observed in hepatocytes , entity and myocytes through uptake and oxidation of glucose to improve the systemic glucose homeostasis .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|adipocytes mitochondria hepatocytes cardiomyocytes wat|adipocytes|pending delivery of sirna into entity for treatment of diabetes and obesity michael p . czech qiong l . zhou zhen y . jiang 12 / 11 / 2002 exclusive
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|cell|adipocytes adipocyte adipose adiponectin characterize|fibroblasts adipocytes myofibroblasts myoblasts liposarcoma|adipocytes|liposarcomas arise by malignant transformation of entity , not necessarily entity from within a lipoma .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hemangi endothelium vessels hepatocytes transformed|epcs mscs hscs pericytes hescs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell-forming , and angiogenic , meaning blood vessel endothelium-forming ,
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hemangi endothelium vessels hepatocytes transformed|epcs hscs pericytes hescs mscs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic ( blood cell forming ) and angiogenic ( blood vessel endothelium forming )
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hemangi endothelium vessels hepatocytes transformed|fibroblasts lineages hepatocytes lymphocytes nuclei|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 5 / 19 / 2015 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hemangi endothelium vessels hepatocytes transformed|epcs mscs hscs pericytes hescs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell forming , and angiogenic , meaning blood vessel
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hemangi endothelium vessels hepatocytes transformed|fibroblasts lineages hepatocytes lymphocytes erythrocytes|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 10 / 7 / 2014 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|hemangi endothelium vessels hepatocytes transformed|epidermal rpe dermal neural corneal|hemangioblasts|development of its rpe cells for conditions involving retinal degeneration · act is evaluating research and development programs for esc-derived entity and dermal regeneration .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|hemangi endothelium vessels hepatocytes transformed|embryos cardiomyocytes islets hepatocytes fibroblasts|hemangioblasts|this patent broadly covers the derivation and growth of human entity from a non-fetal source .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|myel erythroid monocytes colonies myeloid|leukocytes granulocytes lymphocytes leucocytes neutrophils|myeloblasts|acute myeloid leukemia aml is a type of cancer in which the bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells or platelets .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|myel erythroid monocytes colonies myeloid|blasts neutrophils rbcs erythrocytes immature|myeloblasts|comprises normalizing peripheral blood counts , resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells , or entity , to less than 5% .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|myel erythroid monocytes colonies myeloid|progenitors precursors blasts hscs clones|myeloblasts|leukemia aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|myel erythroid monocytes colonies myeloid|cscs mds senescent hscs osteoclasts|myeloblasts|which both failure to differentiate and excessive proliferation in the stem cell compartment result in accumulation of non-functional cells termed entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|myel erythroid monocytes colonies myeloid|platelets megakaryocytes precursors microparticles mps|myeloblasts|the myeloid cells are predominantly immature platelet cells called entity , or blasts , which are the leukemia cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cell|myel erythroid monocytes colonies myeloid|gliomas cscs aml neuroblastoma tumours|myeloblasts|this suggests that differentiation of entity  made possible by inhibition of mutated idh2  may drive the clinical efficacy of enasidenib .  targeting idh mutations is
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|myel erythroid monocytes colonies myeloid|monocytes hematopoietic myeloid monocyte neutrophils|myeloblasts|the gm-csf receptor is expressed on entity and other progenitor cells , and binding results in differentiation and maturation into monocytes .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|myel erythroid monocytes colonies myeloid|progenitors precursors blasts hscs clones|myeloblasts|aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|myel erythroid monocytes colonies myeloid|blasts mds neutrophils monocytes granulocytes|myeloblasts|immature white blood cells known as entity , or blasts proliferate in the bone marrow rather than mature into normal blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|myel erythroid monocytes colonies myeloid|leukocytes granulocytes neutrophils erythrocytes lymphocytes|myeloblasts|acute myeloid leukemia market • bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells , or platelets • if left untreated , aml progresses rapidly to death
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|myel erythroid monocytes colonies myeloid|leukemia malignancies neutrophils leukemias blasts|myeloblasts|acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|myel erythroid monocytes colonies myeloid|blasts leukocytes lymphocytes granulocytes neutrophils|myeloblasts|blast ( % ) refers to the percentage of leukemic entity , or blood cells affected by disease , compared to all blood cells in the sample .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|myel erythroid monocytes colonies myeloid|neutrophils blasts eosinophils counts eosinophilia|myeloblasts|from this trial show that patients with relapsed , refractory acute myeloid leukemia , or aml , experienced a decrease in peripheral blood entity , a measure of clinical activity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|myel erythroid monocytes colonies myeloid|colonies blasts erythrocytes leukocytes granulocytes|myeloblasts|aml is a type of cancer in which the bone marrow makes abnormal entity , a type of white blood cell , red blood cells or platelets .
OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythroid erythrocytes megakaryocytes erythro erythropoietin|myofibroblasts langerhans fibroblasts melanocytes lymphocytes|proerythroblasts|on stained slides the cells had the features of entity .
OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythroid erythrocytes megakaryocytes erythro erythropoietin|erythrocytes neutrophils platelets cfu megakaryocytes|proerythroblasts|increase in overall numbers of entity in mice the rapid expansion of the pro-e population also coincided with decreased numbers of erythroid burst-forming units and erythroid
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|interneurons gabaergic interne neurones gaba|interneurons synapses circuits neurones terminals|interneurons|specifically , inhibitory gabaergic entity are susceptible to excessive excitatory amino acid release .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|interneurons gabaergic interne neurones gaba|interneurons axons motoneurons synapses nerves|interneurons|this loss of nav1 . 1 channels in inhibitory entity and other nerve cells results in dravet syndrome .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|elongated resembled myotubes contain multinucleated|myotubes myoblasts fibroblasts cardiomyocytes myocytes|myotubes|in non-clinical studies with human entity grown from 35 different nmdmd patients , ataluren also exhibited a bell-shaped dose-response curve with maximal dystrophin staining observed at 10
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts myoblasts myotubes boys carriers|myotubes|force increased exon skipping in human dmd entity with exon 51 mutation *** p < 0 . 001 in studies in the mdx mouse dmd model , a validated and
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts pbmcs transcriptome lymphocytes mtdna|myotubes|we used rna-sequence ( rna-seq ) analysis of the entity from dm1 patients to create a splice score for control human subjects cells treated with sidmpk . 19 or the inactive sirna , sidmpk . 29 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|crystals seeds granules fibrils nanocrystals|myotubes|mock treated dm1 entity ( open black diamonds ) show the full splice derangement .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|elongated resembled myotubes contain multinucleated|charts subgroups ratings files cohorts|myotubes|when patient entity were analyzed , there was a marked improvement in the splice score of the entity treated with the sidmpk . 19 compared to the inactive sidmpk . 29 ( see figure 11 below ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts retinas hearts embryos chondrocytes|myotubes|as shown in the figure on the right below , we also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|elongated resembled myotubes contain multinucleated|myoblasts mitochondria nuclei myotubes fibroblasts|myotubes|effect of ataluren on dystrophin staining scores in entity isolated from nmdmd mice myotubes from nmdmd patients .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|elongated resembled myotubes contain multinucleated|myoblasts myotubes fibroblasts dmd embryos|myotubes|able to sustain utrophin protein expression based on in vitro data generated in myoblast cells from dmd patients and human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|elongated resembled myotubes contain multinucleated|myotubes capillaries gastrocnemius fibres cardiomyocytes|myotubes|the proprietary compounds bio101 and bio103 on muscle cells in particular regarding protein syntheses and growth in the diameter of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|elongated resembled myotubes contain multinucleated|telomeres mitochondria fibroblasts nuclei adipocytes|myotubes|as depicted below , results from an in vitro study demonstrate that human entity are larger in muscle cells treated with sarconeos ( bio101 ) as compared to untreated control cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts transcripts hearts platelets livers|myotubes|the splice signature approached that of control entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts chondrocytes cardiomyocytes osteoblasts vsmcs|myotubes|the studies used gymnotic uptake , or no transfection reagents , in patient-derived entity ( in vitro ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts oocytes chondrocytes embryos retinas|myotubes|as shown in the figure on the right below , also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|myotubes osteoblasts chondrocytes adipocytes myocytes|myotubes|fgfs can also induce or inhibit differentiation in a variety of cell types ( e . g . of myoblasts into entity ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|elongated resembled myotubes contain multinucleated|melanoma neuroblastoma hescs escc escs|myotubes|in the study , we demonstrated that mbd3l2 was representative of broader dux4-driven gene expression changes in entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|elongated resembled myotubes contain multinucleated|sera pbmcs brains cohorts pbmc|myotubes|administration of our proprietary aso conjugated to a fab targeting tfr1 reduced expression of key dux4 biomarkers in fshd patient entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|fibroblasts myoblasts myotubes lymphocytes pbmc|myotubes|and 50% , respectively , based on our in vitro studies that were undertaken in myoblast cells from patients with dmd and entity from healthy individuals .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|elongated resembled myotubes contain multinucleated|mammals lymphocytes hepatocytes cardiomyocytes drosophila|myotubes|we used active caspase-3 to quantify cell death because it is a protein that has been shown to be an important regulator of the apoptosis pathway in entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|elongated resembled myotubes contain multinucleated|hepatocytes lenses fibroblasts oocytes keratinocytes|myotubes|human entity when dosed with smt c1100 for 7 days demonstrated and increase of utrophin protein of around 50% when compared to
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|elongated resembled myotubes contain multinucleated|myocytes myocardium cardiomyocytes transplants flaps|myotubes|the four hearts and in one heart diacrin noticed an increase in small vessel formation at the site of surviving entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|cdna myoglobin dystrophin sirna mtdna|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts myotubes fibroblasts osteoblasts myofibroblasts|myoblasts|entity are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts myoblast myocytes precursors fibroblasts|myoblasts|genvec , genzyme , and bioheart are all developing products consisting of skeletal entity isolated from muscle , expanded in culture , and injected into a patients heart to repair dead tissue .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|myoblasts differentiate c2c12 myotubes aggregate|chondrocytes platelets fibroblasts mscs lymphocytes|myoblasts|bv , was previously awarded a manufacturing permit from the netherlands ministry of health for the in vitro culture of autologous entity for use as human medications .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|fibroblasts cadavers histology mscs hairs|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|myoblasts differentiate c2c12 myotubes aggregate|embryos cardiomyocytes biomaterials hearts myocardium|myoblasts|in the capacity that we have at diacrin without stressing the facilities and continuing to also be able to produce entity for cardiac repair .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|cdna myoglobin dystrophin sirna mtdna|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts fibroblasts mscs myocytes mitochondria|myoblasts|at the cell culturing site , our proprietary techniques are used to isolate and remove entity from the muscle tissue .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|adenovirus mscs adenoviruses aav bmscs|myoblasts|histopathology confirmed that entity expressing sdf-1a resulted in increased muscle and blood vessel formation in the damaged areas of the hearts , which was not
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|myoblasts differentiate c2c12 myotubes aggregate|mscs myoblasts hmscs msc ascs|myoblasts|when injected into scar tissue within the heart wall , entity have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|scaffolds constructs chambers mscs stents|myoblasts|after expansion , the entity are packaged and delivered to the clinical site for implantation into the injured heart tissue by a surgeon or interventional
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts substitutes allografts matrices scaffolds|myoblasts|intellectual property in connection with products , processes or services developed or provided by genvec other than autologous and allogenic skeletal entity for cardiac therapy .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts tendon myotubes myoblast myocytes|myoblasts|similarly , the fusion of entity with other entity is essential for the formation , growth , and regeneration of skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts myoblast fibroblasts myocytes cardiomyocytes|myoblasts|for example , some of our competitors are exploring whether the use of cells , other than entity , is safer or more effective than myocell .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|stents mscs crt epcs statins|myoblasts|implantation during coronary artery bypass graft ( cabg ) surgery may lead to similar effects , as do recent studies using percutaneous delivery of entity as a stand-alone procedure .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts mscs hmscs myotubes c2c12|myoblasts|ctgf treatment of entity induced their de-differentiation , or failure to become mature muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|fibroblasts cadavers histology mscs hairs|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|myoblasts differentiate c2c12 myotubes aggregate|fibroblasts myoblasts myotubes cardiomyocytes myocytes|myoblasts| wve-n531 induced a dose-dependent increase in dystrophin production ( up to 71% ) in vitro in dmd patient-derived entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|myoblasts differentiate c2c12 myotubes aggregate|myoblasts myoblast progenitors engineering precursors|myoblasts|cellular based therapies such as skeletal entity and embryonic stem cells are being pursued by companies such as bioheart , mg biotherapeutics , a joint venture created by medtronic
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|myoblasts differentiate c2c12 myotubes aggregate|fibroblasts myoblasts mscs cardiomyocytes myofibroblasts|myoblasts|clinical therapy designed to improve cardiac function by populating regions of scar tissue within a 8 patients heart with entity derived from a biopsy of a patients thigh muscle .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid promyelocytic myelogenous lymphoblastic lymphocytic|lymphoblastic|we are developing marqibo for the treatment of acute entity leukemia and other blood cancers including lymphoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid lymphocytic myelogenous lymphoid lymphatic|lymphoblastic|exclusive license agreement pursuant to which we licensed the patent rights to a specific gene mutation with respect to chronic entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid promyelocytic lymphoblastic myelogenous lymphocytic|lymphoblastic|achieve the primary endpoint of efficacy in the phase 2 clinical trial of blinatumomab in patients with acute entity leukemia 10 % 12 . 5 % 6 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid promyelocytic lymphoblastic myelogenous lymphocytic|lymphoblastic|in the second quarter , we initiated a pharmacokinetic study in phase 2 for erwinaze for the treatment of acute entity leukemia in the young adult population .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid lymphoblastic myelogenous lymphocytic lymphoid|lymphoblastic|all patients receiving autologous sb-modified t cells had non-hodgkin lymphoma , and most patients receiving allogeneic car+ t cells had acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic myeloid lymphocytic lymphoid lymphatic|lymphoblastic|of the most important potential uses of annamycin is in the treatment of children with either aml or all ( acute entity leukemia , which is more common in children ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic myeloid myelogenous lymphocytic promyelocytic|lymphoblastic|nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute entity leukemia after at least two prior regimens .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid lymphoblastic myelogenous promyelocytic lymphocytic|lymphoblastic|candidate blinatumomab ( mt103 ) is currently the subject of a european pivotal trial in patients with minimal residual disease positive acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic myeloid lymphocytic myelogenous promyelocytic|lymphoblastic|erwinaze , a biologic product , is used in conjunction with chemotherapy to treat patients with acute entity leukemia , or all , with hypersensitivity to e . coli-derived asparaginase .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic lymphocytic lymphoid myeloid lymphatic|lymphoblastic|pbcar0191 , is an allogeneic car t cell therapy targeting the well-validated tumor target cd19 and is being developed for acute entity leukemia , or all , and non-hodgkin lymphoma , or nhl .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid myelogenous promyelocytic lymphoblastic lymphocytic|lymphoblastic|oncaspar is a first-line biologic used as part of a chemotherapy regimen to treat patients with acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic lymphocytic myeloid lymphoid myelogenous|lymphoblastic|for iclusig is bcr-abl , an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia ( cml ) and philadelphia-chromosome positive acute entity leukemia ( ph+ all ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic lymphocytic lymphoid myeloid myelogenous|lymphoblastic|sar3419 targets cd19 and is a potential new treatment for cd19-expressing b-cell malignancies including nhl and b-cell acute entity leukemia , or b-all .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic lymphocytic lymphoid myeloid lymphatic|lymphoblastic|the fda approved kymriah ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid promyelocytic lymphoblastic myelogenous lymphocytic|lymphoblastic|it is in a phase 2 clinical trial for the treatment of patients with acute entity leukemia and a phase 1 clinical trial for the treatment of patients with non-hodgkin  s lymphoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic myeloid lymphocytic lymphoid myelogenous|lymphoblastic|patients , in august 2011 , we initiated a phase 1 clinical trial of quizartinib in pediatric patients with either relapsed acute entity leukemia , or all , or relapsed aml .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid lymphocytic lymphoblastic myelogenous promyelocytic|lymphoblastic|may 2005 , we commenced an open-label , multicenter phase i and ii study of talotrexin in the treatment of refractory adult entity leukemia or “all .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid myelogenous promyelocytic lymphoblastic lymphocytic|lymphoblastic|the company also acquired the u . s . and canadian marketing rights to oncaspar ( tm ) for use in the treatment of acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|lymphoblastic lymphocytic lymphoid myeloid lymphatic|lymphoblastic|u . s . for advanced non-hodgkins lymphoma , and vincristine sulfate liposome injection ( marqibo® ) approved in the u . s . for advanced adult ph- acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|lymphoblastic lymphocytes lymphocyte leukemia blast|myeloid promyelocytic myelogenous lymphoblastic lymphocytic|lymphoblastic|two other sar3419 phase ii trials are ongoing in relapsed / refractory dlbcl and in acute entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|enterocytes enteroc absorptive pig villous|enterocytes epithelium epithelia fibroblasts crypts|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum low-density lipoprotein ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|enterocytes enteroc absorptive pig villous|enterocytes epithelium intestine microvilli epithelia|enterocytes|by inhibiting nhe3 on the apical surface of the entity , tenapanor reduces absorption of sodium from the small intestine and colon , resulting in an increase in water secretion into the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|enterocytes enteroc absorptive pig villous|bloodstream circulation intestine cytosol stomach|enterocytes|we believe that kp201 is then completely hydrolyzed down to hydrocodone and the ligand in the entity , which then release the hydrocodone directly into the blood stream .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|enterocytes enteroc absorptive pig villous|enterocytes epithelium mucins proteases mucin|enterocytes|it can thus inhibit iron absorption from the gi tract by interacting with duodenal entity and limit the release of iron in the bone marrow by interacting with macrophages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|enterocytes enteroc absorptive pig villous|enterocytes epithelium epithelia fibroblasts crypts|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum ldl cholesterol
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|enterocytes enteroc absorptive pig villous|villi epithelia epithelium enterocytes crypts|enterocytes|believe that due to kp201s low binding affinity to the µ-opioid receptors it is absorbed largely intact into the intestinal entity , which are the cells lining the small intestine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|enterocytes enteroc absorptive pig villous|enterocytes epithelium epithelia villi glands|enterocytes|the cellular trans-membrane protein ferroportin , which functions as an export channel for intracellular iron in macrophages , liver hepatocytes , and duodenal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|cell|enterocytes enteroc absorptive pig villous|adipocytes wat lungs bat adipose|enterocytes|this was observed in a preclinical study in mice in which kd026 caused fat accumulation in entity and prevented fat accumulation in the liver tissues .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|cell|enterocytes enteroc absorptive pig villous|enterocytes hepatocytes fibroblasts leukocytes adipocytes|enterocytes|lomitapide also blocks mtp in entity ( cells lining the gastrointestinal tract ) , leading to an accumulation of fat in the intestinal mucosa .
OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|cell|spermatocytes spermatids sertoli contain spermatogonia|testosterone fsh inhibin dihydrotestosterone androstenedione|spermatids|hormone ) drives synthesis of testosterone in the leydig cells of the testes and fsh ( follicle stimulating hormone ) drives production of entity in the sertoli cells .
OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 3)])|OrderedDict([('BIO', 4), ('DIS', 2), ('OTHER', 2)])|cell|spermatocytes spermatids sertoli contain spermatogonia|spermatids cilia spermatozoa spermatogenesis lumen|spermatids|clinical dose on a mg / m2 basis ) in a 6-month iv study had bilateral degeneration of the seminiferous epithelium with retained entity and atrophy of interstitial cells .
OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 3)])|OrderedDict([('BIO', 5), ('DIS', 2), ('OTHER', 2)])|cell|spermatocytes spermatids sertoli contain spermatogonia|spermatids spermatozoa spermatogonia spermatocytes oocytes|spermatids|entity mature over a 72 day cycle in the seminiferous tubules in the testes under the influence of endogenous testosterone produced
OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|spermatocytes spermatids sertoli contain spermatogonia|splenocytes thymocytes erythrocytes hepatocytes embryos|spermatids|to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse entity and murine lymphocytes .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa oocyte spermat semen droplet|sperm|taken from the womans ovarian follicles and fertilized in vitro with either standard insemination , or icsi , in which a single entity is injected by needle into the egg .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1)])|cell|semen spermatozoa motile reacted abnormality|semen card seed oocyte tooth|sperm|the decrease is due to a smaller demand for the entity bank services .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|oocyte fetus follicle oocytes uterus|sperm|each parent , including recombination , or the exchange of dna within the parent chromosomes that occurs during the formation of the entity and the egg that become the fetus .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|seed oocyte ucb semen cornea|sperm|the company operates in two distinct reporting segments , one for the entity bank division and one for its stem-cell and skin care divisions as of december 31 , 2009 and 2008 and for
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|cell|semen spermatozoa motile reacted abnormality|wbc neutrophil leukocyte semen spermatozoa|sperm|this trial showed that androxal® was able to maintain entity counts in men being treated for their low testosterone levels , whereas testim® resulted in suppressed entity levels .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa cytoplasmic semen epididymal fertilization|sperm|the latter include , among other technologies , in vitro fertilization , or ivf , and intracytoplasmic entity injection , or icsi .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa spermatids heads chromosomes nuclei|sperm|lastly , semen samples that had fewer normal entity had slightly , but not significantly , higher sorp values .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|semen spermatozoa motile reacted abnormality|transplants transfusion transfusions kidneys insemination|sperm|of the protocol or for other unanticipated reasons , and we may be unable to achieve the same results with the entity of infertile donors that have been achieved with entity of fertile donors .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|haemoglobin leukocyte lymphocyte erythrocyte hb|sperm|those with an abnormally low entity concentration or overall total number , have significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa semen gametes oocytes cilia|sperm|o application as an enhancement in human intercourse - for couples prone to male factor infertility from immotile or poorly motile entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa volunteers leukocytes platelets oocytes|sperm|the university of pennsylvania safety and efficacy laboratory studies with atp ( the active ingredient in atpotent ) using human and animal entity as well as animal eggs and animal embryos .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|semen spermatozoa motile reacted abnormality|maintaining manage retain monitor virtually|sperm|the contractor must provide full service cryobiology program to include storage of embryos and entity all laboratory equipment and staffing as work load requires .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa oocytes ova embryos microorganisms|sperm|conducted in 20 women and published in the journal of reproductive medicine® in 2009 , ovaprene demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa oocytes follicles pmns cycles|sperm|abnormally few motile entity or few entity with a progressive motility were also associated with significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|fetus larva worm testis pollen|sperm|transgenic animal  shall mean a non-human animal , or an egg , entity or embryo of such animal , which bears in its germline a foreign gene derived from another animal species .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|semen spermatozoa motile reacted abnormality|seed specimen mater entire largest|sperm|continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its entity bank division .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|testosterone androgens hormones dihydrotestosterone estrogens|sperm|that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce entity or both .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('DIS', 2), ('OTHER', 2)])|cell|semen spermatozoa motile reacted abnormality|oocytes spermatozoa fetuses gametes spermatids|sperm|not viable , the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs , entity , and embryos .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|erectile testicular reproductive gonadal ejaculation|sperm|program with androxal as a treatment for men being treated for low testosterone that want to maintain or improve their entity function during treatment .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|cell|semen spermatozoa motile reacted abnormality|spermatozoa microorganisms pathogens viruses oocytes|sperm|conducted in 21 women and published in the journal of reproductive medicine in 2009 , ovaprene® demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes oocytes spermatozoa eggs embryos|gametes|( b ) donors of entity , embryos , somatic cells or human tissue did not receive valuable consideration .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes spermatozoa embryos eggs oocytes|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or " art " , services .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|oocytes eggs gametes semen spermatozoa|gametes|( e ) individuals who consented to donate stored entity , embryos , somatic cells , or human tissue were not reimbursed for the cost of storage prior to the decision to donate .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes eggs oocytes embryos spermatozoa|gametes|( c ) a person may not knowingly , for valuable consideration , purchase or sell entity , embryos , somatic cells , or human tissue for research purposes .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes spermatozoa embryos eggs oocytes|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or art , services .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes oocytes spermatozoa eggs semen|gametes|ivf treatment while the procurement , processing and distribution of entity and embryos for use in ivf and other assisted reproduction treatments falls within the scope of the eu rules governing
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 1)])|cell|gametes spermatozoa haploid gamet eggs|oocytes gametes spermatogonia spermatozoa eggs|gametes|national stem cell oversight committee , or · been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells , or human tissue gave voluntary and informed consent .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|embryos haploid gametes oocytes spermatozoa|gametes|enactment of this act , that is derived by fertilization , parthenogenesis , cloning , or any other means from one or more human entity or human diploid cells .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|gametes spermatozoa haploid gamet eggs|gametes spermatozoa embryos eggs semen|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as art services .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|oocytes gametes spermatozoa eggs embryos|gametes|( b ) donors of entity , embryos , somatic cells , or human tissue did not receive valuable consideration .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|gametes spermatozoa embryos eggs oocytes|gametes|procedures that require entity ( sperm and eggs ) to be handled in 3 vitro ( outside the body ) are classified as assisted reproductive technology , or " art " ,
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 1)])|cell|gametes spermatozoa haploid gamet eggs|oocytes gametes spermatogonia spermatozoa eggs|gametes|national stem cell oversight committee , or ● been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells or human tissue gave voluntary and informed consent .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|cell|gametes spermatozoa haploid gamet eggs|embryos fetuses gametes blastocysts oocytes|gametes|of a duly authorized institutional review board ( irb ) ; and prohibits the knowing purchase , sale or transfer of human embryos or entity for valuable consideration for research purposes .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|gametes spermatozoa haploid gamet eggs|gametes embryos spermatozoa eggs objects|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology ( " art " ) services .
OrderedDict([('BIO', 4), ('OTHER', 4)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|gametes spermatozoa haploid gamet eggs|oocytes gametes eggs spermatozoa semen|gametes|( d ) donation of entity , embryos , somatic cells , or human tissue was overseen by an irb ( or , in the case of foreign sources , an irb-equivalent ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|pituitary somat prolactin gonadotroph proliferated|granules follicles explants nuclei stores|somatotrophs|gh is an anabolic hormone synthesized , stored in , and secreted from entity of the anterior pituitary gland in response to chemical modulators from the hypothalamus and stomach .
OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|pituitary adenomas rodents gonadotroph trophoblast|monocytes astrocytes microglia lymphocytes fibroblasts|corticotrophs|similarly , dipyridamole did not amplify prednisolone effects in entity , cells that mediate the hpa axis suppression of high-dose glucocorticoid treatment .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|keratinocytes fibroblasts seb contain pigment|melanocytes fibroblasts keratinocytes seb lcs|sebocytes|because there are no preclinical models of acne , human entity , which are the cells that make up the sebaceous glands and secrete sebum , are a useful research tool for a
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|keratinocytes fibroblasts seb contain pigment|dermis cns nose retina epidermis|sebocytes|it has also been shown in a laboratory study that a chemical that blocks acetylcholine from reaching the entity reduces sebum production .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|keratinocytes fibroblasts seb contain pigment|melanocytes keratinocytes fibroblasts kc basophils|sebocytes|acetylcholine has been shown in laboratory studies to increase activity in the sebum-producing skin cells called entity , which form sebaceous glands .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|fibroblasts chondrocytes resembled adhered proliferated|monocytes fibroblasts chondrocytes lymphocytes fls|synoviocytes|synoviocyte inhibitory moa : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|fibroblasts chondrocytes resembled adhered proliferated|joints bones synovium chondrocytes fibroblasts|synoviocytes|rheumatoid arthritis results from interactions between immune cells and entity that leads to joint swelling , pannus formation and bone loss .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts chondrocytes resembled adhered proliferated|fibroblasts glands capillaries myofibroblasts vessels|synoviocytes|the synovium is lined by cells , or entity , which produce a small amount of liquid called synovial fluid that nourishes and lubricates the joint .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|fibroblasts chondrocytes resembled adhered proliferated|neutrophils fibroblasts monocytes keratinocytes platelets|synoviocytes|the entity , in turn , secrete a variety of chemicals that contribute to inflammation , tissue degradation and harmful new blood vessel formation .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 2)])|cell|fibroblasts chondrocytes resembled adhered proliferated|osteoarthritis synovitis chondrocytes synovium osteonecrosis|synoviocytes|of articular joints and joint surfaces , characterized by the rapid , uncontrolled growth of the cells that line the joints , called entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts chondrocytes resembled adhered proliferated|fibroblasts microparticles fibroblast mediators phenotypes|synoviocytes|of most individuals with rheumatoid arthritis , which drive the production of tnf and the recruitment of neutrophils and fibroblast like entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3), ('DRUG', 1)])|cell|fibroblasts chondrocytes resembled adhered proliferated|fibroblasts chondrocytes monocytes fls lymphocytes|synoviocytes|synoviocyte inhibition : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts chondrocytes resembled adhered proliferated|fibroblasts colonies fibroblast progenitors monolayers|synoviocytes|data published today demonstrate that ppi-2458 potently inhibits the growth of both human fibroblast-like entity derived from rheumatoid arthritis patients and human endothelial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|sensory nociceptive mechan proprioceptive afferent|afferents motoneurons spindles recordings branches|mechanoreceptors|in parallel , electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed ( 33 masticatory muscle entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|endothelium primitive trophoblast erythroid mesenchymal|mscs hmscs fibroblasts clones constructs|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to assess the safety and efficacy of the cells in
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|endothelium primitive trophoblast erythroid mesenchymal|vessels epcs erythrocytes ecs vsmcs|angioblasts|recyte will also develop ips cells into primitive entity , which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular system .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|endothelium primitive trophoblast erythroid mesenchymal|mscs hmscs fibroblasts clones constructs|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to test the safety and efficacy of the cells in
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|neutrophils phagocytes monocytes lymphocytes leukocytes|phagocytes|binding of ar-101 to p . aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|players phagocytes contributors leukocytes mediators|phagocytes|important entity include macrophages , that rid the body of dead cells and other debris , and granulocytes , including neutrophils , that contain granules filled
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|h2o2 hyperoxia oxidants peroxynitrite lipopolysaccharide|phagocytes|t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|h2o2 hyperoxia peroxynitrite oxidants ozone|phagocytes|nk / t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|neutrophils phagocytes parasites mitochondria pmns|phagocytes|these defective entity cannot generate superoxide , leading to an inability to kill harmful microorganisms such as bacteria and fungi .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|apcs monocytes phagocytes lymphocytes neutrophils|phagocytes|one part of the innate immune system involves large white blood cells called entity ( literally , " cell-eaters " ) that can engulf and digest foreign microorganisms and other antigens .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|neutrophils phagocytes granulocytes monocytes pmns|phagocytes|have been shown to induce antibodies that are protective in animal models and that facilitate killing of bacteria by human entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|superoxide neutrophils lipids phagocytes nadph|phagocytes|laboratory research has demonstrated that ceplene reduces formation of oxygen radicals from entity , inhibiting nadph oxidase and protecting il-2-activated nk-cells and t-cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|osteoclasts epcs stores osteoblasts lipids|phagocytes|entity were depleted using clodronate loaded liposomes through day 21 .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|enterocytes dcs neutrophils apcs phagocytes|phagocytes|and increasing anti-inflammatory mediators , the production of antimicrobial effectors and increased absorption of pathogens by specially adapted cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|apcs dcs apc leukocytes monocytes|phagocytes|we observed that depletion of entity , including myeloid apcs , significantly reduced our bdc-1001 surrogate-mediated anti-tumor activity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|nk cd3 treg dcs tregs|phagocytes|furthermore , significant increases in entity and cd8 t cells were measured in tumors following bdc-1001 surrogate treatment , further supporting a mechanism that bridges the innate
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|bei bm endogenous ak h2|phagocytes|figure 4 : bdc-1001 surrogate activity dependent on presence of entity scid / beige were dosed systemically with 5 mg / kg on day 0 , 5 and 10 .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|endothelium neutrophil platelets monocytes mitochondria|phagocytes|or other molecules in the class known as histamine type-2 ( h ) receptor agonists bind to the h receptor on the entity , the production and release of free radicals is temporarily prevented .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|phagocytes leukocytes neutrophils mitochondria lymphocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|phagocytes neutrophils leukocytes mitochondria lymphocytes|phagocytes|the release of free radicals by entity results in apoptosis ( programmed cell death ) of nk cells and t cells , thereby destroying their cytotoxic capability and rendering the
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|phagocytes leukocytes neutrophils mitochondria lymphocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and rendering
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|neutrophils eosinophils basophils platelets granulocytes|phagocytes|entity are a class of white blood cells found in abundant quantities at the site of tumors and viral infections .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|iga endotoxin adiponectin ige igm|phagocytes|maxim  s researchers have shown , however , that nk cells and t cells are suppressed by entity , another component of the body  s immune system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|phagocytic polymorphonuclear neutrophil neutrophils phagocyt|leukocytes neutrophils monocytes lymphocytes leucocytes|phagocytes|table of contents results in a dramatic increase in the production of cytokines that orchestrate the proliferation and recruitment of entity to the site of damage , resulting in inflammation .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|lymphocytes pbmcs pbmc splenocytes monocytes|splenocytes|entity were analyzed by flow cytometry to confirm effector / memory phenotype , and cultured with anti-human cd3 antibodies at 2 . 5 mg / ml and anti-human
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|neutrophils pbmcs huvecs lymphocytes splenocytes|splenocytes|entity were lysed and assayed for phospho- nuclear factor kappa b ( nfb ) p65 using an enzyme-linked immunosorbent assay .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|splenocytes sera supernatants pbmcs pbmc|splenocytes|figure 11 : entity from eae mice treated with edp1815 produced an anti-inflammatory cytokine profile .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|lymphocytes splenocytes murine splenic lymphocyte|recipient recipients averaged yielded experiment|splenocytes|svp 1 3 week week naïve recipient lmb-100 transfer entity lmb-100 + / -lmb-100 + / -
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|pbmcs splenocytes pbmc monocytes lymphocytes|splenocytes|cell responses will be assessed by in vivo cd4 and cd8 cell depletion and measure cytotoxicity and gamma-ifn release by entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4)])|cell|lymphocytes splenocytes murine splenic lymphocyte|lymphocytes leukocytes splenocytes monocytes leucocytes|splenocytes|administration for 14 days ( 10 mg / kg , sid , ip ) : no effect on blood count , blood chemistry and cytokine secretion by isolated entity no herg inhibition observed ( in vitro )
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|immunosuppression recipients experiment prophylaxis sepsis|splenocytes|svp prime challenge donor transfer entity day 0 14 aav8-hfix day 0 19 20 21 32 recipient anti-cd25 treg depletion day 0 1 28 anti-aav8 igg
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|monocytes eosinophils pbmcs neutrophils islets|splenocytes|in vitro studies demonstrated that treatment of isolated entity with virulizin ( r ) result in increased il-17e mrna expression .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|monocytes lymphocytes mnc dcs epcs|splenocytes|entity from either young or older atherosclerotic apoe ko mice were isolated from the spleen .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|sera splenocytes brains antisera spleens|splenocytes|to explore further the mechanisms of cns remyelination , we made a panel of monoclonal antibodies ( mabs ) derived from entity of sjl / j mice injected with homogenized spinal cord .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|lymphocytes splenocytes murine splenic lymphocyte|pbmc pbmcs splenocytes lymphocytes dcs|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in elispot ( depicted in
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|lymphocytes splenocytes murine splenic lymphocyte|pbmc splenocytes pbmcs lymphocytes dcs|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in enzyme-linked immune absorbent
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|pbmcs pbmc splenocytes apcs pbl|splenocytes|t cell responses were measured on day 15 by re-stimulating entity with either control ( medium ) or peptides corresponding to each antigen ( 1 , 2 , 6 , 9 , and 12 ) in the mrna vaccine
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|splenocytes lymphocytes sera islets embryos|splenocytes|before transfer , immunized entity were separated or fractionated .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|pbmc pbmcs responders til splenocytes|splenocytes|robust and specific antigen specific cd8+ifng+ t cell responses were detected in entity after re-stimulation with kras mutation 1 peptide and kras mutation 2 peptide .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|splenocytes monocytes neutrophils pbmcs leukocytes|splenocytes|cgen-25007 exhibited anti-inflammatory activity in both human pbmcs and murine entity challenged with various inflammatory stimuli as well as in an animal model of endotoxemia .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|lymphocytes splenocytes murine splenic lymphocyte|splenocytes monocytes abs intraperitoneally once|splenocytes|enumeral platform used for antibody discovery • mice were immunized with pd - 1 - his • entity activated with lps for 3 days •
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|embryos livers lungs brains hepatocytes|splenocytes|these methods were applied to analyze gene expression data from mouse entity exposed to either copaxone® or the purported generic ga .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|splenocytes spleens pbmcs lungs pbmc|splenocytes|cd4+ and cd8+ t cells from entity isolated from bnt162b2-immunized mice were strongly positive for ifn-ɣ and il-2 , producing high levels of the th1 cytokines but minute
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|lymphocytes splenocytes murine splenic lymphocyte|eosinophils eosinophil allergen neutrophils fungus|splenocytes|preincubation of the endothelial cells with blocking antibodies to eotaxin-2 was found to attenuate the adhesion of the entity to these cells ( fig . 15a ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|epidermal epidermis keratinocytes fibroblasts contain|scaffolds constructs fibres matrices hydrogels|corneocytes|in addition , to providing most of the mechanical strength of the tissue , these entity provide a stabilizing scaffold for the mortar .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|epidermal epidermis keratinocytes fibroblasts contain|tears gloves shells coatings sutures|corneocytes|the bricks ,  or entity , provide a durable defense against the ordinary frictional wear and tear of life .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|epidermal epidermis keratinocytes fibroblasts contain|keratinocytes epidermis epithelia lipids microorganisms|corneocytes|the stratum corneum , consisting of flattened and hardened non-living entity held together by a lipid matrix , acts as the main barrier to drug delivery .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|epidermal epidermis keratinocytes fibroblasts contain|fibres sheets surfaces lamellae fibrils|corneocytes|the mortar is primarily made up of fats or lipids that are organized into broad sheets or membranes .  stacks of these membranes fill the spaces between the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cell|epidermal epidermis keratinocytes fibroblasts contain|ceramide triglycerides elastin lipids melanin|corneocytes|keratinocytes , the most common cell type in the outer layer of skin , has been shown to increase the formation of entity and the production of lamellar lipids .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|fused yielded separated mating gave|crosses chimeras hybrids embryos combinations|heterokaryons|elegans to isolate innate immunity mutations , and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 2)])|cell|hepatocytes proliferated cholangi myofibroblasts resembled|hepatocytes fibroblasts myofibroblasts adipocytes peroxisomes|cholangiocytes|the licensed technology describes advanced methods for the production of mature hepatocytes and entity , the primary cell types of the liver .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|hepatocytes proliferated cholangi myofibroblasts resembled|hepatocytes myofibroblasts enterocytes acini ducts|cholangiocytes|specific and robust ccl24 staining was also shown in entity , the epithelial cells of the bile ducts .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|cell|alveolar contain fibroblasts resemble resembled|pneum fibroblasts aec alveolar epithelium|pneumocytes|sars - cov - 2 infects type ii entity in lung alveoli 1 these cells also serve as progenitor cells for repairing damaged alveoli .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|alveolar contain fibroblasts resemble resembled|astrocytes hepatocytes fibroblasts myocytes lymphocytes|pneumocytes|type it entity , known to be primary targets / reservoirs for flu , are plated in a transwell system , which essentially suspends the polarized cell monolayer
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|alveolar contain fibroblasts resemble resembled|alveoli fibres bronchi airways epithelium|pneumocytes|in covid - 19 , infection of type ii entity results in impaired gas exchange and fluid leakage into alveoli .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|she china taiwan australia canada|oncocyte|as of december 31 , 2017 , entity had $2 . 1 million outstanding and payable to biotime and affiliates in connection with the costs incurred under the shared facilities
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|she congress employers medicare surgeons|oncocyte|entity incurred no royalty expenses to date as of december 31 , 2014 .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|onc fibroblast hepatocyte erythroid follicular|mpc lf microfluidic robotic qc|oncocyte|importantly , entitys methods appear to be compliant with commercial manufacturing processes .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|equal foreign historical american canadian|oncocyte|the fact that certain of our executive officers and directors own shares of entity common stock should not be considered to mean that they constitute or are acting in concert as a “group” with
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|onc fibroblast hepatocyte erythroid follicular|biotechnology pharmaceutical medicinal biologics manufacturing|oncocyte|the patent is useful for biotimes subsidiary entity corporation for its cancer diagnostic product development .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|equipment personnel employees medicare claims|oncocyte|on july 2 , 2018 , entity entered into a lease schedule under the lease agreement no . 2 for certain equipment costing approximately $209 , 000 , requiring payments of
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|onc fibroblast hepatocyte erythroid follicular|biotechnology kyoto nih patent pharmaceutical|oncocyte|another subsidiary , entity corporation , focuses on the therapeutic applications of stem cell technology in cancer , including using vascular progenitor cells engineered to destroy
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|biotechnology proteomics genomics rnai nanotechnology|oncocyte|additional information about biotime , recyte therapeutics , cell cure , orthocyte , entity , biotime asia , lifemap sciences , and esi can be found on the web at www . biotimeinc . com .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|onc fibroblast hepatocyte erythroid follicular|fda roche nih illumina dictyostelium|oncocyte|in concert with the protocol development , entity has established a broad range of support assays to monitor and measure vascular progenitor cell differentiation processes .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|she congress cms companies pharmacists|oncocyte|on may 11 , 2017 , entity entered into another master lease line agreement ( “lease agreement no . 2” ) with the same finance company on terms similar to lease agreement no . 1 .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|another imported brazilian american canadian|oncocyte|to beneficially own the shares owned by broadwood , in the aggregate beneficially own approximately 18 . 9% of the outstanding shares of entity common stock as of april 22 , 2019 .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|employers courts parties practitioners clients|oncocyte|under the provisions of the contracts , entity may be required to incur severance obligations for matters relating to changes in control , as defined , and involuntary terminations .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|california american healthcare edwards british|oncocyte|you should direct any requests to : entity corporation 15 cushing irvine , california 92618 409-7600 s-11 3 , 523 , 776 shares common stock january
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|fda congress cms industry companies|oncocyte|entity will reimburse sbmri for 25% of the costs incurred in filing , prosecuting , and maintaining patent protection , subject to entity&#8217 ; s approval of the costs .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|onc fibroblast hepatocyte erythroid follicular|she psychiatry medicare buprenorphine cms|oncocyte|entity has entered into employment contracts with certain executive officers .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|china science japan eu english|oncocyte|references to “entity , ” “we , ” “us , ” and “our” are references to entity corporation .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|canada today government manufacturer master|oncocyte|of royalty bearing products commence , the annual fee will be credited towards entity  s royalty payment obligations for the applicable year .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|stock bird english salmon rock|oncocyte|in note 3 , the asterias shares of common stock lineage held generated similar deferred tax liabilities to lineage as the entity shares discussed above .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|fda industry china nih europe|oncocyte|entity has expanded and banked large numbers of vascular progenitor cells derived from multiple hes cell lines , including clinical-grade stem cells provided by us and our subsidiary esi .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|onc fibroblast hepatocyte erythroid follicular|fda congress law government nice|oncocyte|except as required by law , entity disclaims any intent or obligation to update these forward-looking statements .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|fibroblasts amniotic trophoblast erythroid circulating|chromosomes microorganisms spermatozoa staphylococci nuclei|amniocytes|fluorescence images demonstrating hybridization of the cep x / y and lsi 21 probes on uncultured entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|u937 neutrophils monocytes jurkat transfected|lymphocytes granulocytes neutrophils eosinophils platelets|promonocytes|two leukine treated patients had progressive increase in circulating monocytes and entity and blasts in the marrow which reversed when leukine was discontinued .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|hematocrit platelets haematocrit hct reticulocyte|reticulocytes|to six months have shown a profound and durable reduction in hemolysis ( red blood cell destruction ) as assessed by hemoglobin , entity and / or bilirubin .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 3), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|rituximab corticosteroids statins anticoagulants platelets|reticulocytes|the streck patents relate to the addition of entity to hematology controls .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|rituximab erythropoietin hydroxyurea biologics cyclophosphamide|reticulocytes|is successful , after cancellation of the streck patents , the company may be issued a patent covering integrated hematology controls containing entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|rbcs bilirubin hence ldh mps|reticulocytes|ldh and bilirubin are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|erythrocytes survivors calves neonates newborns|reticulocytes|mg / kg , *** ) , elevated hemoglobin concentrations in entity ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|proteinuria falls hba1c albuminuria a1c|reticulocytes|we observed an 18% reduction in entity in the 10 mg treatment arm relative to the placebo arm .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|oocytes eggs blastocysts embryos erythrocytes|reticulocytes|then exposed to a defined media formulation to promote further expansion and differentiation until they differentiate and mature into enucleated entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|thrombosis rebleeding hemolysis hyperbilirubinemia dvt|reticulocytes|improvement in the hemolytic anemia would be expected to result in a decrease in entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|immature rbcs erythrocytes reticulocyte blasts|reticulocytes|products provide a means of assessing the linearity of hematology analyzers for white blood cells , red blood cells , platelets and entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|ldh rbcs hence bilirubin mps|reticulocytes|bilirubin and ldh are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|immature rbcs erythrocytes reticulocyte eos|reticulocytes|these controls are designed for manual and automated counting of entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|hematocrit pcv hct erythropoietin platelets|reticulocytes|the increase in hemoglobin levels was preceded by an increase in entity showing that an increase in hemoglobin levels is a result of a physiologic increase in rbc production .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|neutrophils hematology platelets lymphocytes neutrophil|reticulocytes|dose ( mg / kg / day ) average bodyweight at end ofstudy hematology results at end of study entity ( x 103 / µl ) neutrophils ( x 103 / µl ) control - 603 m / 324 f
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|oocytes embryos gametes eggs erythrocytes|reticulocytes|at this stage , the enucleated entity are rcts that express one or more biotherapeutic proteins in the cytosol or on the cell surface .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|platelets ast plt crp bilirubin|reticulocytes|while gbt4 showed improvement in hemoglobin , entity and ldh levels in the first 15 days , these values worsened after day 15 .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|reticulocyte lymphocytes hematocrit leukocytes bilirubin|reticulocytes|levels and improved clinical measures of hemolysis at 16 weeks , as evaluated by changes from baseline in hemoglobin , percent of entity , and percent of unconjugated bilirubin .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|hematocrit platelets haematocrit pcv hct|reticulocytes|robust and sustained increase in red blood cells , hemoglobin and entity , supporting monthly or less frequent dosing .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|hematocrit creatinine platelets haematocrit crp|reticulocytes|receiving the 300 mg dose , measuring changes in parameters over the 14-day treatment and 7-day follow-up period including hemoglobin and entity , as well as tolerability and safety .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|erythrocytes lymphocytes hepatocytes splenocytes leukocytes|reticulocytes|standard in vivo genotoxicity studies in rodents , including a 2-day comet assay and a 28-day evaluation of micronucleated entity , revealed no test-article effects on genotoxicity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|cell|erythrocytes erythroid platelets erythrocyte nucleated|hematocrit creatinine wbc crp platelets|reticulocytes|( 700 mg ) 8 ( 900 mg ) 9 ( 3 per cohort ) akb-6548 was well tolerated , and dose responsive increases in entity and hemoglobin levels were demonstrated .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|granulocytes monocytes blasts neutrophils basophils|promyelocytes|in apl , there is an abnormal accumulation of immature granulocytes called entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|blasts neutrophils monocytes dcs basophils|promyelocytes|in apl , immature white blood cells called entity accumulate in the bone marrow .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|lymphocyte lymphocytes leukocyte neutrophil wbc|promyelocytes|in addition , the data showed that plinabulin has a superior immune profile compared to neulasta based on entity and immature neutrophil data from the clinical study .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2), ('DRUG', 1)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|platelets megakaryocytes erythrocytes leukocytes adipocytes|promyelocytes|the overgrowth of entity leads to a shortage of normal white and red blood cells and platelets in the body , which causes many of
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|blasts progenitors precursors granulocytes monocytes|promyelocytes|differentiation therapy causes leukemic entity to mature and undergo cell death .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|megakaryocytes eosinophils erythrocytes blasts platelets|promyelocytes|the accumulation of entity in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|neutrophils granulocytes eosinophils monocytes myeloid|granulocytes dcs neutrophils rbcs immature|promyelocytes|this fusion gene leads to the overproduction of immature white blood cells called entity and the underproduction of healthy blood cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|resemble resembled neutrophils granulocytes named|lymphocytes monocytes eosinophils platelets erythrocytes|metamyelocytes|associated with evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , entity and granulocytes ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|cell|astrocytes glial neurones glia oligodendrocytes|pituitary adipocytes gh hypothalamus islets|pituicytes|mechanism of action of lum-201 ghsr1a activation via lum-201 binding induces gh release , as demonstrated in vitro in rat entity ( lum-201 ec50 1 . 3 nm ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cell|astrocytes glial neurones glia oligodendrocytes|islets adipocytes gh explants monkeys|pituicytes|in addition , the treatment of entity with lum-201 augments the effect of ghrh on gh secretion , as the two compounds synergistically stimulated gh release from rat
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|corneal resembled fibroblasts keratinocytes proliferated|platelets neutrophils fibroblasts lymphocytes eosinophils|keratocytes|activated entity have been associated with increased collagen deposition and collagen disorganization which correlate with corneal haze and regression of the correction
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|corneal resembled fibroblasts keratinocytes proliferated|keratinocytes astrocytes scs eosinophils ascs|keratocytes|the superficial entity initially undergo apoptosis , followed by proliferation and activation of the remaining entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|corneal resembled fibroblasts keratinocytes proliferated|fibroblasts myofibroblasts chondrocytes fibroblast epithelium|keratocytes|treatment resulted in a reduction of pro-fibrotic gene expression from day 7-14 post-injury , indicating that target engagement was achieved in entity and myofibroblasts in the corneal stroma .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|fibroblasts myofibroblasts contain resemble fibro|fibroblasts myofibroblasts mscs adipocytes hscs|fibrocytes|igf-1r , the receptor for igf-1 , is highly expressed in entity , cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts myofibroblasts contain resemble fibro|mediators chemokines subtypes phenotypes subpopulations|fibrocytes|inflammation and when chronically activated , drives the development of fibrosis via several pathways and several cell inflammatory cell types and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes fungi mammals insects|melanocytes|entity produce melanin , the pigment that determines skin color and protects the body from ultraviolet radiation .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes melanin tyrosinase microorganisms|melanocytes|tanning is mediated by entity producing melanin , which is subsequently transferred to the keratinocytes .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes melanocyte keratinocytes basophils langerhans|melanocytes|vitiligo is an autoimmune condition in which the skin turns white due to the loss of entity , cells that produce the pigment melanin , which gives skin color .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes melanocyte epidermis keratinocytes melanocytic|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes melanin keratinocytes pigmentation melanocyte|melanocytes|melanin is produced by entity and is the pigment that gives human skin , hair and eyes their color .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes melanocyte langerhans melanocytic|melanocytes|the skin cells that produce the melanins are called entity and comprise 5 to 10% of the total cellular population in the epidermis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes epidermis melanoma langerhans|melanocytes|melanoma is a malignant tumor of entity , a potentially dangerous form of skin cancer .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes epithelium melanocyte fibroblasts|melanocytes|cutaneous melanomamelanoma tumors originate in the pigment-producing entity in the basal layer of the epidermis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes nevi precursors epidermis|melanocytes|· melanoma : melanoma is a cancer that begins in specific skin cells called entity , and exposure to ultraviolet rays is a major risk factor for most melanomas .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes fibroblasts adipocytes myofibroblasts appendages|melanocytes|the epidermis is comprised of specialized cells such as keratinocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|nevus precursor melanocytic melanoma neoplastic|melanocytes|melanoma begins in entity cells that make a pigment called melanin .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes melanocyte keratinocytes epidermis melanocytic|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation of the skin .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes nevi melanin nevus melanocyte|melanocytes|melanoma is a disease in which pigmented cells in the skin , called entity , turn into cancer cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes precursors nevi fibroblasts|melanocytes|melanoma occurs when entity ( pigment cells ) become malignant .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|fibroblasts melanocytes keratinocytes hepatocytes lymphocytes|melanocytes|normal entity do not express mcam , but expression is turned on and continues to increase as the cells become more malignant .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cell|melanocytes melanin keratinocytes pigment melanocyte|tumours neoplasms malignancies polyps cancers|melanocytes|malignant melanoma - predominantly a skin cancer , malignant melanoma can also occur in entity found in the bowel and the eye .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes melanocyte epidermis melanocytic keratinocytes|melanocytes|melanoma is a cancer of the entity , the cells that produce pigment in the skin .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes keratinocytes precursors nevi fibroblasts|melanocytes|melanoma melanoma is a cancer that begins in specific skin cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|fundus conjunctiva adnex choroid vicinity|melanocytes|melanoma is primarily a skin tumor , although it may also occur less frequently in the entity of the eye .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes melanin keratinocytes pigment melanocyte|melanocytes conjunctiva epidermis dermis melanocyte|melanocytes|melanoma is a malignant tumor of the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|producing necrotic contain yielded fungi|bacterium pathogens spores pathogenic parasites|endospores|proteins and cross-linking of unprotonated proteins thereby denaturing the proteins to corrupt and penetrate the bacterial walls to kill the entity and other microorganisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|differentiate comprise divide aggregate colonies|precursors axons neuroblast progenitors nbs|neuroblasts|a neuroblastoma tumor develops from immature nerve cells called entity and arises predominantly in the adrenal glands and abdomen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|differentiate comprise divide aggregate colonies|vaccines chemicals mabs libraries aptamers|neuroblasts|the license also covers methods for the production and screening of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|separated stained contain vesicles nuclei|hepatocytes electroporation lymphocytes microorganisms fibroblasts|protoplasts|electroporation is a method for increasing dna uptake by entity through prior exposure to a high voltage , which results in the temporary formation of small pores in the cell membrane .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|contain pigment melan melanin comprise|melanocytes photoreceptors rpe keratinocytes basophils|melanophores|entity are pigment-bearing cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cell|contain pigment melan melanin comprise|melanocytes carotenoids anthocyanins rbcs photoreceptors|melanophores|for most types of lower animals , entity are the primary chromatophores responsible for skin color control .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|contain pigment melan melanin comprise|melanocytes melanin melanocyte microglia melan|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|contain pigment melan melanin comprise|melanocytes keratinocytes lcs photoreceptors fibroblasts|melanophores|entity are amphibian cells that are responsible for skin color .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|contain pigment melan melanin comprise|melanocytes melanin melanocyte microglia melan|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|contain pigment melan melanin comprise|algae microalgae microorganisms cyanobacteria flowers|melanophores|entity undergo a color change in response to light or stimulation by chemicals .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|spher erythrocytes transformed resembled yielded|hemolysis thrombocytopenia anaemia hematocrit leukocytosis|spherocytes|the laboratory evaluation of waiha begins with a peripheral blood analysis revealing evidence of extravascular hemolysis ( entity , low haptoglobin , elevated bilirubin and elevated ldh ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|blasts hematopoiesis transfusions thrombocytopenia splenomegaly|sideroblasts|treatment of anemia failing an erythropoiesis stimulating agent in adult patients with very low- to intermediate-risk mds who have ring entity and require rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes karyotypes blasts karyotype hypoplasia|sideroblasts|patients to evaluate the efficacy and safety of luspatercept in patients with anemia due to lower-risk mds with ring entity who require regular rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes karyotypes karyotype cytogenetics blasts|sideroblasts|the medalist trial , a global phase 3 study in patients with very low , low , or intermediate risk , mds with ring entity who require red blood cell transfusions , is currently enrolling .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|shaped chromosomes blue stained positivity|sideroblasts|when at least 15% of the cells in an mds patients bone marrow are ring entity , this patient is considered rs positive .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|blasts transfusions mds hematopoiesis thrombocytopenia|sideroblasts|new class of therapy , for the treatment of adult patients with very low- to intermediate-risk mds-associated anemia who have ring entity and require red blood cell ( rbc ) transfusions .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes blasts karyotypes karyotype cytogenetics|sideroblasts|the phase 3 mds medalist trial targets patients with very low , low or intermediate risk mds with ring entity who require rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes erythrocytes hematopoiesis lymphocytes platelets|sideroblasts|patients with mf that has transformed into aml , known as blast-phase mf , and in patients with refractory anemia with ringed entity , or rars , a subpopulation of mds .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes cytogenetics karyotypes karyotype 17p|sideroblasts|the majority of patients with mds that develop cytopenias lack ring entity or a single , defining splicing factor mutation and are termed non-rs .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes blasts erythrocytes rods hematopoiesis|sideroblasts|clinical safety and efficacy data on imetelstat from patients with a form of mds known as refractory anemia with ringed entity ( mds-rars ) enrolled as part of the mayo clinic pilot study .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|erythroid sider pigment erythrocytes erythropoiesis|sider chromosomes syndromes erythropoiesis hematopoiesis|sideroblasts|of contents subgroup of patients with mds that show the presence of iron deposits around the mitochondria , known as ring entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|erythroid sider pigment erythrocytes erythropoiesis|neutropenia hemorrhage whom fever episodes|sideroblasts|all patients presented with ring entity were rbc transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent ( esa ) therapy , or were esa naïve
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|erythroid sider pigment erythrocytes erythropoiesis|blasts erythrocytes neutrophils rbcs hypoplasia|sideroblasts|and safety of luspatercept versus placebo in patients with anemia due to very low , low , or intermediate-risk mds with ring entity ( ≥ 15% ) who require red blood cell transfusions .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|chromosomes syndromes erythrocytes phenotypes anomalies|sideroblasts|these ring entity are associated with ineffective erythropoiesis and anemia .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|erythroid sider pigment erythrocytes erythropoiesis|erythrocytes rbcs blasts platelets chromosomes|sideroblasts|in the overall trial population , the rate of ≥8-week rbc ti did not differ based on the presence of ringed entity , indicating activity of imetelstat across different subtypes of mds .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cell|cytotoxicity incubation platelets spherical abstract|hb wbc crp bun bilirubin|retic|g / dl . this was thought to be not clinically possible for a hgb at this level in conjunction with markedly elevated entity and low rbc counts .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cytotoxicity incubation platelets spherical abstract|centr hem plasm hepat nucle|retic|mg / kg , *** ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cytotoxicity incubation platelets spherical abstract|centr hem plasm nucle hepat|retic|mg / kg ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cytotoxicity incubation platelets spherical abstract|revised counting manual colorimetric quantification|retic|the entity procedure , which is now implemented , measures the number of entityulocytes ( immature red blood cells produced in the bone marrow ) and
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|cytotoxicity incubation platelets spherical abstract|hem centr leuc nucle mononucle|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p < 0 . 005 , *
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|cytotoxicity incubation platelets spherical abstract|hem centr leuc nucle hepat|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p 2 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cytotoxicity incubation platelets spherical abstract|nucle hem plasm anis autom|retic|in may 1996 , the company received fda 510 ( k ) clearances for two additional commonly performed microscope procedures : entityulocyte count ( entity ) and anti-nuclear antibodies ( anas ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|clones clonal transfected transformed expanded|deletions rearrangements rnas expansions lymphocytes|subclones|progressive disease to elucidate whether these alterations were newly acquired following ibrutinib exposure or represent selective expansions of pre-existing small entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|clones subpopulations suspensions pools lysates|subclones|evidence against the existence of mammalian tpe comes from a comparison of mrna levels for a telomeric neo gene in entity of sv40-transformed human fibroblasts with varying telomere lengths .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|transfection mixtures lysates labeling construction|subclones|such non-limiting examples include : entity of unmodified cell lines , purified or fractionated subsets of materials provided by atcc , proteins expressed by dna / rna supplied by atcc ,
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|lysates mixtures construction microarrays panels|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by university , monoclonal
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|lysates mixtures transfection microarrays combinations|subclones|some examples include : entity of unmodified or modified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|mabs reagents others references epitopes|subclones|the term " moab 7e11 " includes all entity claimed in such patent .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|mixtures propagation subpopulations combinations collections|subclones|some examples include : entity of cell lines ; purified or fractionated subsets of the original materials or progeny ; dna or rna ; genetic material ; secreted or
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|transfection mixtures construction lysates combinations|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by genencor or
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|clones clonal transfected transformed expanded|insertions duplications additions substitutions deletions|subclones|with information concerning the enzymes being used for ongoing subcloning to determine -9- 11 the absolute orientation and position of entity and deletions with respect to the original clone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|progeny unmodified clones transformed mutated|subclones|( i ) licensed products means materials and all progeny , entity , and unmodified derivatives of the cell clones .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|digests templates gels standards libraries|subclones|concentrate samples and load curagen  s dna sequencing gels , allowing the integrated system to generate base called sequences directly from dna entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|transfection lysates mixtures labeling construction|subclones|some examples include : entity of unmodified cell lines , purified or fractionated subsets of the material , proteins expressed by dna / rna supplied by m . i . t . , or monoclonal
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|clones clonal transfected transformed expanded|subunits batches impurities deletions plasmids|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|clones clonal transfected transformed expanded|clones daughters sons progeny hybrids|subclones|biological materials means the materials identified in appendix a together with any progeny , entity , or derivatives thereof provided by the foundation or created by licensee .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|clones clonal transfected transformed expanded|clones lymphocytes cancers thymocytes subpopulations|subclones|in the face of immune pressure , entity susceptible to t cell killing are eliminated , leaving behind resistant tumor clones that are mhc deficient , and hence no longer
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|clones clonal transfected transformed expanded|subunits batches impurities deletions plasmids|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clonal transfected transformed expanded|documents comments publications modifications vaccines|subclones|materials shall mean the tangible material specifically described in exhibit a and physically transferred to licensee and any unmodified copies , progeny and entity made therefrom .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|allogeneic cd34 msc conditioning engraftment|onc bio rhu auto epi|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( “licensed products” ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1), ('DRUG', 1)])|cell|allogeneic cd34 msc conditioning engraftment|rhu bevacizumab onc bio epi|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1), ('DRUG', 1)])|cell|allogeneic cd34 msc conditioning engraftment|rhu bevacizumab onc bio epi|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#8220 ; licensed products&#8221 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('BIO', 2), ('DIS', 1)])|cell|allogeneic cd34 msc conditioning engraftment|bevacizumab onc rhu carboplatin autologous|allostim|the license granted covered two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|allogeneic cd34 msc conditioning engraftment|onc autologous auto bevacizumab bio|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( “licensed products” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|van fur ultra die med|pharmaceutical generic racemic pure bla|carticel|the improvement in gross margin is primarily the result of an increase in entity [ r ] aucc sales and a reduction in labor and manufacturing expenses and decreased material expenses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|van fur ultra die med|platinum radiofrequency tio epinephrine ortho|carticel|through june 30 , 1997 , gtr had received approximately $5 . 1 million in revenues from u . s . sales of entity ( tm ) acc since its market introduction in march 1995 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|van fur ultra die med|others evar athletes tavi aaa|carticel|efficacy data demonstrating durability of repair is now out to 20 years for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|van fur ultra die med|tio nickel titanium tet lif|carticel|the following table summarizes the early results of the commercialization of entity ( tm ) acc in the u . s . :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|van fur ultra die med|generic patent cob pure otc|carticel|if gtr were prohibited from marketing entity ( tm ) aucc in the u . s . , its results of operations would be materially adversely affected .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|van fur ultra die med|forceps histology brush cytology histopathology|carticel|the company recognizes maci ( or entity ) kit revenue upon delivery of the biopsy kit at which time the customer ( the doctor ) is in control of the
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|van fur ultra die med|trastuzumab paclitaxel tacrolimus platinum doxorubicin|carticel|in august 1997 , the fda approved gtr  s bla for entity ( tm ) aucc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|van fur ultra die med|pharmaceutical medicare pharmacy market tax|carticel|for the first half of 2015 , total entity and epicel net product revenues increased approximately 17% over pro-forma net product revenues for the same period in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|van fur ultra die med|blue bt lit hbo cochlear|carticel|the blue cross blue shield association has determined that its technology assessment committee does not believe that entity chondrocytes meets all of its published criteria for new treatments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|van fur ultra die med|tablets cigarettes vaccines chemicals chips|carticel|the cambridge facility has been used for u . s . manufacturing and distribution of entity , worldwide manufacturing and distribution of epicel and production of maci for clinical testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|van fur ultra die med|ile bir ya ici van|carticel|orthopaedics gabi*  sepra  synvisc®  provisc® ( alcon )  entity  hylaform® ( inamed ) focused on treating disease and restoring health through local effects on biology
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|van fur ultra die med|market medicare brand pharmaceutical tax|carticel|total entity and epicel net product revenues in the second quarter increased approximately 31% over pro-forma second-quarter net product revenues in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|van fur ultra die med|ortho generic api eu xp|carticel|the commercial success of entity ( tm ) aucc will also depend materially on the ability of gtr to increase the approval rate for reimbursement of the product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|van fur ultra die med|cochlear penile orthopaedic contraceptive zygomatic|carticel|total revenues for the quarter ended june 30 , 2015 were $13 . 6 million and included $9 . 1 million in net sales of entity implants and surgical kits and $4 . 3 million in net sales of epicel .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|van fur ultra die med|colonoscopy endoscopy laparoscopy ercp misoprostol|carticel|the increase is primarily due to higher demand for entity , offset , in part , by a decline in sales of epicel due to a decrease in patients requesting this service .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|van fur ultra die med|kel fibro neuros rhin hibern|carticel|genzyme believes that entity chondrocytes does in fact meet all of these criteria and are discussing the evaluation with the blue cross blue shield
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|van fur ultra die med|eu platinum liposomal gd ru|carticel|( 5% ) 16 ( 76% ) 1 ( 5% ) 4 ( 19% ) gtr has compiled safety data on 460 patients who have undergone treatment with entity ( tm ) acc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|van fur ultra die med|arthroscopy prp arthroplasty resurfacing olt|carticel|entity is indicated for the repair of symptomatic cartilage defects of the femoral condyle ( medial , lateral or trochlea ) caused by acute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|van fur ultra die med|arthroscopy surgeons resurfacing arthroplasty surgeries|carticel|market opportunity for entity in the u . s . annually , there are approximately 1 million arthroscopic procedures and more than 250 , 000 cartilage surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|van fur ultra die med|eu trastuzumab tio platinum aac|carticel|gtr is conducting additional research relating to entity ( tm ) aucc pursuant to a sponsored research agreement with the university of gotenburg in sweden and certain physicians , including the two
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|van gen roche rituximab nov|p13 atg dt val rituximab|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t-cell product designed to accelerate immune recovery after hsct and to reduce relapse of leukemia following
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|van gen roche rituximab nov|cel adv rituximab atg adenovirus|rivogenlecleucel|rimiducid will be administered to inactivate entity ( rivo-cel ) in the event of gvhd not responsive to standard of care treatment updated 8 nov 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2), ('DIS', 1)])|cell|van gen roche rituximab nov|cel rituximab everolimus sirolimus adv|rivogenlecleucel| rivo-cel ( entity , formerly known as bpx-501 ) is a product candidate intended to improve hsct outcomes in the treatment of hematologic malignancies , including
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|van gen roche rituximab nov|p13 val atg rituximab cel|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t cell product designed to reduce the rate of relapse of leukemia following a stem cell
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|uncontrolled slow incomplete nonspecific burst|kymriah|– conserving the clinically validated cd19 car cell manufacturing process minimizes confounding risks penn process , not novartis process ; avoids entity release
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|manufactured approved released supplied licensed|kymriah|the fda has also approved two non-aav gene therapy products , entity by novartis international ag , for pediatric and young adult patients with a form of acute lymphoblastic leukemia and yescarta by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|ku kur kar ky china|licensed humanized producing car cd19|kymriah|two such companies , novartis international ag ( entity® ) and kite pharma inc . / gilead sciences , inc . ( yescarta® ) , have now commercialized autologous car+ t cells against cd19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|ku kur kar ky china|cannabis honey marijuana ginseng she|kymriah|the company did not recognize royalty revenue in the comparative periods in the prior year given that entity was first approved for commercial sale in the second half of 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cell|ku kur kar ky china|crs allergic uc sar ibd|kymriah|only 20% of entity or yescarta patients treated with tocilizumab had resolution of signs and symptoms 6 days after onset of crs and ~50%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|abbott usa 3m sham 2x|kymriah|nomenclature ‘zuma-19 , may be the basis for the registration of lenzilumab , given the similar trial design to yescartas and novartiss entity® ( “entity” or “entity®” ) registration trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|california fda florida google oregon|kymriah|both entity and yescarta carry “black box” warnings in their labels for nt and crs and are subject to a rems program ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|helps helped reduces improves leaders|kymriah|maintaining clear leadership in share of voice entity polivy xpovio yescarta share of voice aug sep oct monjuvi compared to >50% monjuvi monjuvi 50% 30% 0% hcp engagement
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|cell|ku kur kar ky china|mitoxantrone fludarabine cytarabine rituximab etoposide|kymriah|the fda approved entity ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|cell|ku kur kar ky china|rituximab etanercept infliximab thalidomide ivig|kymriah|because of the risk of cytokine release syndrome and neurological events , entity is being approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|japan approved domestic china launched|kymriah|september 2018 , we entered into a license and collaboration agreement with novartis to manufacture and supply their car-t cell therapy entity® in china .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|trade another usp patent acs|kymriah|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to yescarta or entity source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 1), ('DIS', 1)])|cell|ku kur kar ky china|ranibizumab bevacizumab gdnf erythropoietin dystrophin|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , namely , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|roche abbott affymetrix hope leiden|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|ku kur kar ky china|dabigatran valsartan clopidogrel statins linezolid|kymriah|in august 2017 , novartis received fda approval for entity and paid the company $2 . 5 million as a result of the achievement of a related milestone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|ku kur kar ky china|immunotherapy rituximab mva ada electroporation|kymriah|entity is a genetically-modified autologous t-cell immunotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|ku kur kar ky china|pharmaceuticals retard alfa roche xl|kymriah|there are currently two car-t therapies approved in the u . s . and eu , novartis entity ( tisagenlecleucel ) and gilead / kites yescarta ( axicabtagene ciloleucel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|ku kur kar ky china|say entitled berlin japan washington|kymriah|commenting on the results , joseph jimenez , ceo of novartis , said : “novartis became the first company to commercialize a car-t therapy , entity , in q3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|ku kur kar ky china|rituximab cd19 immunotherapy mab car|kymriah|• entity ( tisagenlecleucel ) is a cd19-directed genetically modified autologous chimeric antigen receptor t-cell ( car-t ) therapy delivered as an intravenous infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|cell|ku kur kar ky china|rituximab approved cytarabine pemetrexed bevacizumab|kymriah|yescarta has been approved for the treatment of relapsed or refractory large b-cell lymphoma and entity for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|del van una aba era|car rituximab roche cd19 rai|yescarta|in 2017 , the fda approved the first two car-t cell therapies , kymriah and entity , after these products demonstrated strong efficacy in select relapsed or refractory b cell malignancies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|del van una aba era|approved rituximab bortezomib relapsed licensed|yescarta|one of these therapies , entity® obtained accelerated approval for treatment of refractory non-transplant-eligible dlbcl patients in october 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|others soon approved car breakthrough|yescarta|finally , two car-t cell therapies were just approved for the treatment of all – kymriah™ ( novartis ) and entity™ ( gilead ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|approved licensed fda manufacturing fur|yescarta|novartis kymriah™ and gileads entity™ , two gene-modified cell-based therapies , are approved in both the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|del van una aba era|chemicals foods antimicrobials medicines reagents|yescarta|further , if contaminants are discovered in our supply of entity or in the manufacturing facilities , such manufacturing facilities may need to be closed for an extended period of time to
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|cell|del van una aba era|rituximab bortezomib fludarabine imatinib trastuzumab|yescarta|in october 2017 , kite obtained fda approval to commercialize entity for the treatment of adults with relapsed / refractory diffuse large b-cell lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|del van una aba era|dabigatran clopidogrel clozapine propofol pci|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|del van una aba era|usp fda linezolid celecoxib comparator|yescarta|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to entity or kymriah source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|cell|del van una aba era|docetaxel capecitabine bevacizumab sunitinib erlotinib|yescarta|the objective of the phase 2 trial is to determine the effect of mavrilimumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|del van una aba era|qol aml efs prophylaxis leukemia|yescarta|kite has published data on entity in all as well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|names notes contents patent articles|yescarta|arcalyst® is a registered trademark of regeneron pharmaceuticals , inc . and entity® is a registered trademark of gilead sciences , inc . , or its related companies . ​5 table of contentspart 
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|companies award contributions marks industry|yescarta|the royalties stem from sales and milestones related to the entity® product .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|cell|del van una aba era|atg irinotecan sorafenib everolimus oxaliplatin|yescarta|additionally , in october 2017 , kite received approval from the fda for entity ( axicabtagene ciloleucel ) , formerly known as kte-c19 , for treatment of patients with r / r nhl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|approval fda approved claims versions|yescarta|both kymriah® and entity® were approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|del van una aba era|adoptive vaccines immunotherapy rituximab car|yescarta|two car-t therapies have been approved to treat large b-cell lymphoma , kymriah® and entity® , and others are being tested in clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|del van una aba era|therapeutics preclinical approved translational pharmaceutical|yescarta|pipeline , building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at kite and gilead , including entity® , tecartus® and magrolimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|del van una aba era|dabigatran clopidogrel clozapine propofol pci|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|abc atg atl aq opc|yescarta|the initial results of axicabtagene ciloleucel ( entity ) , the prognosis of high-grade chemo refractory nhl , is dismal with a medium survival time of a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cell|del van una aba era|rituximab immunotherapy docetaxel thalidomide temozolomide|yescarta|entity is a therapy for patients who have not responded to or who have relapsed after at least two other kinds
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|del van una aba era|reactivation unusual atypical relapsed remission|yescarta|this was notable given the patient had relapsed following treatment with entity® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|yellow acetate bei tab nickel|rituximab approved corrected approval smart|tabelecleucel|recent highlights and anticipated upcoming milestones tab-cel® ( entity ) • two phase 3 clinical studies are ongoing ( match and allele ) to evaluate tab-cel® for patients with ebv+ ptld
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|yellow acetate bei tab nickel|sip rituximab slit mva immunotherapy|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda- and ema-approved therapy for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cell|yellow acetate bei tab nickel|sip rituximab dcs slit rit|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda and ema approved therapy
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|cell|yellow acetate bei tab nickel|immunotherapy rituximab trastuzumab car dcs|tabelecleucel|with entity poised to potentially become the first approved off-the-shelf t-cell therapy and a robust pipeline of high potential candidates , our ambition
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|lumbar cranial pelvic vertebral sciatic|tendon|and adcon-t / n to be marketed in the 19 european union countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|tendon capsular acl tendin ligament|tendon|warnings and precautions risk of tendinitis , entity rupture , peripheral neuropathy and central nervous system effects is increased with use of fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon tear tendons tears flexor|tendon meniscus meniscal osteochondral tendons|tendon|and / or product development for various treatments for or involving fracture repair , spine fusion surgery , cartilage defect repair and ligament and entity repair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|tendon tendons meniscus meniscal suture|tendon|graftjacket® maxforce extreme is a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of entity and ligament repairs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|ophthalmic cataract orthopaedic craniofacial cranial|tendon|now being sold in all major countries in the eu , as well as australia and new zealand for use in entity and peripheral nerve surgeries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|tendon muscular hernia tendons ulcer|tendon|therapeutic devices utilizing its nonthermal ultrasound technology ( " orthosound " ) for use in medical applications that relate to bone , cartilage , ligament or entity diagnostics and healing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|tendon tear tendons tears flexor|enamel tendon epithelium fascia capsule|tendon|extent the gingiva functions as part of the apparatus holding the tooth to the jaw ) , ligament ( including the periodontal ligament ) , entity and / or cartilage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|tissue|tendon tear tendons tears flexor|hypersensitivity allergic neuropsychiatric seizure cns|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon tear tendons tears flexor|nail osteoporosis tooth tendon joints|tendon|bone & entity pill it consists of extracts of a variety of chinese medicinal herbs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|tissue|tendon tear tendons tears flexor|hypersensitivity allergic neuropsychiatric seizure cns|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|tendon joints tooth muscular articular|tendon|the medicinal product is to be taken orally for the purpose of curing bone and entity disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|tissue|tendon tear tendons tears flexor|fluoroquinolone ciprofloxacin quinolone moxifloxacin fluoroquinolones|tendon|warnings regarding the risk of entity related adverse events were already included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|tendon tendons meniscus bony cuff|tendon|graftjacket® is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|tendon meniscal acl meniscus dural|tendon|by augmenting the strength of the entity repair and incorporating biologically , graftjacket® regenerative tissue matrix increases surgeons confidence in the surgical outcome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|tendon tendons meniscus bony cuff|tendon|graftjacket® matrix is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon tear tendons tears flexor|tendin pharyng burs epididym my|tendon|fluoroquinolones are 26 known for several undesirable effects such as entityitis , achilles entity rupture , c . difficile colitis , and hepatotoxicity and central nervous system side effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|tendon tear tendons tears flexor|lumbar cranial vertebral sciatic pelvic|tendon|adcon-l and adcon-t / n to be marketed in the 19 european countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|tissue|tendon tear tendons tears flexor|fluoroquinolone quinolone ciprofloxacin fluoroquinolones moxifloxacin|tendon|currently , warnings regarding the risk of entity related adverse events are included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|tendon meniscal ligament bony meniscus|tendon|ligament and entity repair ligaments are the soft tissues that connect bone to bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tear tendons tears flexor|hepatocellular chromosomal ocular mucosal corneal|tendon|further , in july 2008 , the fda requested manufacturers of fluoroquinolones to include a black box warning for entity damage .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|macula macular photoreceptors retina foveal|macular macula corneal choroidal ocular|macula|optina for diabetic entity edema on october 7 , 2013 , we received positive results from the interim analysis of optina trial for diabetic macular edema .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|macula macular photoreceptors retina foveal|glaucoma retina strabismus retinoblastoma royal|macula|company presented preclinical data at the association for research and vision in opthalmology conference in may 2012 , and at the entity society meeting in june 2012 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|macula macular photoreceptors retina foveal|cornea peritoneum epidermis conjunctiva epithelium|macula|the leakage of fluid , solutes , proteins and immune cells cause the entity to swell and thicken .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|choroid macula retina vitreous photoreceptors|macula|described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina , entity or nerve fiber bundle .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|fovea macula choroid hole disk|macula|in patients with dme , leakage from these abnormal blood vessels occurs in the central portion of the retina , called the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|retina macula choroid photoreceptors fovea|macula|introduction to amd amd is a progressive and irreversible disorder of the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|fovea retina macula choroid rpe|macula|the entity is the central portion of the retina in the eye and is responsible for both high acuity vision and color
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|nih american texas michigan dutch|macula|according to the entity vision research foundation , as many as 15 million people in the united states suffer from some form of amd , with more
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular photoreceptors retina foveal|retina macula globe cornea choroid|macula|these vessels can leak fluid and blood , which may lead to swelling and damage of the entity causing vision loss .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|fovea periphery macula vf fundus|macula|implies , usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) because of damage to the retina .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|macula macular photoreceptors retina foveal|vitre macular retinopathy zona mala|macula|for age-related entityr degeneration , or amd , which is a disorder of the central portion of the retina , known as the entity , that may result in blindness .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|retina fovea macula rpe choroid|macula|or neovascularization , causes vision loss due to blood and protein - 94 - table of contents leakage below the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|tissue|macula macular photoreceptors retina foveal|headache fertility epilepsy orthopaedic menopause|macula|the principal investigator of study 003 presented a case report from the first patient to complete the protocol at the entity society meeting on february 19 , 2014 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|retina macula choroid vitreous rpe|macula|in the dry form , there is a breakdown of retinal pigment epithelial cells in the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|choroid macula vitreous retina fovea|macula|the wet form is caused by growth of abnormal blood vessels ( cnv ) under the central part of the retina or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|tissue|macula macular photoreceptors retina foveal|hemangioma neovascularization telangiectasia retinopathy fovea|macula|an eye disease characterized by the growth of abnormal blood vessels under the central part of the retina , called the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|mala peri prere chorio microcys|macula|entityr edema is the build-up of fluid that can cause abnormal swelling of the macula , the portion of the retina responsible for central vision and color perception .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular photoreceptors retina foveal|fovea macula retina pupil macular|macula|the central portion of the retina is the entity , which is the region responsible for seeing color and the acute central vision necessary for activities such as reading , face
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|fovea macula periphery fundus vf|macula|that usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|macula macular photoreceptors retina foveal|choroid vitreous retina macula fovea|macula|this process , known as angiogenesis or neovascularization , results in fragile blood vessels that leak fluid and blood into the entity , the center portion of the retina .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|perine nerves sheath vessels fascia|nerves dermis axon myelin endothelium|perineurium|the lamellar structure of the entity and a deficiency in collagen packing in the endoneurium was observed more frequently and to a larger extent in fibromyalgia
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|nerves vec axons fascia tendon|dermis fascia nerves capillaries stroma|endoneurium|the lamellar structure of the perineurium and a deficiency in collagen packing in the entity was observed more frequently and to a larger extent in fibromyalgia patients than in controls .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|urothelial uroth epithelium involves contains|epithelium epithelia fibroblasts detrusor glands|urothelium| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|epithelium detrusor fascia epithelia capsule|urothelium|months post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial uroth epithelium involves contains|urothelial uroth transitional detrusor muscular|urothelium|bladder carcinoma is a specific form of bladder cancer resulting from the development and progression of cancerous tumors within the entity layer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|urothelial uroth epithelium involves contains|pelvis ureter kidneys urethra genitourinary|urothelium|eligible patients included those with transitional cell carcinoma of the entity , including renal pelvis , ureters , urinary bladder , and urethra .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|urethra epithelium rectum vagina peritoneum|urothelium|not effectively permeating the entity  rtgel delivered treatment to the bladder as expected with dwell time of up to 10 hours
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|urothelial uroth epithelium involves contains|cilia epithelium microvilli erm detrusor|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|epithelium detrusor fascia epithelia capsule|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|epithelium urothelial lining epithelia uroth|urothelium|upper tract urothelial carcinoma ( utuc ) utuc refers to malignant changes of the entity ( the epithelial lining ) of the upper urinary tract of the calyces , renal pelvis and ureter .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|urothelial uroth epithelium involves contains|epithelium detrusor urethra epithelia capsule|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|epithelium epidermis capsule submucosa crypts|urothelium|beneath the entity , there is a layer called the lamina propria .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|urothelial uroth epithelium involves contains|conjunctiva retina cornea sclera tendon|urothelium|apollo trial did not meet the primary endpoint , believed to be the result of botox not effectively permeating the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|urothelial uroth epithelium involves contains|cilia epithelium microvilli erm cytoskeleton|urothelium|one theory of pbss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|urethra epithelium detrusor vagina lumen|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag , layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|urothelial uroth epithelium involves contains|cilia epithelium microvilli erm detrusor|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|urothelial uroth epithelium involves contains|epithelium bbb endothelium epidermis capsule|urothelium|implantation of stray " floating " tumor cells in areas in which the entity has been disrupted may be followed by the growth of the implanted cells to form a new tumor .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|urothelial uroth epithelium involves contains|cilia epithelium microvilli erm podocyte|urothelium|one theory of bpss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial uroth epithelium involves contains|transitional squamous luminal urothelial columnar|urothelium|the innermost lining is comprised of cells called urothelial or transitional cells , and this inner layer is called the entity or transitional epithelium .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|urothelial uroth epithelium involves contains|urethra epithelium detrusor vagina lumen|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial uroth epithelium involves contains|physiology musculature innervation pathophysiology contractility|urothelium|be well positioned , as it will address both the acute pain the patient experiences and the dysfunctional aspect of the entity of the bladder wall .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|stratified lined corneal keratin secretory|crypts submucosa muscularis lumen epithelium|epithelium|overview of ibd ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the entity and the submucosa of the colon .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia zone gland retina|epithelium|key portions of the eye that were evaluated for levels of drug remaining were the sclera-choroid-retinal pigmented entity , or scr , the neural retina and the vitreous .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia endothelium rpe gland|epithelium|in occult lesions , all of the blood vessels are below the retinal pigment entity , or rpe , and the areas on angiograms have a stippled appearance .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia lining lumen vasculature|epithelium|this includes injuries to the hematopoietic and immune systems , the entity of the digestive tract and hair follicles .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|stratified lined corneal keratin secretory|fibroblasts papilla fibroblast epithelium epidermis|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|stratified lined corneal keratin secretory|fibroblasts papilla fibroblast epithelium epidermis|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity , which should lessen the occurrence of ras .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia gland rpe endothelium|epithelium|by the much greater amount of the fluorescent protein expressed ) with aav8 as compared to aav2 in the retinal pigment entity ( rpe ) and to the photoreceptor ( pr ) layer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|epithelium intestine organism stomach neutrophil|epithelium|of calcium and phosphate ions , which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the entity and permeating the mucosal lesion in mucositis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|stratified lined corneal keratin secretory|endothelium epithelium button suture ulcer|epithelium|these events are commonly observed following removal of the corneal entity and in the treatment group of our trials , occurred at a higher incidence than observed in control patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|stratified lined corneal keratin secretory|architecture epithelium histology patency anatomy|epithelium|pathologic analysis showed marked effects on breast duct entity in ducts treated with either drug compared with untreated ducts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|stratified lined corneal keratin secretory|epithelium microcirculation villi microvasculature architecture|epithelium|blood causes a prolonged period of low blood flow to the intestines that can lead to damage to the intestinal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|epithelium crypts epithelia crypt enterocytes|epithelium|the expression of il-15 in the intestinal entity is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|stratified lined corneal keratin secretory|epithelium endothelium cornea retina stroma|epithelium|the procedure involves the removal of " bowman  s layer , " an intermediate layer between the entity ( outer corneal layer ) and the stroma ( middle corneal layer ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|stratified lined corneal keratin secretory|epithelium follicle fibroblast keratinocyte papilla|epithelium|the hair matrix entity is one of the fastest growing cell populations in the human body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|tissue|stratified lined corneal keratin secretory|mucus mucin mucins carcinogens prostaglandins|epithelium|the gi tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia retina nuclei rpe|epithelium|loss of the functional oca2 protein results in a lack of pigment in the retinal pigment entity and the underlying choroid layers .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia gland endothelium rpe|epithelium|for lca2 , retinal function was restored by reconstituting gene function in the retinal pigment entity ( rpe ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|lumen epithelium passages route circulation|epithelium|the nasal administration is intended to determine if physiologic measurement of cftr function can be obtained in the nasal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|stratified lined corneal keratin secretory|epithelium epithelia mucus flora milieu|epithelium|our vaginal products adhere to the vaginal entity until discharged upon normal cell turnover , a physiological process that can take 72 hours , or longer , and provide sustained and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|tissue|stratified lined corneal keratin secretory|epithelium septum gland passage polyp|epithelium|however , the nasal entity is the most accessible site for measuring cftr function in humans and provides a human model of epithelial cell uptake
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|gives ectoderm ectodermal epidermal contains|ectoderm endoderm neural epithelium ectodermal|ectoderm|and the capability to differentiate into cells representing the three germ layers - endoderm ( gut epithelium ) , mesoderm ( striated muscle ) and entity ( neural epithelium ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|hematopoietic neural ips nk islet|endoderm|the third patent , granted in the united states , covers the method for deriving entity cells using stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|mesoderm mesodermal endoderm ectoderm undifferentiated|endoderm|territory patent no . general subject matter expiration us 7 , 763 , 466 method to produce entity cells may 2025 us 7 , 955 , 849 method of enriching population of mesoderm cells may 2023 us
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|mesenchymal satellite dendritic nk ips|endoderm|in particular , entity cells make cells of internal organs such as the lung , pancreas , and liver as well as other internal cell types .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|endoderm ectoderm mesoderm visceral epithelium|ips somatic pluripotent neural progeny|endoderm|by way of example , we are currently a party to an interference proceeding that involves patent filings for making entity cells from hescs .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|endoderm vulv spermatogonia mesodermal neuroect|endoderm|that the derivation of any of the entityal lineage cells from embryonic stem cells would necessarily pass through the definitive entity stage .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|proof therapeutics indications science remedies|endoderm|if we are not successful in the viacyte appeal , viacyte would retain its patent claims directed to definitive entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|endoderm hepatocytes hepatocyte autophagy islet|endoderm|definitive entity is an early pre-cursor of numerous cell types including liver and β-cells of the pancreas that could potentially treat diabetes ,
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|endoderm ectoderm mesoderm visceral epithelium|hematopoietic precursor endoderm ips mammalian|endoderm|entity cells develop into the internal organs such as the heart , liver , pancreas and intestines , among other cell types .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|schwann hematopoietic haematopoietic satellite mesenchymal|endoderm|australia patent 2010200610 – the claims in this patent relate to cell cultures comprising entity cells , one of the three major lineages of cells that make up the human body .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|endoderm ectoderm mesoderm visceral epithelium|proper ear follicle covering sensory|endoderm|stem cells and pluripotency stem cell primative and thus unspecialized self-renewing can differentiate into cells with specific functions ectoderm mesoderm entity skin hair brain nerves etc .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|endoderm ectoderm myocardium epithelium epidermis|endoderm|mesentity cells are precursor cells that differentiate into mesoderm and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|endoderm ectoderm mesoderm visceral epithelium|mammalian hematopoietic germ haematopoietic leukemia|endoderm|these rulings related to interference proceedings involving patent filings relating to definitive entity cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mesoderm endoderm mesenchyme tooth epithelium|mesoderm|emt is essential for numerous developmental processes including entity formation and neural tube formation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|satellite precursor myogenic mesenchymal ips|mesoderm|entity cells develop into muscle , bone and blood , among other cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian murine drosophila myeloid insect|mesoderm|developing a drug-targeting platform based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|hematopoietic lymphoid hematopoiesis erythroid embryogenesis|mesoderm|the libraries and screens will focus on genes important to entity and early hematopoietic development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mesoderm ectoderm mesodermal ectodermal neural|mesoderm|produce such cells , and applications of such cells for es cell-derived immature pluripotent precursors of all the cells of the entity and endoderm lineages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian anticancer melanoma secretory innovative|mesoderm|table of contents raptors entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian myeloid multicellular melanoma exosome|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mantle icm labyrinth epithelium epidermis|mesoderm|in the early embryo , the middle layer of cells ( known as the entity ) and certain portions of the outer cell layers give rise to groups of cells that differentiate into bone marrow stroma ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|engineering ontology mimicking worth termed|mesoderm|promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian pharmaceutical multicellular innovative therapeutics|mesoderm|- 38 - table of contents our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian murine drosophila myeloid dictyostelium|mesoderm|are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mesoderm ectoderm trophoblast mesodermal endoderm|mesoderm|mesendoderm cells are precursor cells that differentiate into entity and endoderm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|named engineering termed mimicking ontology|mesoderm|and drug delivery platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mesodermal mesenchymal ectodermal neural hematopoietic|mesoderm|the seven new cell lines have markers of diverse entity and neural crest cell types and are designated w11 , z2 , sk31 , sm35 , t36 , en51 , and en55 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|myeloid melanoma mammalian synapse lysosome|mesoderm|is a promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated protein ( rap ) and entity development protein ( mesd ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|innovative anticancer pharmaceutical exosome next|mesoderm|· our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|mammalian myeloid multicellular melanoma exosome|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|innovative anticancer exosome pharmaceutical therapeutics|mesoderm|• our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|innovative exosome anticancer pharmaceutical mammalian|mesoderm| our entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesodermal dorsal endoderm mesenchymal|organism extremities limbs skeleton vertebrate|mesoderm|mesenchymal stem cells ( mscs ) : embryonic-like cell capable of differentiating into multiple tissues of the entity , including cartilage , bone , tendon , ligament , muscle , stroma and fat .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|lamina fascia cri stratum retina|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial ( ht-29 ) cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|lamina laminae c2 viii c3|muscularis lamina substantia laminae reticular|lamina|beneath the urothelium , there is a layer called the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina substantia muscularis stratum pars|lamina|the adaptive response is mediated by gluten-reactive cd4+ t cells in the entity propria that recognize gluten-derived peptides when presented by the hla class ii molecules dq2 or dq8 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia tunic stratum|lamina|gliadin fragments in celiac disease , they are able to pass thru the leaky paracellular pathway from the lumen to the entity propria , where the immune cells reside and are then activated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia laminae stratum|lamina|targeted localization of amt-101 to the gi tissue entity propria is expected to translate into clinically meaningful reductions in inflammation and disease activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia stratum mucosal|lamina|gi tissue or entering into systemic circulation : when designing our product candidates , we can target the therapeutic payload to the entity propria of the local gi tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia mucosal tunic|lamina|in healthy bowel wall , bacteria cannot pass from the lumen to the entity propria because tight junctions are maintained between the epithelial cells ( intact barrier function of the bowel wall ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|fda industry approval medicare congress|lamina|on february 25 , 2015 , the company entered into the license agreement with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia stratum laminae|lamina|at any given time , over 70% of an individuals immune system resides in the entity propria , which is the target-rich tissue of the intestinal tract .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|dura lamina pedicle endplate facet|lamina|in a decompressive laminectomy , the surgeon removes bone , known as the entity , from the back part of the symptomatic vertebrae over the spinal canal to create more space for , and relieve pressure
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia propria sinus|lamina|cell-secreted gp96-ig-peptide complexes induce entity propria and intraepithelial cd8+ cytotoxic t lymphocytes in the intestinal mucosa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|she france brazil india today|lamina|entity is a private corporation over which dr . raouf guirguis has sole control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|healthcare union market gm british|lamina|&#160 ; on february 25 , 2015 , the company entered into a license agreement with entity equities corporation ( &#8220 ; entity&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|lamina stratum zona laminar empty|lamina|these data were collected in tests in human entity cribrosa cells grown from human optic nerve heads and from human intestinal epithelial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|lamina laminae c2 viii c3|herniation disk segment fragment vertebra|lamina|of all or part of a damaged disc , and laminectomy , which is the removal of all or part of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia stratum laminae|lamina|in the gut antigens such as gluten are processed by resident dendritic cells in the entity propria which then migrate to the local mesenteric 31 lymph nodes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|lamina laminae c2 viii c3|lamina muscularis substantia colonic propria|lamina|disease activity index , colonic leukocytic infiltration , entity propria neutrophils and colonic tnf expression were used as endpoints .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|lamina fascia cri fovea retina|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|lamina laminae c2 viii c3|muscularis lamina substantia propria uroth|lamina|ta and cis are limited to the urothelial layer , and t1 is limited to the layer below , which is the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina laminae c2 viii c3|lamina macaca cri murine zona|lamina|by inhibiting factor 5a , we were able to reduce tnf-a induced apoptosis by 80% in entity cribrosa cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|limbs myocardium joints regenerate tendon|myocardium|finally , the cells could promote regeneration of viable new tissue , improving the functional capacity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts circulation arteries lungs|myocardium|thus such a molecule should have desirable properties in experiments aimed at inducing collateral circulation in the entity of patients with coronary stenosis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|myocardium infarcted infarction infarct scar|myocardium mitochondria ventricle myocyte cardiomyocyte|myocardium|may also provide information on cardiac mitochondrial membrane potential , enabling global and regional assessment of the electro-physiologic integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|lungs thorax esophagus myocardium trachea|myocardium|characterized by thoracic pain and a feeling of suffocation , most often due to anoxia ( lack of oxygen supply ) to the entity precipitated by physical exertion or excitement .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|myocardium infarcted infarction infarct scar|myocardium ventricle circulation veins atrium|myocardium|the primary objectives of this trial are to evaluate the safety and efficacy of injecting 150 million mpcs into the native entity of lvad recipients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|myocardium infarcted infarction infarct scar|graphene electrolyte lattice bilayer semiconductor|myocardium|cm1 has been shown to couple electrically and mechanically with the host entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|myocardium infarcted infarction infarct scar|myocardium infarction infarct ventricle circulation|myocardium|the death of myocardial cells first occurs in the area of entity that is most distal to the arterial blood supply , the endocardium .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|myocardium infarcted infarction infarct scar|myocardium myocytes myocyte septum cardiomyocytes|myocardium|potassium channels that control normal functioning of the middle layer of heart wall composed of cardiac muscle , or the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts cardiomyocytes ventricle myocytes|myocardium|the hesc-cm treated heart ( right ) shows a large graft of human heart muscle ( green ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium infarcted infarction infarct scar|myocardium myocyte myocytes pacemaker pump|myocardium|appear to target these channels which mediate atrial arrhythmia without disrupting potassium channels that control normal functioning of the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium infarcted infarction infarct scar|myocardium cardiomyocytes myocytes hearts scar|myocardium|the heart of an nhp by hesc-cm transplantation the saline-treated heart ( left ) shows infarct scar tissue ( blue ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts zones kidneys limbs|myocardium|responsive relationship , with higher doses of bone marrow mononuclear cells resulting in reduced fibrosis and increased microvascular change in infarcted entity 60 days after treatment .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|myocardium infarcted infarction infarct scar|myocardium places situations environments circumstances|myocardium|the targeted 24 table of contents cardiomyocytes are expected to produce sustained therapeutic protein levels in the entity where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts hindlimb limbs kidneys|myocardium|when injected into ischemic entity , mlcs are very potent inducers of large caliber arteriogenesis compared to 104 table of contents index to financial statements
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium cns hearts hippocampus retina|myocardium|bfpet has been designed to effectively differentiate among those cells of the entity that are ischemic , infarcted and those that are healthy .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts vessels conduits arteries|myocardium|physicians to screen for coronary artery disease , to assess flow rates and flow reserve , and to distinguish viable from nonviable entity for bypass and transplant candidates .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardium infarcted infarction infarct scar|myocardium hearts vessels arteries territories|myocardium|if blood flow can be restored to at-risk entity , more heart muscle can be saved from irreversible damage or death .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|myocardium infarcted infarction infarct scar|myocardium septum ventricle apex interstitium|myocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the entity and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium infarcted infarction infarct scar|lungs retina myocardium capillaries circulation|myocardium|this results in the solution entering the entity via post capillary venules .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium infarcted infarction infarct scar|myocardium ventricle pericardium myocyte endothelium|myocardium|we believe that ik-5001 will work as a temporary structural support while the damaged entity heals by replacing the dead tissue that would normally support the wall of the heart .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|mesothelial mesoth contains involves fibroblasts|bios gm murine monoclonal another|mesothelium|the company will license entity mab from the nih and in return the agreement , requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesothelial mesoth contains involves fibroblasts|pleura peritoneum pericardium mesothelial epithelium|mesothelium|mesothelioma mesothelioma is a rare form of cancer in which malignant cells develop in the entity , a protective lining that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|mesothelial mesoth contains involves fibroblasts|monoclonal melanoma mesothelioma carcinoembryonic candidate|mesothelium|of march 22 , 1999 , the company and nih entered into an exclusive worldwide licensing agreement to develop and commercialize a entity antigen therapy ( mesothelin mab ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|mesothelial mesoth contains involves fibroblasts|gm bios murine monoclonal mab|mesothelium|the company will license entity mab from the nih and in return , the agreement requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesothelial mesoth contains involves fibroblasts|pleura pericardium peritoneum pleural diaphragm|mesothelium|malignant pleural mesothelioma is an aggressive form of cancer that occurs in the entity , the thin layer of tissue that covers the lungs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|mesothelial mesoth contains involves fibroblasts|pleura peritoneum pericardium mediastinum thorax|mesothelium|differentiating mesothelioma from adenocarcinoma mesothelioma is a cancer that develops in the entity - a protective sac that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesothelial mesoth contains involves fibroblasts|peritoneum vicinity surfaces walls remainder|mesothelium|when ovarian cancer spreads to the entity of the organs within the peritoneal cavity , it can result in encasement of these organs with significant pain and eventual
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesothelial mesoth contains involves fibroblasts|pleura peritoneum pericardium pleural interstitium|mesothelium|about malignant mesothelioma malignant mesothelioma is a cancer that originates in the entity – the tissue that surrounds different organs in the body .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|enamel dentine caries mineralized pulp|dentine enamel tooth pdl roots|dentine|the lactic acid erodes the mineral in enamel and entity , weakening the tooth and ultimately resulting in decay .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|enamel caries dentine wear tooth|enamel acellular oligomeric exogenous endogenous|enamel|ongoing dental projects include : o an entity matrix protein-based product for endodontic therapy ( treatment of dental pulp ) - a phase i trial is underway .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|surfaces pulp enamel dentine tooth|enamel|fluorinex has developed a unique device that delivers fluoride ions directly to the tooth entity via a sophisticated electro-chemical technique .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|enamel caries dentine wear tooth|enamel acellular investigational amorphous oligomeric|enamel|o an entity matrix protein-based product to reduce pain and discomfort following scaling and root planing of periodontal pockets - a phase ii
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|market markets zealand kong marketing|enamel|in nail entity , sally hansen® , the number one brand , increased its market share to 27 . 4% .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|rubber latex foam powder plastic|enamel|toilet core walls shall receive 2 coats latex entity paint .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|transparent coded gloss sized sealed|enamel|d . exposed columns and ironwork at open ceiling areas shall be cleaned , primed painted with semi-gloss entity paint to cover .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|enamel caries dentine wear tooth|enamel sure smart prisma caries|enamel|entity care is the first toothpaste to combine the cleaning and whitening properties of baking soda with fluoride and patented liquid calcium to fill tooth surfaces and restore enamel luster .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|enamel tooth salivary dentine ocular|enamel|the active ingredient is the entity matrix protein amelogenin and the product has been launched in north america , europe and japan for treatment of patients who
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|enamel crown pulp surfaces roots|enamel|derives its energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which , in turn , erodes the tooth entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|enamel caries dentine wear tooth|caries tooth universal fluoride immediate|enamel|- more - early in the quarter , the company launched arm & hammer entity care toothpaste , its most important oral care initiative in several years .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|cleaning clean rough handling interior|enamel|wash and polish all mirrors , powder shelves , bright work and entity surfaces , including flushometers , piping , toilet set hinges , and all metal .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|enamel caries dentine wear tooth|plug shield tags clip wax|enamel|will continue to market multiple nat robbins color cosmetics items including lipliner pencils , lipsticks , eyeliner pencils , eye shadow , mascara , nail entity and assorted accessories .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|olive apple orange instrumented industrial|enamel|simply wow™ was compared to orange clean , fantastik and formula 409 for the ability to remove cooked-on grease from an entity stovetop .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|nail print color polish plate|enamel|number of its principal product categories in the u . s . mass-market distribution channel , including the lip , eye , face makeup and nail entity categories .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|surfaces enamel roots matrices deposits|enamel|hap is naturally found in bone and tooth entity and is rapidly integrated into the human body .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|cosmetics nails substitutes polish hygiene|enamel|remover and nail care products in certain countries outside the u . s . in 2003 , the company launched colorstay always on nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|filler spray nail substitute enhancer|enamel|on net sales of a hair-off mitten that is a depilatory-product accessory , and nutra nail 60 , a fast- acting nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|enamel tooth dentine pulp crown|enamel|as a person ages the adult teeth often become darker due to changes in the mineral structure of the tooth , as the entity becomes less porous and phosphate-deficient .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel caries dentine wear tooth|floor concrete interior ground ceiling|enamel|floors , hand brush corners and hand brush toilet edges with approved germicidal detergent solution . 2 . wash completely all partitions , tile walls and entity surfaces .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|enamel caries dentine wear tooth|enamel pulp hydroxyapatite tubules roots|enamel|tooth decay is characterized by the dissolution of entity and dentin , eventually resulting in the destruction of the entire tooth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel osteoclast mineralized dentine calcified|junction sheath ligament attachments contacts|cementum|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root entity , gingiva and / or periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|enamel osteoclast mineralized dentine calcified|canals dentine roots walls hairs|cementum|by coating the surface of the exposed dental root with emdogaingel during periodontal surgery , new root entity , periodontal ligament fibers , and surrounding bone tissue can be formed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|enamel osteoclast mineralized dentine calcified|sheath epithelium apex canal epidermis|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jawbone and cushions the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|enamel osteoclast mineralized dentine calcified|sheath epithelium apex canal dentine|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jaw bone and cushions
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|enamel osteoclast mineralized dentine calcified|ligament tooth gingiva dentine pdl|cementum|the extent , the gingiva functions as 6 7 part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|enamel osteoclast mineralized dentine calcified|tendons fascia nerves enamel gingiva|cementum|the periodontal setting , these agents do not directly stimulate the repair of other important tissues such as periodontal ligaments or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|enamel osteoclast mineralized dentine calcified|ligament tooth gingiva dentine pulp|cementum|only to the extent , the gingiva functions as part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|enamel osteoclast mineralized dentine calcified|pulp tooth tendon enamel epithelium|cementum|are utilized even though these methods do not have the same capability as emdogain of regenerating the tissues - bone , entity and ligament - that make up the tooth-supporting structures .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|periodontal tooth periodontitis periodon subgingival|gum gingiva tongue tooth oropharynx|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provide a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|periodontal tooth periodontitis periodon subgingival|gum gingiva tongue tooth oropharynx|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provides a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|periodontal tooth periodontitis periodon subgingival|epidermis cornea retina acl tendon|periodontium|these patents relate to the biodegradable in situ forming implants and the biodegradable system for regenerating the entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|periodontal tooth periodontitis periodon subgingival|gingiva tmj jaws dentition tooth|periodontium|dr . caton has conducted many studies evaluating various treatment modalities for periodontitis and other diseases involving the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endothelium modulate denuded relaxation modulates|endothelium beds myocytes walls ecs|endothelium|drug candidate indicates that consistent increases in gb3 levels were measured in cardiomyocytes ( as opposed to decreases measured in vascular entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|endothelium modulate denuded relaxation modulates|club itself board committee journal|endothelium|research articles , serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|endothelium modulate denuded relaxation modulates|endothelium intima epithelium microvasculature ecm|endothelium|in the inflammatory component , white blood cells begin to roll along and then adhere to the entity , the thin layer of cells that lines the interior surface of blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|endothelium modulate denuded relaxation modulates|airways capillaries lungs myocardium nerves|endothelium|that the company believes may be important in identifying unique sites on the lining of the blood vessels or the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|tissue|endothelium modulate denuded relaxation modulates|endothelium vasculature intima arteries myocardium|endothelium|atherosclerotic plaque to 732 nanometer light delivered through a catheter resulted in elimination of the lesions without damage to the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|tissue|endothelium modulate denuded relaxation modulates|endothelium intima aorta vasculature plaques|endothelium|atherosclerotic apoe ko mice corresponding to initial steps of atherosclerosis that comprise cell to cell adhesion of monocytes / macrophages to the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|endothelium modulate denuded relaxation modulates|endothelium apc epithelium erythrocyte fibroblast|endothelium|the interaction between certain cell adhesion molecules on the surface of both the leukocyte and the entity facilitates these contacts .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|tissue|endothelium modulate denuded relaxation modulates|platelets neutrophils leukocytes endothelium monocytes|endothelium|into inflamed areas because sle ( x ) present on the surface of white blood cells binds to selectin molecules present on activated entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endothelium modulate denuded relaxation modulates|endothelium neutrophil neutrophils bacterium fungus|endothelium|nitric oxide produced by the entity also inhibits the clumping of platelets , which are cells in the blood that promote clotting , and the adhesion of platelets
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|tissue|endothelium modulate denuded relaxation modulates|intima ecs endothelium smcs fibroblasts|endothelium|initially , this new tissue consists of healthy cells from the lining of the arterial wall ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endothelium modulate denuded relaxation modulates|lumen endothelium outgrowth walls microvasculature|endothelium|large caliber arteriogenesis compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the entity of capillaries .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|endothelium modulate denuded relaxation modulates|thrombus thrombosis thrombi lumen endothelium|endothelium|clot is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|tissue|endothelium modulate denuded relaxation modulates|thrombus thrombosis vasculitis endothelium thrombi|endothelium|cascade is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|endothelium modulate denuded relaxation modulates|endothelium pericytes myocytes progenitors astrocytes|endothelium|these experiments used cells important in human disease and aging--retinal pigment epithelium , fibroblasts , and vascular entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endothelium modulate denuded relaxation modulates|endothelium walls beds surfaces plaques|endothelium|white blood cells express carbohydrates on their surfaces that bind to e-selectin that is present on inflamed vascular entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|endothelium modulate denuded relaxation modulates|endothelium microvasculature microcirculation bbb thrombus|endothelium|specifically , we believe that by inhibiting selectin-mediated adhesion of white blood cells to the entity , rivipansel prevents propagation of voc and promotes early resolution .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|endothelium modulate denuded relaxation modulates|endothelium intima microvasculature epithelium lining|endothelium|the entity , a single-cell lining of the arteries that acts as an interface between the blood and arterial wall , is impaired in
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|endothelium modulate denuded relaxation modulates|vasculature microvasculature vessels endothelium microvessels|endothelium|protein markers , unique to the surface of the entity in specific organs and those markers that distinguish tumor blood vessels from those vessels in healthy tissue , are thought to
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|tissue|endothelium modulate denuded relaxation modulates|endothelium intima macrophage vasculature epithelium|endothelium|an overgrowth of the entity that forms capillaries and lines blood vessel interiors contributes to atherosclerosis .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|endothelium modulate denuded relaxation modulates|endothelium platelets microvasculature neutrophil epithelium|endothelium|binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|tendon involves fibrous fibro contains|endplate hyaline acl c2 gracilis|fibrocartilage|another type of cartilage ( entity ) serves a shock-absorbing function in the knee and in the spine between the vertebrae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon involves fibrous fibro contains|formations microstructures meniscus protrusions nodules|fibrocartilage|biopsies from 135 of 141 of these re-looks showed the development of meniscus-like entity , confirming the devices effectiveness as a surgical mesh .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|tissue|tendon fascia cartilaginous calcified tendons|chondrocytes osteoblasts mesenchyme osteoclasts chondrocyte|perichondrium|model was completed and bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|tissue|tendon fascia cartilaginous calcified tendons|chondrocytes osteoblasts mesenchyme osteoclasts chondrocyte|perichondrium|by dr . yu yamaguchi , bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|mesangial mesang podocytes glomeruli glomerular|capillaries interstitium walls epithelium podocytes|mesangium|igan is a nonsystemic renal disease that is characterized by predominant iga deposition in the glomerular entity , causing mesangial proliferation and fibrosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|mesangial mesang podocytes glomeruli glomerular|capillaries interstitium walls podocytes endothelium|mesangium|iga nephropathy igan is a common glomerulopathy diagnosed by the predominant histologic presence of galactose-deficient iga1 deposits in the glomerular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesangial mesang podocytes glomeruli glomerular|lumen walls vicinity interstitium lining|mesangium|these iga containing immune complexes deposit in the entity of glomeruli in the kidney and are proinflammatory .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|mesangial mesang podocytes glomeruli glomerular|kidneys glomeruli nephron gbm vasculature|mesangium|chronic activation of inflammatory pathways also leads to long-term structural alterations in the entity , which results in reduced glomerular surface area and gfr .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|trophoblast embryogenesis embryos neuroect primitive|epidermal germ mesenchymal ectodermal precursor|neuroectoderm|entity cells are committed to developing into cells of the skin and nervous systems .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|trophoblast embryogenesis embryos neuroect primitive|endoderm mesoderm ectoderm epi ectodermal|neuroectoderm|with the differentiation signals resulting from the physical attributes of the cell culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|trophoblast embryogenesis embryos neuroect primitive|epidermal precursor mesenchymal ectodermal schwann|neuroectoderm|entity cells are committed to developing into cells of the skin and cells of the nervous system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|trophoblast embryogenesis embryos neuroect primitive|endoderm mesoderm ectoderm pluripotency osteogenesis|neuroectoderm|van rooijen m , xu x , zweigerdt r , mummery c , passier r . insulin redirects differentiation from cardiogenic mesoderm and endoderm to entity in differentiating human embryonic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|trophoblast embryogenesis embryos neuroect primitive|endoderm mesoderm ectoderm ectodermal epi|neuroectoderm|together with the differentiation signals resulting from the physical attributes of the culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tonsil tonsillar follicular histology cystic|slide sponge cutting stone clip|tonsil|the company introduced during fiscal 1995 a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|tissue|tonsil tonsillar follicular histology cystic|absorbable mesh fascial hemostatic anchoring|tonsil|( b ) entity sponges - a round , fiber filled gauze constructed with a strong abdominal tape string sewn into the sponge to anchor
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tonsil tonsillar follicular histology cystic|cervix esophagus rectum nasopharynx stomach|tonsil|tumor shrinkage was also seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|tissue|tonsil tonsillar follicular histology cystic|tonsillar tonsil splenic follicular lymphoblastoid|tonsil|tjx7 has been shown to completely inhibit the migration of primary human entity b cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil tonsillar follicular histology cystic|sponge cutting suction infusion traction|tonsil|the company has also introduced a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are used in a variety of surgical procedures .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tonsil tonsillar follicular histology cystic|cervix esophagus rectum stomach nasopharynx|tonsil|tumor shrinkage also was seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil tonsillar follicular histology cystic|sponge suction rubber cutting needle|tonsil|products used primarily in the operating room environment ; medical action introduces a line of specialty sponges , which include dissecting sponges , entity sponges , stick sponges and eye spears .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|joints functionality independence cognition bones|cartilage|it has a dual method of action that could provide the unique benefit of protecting bones and preserving entity in patients with osteoarthritis and osteoporosis , all in one medication .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|articular damaged chondrocytes hyaline engineered|corneal tendon ivd osteochondral enamel|cartilage|in comparison with tissue stiffness , streaming potentials measured showed almost identical behavior for the normal and degraded entity explant .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|tissue|articular damaged chondrocytes hyaline engineered|meniscus meniscal osteochondral ligament osteoarthritis|cartilage|developed and commercialized chondrocelect , the first cell-based medicinal product to receive marketing authorization from the ema , which was indicated for entity repair in the knee .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|articular damaged chondrocytes hyaline engineered|meniscal meniscus ligament tendon osteochondral|cartilage|the secondary endpoints were entity repair at 12 months by assessment of changes of the knee joint entitys volume measured with 3d spgr quantitative mri ,
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|articular damaged chondrocytes hyaline engineered|osteoclasts osteoblasts osteoid callus osteoclast|cartilage|these compounds induce the formation of entity and regenerates new bone .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|articular damaged chondrocytes hyaline engineered|recording waveform ecg voice record|cartilage|the handle ; o software for the acquisition of electrical signals and for the analysis and interpretation of data to quantify entity quality ; and o a computer system .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|articular damaged chondrocytes hyaline engineered|semen meat wine voice sputum|cartilage|the simplicity of the technique for the assessment of entity quality was demonstrated .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|tendon tooth periodontal ligament nail|cartilage|in both of these prior positions dr . christgau worked in the area of bone and entity research .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|surfaces capsule lining joints apparatus|cartilage|disease that affects almost 1% of the adult population worldwide and it ultimately results in irreversible damage of the joint entity and bone .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|lining chondrocytes surfaces discs chondrocyte|cartilage|oa background oa is a joint disorder involving the degeneration of the articular entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|surfaces lining chondrocytes facets disks|cartilage|treatment of various injuries and degeneration of other tissue structures such as the intervertebral disc of the spine and articular entity of degenerated joints .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|articular damaged chondrocytes hyaline engineered|joints synovium fascia tendon peritoneum|cartilage|sarcomas are cancers of the bone , entity , fat , muscle , blood vessels , or other connective or supportive tissue .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|articular damaged chondrocytes hyaline engineered|tendons chondrocytes nerves enamel ligaments|cartilage|entity on any of these surfaces can be damaged due to disease or injury , leading to pain and inflammation requiring knee
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|articular damaged chondrocytes hyaline engineered|stresses trabeculae proteoglycans gaps loads|cartilage|it assists in regained mobility as it refurbishes entity in the bone end of joints , consisting of the same cellular structure , collagen type ii .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|meniscal ligament meniscus shoulder arthroscopic|cartilage|a fully functional clinical version of the arthro-bst ( tm ) was presented at the third meeting of the international entity repair society ( icrs ) in sweden in april 2000 .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|articular damaged chondrocytes hyaline engineered|joints synovium tendon ligaments vasculature|cartilage|from a mouse with cia with no treatment showing severe inflammation in the joint with sever damage to bone and entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|lining fibroblasts chondrocytes proteoglycans fluids|cartilage|major teaching hospital and other institutions have demonstrated that the use of the company  s compounds inhibit the loss of synovial entity in the joint .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|articular damaged chondrocytes hyaline engineered|surfaces lining chondrocytes margins facets|cartilage|this condition grows more severe over time and leads to progressive thinning of articular entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 2)])|tissue|articular damaged chondrocytes hyaline engineered|adipose tendon cardiomyocytes epithelium adipocytes|cartilage|product development programs utilize adult bone marrow stem and progenitor cells for forming solid tissues such as bone , vascular tissue , entity , and blood and immune system cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|articular damaged chondrocytes hyaline engineered|encouraging histological promising theoretical morphological|cartilage|additional studies are being carried out to confirm the entity regrowth .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|mesenchyme mesenchymal fibroblasts contains epithelia|morphogenesis mesenchyme bones skeleton patterning|mesenchyme|the scientific publication demonstrates that 4d20 . 8 cells possess site-specific markers of craniofacial entity , in particular , markers of proximal mandibular entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|ependym glia astrocytes vessels plexus|parenchyma microglia capillaries microvessels glia|ependyma|filters toxins 1 cerebrospinal fluid ( csf ) – brain barrier / glymphatic system : extracts toxins from the brain 2 ventricle brain entity ( glial cells ) astrocytes ( glial cells )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|umb umbilical dorsal midline your|genitalia penis tongue cervix ears|umbilicus|it usually involves the face , digits , arms , inguinal area , anogenital area , entity and nipples , and can also affect the hair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|umb umbilical dorsal midline your|ankle heel thigh shoulder endpoint|umbilicus|reductions observed in the circumference at the entity and treatment area volume were the same in both the placebo and lipo-202 treatment groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|umb umbilical dorsal midline your|endpoint ankle waist thigh heel|umbilicus|manual tape measure procedure , the 0 . 4 µg total weekly dose of lipo-202 produced significant reductions in abdominal circumference at the entity compared to placebo .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis epithelium epithelia keratinocytes|epidermis|most common form of skin cancer , is an uncontrolled growth of abnormal cells arising from the squamous cells in the entity , the skins outermost layer .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermal epidermis stratified involves contains|pulp person epidermis esophagus ear|epidermis|skin in order to achieve enough heating at the required depth significantly increases the risk of damaging or burning the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis epithelium cornea epidermal|epidermis|bcc develops in the basal , or lower , layer of the entity , and accounts for approximately 80% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis nail joints epithelium plaques|epidermis|psoriasis , for example , which is characterized by inflammation and accelerated growth of the entity , can sometimes be triggered by a simple cut or abrasion to the skin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis scalp follicle follicles|epidermis|removal is based upon the selective heating of hair follicles while cooling the surface of the skin to protect the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis scalp trunk nipple|epidermis|scc usually develops in the entity , the upper layer of the skin , and accounts for approximately 16% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epithelium epidermal epithelia subcutaneous|epidermis|autologous skin regeneration construct of its kind , which can regrow full-thickness and functional polarized skin , including all layers ( dermis & entity ) , hair , and skin appendages .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epithelium fascia dermis vasculature|epidermis|by precisely focusing ultrasound energy to cause permanent disruption , or ablation , of fat cells , or adipocytes , without damage to the entity , dermis or underlying tissues and organs .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epidermal epithelium fibroblasts nail|epidermis|to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , entity and dermis level .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|epidermal epidermis stratified involves contains|follicles follicle epithelium ovary epidermis|epidermis|the cold sapphire tip protects the entity while allowing the laser light to efficiently destroy the target follicles .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|epidermal epidermis stratified involves contains|epidermis keratinocytes dermis epithelium keratinocyte|epidermis|plaque psoriasis is a disease marked by hyperproliferation of the entity , resulting in inflamed and scaly skin plaques .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epithelium fibroblasts nail epidermal|epidermis|designed to penetrate below the skin  s surface to correct damage in all layers of the skin ( the stratum corneum , the entity and the dermis ) and accelerate cellular turnover .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|epidermal epidermis stratified involves contains|epidermis epithelium keratinocytes cervix keratinocyte|epidermis|topical interferon alpha-2b is intended to deliver interferon alpha-2b therapy to the viable entity , combating hpv infections where they would otherwise cause abnormal cellular proliferation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epidermal epithelium epithelia keratinocytes|epidermis|the ability to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the entity and dermis level .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermal epidermis stratified involves contains|epidermis trunk nose scar dermis|epidermis|these changes can visibly affect the shape of the entity and resemble an orange peel-like dimpling of the skin . 1 in the normal subcutaneous fat layer directly under the skin , there
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis sc epidermal nail|epidermis|keratinocytes are the predominant cell type in the entity , the outermost layer of the skin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermal subcutaneous deeper follicular epidermis|epidermis|our products will be naturally infused into hair follicles , dermis and entity layers of the scalp through the direct application and use of all-natural products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|epidermal epidermis stratified involves contains|epidermis epithelium dermis epidermal fibroblasts|epidermis|vii collagen , or col7 , that forms anchoring fibrils that bind the dermis , or inner layer of the skin , to the entity , or outer layer of the skin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epidermal epidermis stratified involves contains|epidermis dermis melanocyte melanocytes organism|epidermis|concentration of hydroquinone , which is designed to correct skin pigmentation problems by normalizing the production of new melanin in the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|epidermal epidermis stratified involves contains|aureus epidermidis staphylococcal marcescens subtilis|epidermis|azitra inc . is developing azt-02 , a staphylococcus entity strain engineered to express lekti in preclinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesh tendon acetabular titanium medial|appendix section chapter table digit|anlage|thereof ; 4 . 1 . 3 all running expenses as defined in appendix 3 to section 27 , subsection 1 , of the second computation order ( entity 3 zu section 27 abs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesh tendon acetabular titanium medial|berlin von germany west august|anlage|the business address for each of the persons listed below other than christopher k . norton is messeturm , friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesh tendon acetabular titanium medial|entities chapter person dilemma ech|anlage|l . der verkaufer verkauft und ubertragt hiermit samtliche vertrags-erfindungen und vertrags-schutzrechte , die in den in entity 1 und entity 2 beigefugten schutzrechtskaufvertragen definiert sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesh tendon acetabular titanium medial|eine von der die sich|anlage|des verschmelzungsplans ) wird die übernehmende gesellschaft die neue satzung , wie sie als entity 2 dem verschmelzungsplan beigefügt ist , beschließen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesh tendon acetabular titanium medial|von war mit sich der|anlage|zeitpunkt dieser lizenzerklärung im eigentum der sag stehen , darin insbesondere eingeschlossen die patente und patentanmeldungen gemäss entity 2 , die sich auf die substanz prostone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesh tendon acetabular titanium medial|bei von dur war eine|anlage|verkauft und ubertragen werden daher insbesondere die in der entity 3 aufgefuhrten vermogensgegenstande und rechte ( insgesamt der , , kaufgegenstand " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|mesh tendon acetabular titanium medial|von sind mit sich eine|anlage|schutzrechtsanmeldungen , die vom dkfz parallel dazu gemäß entity 2 vorgenommen worden sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesh tendon acetabular titanium medial|berlin von germany law hall|anlage|the principal business address of each of gscp ii germany and gs ohg is messeturm friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesh tendon acetabular titanium medial|der germany vers sept novo|anlage|belastungen des in entity 1 . 1 beschriebenen grundbesitzes in abteilung iii des grundbuchs werden vom käufer nicht übernommen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|mesh tendon acetabular titanium medial|von war bei sich mit|anlage|schutzrechtsanmeldungen gemäß entity 2 zugrundeliegenden erfindungen zu zahlen ist , steht den erfindern von asta pharma ein anteil von 20% zu .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|mesh tendon acetabular titanium medial|von mit eine sich aus|anlage|​ die satzung der übernehmenden gesellschaft , als aus der gesellschaft hervorgehende gesellschaft , ist als entity 1 zu diesem verschmelzungsplan beigefügt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|mesh tendon acetabular titanium medial|von wer eine zur mit|anlage|dr . thomas drosdeck beiten burkhardt rechtsanwaltsgesellschaft mbh bockenheimer entity 15 mozartplatz 60322 frankfurt am main germany 30 . 13 execution by counterpart .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mesh tendon acetabular titanium medial|der von fi fp wf|anlage|rechten und ansprüchen gegen sie an pcof 1 llc ( der zessionar ) im wege der sicherungsabtretung abgetreten haben , einschließlich der in entity 1 genannten forderungen .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|osteoid calcified mineralized calcification osteoclast|osteoid tendon adipose callus synovial|osteoid|the six patients had mean entity volume / bone volume decreases from 24 . 3 percent to 7 . 0 percent , representing a 71 percent improvement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|osteoid calcified mineralized calcification osteoclast|osteoid trabecular callus nodule ash|osteoid|at 48 weeks , all ten patients with evaluable paired bone biopsies demonstrated meaningful improvements from baseline in mean entity volume / bone volume .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoid calcified mineralized calcification osteoclast|trabecular osteoid callus mucosal calcaneal|osteoid|the patients also demonstrated mean improvements of 32% and 26% in entity thickness and entity surface / bone surface parameters respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|anatomy fascia septum junction ligaments|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery and are not good candidates for a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia tendon muscular rectus circular|fascia sheath aspect nerves digits|fascia|background dupuytrens disease is a slowly progressive fibroproliferative disease of the palmar entity in the hand .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|vital warning ecg consent interim|fascia|any changes or additions to the entity sign shall be subject to landlords prior written approval , in landlords sole discretion , and shall be made at tenant  s sole cost and expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|fascia dermis tendons tendon bones|fascia|plantar fibromatosis is a non-malignant thickening of the feets deep connective tissue or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|warning vital signature danger cardinal|fascia|for all purposes under the lease , the entity sign shall be deemed to be tenant  s off-premises equipment . 7 . brokerage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|floor concrete building fabric equipment|fascia|tenant shall repair , paint , and / or replace the building entity surface to which its signs are attached upon vacation of the premises , or the removal or alteration of its signage ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|fascia tendon muscular rectus circular|walls porosity lining valves holes|fascia|no alteration shall ( i ) affect the exterior walls , entity or fenestration of the building or the demising walls of the premises , ( ii ) affect any part of the project other than
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|fascia tendon muscular rectus circular|fascia epidermis dermis epidermal tendon|fascia|are you going to start accepting dermis , entity and pericardium recoveries?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|fascia dura lamina north tensor|fascia|the revenue increase was primarily due to an increase in the demand for our entity lata products to treat incontinence and urologic and gynecologic defects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|fascia tendon muscular rectus circular|bones ligaments vessels nerves vasculature|fascia|muscoloskeletal conditions  means conditions of the muscles , bones , joints ( including the intervertebral discs ) , ligaments , tendons , cartilage and entity of the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|anatomy fascia septum junction scar|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|road shall require turns roads|fascia|green  s dairy road a . all entity signs to be single faced cabinets , and shall be constructed of 100% aluminum with stencil cut aluminum backgrounds with white
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|dermis epidermis extremities scalp limbs|fascia|cutaneous eosinophilias are inflammatory diseases that manifest in dermal and subcutaneous layers including the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|note notice book name mark|fascia|signage no entity , sign , name plate , bill , notice , placard , advertisement or similar device shall be affixed to or displayed in or on any
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|fascia dura lamina tensor sinus|fascia|meanwhile , the company is offering alternative tissues such as entity lata and bovine pericardium to the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia tendon muscular rectus circular|instruments appliances prostheses equipment objects|fascia|kind and quality and having made good any material physical damage resulting from the removal of any tenant  s fixtures , fittings , entity or signs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia tendon muscular rectus circular|fascia heel plate fasciitis ligament|fascia|the plantar entity is the foots shock absorber .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|fascia tendon muscular rectus circular|joints nerves tendons vasculature bones|fascia|a therapeutic protein and / or bioactive rna for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|fascia tendon muscular rectus circular|annual pharmaceutical projected healthcare monthly|fascia|entity inventories are higher than normal by $720 due to reduced demand and the anticipation of the launch of a new
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|fascia tendon muscular rectus circular|joints nerves tendons fascia bones|fascia|therapeutic protein and / or bioactive ribonucleic acid for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|incision orifice eus transabdominal endovascular|ecm interstitium cytoskeleton fibrils dermis|endomysium|- 5 - in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|incision orifice eus transabdominal endovascular|ecm cytoskeleton interstitium sarcomere skeleton|endomysium|in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|resembles involves contains comprises regulates|nose tongue ear smell rectum|neuroepithelium|the entity is the tissue by which man detects the presence of odor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|resembles involves contains comprises regulates|epithelium nerves tracts canals canal|neuroepithelium|smell ) can result from a number of causes , including mechanical obstruction of the nasal cavity and damage to the olfactory entity , the olfactory bulb , or the nerves between them .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|mole what baby seeds you|mole choriocarcinoma trophoblast thymoma seminoma|mole|the major histologic entities for this disease include complete molar pregnancy , partial molar pregnancy , invasive entity , and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole what baby seeds you|person decade month millimeter tooth|mole|mm  shall mean one-thousandth of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|tissue|mole what baby seeds you|mole choriocarcinoma trophoblast gtn carcinomas|mole|the term gestational trophoblastic neoplasia ( gtn ) is used when molar and non-molar pregnancies become malignant , and comprise the morphologic entities of invasive entity and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole what baby seeds you|eruption bcc entities dermat dermatological|mole|to 12-month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|mole what baby seeds you|lymphadenopathy malignancy calcification ulceration calcifications|mole|cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole what baby seeds you|eruption bcc dermatological dermat entities|mole|to 12 month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|mole what baby seeds you|lymphadenopathy malignancy ulceration calcification calcifications|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|tissue|mole what baby seeds you|nevus melanoma neoplasm malignancy nodule|mole|present in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole what baby seeds you|trait phenomenon biomarker specimen person|mole|we believe that their software , at present , cannot define whether a entity is a new one or not .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole what baby seeds you|mole mmol liter mm2 nmol|mole|referred to antibodies excluded from the licence 1all antibodies to alpha tumour necrosis factor having an association constant greater than 106l / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole what baby seeds you|cytos intr subn subc inqu|mole|tks , tps , stks and related downstream signalling entitycules ( target identification ) and vali- dation of the role , if any , of those entity- cules in a given disease ( target valida- tion ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole what baby seeds you|neoplasm phenomenon entities anomaly event|mole|the abcd rule is defined as follows : a ● asymmetry , a benign entity that is not asymmetrical ; b ● border , a benign entity has smooth , even borders , unlike melanomas ; c ● color .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|mole what baby seeds you|nevus melanoma color mole pigmentation|mole|one of the best early indicators of melanoma is a new or changing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole what baby seeds you|others colleagues johnson lewis jones|mole|/ s / weisberg , polansky , kulberg , einhorn & entity , llp carle place , new york july 30 , 1996 exhibit 23 . 8 consent of independent certified public accountants we consent to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole what baby seeds you|mole abortion cysts abortus gestation|mole|choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy , but most commonly develops after complete hydatidiform entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|tissue|mole what baby seeds you|nevus melanoma malignancy neoplasm nodule|mole|itself in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|mole what baby seeds you|lymphadenopathy malignancy ulceration calcification calcifications|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|mole what baby seeds you|manner neoplasm person gland melanoma|mole|it may begin in a entity as skin melanoma , but can also begin in other pigmented tissues , such as in the eye or in the intestines .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|dermis stroma capsule intima ecm|dermis|the entity is comprised largely of connective tissue fibers made of collagen and elastin .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|acellular epidermal autologous fibroblasts dermal|myocardium cornea dermis nerves joints|dermis|muscle cells , azx100 may inhibit the scarring that results from wound healing and may mitigate fibrotic disease states in the entity , blood vessels , lungs , liver and other organs .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|acellular epidermal autologous fibroblasts dermal|joints cornea epidermis discs retina|dermis|type 1 collagen is the primary fibril-forming collagen in bone , entity , tendons and ligaments and is the most abundant protein in the human body .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|dermis forehead cheek scalp sc|dermis| hst-002 is a human-derived collagen and extracellular matrix dermal filler intended to be injected into the entity for the treatment of facial folds and wrinkles .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|dermal dermis scaffold biomaterial tendon|dermis|our acellular entity scaffolds are utilized in wound care and plastic and reconstructive procedures .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|epidermis dermis epithelium capillaries interstitium|dermis|temporarily permeable , allowing a drug to diffuse through the stratum corneum in the epientity , and then into and through the entity , where it can enter the bloodstream through the capillaries .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|dermis wounds omentum scalp fascia|dermis|we believe that the fibroblasts created by our isolagen process and injected into the patient  s entity continue to multiply and lead to the production of collagen and elastin .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|capital papillomavirus rights donation reproduction|dermis|human entity initiatives training sales force product introduced in 2nd quarter to clinical sites product launched july 2007 markets currently a $50
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|dermal epidermal porcine autologous viable|dermis|with the dermavac , entity mos are rapidly harvested under local anesthetic from just under the skin to provide unique tissue structures with long-term viability
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|forehead scalp dorsum heel nose|dermis|( mos )  our proprietary device , the dermavac , is used to extract a small piece of tissue from the skins lower level , the entity of the patient .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|hydration epidermal melanin dermis epidermis|dermis|penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , epientity and entity level .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|boston dermis dressings dar technologies|dermis|at ciba-geigy , novartis , prosanos , adventrx participated / led development and launch of voltaren , apligraf , femara and exjade 4 5 epientity dermis subcut .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|dermis epidermis hydration deeper sweat|dermis|in undamaged skin , the epientity , or the surface layer of skin , and entity , the deeper layer , form a protective barrier against the external environment .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|acellular epidermal autologous fibroblasts dermal|embryos spermatozoa allografts semen transplants|dermis|in october 2001 , the company entered into a project with mentor for use of tutoplast ( r ) processed entity in urological and gynecological indications .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|epidermis dermis cuticle corneum permeability|dermis|due to the structure of the skin , its two main layers , the outer epientity and inner entity , effectively inhibit the transdermal delivery of most therapeutics .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|bloodstream intestine circulation interstitium peritoneum|dermis|small molecular weight sodium hyaluronate can penetrate into the entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|epidermis dermis appendages fascia musculature|dermis|skin means that part of the human anatomy consisting of the entity , the epientity , and the appendages of the skin , to wit , the nails , the hair and hair follicles , the sudoriferous and
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|dermis pericardium fascia mesh omentum|dermis|currently rely on single source suppliers for the silicone and fabric used in our male prostheses and for the porcine entity and mesh used in many of our female products .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|acellular epidermal autologous fibroblasts dermal|epithelium lumen intestine spaces propria|dermis|small molecular weight sodium hyaluronate can penetrate into the 7 table of contents entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|acellular epidermal autologous fibroblasts dermal|needle antenna transducer blade scalp|dermis|the faces handpiece uses a vacuum to fold the skin between two electrodes , ensuring tight contact and positioning the entity in direct alignment with the path of radio frequency energy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|endocardial endocard myocardium epicardial ventricle|septum apex scar ventricle myocardium|endocardium|of myocardial cells first occurs in the area of myocardium that is most distal to the arterial blood supply , the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|endocardial endocard myocardium epicardial ventricle|septum vasculature apex endothelium periphery|endocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the entity to the myocardium and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|periodontal gingiva buccal enamel circular|pulp tooth enamel ligament gingiva|gingiva|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root cementum , entity and / or periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|periodontal gingiva buccal enamel circular|saliva chemicals gum liquids substrates|gingiva|exposure of the gel on the strips to the entity ( gums ) should be avoided since it can cause irritation to the tissue .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|periodontal gingiva buccal enamel circular|gum lips tongue cheek chewing|gingiva|in heart rate ; ( ii ) focal hyperpigmentation ( darkening of the skin on certain parts of the body ) , including the face , gums ( entity ) and breasts ; and ( iii ) nausea .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|periodontal gingiva buccal enamel circular|scalp pulp cheek forearm gingiva|gingiva|in the case of the dental product , a 1mm biopsy is taken from the patient  s entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|periodontal gingiva buccal enamel circular|scalp arms trunk legs extremities|gingiva|focal hyperpigmentation : reported by 1% of patients who received up to 8 doses per month , including involvement of the face , entity and breasts .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|periodontal gingiva buccal enamel circular|others retina kidneys joints skeleton|gingiva|lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , sinuses , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|periodontal gingiva buccal enamel circular|retina skeleton intestines joints lungs|gingiva|common lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament tendon meniscus suture acl|ligament|a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of tendon and entity repairs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|tendon ligament meniscus dermal tooth|ligament|begun to earn royalties on a portion of the estimated 2005 $800 million to $1 billion u . s . tissue market , which includes entity , tendon and bone allografts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament tendon tendons ligaments meniscus|ligament|first albany annual growth conference page 15 entity and tendon repairs , we mentioned , is still in preclinical work .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament triangular anatomic carpal tendon|ligament tendon meniscus synovial fascia|ligament|group ; and  use our glucan technology to develop product candidates for intra-operative and injection applications in tendon , entity and bone surgeries and injuries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament ligaments ccl capsule canal|ligament|the impact of fortetropin® on reducing muscle atrophy in dogs after tibial-plateau-leveling osteotomy ( tplo ) surgery to repair the cranial cruciate entity ( ccl ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|ligament triangular anatomic carpal tendon|ligament meniscal musculoskeletal meniscus osteochondral|ligament|svf is a regenerative treatment for a number of conditions including osteoarthritis , tendon repair , entity injuries and other traumatic and degenerative diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament retaining replacement tendon ligaments|ligament|announced receipt of the technical section complete letter for effectiveness for nocita to provide local post-operative analgesia for cranial cruciate entity surgery in dogs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament triangular anatomic carpal tendon|penile meniscal auricular shoulder fixation|ligament|continues to develop a collagen based tissue patch , a collagen and calcium phosphate based bone cement , and a collagen based entity prosthesis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ligament triangular anatomic carpal tendon|ligament ligaments sheath epithelium fibroblasts|ligament|of periodontal pockets ( spaces between the gum and tooth ) resulting from loss of the tooth  s supporting structure ( bone and periodontal entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament triangular anatomic carpal tendon|ligament tendon synovial fascia meniscus|ligament|for the technology include pressure ulcer ( bed sore ) prevention , chronic wounds , burns , dermatology , and product testing and superficial tendon and entity pathology .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament triangular anatomic carpal tendon|meniscal meniscus tendon dural rotator|ligament|college of veterinary medicine at kansas state university&#160 ; to study the impact of fortetropin on reducing muscle atrophy in dogs after entity tear repair surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|ligament triangular anatomic carpal tendon|ligament tendon meniscus synovium ligaments|ligament|stimulation of growth factors and the potential use of ultrasound technology in diagnostic and therapeutic applications relating to bone , cartilage , entity or tendon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament ligaments acl tendon longus|ligament|for example , attempts to replicate mouse anterior cruciate entity , or acl , transection findings using different animal models of osteoarthritis , or oa , have proven to be challenging , as it is
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|ligament triangular anatomic carpal tendon|tendon synovium ligaments tendons bursa|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity performed annually in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|ligament triangular anatomic carpal tendon|tendon synovium ligaments meniscus tendons|ligament|studies with engineered cartilage and bone for reconstructive applications and have constructed an entire joint consisting of bone , cartilage and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament ligaments acl tendon retaining|ligament|the agreement covers such products as , bone-tendon-bone ( btb ) implants used for acl ( anterior cruciate entity ) procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ligament triangular anatomic carpal tendon|ligament meniscus meniscal tendon osteochondral|ligament|to extend its worldwide license for chrysalin to include the rights for orthopedic " soft tissue " indications , including cartilage , tendon and entity repair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ligament triangular anatomic carpal tendon|ligaments joints nerves fascia ligament|ligament|of protein synthesis at a particular site in the body and can be used in soft tissue such as skin , entity , tendons and cartilage , as well as hard tissue such as bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament triangular anatomic carpal tendon|ligament junction canal foramen ligaments|ligament|the spacer is placed between the spinous processes through the interspinous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|ligament triangular anatomic carpal tendon|synovium ligaments tendon tendons ligament|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity , performed annually in the united states .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin glial fibrous connective neuropil|myelin|we refer to the axon and its surrounding entity sheath as a nerve fiber .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin tendon fibrous follicular epidermal|myelin|the disease is believed to be caused by the destruction of entity sheaths by the body  s own immune system .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|myelin contain contains oligodendrocytes lipids|axonal axon myelin fasci synaptic|myelin|loss of entity insulation in surviving axons can cause nerve impulses to be delayed or lost entirely , resulting in impaired neurological function .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|myelin contain contains oligodendrocytes lipids|myelin fibrous dural neural damaged|myelin|we believe a therapy that could repair entity sheaths has the potential to restore neurological function to those affected by deentityating conditions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|myelin contain contains oligodendrocytes lipids|myelin glial fibrous astrocytic perineural|myelin|the entity sheath that surrounds axons in the brain and spinal cord provides insulation that facilitates the transmission of nerve impulses .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin tendon perineural axonal glial|myelin|ms attacks the covering surrounding nerve cells , or entity sheaths , leading to loss of entity ( deentityation ) and nerve damage .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin fibrous axon oligodendrocyte optic|myelin|the entity sheath is composed of multiple layers of tightly packed cell membrane and is vulnerable to damage in conditions like ms
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|myelin contain contains oligodendrocytes lipids|myelin fibrous granular boundary outer|myelin|by neurons as well as remove compounds that are toxic to them ; and  form the insulating entity layer around the axons of neurons , enabling their normal function for signal transmission .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin glial fibrous axonal oligodendrocyte|myelin|multiple sclerosis , or ms , is an autoimmune disease in which immune cells attack and destroy the entity sheath , which insulates neurons in the brain and spinal cord .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|myelin contain contains oligodendrocytes lipids|myelin tendon glial neural fibrous|myelin|when the entity sheath is destroyed , nerve messages are sent more slowly and less efficiently .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myelin contain contains oligodendrocytes lipids|myelin oligodendrocytes axons consciousness microtubules|myelin|the loss of entity disrupts the conduction of nerve impulses , producing the symptoms of multiple sclerosis including vision loss , incontinence , short-term memory loss , fatigue ,
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|myelin glial fibrous myelinated synaptic|myelin|reentityation reentityation is the process propagating oligodendrocyte precursor cells to form oligodendrocytes to create new entity sheaths on deentityated axons in the cns .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|myelin contain contains oligodendrocytes lipids|adipose fascia myelin dermis dura|myelin|entity is the fatty tissue that surrounds and protects the nerve fibers of the central nervous system and facilitates the flow of nerve impulses to and from the brain .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|myelin contain contains oligodendrocytes lipids|cns axonal axon myelin neuron|myelin|clene also has state of matter claims for entity protection , remyelination , neuroprotection that will last until 2032 and manufacturing device and process patents that will last beyond 2030 .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|myelin contain contains oligodendrocytes lipids|myelin sheath capsule fascia insula|myelin|in laboratory studies , dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer , called entity , has been damaged .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin contain contains oligodendrocytes lipids|lymphoid neural parenchymal glial connective|myelin|the identified autoimmune mechanisms directed at entity tissue of the cns may play an important role in the pathogenesis of ms .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myelin contain contains oligodendrocytes lipids|myelin wm axons cns axon|myelin|currently , there is no available therapy indicated to repair entity that has been destroyed in ms or other deentityating diseases .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|cns neural axonal cerebrovascular bbb|myelin|to evaluate the effect of ehp-101 on entity damage in a cuprizone-induced deentityation murine model , brain coronal sections from animals after 6 weeks of cpz 0 . 2% diet and
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|fascia adipose dermis omentum adipocytes|myelin|entity , a fatty tissue , surrounds and protects the nerve fibers of the cns and helps those nerve fibers to conduct electrical impulses .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|myelin contain contains oligodendrocytes lipids|tetanus melanoma cognate autologous myelin|myelin|to formulate tovaxin t cell vaccine , the patient  s own entity peptide-specific activated t cell lines are harvested and attenuated on the day of vaccine administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|comprise require undergo multicellular contain|ipscs xenografts mscs hmscs hescs|organoids|as a stem cell derived system , entity are a renewable model permitting repeat testing from a single patients biopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|comprise require undergo multicellular contain|enrolled register collection genotyped participating|organoids|out of the hubrecht institute , knaw and university medical center utrecht in the netherlands to evaluate the nonsense-bearing cf patient entity in its biobank .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|comprise require undergo multicellular contain|fibroblasts lungs cilia neutrophils epithelia|organoids|entity derived from nonsense mutation cf patients lack apparent swelling in this system due to their lack of functional cftr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|comprise require undergo multicellular contain|sputum saliva lungs sera fibroblasts|organoids|in a poster titled : “cftr protein detection in entity from healthy and cf patients with nonsense mutations support using organoid model to test elx-02 mediated cftr read-through restoration” , we
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|comprise require undergo multicellular contain|carriers fibroblasts clones embryos fetuses|organoids|significant restoration of cftr protein expression as measured via a capillary-based immunoassay approach in multiple g542x or w1282x nonsense carrying entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|comprise require undergo multicellular contain|fibroblasts cftr myocytes hepatocytes epithelia|organoids|·g542x entity treated with elx-02 demonstrate proper cell surface cftr localization on the apical surface , which is consistent with increased cftr , mrna ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|tissue|comprise require undergo multicellular contain|mscs fibroblasts dcs neutrophils monocytes|organoids|the ex vivo portion of the study will quantify the functional response of patient-derived entity to pti investigational agents dirocaftor , posenacaftor and nesolicaftor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|tissue|comprise require undergo multicellular contain|sera lymphocytes fibroblasts neutrophils pbmcs|organoids|entity from over 100 individuals bearing rare nonsense mutations in the cftr have been collected and are being tested for responsiveness to elx-02 in the laboratory .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|comprise require undergo multicellular contain|xenografts cohorts datasets cancers melanomas|organoids|the first dataset evaluated elx-02 in 31 patient-derived entity and demonstrated activity in the majority of them .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|spheroids xenografts beads spheroid chips|organoids|to change the classic model of drug discovery using 3d bioprinted human tissues and other 3d models ( sometimes known as “entity” or “organs on a chip” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|xenografts panels cohorts clones xenograft|organoids|high content imaging to identify mcla-158 after screening hundreds of bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|volunteers laboratories organism specimen bioassay|organoids|going concern the company has a history of operating losses as it has developed its human entity for drug toxicity and efficacy testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|comprise require undergo multicellular contain|nuclei slices fibroblasts retina lysates|organoids|we also plan to test the editor for editing efficiency in human retinal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|retrospectively institution intraoperatively surgeon files|organoids|the internal position was subject to change upon review of additional clinical and ex vivo data from the patient derived entity when such data were made available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|xenografts panels cohorts sera datasets|organoids|content imaging to identify mcla-158 after screening more than 500 bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|xenografts cscs spheroids ctcs ipscs|organoids|entity are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|comprise require undergo multicellular contain|microenvironment suppressor milieu transcriptome proteome|organoids|of cancers . 1 they may include : smarca4 , arid1a , and smarcb4 swi / snf complex mutations sensitize to lsd1 immunomodulatory effects , turning cold tumor entity hot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|tissue|comprise require undergo multicellular contain|melanoma epilepsy nsclc uc tumours|organoids|the intent of the program is to use these positive results to enroll patients with responsive entity in a prospective trial with elx-02 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|tissue|comprise require undergo multicellular contain|sputum lymphocytes neutrophils leukocytes pbmcs|organoids|hit-cf recently announced completion of the first phase of the program with the collection of entity from patients at 47 of the biggest cystic fibrosis centers in 16 countries throughout europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|comprise require undergo multicellular contain|xenografts tumours xenograft sera explants|organoids|humanized anrp2-10 decreased viability , inhibited formation of mammospheres and anchorage-independent growth in cells or entity from tnbc patients .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon perioste vascularized healed osteoblasts|wounds tendons joints myocardium nerves|periosteum|graftjacketò regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon perioste vascularized healed osteoblasts|wounds tendons joints myocardium nerves|periosteum|graftjacket® regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tendon perioste vascularized healed osteoblasts|lining roof foundation fascia dura|periosteum|● the pericranium is the entity ( a membrane that lines the outer surface of all bones ) of the skull bones and provides nutrition to the bone
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon perioste vascularized healed osteoblasts|meniscal tendon capsular synovial meniscus|periosteum|for maci is less invasive than for carticel , entailing a mini-arthrotomy or even arthroscopic delivery , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon perioste vascularized healed osteoblasts|dura appendix diaphragm nipple roof|periosteum|the entity is a membrane covering the shin bone .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tendon perioste vascularized healed osteoblasts|trabecular periosteal cancellous vertebral epiphyseal|periosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of entity and endosteum bone mineral mass .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|tendon perioste vascularized healed osteoblasts|fascia omentum autograft tendon dura|periosteum|a small piece of entity , the membrane that covers bone , is taken from the patient  s lower leg and sutured over the defect to hold the cells in place .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|tendon perioste vascularized healed osteoblasts|debridement union drainage fixation hemostasis|periosteum|at surgery , entity was lacking ; the wound was debrided , and the bone fragments realigned .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tendon perioste vascularized healed osteoblasts|tibia femur skull plate mandible|periosteum|the periosteal patch is a thin collagen membrane that is cross linked and functions as a patch on the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|tendon perioste vascularized healed osteoblasts|meniscal tendon synovial periosteal osteochondral|periosteum|the implant procedure for maci is less invasive than for carticel , entailing a mini-arthrotomy , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon perioste vascularized healed osteoblasts|peritoneum omentum sclera diaphragm capsule|periosteum|the cultured cells are then implanted under the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum abdomen thorax intestine pelvis|peritoneum|it is also used in surgery for treating a wide range of localized infections in the entity ( the lining of the abdominal cavity ) , as well as the eye , ear , nose and throat , and sinuses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum omentum fascia mesentery pelvis|peritoneum|it is formed by small , round cancer cells surrounded by scar-like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum diaphragm mesothelial omentum capsule|peritoneum|peritoneal dialysis removes waste products and excess fluids from the blood by use of the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum lungs mediastinum omentum pericardium|peritoneum|antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the pleura , pericardium and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum intestine abdomen organism appendix|peritoneum|peritonitis is a bacterial infection of the entity which can result in serious adverse health consequences , including death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|nose breath forehead stomach tongue|peritoneum|a machine is used to " cycle " solution to and from the patient  s entity during sleep .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum diaphragm fascia intestine pleura|peritoneum|upon immediate penetration of the entity , the membrane that forms the lining of the abdominal cavity , our kii® fios® first-entry creates a space for the tip
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum pericardium lungs diaphragm stomach|peritoneum|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , pleura , entity ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|dead subcutaneous intraperitoneal dialysate retroperitoneal|peritoneum|peritoneal dialysis uses the entity space in the abdomen as a dialyzer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|rectum urethra ureter intestine kidneys|peritoneum|these studies established that local injection of up to one billion mak cells in the pleural cavity , bladder or entity is well-tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|bag cartridge reservoir diaphragm cannula|peritoneum|the entity operates as the filtering membrane and , after a specified dwell time , the solution is drained and disposed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|intestine stomach esophagus mesentery aorta|peritoneum|fibrosis can affect any tissue and organ system , and is most common in the heart , liver , lung , entity , and kidney .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum omentum fascia mesentery pelvis|peritoneum|it is formed by small , round cancer cells surrounded by scar‑like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum diaphragm ultrafiltration mesothelial capsule|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|lungs peritoneum kidneys intestine intestines|peritoneum|aggressive human pancreatic cancer cell line , l3 . 6pl , that is known to metastasize from the pancreas to the liver and the entity in mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum uterus endometrium ovaries ovary|peritoneum|ovarian cancer by age 70 . ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|islets omentum peritoneum striatum livers|peritoneum|experiments were conducted using encapsulated pig islets transplanted into the entity of a diabetic rat model .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|tubing cannula bag needle tubes|peritoneum|introduces a sterile 77 85 dialysis solution from a solution bag through a tube into the peritoneal cavity and the entity operates as the filtering membrane .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum uterus endometrium ovaries ovary|peritoneum|ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|intraperitoneal peritoneum subcutaneous mesothelial parietal|peritoneum diaphragm ultrafiltration pericardium bag|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area , as a filter .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural cystic resected pleura perforation|pleura lungs pericardium diaphragm peritoneum|pleura|however , the distinction between mesothelioma and carcinomas that involve the entity , in particular peripheral pulmonary adenocarcinoma , can be challenging .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|pleural cystic resected pleura perforation|stor pear schistosoma m5 clark|pleura|entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and 104 table of contents entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura peritoneum lungs pleural pericardium|pleura|malignant mesothelioma is a rare cancer , primarily affecting the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|pleural cystic resected pleura perforation|bursa spindle zona aura mesothelioma|pleura|microrna to help differentiate malignant entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|pleural cystic resected pleura perforation|lining parenchyma interstitium pleura epithelium|pleura|mesothelioma overview malignant mesothelioma is a malignant tumor of mesothelial cells which make up the entity , or tissue lining , of many internal organs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|tissue|pleural cystic resected pleura perforation|lungs kidneys retina intestine intestines|pleura|and certain of annapurnas scientific founders teams demonstrated that this aav serotype also allows very efficient delivery to the heart , entity and liver , as well as additional organs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|emphysema atelectasis pleura pneumothorax fascia|pleura|entity refers to the thin layer of tissue that lines the chest cavity and covers the lungs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura peritoneum lungs pericardium pleural|pleura|malignant mesothelioma is a rare cancer , primarily affecting 8 the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural cystic resected pleura perforation|pleura diaphragm pericardium peritoneum lungs|pleura|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , entity , peritoneum ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural cystic resected pleura perforation|pleura mediastinum peritoneum stomach esophagus|pleura|mirview™ meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura mediastinum peritoneum pleural stomach|pleura|mirviewtm meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|kidneys peritoneum intestines pleura nodes|pleura|dissemination through the blood may also occur , affecting the lungs and entity , liver , and bones .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural cystic resected pleura perforation|pleura peritoneum lungs diaphragm mediastinum|pleura|targets mesothelin , an antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the entity , pericardium and peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|pleural cystic resected pleura perforation|pleura peritoneum mediastinum pericardium diaphragm|pleura|and is able to accurately diagnose mesothelioma and distinguish it from lung adenocarcinoma and other malignancies involving the lung and entity with very high sensitivity and specificity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|pleural cystic resected pleura perforation|fascia peritoneum ligaments adipose tendon|pleura|visceral pain is defined as pain that originates within muscle , entity , connective tissue , nervous system or solid organs within the abdomen or peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura mesothelioma bronchus peritoneum mediastinum|pleura|is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura mediastinum peritoneum mesothelioma pleural|pleura|squamous non-small cell lung cancer ; and · mirviewtm meso : for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|pleural cystic resected pleura perforation|peritoneum pleura pericardium parenchyma mediastinum|pleura|mesothelioma most commonly occurs in the entity surrounding the lung , but occasionally involving the peritoneum surrounding internal organs of the digestive tract , the lining of the heart
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural cystic resected pleura perforation|pleura mediastinum peritoneum stomach esophagus|pleura|mirview® meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleural cystic resected pleura perforation|pleura mediastinum peritoneum mesothelioma bronchus|pleura|squamous from non squamous non-small cell lung cancer ; and 3 . mirview® meso — for differentiating mesothelioma from carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|seeds retrieved yielded strontium endos|maintaining modulate regulates hence influencing|endosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of periosteum and entity bone mineral mass .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|genus vulgaris ovary hymen section|peritoneum visceral beyond deeper stomach|subserosa|tumor penetrates muscularis propria and invades entity t4 : tumor directly invades other organs or structures or perforates visceral peritoneum nodal status ( n ) nx : regional lymph nodes cannot
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|adventi lumen intima luminal intimal|balloon sheath intima lumen reservoir|adventitia|delivery catheter that allows prt-201 to be administered locally in the outer layer of the artery , which is called the entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|submucosal submucosa subepithelial muscularis muscular|walls submucosa lumen epithelium lining|submucosa|it is associated with hyperplasia and hypertrophy of the mucus-producing glands found in the entity of large cartilaginous airways .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|submucosal submucosa subepithelial muscularis muscular|submucosa sis epithelium fibroblasts segment|submucosa|development and manufacture of the regentys ecmh™ ( extracellular matrix hydrogel ) rectal solution , an extracellular matrix hydrogel derived from small intestinal entity ( sis ) of pigs .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|submucosa epithelium mesentery lymphatics muscularis|submucosa|sites include the dermis , gut mucosa and entity , conjunctiva and pulmonary alveoli and airways .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|submucosa lumen muscularis crypts stroma|submucosa|ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the epithelium and the entity of the colon .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|fibroblasts epithelium myofibroblasts adipocytes nerves|submucosa|post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|submucosal submucosa subepithelial muscularis muscular|submucosa muscularis propria epithelium vessels|submucosa|tx : primary tumor can not be assessed tis : carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DRUG', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|fibroblasts myofibroblasts epithelium endothelium adipocytes|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|fibroblasts myofibroblasts epithelium adipocytes nerves|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|submucosal submucosa subepithelial muscularis muscular|lumen dome submucosa orifice opening|submucosa|this material is injected into the entity of the bladder at the junction of the ureter and bladder in order to reduce the size of the opening
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|fibroblasts epithelium myofibroblasts adipocytes pericytes|submucosa|months post-implantation the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|submucosa muscularis peritoneum vessels mesentery|submucosa|carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa t4 : tumor directly invades other organs or
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1)])|tissue|submucosal submucosa subepithelial muscularis muscular|fibroblasts myofibroblasts epithelium adipocytes pericytes|submucosa| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|pericardium diaphragm atria scar aorta|epicardium|extensive adhesions form between the surface of the heart ( entity ) and the inner surface of the sternum after virtually every open-heart surgical procedure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|ecm cytoskeleton sarcomere emt endothelium|epicardium|the entity plays a critical role in the differentiation , expansion , and maturation of cardiomyocytes during development , or during cardiac repair responses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|surfaces walls margins border margin|epicardium|heart toxicity ( epicardial hyperplasia with inflammation primarily on the entity of the atria ) was observed in the 0 . 75 and 1 . 5 mg / kg / day groups .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|outside myocardium periphery ventricle ventricles|epicardium|to the inside of the heart ; and surgical cardiac ablation devices , which are used to ablate cardiac tissue from the entity ( outside the heart ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|interstitium vasculature septum endothelium periphery|epicardium|occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the myocardium and ultimately to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|campylobacter mycobacterium yielded genus mycoplasma|myocardium atrium ventricles ventricle pericardium|epicardium|• mpc-150-im , injected directly into the entity , is being evaluated in a phase 2b trial in patients with nyha class iv / end-stage heart failure who have received a
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|intima plaques intimal atherosclerotic neointimal|neointimal intimal medial neoin anastomotic|intima|in a rat model of percutaneous transluminal balloon angioplasty , the researchers demonstrated that elafin administration prevented entity hyperplasia .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima plaques intimal atherosclerotic neointimal|jet ultra spray mix paste|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , gentlelase , vbeam perfecta , picoway , co2re , co2re entity , profound and elōs plus .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|intima plaques intimal atherosclerotic neointimal|intima intimal medial lamina fibrous|intima|the study did not show any statistically significant difference in carotid entity media thickness between subjects in the two treatment arms .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima plaques intimal atherosclerotic neointimal|jet spray foam paste ultra|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elos plus .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|intima plaques intimal atherosclerotic neointimal|intima lumen epithelium tunic endothelium|intima|similarly , okuda et al53 reported a higher rate of age-dependent telomere attrition in both the entity and media of the distal versus proximal human abdominal aorta .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|intima plaques intimal atherosclerotic neointimal|intimal medial intima systolic ultrasonographic|intima|the fda  s primary grounds for rejecting the claim relate to the clinical utility of evaluating skin cholesterol with carotid wall entity thickness ( cimt ) as the clinical endpoint .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|intima plaques intimal atherosclerotic neointimal|intimal intima medial neointimal fibrous|intima|the study also showed that tesamorelin improved triglycerides , c-reactive protein and carotid entity medial thickness , a cardiovascular marker , without aggravating glucose .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima plaques intimal atherosclerotic neointimal|jet spray paste foam ultra|intima|the company has a wide portfolio of trusted , leading products including ultrashape power , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elōs plus .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|tissue|intima plaques intimal atherosclerotic neointimal|intimal intima medial atherosclerotic arteries|intima|sterol levels ( university of wisconsin ) l determine relationship between skin sterol and cad as measured by carotid entity medial thickness
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|intima plaques intimal atherosclerotic neointimal|neointimal intimal medial neoin anastomotic|intima|in 2013 , the researchers demonstrated that elafin administration prevented entity hyperplasia in a rat model of percutaneous transluminal balloon angioplasty .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|intima plaques intimal atherosclerotic neointimal|endothelium walls lining intima epithelium|intima|the saline / chemical irritates the entity ( lining ) of the vein , causing it to collapse .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima plaques intimal atherosclerotic neointimal|prototype screw shell fixation modular|intima|we are positioned to address this growth segment with our core entity device , which we anticipate releasing internationally in 2016 .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|intima plaques intimal atherosclerotic neointimal|intima vasculature lumen circulation interstitium|intima|smooth muscle cell migration into the entity mediated by growth factors such as platelet-derived growth factor ( " pdgf " ) is thought to play an important role in the entityl
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|intima plaques intimal atherosclerotic neointimal|intima medial intimal fibrous neointimal|intima|this trial is called restore-it , or the randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and entity media thickness .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|intima plaques intimal atherosclerotic neointimal|intima muscularis vaginalis propria lamina|intima|it is characterized by the thickening of the tunica entity of a blood vessel as a complication of a reconstruction procedure or endarterectomy , the surgical removal of plaque from an
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|insert incorporate integrate introduce clone|clone|blunt ends , however , have a slight affinity for one another , which makes it possible for researchers to entity these fragments into blunt-ended cloning vectors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|characterize clone validate characterise classify|clone|the company is utilizing this technology to discover and entity the genes that code for human receptor subtypes that may be associated with specific disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|clone microenvironment milieu niche infiltrate|clone|several cases , including cmml and aml , tumor microenvironmental pdcs have been shown to be neoplastic and part of the malignant entity , indicating a potential need for therapeutic targeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cdna clone another p1 neither|transcript rearrangement deletions haplotype translocation|clone|in fact , the presence of the hmga2 entity has steadily declined over time to the point that it is no longer the most common entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|cdna clone another p1 neither|clone myeloma plasmacyt colony neoplasm|clone|multiple myeloma is a condition in which these plasma cells become malignant , with a single entity growing at an uncontrolled pace .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|manipulate purify expand clone amplify|clone|following leaps identification of the cell of interest , we entity the cell , thereby generating millions of cells that produce high concentrations of the biological molecule of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|description clone mimic characterisation fragment|clone|heska has produced a molecular entity of the cellular receptor for the ige antibody .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|cdna clone another p1 neither|candidate scaffold reagent prodrug prototype|clone|a entity with a “highly similar” profile to herceptin has been chosen for further process development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|cdna clone another p1 neither|clone neoplasms melanoma neoplasm hematopoiesis|clone|these data suggest that imetelstat inhibits the progenitor cells of the malignant entity believed to be responsible for the underlying disease in a relatively selective manner .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|characterize clone validate characterise localize|clone|it is utilizing this technology both to discover and entity the genes that code for human receptor subtypes associated with specific disorders and to design compounds that can potentially be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|genomic cdna est bac snp|clone|our omnibank mouse entity library and its backup are stored in liquid nitrogen freezers located at our facility in the woodlands , texas , and our
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|screen isolate clone discover validate|clone|in addition , we plan to utilize our high-throughput capabilities to rapidly entity and expression-test thousands of genes for drug development and agriculture .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|named create designated member another|clone|the company , on the following boards of directors of the companys partners and affiliates ( each , a p & a board ) : entity international pty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|modify engineer introduce disrupt manipulate|clone|in addition , conventional genetic engineering techniques for protein production may face technical limitations arising from the need to first entity the gene of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|clone validate characterize isolate sort|clone|these companies are competing with one another to be the first to identify , entity and express the finite number of genes thought to be of commercial importance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|characterize manipulate uncover analyse inactivate|clone|tools and approaches in bacterial molecular genetics , which allow it to create and use gene mutants to quickly and directly entity essential bacterial genes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|amplify clone isolate insert create|clone|pcr cloning is another method that can be used to entity a dna fragment when some information about its sequence is known .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|clone isolate amplify screen overexpress|clone|in 1998 we began marketing our " high-throughput " gene cloning and expression technology , which allows us to entity and expression-test genes on an industrial scale .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|batch clone kind colony passage|clone|a mab is a type of protein that is produced by a single entity of cells or cell line and made to bind to a specific substance in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cdna clone another p1 neither|characterize clone validate manipulate classify|clone|this strategy consists of four principal objectives , the first of which is to aggressively discover and entity g protein-coupled receptor genes .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|floor building next bottom roof|basement|situated in the building upon lot c and adjacent to said common area leading from the second floor to the entity ; all as set forth in said deed recorded in book 7370 , page 304 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|west rear interior east south|basement|scope 1 . 1 location altarex will occupy the west wing on the first floor plus some space in the entity as shown on the attached plan .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|attempt netherlands country usa icu|basement|some hospitals have constructed a dedicated o . r . in the entity to reduce the transportation distance .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|vicinity radius neighborhood interior city|basement|this termination option will not apply to any space in the entity of 320 bent street if the company has exercised its option to continue to lease such entity space .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|specialized rural remote trained dedicated|basement|but these entity o . r .  s are remote from the surgical center , creating staffing and logistical difficulties .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|enclosed floor concrete confined adjacent|basement|any vault or entity space not within the property line of the building , which tenant may be permitted to use or occupy , shall be
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|basement mucous anchoring interstitial border|basement|additional biological activities shown to reduce inflammation , stimulate the formation of collagen , and up-regulate the expression of laminin-5 , a subepithelial entity membrane protein .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|basement laminin intercellular fibronectin gels|basement synovial tympanic amniotic mucous|basement|separating the two is the specialized type of extracellular matrix , known as the entity membrane .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|basement laminin intercellular fibronectin gels|basement filtration ultrafiltration mesangial podocyte|basement|as is caused by a genetic defect in type iv collagen , a component of the glomerular entity membrane in the kidney , resulting in defects in its structure and function .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|next 2nd adjacent another 4th|basement|) sublessor and sublessee each agree to log access to the server room on the 2nd floor and entity network room , and to provide these access logs to the other party if requested .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|transportation camera printing flight drilling|basement|use of any mezzanine , entity or storage space shall be at no additional charge and the area of such space shall not be included in
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|equipment vehicles transportation board cars|basement|in particular , access to the building and courtyard , vehicle passage , building and entity or other open areas and spaces must not be blocked with objects of any kind .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|waiting allocated web telephone grant|basement|if landlord leases the entity space to other tenants before service of a notice from the tenant exercising this additional right of first offer , the
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|tissue|basement laminin intercellular fibronectin gels|basement cytoplasmic heparan luminal outer|basement|tumors must ordinarily degrade the entity membrane and extracellular matrix of surrounding tissues in order to grow and heparanase is an enzyme that facilitates this process .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|basement laminin intercellular fibronectin gels|enclosed empty confined dead another|basement|no vault or entity space not within the property line of the building is leased hereunder , anything to the contrary indicated elsewhere in this lease notwithstanding .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|basement laminin intercellular fibronectin gels|ceiling front windows walls holes|basement|f of dry bulb , 74 ( degrees ) f wet bulb of zero f . new equipment to be placed on the roof and in entity ( location to be determined as tenant requirements are finalized ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|basement laminin intercellular fibronectin gels|basement mucous amniotic tympanic synovial|basement|by definition , carcinomas that originate on the epithelial side of the entity membrane are considered to be benign , as long as the cells forming them remain on the same side .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|basement laminin intercellular fibronectin gels|basement amniotic mucous synovial mucosal|basement|however , many carcinomas acquire the ability to penetrate the entity membrane , and individual cancer cells or groups of cancer cells begin to invade the stroma .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|basement laminin intercellular fibronectin gels|roof floor ceiling walls bottom|basement|tenant shall not enter into or upon the roof or entity of the building or any storage , heating , ventilation , air-conditioning , mechanical or elevator machinery housing areas .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|glioblastoma medulloblastoma astrocytoma neuroblastoma meningioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|astrocytoma glioma astrocytomas gbm gliomas|oligodendroglioma|the patients in the resection injection trial predominantly had gbm ( 79 . 1% ) with other histologies including aa ( 11 . 6% ) , anaplastic entity ( 2 . 3% ) and other ( 7 . 0% ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|meningioma glioblastoma astrocytoma medulloblastoma schwannoma|oligodendroglioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , entity , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|glioblastoma medulloblastoma astrocytoma neuroblastoma meningioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|gbm glioblastoma glioma medulloblastoma gliomas|oligodendroglioma|p / 19q loss is diagnostic for entity , and helps to determine sensitivity to response to chemotherapy , radiation and temozolomide treatment .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|meningioma astrocytoma glioblastoma glioma medulloblastoma|oligodendroglioma|the main glioma types are astrocytoma ( which includes glioblastoma ) , entity , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|astrocytoma glioma gliomas astrocytomas glioblastoma|oligodendroglioma|three patients have completed the study to date , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|anaplastic glioblastoma gliomas glioma astrocytoma|astrocytoma glioma gliomas astrocytomas glioblastoma|oligodendroglioma|patients had completed the study at the time of the abstract , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma gliomas astrocytomas glioma meningioma|astrocytoma|bt-8 phase ii study of antineoplastons a10 and as2-1 in patients with anaplastic entity ; revised 4 / 14 / 97 ; revised 9 / 15 / 97 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|glioblastoma melanoma neuroblastoma glioma medulloblastoma|astrocytoma|based on phase i and ii data , the company may conduct additional phase ii clinical trials in entity ( a type of primary brain cancer ) , ovarian and non-small cell lung cancers .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|glioma astrocytoma gliomas glioblastoma gbm|astrocytoma|we intend to commence a pivotal 396-patient phase iii randomized , multicenter clinical trial of tvi-brain-1 in newly diagnosed grade 4 entity patients .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma adenoma astrocytomas adenomas epilepsy|astrocytoma|afinitor is also approved for subependymal giant cell entity ( sega ) and renal angiomyolipoma associated with tuberous sclerosis complex ( tsc ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma glioma glioblastoma meningioma anaplastic|astrocytoma|the main glioma types are entity ( which includes glioblastoma ) , oligodendroglioma , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas glioma adenoma glioblastoma|astrocytoma|afinitor is also approved for subependymal giant cell entity and renal angiomyolipoma associated with tuberous sclerosis complex .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma glioma gliomas astrocytomas glioblastoma|astrocytoma|glioblastoma multiforme , or gbm , also called grade iv entity , is the most common type of malignant primary brain tumor , comprising about 30% of all primary brain tumors in adults .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|mesothelioma hyperthermia melanoma histiocytosis schwannoma|astrocytoma|the patient died in december 2003 , and the case was originally reported by a clinical trial investigator as malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|glioma gliomas astrocytoma glioblastoma astrocytomas|astrocytoma|center at san antonio initiated a clinical trial of th-302 in combination with bevacizumab in patients with recurrent high grade entity including glioblastoma .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas glioma gliomas glioblastoma|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the u . s . food and drug administration .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|rabies cholera cdi leptospirosis tetanus|astrocytoma|hospital and select , dated august 15 , 2000 , to perform and conduct a clinical trial study of verotoxin for treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas gliomas meningioma glioma|astrocytoma|current treatments for glioblastoma and anaplastic entity involve surgical resection , radiation therapy , and chemotherapy .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|melanoma glioma astrocytoma meningioma gliomas|astrocytoma|initially primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma adenoma astrocytomas adenomas arteritis|astrocytoma|in november , the japanese health authority approved afinitor for the treatment of renal angiomyolipoma and subependymal giant cell entity ( sega ) associated with tsc .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas glioma gliomas glioblastoma|astrocytoma|the time from the initial brain tumor diagnosis to enrollment on the study ranged from four months to 301 months ( this last timing for a patient diagnosed with childhood anaplastic entity ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas glioma gliomas meningioma|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma astrocytomas gliomas glioma meningioma|astrocytoma|the protocol included the provision to enroll up to 24 patients with recurrent supratentorial anaplastic entity and glioblastoma multiforme ( " gbm " ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|melanoma astrocytoma glioma meningioma schwannoma|astrocytoma|our initial focus is on patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma meningioma glioblastoma osteosarcoma glioma|astrocytoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , entity , oligodendroglioma , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioblastoma astrocytoma anaplastic glial astrocytic|astrocytoma glioblastoma astrocytomas glioma meningioma|astrocytoma|patients ( 69% ) entered the study with a diagnosis of glioblastoma multiforme , seven of which were secondary to transformation from anaplastic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|fibroids leiomyoma leiomyomas sarcoma leiomyosarcoma|carcinosarcoma|additional cabozantinib data presentations included results from trials in endometrial cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|sarcoma uterine resembles anaplastic metastas|sarcoma leiomyosarcoma leiomyoma malignancy endometriosis|carcinosarcoma|four patients ( three ovarian cancer patients and one uterine entity patient ) had a partial response , and 17 patients had stable disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|leiomyosarcoma sarcoma leiomyoma mesothelioma neoplasm|carcinosarcoma|one patient , a 63 year old female with a poorly differentiated uterine entity , had a complete response .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cancer|sarcoma uterine resembles anaplastic metastas|uterine endometrial melanoma esophageal testicular|carcinosarcoma|objective responses were seen in eight patients including ovarian , breast , entity , and peritoneal mesothelioma , seven of whom had prior therapy with paclitaxel or docetaxel .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|sarcoma uterine resembles anaplastic metastas|nsclc mbc tnbc glioblastoma gbm|carcinosarcoma|the study has been expanded to include dkn-01 monotherapy and paclitaxel combination cohorts in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|glioblastoma leiomyosarcoma osteosarcoma melanoma mesothelioma|carcinosarcoma|partial responses in patients with endometrial cancer , and dkn-01 plus paclitaxel has generated a partial response in a patient with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|tp53 kras pik3ca pten fgfr|carcinosarcoma|patients , including those with entity and wnt pathway alterations , have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|enrolled surviving participating eligible screened|carcinosarcoma| gynecologic cancers study : updated follow-up data from the entity patients is expected in late 2020 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|sarcoma uterine resembles anaplastic metastas|cervix endometrial corpus uterine endometrioid|carcinosarcoma|over 40% of uterine entity cancers and 10% to 20% of ovarian and stomach cancers harbor ccne1 amplification .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|sarcoma uterine resembles anaplastic metastas|nsclc melanoma ipf osteosarcoma acs|carcinosarcoma|patient follow-up is continuing in this study , which has been expanded to include focused cohorts of patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|sarcoma leiomyosarcoma sarcomas leiomyoma leiomyomas|carcinosarcoma|the partial responses occurred in patients with ovarian cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma uterine resembles anaplastic metastas|comparator entire randomization investigational comparative|carcinosarcoma|enrollment has recently completed in the entity groups .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|sarcoma uterine resembles anaplastic metastas|adenoma adenomas neoplasia carcinomas neoplasms|carcinosarcoma|no mammary adenoma was diagnosed by the pathologists who provided the original study report ; the incidence of mammary entity did not change from the initial report .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|sarcoma uterine resembles anaplastic metastas|nsclc melanoma osteosarcoma mind sarcoma|carcinosarcoma|odkn-01 plus paclitaxel in entity : fifteen patients with carcinosarcoma were enrolled in the dkn-01 plus paclitaxel arm , six of whom were evaluable for response as of the data-cut off
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|sarcoma uterine resembles anaplastic metastas|psoriasis sle uveitis jia uc|carcinosarcoma|in addition , based on the clinical activity observed in part 1 , we have added a cohort for patients with entity in part 2 of the study .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|cystic teratoma ovary gestational testicular|hemorrhage infarction abscess gliosis hematoma|teratoma|were not only insufficient for regeneration or reconstruction of the damaged cns , but also accompanied by unacceptably high incidents of entity and / or neoplasm formation .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cystic teratoma ovary gestational testicular|tumorigenicity cytotoxicity aneuploidy tumorigenesis emt|teratoma|there was no evidence of entity , or tumor growth , in these cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cystic teratoma ovary gestational testicular|comparative formal theoretical retrospective expert|teratoma|$ 47 , 535 project 2 : entity assessment of the generation of three germ layers scope of work the goal of this project is to assess the
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cystic teratoma ovary gestational testicular|teratoma colony sphere chimera foci|teratoma|pluripotent properties of wolfram syndrome-ipscs were also assessed by entity formation on intramuscular injection of undifferentiated wolfram syndrome-ipscs into scid mice .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cystic teratoma ovary gestational testicular|xenografts tumours chimeras colonies leukemia|teratoma|in a humanized mouse model on left : human ipsc proliferate ( as visualized by luminescence of live cells ) and form entity in nsg mice ( n=3 ) with adoptive transferred human nk cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cystic teratoma ovary gestational testicular|teratoma colony spheroid sphere thrombus|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cystic teratoma ovary gestational testicular|teratoma colony sphere scar fistula|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been 264 table of contents observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|cystic teratoma ovary gestational testicular|scar granuloma myelin amyloid collateral|teratoma|included in the safety package were studies that showed no evidence of entity formation 12 months after injection of clinical grade grnopc1 into the injured spinal cord of rats and mice .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cystic teratoma ovary gestational testicular|malign cancerous neoplastic malignancy tumorigenic|teratoma|know that one of the scientific tests to determine that the cells are hescs , is whether they can produce a entity or benign tumor .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|seminoma histology testicular histologically histological|dyspnoea dyspnea cough oedema dizziness|seminoma|dyspnoea 1 chest pain 1 entity 1 weight increased 1 hot flush 1 mood swings 1 erectile dysfunction 1 uri 1 hot flush 1 headache 1
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma augmentation sarcomas engineering reconstructions|sarcoma|based on the outcome of picasso 3 in soft tissue entity and the resulting revision in the companys development plans for palifosfamide , enrollment in this study was suspended with 188 patients
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|melanoma leukemia sarcoma myeloma nhl|sarcoma|institute of health ( which we refer to as nih ) and physician collaborators , salarius believes that there are approximately 500 ewing entity patients diagnosed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sponsored anticancer funded anthrax hepatitis|sarcoma|contracts and agreements nci entity vaccine grant in july 2010 , the national cancer institute ( “nci” ) awarded the company a small business innovation research
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas osteosarcoma ewing rhabdomyosarcoma|sarcoma|endorex has received orphan drug designation for immther ( r ) by the fda for two types of bone cancer , ewings entity and osteogenic entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|specimen malignancy neoplasia neoplasm slide|sarcoma|but pathologists ( doctors who specialize in diagnosing cancers by how they look under the microscope ) , may not always agree on the exact type of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas lymphomas granulomatosis encephalitis|sarcoma|thalidomide , as well as to the orphan drug designations we already received for its use in brain cancer and kaposi  s entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|oncology sarcoma retinoblastoma leukemia rhabdomyosarcoma|sarcoma|he holds the position of the french entity group , and acts as network director of the european reference network for rare adult cancers ( euracan ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcomas sarcoma tumours neoplasms malignancies|sarcoma|we also received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue entity , including angioentity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma liposarcoma sarcomas lipoma mesothelioma|sarcoma|the most common types of entity in adults are undifferentiatedpleomorphic entity ( previously called malignant fibrous histiocytoma ) , lipoentity , and leiomyoentity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|neoplasms tumours leiomyomas sarcomas leiomyoma|sarcoma|for example , leiomyoentitys are the most common abdominal entity , while lipoentitys and undifferentiated pleomorphic entity are most common in legs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|resuscitation cornea breastfeeding alzheimer chiropractic|sarcoma|patel is a member of the board of directors for the entity foundation of america .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas rhabdomyosarcoma osteosarcoma tumorigenesis|sarcoma|ewing entity is driven by an easily diagnosed chromosomal translocation , i . e . , ews-fli sankar et al . clinical cancer research 20 . 17 oncogenes ( tumor growth )
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas osteosarcoma chondrosarcoma fibrosarcoma|sarcoma|synovial entity is an ini1-deficient tumor of particular interest for treatment with an ezh2 inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|oncology epilepsy neurosurgical orthopaedic cardiology|sarcoma|“the entity community has been very supportive following the esmo presentation in which we showed a clear benefit for adp-a2m4 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas tumours osteosarcoma neoplasms|sarcoma|and mcl and are also conducting a dose-escalation phase 1 trial of tk216 in patients with relapsed or refractory ewing entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|comprising utilizing incorporating carrying employing|sarcoma|kaposis entity the novel mt-1000 class constructs are designed to specifically deliver doxorubicin , a chemotoxin , which can kill ks tumor cells
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas tumours rhabdomyosarcoma osteosarcoma|sarcoma|during the three months ended sept . 30 , 1998 , the company expanded the clinical trial for immther ( r ) in ewings entity to memorial sloan-kettering , a major cancer center .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas fibrosarcoma osteosarcoma leiomyosarcoma|sarcoma|our preclinical data for synovial entity we have generated in vivo proof of concept data that demonstrates antitumor activity of fhd-609 in synovial sarcoma cdx models .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas osteosarcoma ewing tumours|sarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyoentity , ewings entity and osteoentity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma ewing leiomyosarcoma sarcomas osteosarcoma|sarcoma sarcomas tumours osteosarcoma rhabdomyosarcoma|sarcoma|current treatment for ewing entity consists of an intensive chemotherapy regime , radiation and often disfiguring surgeries .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|scid nude xenograft humanized athymic|osteosarcoma|+ mbil-15 nk cells ( graphical ) the graphical data above are an average of the mice studied in the entity mouse model shown above .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|osteosarcoma others rhabdomyosarcoma sarcoma leukemia|osteosarcoma|rare pediatric disease designations for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|publication comparative audit retrospective registration|osteosarcoma|: 93 , 1995 junovan : phase iii entity results overall survival years proportion surviving 0 1 2 3 4 5 6 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 -
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|neuroblastoma medulloblastoma rhabdomyosarcoma leukemia melanoma|osteosarcoma|overexpressed , including her2+ gastric , endometrial , ovarian , colorectal , lung , pancreatic , cervical , and bladder cancers , as well as her2+ pediatric indications including entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|carcinogenicity hypersensitivity toxicities malignancy neurotoxicity|osteosarcoma|typically , treatment duration is limited to two years because of the risk of entity revealed in preclinical testing .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|osteosarcoma sarcoma neuroblastoma leukemia melanoma|osteosarcoma|her2 is overexpressed in certain solid-tumor cancers , including pediatric bone cancer ( or entity ) , breast cancer , esophageal , and gastric cancer .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|neuroblastoma medulloblastoma rhabdomyosarcoma retinoblastoma osteosarcoma|osteosarcoma|according to the childrens oncology group , the survival of children with entity has remained at 60-65 percent since the mid-1980s .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|osteosarcoma chondrosarcoma gct rhabdomyosarcoma hemangioma|osteosarcoma|entity is a bone tumor that occurs predominantly in adolescents and young adults .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|hypercalcemia hypocalcemia osteoporosis hyperkalemia hemorrhage|osteosarcoma|because of the potential risk of entity , natpara is recommended only for patients who cannot be well-controlled on calcium and active forms of vitamin d alone .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|ibd melanoma sle psoriasis sarcoidosis|osteosarcoma|assuming similar prevalence as in the united states , we estimate approximately 1 , 500 patients diagnosed with entity per year in europe .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|esrd disabilities ibd epilepsy ckd|osteosarcoma|any revenues generated will be limited by the number of patients with entity , our ability to obtain appropriate pricing and reimbursement for junovan , and the effects of competition .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|melanoma ibd sarcoidosis psoriasis leukemia|osteosarcoma|each year , approximately 1 , 000 new patients are diagnosed with entity in the united states .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|mammary melanoma leukemia osteosarcoma cancers|osteosarcoma|filed for a product license from the usda for at-014 , a novel her2 / neu-directed cancer immunotherapy for the treatment of canine entity and other cancers .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|leprosy rabies measles autism leishmaniasis|osteosarcoma|entity is an orphan disease with fewer than 1 , 000 new cases diagnosed in the united states each year .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|melanoma osteosarcoma nsclc crc hnscc|osteosarcoma|cxcr4 antagonist to determine whether inhibition of cxcr4 leads to a decrease of lung metastases in a mouse model of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|osteosarcoma glioma melanoma rhabdomyosarcoma glioblastoma|osteosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|autoimmunity cancers hepatitis leukemia neurodegeneration|osteosarcoma|it is unknown if tymlos will cause entity in humans .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|glioma melanoma glioblastoma osteosarcoma medulloblastoma|osteosarcoma|in subsequent testing in mouse xenograft models of neuroblastoma , ewing sarcoma , rhabdomyosarcoma and entity , clr 131 provided significant benefits on tumor growth rates and survival .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|mcc nsclc osteosarcoma glioblastoma mpm|osteosarcoma|the standard treatment for entity is tumor resection with combination chemotherapy before and after surgery .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|osteosarcoma sarcoma malignancy anaplastic metastas|orthotopic osteosarcoma xenograft preclinical murine|osteosarcoma|the presentation will discuss the work related to the anti-metastatic properties of ctce-9908 in an entity model and the potential mechanisms involved .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|musculoskeletal glomus ewing osseous mesenchymal|chondrosarcoma|the most common locations for entity tumors are the bones of the extremities and the pelvis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|osteosarcoma chondrosarcoma gct neuroblastoma sarcoma|chondrosarcoma|entity is a rare , life-threatening bone cancer .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|neuroblastoma osteosarcoma sarcoma rhabdomyosarcoma leukemia|chondrosarcoma|idh2 mutations have also been found in several solid tumor types such as melanoma , glioma and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|mesothelioma mpm sarcoma pleural asbestos|chondrosarcoma|we expect to announce additional data from the entity and malignant pleural mesothelioma treatment cohorts in the fourth quarter of 2020 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|neuroblastoma glioblastoma medulloblastoma meningioma melanoma|chondrosarcoma|idh1 mutation alterations are seen in aml , glioma , entity , and intrahepatic cholangiocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|rhabdomyosarcoma leiomyosarcoma osteosarcoma liposarcoma fibrosarcoma|chondrosarcoma|partial responses were seen , in one patient each , with entity , extra-skeletal myxoid entity , leiomyosarcoma and a desmoid tumor .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|osteosarcoma rhabdomyosarcoma chondrosarcoma leiomyosarcoma sarcomas|chondrosarcoma|” in this phase 2 study , the single agent activity of krx-0401 is being evaluated in patients with entity , alveolar soft part sarcomas and extra-skeletal myxoid entitys .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|melanoma sarcoma mesothelioma glioblastoma neuroblastoma|chondrosarcoma|at the 3 . 1 mg / m2 dose level , one patient with prostate cancer and one with entity had no dlt during 4 and 9 cycles of treatment , respectively .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|sarcoidosis gca pheochromocytoma endometriosis hcm|chondrosarcoma|entity predominantly affects middle-aged and older adults , usually occurring in patients over 40 years old , with the incidence gradually increasing up
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|mesothelioma sclc nsclc mpm ipf|chondrosarcoma|both malignant pleural mesothelioma and entity are serious , life-threating medical conditions with very limited treatment options , for which inbrx-109 could fulfill an unmet medical need .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|nsclc melanoma crc hnscc sclc|chondrosarcoma|the preclinical data support infinitys ongoing phase 2 double-blind , randomized , placebo-controlled trial of ipi-926 in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|melanoma sarcoma neuroblastoma myeloma sarcomas|chondrosarcoma|and tolerability as a single agent in patients with advanced solid tumors with an idh1 mutation , including glioma , cholangiocarcinoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|glioma melanoma glioblastoma neuroblastoma meningioma|chondrosarcoma|includes 2 patients with triple negative breast cancer , 1 renal cell carcinoma patient , 1 mesothelioma patient and 1 idh1 mutant entity patient .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|gist pdac nsclc melanoma glioblastoma|chondrosarcoma|in particular , there are no approved effective systemic therapy options for recurrent , unresectable and metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|osteosarcoma osteoporosis chondrosarcoma sarcoma myeloma|chondrosarcoma|in the united states , entity accounts for approximately one-third of the 2 , 000 cases of primary bone cancer 5 table of contents diagnosed each year .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondrosarcoma mesenchymal chondro anaplastic sarcoma|nsclc melanoma osteosarcoma hnscc crc|chondrosarcoma|initiated a phase 2 clinical trial evaluating ipi-926 as a single agent in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cystic serous mucinous papillary ovary|papillary cystic serous mucinous endometrioid|cystadenocarcinoma|reactivity was higher in particular subsets of these cancers ; for example , over 80% of serous entity ovarian cancer tumors were reactive .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cystic serous mucinous papillary ovary|adenocarcinomas carcinomas serous melanoma neoplasms|cystadenocarcinoma|the patients tumor types were as follows : colon , rectal , breast , pancreatic , esophageal , gastric , papillary entity , cholangiosarcoma , carcinoid , unknown primary .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|adenoma carcinomas dysplasia adenomas neoplasia|carcinoma|hepatitis c viral infection ( " hcv " ) is a potentially deadly disease that , if not treated , may lead to cirrhosis and hepatocellular entity , or liver cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers malignancy neoplasia sarcoma|carcinoma|dart study , a randomized , double-blind study of dalantercept plus axitinib , compared to placebo plus axitinib in patients with advanced renal cell entity ( rcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas adenoma adenomas cancers neoplasms|carcinoma|we are working to develop and potentially commercialize tivozanib in the u . s . as a treatment for rcc and hepatocellular entity , or hcc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers adenoma cirrhosis leukemia|carcinoma|trials in colon cancer , gastric cancer , small cell lung cancer and hepatocellular entity are investigator-sponsored .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas adenoma cancers cholangiocarcinoma neoplasms|carcinoma|ended march 31 , 2002 , we disclosed plans to pursue phase 3 clinical studies with t67 for the treatment of hepatocellular entity , or primary liver cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|scc npc carcinomas papillomas cancers|carcinoma|in addition , argx-110 is being evaluated in an open-label phase 1 clinical trial in patients with nasopharyngeal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers malignancy malignancies crisis|carcinoma|programs of archexin and will cease enrollment in the current phase iia clinical study of archexin in metastatic renal cell entity ( mrcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas neoplasia adenoma neoplasms cancers|carcinoma|by approximately 20 weeks of age , mice began to develop hepatocellular entity ( hcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|replacement melanoma activator nevus sarcoma|carcinoma|net revenue from our two collaborations with genentech unless and until we obtain fda approval to commercialize our basal cell entity product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers sarcoma neoplasms malignancies|carcinoma|approved in more than 80 countries and regions including the us , eu member states and japan for advanced renal cell entity following vascular endothelial growth factor-targeted therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|epithelium gland glands acini ducts|carcinoma|; 32 : 1207–1218 vx15 ( pepinemab ) anti-sema4d antibody for cancer sema4d expression is concentrated at invasive margin of tumor mammary entity ( tubo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas carcinogenesis cancers adenoma neoplasia|carcinoma|our focus on hepatocellular entity , or hcc , is based on the fact that liposomal nanoparticle formulations have a tendency to deliver their payload to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas sarcoma adenoma cholangiocarcinoma leukemia|carcinoma|t67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular entity , a refractory malignancy for which there are no approved systemic chemotherapeutic agents .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers malignancy neoplasm sarcoma|carcinoma|archexin received " orphan drug " designation from the fda for five cancer indications ( renal cell entity ( rcc ) , glioblastoma , ovarian cancer , stomach cancer and pancreatic cancer ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers malignancies tumours adenocarcinomas|carcinoma|we initiated a phase ii clinical trial in the third quarter of 2002 in patients with renal cell entity expressing the muc1 antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers sarcoma leukemia malignancy|carcinoma|when used in combination with the checkpoint inhibitor opdivo , nktr-214 showed important clinical responses in melanoma , renal cell entity and nsclc patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|carcinomas cancers carcinogenesis hepatoma cholangiocarcinoma|carcinoma|with tekmira to develop sirna to silence the csn5 gene , which could represent a novel therapeutic target to treat hepatocellular entity ( hcc ) and other cancers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|cancers carcinomas tumours neoplasm leukemia|carcinoma|lung cancer , including nsclc and small cell lung entity , or sclc , is the most common form of human cancer , and about 80% of diagnosed lung cancer cases are categorized
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|transitional tubul melanoma sarcoma carcinomas|carcinoma|bacillus calmette-guérin ( bcg ) -refractory entity in situ ( cis ) bladder cancer—cis of the urinary bladder is a rare form of bladder cancer , affecting about 7 of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|papillary hepatocellular squamous neuroendocrine ductal|sarcoma carcinomas malignancy cancers leukemia|carcinoma|renal cell entity doesn  t respond to chemotherapy and 15 to 20% of the patients respond to cytokine ( il2 or ifn-y ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|mesothelioma melanoma sarcoma endometriosis leiomyosarcoma|cholangiocarcinoma|phase 1 / 2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer ( nsclc ) , ovarian cancer , malignant pleural / peritoneal mesothelioma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|cholangiocarcinoma hepatocellular gallbladder intrahepatic hepatobiliary|cholangiocarcinoma|biliary cancers , including entity , gallbladder and ampullary carcinoma , are cancers originating in the bile duct , a vessel that transports bile from the liver to
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 3)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|gout hyperuricemia urolithiasis aki hyponatremia|cholangiocarcinoma|[ *** ] after a specified period of time following regulatory approval of varlitinib for the treatment of entity in south korea and ( ii ) milestone payments of $
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|japan canada brazil taiwan china|cholangiocarcinoma|additionally , we made a payment of $325 , 000 to hyundai in order to buy back the rights to commercialize varlitinib in entity ( cca ) and recorded as operating costs in february 2019 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|glioblastoma leukemia glioma melanoma neuroblastoma|cholangiocarcinoma|that ros1 is rearranged in non-small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , gastric cancer patients and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|cml nsclc aml regimens tkis|cholangiocarcinoma|in november , the fda accepted the new drug application ( nda ) for pemigatinib in second-line entity for priority review .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|melanoma mesothelioma leukemia cholangiocarcinoma neuroblastoma|cholangiocarcinoma|compared to phenoxodiol , triphendiol has substantially greater activity in laboratory testing against pancreatic cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|melanoma mesothelioma leukemia glioblastoma sarcoma|cholangiocarcinoma|dkn-01 is in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|gliomas glioblastoma glioma nsclc neuroblastoma|cholangiocarcinoma|the fda has also granted fast-track designation to ivosidenib for treatment of patients with previously treated , unresectable or metastatic entity with and idh1 mutation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|gallbladder cholangiocarcinoma hepatocellular hepatobiliary hepatoma|cholangiocarcinoma|had been granted orphan drug status by the fda for the treatment of pancreatic cancer and for the treatment of entity , or bile duct cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|cancers cholangiocarcinoma tumours malignancy malignancies|cholangiocarcinoma|biliary tract cancer consists of intra-hepatic and extra-hepatic entity ( cancer of the bile duct ) , cancer of the gall bladder and papilla of vater ( the final portion of the bile
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|plc icc cca ccc phc|cholangiocarcinoma|one type of liver cancer ( entity ) that is rare in most parts of the world has high incidence rates in thailand and other parts of asia
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|cholangiocarcinoma icc cca cholestasis ccc|cholangiocarcinoma|the development of rly-4008 will focus on solid tumor patients with fgfr2 alterations , including intrahepatic entity ( icc ) patients harboring fgfr2 gene fusions .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|cholangiocarcinoma cholestasis obstruction steatosis dilatation|cholangiocarcinoma|“icca” means intrahepatic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|gallbladder hepatocellular stomach esophageal cholangiocarcinoma|cholangiocarcinoma|in october 2017 , we initiated a phase 1b / 2 clinical trial to assess tecentriq with pegph20 in patients with entity and gall bladder cancer ( halo 110-101 / matrix ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|osteoporosis osteoarthritis glaucoma psoriasis oab|cholangiocarcinoma|opaganib received orphan drug designation from the u . s . fda for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|melanoma mesothelioma escc leukemia sarcoma|cholangiocarcinoma|dkn-01 is currently being studied in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|require warrant warrants requiring warranted|cholangiocarcinoma|breast cancer gastric cancer , nsclc pancreas cancer , gastric cancer gall bladder cancer , entity robust pan-tumor testing of pegph20 17 1 pending continued enrollment rate .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|leukemia melanoma neuroblastoma osteosarcoma glioma|cholangiocarcinoma|studies suggest that ros1 is rearranged in non small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic hilar unresectable duct|nsclc pretreated crpc eligible mbc|cholangiocarcinoma|the company commenced a second combination trial , examining the combination of prolindac and gemcitabine in entity patients , in the fourth quarter of 2011 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|nevus nevi mimic follicular bcc|cin mace crc ich isr|keratoacanthoma|in the pooled safety population , cuscc and entity occurred in 7% and 1 . 9% of 351 patients , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|nevus nevi mimic follicular bcc|fever seizure rash thrombocytopenia diarrhea|keratoacanthoma|the two trsaes included a grade 2 infusion reaction and a grade 1 entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|nevus nevi mimic follicular bcc|psoriasis leukemia bcc osteosarcoma dysplasia|keratoacanthoma|tafinlar results in an increased incidence of cutaneous squamous cell carcinoma ( cuscc ) , entity and melanoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|nevus nevi mimic follicular bcc|scc melanoma bcc melanomas papillomas|keratoacanthoma|in the columbus trial , cutaneous squamous cell carcinoma , including entity , occurred in 2 . 6% and basal cell carcinoma occurred in 1 . 6% of patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|nevus nevi mimic follicular bcc|scc melanoma bcc lymphomas melanomas|keratoacanthoma|cutaneous squamous cell carcinoma , including entity , occurred in 7% of patients receiving the combination and 19% of patients receiving tafinlar as a single agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers ductal malignancy carcinomas malignancies|adenocarcinoma|treatment of cervical cancer and other solid tumors , including head and neck cancer , squamous non-small-cell lung cancer , or nsclc , pancreatic entity and colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|mucinous ductal neuroendocrine papillary squamous|leiomyosarcoma scc sarcoma idc spt|adenocarcinoma|entity of the pancreas , which accounts for approximately 95% of all cases of pancreatic cancer , has a median overall survival of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|melanoma glioblastoma leukemia glioma nsclc|adenocarcinoma|o ing-1 is a human engineered ( tm ) monoclonal antibody developed by us to specifically target tumor cells in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|mucinous ductal neuroendocrine papillary squamous|ductal adenocarcinomas exocrine pdac mucinous|adenocarcinoma|it is estimated that around 65 , 000 patients were diagnosed with pancreatic cancer ( mainly entity ) in the united states and the top 5 eu countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers malignancies malignancy adenocarcinomas carcinomas|adenocarcinoma|of medicine , which investigated marker therapeutics , inc . s ( the “company” ) multitaa t cell therapy for the treatment of patients with pancreatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|malignancy cancers malignancies carcinomas adenocarcinomas|adenocarcinoma|clinical trial led by baylor college of medicine ( bcm ) , evaluating the companys multitaa t cell therapy in patients with pancreatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas neoplasia neoplasms carcinomas malignancies|adenocarcinoma|am0010 development for the treatment of pancreatic ductal entity in our phase 1 / 1b clinical trial , we treated 22 pdac patients with am0010 monotherapy and 21 patients with am0010 in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers adenocarcinomas malignancies carcinomas malignancy|adenocarcinoma|trial evaluating keytruda as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas neuroendocrine carcinoid adenoma undifferentiated|adenocarcinoma|types of nsclc include squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|mucinous ductal neuroendocrine papillary squamous|squamous cancers cystic smoke a549|adenocarcinoma|studies suggest that ros1 is rearranged in non small cell lung entity cancer patients , stomach cancer patients , glioblastoma patients and cholangiocarcinoma patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas carcinomas scc melanoma malignancies|adenocarcinoma|the u . s . food and drug administration ( fda ) approved abraxane in combination with gemcitabine as first-line treatment of patients with metastatic entity of the pancreas .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas neuroendocrine carcinoid adenoma undifferentiated|adenocarcinoma|about 85% of lung cancers are nsclc , which has different subtypes , including squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|carcinomas scc melanoma cancers tumours|adenocarcinoma|the study will target enrolling 35 patients with histologically or cytologically confirmed diagnosis of invasive entity originating in the breast .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers carcinomas gland adenocarcinomas enlargement|adenocarcinoma|and multiple myeloma , and expects to commence clinical trials of maxamine for the treatment of additional cancers , such as prostate entity , in 1998 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers carcinomas adenocarcinomas neoplasms carcinogenesis|adenocarcinoma|high msi is present in about 15% of gastrointestinal tumor cancers , including in approximately 22% of stomach entity and 16% of colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|mucinous ductal neuroendocrine papillary squamous|endometriosis neoplasia aip metaplasia malignancy|adenocarcinoma|entity is a general term that refers to a cancer that starts in glandular tissues anywhere in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|mucinous ductal neuroendocrine papillary squamous|coinfection cin chlamydia asc dysplasia|adenocarcinoma|· inability to detect entitys — pap tests are unable to detect the presence of the more virulent entity ( clinical laboratory medicine , 20 : 140 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas carcinomas cancers malignancies scc|adenocarcinoma|abraxane® was approved for the treatment of metastatic entity of the pancreas in the united states in september 2013 and the european union in december 2013 . net sales of abraxane®
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|adenocarcinomas carcinomas neoplasia neoplasms neoplasm|adenocarcinoma|our phase 1 clinical trial , which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|mucinous ductal neuroendocrine papillary squamous|cancers tumours carcinogenesis carcinomas neoplasia|adenocarcinoma|the first target of the collaboration is early stage lung entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|blast sarcoma solitary neoplasm anaplastic|diagnostics pharmaceuticals vaccines prostheses instruments|blastoma|neuroentity - market insights , epidemiology and market forecast - 2027 the market of neuro entity in 7mm was found to be usd 733 . 58 million in 2016 , and is expected to increase at from 2016 -
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma locoregional documented cns disseminated|melanoma|five patients experienced entity relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|paclitaxel docetaxel antiretroviral sequential rituximab|melanoma|that our cash reserves are sufficient to fund two years of anticipated operating activities , including our recently announced phase ii entity combination trial .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma glioma glioblastoma neuroblastoma osteosarcoma|melanoma|in preclinical studies conducted by the company  s scientists , tlc ell-12 has been shown to be active in tumor models of entity , lung cancer , leukemia and multiple drug resistant cell lines .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma cancers osteosarcoma pca malignancies|melanoma|provectus has completed phase 2 trials of pv-10 as a therapy for metastatic entity , and of ph-10 as a topical treatment for atopic dermatitis and psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|sclc melanoma nsclc glioblastoma gbm|melanoma|• data from the nsclc and entity cohorts of the encore 601 trial will each be featured during oral presentations at the american association of cancer research
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|gbs gd autism epilepsy rabies|melanoma|bms / p  s most advanced program involves a vaccine called gmk that incorporates qs-21 with a ganglioside preparation called gm2 to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma neuroblastoma gist nsclc osteosarcoma|melanoma|what im trying to say here is we have completely changed the outcome and treatment of patients with metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma nsclc neuroblastoma cancers sclc|melanoma|we introduced canvaxin that was manufactured using this new process into our two phase 3 clinical trials for advanced-stage entity in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|cancers nsclc malignancies cholangiocarcinoma crc|melanoma|triphendiol has recently been granted orphan drug status by the fda for pancreatic and bile duct cancers , and late stage entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|hepatitis melanoma cirrhosis hepatoma antidiabetic|melanoma|the company has received orphan drug designations from the fda for its entity and hepatocellular carcinoma indications .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma crc pca osteosarcoma cancers|melanoma|accordingly , a comparable distribution of patients with liver metastases is important in clinical trials of metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma crc gist nsclc osteosarcoma|melanoma|it was approved to treat metastatic entity by the fda in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma nsclc cancers malignancies neuroblastoma|melanoma|the first oncolytic immunotherapy , imlygic , also known as t-vec , which was approved by the fda for the treatment of advanced entity in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma neuroblastoma osteosarcoma crc nsclc|melanoma|have completed enrollment in part i of a phase 3 trial for renal cell carcinoma and a phase 3 trial for metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma glioma mesothelioma neoplasm astrocytoma|melanoma|the improvement in two and three year survival remained statistically significant in the subpopulation of advanced malignant entity patients with liver metastases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma neuroblastoma aml gist glioma|melanoma|the pivotal phase iii study in high-risk entity patients completed enrollment in 1999 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma glioblastoma neuroblastoma melanomas mesothelioma|melanoma|product has potential utility in adjuvant therapy and for the treatment of advanced cancers that express the gd2 ganglioside , including entity , small cell lung cancer and sarcoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma nsclc crc neuroblastoma gist|melanoma|we  re recruiting patients with metastatic entity for a phase i safety study in israel .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|melanoma melanomas melanocytes nevi indolent|melanoma glioma gliomas ascites mesothelioma|melanoma|and metastatic breast cancer ; and intron a injection , marketed for numerous anticancer indications worldwide , including as adjuvant therapy for malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|melanoma melanomas melanocytes nevi indolent|monotherapy pivotal ongoing pilot adjuvant|melanoma|the most common adverse events associated with our entity trials have consisted of flu-like symptoms such as fever , chills and nausea .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma osteosarcoma rhabdomyosarcoma fibrosarcoma chondrosarcoma|leiomyosarcoma|or cbr , rates was achieved in the three most prevalent types of sarcoma , namely bone sarcoma ( cbr rate of 30% ) , entity ( 33% ) and liposarcoma ( 30% ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|chondrosarcoma leiomyosarcoma neuroblastoma melanoma liposarcoma|leiomyosarcoma|these include patients with osteosarcoma , ewing sarcoma family tumours , malignant fibrous histiocytoma , synovial sarcoma , fibrosarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|pilot collaborative retrospective entire epic|leiomyosarcoma|the entity study was initiated and screening of patients began in early 2006 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|glioblastoma melanoma nsclc eligible neuroblastoma|leiomyosarcoma|we also enrolled a first entity patient in the phase 2 basket arm evaluating ide196 as monotherapy , expanding the tissue-agnostic approach to additional solid tumors harboring
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|melanoma nsclc mbc neuroblastoma tnbc|leiomyosarcoma|out of 2 heavily pre-treated stage iv entity patients and 1 heavily pre-treated triple negative breast cancer patient experienced stable disease as best response .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|melanoma neuroblastoma carcinoid ewing medulloblastoma|leiomyosarcoma|developed a fully-human antibody , designated imc-3g3 , that effectively blocks the function of pdgfra and inhibits the growth of glioblastoma and entity tumors in animal models .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|sarcomas melanoma lymphomas mesothelioma melanomas|leiomyosarcoma|elevated cd47 has been reported in solid tumors , including breast , colon , ovarian , brain , liver and prostate cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|sts rhabdomyosarcoma osteosarcoma leiomyosarcoma lms|leiomyosarcoma|doxorubicin has historically been the standard of care for the treatment of entity and other sts .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma osteosarcoma rhabdomyosarcoma fibrosarcoma chondrosarcoma|leiomyosarcoma|this multicenter clinical trial is to assess the efficacy of ap23573 in four groups of sarcomas : bone sarcoma , entity , liposarcoma , and other soft tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|anaplastic glioblastoma gbm medulloblastoma brainstem|leiomyosarcoma|●results by year end are expected from ongoing clinical trials evaluating ptc596 in entity and diffuse intrinsic pontine glioma ( dipg ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|melanoma nsclc esophageal oropharyngeal leukemia|leiomyosarcoma|on these findings , as well as pre-clinical data , the phase 2 dose employed in the arq 501 monotherapy trials in entity and head and neck cancer is 450 mg / m2 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|aml mcl nhl osteosarcoma mf|leiomyosarcoma|ptc596 is also being evaluated in entity , or lms , in patients who have relapsed or are refractory to current treatments .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma fibrosarcoma osteosarcoma rhabdomyosarcoma sarcoma|leiomyosarcoma|the most common types of sarcoma in adults are undifferentiatedpleomorphic sarcoma ( previously called malignant fibrous histiocytoma ) , liposarcoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma osteosarcoma rhabdomyosarcoma fibrosarcoma liposarcoma|leiomyosarcoma|clinical-benefit responses were demonstrated in 39% of bone sarcoma patients , 50% of entity , 21% of liposarcoma , and 24% of other soft-tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma osteosarcoma rhabdomyosarcoma liposarcoma fibrosarcoma|leiomyosarcoma|the 246 patients with entity or liposarcoma comprise 57% of the total trial population .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|pilot pivotal companion ongoing multicenter|leiomyosarcoma|interim data from the entity study show a 17 . 5 percent objective response rate among patients to monotherapy treatment with arq 501 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|teratoma myeloma adipose chondrosarcoma melanoma|leiomyosarcoma|-- the cbr rates were not statistically different among the four sub-groups ( i . e . , bone , 30% ; entity , 33% ; liposarcoma , 30% ; and other , 23% ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|rhabdomyosarcoma osteosarcoma fibrosarcoma leiomyosarcoma chondrosarcoma|leiomyosarcoma|axl is a tyrosine kinase receptor that is highly expressed and activated in numerous human sarcomas , including aggressive subtypes of entity , ewings sarcoma and liposarcoma .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma sts fibrosarcoma osteosarcoma rhabdomyosarcoma|leiomyosarcoma|entity and liposarcoma are the two most common types of sts and accounted for 57% of the patients enrolled in the
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|leiomyosarcoma sarcoma leiomyoma malignancy intravascular|leiomyosarcoma osteosarcoma sarcoma glioblastoma fibrosarcoma|leiomyosarcoma|trabectedin ( yondelis® ) was approved in 2015 for patients with entity or liposarcoma that have had prior treatment with an anthracycline such as doxorubicin .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|neuroblastoma melanoma leukemia cancers rhabdomyosarcoma|rhabdomyosarcoma|indications for our impact therapeutic vaccines and have developed cell lines for ovarian cancer , triple negative breast cancer and pediatric entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma myeloma retinoblastoma sarcoma osteosarcoma|rhabdomyosarcoma|vincristine is used to treat hodgkin  s disease , leukemia , entity , neuroblastoma , and wilms  tumor .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma neuroblastoma medulloblastoma retinoblastoma glioma|rhabdomyosarcoma|rare pediatric disease designations and odds were granted for the treatment of , neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma medulloblastoma glioma neuroblastoma glioblastoma|rhabdomyosarcoma|in 2018 , the fda granted orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|neuroblastoma medulloblastoma rhabdomyosarcoma leukemia retinoblastoma|rhabdomyosarcoma|granted orphan drug designation to clr 131 , the companys lead phospholipid drug conjugate™ ( pdc ) product candidate , for the treatment of entity , a rare pediatric cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|neuroblastoma rhabdomyosarcoma melanoma osteosarcoma retinoblastoma|rhabdomyosarcoma|since then the drug has been used to treat various types of cancer , including wilms tumor , entity , ewing  s sarcoma , trophoblastic neoplasm , and testicular cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma glioma medulloblastoma glioblastoma neuroblastoma|rhabdomyosarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma glioblastoma melanoma glioma neuroblastoma|rhabdomyosarcoma|pv-10 is also undergoing preclinical study for pediatric solid tumor cancers ( including neuroblastoma , ewing sarcoma , entity , and osteosarcoma ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma glioma medulloblastoma glioblastoma neuroblastoma|rhabdomyosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma medulloblastoma neuroblastoma osteosarcoma retinoblastoma|rhabdomyosarcoma|description / conclusion the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|combinations collaboration conjunction japan nsclc|rhabdomyosarcoma|the nci has initiated a phase i / ii clinical trial in entity of ganitumab with the kinase inhibitor dasatinib based on promising preclinical animal model data with this combination .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma neuroblastoma medulloblastoma glioma glioblastoma|rhabdomyosarcoma|multiple myeloma as well as orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|sarcoma rhabdomyosarcoma fibrosarcoma osteosarcoma leiomyosarcoma|rhabdomyosarcoma|“entity is the most common type of tissue sarcoma in children .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma medulloblastoma neuroblastoma osteosarcoma ewing|rhabdomyosarcoma|the poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma medulloblastoma neuroblastoma osteosarcoma ewing|rhabdomyosarcoma|the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|rhabdomyosarcoma chondrosarcoma leiomyosarcoma neuroblastoma fibrosarcoma|rhabdomyosarcoma|entity is a skeletal muscle neoplasm occurring primarily in the first decade of life , while osteosarcoma , a bone neoplasm , occurs primarily
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|chondrosarcoma rhabdomyosarcoma neuroblastoma osteosarcoma glioblastoma|rhabdomyosarcoma|is to investigate the gene expression patterns stimulated by sca using two malignant tumor cell lines , saos-2 ( osteosarcoma ) and rd ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|rhabdomyosarcoma anaplastic sarcoma embryonal ewing|nsclc leukemia crpc glioma melanoma|rhabdomyosarcoma|the nci has conducted pk / pd and dose escalation studies in preclinical models of entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|autoimmune_disease|polyneuropathy neuropathy demyelinating segmental multiplex|polyneuropathy myelopathy syndromes dystrophy arthropathy|polyradiculoneuropathy|oral 2008 2015 / iii chronic inflammatory demyelinating entity 2012 2016 / iii hsc835 tbd stem cell regeneration stem cell transplantation
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|autoimmune_disease|polyneuropathy neuropathy demyelinating segmental multiplex|polyneuropathy neuropathies neuropathy myelopathy syndromes|polyradiculoneuropathy|a phase ii / iii study of gilenya in patients with chronic inflammatory demyelinating entity was initiated in 2012 .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|autoimmune_disease|polyneuropathy neuropathy demyelinating segmental multiplex|polyneuropathy neuropathies syndromes neuropathy myelopathy|polyradiculoneuropathy|development work for a u . s . pediatric indication to treat primary immunodeficiencies and a phase 3 indication in chronic inflammatory demyelinating entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cardiovascular_disease|uncontrolled systolic your personality incident|abortion osteoporosis infertility amenorrhea anaemia|hypertension|addition , matria provides home healthcare services for the management of other complicated obstetrical and gynecological conditions , such as pregnancy induced entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|uncontrolled systolic your personality incident|discomfort hypothermia sedation hyperthermia desaturation|hypertension|however , the letter indicated that such a boxed warning could be reconsidered if suitable data demonstrating a lack of severe entity in a fully supine position were provided .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|uncontrolled systolic your personality incident|osteoporosis dyslipidemia psoriasis osteoarthritis epilepsy|hypertension|aventis claims its therapeutic innovations rank among the leading treatments for lung and breast cancer , thrombosis , seasonal allergies , diabetes and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|uncontrolled systolic your personality incident|eosinophilia infiltrates exacerbations hypoxemia hemodynamics|hypertension|pulmonary entity in interstitial lung diseases market there are no therapies currently approved for ph-ild .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|uncontrolled systolic your personality incident|cardiology pharmacology physiology epidemiology echocardiography|hypertension|dr . oparil has an extensive bibliography in clinical cardiology and entity , including over 350 journal articles , books and book chapters .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|cardiovascular_disease|uncontrolled systolic your personality incident|gout osteoporosis psoriasis osteoarthritis glaucoma|hypertension|the subpoena requests documents relating to benicar® , benicar hct® , and azor® , prescription medications approved for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|angina chf bradycardia arrhythmias dyspnea|hypertension|the king board made note of mylans proprietary product nebivolol , a beta blocker for the treatment of entity , the nda for which was accepted for filing in june by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|cardiovascular_disease|uncontrolled systolic your personality incident|vasoconstriction hemorrhage hypoplasia arteries vasodilation|hypertension|he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary entity of the newborn .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|thromboembolism obstruction pah remodelling thrombosis|hypertension|release announcing united states food and drug administration approval of intravenous dosing of remodulin for the treatment of pulmonary arterial entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|hypertensives neuropathy allergy sarcoidosis glaucoma|hypertension|rhopressa® , and our product candidate , roclatantm , are designed to lower intraocular pressure ( iop ) in patients with open-angle glaucoma or ocular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|uncontrolled systolic your personality incident|fever diarrhea dizziness neutropenia stomatitis|hypertension|most common non-hematologic adverse reactions : ( ≥20% ) were entity , rash , abdominal pain , fatigue , headache , dry skin , constipation , arthralgia , nausea , and pyrexia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|dyslipidemia microalbuminuria hypertriglyceridemia hypercholesterolemia hyperglycemia|hypertension|have been found to be an independent predictor of a number of cardiovascular risk factors including obesity , abnormal lipid levels , entity , type 2 diabetes , and systemic inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|uncontrolled systolic your personality incident|cough oedema arrhythmias angina nephropathy|hypertension|about plendil plendil ( felodipine ) is a calcium antagonist for the treatment of entity and angina .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|acne bph osteoarthritis glaucoma endometriosis|hypertension|lotrel ( +11% us ) , the leading us fixed combination treatment for entity , sustained double-digit sales growth well ahead of market ( +6% ytd ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|uncontrolled systolic your personality incident|tremor hypertensives headaches headache epilepsy|hypertension|therapy for depression , is approved in the united states as inversine for the management of moderately severe to severe essential entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|uncontrolled systolic your personality incident|pheochromocytoma headache angina anaphylaxis headaches|hypertension|phentolamine has been approved by the fda for the treatment of entity and for use in the diagnosis of certain tumors of the adrenal gland , and has been used " off-label " by urologists ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|uncontrolled systolic your personality incident|commercially app brand analgesics brands|hypertension|partner product / candidate application status teva clonidine tds entity marketed par fentanyl tds pain marketed p&g crest whitestrips ( 5 products )
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|uncontrolled systolic your personality incident|thromboembolism embolism emboli nodules infiltrates|hypertension|pulmonary entity may be present in as many as 74% of patients depending on how the pulmonary entity ( “ph” ) is defined .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|cardiovascular_disease|uncontrolled systolic your personality incident|epilepsy headache headaches tremor seizures|hypertension|we cannot be certain that darusentan for the treatment of resistant entity will be approved in the united states or in countries outside of the united states or whether marketing approvals will
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|uncontrolled systolic your personality incident|epilepsy seizures anaphylaxis wounds fever|hypertension|except for inversine for the management of entity , neither the fda nor any foreign regulatory authority has approved any of our product candidates for marketing .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|sle ssc itp psoriasis vasculitis|vasculitis|dr . jaynes research includes investigator-initiated international trials and the introduction of newer therapies in entity and sle with collaborators on five continents .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis syndromes granulomatosis pneumonia|vasculitis|ifx-1 is currently being developed for various inflammatory indications , including hidradenitis suppurativa , anca-associated entity and pyoderma gangraenosum .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis syndromes uveitis pneumonia|vasculitis|rituxan we are currently planning for phase iii clinical trials in systemic lupus eruthematosus , lupus nephritis and anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis anca myeloperoxidase nephropathy|vasculitis|ccx168 for anca-associated entity understanding anca-associated entity ancas are autoantibodies that attack certain type of white blood cells called neutrophils .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis pneumonia granulomatosis syndromes|vasculitis|ifx-1 is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and covid-19 induced pneumonia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 2)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis arteritis arteriosclerosis psoriasis atherogenesis|vasculitis|entity is an inflammatory process of blood vessels , histopathologically characterized by vessel wall destruction and occlusion of the vascular lumen .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|psoriasis pemphigus scleroderma sarcoidosis vitiligo|vasculitis|test could be used by clinicians in the management of several autoimmune diseases , including but not limited to rheumatoid arthritis , entity and irritable bowel disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|inactive preclinical sle passive refractory|vasculitis|in 2012 , we plan to initiate phase 3 trials of benlysta in entity and active lupus nephritis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis nephritis nephropathy uveitis|vasculitis|of those cells to do damage in response to c5a activation , which is known to be the driver of anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|myeloma nephropathy amyloidosis vasculitis purpura|vasculitis|all iga protease-mediated diseases , including iga nephropathy , linear iga bullous dermatitis , iga pemphigus , and henoch-schonlein purpura ( also known as iga entity ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|quantified preventable documented stated avoided|vasculitis|the method of claim 1 , wherein the adverse effect is entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis aav wg glomerulonephritis gpa|vasculitis| completed enrollment of the companys pivotal phase iii advocate trial of avacopan for the treatment of anca-associated entity ; top line data expected in the fourth quarter of 2019 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|deposits thrombi coagulation lysis hemolysis|vasculitis|toxicological findings included changes in hematologic and chemistry parameters and fibrinoid entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|sle psoriasis vitiligo nmo fibromyalgia|vasculitis|actually , my first experience outside of ms was treating a condition called entity and thats another autoimmune disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis uveitis pneumonia syndromes|vasculitis|rituxan is also being evaluated in lupus nephritis and anca-associated entity in collaboration with biogen idec .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|obstruction narrowing vasculopathy vasculitis insult|vasculitis|in egpa , patients usually develop asthma initially , before the entity extends to inflammation in the walls of small blood vessels that supply tissues in the lungs , sinuses , skin , nerves and
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis granulomatosis purpura lymphadenopathy fever|vasculitis|as basal cell cancer in the area of laviv® injections and the risk of immune-mediated hypersensitivity reactions such as leukocytoclastic entity ) , which must be completed by 2016 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis vasculopathy granulomatosis gpa|vasculitis|anca-associated entity is a rare autoimmune disease that largely affects the small blood vessels of the kidneys , lungs , sinuses , and a variety
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis pemphigus wg syndromes|vasculitis|vilobelimab is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and severe covid‑19 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis vascul necrotizing urticaria anca|vasculitis glomerulonephritis syndromes granulomatosis uveitis|vasculitis|evaluated in phase iii clinical trials for anti-tnf ( tumor necrosis factor ) refractory rheumatoid arthritis , primary progressive multiple sclerosis , and anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis vasculitis vasculopathy granuloma synovitis|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-large blood vessels .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myocarditis gca myositis vasculitis|arteritis|abbvie initiated a phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca encephalitis myocarditis granuloma|arteritis|targeting gm-csfrα ) ·kiniksa recently announced positive data from the global phase 2 clinical trial of mavrilimumab in giant cell entity ( gca ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca granulomatosis aspiration granuloma|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myositis myocarditis granuloma vasculitis|arteritis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca vasculitis synovitis granuloma|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , or gca , an inflammatory disease of the blood vessels .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca granuloma myositis granulomas|arteritis|current treatment landscape for giant cell entity glucocorticoids , a type of corticosteroid , are the mainstay for the treatment of gca because they normalize inflammatory markers and resolve
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myocarditis myositis vasculitis gca|arteritis|testing gevokizumab in a variety of small clinical studies , including polymyositis / dermatomyositis and schnitzler syndrome ; a third study in giant cell entity , is expected to open shortly .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myocarditis myositis granuloma vasculitis|arteritis|in 2013 , servier began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|vasculopathy arteriosclerosis thrombosis sclerosis preconditioning|arteritis|developed to address the accelerated inflammation of grafted blood vessels common in chronic organ transplant rejection and known as transplant entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myocarditis gca vasculitis myositis|arteritis|an ongoing phase iii study , announced in november 2015 , is currently investigating sirukumab in giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca granulomatosis aspiration granuloma|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the blood vessels that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis myocarditis granuloma myositis synovitis|arteritis|the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid arthritis , ankylosing spondylitis , giant cell entity and related disorders .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis vasculitis vasculopathy myocarditis gca|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-to-large arteries .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca psoriasis granuloma synovitis|arteritis|· kiniksa plans to advance to a phase 2 clinical trial of mavrilimumab for the treatment of giant cell entity in the second half of 2018 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|arteritis obstructive nod necrotizing vasculitis|arteritis gca myocarditis encephalitis granulomatosis|arteritis|in november 2015 gsk announced the start of a phase iii study of sirukumab for patients with giant cell entity ( gca ) , and plans to start a study in asthma were disclosed at gsk  s r&d day .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|incidents temperatures discomfort cellulitis contamination|phlebitis|intermune requested this self-imposed clinical hold in part due to the observance of entity at the infusion site judged to be unexpectedly greater in incidence and severity than anticipated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|vasculitis thrombosis hemorrhage ulceration haemorrhage|phlebitis|levels were generally well tolerated with one subject at the 5 mg / kg dose level experiencing moderate localized blood vessel inflammation , or entity , that was attributed to the study drug .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|irritation discomfort flushing intolerance hypersensitivity|phlebitis|the product may also cause entity ( vein irritation ) in approximately one-third of treated patients .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombosis veins coagulation embolism aspiration|phlebitis|for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery - thrombus deep entity , etc .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombosis veins embolism aspiration dvt|phlebitis|hepatitis ) propylgallate for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery-thrombus deep entity , etc .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|hematoma haematoma hemorrhage haemorrhage perforation|phlebitis|blood collection by venipuncture is associated with mild discomfort , and the possibility of localized bruising , entity , or extravasation .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|vasoconstriction vasospasm thrombosis hemolysis hemorrhage|phlebitis|other events such as entity , mechanical block of the capillaries or arterioles , activation of platelets , or subsequent generation of microthrombi are also possible .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombosis thromboembolism sepsis bacteremia fever|phlebitis|peripheral venous catheters have been associated with a 7% to 9% incidence of entity and a 0 . 2% to 0 . 4% incidence of bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|discomfort thrombosis neurotoxicity extravasation irritation|phlebitis|sdp-016 is designed to reduce the vein irritation and entity associated with the iv-delivered drug .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|privacy security confidentiality transparency packaging|phlebitis|in terms of entity , which is another thing that the fda mentioned in their complete response , that is something that we feel has been
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|erythema pruritus rash itching cellulitis|phlebitis|patients who received dyloject ( tm ) also had a lower incidence and severity of entity at the site of intravenous administration compared to those given voltarol ( r ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombosis sepsis thromboembolism bacteremia fever|phlebitis|peripheral venous catheters have been associated with entity and bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|delays hai neurotoxicity bsi tracheostomy|phlebitis|we believe that some clinicians elect to use a central line or a different chemotherapeutic regimen as a means to avoid entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|irritation pruritus dryness burning itching|phlebitis|we believe the current formulations of these drugs have limitations , such as entity , erythema and hypersensitivity reactions , that present opportunities for improvement .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|pruritus urticaria itching fever stomatitis|phlebitis|the most common adverse reactions in clinical trials associated with cinryze were rash , headache , nausea , erythema , entity and local reactions at the injection site .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|ulceration ulcer scar ulcers scarring|phlebitis|local none pain pain and swelling with inflammation or entity ulceration plastic surgery indicated fever of unknown origin
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombosis vasculitis eclampsia aneurysms strokes|phlebitis|cerebral infarction and thrombosis , brain damages like apoplectic sequela , cerebral trauma , brain surgery sequela , also used for thromboangitis obliterans and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|mucositis diarrhea stomatitis neurotoxicity anaemia|phlebitis|clinically significant toxicities observed to date include neutropenia , thrombocytopenia and mild to moderate entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|thrombocytopenia myelosuppression hemorrhage vasculitis leukopenia|phlebitis|the main side effect at the maximum dose tested was moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|venous subcutaneous vasculitis phleb veins|myelosuppression thrombocytopenia leukopenia fever vasculitis|phlebitis|the main side effect at the maximum dose tested has been moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|thrombosis embolism cellulitis dvt osteomyelitis|thrombophlebitis|eight of the patients had pulmonary embolism and / or deep vein thrombosis with three additional patients reporting an event of superficial entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|a2 a1 lipase ai saa|thrombophlebitis| 1 % elevated lipase   1 % entity ( associated with infusion sites )  1 %  a for the
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|thrombosis embolism venous hemorrhage ulcer|thrombophlebitis|events included : deep venous thrombosis , pulmonary embolism , superficial entity , and retinal vein thrombosis with vision loss .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|cellulitis ulcers osteomyelitis thrombosis ulceration|thrombophlebitis|no venous thromboembolism events or occurrences of superficial entity were observed or reported .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|thrombosis infarction embolism thromboembolism thrombus|thrombophlebitis|thalidomide in combination with other agents may have an increased incidence of thromboembolic events such as pulmonary embolism , deep vein entity , entity , or thrombosis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|ninth 2nd largest fifth next|thrombophlebitis|both saes have subsequently resolved , with the entity sae verbally reported to the company as resolved following the safety data cut-off date .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|septic venous aseptic pelvic thrombosis|nausea irritation tolerability analgesia pruritus|thrombophlebitis|entity ( vein irritation ) was significantly less with dyloject than with ketorolac or placebo .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|pe pte pae ape spe|thromboembolism|pulmonary embolism : a pulmonary embolism , or entity , occurs when a blood clot , generally a venous thrombus , becomes dislodged from its site of formation and embolizes to the
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism embolism arrhythmias revascularization pneumonia|thromboembolism|poaf is independently associated with an increased risk of morbidity and mortality caused by stroke , heart failure , ventricular arrhythmias , entity and bleeding from anticoagulation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis ulcers thromboembolic embolism|thromboembolism|james d . extended-duration prohylaxis against venous entity after total hip or knee replacement : a meta-analysis of the randomized trials .  the lancet .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thrombosis coagulation fibrinolysis tumorigenesis hemostasis|thromboembolism|inhibition of intracellular signaling involved in tumor growth and metastases and 2 ) inhibition of early coagulation processes associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis thromboembolic embolism infarction|thromboembolism|risk factors for arterial vascular disease and / or venous entity ( vte ) should be managed appropriately .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thrombosis thromboembolism hemorrhage vte dvt|thromboembolism|heparin is also used to prevent the occurrence of entity and to prevent clotting during dialysis and other surgical procedures , particularly vascular surgery .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis embolism ulcers ulceration|thromboembolism|and states that esas increase the risk of death and major adverse cardiovascular events , such as myocardial infarction , stroke , venous entity and thrombosis of vascular access .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis embolism thromboembolic infarction|thromboembolism|a risk associated with hormonal contraceptives is a rare but serious adverse event called venous entity , or vte , which involves the formation of a blood clot in a vein .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis ulceration ulcers embolism|thromboembolism|fdas approval of annovera™ , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis embolism thromboembolic insufficiency|thromboembolism|xa in phase 3 development for extended duration prophylaxis , or preventive treatment , of a form of thrombosis known as venous entity , or vte , in acute medically ill patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|infarction infarctions infarcts hemorrhage embolism|thromboembolism|similarly , cerebral entity and cerebral vasculitis would be unexpected ( by virtue of greater specificity ) if the labeling only listed cerebral vascular accidents .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|cvd dyslipidemia ckd osteoporosis hyperglycaemia|thromboembolism|pipeline we aim to broaden our cv portfolio into the areas of entity , dyslipidaemia , type 2 diabetes / metabolic syndrome , atrial fibrillation and vascular disease prevention .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis thrombi stasis catheterization|thromboembolism|are in danger of forming life-threatening blood clots as a result of atrial fibrillation , prosthetic heart valve replacement or venous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis embolism thromboembolic insufficiency|thromboembolism|the committees concluded that users of evra have an increased risk of venous entity , or vte compared to users of second generation contraceptives , such as those containing lng .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|anaphylaxis delirium psoriasis rls osteoporosis|thromboembolism|patients and physicians are advised to be observant for the signs and symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis thromboembolic embolism infarction|thromboembolism|of the ag200-15 patch , levonorgestrel ( lng ) , is considered as one of the safest progestins , with the lowest risk for venous entity ( vte ) when combined with ee .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis ulceration ulcers embolism|thromboembolism|the approval of annovera , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism thrombosis endocarditis embolism reoperation|thromboembolism|in the ats heart valve is intended to lower the likelihood of blood clot formation and the resulting incidence of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|pneumonia myocarditis endocarditis hepatitis seizures|thromboembolism|response clinical tests are commercially available for the aid in early detection of heart attack , congestive heart failure , entity , sepsis , influenza a and b and rsv .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|venous thromboembolic thromboembolism thrombosis prophylaxis|thromboembolism ulcers ulceration thrombosis ulcer|thromboembolism|there were approximately 510 , 000 patients being treated for venous entity in the united states in 2005 .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism thromboembolism aspiration hemorrhage oedema|embolism|pulmonary entity is the most common preventable cause of hospital death and a leading cause of increased length of hospital stay .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism hemorrhage haemorrhage thromboembolism infarction|embolism|to sell abbokinase for the treatment of acute massive pulmonary entity , we are required to continue an ongoing 200-patient immunogenicity clinical trial that commenced in 2003 .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|thrombosis thrombi thrombus thromboembolism emboli|embolism|will look natural to blood as it passes through the valve , thus inhibiting platelet aggregation that may later lead to entity or blood clots .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism thromboembolism hemorrhage emboli infarction|embolism|urokinase is an fda-approved thrombolytic , or clot-dissolving agent , indicated for the treatment of acute massive pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism emboli infarction hemorrhage thromboembolism|embolism|the primary efficacy endpoint is the occurrence of venographically-confirmed dvt , pulmonary entity , or death during the treatment phase , when measured at day 30 .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism emboli contusion thromboembolism hemorrhage|embolism|allegedly sustained as a result of their product use ; the most common alleged injuries are deep vein thrombosis and pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism contusion emphysema infarction thromboembolism|embolism|used berlex hrt products together with other hrt products and suffered injuries , including breast cancer , ovarian cancer , stroke and pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism infarction emboli herniation infarct|embolism|one patient in the mst-188 group died due to cardiopulmonary arrest , which was considered secondary to a fat entity based on autopsy .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism hemorrhage oedema infiltrates emboli|embolism|patients were dyspnea ( 7 percent ) , pneumonia ( 5 percent ) , hypoxia ( 4 percent ) , neoplasm progression ( 4 percent ) , pyrexia ( 2 percent ) and pulmonary entity ( 2 percent ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism hemorrhage haemorrhage thromboembolism infarction|embolism|abbokinase is fda approved and marketed for the treatment of acute massive pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism exacerbation hemorrhage thromboembolism embol|embolism|the blood clots can travel to the lung and cause a pulmonary entity development all activities required to bring a new drug to the market .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism abscess hemorrhage infarction nodule|embolism|in two cases , the patient developed a pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism haemorrhage hemorrhage emboli infarction|embolism|numerous companies either offer or are developing competing treatments for ischemic stroke , massive pulmonary entity and catheter occlusion , the three indications we are currently targeting .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism thromboembolism emboli hemorrhage infarction|embolism|ivc filters have been shown in several studies to significantly reduce the risk of pulmonary entity and related mortality in certain high risk patient populations .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism thromboembolism emboli infarction embol|embolism|triage d-dimer test as an aid in the assessment and evaluation of patients suspected of having thromboembolic events , including pulmonary entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism thromboembolism sequestration emboli hemorrhage|embolism|in some cases , a venous clot can cause lung injury ( pulmonary entity ) by migrating from the veins to the lungs .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism hemorrhage oedema haemorrhage abscess|embolism|were a total of 48 serious adverse events , two of which were determined to be related to glybera , a pulmonary entity and fever .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism emboli thromboembolism infarction embol|embolism|patients at high risk for pulmonary entity are typically patients undergoing a significant surgical procedure , trauma patients or patients that have experienced a previous embolic event .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|embolism hemorrhage thromboembolism abscess aspiration|embolism|the most frequent ( >1% ) principal diagnoses were als , sepsis , respiratory failure , aspiration pneumonia , pneumonia , pulmonary entity , and urinary-tract infection ( table 2 ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|embolism clot emboli thrombus venous|hemorrhage embolism nodule infiltrate infarction|embolism|in addition , one patient was reported to have a pulmonary entity ( grade 4 ) that was an incidental finding on ct scan .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis transfusion hemorrhage thromboembolism hemolysis|thrombosis|pnh is a rare chronic blood disease characterized by severe anemia and risk of blood clotting or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|bsi sepsis bacteremia bacteraemia pneumonia|thrombosis|crbsis and entity represent key complications among hemodialysis , intensive care , cancer and total parenteral nutrition , or tpn , patients with cvcs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|stenoses thrombosis aneurysms occlusions thrombus|thrombosis|the angiojet system is marketed in the united states for treatment of dialysis access graft entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thrombus thrombi thromboembolism dvt|thrombosis|potential applications of catheter delivered thrombolytics include apao ( acute peripheral arterial occlusion ) , dvt ( deep vein entity ) , and ischemic stroke .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis hemorrhage vasospasm thromboembolism infarction|thrombosis|the most devastating consequence of chronic hemolysis is entity , which can occur in blood vessels throughout the body , damaging vital organs and causing premature death .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thrombi thrombus thromboembolism thrombo|thrombosis|cs-3030 is an oral direct factor xa inhibitor used to treat deep vein entity , or blood clots , and pulmonary embolism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thromboembolism ulcers thrombi insufficiency|thrombosis|in early 2003 , lovenox will be submitted in japan for the prevention of deep-vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thrombi thrombus thromboembolism insufficiency|thrombosis|venous clots occur principally in the arms or legs ( deep vein entity ) , and may cause local inflammation , chronic pain and other complications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|osteoporosis ileus oedema delirium restenosis|thrombosis|candidates include kaitong , a lipid emulsion of alprostadil for the treatment of peripheral vascular diseases , cardiocerebral microcirculation disorder and post-surgery entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|angina arrhythmia arrhythmias dyslipidemia hypercholesterolemia|thrombosis|rnapc2 was originally developed as a cardiovascular therapy for entity and other indications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|myocardium spasm another thrombus lumen|thrombosis|angina is caused by partial blockage of a coronary artery from entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thromboembolism catheters occlusions insufficiency|thrombosis|positioned angiomax as a replacement for heparin , which is a widely used , inexpensive , generic drug used in patients with arterial entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|healthcare endovascular thrombolysis pharmaceutical thrombolytic|thrombosis|we are initially targeting three segments of the entity market in which safe and rapid removal of blood clots is essential for patient care , including ischemic stroke , pulmonary embolism
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thrombi pseudoaneurysm hemorrhage dvt|thrombosis|entity can be treated surgically or through drug therapy with anticoagulant and thrombolytic drugs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thromboembolism infarction thrombus thrombi|thrombosis|patients withdrew due to adverse events ( one due to a recurrence of crohns disease and one due to deep vein entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|vte hit thrombosis dvt ich|thrombosis|may 2015 , we entered into an exclusive license agreement with bayer to develop and commercialize ionis-fxirx for the prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|allergy immunology others sepsis cardiology|thrombosis|the therapeutic areas pursued by celera included oncology , autoimmunity , respiratory diseases and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thromboembolism thrombosis insufficiency ulceration stasis|thrombosis|each year in the u . s . , over 270 , 000 patients are diagnosed with venous entity and approximately 50 , 000 patients die from pulmonary embolisms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thromboembolism thrombi thrombus embolism|thrombosis|that trial was discontinued due to the hypotension and because defibrotide can also be administered orally to prevent deep vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|venous thrombosis thrombus sinus thrombotic|thrombosis thrombi thromboembolism thrombus infarction|thrombosis|as an anticoagulant , or blood thinner , to prevent clotting of blood in the vein , commonly referred to as deep vein entity , and acute coronary syndromes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|reproduction neurogenesis carcinogenesis spermatogenesis epilepsy|arteriosclerosis|served as vice president of research at the winters institute , a non-profit biomedical research institution , at which dr . waitz studied entity in primates .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|thrombosis vasculitis gca dissection calcification|arteriosclerosis|the skin , copd in the lung , fibrotic disease in the liver and kidney , crohn  s disease in the intestine , chf and entity in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|infarction vasospasm hemorrhage aneurysms embolism|arteriosclerosis|pharmaceutical research conducted to date indicates that aso 989 has the potential to treat ischemia of extremities , cerebral thrombosis , cerebral entity and coronary heart disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|insufficiency spasm vasospasm syndromes thrombosis|arteriosclerosis|designed to treat the symptoms of coronary entity , angina pectoris and hyperlipemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|hyperlipidemia dyslipidemia osteoporosis hypercholesterolemia angina|arteriosclerosis|the product can be used in treatment of anoxemic cardiovascular and cerebrovascular disease , as well as hypertension and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|thrombocytopenia endocarditis angina retinopathy cirrhosis|arteriosclerosis|this product is used to treat ischemic heart and cerebrovascular diseases , entity and cerebral thrombosis bezoar antipyrotic tablet .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|turbulence thrombosis leakage vasospasm friction|arteriosclerosis|moreover , damage to the blood vessels may cause blockage due to entity and lead to the tearing of the vessels .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|gallstones cholangitis recurrences jaundice hypercholesterolemia|arteriosclerosis|claims fabacs , including aramchol , as well as methods for preventing or dissolving cholesterol gallstones in bile and reducing or preventing entity using fabacs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|osteoarthritis allergy glaucoma epilepsy osteopenia|arteriosclerosis|of variations in a gene which control blood levels of a protein and predict increased disposition or susceptibility to osteoporosis , entity , cancer and immune disorders .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|hemostasis thrombosis coagulation autoimmunity platelets|arteriosclerosis|he is also a member of the american heart association council on stroke , and council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|comorbidities arteriosclerosis pathologies morbidities illnesses|arteriosclerosis|million patients require bypass surgery each year because of age related entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|hemostasis thrombosis autoimmunity anticoagulation coagulation|arteriosclerosis|on april 20 , 2012 , alnylam presented aln-pcs data at the american heart associations entity , thrombosis , and vascular biology ( atvb ) 2012 scientific sessions held in chicago , il .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|infarction palsy ischaemia hemorrhage embolism|arteriosclerosis|used for coronary heart disease , angina , cerebral entity , ischemic cerebrovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|sepsis osteoporosis glioblastoma pah psoriasis|arteriosclerosis|in vivo validation of this model , enabling a route to screen for compounds against this target specifically to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|melanoma coordinating burns neuroimaging arrhythmia|arteriosclerosis|since 1973 , he has served as director of the entity center at the massachusetts institute of technology ( " mit " ) , of which he was the founder .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|hemostasis lipids thrombosis coagulation autoimmunity|arteriosclerosis|with non hdl -c ( ³130 mg / dl ) in type 2 diabetes mellitus” was given at the american heart association , council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|chd cvd ihd scd acs|arteriosclerosis|balancing female hormones may lower the risk of entity by utilizing the bodys natural protection against heart diseases before menopause .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|thrombosis hyperglycemia vasospasm embolism anticoagulants|arteriosclerosis|and chronic peripheral vascular-metabolic disorders , brain occlusion , occlusion of retina central vein , acute and chronic cerebral vascular-metabolic disorders caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|osteoporosis cancers dyslipidemia osteoarthritis hypercholesterolemia|arteriosclerosis|excess dietary fat is the primary cause of obesity , heart disease , high blood pressure , diabetes , entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|arteriosclerosis atherosclerotic vessels arterio vasculopathy|glaucoma neurodegeneration osteoporosis blindness infertility|arteriosclerosis|angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer , blindness and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|cancers candidiasis endometriosis acne tumours|atherosclerosis|patent applications also cover estrogen-related compounds with anti-fungal activity and the treatment of localized entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2), ('BIO', 2)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|arteriosclerosis atherogenesis calcification dyslipidemia hypercholesterolemia|atherosclerosis|chd usually results from entity , a hardening and narrowing of the arteries caused by a buildup of fatty plaque composed of cholesterol and other lipids ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 3), ('DRUG', 3), ('OTHER', 3)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|hypercholesterolemia dyslipidemia hyperlipidemia fh chd|atherosclerosis|current treatments : most patients with entity have high levels of a particular type of cholesterol particle known as ldl-c . the current standard of care is treatment
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3), ('BIO', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|dyslipidemia nafld hypercholesterolemia arteriosclerosis hyperlipidemia|atherosclerosis|several studies have demonstrated that lxr agonists will promote rct in vivo in mice and prevent the development of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|statins aspirin hyperlipidemia hyperhomocysteinemia osa|atherosclerosis|test cleared by the fda to aid in assessing risk for both coronary heart disease and ischemic stroke associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 4), ('DRUG', 3), ('OTHER', 3), ('BIO', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|hypercholesterolemia hyperlipidemia thrombosis atherogenesis dyslipidemia|atherosclerosis|preclinical studies conducted by pharmacyclics and our collaborators have demonstrated that texaphyrins also accumulate in vascular plaque caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|atherogenesis autoimmunity myocarditis arrhythmias cardiomyopathy|atherosclerosis|chlamydia pneumoniae ( " c . pneumoniae " ) infections may play a role in entity in heart diseases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|hemodynamics cardiomyopathy chf contractility fitness|atherosclerosis|oxidative stress ( the physiological condition of inadequate oxygen supply ) may worsen entity and make heart muscle more susceptible to damage .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|neurodegenerative epilepsy neurodegeneration thrombosis autoimmunity|atherosclerosis|mitochondrial-derived peptides ( mdps ) into mbts offers the potential to address a broad range of diseases including type 2 diabetes , cancer , entity and neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('DRUG', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|periodontitis psoriasis sepsis endometriosis ibd|atherosclerosis|inhibitors of certain classes of pdes , in particular pde4 , may be novel compounds for the treatment of inflammation related to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('DRUG', 5), ('OTHER', 2)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|hypercholesterolemia dyslipidemia hyperlipidemia hyperhomocysteinemia hyperuricemia|atherosclerosis|entity is the major cause of cardiovascular disease , peripheral artery disease and cerebral artery disease , and can cause heart attack , loss
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|photodynamic topical adjunctive photothermal replacement|atherosclerosis|entity therapy antrin for photoangioplasty of atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|sepsis eclampsia others pneumonia epilepsy|atherosclerosis|including hemorrhage , severe trauma , ischemic heart disease , diabetes , acute myocardial infarction , acute transient cerebral ischemic attack , sickle cell disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|neuroscience geriatric collaborative others ongoing|atherosclerosis|spent 11 years at bristol-myers squibb ( nyse : bmy ) , from 1986 to 1997 , in various capacities , including executive director , heart failure and entity clinical research .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1), ('BIO', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|arteriosclerosis scleroderma calcification psoriasis gout|atherosclerosis|entity is a disease that is commonly referred to as a hardening of the arteries and is characterized by the deposition
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|lumen luminal arteries atherosclerotic sinus|atherosclerosis|ldl and hdl particle in coronary entity size were also important predictors of disease progression .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|psoriasis osteoarthritis periodontitis sepsis gout|atherosclerosis|thc has been found to reduce inflammation in chronic inflammatory diseases , such as entity and rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|atherogenesis arteriosclerosis chd dyslipidemia cvd|atherosclerosis|elevated plasma cholesterol and triglycerides are independent risk factors for entity , the buildup of cholesterol rich lesions and plaques in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|psoriasis osteoporosis acromegaly aml endometriosis|atherosclerosis|in february 2005 , we initiated phase i trials on rus 3108 , our drug candidate for the treatment of entity , in ireland .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|atherosclerotic plaques predicts arteries vessels|ckd preeclampsia chf t2dm esrd|atherosclerosis|the medical literature that increased vascular oxidative stress is a primary mechanism of impaired blood vessel elasticity in patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|termed simulating hemorrhagic sudden mimicking|stroke|ep-4104 ( dantrolene ) for exertional heat entity exertional heat stroke , or ehs , is a rare , emergency and serious medical condition that is potentially life-threatening .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|subtypes suffer neurology strokes tia|triage expert alert guideline trigger|stroke|the triage meter , triage micro product line and triage entity panel are not included .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|subtypes suffer neurology strokes tia|preconditioning reperfusion myocardium cardiomyopathy insult|stroke|kingdom to determine the safety , efficacy and pharmacokinetics of ldp-01 for the reduction of reperfusion tissue damage associated with ischemic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|strokes burns orthopedic tbi neurosurgery|stroke|the majority of people with ms and sci experience some form of spasticity , as do many people following entity or brain injuries .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|strokes cardiomyopathy colitis syndromes myelopathy|stroke|and drug administration , or fda , to initiate a third clinical study administering multistem to patients for the treatment of ischemic entity , a leading cause of death and disability .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|ibd hospitalized asthmatic asian sle|stroke|pfizer is expected to conduct additional safety and tolerability studies in entity patients later this year .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|subtypes suffer neurology strokes tia|cardiomyopathy angina syndromes nephropathy colitis|stroke|the last subjects follow-up assessment in the company  s non-gcp phase ii trial evaluating nsi-566 , for the treatment of chronic ischemic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|epilepsy osteoporosis suicide pneumonia concussion|stroke|entity is currently the third leading cause of death , and the leading cause of disability , in the united states .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|subtypes suffer neurology strokes tia|cardiomyopathy cerebrovascular attack angina strokes|stroke|there is a tremendous need for new ways to treat ischemic entity patients ,  said anne legrand , senior vice president and general manager , ultrasound , for philips medical systems .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|handicap sport epilepsy neuroprotection others|stroke|$30 , 000 that is part of the $342 , 000 small business innovation research grant from the national institute of neurological disease and entity , and $10 , 000 in licensing revenue .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|subtypes suffer neurology strokes tia|japan europe canada china india|stroke|if the company  s anticipated phase i / iia study in entity is supportive , the company will consider pursuing an ind filing for myocardial infarction in the united states .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|alzheimer melanoma parkinson cocaine antiretroviral|stroke|currently , the company  s parkinson  s disease , aids dementia and entity product candidates are all in or have just recently completed phase i clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|triage sepsis toxicology expert toxin|stroke|shortness of breath panel , triage d-dimer test and triage tox drug screen and others currently under development , including the triage entity panel .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|neural cns axonal locomotor neuron|stroke|recent advances in entity recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|osteoporosis dyslipidemia osteoarthritis suicide strokes|stroke|individuals that are clinically obese have elevated rates of cardiovascular disease , entity , certain types of cancer and diabetes .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|epilepsy strokes glaucoma hemorrhage neurodegenerative|stroke|of researching , developing and providing medical technologies to restore the vision of patients with neurological visual loss predominantly resulting from entity or traumatic brain injury .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|subtypes suffer neurology strokes tia|infarction hospitalization angina chd syncope|stroke|factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|subtypes suffer neurology strokes tia|tumours infarction abscess concussion hemorrhage|stroke|our initial targeted medical conditions are brain entity and wound healing .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|subtypes suffer neurology strokes tia|event episode attack infarction strokes|stroke|study in the u . s . to evaluate the safety and efficacy of the starflex® closure technology to prevent a recurrent embolic entity and / or tia in patients with a pfo .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|subtypes suffer neurology strokes tia|epilepsy strokes parkinsonism encephalitis vasculitis|stroke|these underlying neurologic conditions include but are not limited to als , ms , alzheimers disease , parkinsons disease , entity and traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysms aneurysmal aaa atherosclerotic endovascular|aneurysm|procedures in which these catheters are used include angioplasty , embolization , abdominal aortic entity ( aaa ) stent-grafts and vena cava filter placements .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|orthopaedic elective orthopedic ambulatory cataract|aneurysm|studies in which hetacool will be used to replace all of the patient  s circulating blood volume at near-freezing temperatures in entity surgery .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|coarctation valvular bifurcation prosthetic endovascular|aneurysm|usually aortic entity reconstruction surgery involves much more blood loss than post cardiopulmonary bypass surgery .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|endovascular neurosurgical ligation microsurgical metallic|aneurysm|needs of neurosurgeons with a range of implantable and single-use products , including cerebral spinal fluid shunts , external drainage products and entity clips .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|dissection coarctation anomaly tear anatomy|aneurysm|in patients with a known aortic entity or patients who are at greater risk for aortic entitys , reserve baxdela for use only when there are no alternative
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|eligible evaluable melanoma nsclc enrolled|aneurysm|as of december 18 , 2001 , a total of 39 entity cases have been treated in the trial .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysms thrombosis perforation insufficiency regurgitation|aneurysm|fluoroquinolones have been associated with an increased risk of aortic entity and dissection , especially in elderly patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|asd aaa aso avf mva|aneurysm|however , transcatheter devices currently used to repair an entity are often too large to be considered a truly minimally invasive procedure .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|cisterna aneurysmal puerper tactic coincident|aneurysm|outcomes and transform the management of entityal subarachnoid hemorrhage , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysms sah avms avm va|aneurysm|patients who require an external ventricular drain ( evd ) , and undergo either neurosurgical clipping or endovascular coiling for repair of their entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|dissection aneurysms coarctation arteriosclerosis dilatation|aneurysm|in the united states each year , abdominal aortic entity -- a weakening of the walls of one of the body  s main arteries , sometimes to the point of rupture --
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|avm ivh abscess avf aneurysmal|aneurysm|the les utilizes a material which is delivered as a liquid that fills and conforms to the shape of an entity or avm .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|endovascular prosthetic interposition replacement coil|aneurysm|company is considering for study are peripheral avms , uterine fibroid tumors , liver tumors and persistent endoleaks related to abdominal aortic entity graft treatments .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aaa aorta uterus tendon diaphragm|aneurysm|after the ruptured entity is repaired , these patients remain at risk for multiple complications that are managed over the course of the patients treatment
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysms dissection coarctation dilatation thrombosis|aneurysm|endologix  s first product , the powerlink system , is a catheter-based alternative treatment for abdominal aortic entity , or aaa .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysmal cisterna evacuation epidemic coincident|aneurysm|transform the management of entityal subarachnoid hemorrhage , or asah , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|neoplasm avm meningioma malformation hemangioma|aneurysm|in a surgical procedure to treat a brain entity , a clip is placed across the base , or neck , of the entity for the purpose of excluding the entity from further blood flow .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|aneurysms dissection pathologies coarctation emergencies|aneurysm|it is a direct side effect of an aortic clamping procedure during a surgical operation to treat abdominal aortic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|mesh clip titanium wire alloy|aneurysm|titanium entity clip was developed in collaboration with biotek engineering , inc . ( " biotek " ) under an exclusive worldwide royalty bearing license to the patents
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysmal false aneurysms ruptured giant|fistula hernia obstruction vsd deformity|aneurysm|be treated through a combination of pharmacological therapy and non-invasive monitoring or undergo a major surgical procedure to repair the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|cavernous hemangioma cystic hereditary subcutaneous|pneumonia mastitis gangrene leprosy fever|angiomatosis|he discovered two previously uncharacterized , uncultivated bacterial pathogens , agents of bacillary entity and whipple  s disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|cavernous hemangioma cystic hereditary subcutaneous|telangiectasia dysplasia syndromes sclerosis polyposis|angiomatosis|sws , also known as encephalofacial entity , is a neurocutaneous disorder that occurs as a sporadic congenital condition .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema cancers retinoblastoma hypercholesterolemia melanoma|angioedema|members of the medical and regulatory teams that successfully developed the orphan drug , cinryze , which is used to treat hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hae hemophilia hypercholesterolemia hypothyroidism|angioedema|firazyr for hereditary entity ( “hae” ) in the us prior to shires acquisition , in april 2008 jerini received a not approvable letter for firazyr for
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema syndromes hemolysis thromboembolism thrombosis|angioedema|our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary entity , or hae .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|hae angioedema gout attacks urticaria|angioedema|submitted a therapeutic biologic application ( bla ) to the fda for ruconest® seeking approval for the treatment of acute attacks of entity in patients with hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hae hemophilia hemorrhagic headache|angioedema|clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary entity ( “hae” ) attacks .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hemophilia hypercholesterolemia hae ataxia|angioedema|disease description • hereditary entity ( hae ) is a rare , autosomal dominant genetic disorder 1 • hae is characterized by recurrent , unpredictable , debilitating and potentially life
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|hae angioedema gout asthmatic angina|angioedema|identified several proprietary , small molecule kallikrein inhibitors in an effort to produce an orally administered therapy for the prevention of entity attacks .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hypercholesterolemia syndromes polyposis neutropenia|angioedema|therapeutic compounds for the treatment of chronic inflammatory diseases , with initial development to be focused on the treatment of hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hypercholesterolemia hemophilia urticaria neutropenia|angioedema|the most advanced indication for dx-88 is in the treatment of hereditary entity ( hae ) , a potentially life-threatening inflammatory condition .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|hae angioedema anaphylaxis gout urticaria|angioedema|the study is designed to examine the use of c1-inh in both treating acute attacks of entity and in preventing the onset of such attacks .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hypercholesterolemia hemophilia emphysema hypothyroidism|angioedema|includes product candidates designed to treat wet age-related macular degeneration ( wamd ) and rare diseases alpha-1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hypercholesterolemia melanoma pheochromocytoma cancers|angioedema|company completes the randomization of 68 evaluable subjects in its phase iii clinical trial for the acute treatment of hereditary entity on or before december 31 , 2006 ( the “options” ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|melanoma carrier toxicology oncology neuroblastoma|angioedema|dyax retains exclusive rights to dx-88 in all other indications , including its hereditary entity program , currently in its second phase 3 trial , as well as for the manufacturing of dx-88 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hemorrhagic hemophilia hae hypercholesterolemia|angioedema|two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily , oral treatments for the prevention of hereditary entity ( hae ) attacks .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema urticaria hypercholesterolemia thromboembolism arrhythmias|angioedema|( berotralstat ) for prophylaxis to prevent attacks of hereditary entity in adults and pediatric patients 12 years and older .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hypercholesterolemia emphysema hemophilia hypothyroidism|angioedema|gene therapy programs to address unmet needs in wet amd and rare diseases alpha 1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema attacks thrombosis vasculitis oedema|angioedema|of c1-inh activity , activated c1 and plasmin generate certain inflammatory mediators which are thought to be causal factors of the entity observed in patients with hae .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|cancers angioedema neuropathies syndromes melanoma|angioedema|and senior medical director , where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|angioedema hae attacks proteinuria tma|angioedema|published studies by others have shown c1-inh treatment to resolve entity in 30 minutes to two hours , compared to 24-72 hours when untreated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|angioedema urticaria hereditary attacks diagnose|hae angioedema episodic headache painful|angioedema|we market and sell cinryze in the united states for routine prophylaxis against entity attacks in adolescent and adult patients with hae .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|diarrhoea diarrhea pruritus dizziness headache|hypotension|the most frequently observed adverse events in both the placebo and treatment groups were nausea , vomiting and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|anaemia mucositis leukopenia diarrhea neutropenia|hypotension|the most common were neutropenia , thrombocytopenia , and entity ( 19% each ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|arrhythmias vasoconstriction hemorrhage hypoglycemia vasospasm|hypotension|we believe that this characteristic would offer a safety advantage over current vasodilators , which can cause dangerous entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|hyperglycemia headache hyperthermia hypoglycemia hyponatremia|hypotension|of symptoms associated with idiopathic and diabetic gastroparesis , and our norepinephrine and serotonin reuptake inhibitor ( " nsri " ) td-9855 in neurogenic orthostatic entity ( " noh " ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|hypoglycemia seizures diarrhea hypothyroidism bradycardia|hypotension|in the 50 mcg dex-in treatment group and one in the 35 mcg dex-in treatment group ) discontinued due to symptomatic entity and one subject ( 35 mcg dex-in ) due to fever .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|tachycardia bradycardia arrhythmia apnea syncope|hypotension|no patients with blood pressure decrease , entity nor with bradycardia required medication to treat these events .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|dizziness intolerance vertigo nystagmus ataxia|hypotension|like other opioids ( e . g . , heroin , methadone , oxycodone , morphine ) , bunavail may produce orthostatic entity ( dizzy spells ) in ambulatory individuals .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|corticosteroids statins methotrexate steroids cyclosporine|hypotension|profile , in particular its ability to provide clinical benefit without adding to the systemic effects of other therapies such as entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|intolerance dizziness tachycardia tremor falls|hypotension|our preclinical studies indicate that ( s ) -doxazosin exhibits potential for a reduction in orthostatic entity and is potentially more potent than the parent drug .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|fever urticaria flushing burning erythema|hypotension|these reactions consisted of erythema , pruritus , and entity and occurred within hours of administration of chemotherapy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|fever flushing erythema urticaria pruritus|hypotension|reactions are characterized by transient entity and an allergic type response , which appear to cease upon stopping drug administration .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|arrhythmias headaches seizures bradycardia headache|hypotension|vazculep is indicated for the treatment of clinically important entity occurring in the setting of anesthesia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|hypoglycaemia hyperglycaemia hyperkalemia oedema proteinuria|hypotension|benefit from aliskiren and there was a higher incidence of adverse events related to non-fatal stroke , renal complications , hyperkalaemia and entity in this high-risk population .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|sequelae exacerbations hypoglycemia immunosuppression neutropenia|hypotension|however , such patients may be subject to protracted severe entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|hospitalization infusions courses sedation anticoagulation|hypotension|in the acute care setting , this should allow the physician to alter the dose and avoid prolonged entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|diarrhea headache nausea diarrhoea rash|hypotension|in humans , and it was shown to be well tolerated , with the most common adverse events reported being gi toxicities , entity and fatigue .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|diarrhea vomiting constipation insomnia flushing|hypotension|the most frequently reported aes included somnolence , dizziness , nausea , headache , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|paclitaxel mtx vancomycin methotrexate infusion|hypotension|the data suggest that the limiting side effect of entity is related to peak plasma drug level , which means that slower infusions could allow delivery of more drug .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|dizziness flushing insomnia sedation pruritus|hypotension|dosing , seven of the 40 olinciguat-treated subjects reported headache , seven reported tachycardia , three 78 table of contents ​ ​ reported entity and three reported nausea .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|orthostatic hemodynamic postural uncontrolled haemodynamic|vasospasm uti hemorrhage hypoglycemia hypocalcemia|hypotension|no other adverse events of symptomatic entity were seen in the 95 patients treated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|telangiectasia hereditary telangiect angio cavernous|sah bm mas hemangiomas epcs|angiodysplasia|the gi blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled , leaky capillaries ( entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|telangiectasia telangiect nevus pigment psoriasis|pws amblyopia vitiligo psoriasis strabismus|telangiectasis|treatment options for entity are limited to corrective surgery or mixed light pulse therapy , known as photoderm , which directs a series of light pulse
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|telangiectasia telangiect nevus pigment psoriasis|telangiectasia scars venules capillaries pores|telangiectasis|rosacea progresses to a severe stage , dilated blood vessels that become distended under the surface of the skin , known as entity , appear .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|telangiectasia telangiect nevus pigment psoriasis|dryness erythema pruritus scarring itching|telangiectasis|however , local side effects are common , in particular skin thinning , entity , bruising , hypopigmentation , acne , striae and secondary infection .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|sepsis pneumonia bacteremia leukemia thrombosis|endocarditis|as you saw from our press release yesterday , we have continued to make progress in our phase 3 trail in entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis keratitis endophthalmitis peritonitis osteomyelitis|endocarditis|exebacase to potentially re-sensitize mrsa to penicillin derivatives and first generation cephalosporins , both in vitro and in the rabbit infective entity model .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|bacteremia abscesses endocarditis bacteraemia abscess|endocarditis|the primary efficacy endpoint is clinical response at day 14 in patients with mrsa bacteremia , including right-sided entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis pneumonia osteomyelitis vap bacteraemia|endocarditis|in addition to background standard of care soc antibiotics compared to soc antibiotics alone for the treatment of staph aureus bacteremia , including entity in adult patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis osteomyelitis peritonitis sepsis bacteremia|endocarditis|these infections may lead to complications associated with staphylococcal bacteremia , including infectious arthritis , pneumonia , septic shock , entity and abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis bacteremia abscesses osteomyelitis pneumonia|endocarditis| data from this study , if positive , could support an expansion of the current label to include right-sided entity and / or complicated bacteremia due to s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|aneurysms tumours chd endocarditis nsclc|endocarditis|key points from the meeting with the fda are highlighted below :  further enrollment of patients with left-sided entity is not required .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis endophthalmitis ulcers aneurysms pericarditis|endocarditis|especially cardiac devices which contribute substantially to the growing prevalence of staph aureus bacteremia , and secondary infections such as infective entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|mrsa sepsis pathogens osteomyelitis endocarditis|endocarditis|for the expanded label for cubicin® ( daptomycin for injection ) in the treatment of staphylococcus aureus bacteremia with known or suspected entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|bloodstream pneumonia nosocomial ear airways|endocarditis|that patients acquire while being treated or cared for in a hospital or out-patient setting and include , among others , pneumonia , entity and bloodstream infections , or bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis keratitis endophthalmitis hepatitis gastroenteritis|endocarditis|of further concern , the incidence of infective entity is increasing , with over 47 , 000 cases in 2011 , due to the growth of the at-risk populations , such as adults with
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis fever sepsis bacteremia osteomyelitis|endocarditis|gentamicin is an antibiotic used to treat entity , septicemia and bacterial , bone , respiratory tract , soft tissue , urinary tract and other infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis sepsis pneumonia endophthalmitis peritonitis|endocarditis|taken either drug has any invasive procedure for which antibiotic prophylactic treatment is recommended to prevent the development of bacterial entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|approved ambulatory inpatient urgent inappropriate|endocarditis|to get just what  hopefully get what youre looking for or do you feel like youre at loggerheads on an entity indication?
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|endocarditis septic staphylococcus staphylococcal aureus|endocarditis bacteremia mrsa biofilms thromboembolism|endocarditis|the silzone® coating was intended to reduce the risk of entity , a bacterial infection affecting heart tissue , which is associated with replacement heart valves .
#Masked F1-score:0.93|CLS F1-score:0.91|Masked Confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 1082), ('DIS', 58), ('OTHER', 146), ('BIO', 9)])), ('DIS', OrderedDict([('DRUG', 82), ('DIS', 1517), ('OTHER', 122), ('BIO', 14)])), ('OTHER', OrderedDict([('DRUG', 0), ('DIS', 0), ('OTHER', 0), ('BIO', 0)])), ('BIO', OrderedDict([('DRUG', 116), ('DIS', 326), ('OTHER', 280), ('BIO', 798)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('DIS', 1.0), ('OTHER', 0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.84), ('DIS', 0.87), ('OTHER', 0), ('BIO', 0.53)]), 'f1_score': OrderedDict([('DRUG', 0.91), ('DIS', 0.93), ('OTHER', 0), ('BIO', 0.69)]), 'max_f1': 0.93}|CLS confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 1078), ('OTHER', 81), ('DIS', 136), ('BIO', 0)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 90), ('OTHER', 232), ('DIS', 1398), ('BIO', 15)])), ('BIO', OrderedDict([('DRUG', 114), ('OTHER', 357), ('DIS', 282), ('BIO', 767)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.83), ('OTHER', 0), ('DIS', 0.81), ('BIO', 0.5)]), 'f1_score': OrderedDict([('DRUG', 0.91), ('OTHER', 0), ('DIS', 0.9), ('BIO', 0.67)]), 'max_f1': 0.91}
